{"2ccd1a48ee096431aebb6f73e05e9203cc5450d9": [["The ProblemRecent events had put tremendous stress on our health care system.", [["The ProblemRecent events", "PROBLEM", 0, 24]]], ["The Centers for Disease Control terms the COVID-19 outbreak a pandemic.", [["Disease Control", "TREATMENT", 16, 31], ["the COVID", "TEST", 38, 47]]], ["Our last pandemic was in 1918, and resulted in nearly 50 million deaths globally and 675,000 deaths in the United States.", [["deaths", "DISEASE", 65, 71], ["deaths", "DISEASE", 93, 99]]], ["The current pandemic has led to a severe, and growing, shortage of mechanical ventilators.The ProblemA survey done by the American Hospital Association in 2009 showed an estimated 62,000 fullfeatured ventilators.", [["a severe", "PROBLEM", 32, 40], ["mechanical ventilators", "TREATMENT", 67, 89], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["growing", "OBSERVATION_MODIFIER", 46, 53], ["mechanical ventilators", "OBSERVATION", 67, 89], ["fullfeatured ventilators", "OBSERVATION", 187, 211]]], ["Nearly half of these are in use for pediatric and neonatal patients.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67]]], ["Long term vent facilities and vent weaning units will likely have some basic ventilators, though the functionality of these devices is not as complete as typically ICU ventilators.", [["Long term vent facilities", "TREATMENT", 0, 25], ["vent weaning units", "TREATMENT", 30, 48], ["some basic ventilators", "TREATMENT", 66, 88], ["these devices", "TREATMENT", 118, 131]]], ["The Strategic National Stockpile (SNS) had nearly 8,500 ventilators prior to the onset of the COVID-19 epidemic, though now this supply is exhausted.", [["the COVID", "TEST", 90, 99]]], ["The American Association for Respiratory Care had suggested that the SNS inventory to increase to 11,000-16,000 ventilators in preparation for a severe influenza pandemic.", [["influenza pandemic", "DISEASE", 152, 170], ["the SNS inventory", "TREATMENT", 65, 82], ["ventilators", "TREATMENT", 112, 123], ["a severe influenza pandemic", "PROBLEM", 143, 170], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["influenza", "OBSERVATION", 152, 161]]], ["SNS will not suffice for the current pandemic.The ProblemThe split ventilator technique is not new, and was described first by Drs. Neyman and Babcock in 2006 to ventilate four simulated patients (Neyman 2006) .", [["SNS", "ANATOMICAL_SYSTEM", 0, 3], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["The Problem", "PROBLEM", 46, 57], ["The split ventilator technique", "TREATMENT", 57, 87], ["pandemic", "OBSERVATION", 37, 45], ["split", "OBSERVATION_MODIFIER", 61, 66], ["ventilator technique", "OBSERVATION", 67, 87], ["not", "UNCERTAINTY", 91, 94], ["new", "OBSERVATION_MODIFIER", 95, 98]]], ["This ventilator ran for 5.5 hours on pressure control, and more than 6 hours on volume control.", [["This ventilator", "TREATMENT", 0, 15], ["pressure control", "TREATMENT", 37, 53], ["volume control", "TREATMENT", 80, 94]]], ["In 2017, after a mass shooting during a music concert in Nevada, Dr. Kevin Menes used one ventilator to ventilate multiple patients (https://epmonthly.com/article/not-heroes-wear-capes-one-las-vegas-ed-savedhundreds-lives-worst-mass-shooting-u-s-history/).", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["a mass shooting", "PROBLEM", 15, 30], ["mass", "OBSERVATION", 17, 21]]], ["However, these patients were by and large acute trauma victims and did not manifest the severe respiratory disease that is typically seen with COVID-19 patients.The ProblemRecently, a group in Belgium described a pressure control mode for split mechanical ventilation (https://medium.com/) (Pinson 2020) .", [["respiratory", "ANATOMY", 95, 106], ["trauma", "DISEASE", 48, 54], ["respiratory disease", "DISEASE", 95, 114], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 152, 160], ["large acute trauma victims", "PROBLEM", 36, 62], ["the severe respiratory disease", "PROBLEM", 84, 114], ["a pressure control mode", "TREATMENT", 211, 234], ["split mechanical ventilation", "TREATMENT", 239, 267], ["large", "OBSERVATION_MODIFIER", 36, 41], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["trauma", "OBSERVATION", 48, 54], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["respiratory disease", "OBSERVATION", 95, 114], ["mechanical ventilation", "OBSERVATION", 245, 267]]], ["Around the same time, due to the rapid spread of COVID-19 through New York City, Dr. Jeremy Beitler and a team at New York Presbyterian hospital at Columbia University proposed a thorough and thoughtful set of best practices for vent splitting using the Neyman and Babcock method (https://www.gnyha.org/news/workingprotocol-for-supporting-two-patients-with-a-single-ventilator/) (Beitler 2020 ).", [["vent splitting", "TREATMENT", 229, 243], ["the Neyman", "TREATMENT", 250, 260]]], ["Beitler and colleagues even began to test this approach on COVID-19 patients (https://www.nytimes.com/2020/03/26/health/coronavirus-ventilator-sharing.html), anticipating that it may soon be necessary to save lives.The ProblemHowever, the approach to vent splitting that has been most widely discussed is ill-suited to the specific challenges of the current COVID-19 pandemic.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["COVID", "TEST", 59, 64], ["vent splitting", "TREATMENT", 251, 265], ["the current COVID", "TEST", 346, 363], ["pandemic", "PROBLEM", 367, 375]]], ["In the Neyman/Babcock/Beitler approach, multiple patients are attached in parallel to the same ventilator without any intervening valves.", [["patients", "ORGANISM", 49, 57], ["valves", "PATHOLOGICAL_FORMATION", 130, 136], ["patients", "SPECIES", 49, 57], ["valves", "OBSERVATION", 130, 136]]], ["Therefore, all patients experience the same airway pressures throughout the respiratory cycle, and ventilator settings cannot be changed for one patient without changing the settings for all others.", [["airway", "ANATOMY", 44, 50], ["respiratory", "ANATOMY", 76, 87], ["patients", "ORGANISM", 15, 23], ["airway", "MULTI-TISSUE_STRUCTURE", 44, 50], ["patient", "ORGANISM", 145, 152], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 145, 152], ["the same airway pressures", "TEST", 35, 60], ["ventilator settings", "TREATMENT", 99, 118], ["airway", "ANATOMY", 44, 50], ["pressures", "OBSERVATION_MODIFIER", 51, 60], ["respiratory cycle", "OBSERVATION", 76, 93]]], ["This approach can be widely used during a mass trauma, where many patients will have healthy lung parenchyma with largely similar ventilation requirements and a straightforward clinical course.", [["lung parenchyma", "ANATOMY", 93, 108], ["trauma", "DISEASE", 47, 53], ["patients", "ORGANISM", 66, 74], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 93, 108], ["patients", "SPECIES", 66, 74], ["This approach", "TREATMENT", 0, 13], ["a mass trauma", "PROBLEM", 40, 53], ["healthy lung parenchyma", "PROBLEM", 85, 108], ["largely similar ventilation requirements", "PROBLEM", 114, 154], ["mass", "OBSERVATION", 42, 46], ["lung", "ANATOMY", 93, 97], ["parenchyma", "ANATOMY_MODIFIER", 98, 108], ["similar", "OBSERVATION_MODIFIER", 122, 129], ["ventilation requirements", "OBSERVATION", 130, 154]]], ["COVID-19 patients, on the other hand, can rapidly develop ARDS, and so ventilator requirements can change quickly and in unpredictable ways.", [["ARDS", "DISEASE", 58, 62], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["COVID", "TEST", 0, 5], ["ARDS", "PROBLEM", 58, 62], ["ventilator requirements", "TREATMENT", 71, 94], ["ARDS", "OBSERVATION", 58, 62]]], ["Hence, patients who initially are well matched on a single ventilator may no longer be well matched as the day progresses.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["a single ventilator", "TREATMENT", 50, 69]]], ["If the COVID-19 pandemic becomes as widespread as is now feared, affecting hundreds of thousands of US patients, the increase in ICU ventilator production may not be sufficient to keep up with patient demand.", [["patients", "ORGANISM", 103, 111], ["patient", "ORGANISM", 193, 200], ["patients", "SPECIES", 103, 111], ["patient", "SPECIES", 193, 200], ["the COVID", "TEST", 3, 12], ["pandemic", "PROBLEM", 16, 24], ["ICU ventilator production", "TREATMENT", 129, 154], ["increase", "OBSERVATION_MODIFIER", 117, 125]]], ["This could lead, in turn, to wrenching decisions about which patients should receive ICU ventilator support -heretofore an unthinkable prospect in the modern era.A Potential Solution -Pressure Regulated Ventilator SplittingHere, we propose a circuit design that allows a provider to individualize and independently adjust the inspiratory pressures, tidal volumes, and positive end-expiratory pressures (PEEP) delivered to multiple patients sharing a single ventilator.", [["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 431, 439], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 431, 439], ["ICU ventilator support", "TREATMENT", 85, 107], ["A Potential Solution -Pressure Regulated Ventilator", "TREATMENT", 162, 213], ["a circuit design", "TREATMENT", 240, 256], ["the inspiratory pressures", "TEST", 322, 347], ["tidal volumes", "TEST", 349, 362], ["positive end-expiratory pressures", "TREATMENT", 368, 401], ["PEEP", "TREATMENT", 403, 407], ["a single ventilator", "TREATMENT", 448, 467], ["Ventilator Splitting", "OBSERVATION", 203, 223], ["inspiratory pressures", "OBSERVATION", 326, 347]]], ["The method described in this report, the Pressure-Regulated Ventilator Splitting protocol, or PReVentS protocol, relies upon currently available and cheaply mass-produced parts that require no special expertise for assembly.", [["the Pressure", "TEST", 37, 49], ["Regulated Ventilator Splitting protocol", "TREATMENT", 50, 89], ["PReVentS protocol", "TREATMENT", 94, 111], ["cheaply mass", "PROBLEM", 149, 161], ["mass", "OBSERVATION", 157, 161]]], ["The PReVentS ventilator splitting device, and associated guidelines for use, could allow for patient management using the well-established and familiar principles of pressurecontrolled ventilation.", [["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["The PReVentS ventilator splitting device", "TREATMENT", 0, 40], ["patient management", "TREATMENT", 93, 111], ["pressurecontrolled ventilation", "TREATMENT", 166, 196], ["ventilator splitting", "OBSERVATION", 13, 33]]], ["The PReVentS method could allow for improved care of multiple patients with different disease courses who are forced to share the same ventilator if no better option exists.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["The PReVentS method", "TREATMENT", 0, 19], ["different disease courses", "TREATMENT", 76, 101], ["the same ventilator", "TREATMENT", 126, 145]]], ["This method has been tested thus far only in the laboratory with mock lungs, and has not yet been deployed in animals or in patients.", [["lungs", "ANATOMY", 70, 75], ["lungs", "ORGAN", 70, 75], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["lungs", "ANATOMY", 70, 75]]], ["However, given the novelty and potential utility of this approach, we deemed it appropriate to provide this information to the broader critical care community at the present time.A Potential Solution -Pressure Regulated Ventilator SplittingThe PReVentS protocol has the potential to address all the points brought up by the Multidisciplinary Statement Against Ventilator Splitting, in a statement released on March 26 th 2020 (Supplemental Text S1; https://www.sccm.org/Disaster/Joint-Statement-on-Multiple-Patients-Per-Ventilato).", [["this approach", "TREATMENT", 52, 65], ["A Potential Solution -Pressure Regulated Ventilator", "TREATMENT", 179, 230], ["The PReVentS protocol", "TREATMENT", 240, 261], ["Ventilator Splitting", "OBSERVATION", 220, 240]]], ["To provide a high-level overview of the potential advantages of the PReVentS protocol, we list the specific concerns in the Multidisciplinary Statement with current ventilator splitting approaches, and for each concern we summarize how the PReVentS protocol may ameliorate the problem:A Potential Solution -Pressure Regulated Ventilator Splitting1.", [["the PReVentS protocol", "TREATMENT", 64, 85], ["current ventilator splitting approaches", "TREATMENT", 157, 196], ["the PReVentS protocol", "TREATMENT", 236, 257], ["A Potential Solution -Pressure Regulated Ventilator Splitting1", "TREATMENT", 285, 347], ["Ventilator Splitting1", "OBSERVATION", 326, 347]]], ["\"Volumes would go to the most compliant lung segments\" -In the PReVentS protocol, inspiratory pressures are individualized to the compliance of each patient, and can be adjusted over time.", [["lung", "ANATOMY", 40, 44], ["lung", "ORGAN", 40, 44], ["patient", "ORGANISM", 149, 156], ["patient", "SPECIES", 149, 156], ["inspiratory pressures", "TEST", 82, 103], ["lung", "ANATOMY", 40, 44], ["segments", "ANATOMY_MODIFIER", 45, 53], ["inspiratory pressures", "OBSERVATION", 82, 103]]], ["\"Positive end-expiratory pressure, which is of critical importance in these patients, would be impossible to manage\" -Positive end-expiratory pressure is individualized to each patient, and can be adjusted over time.\"Monitoring patients and measuring pulmonary mechanics would be challenging, if notimpossible\"-Measuring pulmonary mechanics can be done with a combination of individualized manometry (through either analog manometers or BP transducers) and volume measurement at the ventilator through temporary occlusion of flow to one patient.", [["pulmonary", "ANATOMY", 251, 260], ["pulmonary", "ANATOMY", 321, 330], ["patients", "ORGANISM", 76, 84], ["patient", "ORGANISM", 177, 184], ["patients", "ORGANISM", 228, 236], ["pulmonary", "ORGAN", 251, 260], ["pulmonary", "ORGAN", 321, 330], ["patient", "ORGANISM", 537, 544], ["patients", "SPECIES", 76, 84], ["patient", "SPECIES", 177, 184], ["patients", "SPECIES", 228, 236], ["patient", "SPECIES", 537, 544], ["individualized manometry", "TEST", 375, 399], ["analog manometers", "TREATMENT", 416, 433], ["BP transducers", "TREATMENT", 437, 451], ["volume measurement", "TEST", 457, 475], ["the ventilator", "TREATMENT", 479, 493], ["temporary occlusion of flow", "TREATMENT", 502, 529], ["expiratory pressure", "OBSERVATION", 14, 33], ["pulmonary", "ANATOMY", 251, 260], ["pulmonary", "ANATOMY", 321, 330], ["temporary", "OBSERVATION_MODIFIER", 502, 511], ["occlusion", "OBSERVATION", 512, 521], ["flow", "OBSERVATION", 525, 529]]], ["Tidal volume alarms on the shared ventilator can be set to detect most types of clinical events, More detail on the means by which PReVentS may minimize problems with previous ventilator splitting designs are included in the rest of this document.", [["Tidal volume alarms", "TEST", 0, 19], ["the shared ventilator", "TREATMENT", 23, 44], ["clinical events", "PROBLEM", 80, 95], ["previous ventilator splitting designs", "TREATMENT", 167, 204]]], ["While the PReVentS approach is not without risks, cannot be safely applied to all patients requiring mechanical ventilation, and should not be applied if better alternatives exist, it could be a valuable addition to the armamentarium of approaches will be needed to minimize mortality if a global pandemic like COVID-19 overwhelms the existing supply of ventilators.The PReVentS Ventilator Splitting Circuit -Outline of ApproachHere, we propose a circuit design that allows a health care provider to individualize and independently adjust the inspiratory pressures, PEEPs and tidal volumes delivered to multiple patients who are sharing a single ventilator.", [["COVID-19", "CHEMICAL", 311, 319], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 612, 620], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 612, 620], ["mechanical ventilation", "TREATMENT", 101, 123], ["a global pandemic like COVID", "PROBLEM", 288, 316], ["ventilators", "TREATMENT", 354, 365], ["The PReVentS Ventilator Splitting Circuit", "TREATMENT", 366, 407], ["a circuit design", "TREATMENT", 445, 461], ["the inspiratory pressures", "TEST", 539, 564], ["PEEPs", "TREATMENT", 566, 571], ["tidal volumes", "TREATMENT", 576, 589], ["a single ventilator", "TREATMENT", 637, 656], ["not without", "UNCERTAINTY", 31, 42], ["Ventilator Splitting", "OBSERVATION", 379, 399], ["inspiratory pressures", "OBSERVATION", 543, 564]]], ["This method relies upon currently available and mass-produced parts, that require no special expertise for assembly.", [["mass", "PROBLEM", 48, 52], ["mass", "OBSERVATION", 48, 52]]], ["The PReVentS ventilator splitting circuit allows for patient management using the well-established and familiar principles of pressure-controlled ventilation.", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["The PReVentS ventilator splitting circuit", "TREATMENT", 0, 41], ["patient management", "TREATMENT", 53, 71], ["pressure-controlled ventilation", "TREATMENT", 126, 157], ["ventilator splitting", "OBSERVATION", 13, 33]]], ["The PReVentS method could allow for improved care of multiple patients having different disease courses, who are forced to share the same ventilator if no better option exists.The PReVentS Ventilator Splitting Circuit -Outline of ApproachIn cases of severe lung injury, patients often present with diffuse alveolar injury and high FIO2 requirements.", [["lung", "ANATOMY", 257, 261], ["alveolar", "ANATOMY", 306, 314], ["lung injury", "DISEASE", 257, 268], ["alveolar injury", "DISEASE", 306, 321], ["PReVentS", "CHEMICAL", 180, 188], ["patients", "ORGANISM", 62, 70], ["lung", "ORGAN", 257, 261], ["patients", "ORGANISM", 270, 278], ["alveolar", "MULTI-TISSUE_STRUCTURE", 306, 314], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 270, 278], ["The PReVentS method", "TREATMENT", 0, 19], ["the same ventilator", "TREATMENT", 129, 148], ["The PReVentS Ventilator Splitting Circuit", "TREATMENT", 176, 217], ["severe lung injury", "PROBLEM", 250, 268], ["diffuse alveolar injury", "PROBLEM", 298, 321], ["high FIO2 requirements", "PROBLEM", 326, 348], ["Ventilator Splitting", "OBSERVATION", 189, 209], ["severe", "OBSERVATION_MODIFIER", 250, 256], ["lung", "ANATOMY", 257, 261], ["injury", "OBSERVATION", 262, 268], ["diffuse", "OBSERVATION_MODIFIER", 298, 305], ["alveolar", "ANATOMY_MODIFIER", 306, 314], ["injury", "OBSERVATION", 315, 321], ["high", "OBSERVATION_MODIFIER", 326, 330], ["FIO2 requirements", "OBSERVATION", 331, 348]]], ["These patients are often ventilated using pressure-regulated ventilation modes, to minimize barotrauma and concomitant exacerbation of lung injury.", [["lung", "ANATOMY", 135, 139], ["barotrauma", "DISEASE", 92, 102], ["lung injury", "DISEASE", 135, 146], ["patients", "ORGANISM", 6, 14], ["lung", "ORGAN", 135, 139], ["patients", "SPECIES", 6, 14], ["pressure-regulated ventilation modes", "TREATMENT", 42, 78], ["barotrauma", "PROBLEM", 92, 102], ["concomitant exacerbation", "PROBLEM", 107, 131], ["lung injury", "PROBLEM", 135, 146], ["barotrauma", "OBSERVATION", 92, 102], ["concomitant", "OBSERVATION_MODIFIER", 107, 118], ["exacerbation", "OBSERVATION", 119, 131], ["lung", "ANATOMY", 135, 139], ["injury", "OBSERVATION", 140, 146]]], ["In such clinical scenarios, patients typically require high levels of PEEP (> 10 cmH2O), moderate to high FIO2, and high inspiratory pressures (> 20 cmH2O).", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["PEEP", "TREATMENT", 70, 74], ["high FIO2", "TREATMENT", 101, 110], ["high inspiratory pressures", "TEST", 116, 142], ["moderate", "OBSERVATION_MODIFIER", 89, 97], ["inspiratory pressures", "OBSERVATION", 121, 142]]], ["In the most severe cases, patients are heavily sedated and/or paralyzed, with minimal to no spontaneous ventilatory effort, and with all breaths being delivered by controlled ventilation.The PReVentS Ventilator Splitting Circuit -Outline of ApproachThe PReVentS protocol is designed for the care of such patients, as a last resort when suitable numbers of contemporary ICU ventilators are not available to ventilate each patient individually.", [["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 304, 312], ["patient", "ORGANISM", 421, 428], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 304, 312], ["patient", "SPECIES", 421, 428], ["heavily sedated", "TREATMENT", 39, 54], ["paralyzed", "TREATMENT", 62, 71], ["The PReVentS Ventilator Splitting Circuit", "TREATMENT", 187, 228], ["The PReVentS protocol", "TREATMENT", 249, 270], ["contemporary ICU ventilators", "TREATMENT", 356, 384], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["ventilatory effort", "OBSERVATION", 104, 122], ["Ventilator", "OBSERVATION", 200, 210], ["Splitting Circuit", "OBSERVATION", 211, 228]]], ["The system described herein is novel in its level of individualized control of both Peak Inspiratory Pressure (PIP) and Positive End-Expiratory Pressure (PEEP), allowing for adaptation to differences in lung compliance and body habitus.", [["lung", "ANATOMY", 203, 207], ["body", "ANATOMY", 223, 227], ["lung", "ORGAN", 203, 207], ["body", "ORGANISM_SUBDIVISION", 223, 227], ["both Peak Inspiratory Pressure", "TEST", 79, 109], ["PIP", "TEST", 111, 114], ["Expiratory Pressure", "TEST", 133, 152], ["PEEP", "TREATMENT", 154, 158], ["Inspiratory Pressure", "OBSERVATION", 89, 109], ["Expiratory Pressure", "OBSERVATION", 133, 152], ["lung", "ANATOMY", 203, 207], ["compliance", "OBSERVATION", 208, 218]]], ["Importantly, the system allows for adjustment of PIP and PEEP as support requirements change over time, although respiratory rates will remain the same for each patient.", [["PIP", "GENE_OR_GENE_PRODUCT", 49, 52], ["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["adjustment of PIP", "TREATMENT", 35, 52], ["PEEP", "TREATMENT", 57, 61], ["respiratory rates", "TEST", 113, 130]]], ["For this setup, is it assumed that patients are sedated and paralyzed to a degree such that they do not trigger breaths delivered from the ventilator.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["sedated", "TREATMENT", 48, 55], ["paralyzed", "TREATMENT", 60, 69], ["the ventilator", "TREATMENT", 135, 149]]], ["Ventilation triggers can also be set sufficiently high to prevent inadvertent triggering of breaths.The PReVentS Ventilator Splitting Circuit -Outline of ApproachOur proposed approach is not without risks, and cannot be safely applied to all patients requiring mechanical ventilation -for example, those patients requiring volume-controlled ventilation are not suitable for the PReVentS approach.", [["patients", "ORGANISM", 242, 250], ["patients", "ORGANISM", 304, 312], ["patients", "SPECIES", 242, 250], ["patients", "SPECIES", 304, 312], ["Ventilation triggers", "TREATMENT", 0, 20], ["inadvertent triggering of breaths", "PROBLEM", 66, 99], ["The PReVentS Ventilator Splitting Circuit", "TREATMENT", 100, 141], ["ApproachOur proposed approach", "TREATMENT", 154, 183], ["mechanical ventilation", "TREATMENT", 261, 283], ["volume-controlled ventilation", "TREATMENT", 323, 352], ["the PReVentS approach", "TREATMENT", 374, 395], ["Ventilator Splitting", "OBSERVATION", 113, 133], ["not without", "UNCERTAINTY", 187, 198]]], ["Furthermore, ventilator splitting, in general, should not be applied if better alternatives exist.", [["ventilator splitting", "TREATMENT", 13, 33], ["ventilator splitting", "OBSERVATION", 13, 33]]], ["However, we believe that the PReVentS ventilator splitting circuit could provide a valuable addition to the tools needed to minimize mortality if a global pandemic like COVID-19 overwhelms the existing supply of .", [["COVID-19", "CHEMICAL", 169, 177], ["the PReVentS ventilator splitting circuit", "TREATMENT", 25, 66], ["a global pandemic like COVID", "PROBLEM", 146, 174]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The PReVentS Ventilator Splitting Circuit -Outline of Approachis the (which was not peer-reviewed) The copyright holder for this preprint .The PReVentS Ventilator Splitting Circuit -Outline of Approachventilators.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The PReVentS Ventilator Splitting Circuit", "TREATMENT", 154, 195], ["The copyright holder", "TREATMENT", 253, 273], ["this preprint", "TREATMENT", 278, 291], ["The PReVentS Ventilator Splitting Circuit", "TREATMENT", 293, 334], ["Approachventilators", "TREATMENT", 347, 366], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101], ["Ventilator", "OBSERVATION", 167, 177], ["Splitting Circuit", "OBSERVATION", 178, 195], ["Ventilator", "OBSERVATION", 306, 316], ["Splitting Circuit", "OBSERVATION", 317, 334]]], ["This method has been tested thus far only in the laboratory, and has not yet been deployed in animals or in patients.The PReVentS Ventilator Splitting Circuit -Outline of ApproachAs of April 2nd, 2020, the PReVentS protocol has been tested extensively in the laboratory using mock lungs (Figure 1 ).", [["lungs", "ANATOMY", 281, 286], ["patients", "ORGANISM", 108, 116], ["lungs", "ORGAN", 281, 286], ["patients", "SPECIES", 108, 116], ["Ventilator Splitting Circuit", "TREATMENT", 130, 158], ["the PReVentS protocol", "TREATMENT", 202, 223], ["Ventilator Splitting", "OBSERVATION", 130, 150], ["lungs", "ANATOMY", 281, 286]]], ["More extensive testing is planned in coming days, including extended application in large animals and brief clinical trials in patients.", [["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["More extensive testing", "TEST", 0, 22]]], ["This description is based upon experimental testing under laboratory conditions only.Capabilities of the PReVentS Protocol:-Two (or more) patients may be ventilated using a single contemporary ICU ventilator, or using a single contemporary operating room anesthesia machine -PIP and PEEP are individualized for each patient -PIP and PEEP can be adjusted for each patient over time, as lung compliance changes -Valves minimize cross-patient ventilation, even in extreme circumstances such as chest compressions -Compatible with bacterial and viral filters to minimize infectious cross-contamination -Compatible with individualized real-time patient spirometry and airway manometry -Made entirely from off-the-shelf components, no 3D printed or specialty parts neededFunctional Aspects and Limitations of the PReVentS Protocol:-Pressure-control ventilation mode is optimal and assumed for this design -Pressure readouts on the ventilator screen reflect unmodified pressures delivered by the ventilator, and are not representative of what each patient is seeing -PIP and PEEP for each patient are obtained by adding/subtracting each patient's valve settings from displayed ventilator settings -see below -Tidal volume readout on the ventilator is total tidal volume for both patients -Additional monitors may be deployed in-line for each patient, to measure tidal volumes and airway pressures individually and in real time -FIO2 and respiratory rate are the same for both patients -Tidal volumes will differ for each patient, depending on PIP, PEEP and lung compliance -A short circuit from the ventilator outflow to ventilator inflow is necessary to avoid triggering of circuit occlusion alarm and to allow ventilator bias flow -Because of changes to the expected circuit, ventilator alarms will not always work as expected, and an alternate alarm strategy must be employed (see discussion below)Conceptual Basis of the PreVentS ProtocolThis protocol uses an ICU ventilator in pressure-controlled mode to create fixed inspiratory and expiratory pressures across parallel patient circuits, and relies upon adjustable valves within each patient circuit to independently modify these driving pressures.", [["lung", "ANATOMY", 385, 389], ["chest", "ANATOMY", 491, 496], ["airway", "ANATOMY", 663, 669], ["airway", "ANATOMY", 1373, 1379], ["lung", "ANATOMY", 1550, 1554], ["patients", "ORGANISM", 138, 146], ["patient", "ORGANISM", 316, 323], ["patient", "ORGANISM", 363, 370], ["lung", "ORGAN", 385, 389], ["patient", "ORGANISM", 640, 647], ["airway", "MULTI-TISSUE_STRUCTURE", 663, 669], ["patient", "ORGANISM", 1041, 1048], ["patient", "ORGANISM", 1082, 1089], ["patient", "ORGANISM", 1130, 1137], ["valve", "MULTI-TISSUE_STRUCTURE", 1140, 1145], ["patients", "ORGANISM", 1272, 1280], ["patient", "ORGANISM", 1335, 1342], ["airway", "MULTI-TISSUE_STRUCTURE", 1373, 1379], ["patients", "ORGANISM", 1469, 1477], ["patient", "ORGANISM", 1514, 1521], ["lung", "ORGAN", 1550, 1554], ["patient", "ORGANISM", 2069, 2076], ["patient", "ORGANISM", 2133, 2140], ["patients", "SPECIES", 138, 146], ["patient", "SPECIES", 316, 323], ["patient", "SPECIES", 363, 370], ["patient", "SPECIES", 640, 647], ["patient", "SPECIES", 1041, 1048], ["patient", "SPECIES", 1082, 1089], ["patient", "SPECIES", 1130, 1137], ["patients", "SPECIES", 1272, 1280], ["patient", "SPECIES", 1335, 1342], ["patients", "SPECIES", 1469, 1477], ["patient", "SPECIES", 1514, 1521], ["patient", "SPECIES", 2069, 2076], ["patient", "SPECIES", 2133, 2140], ["experimental testing", "TEST", 31, 51], ["a single contemporary ICU ventilator", "TREATMENT", 171, 207], ["PIP", "TREATMENT", 275, 278], ["PEEP", "TREATMENT", 283, 287], ["PIP", "TREATMENT", 325, 328], ["PEEP", "TREATMENT", 333, 337], ["lung compliance changes", "TREATMENT", 385, 408], ["Valves minimize cross-patient ventilation", "TREATMENT", 410, 451], ["chest compressions", "TEST", 491, 509], ["bacterial and viral filters", "TREATMENT", 527, 554], ["infectious cross-contamination", "PROBLEM", 567, 597], ["patient spirometry", "TEST", 640, 658], ["airway manometry", "TEST", 663, 679], ["the PReVentS Protocol", "TREATMENT", 803, 824], ["Pressure-control ventilation mode", "TREATMENT", 826, 859], ["Pressure readouts", "TEST", 900, 917], ["the ventilator screen", "TEST", 921, 942], ["unmodified pressures", "TREATMENT", 951, 971], ["the ventilator", "TREATMENT", 985, 999], ["PIP", "TREATMENT", 1060, 1063], ["PEEP", "TREATMENT", 1068, 1072], ["patient's valve settings", "TREATMENT", 1130, 1154], ["ventilator settings", "TREATMENT", 1170, 1189], ["Tidal volume", "TEST", 1202, 1214], ["the ventilator", "TREATMENT", 1226, 1240], ["total tidal volume", "TREATMENT", 1244, 1262], ["tidal volumes", "TEST", 1355, 1368], ["airway pressures", "TEST", 1373, 1389], ["FIO2", "TREATMENT", 1421, 1425], ["respiratory rate", "TEST", 1430, 1446], ["Tidal volumes", "TEST", 1479, 1492], ["PIP", "TEST", 1536, 1539], ["PEEP", "TREATMENT", 1541, 1545], ["lung compliance", "TREATMENT", 1550, 1565], ["A short circuit", "TREATMENT", 1567, 1582], ["the ventilator outflow", "TREATMENT", 1588, 1610], ["ventilator inflow", "TREATMENT", 1614, 1631], ["circuit occlusion alarm", "TREATMENT", 1668, 1691], ["ventilator bias flow", "TEST", 1705, 1725], ["the expected circuit", "TREATMENT", 1749, 1769], ["ventilator alarms", "TREATMENT", 1771, 1788], ["an alternate alarm strategy", "TREATMENT", 1827, 1854], ["the PreVentS Protocol", "TREATMENT", 1914, 1935], ["This protocol", "TREATMENT", 1935, 1948], ["an ICU ventilator", "TREATMENT", 1954, 1971], ["pressure-controlled mode", "TREATMENT", 1975, 1999], ["fixed inspiratory and expiratory pressures across parallel patient circuits", "TREATMENT", 2010, 2085], ["adjustable valves", "TREATMENT", 2103, 2120], ["these driving pressures", "TEST", 2173, 2196], ["lung", "ANATOMY", 385, 389], ["compliance", "OBSERVATION", 390, 400], ["Valves", "OBSERVATION", 410, 416], ["chest", "ANATOMY", 491, 496], ["viral filters", "OBSERVATION", 541, 554], ["airway", "ANATOMY", 663, 669], ["pressures", "OBSERVATION_MODIFIER", 962, 971], ["airway", "ANATOMY", 1373, 1379], ["pressures", "OBSERVATION_MODIFIER", 1380, 1389], ["lung", "ANATOMY", 1550, 1554], ["expiratory pressures", "OBSERVATION", 2032, 2052], ["adjustable valves", "OBSERVATION", 2103, 2120]]], ["This is done using the PEEP valves that are ubiquitous in critical care settings -unidirectional valves that remain open as long as the pressure differential across them exceeds a certain, adjustable threshold.", [["valves", "MULTI-TISSUE_STRUCTURE", 97, 103], ["the PEEP valves", "TREATMENT", 19, 34], ["unidirectional valves", "TREATMENT", 82, 103], ["the pressure differential", "TEST", 132, 157], ["PEEP valves", "OBSERVATION", 23, 34], ["valves", "OBSERVATION", 97, 103]]], ["Because our method uses these valves to adjust inspiratory pressures as well as PEEP, we will hereafter refer to them as pressure-gated valves to minimize confusion.Conceptual Basis of the PreVentS Protocol.", [["confusion", "DISEASE", 155, 164], ["these valves", "TREATMENT", 24, 36], ["inspiratory pressures", "TREATMENT", 47, 68], ["PEEP", "TREATMENT", 80, 84], ["pressure-gated valves", "TREATMENT", 121, 142], ["confusion", "PROBLEM", 155, 164], ["the PreVentS Protocol", "TREATMENT", 185, 206], ["valves", "OBSERVATION", 30, 36], ["valves", "ANATOMY", 136, 142]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Conceptual Basis of the PreVentS Protocolis the (which was not peer-reviewed) The copyright holder for this preprint .Conceptual Basis of the PreVentS ProtocolUnder certain situations, these pressure-gated valves can establish a reliable and adjustable pressure drop from upstream to downstream.", [["CC", "CHEMICAL", 0, 2], ["valves", "MULTI-TISSUE_STRUCTURE", 360, 366], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 232, 252], ["this preprint", "TREATMENT", 257, 270], ["these pressure-gated valves", "TREATMENT", 339, 366], ["adjustable pressure drop", "PROBLEM", 396, 420], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101], ["valves", "OBSERVATION", 360, 366], ["pressure drop", "OBSERVATION", 407, 420]]], ["If upstream pressure is held fixed, and the pressure differential between upstream and downstream exceeds the valve's threshold, flow will move through the valve and raise the downstream pressure until the pressure differential no longer exceeds the set threshold.", [["valve", "ANATOMY", 110, 115], ["valve", "ANATOMY", 156, 161], ["valve", "PATHOLOGICAL_FORMATION", 156, 161], ["upstream and downstream", "DNA", 74, 97], ["upstream pressure", "TEST", 3, 20], ["the pressure differential", "TEST", 40, 65], ["the valve's threshold", "TREATMENT", 106, 127], ["the valve", "TREATMENT", 152, 161], ["the downstream pressure", "TEST", 172, 195], ["the pressure differential", "TEST", 202, 227], ["pressure", "OBSERVATION_MODIFIER", 12, 20], ["valve", "ANATOMY", 110, 115], ["valve", "ANATOMY", 156, 161], ["downstream pressure", "OBSERVATION", 176, 195]]], ["At this point the valve will close, and the pressure downstream will be less than the fixed pressure upstream by exactly the threshold pressure of the valve.", [["valve", "ANATOMY", 18, 23], ["valve", "ANATOMY", 151, 156], ["valve", "PATHOLOGICAL_FORMATION", 18, 23], ["valve", "PATHOLOGICAL_FORMATION", 151, 156], ["the valve", "TREATMENT", 14, 23], ["the pressure downstream", "TEST", 40, 63], ["the fixed pressure upstream", "TREATMENT", 82, 109], ["valve", "OBSERVATION", 18, 23], ["valve", "ANATOMY", 151, 156]]], ["Similarly, if downstream pressure is held fixed, and the pressure differential exceeds the valve's threshold, flow will move from upstream to downstream and decrease the upstream pressure until the pressure differential no longer exceeds the set threshold.", [["valve", "PATHOLOGICAL_FORMATION", 91, 96], ["downstream pressure", "TEST", 14, 33], ["the pressure differential", "TEST", 53, 78], ["the upstream pressure", "TEST", 166, 187], ["the pressure differential", "TEST", 194, 219], ["pressure", "OBSERVATION_MODIFIER", 25, 33], ["valve", "ANATOMY", 91, 96], ["upstream pressure", "OBSERVATION", 170, 187], ["pressure", "OBSERVATION_MODIFIER", 198, 206]]], ["At this point the valve will close, and the upstream pressure will be greater than the fixed downstream pressure by exactly the threshold pressure of the valve.", [["valve", "ANATOMY", 18, 23], ["valve", "ANATOMY", 154, 159], ["valve", "PATHOLOGICAL_FORMATION", 18, 23], ["valve", "PATHOLOGICAL_FORMATION", 154, 159], ["the valve", "TREATMENT", 14, 23], ["the upstream pressure", "TEST", 40, 61], ["valve", "ANATOMY", 18, 23], ["greater", "OBSERVATION_MODIFIER", 70, 77], ["downstream pressure", "OBSERVATION", 93, 112], ["valve", "ANATOMY", 154, 159]]], ["It is by this principle that we have designed the PReVentS system to modulate airway pressures for each patient, by modulating pressure-gated valve settings in the inspiratory and expiratory limbs of the circuit.Conceptual Basis of the PreVentS ProtocolDepictions of how the pressure-gated valves are assembled into the PReVentS circuit are displayed below (Figures 1, 2) , followed by instructions for circuit assembly and use.Conceptual Basis of the PreVentS Protocol.", [["airway", "ANATOMY", 78, 84], ["valve", "ANATOMY", 142, 147], ["limbs", "ANATOMY", 191, 196], ["airway", "MULTI-TISSUE_STRUCTURE", 78, 84], ["patient", "ORGANISM", 104, 111], ["valve", "MULTI-TISSUE_STRUCTURE", 142, 147], ["limbs", "ORGANISM_SUBDIVISION", 191, 196], ["valves", "MULTI-TISSUE_STRUCTURE", 290, 296], ["PReVentS circuit", "DNA", 320, 336], ["patient", "SPECIES", 104, 111], ["the PReVentS system", "TREATMENT", 46, 65], ["airway pressures", "TREATMENT", 78, 94], ["modulating pressure-gated valve settings", "TREATMENT", 116, 156], ["the pressure-gated valves", "TREATMENT", 271, 296], ["the PreVentS Protocol", "TREATMENT", 448, 469], ["valve", "ANATOMY", 142, 147], ["inspiratory", "ANATOMY", 164, 175], ["expiratory limbs", "ANATOMY", 180, 196], ["valves", "ANATOMY", 290, 296]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Conceptual Basis of the PreVentS Protocolis the (which was not peer-reviewed) The copyright holder for this preprint . pressure-gated inline valves, derived from PEEP valves for bag-valve-mask assemblies, are in the two-patient circuit.", [["CC", "CHEMICAL", 0, 2], ["valves", "MULTI-TISSUE_STRUCTURE", 295, 301], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 232, 252], ["this preprint", "TREATMENT", 257, 270], ["pressure-gated inline valves", "TREATMENT", 273, 301], ["PEEP valves", "TREATMENT", 316, 327], ["bag", "TREATMENT", 332, 335], ["valve-mask assemblies", "TREATMENT", 336, 357], ["the two-patient circuit", "TREATMENT", 366, 389], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101], ["inline valves", "OBSERVATION", 288, 301], ["PEEP valves", "OBSERVATION", 316, 327], ["valve", "ANATOMY", 336, 341]]], ["Two inspiratory valves control PIP to the two patients.", [["PIP", "GENE_OR_GENE_PRODUCT", 31, 34], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["Two inspiratory valves control PIP", "TREATMENT", 0, 34], ["inspiratory valves", "OBSERVATION", 4, 22]]], ["Two expiratory valves control PEEP to the two patients.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["Two expiratory valves", "TREATMENT", 0, 21], ["PEEP", "TREATMENT", 30, 34], ["expiratory valves", "OBSERVATION", 4, 21]]], ["A \"Bias Flow\" circuit provides a bypass flow path parallel to the two patient paths to prevent automated ventilator alarming due to high circuit resistance, an artifact which is intrinsic to the placing of in-line pressuregated valves.", [["patient", "ORGANISM", 70, 77], ["valves", "TISSUE", 228, 234], ["patient", "SPECIES", 70, 77], ["A \"Bias Flow\" circuit", "TREATMENT", 0, 21], ["a bypass flow path", "TREATMENT", 31, 49], ["automated ventilator", "TREATMENT", 95, 115], ["high circuit resistance", "PROBLEM", 132, 155], ["an artifact", "PROBLEM", 157, 168], ["in-line pressuregated valves", "TREATMENT", 206, 234], ["high circuit resistance", "OBSERVATION", 132, 155], ["artifact", "OBSERVATION", 160, 168], ["pressuregated valves", "OBSERVATION", 214, 234]]], ["It should be noted that this bypass circumvents a set of alarms which clinicians may be used to relying on during patient care (see below). .", [["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121], ["this bypass", "TREATMENT", 24, 35], ["a set of alarms", "TREATMENT", 48, 63], ["bypass", "OBSERVATION", 29, 35]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Components (seeis the (which was not peer-reviewed) The copyright holder for this preprint .Components (seea.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 206, 226], ["this preprint", "TREATMENT", 231, 244], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["4 disposable PEEP valves, pressure range 1.5 -20 cmH2O (eg.", [["disposable PEEP valves", "TREATMENT", 2, 24], ["pressure range", "TEST", 26, 40], ["PEEP valves", "OBSERVATION", 13, 24], ["pressure", "OBSERVATION_MODIFIER", 26, 34]]], ["3/4\" inner diameter tubing, Tygon\u00ae or other brand c.", [["inner", "TISSUE", 5, 10], ["inner diameter tubing", "TREATMENT", 5, 26], ["inner", "OBSERVATION_MODIFIER", 5, 10], ["diameter", "OBSERVATION_MODIFIER", 11, 19], ["tubing", "OBSERVATION", 20, 26]]], ["1\" inner diameter tubing, Tygon\u00ae or other brand d.", [["inner diameter tubing", "TREATMENT", 3, 24], ["inner", "OBSERVATION_MODIFIER", 3, 8], ["diameter", "OBSERVATION_MODIFIER", 9, 17], ["tubing", "OBSERVATION", 18, 24]]], ["1-5/8\" inner diameter flexible tubing, or 1-3/4\" inner diameter Tygon\u00ae tubing e.", [["inner", "TISSUE", 7, 12], ["5/8\" inner diameter flexible tubing", "TREATMENT", 2, 37], ["3/4\" inner diameter Tygon\u00ae tubing", "TREATMENT", 44, 77], ["inner diameter", "OBSERVATION_MODIFIER", 7, 21], ["flexible tubing", "OBSERVATION", 22, 37], ["diameter", "OBSERVATION_MODIFIER", 55, 63], ["Tygon\u00ae tubing", "OBSERVATION", 64, 77]]], ["1-1/2\" by 1\" tubing reducerInstructions for AssemblyMost marketed individual PEEP valves are designed to vent to the outside air, and are not designed to function in-line in the ventilator circuit.", [["tubing reducerInstructions", "TREATMENT", 13, 39], ["PEEP valves", "TREATMENT", 77, 88], ["vent", "TREATMENT", 105, 109], ["the ventilator circuit", "TREATMENT", 174, 196], ["PEEP valves", "OBSERVATION", 77, 88], ["ventilator circuit", "OBSERVATION", 178, 196]]], ["Certain in-line PEEP valves do exist on the market, and may be substituted for the design shown here (eg. the BE 142 Magnetic PEEP valve, Instrumentation Industries Inc.).", [["Certain in-line PEEP valves", "TREATMENT", 0, 27], ["Magnetic PEEP valve", "TREATMENT", 117, 136], ["Instrumentation Industries", "TREATMENT", 138, 164], ["-line", "OBSERVATION_MODIFIER", 10, 15], ["PEEP valves", "OBSERVATION", 16, 27]]], ["If in-line PEEP valves are not readily available, then existing PEEP valves may be modified to function in-line for this design.", [["-line PEEP valves", "TREATMENT", 5, 22], ["PEEP valves", "TREATMENT", 64, 75], ["PEEP valves", "OBSERVATION", 11, 22], ["PEEP valves", "OBSERVATION", 64, 75]]], ["Of note, the key to this overall ventilator splitting design is to provide 4 in-line PEEP valves to modulate inspiratory and expiratory pressure for the two patients.", [["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["4 in-line PEEP valves", "TREATMENT", 75, 96], ["expiratory pressure", "TEST", 125, 144], ["PEEP valves", "OBSERVATION", 85, 96], ["expiratory pressure", "OBSERVATION", 125, 144]]], ["The specific type of PEEP valve is not as critical as its functionality.I.Step 1: Assembling the In-Line Pressure-Gated Valve:I..", [["PEEP valve", "TREATMENT", 21, 31], ["PEEP valve", "OBSERVATION", 21, 31], ["Valve", "ANATOMY", 120, 125]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.I.is the (which was not peer-reviewed) The copyright holder for this preprint .I.a.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 193, 213], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["Use a disposable PEEP valve (eg.", [["a disposable PEEP valve", "TREATMENT", 4, 27], ["PEEP valve", "OBSERVATION", 17, 27]]], ["Disposable PEEP valve from Ambu Inc.), that has adjustable PEEP from 1.5 -20 cmH2O, with a 30mm connector.", [["Disposable PEEP valve", "TREATMENT", 0, 21], ["adjustable PEEP", "TREATMENT", 48, 63], ["a 30mm connector", "TREATMENT", 89, 105], ["PEEP valve", "OBSERVATION", 11, 21]]], ["These valves are typically attached to the outflow of a bag valve mask assembly to apply PEEP to patients undergoing mask ventilation ( Figure 3 ). b.", [["valves", "MULTI-TISSUE_STRUCTURE", 6, 12], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["These valves", "TREATMENT", 0, 12], ["a bag valve mask", "TREATMENT", 54, 70], ["PEEP", "TREATMENT", 89, 93], ["mask ventilation", "TREATMENT", 117, 133], ["valves", "OBSERVATION", 6, 12], ["outflow", "ANATOMY_MODIFIER", 43, 50], ["bag valve", "OBSERVATION", 56, 65]]], ["Cut flexible 1-5/8\" ID tubing to 3-3/4\" length, and attach to 1-1/2\" reducing connector and fasten with ziptie. c.", [["\" ID tubing", "TREATMENT", 18, 29], ["ziptie", "TREATMENT", 104, 110]]], ["Cut 1\" ID tubing to 2-3/4\" length and attach to other end of reducing connector. d.", [["2-3/4\" length", "DNA", 20, 33], ["ID tubing", "TREATMENT", 7, 16], ["reducing connector", "TREATMENT", 61, 79]]], ["Set PEEP valve to desired value, and then insert valved end of PEEP valve into the flexible 1-5/8\" tubing (see Figure 5 for final valve insertion step).", [["valve", "ANATOMY", 130, 135], ["Set PEEP valve", "TREATMENT", 0, 14], ["valved end of PEEP valve", "TREATMENT", 49, 73], ["the flexible 1-5/8\" tubing", "TREATMENT", 79, 105], ["final valve insertion step", "TREATMENT", 124, 150], ["PEEP valve", "OBSERVATION", 4, 14], ["PEEP valve", "OBSERVATION", 63, 73], ["valve", "OBSERVATION", 130, 135]]], ["Fasten with ziptie if desired. e.", [["ziptie", "TREATMENT", 12, 18]]], ["Repeat these steps 3 more times, to produce a total of 4, in-line pressure-gated valves. f.", [["valves", "MULTI-TISSUE_STRUCTURE", 81, 87], ["f.", "SPECIES", 89, 91], ["in-line pressure-gated valves", "TREATMENT", 58, 87], ["valves", "ANATOMY", 81, 87]]], ["Setting of pressure-gated valve values is described below. .", [["valve", "MULTI-TISSUE_STRUCTURE", 26, 31], ["pressure-gated valve values", "TREATMENT", 11, 38], ["valve", "OBSERVATION", 26, 31]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.I.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.03.20052217 doi: medRxiv preprintII.Step 2: Connect T-pieces ( Figure 6 ): a.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 193, 213], ["this preprint", "TREATMENT", 218, 231], ["Connect T-pieces", "TREATMENT", 310, 326], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["Attach T pieces to each other into pairs, using 1 connector cuff to attach each pair. b.", [["1 connector cuff", "TREATMENT", 48, 64]]], ["Attach connector cuffs to ends of T-pieces as shown in Figure 6 . c.", [["Attach connector cuffs", "TREATMENT", 0, 22], ["T-pieces", "TREATMENT", 34, 42], ["connector cuffs", "OBSERVATION", 7, 22]]], ["Repeat to create 2 sets of T-pieces.III.Step 3: Assemble the Inspiratory Limb of the Circuit (Figure 7) : a.", [["T-pieces", "TREATMENT", 27, 35], ["Inspiratory Limb", "ANATOMY", 61, 77]]], ["Choose one of the sets of paired T-pieces to be used for the inspiratory limb. b.", [["inspiratory limb", "ANATOMY", 61, 77], ["limb", "ORGANISM_SUBDIVISION", 73, 77], ["paired T-pieces", "TREATMENT", 26, 41], ["inspiratory limb", "ANATOMY", 61, 77]]], ["Attach an in-line pressure-gated valve, followed by a one-way valve, to each end of the T-assembly.", [["valve", "PATHOLOGICAL_FORMATION", 33, 38], ["valve", "PATHOLOGICAL_FORMATION", 62, 67], ["an in-line pressure-gated valve", "TREATMENT", 7, 38], ["a one-way valve", "TREATMENT", 52, 67], ["valve", "ANATOMY", 33, 38], ["valve", "OBSERVATION", 62, 67]]], ["Flow of valves should be out of the T-piece pair, in both directions. c.", [["Flow of valves", "TREATMENT", 0, 14], ["valves", "OBSERVATION", 8, 14]]], ["TAKE NOTE: At this point it is important for patient safety to add a negative pressure relief valve into the circuit.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["a negative pressure relief valve", "TREATMENT", 67, 99], ["the circuit", "TREATMENT", 105, 116]]], ["To do this, add a T-piece after each of the one-way valves from the previous step, and place another one-way valve onto one open port on each of these T-pieces.", [["a T-piece", "TREATMENT", 16, 25], ["the one-way valves", "TREATMENT", 40, 58], ["valve", "TREATMENT", 109, 114], ["one open port", "TREATMENT", 120, 133], ["valves", "OBSERVATION", 52, 58], ["valve", "OBSERVATION", 109, 114]]], ["Flow of all valves must be inward toward this T-piece. d.", [["Flow of all valves", "TREATMENT", 0, 18], ["this T-piece", "TREATMENT", 41, 53], ["all valves", "OBSERVATION", 8, 18]]], ["At the open port on each of these T-pieces, connect the inspiratory limb of a patient circuit. e.", [["inspiratory limb", "ANATOMY", 56, 72], ["inspiratory limb", "ORGANISM_SUBDIVISION", 56, 72], ["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["the open port", "TREATMENT", 3, 16], ["these T-pieces", "TREATMENT", 28, 42], ["a patient circuit", "TREATMENT", 76, 93], ["open", "OBSERVATION", 7, 11], ["port", "ANATOMY_MODIFIER", 12, 16], ["inspiratory limb", "ANATOMY", 56, 72]]], ["Attach an HME/microbial filter to the end of each patient Y-piece to minimize patient cross-contamination and dissemination of virus into the circuit.III..", [["patient", "ORGANISM", 50, 57], ["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 50, 57], ["patient", "SPECIES", 78, 85], ["an HME/microbial filter", "TREATMENT", 7, 30], ["patient Y-piece", "TREATMENT", 50, 65], ["patient cross-contamination", "PROBLEM", 78, 105], ["dissemination of virus into the circuit", "TREATMENT", 110, 149], ["microbial filter", "OBSERVATION", 14, 30], ["virus", "OBSERVATION", 127, 132]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.III.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.03.20052217 doi: medRxiv preprintIV.Step 4: Assemble the Expiratory Limb of the Circuit (Figure 7) : a.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 195, 215], ["this preprint", "TREATMENT", 220, 233], ["medRxiv", "TREATMENT", 285, 292], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["Utilize the remaining T-piece assembly b.", [["the remaining T-piece assembly", "TREATMENT", 8, 38]]], ["Attach a one-way valve followed by a pressure-gated valve to each side of the assembly (flow of valves should point toward the T-pieces) c.", [["valve", "PATHOLOGICAL_FORMATION", 17, 22], ["a one-way valve", "TREATMENT", 7, 22], ["a pressure-gated valve", "TREATMENT", 35, 57], ["valves", "TREATMENT", 96, 102], ["valve", "OBSERVATION", 17, 22], ["valve", "OBSERVATION", 52, 57], ["valves", "OBSERVATION", 96, 102]]], ["Connect expiratory limb of each set of patient tubing to the free end of each of the pressure-gated valves. d.", [["limb", "ANATOMY", 19, 23], ["limb", "ORGANISM_SUBDIVISION", 19, 23], ["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["patient tubing", "TREATMENT", 39, 53], ["the pressure-gated valves", "TREATMENT", 81, 106], ["expiratory limb", "ANATOMY", 8, 23], ["tubing", "OBSERVATION", 47, 53], ["pressure", "OBSERVATION", 85, 93], ["valves", "ANATOMY", 100, 106]]], ["When available, place in-line flow meters and adapters for pressure transduction between the patient Y-piece and the expiratory limb.V.Step 5: Assemble the Inspiratory to expiratory short-circuit (\"bias flow\"): Use the short length of respiratory tubing (or an additional connector cuff) to connect the inspiratory T-piece pair to the expiratory T-piece pair.", [["expiratory limb", "ANATOMY", 117, 132], ["respiratory", "ANATOMY", 235, 246], ["patient", "ORGANISM", 93, 100], ["limb", "ORGANISM_SUBDIVISION", 128, 132], ["inspiratory T-piece pair", "DNA", 303, 327], ["expiratory T-piece pair", "DNA", 335, 358], ["patient", "SPECIES", 93, 100], ["pressure transduction", "TREATMENT", 59, 80], ["the patient Y-piece and the expiratory limb", "TREATMENT", 89, 132], ["the short length of respiratory tubing", "TREATMENT", 215, 253], ["an additional connector cuff)", "TREATMENT", 258, 287], ["the inspiratory T-piece pair", "TREATMENT", 299, 327], ["expiratory limb", "ANATOMY", 117, 132], ["short length", "OBSERVATION_MODIFIER", 219, 231], ["respiratory tubing", "OBSERVATION", 235, 253]]], ["This is necessary on the ICU ventilators in our hospital, so that bias flow is uninterrupted between the inspiratory and expiratory ports of the ventilator, and the ventilator continues to function.", [["the ICU ventilators", "TREATMENT", 21, 40], ["bias flow", "PROBLEM", 66, 75], ["the ventilator", "TREATMENT", 141, 155], ["the ventilator", "TREATMENT", 161, 175]]], ["A properly-oriented one-way valve can be added to reduce the chance of rebreathing.VI.Step 6 .", [["valve", "MULTI-TISSUE_STRUCTURE", 28, 33], ["A properly-oriented one-way valve", "TREATMENT", 0, 33], ["valve", "OBSERVATION", 28, 33]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.VI.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.03.20052217 doi: medRxiv preprintFunction of the PReVentS Circuit for Tailoring Ventilatory PressuresWhen assembled as described above, the 4 in-line pressure-gated valves combined with 4 inline one-way valves provide a means of tailoring the ventilatory pressures of two patients, independently.", [["CC", "CHEMICAL", 0, 2], ["valves", "MULTI-TISSUE_STRUCTURE", 432, 438], ["valves", "MULTI-TISSUE_STRUCTURE", 470, 476], ["patients", "ORGANISM", 539, 547], ["patients", "SPECIES", 539, 547], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 194, 214], ["this preprint", "TREATMENT", 219, 232], ["the PReVentS Circuit", "TREATMENT", 312, 332], ["Tailoring Ventilatory Pressures", "TREATMENT", 337, 368], ["the 4 in-line pressure-gated valves", "TREATMENT", 403, 438], ["4 inline one-way valves", "TREATMENT", 453, 476], ["tailoring the ventilatory pressures", "TREATMENT", 496, 531], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101], ["valves", "ANATOMY", 432, 438], ["valves", "OBSERVATION", 470, 476], ["ventilatory pressures", "OBSERVATION", 510, 531]]], ["The valve in the inspiratory limb of each patient's circuit provides a step-down in Peak Inspiratory Pressure (PIP) equal to its pressure setting.", [["valve", "ANATOMY", 4, 9], ["inspiratory limb", "ANATOMY", 17, 33], ["valve", "MULTI-TISSUE_STRUCTURE", 4, 9], ["inspiratory limb", "ORGANISM_SUBDIVISION", 17, 33], ["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["The valve", "TREATMENT", 0, 9], ["a step", "TEST", 69, 75], ["Peak Inspiratory Pressure", "TEST", 84, 109], ["valve", "OBSERVATION", 4, 9], ["inspiratory limb", "ANATOMY", 17, 33], ["Inspiratory Pressure", "OBSERVATION", 89, 109], ["pressure", "OBSERVATION_MODIFIER", 129, 137]]], ["So, the effective PIP for a patient is equal to the PIP set on the ventilator minus the pressure-gated valve setting on the inspiratory limb of the circuit supplying that patient (Figure 8) .Function of the PReVentS Circuit for Tailoring Ventilatory PressuresConversely, the pressure-gated valve on the expiratory limb of each patient's circuit provides a step-up in Positive End-Expiratory Pressure.", [["inspiratory limb", "ANATOMY", 124, 140], ["limb", "ANATOMY", 314, 318], ["PIP", "GENE_OR_GENE_PRODUCT", 18, 21], ["patient", "ORGANISM", 28, 35], ["valve", "PATHOLOGICAL_FORMATION", 103, 108], ["inspiratory limb", "ORGANISM_SUBDIVISION", 124, 140], ["patient", "ORGANISM", 171, 178], ["valve", "MULTI-TISSUE_STRUCTURE", 290, 295], ["limb", "ORGANISM_SUBDIVISION", 314, 318], ["patient", "ORGANISM", 327, 334], ["PReVentS Circuit", "PROTEIN", 207, 223], ["patient", "SPECIES", 28, 35], ["patient", "SPECIES", 171, 178], ["patient", "SPECIES", 327, 334], ["the effective PIP", "TREATMENT", 4, 21], ["the ventilator", "TREATMENT", 63, 77], ["the circuit", "TREATMENT", 144, 155], ["the PReVentS Circuit", "TREATMENT", 203, 223], ["Tailoring Ventilatory Pressures", "TREATMENT", 228, 259], ["the pressure-gated valve", "TREATMENT", 271, 295], ["Expiratory Pressure", "TEST", 380, 399], ["valve", "ANATOMY", 103, 108], ["inspiratory limb", "ANATOMY", 124, 140], ["valve", "OBSERVATION", 290, 295], ["expiratory limb", "ANATOMY", 303, 318], ["Expiratory Pressure", "OBSERVATION", 380, 399]]], ["So, the effective Positive End-Expiratory Pressure for a patient is equal to sum of the PEEP setting on the ventilator, and the setting on the pressure-gated valve in the expiratory limb of that patient's circuit.", [["limb", "ANATOMY", 182, 186], ["patient", "ORGANISM", 57, 64], ["valve", "MULTI-TISSUE_STRUCTURE", 158, 163], ["limb", "ORGANISM_SUBDIVISION", 182, 186], ["patient", "ORGANISM", 195, 202], ["patient", "SPECIES", 57, 64], ["patient", "SPECIES", 195, 202], ["Expiratory Pressure", "TEST", 31, 50], ["the ventilator", "TREATMENT", 104, 118], ["the pressure-gated valve", "TREATMENT", 139, 163], ["patient's circuit", "TREATMENT", 195, 212], ["Expiratory Pressure", "OBSERVATION", 31, 50], ["valve", "OBSERVATION", 158, 163], ["expiratory limb", "ANATOMY", 171, 186]]], ["As an example of how the PReVentS ventilator splitting circuit might function for two patients, specific pressures are provided in Figure 9 .", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["ventilator splitting circuit", "TREATMENT", 34, 62], ["specific pressures", "TEST", 96, 114]]], ["In this example, Patient #1 has very poor lung compliance and a high PEEP requirement: to maintain adequate minute ventilation and alveolar recruitment, this patient requires a PIP of 35 cmH2O and a PEEP of 20 cmH2O.", [["lung", "ANATOMY", 42, 46], ["alveolar", "ANATOMY", 131, 139], ["lung", "ORGAN", 42, 46], ["alveolar", "MULTI-TISSUE_STRUCTURE", 131, 139], ["patient", "ORGANISM", 158, 165], ["Patient", "SPECIES", 17, 24], ["patient", "SPECIES", 158, 165], ["very poor lung compliance", "PROBLEM", 32, 57], ["a high PEEP requirement", "TREATMENT", 62, 85], ["a PIP", "TEST", 175, 180], ["a PEEP", "TEST", 197, 203], ["lung", "ANATOMY", 42, 46], ["compliance", "OBSERVATION", 47, 57], ["high PEEP", "OBSERVATION", 64, 73], ["minute ventilation", "OBSERVATION", 108, 126], ["alveolar recruitment", "OBSERVATION", 131, 151]]], ["In contrast, Patient #2 has less-severe lung disease, requiring less ventilatory support overall, and needs a PIP of only 25 cm H2O and a PEEP of 5 cm H2O (Figure 9 ). .", [["lung", "ANATOMY", 40, 44], ["lung disease", "DISEASE", 40, 52], ["H2O", "CHEMICAL", 128, 131], ["H2O", "CHEMICAL", 151, 154], ["H2O", "CHEMICAL", 128, 131], ["H2O", "CHEMICAL", 151, 154], ["lung", "ORGAN", 40, 44], ["Patient", "SPECIES", 13, 20], ["severe lung disease", "PROBLEM", 33, 52], ["less ventilatory support", "TREATMENT", 64, 88], ["a PIP", "TEST", 108, 113], ["a PEEP", "TEST", 136, 142], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["lung", "ANATOMY", 40, 44], ["disease", "OBSERVATION", 45, 52], ["less", "OBSERVATION_MODIFIER", 64, 68], ["ventilatory support", "OBSERVATION", 69, 88]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Function of the PReVentS Circuit for Tailoring Ventilatory Pressuresis the (which was not peer-reviewed) The copyright holder for this preprint .Function of the PReVentS Circuit for Tailoring Ventilatory PressuresTo obtain these target pressures for each patient, the ventilator and PEEP valves would be set up as described below.", [["CC", "CHEMICAL", 0, 2], ["patient", "ORGANISM", 409, 416], ["PReVentS Circuit", "PROTEIN", 315, 331], ["patient", "SPECIES", 409, 416], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["the PReVentS Circuit", "TREATMENT", 166, 186], ["Tailoring Ventilatory Pressuresis", "TREATMENT", 191, 224], ["The copyright holder", "TREATMENT", 259, 279], ["this preprint", "TREATMENT", 284, 297], ["the PReVentS Circuit", "TREATMENT", 311, 331], ["Tailoring Ventilatory Pressures", "TREATMENT", 336, 367], ["these target pressures", "TEST", 377, 399], ["the ventilator", "TREATMENT", 418, 432], ["PEEP valves", "TREATMENT", 437, 448], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101], ["PEEP valves", "OBSERVATION", 437, 448]]], ["The ventilator would be set to pressure-controlled mode, with a ventilator PIP of 40 cmH2O and a ventilator PEEP of 0 cm H2O (Figure 8) .", [["H2O", "CHEMICAL", 121, 124], ["H2O", "CHEMICAL", 121, 124], ["The ventilator", "TREATMENT", 0, 14], ["a ventilator PIP", "TREATMENT", 62, 78], ["a ventilator PEEP", "TREATMENT", 95, 112]]], ["Gas from the ventilator would flow into the inspiratory limb of the circuit, where it would flow across two pressure-gated valves.", [["inspiratory limb", "ANATOMY", 44, 60], ["inspiratory limb", "ORGANISM_SUBDIVISION", 44, 60], ["valves", "PATHOLOGICAL_FORMATION", 123, 129], ["Gas", "TEST", 0, 3], ["the ventilator", "TREATMENT", 9, 23], ["two pressure-gated valves", "TREATMENT", 104, 129], ["inspiratory limb", "ANATOMY", 44, 60], ["valves", "ANATOMY", 123, 129]]], ["For Patient #1, the inspiratory pressure-gated valve would be set at 5 cmH2O, resulting in a pressure drop across the valve of 5 cmH2O -therefore, Patient #1 receives a PIP of 35 cmH2O.", [["valve", "MULTI-TISSUE_STRUCTURE", 47, 52], ["Patient", "SPECIES", 4, 11], ["the inspiratory pressure-gated valve", "TREATMENT", 16, 52], ["a pressure drop", "PROBLEM", 91, 106], ["a PIP", "TREATMENT", 167, 172], ["valve", "OBSERVATION", 47, 52], ["pressure drop", "OBSERVATION", 93, 106], ["valve", "ANATOMY", 118, 123]]], ["In contrast, for Patient #2 the pressure-gated valve would be set at 15 cmH2O, resulting in a drop of 15 cmH2O pressure from the ventilator -therefore, Patient #2 receives a PIP of 25 cmH2O (Figure 9 ).Function of the PReVentS Circuit for Tailoring Ventilatory PressuresThe converse is true on the expiratory limb of the circuit.", [["limb", "ANATOMY", 309, 313], ["valve", "PATHOLOGICAL_FORMATION", 47, 52], ["limb", "ORGANISM_SUBDIVISION", 309, 313], ["PReVentS Circuit", "PROTEIN", 218, 234], ["Patient", "SPECIES", 17, 24], ["the pressure-gated valve", "TREATMENT", 28, 52], ["the ventilator", "TREATMENT", 125, 139], ["a PIP", "TREATMENT", 172, 177], ["the PReVentS Circuit", "TREATMENT", 214, 234], ["Tailoring Ventilatory Pressures", "TREATMENT", 239, 270], ["valve", "ANATOMY", 47, 52], ["cmH2O pressure", "OBSERVATION", 105, 119], ["ventilator", "ANATOMY", 129, 139], ["Ventilatory Pressures", "OBSERVATION", 249, 270]]], ["For Patient #1, the in-line expiratory PEEP valve would provide 15 cmH2O of PEEP.", [["Patient", "SPECIES", 4, 11], ["the in-line expiratory PEEP valve", "TREATMENT", 16, 49], ["PEEP", "TREATMENT", 76, 80], ["PEEP valve", "OBSERVATION", 39, 49], ["15 cmH2O", "OBSERVATION_MODIFIER", 64, 72]]], ["For Patient #2, the in-line expiratory PEEP valve would provide 5 cmH2O of PEEP.", [["Patient", "SPECIES", 4, 11], ["the in-line expiratory PEEP valve", "TREATMENT", 16, 49], ["PEEP", "TREATMENT", 75, 79], ["PEEP valve", "OBSERVATION", 39, 49]]], ["Since the ventilator is set with a PEEP of 0 cmH2O, the total PEEP experienced by each Patient is simply the value set for each in-line expiratory pressure-gated valve.", [["valve", "PATHOLOGICAL_FORMATION", 162, 167], ["the ventilator", "TREATMENT", 6, 20], ["a PEEP", "TREATMENT", 33, 39], ["the total PEEP", "TREATMENT", 52, 66], ["each in-line expiratory pressure", "TREATMENT", 123, 155], ["valve", "ANATOMY", 162, 167]]], ["However, if the PEEP on the ventilator were set at a number higher than zero -say, at 5 cmH2O -then the PEEP experienced by each patient would be the sum of the ventilator set PEEP and the setting of the pressure-gated valve on the expiratory limb of the patient's circuit.", [["limb", "ANATOMY", 243, 247], ["patient", "ORGANISM", 129, 136], ["valve", "MULTI-TISSUE_STRUCTURE", 219, 224], ["limb", "ORGANISM_SUBDIVISION", 243, 247], ["patient", "ORGANISM", 255, 262], ["patient", "SPECIES", 129, 136], ["patient", "SPECIES", 255, 262], ["the PEEP", "TEST", 12, 20], ["the ventilator", "TREATMENT", 24, 38], ["the PEEP", "TREATMENT", 100, 108], ["PEEP", "TREATMENT", 176, 180], ["the pressure-gated valve", "TREATMENT", 200, 224], ["the patient's circuit", "TREATMENT", 251, 272], ["valve", "OBSERVATION", 219, 224], ["expiratory limb", "ANATOMY", 232, 247]]], ["Conversely, on the expiratory limb, the pressure-gated valves provide an effective PEEP of 20 cmH2O for Patient #1, and 5 cmH2O for Patient #2.Function of the PReVentS Circuit for Tailoring Ventilatory Pressures.", [["limb", "ANATOMY", 30, 34], ["limb", "ORGANISM_SUBDIVISION", 30, 34], ["valves", "MULTI-TISSUE_STRUCTURE", 55, 61], ["PReVentS Circuit", "PROTEIN", 159, 175], ["the pressure-gated valves", "TREATMENT", 36, 61], ["an effective PEEP", "TREATMENT", 70, 87], ["the PReVentS Circuit", "TREATMENT", 155, 175], ["Tailoring Ventilatory Pressures", "TREATMENT", 180, 211], ["valves", "ANATOMY", 55, 61], ["Ventilatory Pressures", "OBSERVATION", 190, 211]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Function of the PReVentS Circuit for Tailoring Ventilatory Pressuresis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.03.20052217 doi: medRxiv preprintLaboratory Studies of the PReVentS Circuit:To document proof-of-principle for the PReVentS circuit, and to test its ability to separately control ventilatory pressures for two patients, we assembled the circuit attached to a standard ICU ventilator.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 541, 549], ["patients", "SPECIES", 541, 549], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["the PReVentS Circuit", "TREATMENT", 166, 186], ["Tailoring Ventilatory Pressuresis", "TREATMENT", 191, 224], ["The copyright holder", "TREATMENT", 259, 279], ["this preprint", "TREATMENT", 284, 297], ["the PReVentS circuit", "TREATMENT", 443, 463], ["ventilatory pressures", "TREATMENT", 511, 532], ["the circuit", "TREATMENT", 564, 575], ["a standard ICU ventilator", "TREATMENT", 588, 613], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["Standard test lungs (eg.", [["lungs", "ANATOMY", 14, 19], ["lungs", "ORGAN", 14, 19], ["Standard test lungs (eg.", "TEST", 0, 24], ["lungs", "ANATOMY", 14, 19]]], ["BioMed Device # 1020 or similar) were used to simulate patient lungs.", [["lungs", "ANATOMY", 63, 68], ["patient", "ORGANISM", 55, 62], ["lungs", "ORGAN", 63, 68], ["patient", "SPECIES", 55, 62], ["BioMed Device", "TREATMENT", 0, 13], ["lungs", "ANATOMY", 63, 68]]], ["To simulate a decrease in lung compliance, we applied rubber bands around one of the test lungs to increase their stiffness.", [["lung", "ANATOMY", 26, 30], ["lungs", "ANATOMY", 90, 95], ["lung", "ORGAN", 26, 30], ["lungs", "ORGAN", 90, 95], ["a decrease in lung compliance", "PROBLEM", 12, 41], ["rubber bands", "TREATMENT", 54, 66], ["their stiffness", "PROBLEM", 108, 123], ["decrease", "OBSERVATION_MODIFIER", 14, 22], ["lung", "ANATOMY", 26, 30], ["compliance", "OBSERVATION", 31, 41], ["rubber bands", "OBSERVATION", 54, 66], ["lungs", "ANATOMY", 90, 95], ["stiffness", "OBSERVATION", 114, 123]]], ["Figures 10-14 below show data obtained from the PReVentS circuit as described above.", [["PReVentS circuit", "DNA", 48, 64], ["Figures", "TEST", 0, 7], ["the PReVentS circuit", "TREATMENT", 44, 64]]], ["With the current hand-made valves it is necessary to briefly open the circuit to make valve adjustments.", [["valve", "ANATOMY", 86, 91], ["valves", "MULTI-TISSUE_STRUCTURE", 27, 33], ["valve", "MULTI-TISSUE_STRUCTURE", 86, 91], ["valves", "TREATMENT", 27, 33], ["the circuit", "TREATMENT", 66, 77], ["valve adjustments", "TREATMENT", 86, 103], ["valves", "OBSERVATION", 27, 33], ["valve", "OBSERVATION", 86, 91]]], ["We are working to update the valve design so that pressures can be set without making any disconnects in the PReVentS circuit.I. Experiment #1: Determining Impact of Inspiratory Pressure-Gated Valves on Inspiratory PressuresFor this experiment, the circuit was connected to two mock lungs having similar compliance.", [["valve", "ANATOMY", 29, 34], ["lungs", "ANATOMY", 283, 288], ["valve", "PATHOLOGICAL_FORMATION", 29, 34], ["lungs", "ORGAN", 283, 288], ["pressures", "TREATMENT", 50, 59], ["the PReVentS circuit", "TREATMENT", 105, 125], ["Inspiratory Pressure", "TREATMENT", 166, 186], ["Gated Valves", "TREATMENT", 187, 199], ["Inspiratory Pressures", "TREATMENT", 203, 224], ["the circuit", "TREATMENT", 245, 256], ["valve", "ANATOMY", 29, 34], ["Valves", "OBSERVATION", 193, 199], ["Inspiratory Pressures", "OBSERVATION", 203, 224], ["lungs", "ANATOMY", 283, 288]]], ["The goal of the experiment was to tune the pressure settings in the pressure-gated valves in the inspiratory circuit, and to measure the resultant airway pressures for the two simulated \"patients\" (Figure 10).", [["airway", "ANATOMY", 147, 153], ["airway", "MULTI-TISSUE_STRUCTURE", 147, 153], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["the pressure settings", "TREATMENT", 39, 60], ["the pressure-gated valves", "TREATMENT", 64, 89], ["the inspiratory circuit", "TREATMENT", 93, 116], ["the resultant airway pressures", "TEST", 133, 163], ["valves", "OBSERVATION", 83, 89], ["inspiratory circuit", "OBSERVATION", 97, 116], ["airway pressures", "OBSERVATION", 147, 163]]], ["As described above, the inspiratory pressure for each patient is set by subtracting the setting of that patient's inspiratory pressure-gated valve from the ventilator's peak inspiratory pressure.", [["patient", "ORGANISM", 54, 61], ["patient", "ORGANISM", 104, 111], ["valve", "MULTI-TISSUE_STRUCTURE", 141, 146], ["patient", "SPECIES", 54, 61], ["patient", "SPECIES", 104, 111], ["the inspiratory pressure", "TEST", 20, 44], ["patient's inspiratory pressure", "TEST", 104, 134], ["gated valve", "TREATMENT", 135, 146], ["the ventilator's peak inspiratory pressure", "TEST", 152, 194], ["valve", "ANATOMY", 141, 146], ["inspiratory pressure", "OBSERVATION", 174, 194]]], ["Hence, for a set ventilator PIP of 35, a pressure-gated valve setting of 15 for Lung B results in an inspiratory pressure of 20 for that lung.", [["Lung", "ANATOMY", 80, 84], ["lung", "ANATOMY", 137, 141], ["lung", "ORGAN", 137, 141], ["a set ventilator PIP", "TEST", 11, 31], ["a pressure-gated valve setting", "TREATMENT", 39, 69], ["an inspiratory pressure", "TEST", 98, 121], ["valve", "ANATOMY", 56, 61], ["Lung", "ANATOMY", 80, 84], ["inspiratory pressure", "OBSERVATION", 101, 121], ["lung", "ANATOMY", 137, 141]]], ["Of note, the airway pressures of Lung A were entirely unchanged when varying the PIP of Lung B.II. Experiment #2: Determining Impact of Inspiratory Pressure-Gated Valves on Tidal Volumes.For this experiment, the circuit was connected to two mock lungs having similar compliance.", [["airway", "ANATOMY", 13, 19], ["Lung A", "ANATOMY", 33, 39], ["Lung", "ANATOMY", 88, 92], ["lungs", "ANATOMY", 246, 251], ["airway", "MULTI-TISSUE_STRUCTURE", 13, 19], ["Lung A", "CANCER", 33, 39], ["lungs", "ORGAN", 246, 251], ["Lung B.II.", "SPECIES", 88, 98], ["the airway pressures", "TEST", 9, 29], ["Inspiratory Pressure", "TEST", 136, 156], ["Tidal Volumes", "TEST", 173, 186], ["the circuit", "TREATMENT", 208, 219], ["airway", "ANATOMY", 13, 19], ["pressures", "OBSERVATION", 20, 29], ["Lung", "ANATOMY", 33, 37], ["unchanged", "OBSERVATION_MODIFIER", 54, 63], ["PIP", "OBSERVATION_MODIFIER", 81, 84], ["Lung", "ANATOMY", 88, 92], ["B.II.", "ANATOMY_MODIFIER", 93, 98], ["Inspiratory Pressure", "OBSERVATION", 136, 156], ["Valves", "OBSERVATION", 163, 169], ["Tidal Volumes", "OBSERVATION", 173, 186], ["lungs", "ANATOMY", 246, 251], ["similar compliance", "OBSERVATION", 259, 277]]], ["The goal of the experiment was to tune the pressure settings in the pressure-gated valves in the inspiratory circuit, and to measure the resultant tidal volume for one simulated lung ( Figure 11 ).", [["lung", "ANATOMY", 178, 182], ["lung", "ORGAN", 178, 182], ["the pressure settings", "TREATMENT", 39, 60], ["the pressure-gated valves", "TREATMENT", 64, 89], ["the inspiratory circuit", "TREATMENT", 93, 116], ["the resultant tidal volume", "TEST", 133, 159], ["valves", "OBSERVATION", 83, 89], ["inspiratory circuit", "OBSERVATION", 97, 116], ["tidal volume", "OBSERVATION", 147, 159], ["lung", "ANATOMY", 178, 182]]], ["As is clear from Figure 11 , changing pressure settings on valves in the inspiratory limb of .", [["inspiratory limb", "ANATOMY", 73, 89], ["valves", "MULTI-TISSUE_STRUCTURE", 59, 65], ["inspiratory limb", "ORGANISM_SUBDIVISION", 73, 89], ["changing pressure settings", "TREATMENT", 29, 55], ["valves", "TREATMENT", 59, 65], ["clear", "OBSERVATION", 6, 11], ["valves", "OBSERVATION", 59, 65], ["inspiratory limb", "ANATOMY", 73, 89]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.II. Experiment #2: Determining Impact of Inspiratory Pressure-Gated Valves on Tidal Volumes.is the (which was not peer-reviewed) The copyright holder for this preprint .II. Experiment #2: Determining Impact of Inspiratory Pressure-Gated Valves on Tidal Volumes.the PReVentS circuit provides a linear change in the resultant tidal volume to the lung, as would be expected for a simple rubber ventilator bag having relatively linear compliance.II. Experiment #2: Determining Impact of Inspiratory Pressure-Gated Valves on Tidal Volumes.As described above in Figure 9 , setting the inspiratory pressure-gated valves to a given pressure results in a subtraction of that pressure from the ventilator inspiratory pressure for each patient.", [["lung", "ANATOMY", 498, 502], ["CC", "CHEMICAL", 0, 2], ["II", "CHEMICAL", 154, 156], ["II", "CHEMICAL", 323, 325], ["lung", "ORGAN", 498, 502], ["valves", "MULTI-TISSUE_STRUCTURE", 760, 766], ["patient", "ORGANISM", 879, 886], ["PReVentS", "PROTEIN", 419, 427], ["patient", "SPECIES", 879, 886], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["Inspiratory Pressure", "TEST", 195, 215], ["Gated Valves", "TREATMENT", 216, 228], ["Tidal Volumes", "TEST", 232, 245], ["The copyright holder", "TREATMENT", 283, 303], ["this preprint", "TREATMENT", 308, 321], ["Inspiratory Pressure", "TEST", 364, 384], ["Tidal Volumes", "TEST", 401, 414], ["the PReVentS circuit", "TREATMENT", 415, 435], ["a linear change", "PROBLEM", 445, 460], ["a simple rubber ventilator bag", "TREATMENT", 529, 559], ["Inspiratory Pressure", "TEST", 637, 657], ["Tidal Volumes", "TEST", 674, 687], ["the inspiratory pressure", "TEST", 729, 753], ["gated valves", "TREATMENT", 754, 766], ["the ventilator inspiratory pressure", "TEST", 834, 869], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101], ["Inspiratory Pressure", "OBSERVATION", 195, 215], ["Valves", "OBSERVATION", 222, 228], ["Inspiratory Pressure", "OBSERVATION", 364, 384], ["Valves", "OBSERVATION", 391, 397], ["Tidal Volumes", "OBSERVATION", 401, 414], ["linear", "OBSERVATION_MODIFIER", 447, 453], ["change", "OBSERVATION_MODIFIER", 454, 460], ["resultant", "OBSERVATION_MODIFIER", 468, 477], ["tidal volume", "OBSERVATION", 478, 490], ["lung", "ANATOMY", 498, 502], ["rubber", "OBSERVATION", 538, 544], ["ventilator bag", "OBSERVATION", 545, 559], ["Inspiratory Pressure", "OBSERVATION", 637, 657], ["Valves", "OBSERVATION", 664, 670], ["Tidal Volumes", "OBSERVATION", 674, 687], ["valves", "OBSERVATION", 760, 766], ["ventilator", "OBSERVATION", 838, 848], ["inspiratory pressure", "OBSERVATION", 849, 869]]], ["Hence, for a set ventilator PIP of 35 cmH20, a pressure-gated valve setting of 15 cmH20 for Lung B results in an inspiratory pressure of 20 cmH20 for that lung.", [["Lung", "ANATOMY", 92, 96], ["lung", "ANATOMY", 155, 159], ["valve", "PATHOLOGICAL_FORMATION", 62, 67], ["lung", "ORGAN", 155, 159], ["a set ventilator PIP", "TEST", 11, 31], ["a pressure-gated valve setting", "TREATMENT", 45, 75], ["an inspiratory pressure", "TEST", 110, 133], ["valve", "ANATOMY", 62, 67], ["Lung", "ANATOMY", 92, 96], ["lung", "ANATOMY", 155, 159]]], ["As the setting on the pressure-gated inspiratory valve increases, the resultant inspiratory pressure for that lung decreases, and the resultant tidal volume also decreases, in a linear fashion in this experiment.III. Experiment #3: Determining Impact of Inspiratory Pressure-Gated Valve Adjustment for One Patient OnlyFor this experiment, the circuit was connected to two mock lungs having similar compliance.", [["lung", "ANATOMY", 110, 114], ["lungs", "ANATOMY", 377, 382], ["valve", "MULTI-TISSUE_STRUCTURE", 49, 54], ["lung", "ORGAN", 110, 114], ["lungs", "ORGAN", 377, 382], ["Patient", "SPECIES", 306, 313], ["the pressure-gated inspiratory valve", "TREATMENT", 18, 54], ["the resultant inspiratory pressure", "TEST", 66, 100], ["the resultant tidal volume", "TEST", 130, 156], ["Inspiratory Pressure", "TREATMENT", 254, 274], ["Gated Valve Adjustment", "TREATMENT", 275, 297], ["this experiment", "TREATMENT", 322, 337], ["the circuit", "TREATMENT", 339, 350], ["inspiratory valve", "OBSERVATION", 37, 54], ["resultant", "OBSERVATION_MODIFIER", 70, 79], ["inspiratory pressure", "OBSERVATION", 80, 100], ["lung", "ANATOMY", 110, 114], ["decreases", "OBSERVATION_MODIFIER", 115, 124], ["resultant", "OBSERVATION_MODIFIER", 134, 143], ["tidal volume", "OBSERVATION", 144, 156], ["decreases", "OBSERVATION_MODIFIER", 162, 171], ["Valve", "ANATOMY", 281, 286], ["lungs", "ANATOMY", 377, 382]]], ["The goal of the experiment was to tune settings of the inspiratory pressure-gated valve for one lung, and to measure the resultant tidal volumes for both of the lungs in the PReVentS circuit ( Figure 12 ).", [["lung", "ANATOMY", 96, 100], ["lungs", "ANATOMY", 161, 166], ["valve", "MULTI-TISSUE_STRUCTURE", 82, 87], ["lung", "ORGAN", 96, 100], ["lungs", "ORGAN", 161, 166], ["the inspiratory pressure", "TREATMENT", 51, 75], ["the resultant tidal volumes", "TEST", 117, 144], ["valve", "ANATOMY", 82, 87], ["lung", "ANATOMY", 96, 100], ["tidal volumes", "OBSERVATION", 131, 144], ["lungs", "ANATOMY", 161, 166]]], ["As is clear from Figure 12 , changing the pressure setting on one valve in the inspiratory limb for Patient #1 had a linear effect on the resultant tidal volume of Patient #1, while it had minimal to no effect on the measured tidal volume for Patient #2.", [["inspiratory limb", "ANATOMY", 79, 95], ["limb", "ORGANISM_SUBDIVISION", 91, 95], ["changing the pressure setting", "TREATMENT", 29, 58], ["one valve", "TREATMENT", 62, 71], ["a linear effect", "PROBLEM", 115, 130], ["clear", "OBSERVATION", 6, 11], ["pressure", "OBSERVATION_MODIFIER", 42, 50], ["valve", "OBSERVATION", 66, 71], ["inspiratory limb", "ANATOMY", 79, 95], ["tidal volume", "OBSERVATION", 148, 160]]], ["The PReVentS .", [["PReVentS", "PROTEIN", 4, 12]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.III. Experiment #3: Determining Impact of Inspiratory Pressure-Gated Valve Adjustment for One Patient Onlyis the (which was not peer-reviewed) The copyright holder for this preprint .III. Experiment #3: Determining Impact of Inspiratory Pressure-Gated Valve Adjustment for One Patient Onlycircuit provides a linear change in the resultant tidal volume of Patient #1, as would be expected for a simple rubber ventilator bag having relatively linear compliance.III. Experiment #3: Determining Impact of Inspiratory Pressure-Gated Valve Adjustment for One Patient OnlyAs described above in Figure 9 , setting the inspiratory pressure-gated valves to a given pressure results in a subtraction of that pressure from the ventilator peak inspiratory pressure for each patient.", [["CC", "CHEMICAL", 0, 2], ["patient", "ORGANISM", 915, 922], ["Patient", "SPECIES", 248, 255], ["Patient", "SPECIES", 431, 438], ["Patient", "SPECIES", 707, 714], ["patient", "SPECIES", 915, 922], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["Inspiratory Pressure", "TREATMENT", 196, 216], ["Gated Valve Adjustment", "TREATMENT", 217, 239], ["The copyright holder", "TREATMENT", 297, 317], ["this preprint", "TREATMENT", 322, 335], ["Inspiratory Pressure", "TREATMENT", 379, 399], ["Gated Valve Adjustment", "TREATMENT", 400, 422], ["One Patient Onlycircuit", "TREATMENT", 427, 450], ["a linear change", "PROBLEM", 460, 475], ["a simple rubber ventilator bag", "TREATMENT", 546, 576], ["Inspiratory Pressure", "TREATMENT", 655, 675], ["Gated Valve Adjustment", "TREATMENT", 676, 698], ["the inspiratory pressure", "TEST", 760, 784], ["gated valves", "TREATMENT", 785, 797], ["the ventilator peak inspiratory pressure", "TEST", 865, 905], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101], ["Valve", "ANATOMY", 223, 228], ["Valve", "ANATOMY", 406, 411], ["linear", "OBSERVATION_MODIFIER", 462, 468], ["change", "OBSERVATION_MODIFIER", 469, 475], ["resultant", "OBSERVATION_MODIFIER", 483, 492], ["tidal volume", "OBSERVATION", 493, 505], ["rubber", "OBSERVATION", 555, 561], ["ventilator bag", "OBSERVATION", 562, 576], ["Inspiratory Pressure", "OBSERVATION", 655, 675], ["Valve", "ANATOMY", 682, 687], ["valves", "OBSERVATION", 791, 797], ["inspiratory pressure", "OBSERVATION", 885, 905]]], ["As the setting on the pressure-gated inspiratory valve for Patient #1 increases, the resultant inspiratory pressure for Patient #1 decreases, and the resultant tidal volume for Patient #1 also decreases.", [["the pressure-gated inspiratory valve", "TREATMENT", 18, 54], ["the resultant inspiratory pressure", "TEST", 81, 115], ["the resultant tidal volume", "TEST", 146, 172], ["inspiratory valve", "OBSERVATION", 37, 54], ["inspiratory pressure", "OBSERVATION", 95, 115], ["tidal volume", "OBSERVATION", 160, 172]]], ["Importantly, the tidal volume delivered to Patient #2 is unchanged by these maneuvers, since the ventilatory pressures to Patient #2 are not affected by these maneuvers.IV. Experiment #4: Determining Impact of Changing Compliance in One Patient.For this experiment, the circuit was connected to two mock lungs having similar compliance, and then compliance in one of the lungs was changed in increments, by applying rubber bands around the outside of the ventilator bag.", [["lungs", "ANATOMY", 304, 309], ["lungs", "ANATOMY", 371, 376], ["lungs", "ORGAN", 304, 309], ["lungs", "ORGAN", 371, 376], ["Patient", "SPECIES", 237, 244], ["the tidal volume", "TEST", 13, 29], ["the ventilatory pressures", "TEST", 93, 118], ["IV", "TREATMENT", 169, 171], ["the circuit", "TREATMENT", 266, 277], ["rubber bands", "TREATMENT", 416, 428], ["the ventilator bag", "TREATMENT", 451, 469], ["tidal volume", "OBSERVATION", 17, 29], ["unchanged", "OBSERVATION_MODIFIER", 57, 66], ["ventilatory pressures", "OBSERVATION", 97, 118], ["lungs", "ANATOMY", 304, 309], ["similar compliance", "OBSERVATION", 317, 335], ["lungs", "ANATOMY", 371, 376], ["rubber bands", "OBSERVATION", 416, 428], ["ventilator bag", "OBSERVATION", 455, 469]]], ["The goal of the experiment was to determine the feasibility of maintaining tidal volumes in a patient with decreasing lung compliance, using the pressure-gated valves on the inspiratory limb for that patient to tune inspiratory pressure ( Figure 13 ).", [["lung", "ANATOMY", 118, 122], ["inspiratory limb", "ANATOMY", 174, 190], ["patient", "ORGANISM", 94, 101], ["lung", "ORGAN", 118, 122], ["inspiratory limb", "ORGANISM_SUBDIVISION", 174, 190], ["patient", "ORGANISM", 200, 207], ["patient", "SPECIES", 94, 101], ["patient", "SPECIES", 200, 207], ["tidal volumes", "TEST", 75, 88], ["decreasing lung compliance", "TREATMENT", 107, 133], ["the pressure-gated valves on the inspiratory limb", "TREATMENT", 141, 190], ["tune inspiratory pressure", "TEST", 211, 236], ["tidal volumes", "OBSERVATION", 75, 88], ["lung", "ANATOMY", 118, 122], ["compliance", "OBSERVATION", 123, 133], ["valves", "OBSERVATION", 160, 166], ["inspiratory limb", "ANATOMY", 174, 190]]], ["As is clear from Figure 12 , decreased compliance in Patient #1 could be largely offset, in terms of resulting tidal volume, by titrating the pressure on for Patient #1 on the inspiratory limb.", [["inspiratory limb", "ANATOMY", 176, 192], ["inspiratory limb", "ORGANISM_SUBDIVISION", 176, 192], ["resulting tidal volume", "TREATMENT", 101, 123], ["the pressure", "TEST", 138, 150], ["clear", "OBSERVATION", 6, 11], ["offset", "OBSERVATION", 81, 87], ["tidal volume", "OBSERVATION", 111, 123], ["inspiratory limb", "ANATOMY", 176, 192]]], ["In this study, the tidal volume for Patient #1 was maintained at approximately 330 mL, by means of decreasing the pressure-gated valve set point on the inspiratory limb from .", [["inspiratory limb", "ANATOMY", 152, 168], ["inspiratory limb", "ORGANISM_SUBDIVISION", 152, 168], ["this study", "TEST", 3, 13], ["the tidal volume", "TEST", 15, 31], ["tidal volume", "OBSERVATION", 19, 31], ["valve", "OBSERVATION", 129, 134], ["inspiratory limb", "ANATOMY", 152, 168]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.IV. Experiment #4: Determining Impact of Changing Compliance in One Patient.is the (which was not peer-reviewed) The copyright holder for this preprint .IV. Experiment #4: Determining Impact of Changing Compliance in One Patient.17 to 5 cmH2O as the lung compliance fell.", [["lung", "ANATOMY", 404, 408], ["CC", "CHEMICAL", 0, 2], ["lung", "ORGAN", 404, 408], ["Patient", "SPECIES", 222, 229], ["Patient", "SPECIES", 375, 382], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["IV", "TREATMENT", 154, 156], ["The copyright holder", "TREATMENT", 267, 287], ["this preprint", "TREATMENT", 292, 305], ["IV", "TREATMENT", 307, 309], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101], ["lung", "ANATOMY", 404, 408], ["compliance", "OBSERVATION", 409, 419]]], ["But despite the fact that the setting on the pressure-gated inspiratory valve for Patient #1 was being decreased, the inspiratory pressure and tidal volumes for Patient #2 remained unchanged.", [["valve", "MULTI-TISSUE_STRUCTURE", 72, 77], ["the pressure-gated inspiratory valve", "TREATMENT", 41, 77], ["the inspiratory pressure", "TEST", 114, 138], ["tidal volumes", "TEST", 143, 156], ["inspiratory valve", "ANATOMY", 60, 77], ["inspiratory pressure", "OBSERVATION", 118, 138], ["tidal volumes", "OBSERVATION", 143, 156], ["unchanged", "OBSERVATION_MODIFIER", 181, 190]]], ["This experiment illustrates the potential feasibility of maintaining tidal volumes in one patient with changing lung mechanics, while not affecting the ventilation of the other patient treated with the PReVentS circuit.", [["lung", "ANATOMY", 112, 116], ["patient", "ORGANISM", 90, 97], ["lung", "ORGAN", 112, 116], ["patient", "ORGANISM", 177, 184], ["PReVentS", "GENE_OR_GENE_PRODUCT", 202, 210], ["patient", "SPECIES", 90, 97], ["patient", "SPECIES", 177, 184], ["tidal volumes", "TREATMENT", 69, 82], ["changing lung mechanics", "TREATMENT", 103, 126], ["the PReVentS circuit", "TREATMENT", 198, 218], ["tidal volumes", "OBSERVATION", 69, 82], ["lung", "ANATOMY", 112, 116], ["mechanics", "OBSERVATION", 117, 126]]], ["Figure 13 : Impact of Decreasing Lung Compliance in One Patient.", [["Lung", "ANATOMY", 33, 37], ["Lung", "ORGAN", 33, 37], ["Patient", "SPECIES", 56, 63], ["Decreasing Lung Compliance", "TREATMENT", 22, 48], ["Decreasing", "OBSERVATION_MODIFIER", 22, 32], ["Lung", "ANATOMY", 33, 37], ["Compliance", "OBSERVATION", 38, 48]]], ["Compliance of mock lung for Patient #1 was decreased by sequentially adding rubber bands to the outside of the rubber ventilator bag.", [["lung", "ANATOMY", 19, 23], ["lung", "ORGAN", 19, 23], ["Patient", "SPECIES", 28, 35], ["rubber bands", "TREATMENT", 76, 88], ["the rubber ventilator bag", "TREATMENT", 107, 132], ["lung", "ANATOMY", 19, 23], ["rubber bands", "OBSERVATION", 76, 88], ["rubber", "OBSERVATION", 111, 117], ["ventilator bag", "OBSERVATION", 118, 132]]], ["As Patient #1 compliance decreased, tidal volume could be maintained for Patient #1 by adjusting the pressure-gated valve for Patient #1 on the Inspiratory limb.", [["Inspiratory limb", "ANATOMY", 144, 160], ["Inspiratory limb", "ORGANISM_SUBDIVISION", 144, 160], ["Patient", "SPECIES", 3, 10], ["tidal volume", "TEST", 36, 48], ["the pressure-gated valve", "TREATMENT", 97, 121], ["tidal volume", "OBSERVATION", 36, 48], ["valve", "ANATOMY", 116, 121], ["Inspiratory limb", "ANATOMY", 144, 160]]], ["During these maneuvers, tidal volumes for Patient #2 were not affected.V. Experiment #5: Determining Impact of Changing Applied PEEP by Adjusting Pressure-Gated Valves on the Expiratory Limb.For this experiment, the circuit was connected to two mock lungs having similar compliance, and then the effective PEEP applied to Patient #2 (Lung B, Figure 14) , was increased by increasing the set point of the pressure-gated valve on the expiratory limb for Patient #2.", [["lungs", "ANATOMY", 250, 255], ["Lung", "ANATOMY", 334, 338], ["limb", "ANATOMY", 443, 447], ["Limb", "ORGANISM_SUBDIVISION", 186, 190], ["lungs", "ORGAN", 250, 255], ["valve", "MULTI-TISSUE_STRUCTURE", 419, 424], ["limb", "ORGANISM_SUBDIVISION", 443, 447], ["Patient", "SPECIES", 42, 49], ["these maneuvers", "TEST", 7, 22], ["tidal volumes", "TEST", 24, 37], ["PEEP", "TREATMENT", 128, 132], ["Pressure", "TEST", 146, 154], ["Gated Valves on the Expiratory Limb", "TREATMENT", 155, 190], ["the circuit", "TREATMENT", 212, 223], ["the effective PEEP", "TREATMENT", 292, 310], ["the pressure-gated valve", "TREATMENT", 400, 424], ["Valves", "OBSERVATION", 161, 167], ["Expiratory Limb", "ANATOMY", 175, 190], ["lungs", "ANATOMY", 250, 255], ["Lung", "ANATOMY", 334, 338], ["increased", "OBSERVATION_MODIFIER", 359, 368], ["valve", "ANATOMY", 419, 424], ["expiratory limb", "ANATOMY", 432, 447]]], ["The goal of this experiment was to determine the impact of changing effective PEEP of one patient on ventilatory pressures and gas flows.", [["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["changing effective PEEP", "TREATMENT", 59, 82], ["ventilatory pressures", "TREATMENT", 101, 122], ["gas flows", "TEST", 127, 136], ["gas flows", "OBSERVATION", 127, 136]]], ["As is clear from Figure 15 , adjusting the set point of the expiratory valve for Patient #2 (\"Lung B\") from 5 to 20 cmH2O did not affect the ventilation pressures for Patient #1 (\"Lung A\" in Figure 15 ).", [["Lung", "ANATOMY", 94, 98], ["Lung", "ANATOMY", 180, 184], ["the expiratory valve", "TREATMENT", 56, 76], ["the ventilation pressures", "TEST", 137, 162], ["clear", "OBSERVATION", 6, 11], ["expiratory valve", "ANATOMY", 60, 76], ["Lung", "ANATOMY", 94, 98], ["ventilation pressures", "OBSERVATION", 141, 162], ["Lung", "ANATOMY", 180, 184]]], ["In contrast, the effective PEEP for Patient #2 was increased from 5 to approximately 25 cmH2O by increasing the set point on the expiratory valve for Patient #2 from 5 to 20 cmH2O.V. Experiment #5: Determining Impact of Changing Applied PEEP by Adjusting Pressure-Gated Valves on the Expiratory Limb.As can be seen from careful inspection of Figure 14 , there is some evidence of incomplete exhalation, or \"breath stacking\", in the mock lung used to simulate Patient #2 in this experiment.", [["lung", "ANATOMY", 437, 441], ["Limb", "ORGANISM_SUBDIVISION", 295, 299], ["lung", "ORGAN", 437, 441], ["the effective PEEP", "TREATMENT", 13, 31], ["the expiratory valve", "TREATMENT", 125, 145], ["PEEP", "TREATMENT", 237, 241], ["Pressure", "TEST", 255, 263], ["Gated Valves on the Expiratory Limb", "TREATMENT", 264, 299], ["careful inspection", "TEST", 320, 338], ["incomplete exhalation", "PROBLEM", 380, 401], ["\"breath stacking\"", "PROBLEM", 406, 423], ["expiratory valve", "ANATOMY", 129, 145], ["Valves", "OBSERVATION", 270, 276], ["Expiratory Limb", "ANATOMY", 284, 299], ["some evidence of", "UNCERTAINTY", 363, 379], ["incomplete", "OBSERVATION_MODIFIER", 380, 390], ["exhalation", "OBSERVATION", 391, 401], ["lung", "ANATOMY", 437, 441]]], ["Whether this observation is inherent to the PReVentS circuit, or whether it is an artifact of the specific circuit components or the mock lung utilized for this study, is unclear at the present time.Draft Protocol for Patient ManagementNOTE: This draft protocol has not been tested on animals or patients.", [["lung", "ANATOMY", 138, 142], ["PReVentS", "GENE_OR_GENE_PRODUCT", 44, 52], ["lung", "ORGAN", 138, 142], ["patients", "ORGANISM", 296, 304], ["Patient", "SPECIES", 218, 225], ["patients", "SPECIES", 296, 304], ["the PReVentS circuit", "TREATMENT", 40, 60], ["an artifact of the specific circuit components", "PROBLEM", 79, 125], ["this study", "TEST", 156, 166], ["This draft protocol", "TREATMENT", 242, 261], ["artifact", "OBSERVATION", 82, 90], ["lung", "ANATOMY", 138, 142]]], ["It is intended only as a starting point for thinking about how PReVentS could be valuable in the event that ventilator sharing became superior to all other options.", [["PReVentS", "SIMPLE_CHEMICAL", 63, 71]]], ["Any consideration of ventilator sharing (using this circuit design or any other) must include a thorough evaluation of the technical, medical, legal, and ethical ramifications each time it is instituted.Important Information and Patient Safety Considerations\u2022 Patients should be pharmacologically paralyzed and ventilator trigger settings should be maximized so that only mandatory breaths are delivered by the ventilator. \u2022 Pressure-control ventilation must be used.Important Information and Patient Safety Considerations\u2022 All valves must be in the proper place, inserted in the proper orientation and functioning properly (neither sticking nor leaking). \u2022 Certain ventilator alarms will not work as they do in single-patient operation, and it is critical to implement a comprehensive monitoring and alarm strategy and train all caretakers on it. \u2022 Inspiratory pressures, expiratory pressures, and expiratory volumes should be measured independently for each patient at regular intervals.", [["Patients", "ORGANISM", 260, 268], ["patient", "ORGANISM", 719, 726], ["patient", "ORGANISM", 960, 967], ["Patients", "SPECIES", 260, 268], ["patient", "SPECIES", 719, 726], ["patient", "SPECIES", 960, 967], ["ventilator sharing", "TREATMENT", 21, 39], ["this circuit design", "TREATMENT", 47, 66], ["a thorough evaluation", "TEST", 94, 115], ["pharmacologically paralyzed", "TREATMENT", 279, 306], ["ventilator trigger settings", "TREATMENT", 311, 338], ["the ventilator", "TREATMENT", 407, 421], ["Pressure-control ventilation", "TREATMENT", 425, 453], ["All valves", "TREATMENT", 524, 534], ["Certain ventilator alarms", "TREATMENT", 658, 683], ["a comprehensive monitoring", "TEST", 770, 796], ["alarm strategy", "TREATMENT", 801, 815], ["Inspiratory pressures", "TEST", 850, 871], ["expiratory pressures", "TEST", 873, 893], ["expiratory volumes", "TEST", 899, 917], ["valves", "OBSERVATION", 528, 534], ["ventilator alarms", "OBSERVATION", 666, 683], ["pressures", "OBSERVATION_MODIFIER", 862, 871], ["expiratory pressures", "OBSERVATION", 873, 893], ["expiratory volumes", "OBSERVATION", 899, 917]]], ["Ideally, these measurements should be continuous.", [["these measurements", "TEST", 9, 27]]], ["Even judiciously set alarms on the shared ventilator will not be able to identify certain potentially serious changes in patient status. \u2022 Valves in the patient circuit have the potential to limit flow even when open.Important Information and Patient Safety ConsiderationsTherefore, certain PReVentS circuits (depending on the specific ventilator, tubing, .", [["patient", "ORGANISM", 121, 128], ["patient", "ORGANISM", 153, 160], ["PReVentS", "GENE_OR_GENE_PRODUCT", 291, 299], ["patient", "SPECIES", 121, 128], ["patient", "SPECIES", 153, 160], ["the shared ventilator", "TREATMENT", 31, 52], ["serious changes in patient status", "PROBLEM", 102, 135], ["Valves in the patient circuit", "TREATMENT", 139, 168], ["certain PReVentS circuits", "TREATMENT", 283, 308], ["tubing", "TREATMENT", 348, 354]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Important Information and Patient Safety Considerationsis the (which was not peer-reviewed) The copyright holder for this preprint . and valves used) might have reduced inspiratory flow or expiratory flow when compared to a traditional circuit.", [["CC", "CHEMICAL", 0, 2], ["valves", "ORGAN", 291, 297], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 246, 266], ["this preprint", "TREATMENT", 271, 284], ["valves", "TREATMENT", 291, 297], ["reduced inspiratory flow", "PROBLEM", 315, 339], ["expiratory flow", "PROBLEM", 343, 358], ["a traditional circuit", "TREATMENT", 376, 397], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101], ["valves", "ANATOMY", 291, 297], ["reduced", "OBSERVATION_MODIFIER", 315, 322], ["inspiratory flow", "OBSERVATION", 323, 339], ["expiratory flow", "OBSERVATION", 343, 358]]], ["This would have the effect of slowing both inspiration and expiration, and could lead to reduced inspiratory volume or breath stacking at a given pressure setting and respiratory rate.", [["respiratory", "ANATOMY", 167, 178], ["reduced inspiratory volume", "PROBLEM", 89, 115], ["breath stacking", "PROBLEM", 119, 134], ["pressure setting", "TREATMENT", 146, 162], ["respiratory rate", "TEST", 167, 183], ["reduced", "OBSERVATION_MODIFIER", 89, 96], ["inspiratory volume", "OBSERVATION", 97, 115], ["respiratory rate", "OBSERVATION", 167, 183]]], ["While these occurrences can be adjusted for if they do occur, the provider must be vigilant for them and know how to respond appropriately.Important Information and Patient Safety Considerations\u2022 As the circuit is currently designed, negative circuit pressure near the patient will entrain room air through the negative-pressure relief valve -this will briefly decrease the FiO2 following in-line suctioning, or if the patient makes strong respiratory effort during the ventilator's expiratory phase.", [["respiratory", "ANATOMY", 440, 451], ["FiO2", "CHEMICAL", 374, 378], ["patient", "ORGANISM", 269, 276], ["patient", "ORGANISM", 419, 426], ["patient", "SPECIES", 269, 276], ["patient", "SPECIES", 419, 426], ["the negative-pressure relief valve", "TREATMENT", 307, 341], ["the FiO2", "TREATMENT", 370, 378], ["in-line suctioning", "TREATMENT", 389, 407], ["strong respiratory effort", "PROBLEM", 433, 458], ["the ventilator's expiratory phase", "TEST", 466, 499], ["relief valve", "OBSERVATION", 329, 341], ["respiratory effort", "OBSERVATION", 440, 458]]], ["If even a brief FiO2 decrease is unacceptable for a patient, an oxygen reservoir bag should be added at the negative pressure relief valve.", [["oxygen", "CHEMICAL", 64, 70], ["FiO2", "CHEMICAL", 16, 20], ["oxygen", "CHEMICAL", 64, 70], ["patient", "ORGANISM", 52, 59], ["oxygen", "SIMPLE_CHEMICAL", 64, 70], ["valve", "PATHOLOGICAL_FORMATION", 133, 138], ["patient", "SPECIES", 52, 59], ["a brief FiO2 decrease", "PROBLEM", 8, 29], ["an oxygen reservoir bag", "TREATMENT", 61, 84], ["the negative pressure relief valve", "TREATMENT", 104, 138], ["relief valve", "OBSERVATION", 126, 138]]], ["With proper forethought, steps can also be taken to mitigate FiO2 drop during in-line suctioning (see below). \u2022 While not intrinsic to the PReVentS circuit, with the current hand-made valves it is necessary to briefly open the circuit to make valve adjustments.", [["valve", "ANATOMY", 243, 248], ["FiO2", "CHEMICAL", 61, 65], ["valves", "MULTI-TISSUE_STRUCTURE", 184, 190], ["valve", "MULTI-TISSUE_STRUCTURE", 243, 248], ["FiO2", "TREATMENT", 61, 65], ["in-line suctioning", "TREATMENT", 78, 96], ["the PReVentS circuit", "TREATMENT", 135, 155], ["valves", "TREATMENT", 184, 190], ["the circuit", "TREATMENT", 223, 234], ["valve adjustments", "TREATMENT", 243, 260], ["valves", "OBSERVATION", 184, 190], ["valve", "OBSERVATION", 243, 248]]], ["During this maneuver, ventilation is still maintained for the other patient, and PEEP is maintained for both patients.", [["patient", "ORGANISM", 68, 75], ["patients", "ORGANISM", 109, 117], ["patient", "SPECIES", 68, 75], ["patients", "SPECIES", 109, 117], ["this maneuver", "TREATMENT", 7, 20], ["ventilation", "TREATMENT", 22, 33], ["PEEP", "TREATMENT", 81, 85]]], ["We are currently iterating on valve design to allow pressure adjustment without any circuit disruption.I.Monitoring: When sharing a single ventilator between two patients, the inbuilt safety monitors of the ventilator will not function as they usually do.", [["valve", "ANATOMY", 30, 35], ["valve", "MULTI-TISSUE_STRUCTURE", 30, 35], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["valve design", "TREATMENT", 30, 42], ["pressure adjustment", "TREATMENT", 52, 71], ["any circuit disruption", "PROBLEM", 80, 102], ["a single ventilator", "TREATMENT", 130, 149], ["the ventilator", "TREATMENT", 203, 217]]], ["It is therefore necessary to develop and implement a monitoring strategy that will reliably alert providers to unexpected changes and dangerous events.", [["a monitoring strategy", "TREATMENT", 51, 72], ["dangerous events", "PROBLEM", 134, 150]]], ["In the current crisis, not just ventilators but many types of medical devices are in short supply, which may affect the ability to provide monitoring.", [["ventilators", "TREATMENT", 32, 43], ["medical devices", "TREATMENT", 62, 77], ["monitoring", "TEST", 139, 149], ["crisis", "OBSERVATION", 15, 21]]], ["With that in mind, we propose a minimal monitor setup (that is absolutely required and will identify all the changes in patient condition we have so far considered) and a recommended monitor setup (which provides redundancy, could identify unconsidered situations, and would make patient management significantly easier and safer).", [["patient", "ORGANISM", 120, 127], ["patient", "ORGANISM", 280, 287], ["patient", "SPECIES", 120, 127], ["patient", "SPECIES", 280, 287], ["a minimal monitor setup", "TREATMENT", 30, 53]]], ["Shared ventilator -Measures and displays sum of patient tidal volumes (VTe), summed minute ventilation (Ve), and volume delivered by ventilator with each breath (Vdel).", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["patient tidal volumes", "TEST", 48, 69], ["VTe", "TEST", 71, 74], ["summed minute ventilation", "TREATMENT", 77, 102], ["volume", "TREATMENT", 113, 119], ["ventilator", "TREATMENT", 133, 143]]], ["Additionally, it can identify certain disconnects and occlusions.", [["occlusions", "DISEASE", 54, 64], ["occlusions", "PROBLEM", 54, 64], ["occlusions", "OBSERVATION", 54, 64]]], ["We believe that a carefully set VTe alarm can identify most situations that require provider attention with good sensitivity and specificity (see below and Appendix S1).", [["a carefully set VTe alarm", "PROBLEM", 16, 41], ["specificity", "TEST", 129, 140]]], ["Furthermore, in the absence of superior alternatives, individual patient tidal volumes can be measured with the shared ventilator by briefly occluding the other patient's circuit (which puts the occluded patient into an expiratory hold).", [["patient", "ORGANISM", 65, 72], ["patient", "ORGANISM", 161, 168], ["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 65, 72], ["patient", "SPECIES", 161, 168], ["patient", "SPECIES", 204, 211], ["individual patient tidal volumes", "TEST", 54, 86], ["the shared ventilator", "TREATMENT", 108, 129], ["'s circuit", "TREATMENT", 168, 178], ["tidal volumes", "OBSERVATION", 73, 86]]], ["If measuring independent patient VTe in this manner, be sure to note that many ventilators adjust this measurement for the circuit compliance.", [["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["many ventilators", "TREATMENT", 74, 90], ["this measurement", "TEST", 98, 114], ["the circuit compliance", "TREATMENT", 119, 141]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Minimal Monitors:is the (which was not peer-reviewed) The copyright holder for this preprint .Minimal Monitors:\u00b7 PIP alarm (if available): Low alarm = Set PIP -5 cmH2O, High alarm = Set PIP + 5 cmH2O \u00b7 PEEP alarm (if available): Low alarm = Set PEEP -2 cmH2O, High alarm = Set PIP + 5 cmH2O \u00b7 ETCO2 alarm (if available): Low alarm = Target ETCO2 -5 mmHg, High alarm = Target ETCO2 + 5 mmHg II.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 208, 228], ["this preprint", "TREATMENT", 233, 246], ["PIP alarm", "TEST", 267, 276], ["Set PIP", "TEST", 305, 312], ["Set PIP", "TREATMENT", 336, 343], ["PEEP alarm", "TREATMENT", 356, 366], ["Set PEEP", "TEST", 395, 403], ["High alarm", "TEST", 414, 424], ["Set PIP", "TEST", 427, 434], ["ETCO2 alarm", "TEST", 447, 458], ["Low alarm", "PROBLEM", 475, 484], ["Target ETCO2", "TEST", 487, 499], ["High alarm", "TEST", 509, 519], ["Target ETCO2", "TEST", 522, 534], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["Patient Care: Because ventilation with the PReVentS paradigm relies upon setting individual patient inspiratory pressures and expiratory pressures (similar to any pressure-controlled ventilation mode on a single patient ventilator), most adjustments should be familiar to the provider.", [["patient", "ORGANISM", 92, 99], ["patient", "ORGANISM", 212, 219], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 92, 99], ["patient", "SPECIES", 212, 219], ["ventilation", "TREATMENT", 22, 33], ["individual patient inspiratory pressures", "TEST", 81, 121], ["expiratory pressures", "TEST", 126, 146], ["any pressure", "TEST", 159, 171], ["a single patient ventilator", "TREATMENT", 203, 230], ["inspiratory pressures", "OBSERVATION", 100, 121], ["expiratory pressures", "OBSERVATION", 126, 146]]], ["However, the described circuit and the necessary patient monitoring departs enough from normal practice that it is worthwhile to describe how we propose certain common tasks might be performed.Minimal Monitors:Adjusting PIP or Tidal Volume: Assuming the ventilator PIP (Inspiratory Pressure + PEEP) is set at 40 cmH2O, each patient's PIP is set independently by the inspiratory limb pressure gated valve, and it will be equal to 40 minus the valve setting.", [["limb", "ANATOMY", 378, 382], ["valve", "ANATOMY", 442, 447], ["patient", "ORGANISM", 49, 56], ["patient", "ORGANISM", 324, 331], ["limb", "ORGANISM_SUBDIVISION", 378, 382], ["valve", "PATHOLOGICAL_FORMATION", 442, 447], ["patient", "SPECIES", 49, 56], ["patient", "SPECIES", 324, 331], ["Adjusting PIP", "TREATMENT", 210, 223], ["Tidal Volume", "TEST", 227, 239], ["the ventilator PIP", "TEST", 250, 268], ["Inspiratory Pressure", "TEST", 270, 290], ["PEEP", "TREATMENT", 293, 297], ["each patient's PIP", "TEST", 319, 337], ["the inspiratory limb pressure gated valve", "TREATMENT", 362, 403], ["valve", "OBSERVATION", 398, 403], ["valve", "ANATOMY", 442, 447]]], ["To adjust this PIP for one patient, make the desired adjustment on the inspiratory limb pressure gated valve (decrease the valve setting to increase PIP and VT, increase valve setting to decrease PIP and VT).", [["limb", "ANATOMY", 83, 87], ["valve", "ANATOMY", 123, 128], ["valve", "ANATOMY", 170, 175], ["PIP", "GENE_OR_GENE_PRODUCT", 15, 18], ["patient", "ORGANISM", 27, 34], ["limb", "ORGANISM_SUBDIVISION", 83, 87], ["valve", "MULTI-TISSUE_STRUCTURE", 103, 108], ["valve", "MULTI-TISSUE_STRUCTURE", 123, 128], ["valve", "MULTI-TISSUE_STRUCTURE", 170, 175], ["patient", "SPECIES", 27, 34], ["this PIP", "TREATMENT", 10, 18], ["the inspiratory limb pressure gated valve", "TREATMENT", 67, 108], ["the valve setting", "TREATMENT", 119, 136], ["PIP", "TREATMENT", 149, 152], ["VT", "TREATMENT", 157, 159], ["valve setting", "TREATMENT", 170, 183], ["PIP and VT", "TREATMENT", 196, 206], ["valve", "OBSERVATION", 103, 108], ["valve", "ANATOMY", 123, 128]]], ["Measure this patient's airway pressures to make sure they reflect the desired change.", [["airway", "ANATOMY", 23, 29], ["patient", "ORGANISM", 13, 20], ["airway", "MULTI-TISSUE_STRUCTURE", 23, 29], ["patient", "SPECIES", 13, 20], ["this patient's airway pressures", "TEST", 8, 39], ["airway", "ANATOMY", 23, 29]]], ["Measure this patient's VTe to make sure it is appropriate.", [["patient", "ORGANISM", 13, 20], ["VTe", "CANCER", 23, 26], ["patient", "SPECIES", 13, 20], ["this patient's VTe", "TREATMENT", 8, 26]]], ["View flow tracings on the ventilator or pressure tracings on the patient monitor to alert you to breath stacking.", [["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["View flow tracings", "TEST", 0, 18], ["the ventilator", "TREATMENT", 22, 36], ["pressure tracings", "TEST", 40, 57], ["the patient monitor", "TEST", 61, 80]]], ["Adjust alarms to reflect the new settings.Minimal Monitors:Adjusting PEEP: Assuming the ventilator PEEP is set at 0 cmH2O, each patient's PEEP is set independently by the expiratory limb pressure gated valve.", [["limb", "ANATOMY", 182, 186], ["patient", "ORGANISM", 128, 135], ["limb", "ORGANISM_SUBDIVISION", 182, 186], ["patient", "SPECIES", 128, 135], ["alarms", "TREATMENT", 7, 13], ["PEEP", "TREATMENT", 69, 73], ["the ventilator PEEP", "TREATMENT", 84, 103], ["each patient's PEEP", "TREATMENT", 123, 142], ["the expiratory limb pressure gated valve", "TREATMENT", 167, 207], ["valve", "ANATOMY", 202, 207]]], ["To adjust this PEEP, make the desired adjustment on the expiratory limb pressure gated valve (decrease valve setting to decrease PEEP, increase valve setting to increase PEEP).", [["limb", "ANATOMY", 67, 71], ["limb", "ORGANISM_SUBDIVISION", 67, 71], ["valve", "MULTI-TISSUE_STRUCTURE", 87, 92], ["this PEEP", "TREATMENT", 10, 19], ["the expiratory limb pressure gated valve", "TREATMENT", 52, 92], ["valve setting", "TREATMENT", 103, 116], ["PEEP", "TREATMENT", 129, 133], ["valve setting", "TREATMENT", 144, 157], ["PEEP", "TREATMENT", 170, 174], ["valve", "OBSERVATION", 87, 92]]], ["After this change, consider if you need to adjust the same patient's PIP to maintain a constant driving pressure or tidal volume.", [["patient", "ORGANISM", 59, 66], ["PIP", "GENE_OR_GENE_PRODUCT", 69, 72], ["patient", "SPECIES", 59, 66], ["the same patient's PIP", "TREATMENT", 50, 72], ["a constant driving pressure", "TREATMENT", 85, 112]]], ["Measure this patient's airway pressures to make sure they reflect the desired change.", [["airway", "ANATOMY", 23, 29], ["patient", "ORGANISM", 13, 20], ["airway", "MULTI-TISSUE_STRUCTURE", 23, 29], ["patient", "SPECIES", 13, 20], ["this patient's airway pressures", "TEST", 8, 39], ["airway", "ANATOMY", 23, 29]]], ["Measure this patient's VTe to make sure it is appropriate.", [["patient", "ORGANISM", 13, 20], ["VTe", "CANCER", 23, 26], ["patient", "SPECIES", 13, 20], ["this patient's VTe", "TREATMENT", 8, 26]]], ["View flow tracings on the ventilator or pressure tracings on the patient monitor to alert you to breath stacking.", [["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["View flow tracings", "TEST", 0, 18], ["the ventilator", "TREATMENT", 22, 36], ["pressure tracings", "TEST", 40, 57], ["the patient monitor", "TEST", 61, 80]]], ["Adjust alarms to reflect the new settings.Minimal Monitors:Other Ventilation Changes: Other ventilation parameters, including RR and FiO2, are shared between all patients sharing the ventilator.", [["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["alarms", "TREATMENT", 7, 13], ["Other ventilation parameters", "TEST", 86, 114], ["RR", "TEST", 126, 128], ["FiO2", "TREATMENT", 133, 137], ["the ventilator", "TREATMENT", 179, 193]]], ["Beitler and colleagues provided sound recommendations for tailoring these ventilator settings to the care of multiple patients on a single ventilator (Beitler 2020) .", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["tailoring these ventilator settings", "TREATMENT", 58, 93], ["a single ventilator", "TREATMENT", 130, 149]]], ["Even though respiratory rate is shared, the PReVentS paradigm allows for differential minute ventilation by individualizing patient tidal volumes.", [["respiratory", "ANATOMY", 12, 23], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["respiratory rate", "TEST", 12, 28], ["differential minute ventilation", "TREATMENT", 73, 104], ["individualizing patient tidal volumes", "TEST", 108, 145], ["respiratory rate", "OBSERVATION", 12, 28]]], ["Whenever respiratory rate is adjusted, airway pressures and tidal volumes should be confirmed, alarms should be adjusted, and CO2 should be measured at an appropriate interval.Minimal Monitors:.", [["respiratory", "ANATOMY", 9, 20], ["airway", "ANATOMY", 39, 45], ["CO2", "CHEMICAL", 126, 129], ["CO2", "CHEMICAL", 126, 129], ["airway", "MULTI-TISSUE_STRUCTURE", 39, 45], ["CO2", "SIMPLE_CHEMICAL", 126, 129], ["respiratory rate", "TEST", 9, 25], ["airway pressures", "TEST", 39, 55], ["tidal volumes", "TEST", 60, 73], ["CO2", "TEST", 126, 129], ["airway", "ANATOMY", 39, 45], ["pressures", "OBSERVATION_MODIFIER", 46, 55]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Minimal Monitors:is the (which was not peer-reviewed) The copyright holder for this preprint .Minimal Monitors:Removing a Patient from the Circuit: A patient can be removed from the circuit with minimal effect on the other patient.", [["CC", "CHEMICAL", 0, 2], ["patient", "ORGANISM", 304, 311], ["patient", "ORGANISM", 377, 384], ["Patient", "SPECIES", 276, 283], ["patient", "SPECIES", 304, 311], ["patient", "SPECIES", 377, 384], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 208, 228], ["this preprint", "TREATMENT", 233, 246], ["the circuit", "TREATMENT", 332, 343], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["To do so, clamp the inspiratory limb of the circuit leading to the patient to be removed.", [["inspiratory limb", "ANATOMY", 20, 36], ["limb", "ORGANISM_SUBDIVISION", 32, 36], ["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["the circuit", "TREATMENT", 40, 51], ["inspiratory limb", "ANATOMY", 20, 36]]], ["The ventilator will continue to ventilate the other patient normally.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["The ventilator", "TREATMENT", 0, 14]]], ["The patient can then be removed from the circuit either at the ETT, or (to maintain recruitment) along with the piece of circuit containing the inspiratory check valve and expiratory pressure-gated valve.", [["patient", "ORGANISM", 4, 11], ["valve", "PATHOLOGICAL_FORMATION", 198, 203], ["patient", "SPECIES", 4, 11], ["the piece of circuit", "TREATMENT", 108, 128], ["the inspiratory check valve", "TREATMENT", 140, 167], ["expiratory pressure-gated valve", "TREATMENT", 172, 203], ["valve", "ANATOMY", 198, 203]]], ["Adjust the alarm parameters on the ventilator to reflect that only one patient is being ventilated.Minimal Monitors:ETT Suctioning: If suctioning a patient with an in-line suction catheter, negative pressure generated near the patient Y-piece will open the negative pressure relief valve and entrain room air (see discussion above).", [["patient", "ORGANISM", 71, 78], ["patient", "ORGANISM", 148, 155], ["patient", "ORGANISM", 227, 234], ["patient", "SPECIES", 71, 78], ["patient", "SPECIES", 148, 155], ["patient", "SPECIES", 227, 234], ["the alarm parameters", "TEST", 7, 27], ["the ventilator", "TREATMENT", 31, 45], ["ETT Suctioning", "TREATMENT", 116, 130], ["an in-line suction catheter", "TREATMENT", 161, 188], ["the negative pressure relief valve", "TREATMENT", 253, 287], ["ventilated", "OBSERVATION", 88, 98], ["relief valve", "OBSERVATION", 275, 287]]], ["If suction is sufficiently strong, it may even reduce the inspiratory pressures of the other patient during suctioning.", [["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["suction", "TREATMENT", 3, 10], ["the inspiratory pressures", "TEST", 54, 79], ["suctioning", "TREATMENT", 108, 118], ["inspiratory pressures", "OBSERVATION", 58, 79]]], ["To minimize the risk of hypoxia, increase FiO2 prior to suctioning.", [["hypoxia", "DISEASE", 24, 31], ["FiO2", "CHEMICAL", 42, 46], ["FiO2", "CHEMICAL", 42, 46], ["hypoxia", "PROBLEM", 24, 31], ["increase FiO2", "TREATMENT", 33, 46], ["suctioning", "TREATMENT", 56, 66], ["hypoxia", "OBSERVATION", 24, 31]]], ["If necessary, you can also attach an oxygen reservoir to the negative pressure relief valve.III.Anticipated Events, Effects, and Alarms: It is important to address various conceivable deviations, what effects these events would have on the patients attached to the ventilator, and how the provider would be alerted to these occurrences.", [["oxygen", "CHEMICAL", 37, 43], ["oxygen", "CHEMICAL", 37, 43], ["oxygen", "SIMPLE_CHEMICAL", 37, 43], ["valve", "PATHOLOGICAL_FORMATION", 86, 91], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 240, 248], ["an oxygen reservoir", "TREATMENT", 34, 53], ["the negative pressure relief valve", "TREATMENT", 57, 91], ["various conceivable deviations", "PROBLEM", 164, 194], ["the ventilator", "TREATMENT", 261, 275], ["relief valve", "OBSERVATION", 79, 91]]], ["We have attempted to assemble a comprehensive list of such events and their effects (Appendix S1).", [["such events", "PROBLEM", 54, 65]]], ["A brief summary of some anticipated events and failure modes is presented here.III.Decreased Lung Compliance: A variety of clinical changes could lead to decreased compliance -mucous plug, kinked ETT, breath stacking, pneumothorax, hemothorax.", [["Lung", "ANATOMY", 93, 97], ["mucous", "ANATOMY", 176, 182], ["pneumothorax", "DISEASE", 218, 230], ["hemothorax", "DISEASE", 232, 242], ["Lung", "ORGAN", 93, 97], ["mucous", "TISSUE", 176, 182], ["some anticipated events", "PROBLEM", 19, 42], ["failure modes", "PROBLEM", 47, 60], ["Decreased Lung Compliance", "PROBLEM", 83, 108], ["clinical changes", "PROBLEM", 123, 139], ["decreased compliance", "PROBLEM", 154, 174], ["mucous plug", "PROBLEM", 176, 187], ["kinked ETT", "PROBLEM", 189, 199], ["breath stacking", "PROBLEM", 201, 216], ["pneumothorax", "PROBLEM", 218, 230], ["hemothorax", "PROBLEM", 232, 242], ["failure", "OBSERVATION", 47, 54], ["Lung", "ANATOMY", 93, 97], ["Compliance", "OBSERVATION", 98, 108], ["mucous plug", "OBSERVATION", 176, 187], ["kinked", "OBSERVATION_MODIFIER", 189, 195], ["ETT", "OBSERVATION", 196, 199], ["breath stacking", "OBSERVATION", 201, 216], ["pneumothorax", "OBSERVATION", 218, 230], ["hemothorax", "OBSERVATION", 232, 242]]], ["While these events can pose a profound risk to the affected patient, they will have no effect on the respiration of other patients sharing a PReVentS circuit.", [["patient", "ORGANISM", 60, 67], ["patients", "ORGANISM", 122, 130], ["PReVentS", "GENE_OR_GENE_PRODUCT", 141, 149], ["patient", "SPECIES", 60, 67], ["patients", "SPECIES", 122, 130], ["a PReVentS circuit", "TREATMENT", 139, 157]]], ["Decreased compliance in one patient circuit would reliably decrease the VTe measured at the ventilator, and would trigger an alarm.III.Increased Lung Compliance: The most likely cause of increased compliance in the acutely ill would be lung recovery, or perhaps collection drainage, though other causes such as sudden onset of flail chest could occur.", [["Lung", "ANATOMY", 145, 149], ["lung", "ANATOMY", 236, 240], ["patient", "ORGANISM", 28, 35], ["Lung", "ORGAN", 145, 149], ["lung", "ORGAN", 236, 240], ["patient", "SPECIES", 28, 35], ["the VTe", "PROBLEM", 68, 75], ["the ventilator", "TREATMENT", 88, 102], ["Increased Lung Compliance", "PROBLEM", 135, 160], ["increased compliance", "PROBLEM", 187, 207], ["lung recovery", "PROBLEM", 236, 249], ["collection drainage", "TREATMENT", 262, 281], ["flail chest", "PROBLEM", 327, 338], ["compliance", "OBSERVATION_MODIFIER", 10, 20], ["VTe", "OBSERVATION", 72, 75], ["Lung", "ANATOMY", 145, 149], ["Compliance", "OBSERVATION", 150, 160], ["most likely", "UNCERTAINTY", 166, 177], ["increased", "OBSERVATION_MODIFIER", 187, 196], ["compliance", "OBSERVATION", 197, 207], ["lung", "ANATOMY", 236, 240], ["recovery", "OBSERVATION", 241, 249], ["collection", "OBSERVATION_MODIFIER", 262, 272], ["drainage", "OBSERVATION", 273, 281], ["flail", "OBSERVATION", 327, 332], ["chest", "ANATOMY", 333, 338]]], ["None of these events would change the ventilation of patients sharing the ventilator.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["these events", "PROBLEM", 8, 20], ["the ventilation", "TREATMENT", 34, 49], ["the ventilator", "TREATMENT", 70, 84]]], ["Increased compliance would increase VTe and trigger an alarm.III.Circuit Leak/Disconnect: The effect of a circuit leak on the PReVentS circuit will depend upon where the leak occurs (Appendix S1).", [["Increased compliance", "PROBLEM", 0, 20], ["increase VTe", "PROBLEM", 27, 39], ["Circuit Leak", "PROBLEM", 65, 77], ["a circuit leak", "PROBLEM", 104, 118], ["the PReVentS circuit", "TREATMENT", 122, 142], ["the leak", "PROBLEM", 166, 174], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["VTe", "OBSERVATION", 36, 39], ["Leak", "OBSERVATION", 73, 77], ["leak", "OBSERVATION", 114, 118], ["leak", "OBSERVATION", 170, 174]]], ["In general, if the leak is within a single patient circuit (anywhere between the inspiratory pressure gated valve and the expiratory check valve), other patients sharing the ventilator will maintain their PEEP and receive some degree of ventilation.", [["patient", "ORGANISM", 43, 50], ["valve", "MULTI-TISSUE_STRUCTURE", 108, 113], ["patients", "ORGANISM", 153, 161], ["patient", "SPECIES", 43, 50], ["patients", "SPECIES", 153, 161], ["the leak", "PROBLEM", 15, 23], ["a single patient circuit", "TREATMENT", 34, 58], ["the inspiratory pressure gated valve", "TREATMENT", 77, 113], ["the expiratory check valve", "TREATMENT", 118, 144], ["the ventilator", "TREATMENT", 170, 184], ["their PEEP", "TREATMENT", 199, 209], ["some degree of ventilation", "TREATMENT", 222, 248], ["leak", "OBSERVATION", 19, 23], ["valve", "ANATOMY", 108, 113]]], ["The closer the leak is to the expiratory pressuregated valve, the more normally other patients will be ventilated.", [["valve", "PATHOLOGICAL_FORMATION", 55, 60], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["The closer the leak", "PROBLEM", 0, 19], ["the expiratory pressuregated valve", "TREATMENT", 26, 60], ["leak", "OBSERVATION", 15, 19], ["valve", "OBSERVATION", 55, 60], ["ventilated", "OBSERVATION", 103, 113]]], ["All leaks from the circuit will trigger the low VTe alarm, and some will trigger the circuit disconnect alarm as well.III..", [["All leaks from the circuit", "PROBLEM", 0, 26], ["the low VTe alarm", "PROBLEM", 40, 57], ["leaks", "OBSERVATION", 4, 9]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.III.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 195, 215], ["this preprint", "TREATMENT", 220, 233], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["1101 Of note, if almost any valve within the circuit develops a leak, it will trigger the high VTe alarm.", [["valve", "ANATOMY", 28, 33], ["valve", "PATHOLOGICAL_FORMATION", 28, 33], ["a leak", "PROBLEM", 62, 68], ["the high VTe alarm", "PROBLEM", 86, 104], ["valve", "OBSERVATION", 28, 33], ["leak", "OBSERVATION", 64, 68]]], ["The one exception is the negative pressure relief valve, which will act as a circuit leak and trigger the low VTe alarm.III.Circuit Occlusion/Stuck Valve: The effects of a circuit occlusion are also dependent on the occlusion location (again, see Appendix S1).", [["valve", "PATHOLOGICAL_FORMATION", 50, 55], ["the negative pressure relief valve", "TREATMENT", 21, 55], ["a circuit leak", "PROBLEM", 75, 89], ["the low VTe alarm", "PROBLEM", 102, 119], ["Circuit Occlusion/Stuck Valve", "TREATMENT", 124, 153], ["a circuit occlusion", "TREATMENT", 170, 189], ["negative", "OBSERVATION", 25, 33], ["pressure", "OBSERVATION_MODIFIER", 34, 42], ["relief valve", "OBSERVATION", 43, 55], ["circuit leak", "OBSERVATION", 77, 89], ["Occlusion", "OBSERVATION", 132, 141], ["Stuck Valve", "OBSERVATION", 142, 153], ["circuit occlusion", "OBSERVATION", 172, 189], ["dependent", "OBSERVATION_MODIFIER", 199, 208], ["occlusion", "OBSERVATION", 216, 225]]], ["However, any occlusions on a patient circuit between the inspiratory T-piece and the expiratory T-piece will have no effect on the ventilation of other patients sharing the ventilator.", [["occlusions", "DISEASE", 13, 23], ["patient", "ORGANISM", 29, 36], ["patients", "ORGANISM", 152, 160], ["patient", "SPECIES", 29, 36], ["patients", "SPECIES", 152, 160], ["any occlusions", "PROBLEM", 9, 23], ["a patient circuit", "TREATMENT", 27, 44], ["the inspiratory T-piece", "TREATMENT", 53, 76], ["the expiratory T-piece", "TREATMENT", 81, 103], ["the ventilation", "TREATMENT", 127, 142], ["the ventilator", "TREATMENT", 169, 183], ["occlusions", "OBSERVATION", 13, 23]]], ["All circuit occlusions will trigger the low VTe alarm, and some will trigger an occlusion alarm as well.III.Most stuck valves will register as circuit occlusions, with the exception of negative pressure relief valves.", [["occlusions", "DISEASE", 12, 22], ["occlusions", "DISEASE", 151, 161], ["valves", "PATHOLOGICAL_FORMATION", 119, 125], ["valves", "PATHOLOGICAL_FORMATION", 210, 216], ["All circuit occlusions", "TREATMENT", 0, 22], ["the low VTe alarm", "PROBLEM", 36, 53], ["an occlusion alarm", "PROBLEM", 77, 95], ["Most stuck valves", "PROBLEM", 108, 125], ["circuit occlusions", "TREATMENT", 143, 161], ["negative pressure relief valves", "TREATMENT", 185, 216], ["circuit occlusions", "OBSERVATION", 4, 22], ["occlusion", "OBSERVATION", 80, 89], ["stuck valves", "OBSERVATION", 113, 125], ["negative", "OBSERVATION", 185, 193], ["pressure", "OBSERVATION_MODIFIER", 194, 202], ["relief valves", "OBSERVATION", 203, 216]]], ["An occlusion at this valve could go unnoticed until a patient is suctioned or makes a respiratory effort.", [["respiratory", "ANATOMY", 86, 97], ["valve", "PATHOLOGICAL_FORMATION", 21, 26], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["An occlusion at this valve", "PROBLEM", 0, 26], ["a respiratory effort", "PROBLEM", 84, 104], ["occlusion", "OBSERVATION", 3, 12], ["valve", "OBSERVATION", 21, 26], ["respiratory effort", "OBSERVATION", 86, 104]]], ["In that case, the affected patient might experience negative airway pressures until the next inspiratory phase.", [["airway", "ANATOMY", 61, 67], ["patient", "ORGANISM", 27, 34], ["airway", "MULTI-TISSUE_STRUCTURE", 61, 67], ["patient", "SPECIES", 27, 34], ["airway pressures", "TEST", 61, 77], ["airway pressures", "OBSERVATION", 61, 77]]], ["It is therefore necessary that the negative pressure relief valve in each patient circuit is tested before initiating ventilation with a PReVentS circuit.III.Patient Ventilatory Effort: While it is important that patients not spontaneously breathe for the PReVentS protocol, it is also important that the system be robust to unanticipated ventilatory effort.", [["valve", "PATHOLOGICAL_FORMATION", 60, 65], ["patient", "ORGANISM", 74, 81], ["patients", "ORGANISM", 213, 221], ["patient", "SPECIES", 74, 81], ["Patient", "SPECIES", 158, 165], ["patients", "SPECIES", 213, 221], ["the negative pressure relief valve", "TREATMENT", 31, 65], ["each patient circuit", "TREATMENT", 69, 89], ["ventilation", "TREATMENT", 118, 129], ["a PReVentS circuit", "TREATMENT", 135, 153], ["the PReVentS protocol", "TREATMENT", 252, 273], ["pressure", "OBSERVATION_MODIFIER", 44, 52], ["relief valve", "OBSERVATION", 53, 65], ["Ventilatory Effort", "OBSERVATION", 166, 184], ["ventilatory effort", "OBSERVATION", 339, 357]]], ["Depending upon how ventilatory efforts align with the ventilator cycle, the effects on the spontaneously breathing patient will be variable (Appendix S1).", [["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["the ventilator cycle", "TREATMENT", 50, 70]]], ["In general, the spontaneously-breathing patient's tidal volumes will increase, and room air may be entrained through the negative pressure relief valve into that patient's circuit.", [["patient", "ORGANISM", 40, 47], ["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 40, 47], ["patient", "SPECIES", 162, 169], ["tidal volumes", "TEST", 50, 63], ["the negative pressure relief valve", "TREATMENT", 117, 151], ["patient's circuit", "TREATMENT", 162, 179]]], ["We anticipate that there will be no effect on the other patient's ventilation or FiO2.", [["FiO2", "CHEMICAL", 81, 85], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["FiO2", "TREATMENT", 81, 85]]], ["Respiratory effort will trigger the high VTe alarm.III.Attempted Chest Compressions: We do not recommend that chest compressions be performed upon a patient attached to a shared ventilator -with our proposed circuit design, it would be easy and safe to disconnect the patient in arrest without releasing an infected aerosol or interrupting ventilation to the paired patient.", [["chest", "ANATOMY", 110, 115], ["chest", "ORGANISM_SUBDIVISION", 110, 115], ["patient", "ORGANISM", 149, 156], ["patient", "ORGANISM", 268, 275], ["patient", "ORGANISM", 366, 373], ["patient", "SPECIES", 149, 156], ["patient", "SPECIES", 268, 275], ["patient", "SPECIES", 366, 373], ["the high VTe alarm", "PROBLEM", 32, 50], ["Chest Compressions", "TREATMENT", 65, 83], ["chest compressions", "TREATMENT", 110, 128], ["a shared ventilator", "TREATMENT", 169, 188], ["our proposed circuit design", "TREATMENT", 195, 222], ["arrest", "PROBLEM", 279, 285], ["an infected aerosol", "TREATMENT", 304, 323], ["interrupting ventilation", "TREATMENT", 327, 351], ["Chest", "ANATOMY", 65, 70], ["chest", "ANATOMY", 110, 115], ["infected", "OBSERVATION_MODIFIER", 307, 315], ["aerosol", "OBSERVATION", 316, 323]]], ["However, it is possible that one patient may undergo chest compressions while the patient is still attached to the ventilator.", [["chest", "ANATOMY", 53, 58], ["patient", "ORGANISM", 33, 40], ["chest", "ORGANISM_SUBDIVISION", 53, 58], ["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 33, 40], ["patient", "SPECIES", 82, 89], ["chest compressions", "TREATMENT", 53, 71], ["the ventilator", "TREATMENT", 111, 125], ["chest", "ANATOMY", 53, 58]]], ["In our laboratory testing, simulated chest compressions on one patient attached to the PReVentS circuit led to only minor changes in airway pressures for the other patient, and the ventilatory pattern to the second patient remained regular.ConclusionsThe PReVentS circuit and protocol may provide a means to care for multiple patients, all having severe lung disease, with one ventilator.", [["chest", "ANATOMY", 37, 42], ["airway", "ANATOMY", 133, 139], ["lung", "ANATOMY", 354, 358], ["lung disease", "DISEASE", 354, 366], ["chest", "ORGANISM_SUBDIVISION", 37, 42], ["patient", "ORGANISM", 63, 70], ["airway", "MULTI-TISSUE_STRUCTURE", 133, 139], ["patient", "ORGANISM", 164, 171], ["patient", "ORGANISM", 215, 222], ["patients", "ORGANISM", 326, 334], ["lung", "ORGAN", 354, 358], ["patient", "SPECIES", 63, 70], ["patient", "SPECIES", 164, 171], ["patient", "SPECIES", 215, 222], ["patients", "SPECIES", 326, 334], ["our laboratory testing", "TEST", 3, 25], ["simulated chest compressions", "TREATMENT", 27, 55], ["the PReVentS circuit", "TREATMENT", 83, 103], ["minor changes in airway pressures", "PROBLEM", 116, 149], ["The PReVentS circuit", "TREATMENT", 251, 271], ["protocol", "TREATMENT", 276, 284], ["severe lung disease", "PROBLEM", 347, 366], ["one ventilator", "TREATMENT", 373, 387], ["chest", "ANATOMY", 37, 42], ["minor", "OBSERVATION_MODIFIER", 116, 121], ["changes", "OBSERVATION", 122, 129], ["airway pressures", "OBSERVATION", 133, 149], ["severe", "OBSERVATION_MODIFIER", 347, 353], ["lung", "ANATOMY", 354, 358], ["disease", "OBSERVATION", 359, 366]]], ["Unlike previously described approaches, the tailoring of ventilatory pressures for each patient, and the ability to titrate those pressures over time, may provide a more useful means of stretching ventilator resources.ConclusionsThe PReVentS circuit design must still be tested in animals and in patients.", [["patient", "ORGANISM", 88, 95], ["patients", "ORGANISM", 296, 304], ["patient", "SPECIES", 88, 95], ["patients", "SPECIES", 296, 304], ["ventilatory pressures", "TREATMENT", 57, 78], ["stretching ventilator resources", "TREATMENT", 186, 217], ["The PReVentS circuit design", "TREATMENT", 229, 256], ["ventilatory pressures", "OBSERVATION", 57, 78]]], ["Such testing will almost certainly bring about additional system improvements and modifications.", [["Such testing", "TEST", 0, 12]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Conclusionsis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 202, 222], ["this preprint", "TREATMENT", 227, 240], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["1101 expect to improve the means of set point adjustment for in-line valves in the circuit.", [["in-line valves in the circuit", "TREATMENT", 61, 90], ["line valves", "OBSERVATION", 64, 75]]], ["Furthermore, additional in vivo experimentation will clarify the best monitors and strategies to assure the safety of both patients attached to the ventilator.", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["strategies", "TREATMENT", 83, 93], ["the ventilator", "TREATMENT", 144, 158]]]], "PMC7445312": [["Ethics StatementThe study protocol was exempted from review by the Public Institutional Review Board designated by the Ministry of Health and Welfare (approval No.", [["The study protocol", "TEST", 16, 34]]], ["P01-202005-31-006).", [["P01-202005-31-006", "CHEMICAL", 0, 17]]]], "237898ac24bdee989edb832243d04c45d984755c": [["Introduction.Susceptibility to certain autoimmune diseases is highly correlated with specific polymorphic residues in molecules encoded by the class II region of the major histocompatibility complex (MHC) [42] .", [["autoimmune diseases", "DISEASE", 39, 58], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 166, 198], ["class II region", "PROTEIN", 143, 158], ["major histocompatibility complex", "PROTEIN", 166, 198], ["MHC", "PROTEIN", 200, 203], ["autoimmune diseases", "PROBLEM", 39, 58], ["specific polymorphic residues in molecules", "PROBLEM", 85, 127]]], ["Therefore, sequence analysis of the protein-coding regions of class II MHC genes has been of considerable importance in clarifying mechanisms of autoimmunity [41] .Introduction.It has also been proposed that aberrant expression of class II MHC genes may predispose to autoimmumty [41] .", [["autoimmunity", "DISEASE", 145, 157], ["autoimmumty", "DISEASE", 268, 279], ["class II MHC", "GENE_OR_GENE_PRODUCT", 62, 74], ["class II MHC", "GENE_OR_GENE_PRODUCT", 231, 243], ["protein-coding regions", "DNA", 36, 58], ["class II MHC genes", "DNA", 62, 80], ["class II MHC genes", "DNA", 231, 249], ["sequence analysis", "TEST", 11, 28], ["the protein", "TEST", 32, 43], ["autoimmunity", "PROBLEM", 145, 157]]], ["Class II MHC molecules have a highly restricted tissue distribution, being normally expressed only on B lymphocytes, macrophages, dendritic cells and activated T lymphocytes [14] .", [["tissue", "ANATOMY", 48, 54], ["B lymphocytes", "ANATOMY", 102, 115], ["macrophages", "ANATOMY", 117, 128], ["dendritic cells", "ANATOMY", 130, 145], ["T lymphocytes", "ANATOMY", 160, 173], ["Class II MHC", "GENE_OR_GENE_PRODUCT", 0, 12], ["tissue", "TISSUE", 48, 54], ["B lymphocytes", "CELL", 102, 115], ["macrophages", "CELL", 117, 128], ["dendritic cells", "CELL", 130, 145], ["T lymphocytes", "CELL", 160, 173], ["Class II MHC molecules", "PROTEIN", 0, 22], ["B lymphocytes", "CELL_TYPE", 102, 115], ["macrophages", "CELL_TYPE", 117, 128], ["dendritic cells", "CELL_TYPE", 130, 145], ["activated T lymphocytes", "CELL_TYPE", 150, 173], ["Class II MHC molecules", "PROBLEM", 0, 22], ["dendritic cells", "PROBLEM", 130, 145], ["activated T lymphocytes", "PROBLEM", 150, 173], ["highly", "OBSERVATION_MODIFIER", 30, 36], ["restricted tissue", "OBSERVATION_MODIFIER", 37, 54], ["lymphocytes", "ANATOMY", 104, 115], ["macrophages", "ANATOMY", 117, 128], ["dendritic cells", "OBSERVATION", 130, 145]]], ["Ectopic expression of class II MHC molecules has been demonstrated in a variety of organ-specific autoimmune states, including thyroid disease, insulindependent diabetes mellitus and multiple sclerosis (MS) (reviewed in [32, 431) .Introduction.In vitro, the presence of class II MHC molecules is sufficient for effective antigen presentation (reviewed in [13] ); therefore it has been speculated that ec-tGpic class II MHC expression could facilitate local immune responses.", [["organ", "ANATOMY", 83, 88], ["thyroid", "ANATOMY", 127, 134], ["thyroid disease", "DISEASE", 127, 142], ["insulindependent diabetes mellitus", "DISEASE", 144, 178], ["multiple sclerosis", "DISEASE", 183, 201], ["MS", "DISEASE", 203, 205], ["class II MHC", "GENE_OR_GENE_PRODUCT", 22, 34], ["organ", "ORGAN", 83, 88], ["thyroid", "ORGAN", 127, 134], ["class II MHC", "GENE_OR_GENE_PRODUCT", 270, 282], ["ec-tGpic class II MHC", "GENE_OR_GENE_PRODUCT", 401, 422], ["class II MHC molecules", "PROTEIN", 22, 44], ["class II MHC molecules", "PROTEIN", 270, 292], ["MHC", "PROTEIN", 419, 422], ["Ectopic expression of class II MHC molecules", "PROBLEM", 0, 44], ["specific autoimmune states", "PROBLEM", 89, 115], ["thyroid disease", "PROBLEM", 127, 142], ["insulindependent diabetes mellitus", "PROBLEM", 144, 178], ["multiple sclerosis (MS)", "PROBLEM", 183, 206], ["class II MHC molecules", "PROBLEM", 270, 292], ["autoimmune", "OBSERVATION", 98, 108], ["thyroid", "ANATOMY", 127, 134], ["diabetes mellitus", "OBSERVATION", 161, 178], ["multiple", "OBSERVATION_MODIFIER", 183, 191], ["sclerosis", "OBSERVATION", 192, 201]]], ["Understanding the regulation of class II MHC expression may therefore provide insight into the pathogenesis of organspecific autoimmunity.", [["autoimmunity", "DISEASE", 125, 137], ["class II MHC", "GENE_OR_GENE_PRODUCT", 32, 44], ["class II MHC", "PROTEIN", 32, 44], ["organspecific autoimmunity", "PROBLEM", 111, 137]]], ["Furthermore, the regulation of this well-characterized family of genes is a model for analysing tissue-specific and inducible gene expression.", [["tissue", "ANATOMY", 96, 102], ["tissue", "TISSUE", 96, 102], ["analysing tissue", "PROBLEM", 86, 102]]], ["In this review, I will focus primarily on the regulation of transcription of human class II MHC genes.Overview of regulation of class H MHC expression.Class II MHC structures are heterodimers; both subunits are integral membrane glycoproteins.", [["membrane", "ANATOMY", 220, 228], ["human", "ORGANISM", 77, 82], ["class II MHC", "GENE_OR_GENE_PRODUCT", 83, 95], ["class H MHC", "GENE_OR_GENE_PRODUCT", 128, 139], ["Class II MHC", "GENE_OR_GENE_PRODUCT", 151, 163], ["membrane glycoproteins", "CELLULAR_COMPONENT", 220, 242], ["human class II MHC genes", "DNA", 77, 101], ["MHC", "PROTEIN", 136, 139], ["Class II MHC structures", "PROTEIN", 151, 174], ["heterodimers", "PROTEIN", 179, 191], ["integral membrane glycoproteins", "PROTEIN", 211, 242], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["membrane glycoproteins", "OBSERVATION", 220, 242]]], ["In human cells, at least three types of class II MHC molecules, HLA-DR, HLA-DQ and HLA-DP, are expressed.", [["cells", "ANATOMY", 9, 14], ["human", "ORGANISM", 3, 8], ["cells", "CELL", 9, 14], ["class II MHC", "GENE_OR_GENE_PRODUCT", 40, 52], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 64, 70], ["HLA-DQ", "GENE_OR_GENE_PRODUCT", 72, 78], ["HLA-DP", "GENE_OR_GENE_PRODUCT", 83, 89], ["human cells", "CELL_TYPE", 3, 14], ["class II MHC molecules", "PROTEIN", 40, 62], ["HLA", "PROTEIN", 64, 67], ["DR", "PROTEIN", 68, 70], ["HLA", "PROTEIN", 72, 75], ["DQ", "PROTEIN", 76, 78], ["HLA", "PROTEIN", 83, 86], ["DP", "PROTEIN", 87, 89], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["HLA", "TEST", 64, 67], ["HLA", "TEST", 72, 75], ["HLA", "TEST", 83, 86], ["human cells", "OBSERVATION", 3, 14], ["DP", "ANATOMY", 87, 89]]], ["Polymorphic genes within the MHC on chromosome six encode the individual ~-and [3-subunits.", [["chromosome", "ANATOMY", 36, 46], ["chromosome", "CELLULAR_COMPONENT", 36, 46], ["MHC", "DNA", 29, 32], ["~-and [3-subunits", "DNA", 73, 90], ["Polymorphic genes", "PROBLEM", 0, 17]]], ["Induction of each haterndimerie eln~ il I~II-IC ~trnetnre involves the coordinate transcription of both subunit genes.", [["I~II", "DNA", 40, 44], ["IC", "DNA", 45, 47], ["trnetnre", "DNA", 49, 57], ["subunit genes", "DNA", 104, 117], ["subunit genes", "OBSERVATION", 104, 117]]], ["A further requirement for constitutive or induced expression may be the presence of a third glycoprotein, the invariant chain, which associates intracellularly with class II MHC ~-and ~-subunits [7] .", [["class II MHC ~-", "GENE_OR_GENE_PRODUCT", 165, 180], ["glycoprotein", "PROTEIN", 92, 104], ["invariant chain", "PROTEIN", 110, 125], ["class II MHC ~-and ~-subunits", "PROTEIN", 165, 194], ["a third glycoprotein", "PROBLEM", 84, 104]]], ["The potential role of the invariant chain was recently discussed, within the context of comprehensive review of posttranslational processing of class II MHC antigens [7] .Overview of regulation of class H MHC expression.There is a spectrum of class II MHC expression at the level of the individual cell.", [["cell", "ANATOMY", 298, 302], ["class II MHC antigens", "GENE_OR_GENE_PRODUCT", 144, 165], ["class H MHC", "GENE_OR_GENE_PRODUCT", 197, 208], ["class II MHC", "GENE_OR_GENE_PRODUCT", 243, 255], ["cell", "CELL", 298, 302], ["invariant chain", "PROTEIN", 26, 41], ["class II MHC antigens", "PROTEIN", 144, 165], ["MHC", "PROTEIN", 205, 208], ["class II MHC", "PROTEIN", 243, 255], ["class II", "OBSERVATION_MODIFIER", 243, 251], ["MHC expression", "OBSERVATION", 252, 266], ["individual cell", "OBSERVATION", 287, 302]]], ["Constitutive class II MHC expression at a high level of cell surface density is observed in B lymphocytes and activated human T lymphocytes.", [["cell surface", "ANATOMY", 56, 68], ["B lymphocytes", "ANATOMY", 92, 105], ["T lymphocytes", "ANATOMY", 126, 139], ["class II MHC", "GENE_OR_GENE_PRODUCT", 13, 25], ["cell surface", "CELLULAR_COMPONENT", 56, 68], ["B lymphocytes", "CELL", 92, 105], ["human", "ORGANISM", 120, 125], ["T lymphocytes", "CELL", 126, 139], ["MHC", "PROTEIN", 22, 25], ["B lymphocytes", "CELL_TYPE", 92, 105], ["activated human T lymphocytes", "CELL_TYPE", 110, 139], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 120, 125], ["Constitutive class II MHC expression", "PROBLEM", 0, 36], ["cell surface density", "TEST", 56, 76], ["activated human T lymphocytes", "PROBLEM", 110, 139], ["cell", "OBSERVATION", 56, 60], ["surface density", "OBSERVATION", 61, 76], ["lymphocytes", "ANATOMY", 94, 105]]], ["Macrophages and dendritic cells constitutively express class II MHC molecules at lower cell surface density and can be induced to enhanced expression.", [["Macrophages", "ANATOMY", 0, 11], ["dendritic cells", "ANATOMY", 16, 31], ["cell surface", "ANATOMY", 87, 99], ["Macrophages", "CELL", 0, 11], ["dendritic cells", "CELL", 16, 31], ["class II MHC molecules", "GENE_OR_GENE_PRODUCT", 55, 77], ["cell surface", "CELLULAR_COMPONENT", 87, 99], ["Macrophages", "CELL_TYPE", 0, 11], ["dendritic cells", "CELL_TYPE", 16, 31], ["class II MHC molecules", "PROTEIN", 55, 77], ["Macrophages", "PROBLEM", 0, 11], ["dendritic cells", "PROBLEM", 16, 31], ["dendritic cells", "OBSERVATION", 16, 31], ["lower cell", "OBSERVATION_MODIFIER", 81, 91], ["surface", "OBSERVATION_MODIFIER", 92, 99], ["density", "OBSERVATION", 100, 107]]], ["A wide variety of parenchymal cells, on which class II MHC molecules are normally undetectable, can be induced to class II MHC expression both in tissue-culture and in vivo [6] .", [["parenchymal cells", "ANATOMY", 18, 35], ["tissue-culture", "ANATOMY", 146, 160], ["parenchymal cells", "CELL", 18, 35], ["class II MHC molecules", "GENE_OR_GENE_PRODUCT", 46, 68], ["class II MHC", "GENE_OR_GENE_PRODUCT", 114, 126], ["tissue", "TISSUE", 146, 152], ["parenchymal cells", "CELL_TYPE", 18, 35], ["class II MHC molecules", "PROTEIN", 46, 68], ["MHC", "PROTEIN", 123, 126], ["A wide variety of parenchymal cells", "PROBLEM", 0, 35], ["culture", "TEST", 153, 160], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["variety", "OBSERVATION_MODIFIER", 7, 14], ["parenchymal cells", "OBSERVATION", 18, 35]]], ["Finally, class II MHC molecules cannot be induced on a minority of cell types, including human foetal neurons in tissue culture [27] .", [["cell", "ANATOMY", 67, 71], ["foetal neurons", "ANATOMY", 95, 109], ["tissue culture", "ANATOMY", 113, 127], ["class II MHC", "GENE_OR_GENE_PRODUCT", 9, 21], ["cell", "CELL", 67, 71], ["human", "ORGANISM", 89, 94], ["foetal neurons", "CELL", 95, 109], ["tissue", "TISSUE", 113, 119], ["class II MHC molecules", "PROTEIN", 9, 31], ["human foetal neurons", "CELL_TYPE", 89, 109], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["human foetal neurons", "PROBLEM", 89, 109], ["tissue culture", "TEST", 113, 127], ["cell types", "OBSERVATION", 67, 77]]], ["The detailed characterization of mechanisms which permit this degree of flexibility in class II MHC gone expression would be of considerable interest.Overview of regulation of class H MHC expression.In several laboratories including our own, it has been documented that expression of class II MHC molecules is directly correlated with the abundance of mRNA encoding class II MHC products (reviewed in [17, 11, 34] ).", [["class II MHC", "GENE_OR_GENE_PRODUCT", 87, 99], ["class H MHC", "GENE_OR_GENE_PRODUCT", 176, 187], ["class II MHC", "GENE_OR_GENE_PRODUCT", 284, 296], ["class II MHC", "GENE_OR_GENE_PRODUCT", 366, 378], ["MHC", "PROTEIN", 96, 99], ["MHC", "PROTEIN", 184, 187], ["class II MHC molecules", "PROTEIN", 284, 306], ["mRNA", "RNA", 352, 356], ["class II MHC products", "PROTEIN", 366, 387], ["The detailed characterization", "TEST", 0, 29]]], ["Therefore, processes affecting the steadystate levels of these mRNA are crucially important in regulating the expression of class II MHC molecules.", [["steadystate", "GENE_OR_GENE_PRODUCT", 35, 46], ["class II MHC molecules", "GENE_OR_GENE_PRODUCT", 124, 146], ["mRNA", "RNA", 63, 67], ["class II MHC molecules", "PROTEIN", 124, 146]]], ["It is likely that a major contribution to increased steadystate levels of class II MHC mRNA in cells exposed to interferon-y results from increased transcription of the cognate genes [4] .C/s-regulatory sequences.The accurate and efficient transcription of eukaryotic genes requires regulatory DNA sequence elements designated as promoters; for genes transcribed by RNA polymerase II, these elements are located 5' of the mRNA-cap site.", [["cells", "ANATOMY", 95, 100], ["class II MHC", "GENE_OR_GENE_PRODUCT", 74, 86], ["cells", "CELL", 95, 100], ["interferon-y", "GENE_OR_GENE_PRODUCT", 112, 124], [".C", "GENE_OR_GENE_PRODUCT", 187, 189], ["DNA", "CELLULAR_COMPONENT", 294, 297], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 366, 383], ["class II MHC mRNA", "RNA", 74, 91], ["interferon", "PROTEIN", 112, 122], ["cognate genes [4] .C/s-regulatory sequences", "DNA", 169, 212], ["eukaryotic genes", "DNA", 257, 273], ["regulatory DNA sequence elements", "DNA", 283, 315], ["promoters", "DNA", 330, 339], ["RNA polymerase II", "PROTEIN", 366, 383], ["mRNA-cap site", "DNA", 422, 435], ["increased steadystate levels", "PROBLEM", 42, 70], [".C/s", "TEST", 187, 191], ["regulatory DNA sequence elements", "TREATMENT", 283, 315], ["eukaryotic genes", "OBSERVATION", 257, 273]]], ["Sequence analysis of Y-flanking regions of numerous class II MHC genes has revealed several conserved sequences, which by virtue of their conservation are candidate regulatory elements (reviewed in [17, 18, 30] ).", [["class II MHC", "GENE_OR_GENE_PRODUCT", 52, 64], ["Y-flanking regions", "DNA", 21, 39], ["class II MHC genes", "DNA", 52, 70], ["regulatory elements", "DNA", 165, 184], ["Sequence analysis", "TEST", 0, 17], ["Y-flanking regions", "PROBLEM", 21, 39]]], ["In particular, two short DNA segme~ts, which have been designated class II MHC X and Y boxes, haw.\" been identified in the promoters of all human class II MHC genes (reviewed in [17, 40] ).", [["DNA", "CELLULAR_COMPONENT", 25, 28], ["class II MHC X", "GENE_OR_GENE_PRODUCT", 66, 80], ["human", "ORGANISM", 140, 145], ["class II MHC", "GENE_OR_GENE_PRODUCT", 146, 158], ["DNA segme~ts", "DNA", 25, 37], ["class II MHC X", "DNA", 66, 80], ["Y boxes", "DNA", 85, 92], ["promoters", "DNA", 123, 132], ["human class II MHC genes", "DNA", 140, 164], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["two short DNA segme~ts", "PROBLEM", 15, 37]]], ["Homologous sequence elements are present in the promoters of murine class II MHC genes as well [.26 ].", [["murine", "ORGANISM", 61, 67], ["class II MHC", "GENE_OR_GENE_PRODUCT", 68, 80], ["Homologous sequence elements", "DNA", 0, 28], ["promoters", "DNA", 48, 57], ["murine class II MHC genes", "DNA", 61, 86], ["murine", "SPECIES", 61, 67], ["Homologous sequence elements", "PROBLEM", 0, 28]]], ["In the human DR-= promoter region, the X box is located at -108 to -95 relative to the mRNA-cap site; the Y box is located downstream at -74 to -61 [17] .", [["human", "ORGANISM", 7, 12], ["DR", "GENE_OR_GENE_PRODUCT", 13, 15], ["human DR-= promoter region", "DNA", 7, 33], ["X box", "DNA", 39, 44], ["mRNA-cap site", "DNA", 87, 100], ["Y box", "DNA", 106, 111], ["-74 to -61 [17]", "DNA", 137, 152], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["the X box", "TREATMENT", 35, 44], ["the Y box", "TEST", 102, 111]]], ["The Y box contains contains an inverted form of the sequence CCAAT.", [["Y box", "DNA", 4, 9], ["CCAAT", "DNA", 61, 66], ["The Y box", "TREATMENT", 0, 9], ["the sequence CCAAT", "TEST", 48, 66]]], ["This sequence element is a general transcriptional activator, ~Ld it has been proposed that the Y box exerts its function in part by associating with the universal CCAAT-binding tr~mscription factor [9, 10] .", [["Ld", "GENE_OR_GENE_PRODUCT", 63, 65], ["CCAAT-binding tr~mscription factor", "GENE_OR_GENE_PRODUCT", 164, 198], ["general transcriptional activator", "PROTEIN", 27, 60], ["Ld", "PROTEIN", 63, 65], ["Y box", "DNA", 96, 101], ["CCAAT-binding tr~mscription factor", "PROTEIN", 164, 198], ["the Y box", "TREATMENT", 92, 101]]], ["Boss and Sl~rominger demonstrated the relevance of the conserved X and Y boxes for expression of a transfected DQ-[3 gene in human fibroblasts [5] .", [["fibroblasts", "ANATOMY", 131, 142], ["DQ-[3", "GENE_OR_GENE_PRODUCT", 111, 116], ["human", "ORGANISM", 125, 130], ["fibroblasts", "CELL", 131, 142], ["X and Y boxes", "DNA", 65, 78], ["transfected DQ-[3 gene", "DNA", 99, 121], ["human fibroblasts", "CELL_TYPE", 125, 142], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["a transfected DQ", "TEST", 97, 113]]], ["Plasmids containing DQ-[3 genes truncated progressively within 5'-flanking sequences were assayed in stably transfected cells for their ability to direct the synthesis of DQ-[~ mRNA [5] .", [["cells", "ANATOMY", 120, 125], ["DQ-[3", "GENE_OR_GENE_PRODUCT", 20, 25], ["cells", "CELL", 120, 125], ["DQ", "GENE_OR_GENE_PRODUCT", 171, 173], ["DQ-[3 genes", "DNA", 20, 31], ["5'-flanking sequences", "DNA", 63, 84], ["stably transfected cells", "CELL_LINE", 101, 125], ["DQ", "PROTEIN", 171, 173], ["flanking sequences", "TEST", 66, 84]]], ["Deletions encroaching upon the X-and Y-box sequences resulted in decreased basal DQ-[3 expression, suggesting that these se:luence elements were positive regulators of class II MHC expression.", [["DQ-[3", "GENE_OR_GENE_PRODUCT", 81, 86], ["class II MHC", "GENE_OR_GENE_PRODUCT", 168, 180], ["X-and Y-box sequences", "DNA", 31, 52], ["DQ", "PROTEIN", 81, 83], ["luence elements", "DNA", 124, 139], ["class II MHC", "PROTEIN", 168, 180], ["Deletions encroaching", "PROBLEM", 0, 21], ["Y-box sequences", "TEST", 37, 52], ["decreased basal DQ", "PROBLEM", 65, 83], ["decreased", "OBSERVATION_MODIFIER", 65, 74], ["basal", "ANATOMY_MODIFIER", 75, 80]]], ["L~et.ions which eliminated the uI~stream X box and portions of the spacer between the X and Y boxes directed the synthesis of suprabasal DQ-[3 mRNA, suggesting that a negative regulatory element could be present in the spacer [5] .C/s-regulatory sequences.An additional conserved DNA sequence has been ident~.fied in all human class II MHC promoters analysed to is homologous to the octamer sequence, Wl'liCh was first characterized in the promoters of immunoglobulin genes and has subsequently been identified in promoters of numerous eukaryotic genes [37, 39] .", [["L~et.ions", "CHEMICAL", 0, 9], ["DQ-[3", "GENE_OR_GENE_PRODUCT", 137, 142], ["DNA", "CELLULAR_COMPONENT", 280, 283], ["human", "ORGANISM", 321, 326], ["class II MHC", "GENE_OR_GENE_PRODUCT", 327, 339], ["Wl'liCh", "GENE_OR_GENE_PRODUCT", 401, 408], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 453, 467], ["uI~stream X box", "DNA", 31, 46], ["X and Y boxes", "DNA", 86, 99], ["suprabasal DQ-[3 mRNA", "RNA", 126, 147], ["negative regulatory element", "DNA", 167, 194], ["spacer [5] .C/s-regulatory sequences", "DNA", 219, 255], ["conserved DNA sequence", "DNA", 270, 292], ["human class II MHC promoters", "DNA", 321, 349], ["octamer sequence", "DNA", 383, 399], ["Wl'liCh", "DNA", 401, 408], ["promoters", "DNA", 440, 449], ["immunoglobulin genes", "DNA", 453, 473], ["promoters", "DNA", 514, 523], ["eukaryotic genes", "DNA", 536, 552], ["human", "SPECIES", 321, 326], ["human", "SPECIES", 321, 326], ["the uI~stream X box", "TREATMENT", 27, 46], ["the spacer between the X and Y boxes", "TREATMENT", 63, 99], ["a negative regulatory element", "PROBLEM", 165, 194], [".C/s-regulatory sequences", "TEST", 230, 255], ["An additional conserved DNA sequence", "TEST", 256, 292], ["immunoglobulin genes", "TREATMENT", 453, 473], ["stream", "OBSERVATION_MODIFIER", 34, 40], ["suprabasal", "ANATOMY_MODIFIER", 126, 136]]], ["Whereas octamer sequences occur in a fixed position upstream of all immunoglobulin genes, their location in class II MHC genes is not conserved, and theLr rdevance for class II MHC expression has not been addressed by deletion analysis.C/s-regulatory sequences.Several conserved elements in class II MHC gone promoters have been analysed with regard to their potential significance for tissue-sr.ecific or interferon-~--inducible expression.", [["tissue", "ANATOMY", 386, 392], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 68, 82], ["class II MHC", "GENE_OR_GENE_PRODUCT", 108, 120], ["class II MHC", "GENE_OR_GENE_PRODUCT", 168, 180], ["C", "GENE_OR_GENE_PRODUCT", 236, 237], ["class II MHC", "GENE_OR_GENE_PRODUCT", 291, 303], ["tissue", "TISSUE", 386, 392], ["interferon", "GENE_OR_GENE_PRODUCT", 406, 416], ["octamer sequences", "DNA", 8, 25], ["immunoglobulin genes", "DNA", 68, 88], ["class II MHC genes", "DNA", 108, 126], ["MHC", "PROTEIN", 177, 180], ["C/s-regulatory sequences", "DNA", 236, 260], ["class II MHC gone promoters", "DNA", 291, 318], ["interferon", "PROTEIN", 406, 416], ["octamer sequences", "TEST", 8, 25], ["deletion analysis", "TEST", 218, 235], ["C/s", "TEST", 236, 239], ["tissue-sr.ecific", "PROBLEM", 386, 402], ["interferon", "TREATMENT", 406, 416], ["immunoglobulin genes", "OBSERVATION", 68, 88]]], ["Promoter elements extending approximately 200 nucleotides upstream of the cap site are sufficient for both tissue-specific and interferon-f-inducible expression of transfected genes in several cell types, including human glioblastoma cells [ 3\u00b0 36] .", [["cap site", "ANATOMY", 74, 82], ["tissue", "ANATOMY", 107, 113], ["cell", "ANATOMY", 193, 197], ["glioblastoma cells", "ANATOMY", 221, 239], ["glioblastoma", "DISEASE", 221, 233], ["nucleotides", "CHEMICAL", 46, 57], ["tissue", "TISSUE", 107, 113], ["interferon-f", "GENE_OR_GENE_PRODUCT", 127, 139], ["cell", "CELL", 193, 197], ["human", "ORGANISM", 215, 220], ["glioblastoma cells", "CELL", 221, 239], ["Promoter elements", "DNA", 0, 17], ["cap site", "DNA", 74, 82], ["interferon", "PROTEIN", 127, 137], ["transfected genes", "DNA", 164, 181], ["human glioblastoma cells", "CELL_TYPE", 215, 239], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["Promoter elements", "PROBLEM", 0, 17], ["the cap site", "PROBLEM", 70, 82], ["transfected genes in several cell types", "PROBLEM", 164, 203], ["human glioblastoma cells", "PROBLEM", 215, 239], ["cap", "OBSERVATION_MODIFIER", 74, 77], ["transfected genes", "OBSERVATION", 164, 181], ["several cell types", "OBSERVATION", 185, 203], ["glioblastoma cells", "OBSERVATION", 221, 239]]], ["For the expression of the DQ-[~ gene in fibroblasts, deletion to -128, within an element designated the W box, abolishes interferon-y inducibility, but elevates basal expression levels, suggesting that the W box may contain an interferon-y-inducible negative regulatory element [5] .", [["fibroblasts", "ANATOMY", 40, 51], ["DQ", "GENE_OR_GENE_PRODUCT", 26, 28], ["fibroblasts", "CELL", 40, 51], ["interferon-y", "GENE_OR_GENE_PRODUCT", 121, 133], ["DQ-[~ gene", "DNA", 26, 36], ["fibroblasts", "CELL_TYPE", 40, 51], ["deletion to -128", "DNA", 53, 69], ["W box", "DNA", 104, 109], ["interferon", "PROTEIN", 121, 131], ["W box", "DNA", 206, 211], ["interferon", "PROTEIN", 227, 237], ["negative regulatory element", "DNA", 250, 277], ["the DQ", "TEST", 22, 28], ["deletion", "PROBLEM", 53, 61], ["the W box", "TREATMENT", 100, 109], ["interferon-y inducibility", "PROBLEM", 121, 146], ["elevates basal expression levels", "PROBLEM", 152, 184], ["the W box", "PROBLEM", 202, 211], ["fibroblasts", "ANATOMY", 40, 51]]], ["Another putative regulatory element, termed the Z box, is similarly located upstream of the X box in the DR-~-gene promoter [40] .Trans-acting factors.The mechanism by which individual DNA elements provide promoter and enhancer function involves association with specific putative transcription factors.", [["DR-~-", "GENE_OR_GENE_PRODUCT", 105, 110], ["Trans-acting factors", "GENE_OR_GENE_PRODUCT", 130, 150], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["putative regulatory element", "DNA", 8, 35], ["Z box", "DNA", 48, 53], ["X box", "DNA", 92, 97], ["DR-~-gene promoter", "DNA", 105, 123], ["Trans-acting factors", "PROTEIN", 130, 150], ["DNA elements", "DNA", 185, 197], ["transcription factors", "PROTEIN", 281, 302], ["the Z box", "TREATMENT", 44, 53], ["regulatory element", "OBSERVATION", 17, 35]]], ["It was recently demonstrated that interferon-T-induced transcription of DR-~ genes in HeLa cells requires de novo protein synthesis [4] .", [["HeLa cells", "ANATOMY", 86, 96], ["interferon-T", "CHEMICAL", 34, 46], ["interferon-T", "GENE_OR_GENE_PRODUCT", 34, 46], ["DR-~", "GENE_OR_GENE_PRODUCT", 72, 76], ["HeLa cells", "CELL", 86, 96], ["interferon", "PROTEIN", 34, 44], ["DR-~ genes", "DNA", 72, 82], ["HeLa cells", "CELL_LINE", 86, 96], ["interferon", "TREATMENT", 34, 44], ["HeLa cells", "PROBLEM", 86, 96], ["de novo protein synthesis", "TREATMENT", 106, 131]]], ["This observation suggested that the synthesis of a transcription factor or production of an activity capable of modifying a preexisting factor is essential for the induction of class II MHC expression by interferon-y in HeLa cells [4] .", [["HeLa cells", "ANATOMY", 220, 230], ["class II MHC", "GENE_OR_GENE_PRODUCT", 177, 189], ["interferon-y", "GENE_OR_GENE_PRODUCT", 204, 216], ["HeLa cells", "CELL", 220, 230], ["transcription factor", "PROTEIN", 51, 71], ["class II MHC", "PROTEIN", 177, 189], ["interferon", "PROTEIN", 204, 214], ["HeLa cells", "CELL_LINE", 220, 230], ["a transcription factor", "PROBLEM", 49, 71], ["the induction of class II MHC expression", "TREATMENT", 160, 200], ["interferon-y in HeLa cells", "TREATMENT", 204, 230]]], ["This requirement was specific for class II MHC gene transcription, since expression of class l MHC genes was insensitive t\u00a2 ir.~hibition of protein synthesis[4].Several lines of additional evidence indicate that trans-regulatory factors, at least some of which are encoded outside the MHC, are essential for both constitutive and induced class II MHC expression.", [["class II MHC", "GENE_OR_GENE_PRODUCT", 34, 46], ["class l MHC", "GENE_OR_GENE_PRODUCT", 87, 98], ["MHC", "GENE_OR_GENE_PRODUCT", 285, 288], ["class II MHC", "GENE_OR_GENE_PRODUCT", 338, 350], ["class II MHC gene", "DNA", 34, 51], ["class l MHC genes", "DNA", 87, 104], ["trans-regulatory factors", "PROTEIN", 212, 236], ["MHC", "PROTEIN", 285, 288], ["MHC", "PROTEIN", 347, 350], ["class II MHC gene transcription", "TREATMENT", 34, 65], ["protein synthesis", "TREATMENT", 140, 157], ["trans-regulatory factors", "PROBLEM", 212, 236]]], ["A particularly convincing demonstration has come from analysis of the severe combined immunodeficiency (SCID) phenotype, in which cells fail to express class II MHC antigens or their transcripts, and cannot be induced to express class II MHC molecules by interferon-y, but contain invariantchain transcripts [31] .", [["cells", "ANATOMY", 130, 135], ["immunodeficiency", "DISEASE", 86, 102], ["SCID", "DISEASE", 104, 108], ["cells", "CELL", 130, 135], ["class II MHC antigens", "GENE_OR_GENE_PRODUCT", 152, 173], ["class II MHC molecules", "GENE_OR_GENE_PRODUCT", 229, 251], ["interferon-y", "GENE_OR_GENE_PRODUCT", 255, 267], ["invariantchain", "GENE_OR_GENE_PRODUCT", 281, 295], ["class II MHC antigens", "PROTEIN", 152, 173], ["class II MHC molecules", "PROTEIN", 229, 251], ["invariantchain transcripts", "RNA", 281, 307], ["the severe combined immunodeficiency (SCID) phenotype", "PROBLEM", 66, 119], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["immunodeficiency", "OBSERVATION", 86, 102]]], ["The SCID phenotype has been mapped genetically outside the MHC [31] .", [["MHC", "PROTEIN", 59, 62], ["The SCID phenotype", "PROBLEM", 0, 18], ["SCID", "OBSERVATION", 4, 8]]], ["In an elegan. series of experiments, Reith and co-~orkers assayed nuclear extracts of B lymphocytes from SCID patients and normal controls for activities which bound DR-Qt putative regulatory se-quences [35] .", [["nuclear extracts", "ANATOMY", 66, 82], ["B lymphocytes", "ANATOMY", 86, 99], ["nuclear extracts", "ORGANISM_SUBSTANCE", 66, 82], ["B lymphocytes", "CELL", 86, 99], ["SCID", "ORGANISM", 105, 109], ["patients", "ORGANISM", 110, 118], ["DR-Qt", "GENE_OR_GENE_PRODUCT", 166, 171], ["B lymphocytes", "CELL_TYPE", 86, 99], ["DR", "PROTEIN", 166, 168], ["patients", "SPECIES", 110, 118], ["lymphocytes", "ANATOMY", 88, 99]]], ["Whereas control nuclear extracts contained potential transcription factors which bound X box, Y box and immunoglobulin-gene-related octamer sequences, several SCID extracts exhibited a striking defidency of the X-box-binding activity, indicating its centrality in this phenotype [35] .[4].It has also been documented that nuclear extracts of Raji cells (a B-lymphoma-derived human line), contain activities which exhibit sequence-specific association with DNA fragments containing W-box, X-box and Y-box sequences [28] .", [["nuclear extracts", "ANATOMY", 16, 32], ["extracts", "ANATOMY", 164, 172], ["nuclear extracts", "ANATOMY", 322, 338], ["Raji cells", "ANATOMY", 342, 352], ["B-lymphoma", "ANATOMY", 356, 366], ["line", "ANATOMY", 381, 385], ["lymphoma", "DISEASE", 358, 366], ["extracts", "ORGANISM_SUBSTANCE", 24, 32], ["Y box", "GENE_OR_GENE_PRODUCT", 94, 99], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 104, 118], ["SCID extracts", "ORGANISM", 159, 172], ["nuclear extracts", "ORGANISM_SUBSTANCE", 322, 338], ["Raji cells", "CELL", 342, 352], ["B-lymphoma", "CANCER", 356, 366], ["human", "ORGANISM", 375, 380], ["DNA", "CELLULAR_COMPONENT", 456, 459], ["transcription factors", "PROTEIN", 53, 74], ["X box", "DNA", 87, 92], ["Y box", "DNA", 94, 99], ["immunoglobulin-gene", "DNA", 104, 123], ["octamer sequences", "DNA", 132, 149], ["X-box", "DNA", 211, 216], ["Raji cells", "CELL_LINE", 342, 352], ["B-lymphoma-derived human line", "CELL_LINE", 356, 385], ["DNA fragments", "DNA", 456, 469], ["W-box", "DNA", 481, 486], ["X-box", "DNA", 488, 493], ["Y-box sequences", "DNA", 498, 513], ["human", "SPECIES", 375, 380], ["human", "SPECIES", 375, 380], ["potential transcription factors", "PROBLEM", 43, 74], ["Y box", "TEST", 94, 99], ["immunoglobulin", "TEST", 104, 118], ["related octamer sequences", "PROBLEM", 124, 149], ["several SCID extracts", "PROBLEM", 151, 172], ["Raji cells", "PROBLEM", 342, 352], ["a B-lymphoma-derived human line", "TREATMENT", 354, 385], ["DNA fragments", "PROBLEM", 456, 469], ["W-box", "TREATMENT", 481, 486], ["Y-box sequences", "TEST", 498, 513], ["Raji cells", "OBSERVATION", 342, 352]]], ["The specificity of this binding was demonstrated by gel retardation, DNase-I-footprinting and methylation interference analyses [28] .", [["DNase-I", "GENE_OR_GENE_PRODUCT", 69, 76], ["DNase", "PROTEIN", 69, 74], ["this binding", "PROBLEM", 19, 31], ["gel retardation", "PROBLEM", 52, 67], ["DNase-I-footprinting", "TREATMENT", 69, 89], ["methylation interference analyses", "TEST", 94, 127]]], ["No differences were observed, however, between class-II-MHC-expressing Raji cells and class-II-MHC-negative variants, indicating that the Raji cell nuclear factors which associate with these sequence elements are not sufficient for expression of class II MHC genes [28] .[4].The recent isolation by Liou and coworkers of cDNA clones corresponding to potential X-box-binding transregulatory factors will facilitate investigation of their physiologic role in governing class II MHC expression [20] .", [["Raji cells", "ANATOMY", 71, 81], ["Raji cell", "ANATOMY", 138, 147], ["class-II-MHC", "GENE_OR_GENE_PRODUCT", 47, 59], ["Raji cells", "CELL", 71, 81], ["class-II-MHC", "GENE_OR_GENE_PRODUCT", 86, 98], ["Raji cell", "CELL", 138, 147], ["class II MHC", "GENE_OR_GENE_PRODUCT", 246, 258], ["cDNA clones", "CELL", 321, 332], ["class II MHC", "GENE_OR_GENE_PRODUCT", 467, 479], ["MHC", "PROTEIN", 56, 59], ["Raji cells", "CELL_LINE", 71, 81], ["MHC", "PROTEIN", 95, 98], ["Raji cell nuclear factors", "PROTEIN", 138, 163], ["class II MHC genes", "DNA", 246, 264], ["cDNA clones", "DNA", 321, 332], ["X-box-binding transregulatory factors", "PROTEIN", 360, 397], ["MHC", "PROTEIN", 476, 479], ["Raji cells", "TEST", 71, 81], ["the Raji cell nuclear factors", "PROBLEM", 134, 163], ["The recent isolation", "TREATMENT", 275, 295], ["cDNA clones", "PROBLEM", 321, 332], ["box-binding transregulatory factors", "TREATMENT", 362, 397], ["Raji cells", "OBSERVATION", 71, 81], ["negative variants", "OBSERVATION_MODIFIER", 99, 116], ["Raji cell", "OBSERVATION", 138, 147]]], ["Surprisingly, two clones identified by screening a lambda-phage expression library with labelled oligodeoxynucleotides were distinct, although both encoded X-box-binding activities [20] .", [["lambda-phage expression library", "DNA", 51, 82], ["X-box", "DNA", 156, 161], ["a lambda-phage expression library", "TREATMENT", 49, 82], ["labelled oligodeoxynucleotides", "TREATMENT", 88, 118]]], ["Furthermore, the binding activity was specific for the murine class II A-~ promoter, in that fragments containing E-= X-box sequences were not bound [20] .Other modulators of class II MHC expression.It is unclear how the interaction of interferon-y with its receptor results in transcription of specific genes.", [["fragments", "ANATOMY", 93, 102], ["murine", "ORGANISM", 55, 61], ["class II A", "GENE_OR_GENE_PRODUCT", 62, 72], ["class II MHC", "GENE_OR_GENE_PRODUCT", 175, 187], ["interferon-y", "GENE_OR_GENE_PRODUCT", 236, 248], ["murine class II A-~ promoter", "DNA", 55, 83], ["E-= X-box sequences", "DNA", 114, 133], ["class II MHC", "PROTEIN", 175, 187], ["interferon", "PROTEIN", 236, 246], ["murine", "SPECIES", 55, 61], ["A-~ promoter", "TREATMENT", 71, 83], ["box sequences", "TEST", 120, 133], ["interferon-y", "TREATMENT", 236, 248]]], ["The successful cloning of the human receptor for interferon-y by Aguet and coworkers should facilitate rapid progress m characterization of this transmembrane-signaling event [1] .Other modulators of class II MHC expression.In addition to the prototypic inducer, interferon--r, a great diversity of other influences have been demonstrated to affect class II MHC expression.", [["transmembrane", "ANATOMY", 145, 158], ["human", "ORGANISM", 30, 35], ["interferon-y", "GENE_OR_GENE_PRODUCT", 49, 61], ["transmembrane", "CELLULAR_COMPONENT", 145, 158], ["class II MHC", "GENE_OR_GENE_PRODUCT", 200, 212], ["interferon--r", "GENE_OR_GENE_PRODUCT", 263, 276], ["class II MHC", "GENE_OR_GENE_PRODUCT", 349, 361], ["human receptor", "PROTEIN", 30, 44], ["class II MHC", "PROTEIN", 200, 212], ["interferon", "PROTEIN", 263, 273], ["MHC", "PROTEIN", 358, 361], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["the prototypic inducer", "TREATMENT", 239, 261], ["interferon", "TREATMENT", 263, 273]]], ["Other positive modulators of class II MHC expression include murine coronavirus particles, which specifically induce class II MHC expression in rat asUocytes, but not in microglia [23] .", [["asUocytes", "ANATOMY", 148, 157], ["microglia", "ANATOMY", 170, 179], ["class II MHC", "GENE_OR_GENE_PRODUCT", 29, 41], ["murine coronavirus", "ORGANISM", 61, 79], ["class II MHC", "GENE_OR_GENE_PRODUCT", 117, 129], ["rat", "ORGANISM", 144, 147], ["asUocytes", "CANCER", 148, 157], ["microglia", "CELL", 170, 179], ["class II MHC", "PROTEIN", 29, 41], ["MHC", "PROTEIN", 126, 129], ["rat asUocytes", "CELL_TYPE", 144, 157], ["microglia", "CELL_TYPE", 170, 179], ["murine", "SPECIES", 61, 67], ["coronavirus", "SPECIES", 68, 79], ["rat", "SPECIES", 144, 147], ["murine coronavirus", "SPECIES", 61, 79], ["rat", "SPECIES", 144, 147], ["murine coronavirus particles", "PROBLEM", 61, 89], ["coronavirus particles", "OBSERVATION", 68, 89]]], ["Simian immunodeficiency virus induces class II MHC expression in infected tissue culture cells [16] .", [["tissue culture cells", "ANATOMY", 74, 94], ["Simian immunodeficiency virus", "DISEASE", 0, 29], ["Simian immunodeficiency virus", "ORGANISM", 0, 29], ["class II MHC", "GENE_OR_GENE_PRODUCT", 38, 50], ["tissue culture cells", "CELL", 74, 94], ["MHC", "PROTEIN", 47, 50], ["infected tissue culture cells", "CELL_LINE", 65, 94], ["Simian immunodeficiency virus", "SPECIES", 0, 29], ["Simian immunodeficiency virus", "SPECIES", 0, 29], ["Simian immunodeficiency virus", "PROBLEM", 0, 29], ["infected tissue culture cells", "PROBLEM", 65, 94], ["infected tissue", "OBSERVATION_MODIFIER", 65, 80]]], ["Tumour necrosis factor can synergize with interferon-~, or measles virus infection for induction of class II MHC expression [25, 33] .", [["necrosis", "DISEASE", 7, 15], ["infection", "DISEASE", 73, 82], ["Tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 0, 22], ["interferon", "GENE_OR_GENE_PRODUCT", 42, 52], ["measles virus", "ORGANISM", 59, 72], ["class II MHC", "GENE_OR_GENE_PRODUCT", 100, 112], ["Tumour necrosis factor", "PROTEIN", 0, 22], ["interferon", "PROTEIN", 42, 52], ["MHC", "PROTEIN", 109, 112], ["measles virus", "SPECIES", 59, 72], ["Tumour necrosis factor", "PROBLEM", 0, 22], ["interferon", "TREATMENT", 42, 52], ["measles virus infection", "PROBLEM", 59, 82], ["necrosis", "OBSERVATION", 7, 15]]], ["B-cell stimulation factor type 1 (BSF-1) enhances expression of class II MHC on resting B lyrnphocytes; intriguingly, interferon-~, appears to downregulate this induction [29] .Other modulators of class II MHC expression.Varied additional influences downregulate class II MHC expression.", [["B lyrnphocytes", "ANATOMY", 88, 102], ["B-cell stimulation factor type 1", "GENE_OR_GENE_PRODUCT", 0, 32], ["BSF-1", "GENE_OR_GENE_PRODUCT", 34, 39], ["class II MHC", "GENE_OR_GENE_PRODUCT", 64, 76], ["B lyrnphocytes", "GENE_OR_GENE_PRODUCT", 88, 102], ["interferon-~", "GENE_OR_GENE_PRODUCT", 118, 130], ["class II MHC", "GENE_OR_GENE_PRODUCT", 197, 209], ["class II MHC", "GENE_OR_GENE_PRODUCT", 263, 275], ["B-cell stimulation factor type 1 (BSF-1", "PROTEIN", 0, 39], ["class II MHC", "PROTEIN", 64, 76], ["interferon", "PROTEIN", 118, 128], ["class II MHC", "PROTEIN", 197, 209], ["class II MHC", "PROTEIN", 263, 275], ["B-cell stimulation factor type", "TEST", 0, 30], ["resting B lyrnphocytes", "PROBLEM", 80, 102], ["interferon", "TREATMENT", 118, 128]]], ["These include immune complexes and a-foetoprotein, as well as hormones such as interferons-a/13, norepinephrine, prostaglandins, cortic,,asteroids and transforming growth factor [~1 [2, 8, 11, 12, 15, 19, 21, 38, 44] .", [["norepinephrine", "CHEMICAL", 97, 111], ["prostaglandins", "CHEMICAL", 113, 127], ["norepinephrine", "CHEMICAL", 97, 111], ["prostaglandins", "CHEMICAL", 113, 127], ["a-foetoprotein", "SIMPLE_CHEMICAL", 35, 49], ["interferons-a/13", "GENE_OR_GENE_PRODUCT", 79, 95], ["norepinephrine", "SIMPLE_CHEMICAL", 97, 111], ["prostaglandins", "SIMPLE_CHEMICAL", 113, 127], ["cortic", "SIMPLE_CHEMICAL", 129, 135], ["immune complexes", "PROTEIN", 14, 30], ["a-foetoprotein", "PROTEIN", 35, 49], ["interferons", "PROTEIN", 79, 90], ["transforming growth factor", "PROTEIN", 151, 177], ["immune complexes", "PROBLEM", 14, 30], ["a-foetoprotein", "TREATMENT", 35, 49], ["interferons", "TREATMENT", 79, 90], ["norepinephrine", "TREATMENT", 97, 111], ["prostaglandins", "TREATMENT", 113, 127], ["cortic", "TREATMENT", 129, 135], ["asteroids", "TREATMENT", 137, 146], ["transforming growth factor", "TEST", 151, 177], ["immune complexes", "OBSERVATION", 14, 30]]], ["Although almost no information is available about the mechanism of action of these agents, it has been demonstrated in several cases ~hat decreased expression of class II MI[-IC rnnloenla~ i~ aeenrnnanlod hv ......Other modulators of class II MHC expression.It\" J decreased abundance of the cognate mRNA [8, 11] .Conclusions.The impression which arises from these studies of regulation of class II MHC transcription is one of formidable complexity, which is apparent in several respects: regulation involves multiple cis-regulatory DNA elements and a diversity of trans-acting protein factors, which may function differently in different cell types and in response to varying physiologic stimuli.", [["cell", "ANATOMY", 638, 642], ["class II MHC", "GENE_OR_GENE_PRODUCT", 234, 246], ["class II MHC", "GENE_OR_GENE_PRODUCT", 389, 401], ["DNA", "CELLULAR_COMPONENT", 532, 535], ["trans-acting protein factors", "GENE_OR_GENE_PRODUCT", 564, 592], ["cell", "CELL", 638, 642], ["class II MHC", "PROTEIN", 234, 246], ["cognate mRNA", "RNA", 291, 303], ["class II MHC", "PROTEIN", 389, 401], ["cis-regulatory DNA elements", "DNA", 517, 544], ["trans-acting protein factors", "PROTEIN", 564, 592], ["these agents", "TREATMENT", 77, 89], ["class II MI", "PROBLEM", 162, 173], ["IC rnnloenla", "TREATMENT", 175, 187], ["these studies", "TEST", 358, 371], ["multiple cis-regulatory DNA elements", "PROBLEM", 508, 544], ["trans-acting protein factors", "TREATMENT", 564, 592], ["varying physiologic stimuli", "TEST", 668, 695], ["J decreased", "OBSERVATION_MODIFIER", 262, 273], ["formidable", "OBSERVATION_MODIFIER", 426, 436], ["complexity", "OBSERVATION", 437, 447], ["multiple", "OBSERVATION_MODIFIER", 508, 516], ["cis-regulatory DNA elements", "OBSERVATION", 517, 544], ["different cell types", "OBSERVATION", 628, 648], ["varying", "OBSERVATION_MODIFIER", 668, 675], ["physiologic stimuli", "OBSERVATION", 676, 695]]], ["Finally, the individual class II MHC molecules, DR, DQ and DP, are differentially expressed, both in cells constitutively class-II-MHC-positive and under certain conditions of induction [17] .Conclusions.In addition to the already evident complexity of class II MHC regulation at the single-cell level, there i~ clearly genetic variability in control of class II MHC expression in populations of organisms.", [["cells", "ANATOMY", 101, 106], ["cell", "ANATOMY", 291, 295], ["class II MHC", "GENE_OR_GENE_PRODUCT", 24, 36], ["DR", "GENE_OR_GENE_PRODUCT", 48, 50], ["DQ", "GENE_OR_GENE_PRODUCT", 52, 54], ["DP", "GENE_OR_GENE_PRODUCT", 59, 61], ["cells", "CELL", 101, 106], ["class-II-MHC", "GENE_OR_GENE_PRODUCT", 122, 134], ["class II MHC", "GENE_OR_GENE_PRODUCT", 253, 265], ["class II MHC", "GENE_OR_GENE_PRODUCT", 354, 366], ["class II MHC molecules", "PROTEIN", 24, 46], ["DR", "PROTEIN", 48, 50], ["DQ", "PROTEIN", 52, 54], ["DP", "PROTEIN", 59, 61], ["MHC", "PROTEIN", 131, 134], ["class II MHC", "PROTEIN", 253, 265], ["class II MHC", "PROTEIN", 354, 366], ["DP", "TEST", 59, 61], ["class II MHC regulation", "PROBLEM", 253, 276], ["organisms", "PROBLEM", 396, 405], ["DP", "ANATOMY", 59, 61], ["genetic", "OBSERVATION_MODIFIER", 320, 327], ["variability", "OBSERVATION_MODIFIER", 328, 339]]], ["Furthermore, these variations may be specific to cell types or tissues.", [["cell", "ANATOMY", 49, 53], ["tissues", "ANATOMY", 63, 70], ["cell", "CELL", 49, 53], ["tissues", "TISSUE", 63, 70], ["cell types", "OBSERVATION", 49, 59]]], ["Most relevant for MS, it has been demonstrated that inducibility of class II MHC on astrocytes by interferon-T and by the coronavirus JHM correlates with susceptibility to experimental autoimmune encephalomyelitis (EAE) [22, 24] .", [["astrocytes", "ANATOMY", 84, 94], ["MS", "DISEASE", 18, 20], ["autoimmune encephalomyelitis", "DISEASE", 185, 213], ["EAE", "DISEASE", 215, 218], ["class II MHC", "GENE_OR_GENE_PRODUCT", 68, 80], ["astrocytes", "CELL", 84, 94], ["interferon-T", "GENE_OR_GENE_PRODUCT", 98, 110], ["coronavirus JHM", "ORGANISM", 122, 137], ["class II MHC", "PROTEIN", 68, 80], ["astrocytes", "CELL_TYPE", 84, 94], ["interferon-T", "PROTEIN", 98, 110], ["coronavirus JHM", "PROTEIN", 122, 137], ["MS", "PROBLEM", 18, 20], ["the coronavirus JHM", "PROBLEM", 118, 137], ["experimental autoimmune encephalomyelitis", "PROBLEM", 172, 213], ["autoimmune encephalomyelitis", "OBSERVATION", 185, 213]]], ["Several testable hypotheses about the relationship of regulation of class II MHC expression to MS may be formulated.Conclusions.1) Susceptibility to MS may correlate with a generalized (non-tissue-specific) abnormality of regulation of MHC expression; this abnormality cauld be isotype-limited.Conclusions.2) Pre~sposition for developing MS may correlate with a geneticallydetermined or -acquired class-II-MHChyperinducibility, which is expressed only in neuroepithelial cells.Conclusions.3) MS susceptibility could correlate with physiologic abnormalities in regard to one of the hormones implicated in regulation of class II MHC expression.Conclusions.The rapid acquisition of knowledge about the regulation of class rI MHC expression should permit these issues to be addressed in the near future.", [["tissue", "ANATOMY", 190, 196], ["neuroepithelial cells", "ANATOMY", 455, 476], ["MS", "DISEASE", 95, 97], ["MS", "DISEASE", 149, 151], ["MS", "DISEASE", 338, 340], ["class II MHC", "GENE_OR_GENE_PRODUCT", 68, 80], ["tissue", "TISSUE", 190, 196], ["MHC", "GENE_OR_GENE_PRODUCT", 236, 239], ["neuroepithelial cells", "CELL", 455, 476], ["class II MHC", "GENE_OR_GENE_PRODUCT", 618, 630], ["class rI MHC", "GENE_OR_GENE_PRODUCT", 713, 725], ["class II MHC", "PROTEIN", 68, 80], ["MHC", "PROTEIN", 236, 239], ["MHChyperinducibility", "PROTEIN", 406, 426], ["neuroepithelial cells", "CELL_TYPE", 455, 476], ["class II MHC", "PROTEIN", 618, 630], ["MHC", "PROTEIN", 722, 725], ["a generalized (non-tissue-specific) abnormality of regulation of MHC expression", "PROBLEM", 171, 250], ["this abnormality", "PROBLEM", 252, 268], ["developing MS", "PROBLEM", 327, 340], ["MHChyperinducibility", "PROBLEM", 406, 426], ["MS susceptibility", "PROBLEM", 492, 509], ["physiologic abnormalities", "PROBLEM", 531, 556], ["generalized", "OBSERVATION_MODIFIER", 173, 184], ["non-tissue", "OBSERVATION_MODIFIER", 186, 196], ["MHC expression", "OBSERVATION", 236, 250], ["MS", "OBSERVATION", 338, 340], ["neuroepithelial cells", "OBSERVATION", 455, 476], ["abnormalities", "OBSERVATION", 543, 556], ["rapid", "OBSERVATION_MODIFIER", 658, 663]]]], "PMC7117379": [["IntroductionAmong RNA viruses, the coronavirus has the largest genome, consisting of a 27.7 kb, single-stranded, positive-sense RNA.", [["coronavirus", "ORGANISM", 35, 46], ["27.7 kb, single-stranded, positive-sense RNA", "RNA", 87, 131], ["IntroductionAmong RNA viruses", "PROBLEM", 0, 29], ["the coronavirus", "PROBLEM", 31, 46], ["RNA viruses", "OBSERVATION", 18, 29], ["largest", "OBSERVATION_MODIFIER", 55, 62], ["genome", "OBSERVATION", 63, 69], ["27.7 kb", "OBSERVATION_MODIFIER", 87, 94], ["positive", "OBSERVATION", 113, 121], ["sense RNA", "OBSERVATION", 122, 131]]], ["The structural genes of the coronavirus genome encode spike (S), membrane (M), envelope (E) and nucleocapsid (N) proteins.", [["membrane", "ANATOMY", 65, 73], ["coronavirus", "ORGANISM", 28, 39], ["spike (S)", "GENE_OR_GENE_PRODUCT", 54, 63], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 96, 121], ["structural genes", "DNA", 4, 20], ["coronavirus genome", "DNA", 28, 46], ["spike (S), membrane (M), envelope (E) and nucleocapsid (N) proteins", "PROTEIN", 54, 121], ["coronavirus", "SPECIES", 28, 39], ["the coronavirus genome encode spike", "PROBLEM", 24, 59], ["membrane (M), envelope (E) and nucleocapsid (N) proteins", "PROBLEM", 65, 121], ["structural genes", "OBSERVATION", 4, 20], ["coronavirus genome", "OBSERVATION", 28, 46]]], ["Frequent point mutations in the hypervariable regions of the spike 1 (S1) gene contribute to most of the antigenic determinants of IBV.", [["spike 1", "GENE_OR_GENE_PRODUCT", 61, 68], ["S1", "GENE_OR_GENE_PRODUCT", 70, 72], ["IBV", "ORGANISM", 131, 134], ["hypervariable regions", "DNA", 32, 53], ["spike 1 (S1) gene", "DNA", 61, 78], ["IBV", "SPECIES", 131, 134], ["Frequent point mutations", "PROBLEM", 0, 24], ["IBV", "PROBLEM", 131, 134], ["point mutations", "OBSERVATION", 9, 24], ["IBV", "OBSERVATION", 131, 134]]], ["The N protein participates in binding to the viral RNA genome and forms a ribonucleoprotein (RNP) complex.", [["RNP", "CELLULAR_COMPONENT", 93, 96], ["N protein", "PROTEIN", 4, 13], ["viral RNA genome", "DNA", 45, 61], ["ribonucleoprotein (RNP) complex", "PROTEIN", 74, 105], ["The N protein", "TREATMENT", 0, 13], ["a ribonucleoprotein (RNP) complex", "TREATMENT", 72, 105]]], ["The N- and C-terminal domains (NTD and CTD) of the N protein are mainly involved in RNA binding and oligomerization, respectively (Jayaram et al., 2006).", [["N", "CHEMICAL", 4, 5], ["C", "CHEMICAL", 11, 12], ["N- and C-terminal domains", "PROTEIN", 4, 29], ["NTD", "PROTEIN", 31, 34], ["CTD", "PROTEIN", 39, 42], ["N protein", "PROTEIN", 51, 60], ["The N", "TEST", 0, 5], ["C-terminal domains (NTD", "TREATMENT", 11, 34], ["the N protein", "TEST", 47, 60]]], ["Recent evidence indicates that the NTD shows strong affinity for the transcriptional regulatory sequence (TRS), which lies within the viral leader sequence and also precedes each viral open reading frame (Spencer and Hiscox, 2006).", [["NTD", "PROTEIN", 35, 38], ["transcriptional regulatory sequence", "DNA", 69, 104], ["TRS", "DNA", 106, 109], ["viral leader sequence", "DNA", 134, 155], ["viral open reading frame", "DNA", 179, 203], ["the NTD", "PROBLEM", 31, 38]]], ["This NTD-TRS binding is critical for the control of viral life cycle, including viral packaging, genomic replication and viral transcription (Grossoehme et al., 2009, Hurst et al., 2010).IntroductionIn addition to maintaining the viral RNA in an ordered conformation for replication and transcription, the N protein is also involved in the regulation of cellular transcription, actin reorganization and apoptosis (Kopecky-Bromberg et al., 2007, Surjit et al., 2006).", [["cellular", "ANATOMY", 354, 362], ["NTD", "GENE_OR_GENE_PRODUCT", 5, 8], ["cellular", "CELL", 354, 362], ["actin", "GENE_OR_GENE_PRODUCT", 378, 383], ["NTD", "PROTEIN", 5, 8], ["TRS", "DNA", 9, 12], ["viral RNA", "RNA", 230, 239], ["N protein", "PROTEIN", 306, 315], ["actin", "PROTEIN", 378, 383], ["This NTD", "PROBLEM", 0, 8], ["TRS binding", "PROBLEM", 9, 20], ["viral life cycle", "TREATMENT", 52, 68], ["viral packaging", "TREATMENT", 80, 95], ["genomic replication", "TREATMENT", 97, 116], ["the viral RNA", "TREATMENT", 226, 239], ["replication and transcription", "TREATMENT", 271, 300], ["the N protein", "TREATMENT", 302, 315], ["cellular transcription", "TREATMENT", 354, 376], ["apoptosis", "PROBLEM", 403, 412], ["viral RNA", "OBSERVATION", 230, 239], ["cellular transcription", "OBSERVATION", 354, 376]]], ["Recently, an antibody against the N protein was used as a diagnostic marker of coronaviral infection (Mourez et al., 2007).", [["coronaviral", "ANATOMY", 79, 90], ["coronaviral infection", "DISEASE", 79, 100], ["N protein", "PROTEIN", 34, 43], ["an antibody", "TEST", 10, 21], ["the N protein", "TREATMENT", 30, 43], ["coronaviral infection", "PROBLEM", 79, 100], ["infection", "OBSERVATION", 91, 100]]], ["Moreover, immunization of the N protein alone can elicit sufficiently protective cellular immunity against lethal IBV challenges, indicating that the N protein is an immune-dominant antigen (Cowley et al., 2010).IntroductionBoth genetic mutation and recombination contribute to the natural evolution of RNA viruses.", [["cellular", "ANATOMY", 81, 89], ["cellular", "CELL", 81, 89], ["IBV", "ORGANISM", 114, 117], ["N protein", "PROTEIN", 30, 39], ["N protein", "PROTEIN", 150, 159], ["IBV", "SPECIES", 114, 117], ["immunization", "TREATMENT", 10, 22], ["the N protein", "TREATMENT", 26, 39], ["lethal IBV challenges", "TREATMENT", 107, 128], ["the N protein", "TEST", 146, 159], ["IntroductionBoth genetic mutation", "PROBLEM", 212, 245], ["RNA viruses", "PROBLEM", 303, 314], ["RNA viruses", "OBSERVATION", 303, 314]]], ["Genetic variants attributed to RNA recombination are often found in coronaviruses such as mouse hepatitis virus (MHV) (Keck et al., 1987) and infectious bronchitis virus (IBV) (Cavanagh, 2007, Dolz et al., 2008).", [["mouse hepatitis virus", "DISEASE", 90, 111], ["infectious bronchitis virus", "DISEASE", 142, 169], ["coronaviruses", "ORGANISM", 68, 81], ["mouse hepatitis virus", "ORGANISM", 90, 111], ["MHV", "ORGANISM", 113, 116], ["infectious bronchitis virus", "ORGANISM", 142, 169], ["IBV", "ORGANISM", 171, 174], ["mouse", "SPECIES", 90, 95], ["hepatitis virus", "SPECIES", 96, 111], ["infectious bronchitis virus", "SPECIES", 142, 169], ["mouse hepatitis virus", "SPECIES", 90, 111], ["MHV", "SPECIES", 113, 116], ["infectious bronchitis virus", "SPECIES", 142, 169], ["IBV", "SPECIES", 171, 174], ["Genetic variants", "PROBLEM", 0, 16], ["RNA recombination", "PROBLEM", 31, 48], ["coronaviruses", "PROBLEM", 68, 81], ["mouse hepatitis virus", "PROBLEM", 90, 111], ["infectious bronchitis virus", "PROBLEM", 142, 169], ["RNA recombination", "OBSERVATION", 31, 48], ["infectious", "OBSERVATION_MODIFIER", 142, 152], ["bronchitis", "OBSERVATION", 153, 163]]], ["IBV is an important chicken pathogen that causes severe economic losses for global poultry industry (Cavanagh, 2007).", [["IBV", "ORGANISM", 0, 3], ["chicken", "ORGANISM", 20, 27], ["chicken", "SPECIES", 20, 27], ["IBV", "SPECIES", 0, 3], ["chicken", "SPECIES", 20, 27], ["IBV", "PROBLEM", 0, 3], ["an important chicken pathogen", "PROBLEM", 7, 36], ["severe economic losses", "PROBLEM", 49, 71], ["important chicken", "OBSERVATION_MODIFIER", 10, 27], ["pathogen", "OBSERVATION", 28, 36], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["economic losses", "OBSERVATION", 56, 71]]], ["Genetic recombination in the IBV S1 and N genes has been documented in different field isolates, based on sequence comparisons and phylogenetic incongruence (Cavanagh, 2007).", [["IBV S1", "ORGANISM", 29, 35], ["IBV S1 and N genes", "DNA", 29, 47], ["IBV", "SPECIES", 29, 32], ["Genetic recombination", "PROBLEM", 0, 21], ["sequence comparisons", "TEST", 106, 126]]], ["The high frequency of RNA recombination in coronaviruses is likely caused by their unique mechanism of RNA synthesis, which involves discontinuous transcription and polymerase jumping (Makino et al., 1986).IntroductionIn addition to the sporadic generation of new variants, RNA recombination may also give rise to new viral populations, as suggested by our study of Taiwanese (TW) IBVs (Kuo et al., 2010).", [["The high frequency of RNA recombination", "PROBLEM", 0, 39], ["coronaviruses", "PROBLEM", 43, 56], ["RNA synthesis", "PROBLEM", 103, 116], ["IntroductionIn", "TREATMENT", 206, 220], ["the sporadic generation of new variants", "PROBLEM", 233, 272], ["RNA recombination", "TREATMENT", 274, 291], ["new viral populations", "PROBLEM", 314, 335], ["high", "OBSERVATION_MODIFIER", 4, 8], ["RNA recombination", "OBSERVATION", 22, 39], ["likely caused", "UNCERTAINTY", 60, 73], ["RNA synthesis", "OBSERVATION", 103, 116], ["new", "OBSERVATION_MODIFIER", 314, 317], ["viral", "OBSERVATION", 318, 323]]], ["In general, TW IBVs are genetically closer to Chinese (CH) isolates than to American (US) strains.", [["TW IBVs", "ORGANISM", 12, 19]]], ["The only exception is the N gene of the TW IBV, which shows higher similarity to that of US strains.", [["TW IBV", "ORGANISM", 40, 46], ["N gene", "DNA", 26, 32], ["TW IBV", "SPECIES", 40, 46], ["the TW IBV", "TREATMENT", 36, 46], ["US strains", "PROBLEM", 89, 99]]], ["In particular, recombination in the NTD of the N gene has been detected in most analyzed TW IBVs.", [["NTD", "DNA", 36, 39], ["N gene", "DNA", 47, 53]]], ["This phylogenetic incongruence suggests that RNA recombination can drive viral evolution at a population level.IntroductionHowever, TW IBVs that carry the recombinant NTD may present the same antigenic epitopes, at least in part, as the US Massachusetts- or Connecticut-serotype vaccine strains, which are routinely administrated in chicken to control IBV in Taiwan.", [["TW IBVs", "ORGANISM", 132, 139], ["NTD", "GENE_OR_GENE_PRODUCT", 167, 170], ["Connecticut-serotype", "ORGANISM", 258, 278], ["vaccine", "ORGANISM", 279, 286], ["chicken", "ORGANISM", 333, 340], ["IBV", "ORGANISM", 352, 355], ["recombinant NTD", "PROTEIN", 155, 170], ["antigenic epitopes", "PROTEIN", 192, 210], ["chicken", "SPECIES", 333, 340], ["chicken", "SPECIES", 333, 340], ["IBV", "SPECIES", 352, 355], ["This phylogenetic incongruence", "PROBLEM", 0, 30], ["RNA recombination", "PROBLEM", 45, 62], ["TW IBVs", "TREATMENT", 132, 139], ["the recombinant NTD", "PROBLEM", 151, 170], ["the US Massachusetts", "TEST", 233, 253], ["Connecticut-serotype vaccine strains", "TREATMENT", 258, 294], ["RNA recombination", "OBSERVATION", 45, 62]]], ["This sequence rearrangement may therefore pose a survival disadvantage for the TW recombinants by increasing their susceptibility to vaccine-induced immune surveillance (Chua et al., 2004).", [["a survival disadvantage", "TREATMENT", 47, 70], ["the TW recombinants", "TREATMENT", 75, 94], ["vaccine", "TREATMENT", 133, 140]]], ["Whether this recombination event in the TW IBV enables the offspring of the recombinant founder to become dominant and evolutionally preserved is rather unclear.", [["TW IBV", "ORGANISM", 40, 46], ["TW IBV", "SPECIES", 40, 46], ["this recombination event", "PROBLEM", 8, 32], ["the TW IBV", "TREATMENT", 36, 46], ["dominant", "OBSERVATION", 106, 114]]], ["In this study, we show that TW IBV recombinants have undergone positive selection at two amino acids within the putative crossover region of the NTD.", [["amino acids", "CHEMICAL", 89, 100], ["amino acids", "CHEMICAL", 89, 100], ["TW IBV", "ORGANISM", 28, 34], ["amino acids", "AMINO_ACID", 89, 100], ["putative crossover region", "PROTEIN", 112, 137], ["NTD", "PROTEIN", 145, 148], ["IBV", "SPECIES", 31, 34], ["this study", "TEST", 3, 13], ["TW IBV", "TREATMENT", 28, 34], ["positive selection", "TREATMENT", 63, 81], ["two amino acids", "TREATMENT", 85, 100], ["the NTD", "PROBLEM", 141, 148], ["NTD", "OBSERVATION", 145, 148]]], ["Replacing either of these two residues with the amino acid present in most CH IBVs significantly attenuated the binding capacity of the N protein to synthetic RNA repeats of the viral TRS.", [["amino acid", "CHEMICAL", 48, 58], ["amino acid", "CHEMICAL", 48, 58], ["CH", "CHEMICAL", 75, 77], ["amino acid", "AMINO_ACID", 48, 58], ["N protein", "PROTEIN", 136, 145], ["viral TRS", "DNA", 178, 187], ["these two residues", "TREATMENT", 20, 38], ["the amino acid", "TREATMENT", 44, 58], ["the binding capacity", "PROBLEM", 108, 128], ["the N protein", "TREATMENT", 132, 145], ["binding capacity", "OBSERVATION", 112, 128], ["viral TRS", "OBSERVATION", 178, 187]]], ["These findings suggest that the fitness of recombinant TW IBVs has been increased by positive selection conferring a replication/transcription advantage, even though these variants have been exposed to immune pressure in fowl vaccinated against US-like strains.IBV strains ::: Materials and methodsDetail information of the recruited IBV strains is provided in supplementary Table 1 (Table S1), including the Genbank accession number and the place where the strain was isolated.", [["recombinant TW IBVs", "ORGANISM", 43, 62], ["fowl", "ORGANISM", 221, 225], ["US-like strains", "ORGANISM", 245, 260], ["IBV", "ORGANISM", 261, 264], ["IBV", "ORGANISM", 334, 337], ["fowl", "SPECIES", 221, 225], ["IBV", "SPECIES", 261, 264], ["IBV", "SPECIES", 334, 337], ["recombinant TW IBVs", "TREATMENT", 43, 62], ["a replication/transcription advantage", "TREATMENT", 115, 152], ["immune pressure", "TEST", 202, 217], ["strains", "PROBLEM", 253, 260], ["the recruited IBV strains", "PROBLEM", 320, 345], ["the strain", "PROBLEM", 454, 464], ["increased", "OBSERVATION_MODIFIER", 72, 81]]], ["We analyzed 72 IBV strains, including 26 TW strains, 15 US strains and 31 CH strains.", [["IBV", "ORGANISM", 15, 18], ["IBV", "SPECIES", 15, 18], ["IBV strains", "TEST", 15, 26], ["26 TW strains", "PROBLEM", 38, 51], ["15 US strains", "TEST", 53, 66], ["31 CH strains", "PROBLEM", 71, 84]]], ["The criteria of recruiting the IBV strains based on the decoded both full-length S1 and N genes.", [["IBV", "ORGANISM", 31, 34], ["S1", "GENE_OR_GENE_PRODUCT", 81, 83], ["full-length S1 and N genes", "DNA", 69, 95], ["IBV", "SPECIES", 31, 34], ["the IBV strains", "PROBLEM", 27, 42]]], ["China SD0611 strain is the only exception, whose S1 gene is still not sequenced.IBV strains ::: Materials and methodsAmong the IBV strains, 8 IBVs in the same clade of ME tree in Fig. 1B were chosen from each TW, CH and US groups for the BI analysis and positive selection.", [["S1", "GENE_OR_GENE_PRODUCT", 49, 51], ["IBV", "ORGANISM", 80, 83], ["IBV", "ORGANISM", 127, 130], ["IBVs", "CANCER", 142, 146], ["ME tree", "MULTI-TISSUE_STRUCTURE", 168, 175], ["1B", "GENE_OR_GENE_PRODUCT", 184, 186], ["S1 gene", "DNA", 49, 56], ["China SD0611 strain", "SPECIES", 0, 19], ["IBV", "SPECIES", 80, 83], ["IBV", "SPECIES", 127, 130], ["China SD0611 strain", "PROBLEM", 0, 19], ["the IBV strains", "PROBLEM", 123, 138], ["8 IBVs", "TREATMENT", 140, 146], ["the BI analysis", "TEST", 234, 249], ["Fig", "OBSERVATION", 179, 182]]], ["TW2992/02 and 3374/05 were excluded because of their phylogenetic discordance in S1 and 3382/06 was excluded due to the discordance in N. The length of the tested genes is all the same.", [["their phylogenetic discordance in S1", "PROBLEM", 47, 83]]], ["Notably, TW2575/98 is completely sequenced and is the most studied strain in Taiwan (Kuo et al., 2010).Phylogenetic analysis ::: Materials and methodsPhylogenetic trees based on ME algorithms on the full-length S1 and full-length N genes were analysis by MEGA 4.0.", [["TW2575/98", "GENE_OR_GENE_PRODUCT", 9, 18], ["TW2575/98", "DNA", 9, 18], ["ME algorithms", "DNA", 178, 191], ["full-length S1 and full-length N genes", "DNA", 199, 237], ["Phylogenetic analysis", "TEST", 103, 124], ["ME algorithms", "TEST", 178, 191]]], ["Bootstrap values, estimated from 1000 replicates of the ME analysis, are given.Phylogenetic analysis ::: Materials and methodsFor BI analysis, we compiled the N genes of various IBV strains, including a Taiwanese group (TW2575/98, TW1171/92, TW2296/95, TW3374/05, TW2992/02, TW3071/03, TW97-4 and TP/64), an American group (Mass 41, H120, Cal99, CU-T2, Beaudette, Gray, Connecticut and ArkDPI) and a Chinese group (LDT3, S14, BJ, LX4, CK/CH/LTJ/95I, CK/CH/LHB/96I, SH and SD0611).", [["IBV", "ORGANISM", 178, 181], ["CK", "GENE_OR_GENE_PRODUCT", 435, 437], ["CK", "GENE_OR_GENE_PRODUCT", 450, 452], ["N genes", "DNA", 159, 166], ["CK", "PROTEIN", 435, 437], ["CK", "PROTEIN", 450, 452], ["IBV", "SPECIES", 178, 181], ["Bootstrap values", "TEST", 0, 16], ["the ME analysis", "TEST", 52, 67], ["Phylogenetic analysis", "TEST", 79, 100], ["BI analysis", "TEST", 130, 141], ["various IBV strains", "PROBLEM", 170, 189], ["TW3071/03", "TEST", 275, 284], ["TW97", "TEST", 286, 290], ["TP", "TEST", 297, 299], ["Mass", "TEST", 324, 328], ["H120", "TEST", 333, 337], ["Cal99", "TEST", 339, 344], ["ArkDPI", "TEST", 386, 392], ["LDT3", "TEST", 415, 419], ["BJ", "TEST", 426, 428], ["LX4", "TEST", 430, 433], ["CK", "TEST", 435, 437], ["LTJ", "TEST", 441, 444], ["CK", "TEST", 450, 452], ["LHB", "TEST", 456, 459]]], ["Multiple sequence alignment was performed using the ClustalW program.", [["Multiple sequence alignment", "TEST", 0, 27]]], ["The DNA sequences were translated into amino acid sequences using the software DAMBE 4.5.20.Phylogenetic analysis ::: Materials and methodsPhylogenetic trees were constructed with the 24 amino acid sequences of the N genes by BI analysis.", [["amino acid", "CHEMICAL", 39, 49], ["amino acid", "CHEMICAL", 187, 197], ["amino acid", "CHEMICAL", 39, 49], ["amino acid", "CHEMICAL", 187, 197], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["amino acid", "AMINO_ACID", 39, 49], ["amino acid", "AMINO_ACID", 187, 197], ["DNA sequences", "DNA", 4, 17], ["N genes", "DNA", 215, 222], ["The DNA sequences", "TEST", 0, 17], ["amino acid sequences", "TEST", 39, 59], ["the software DAMBE", "TEST", 66, 84], ["Phylogenetic analysis", "TEST", 92, 113], ["the 24 amino acid sequences", "TREATMENT", 180, 207], ["BI analysis", "TEST", 226, 237]]], ["For the IBV N 1-124 data set, the best-fit model of substitution was the JTT model with a gamma substitution parameter of 0.76.", [["N 1-124", "CHEMICAL", 12, 19], ["the IBV N", "TEST", 4, 13], ["the JTT model", "TREATMENT", 69, 82], ["a gamma substitution parameter", "TEST", 88, 118]]], ["For the IBV N 125-409 data set, the best-fit model was the JTT model with a gamma substitution parameter of 0.96.", [["the IBV N", "TEST", 4, 13], ["a gamma substitution parameter", "TEST", 74, 104]]], ["MrBayes 3.1.2 was used for BI analysis.", [["MrBayes", "TEST", 0, 7], ["BI analysis", "TEST", 27, 38]]], ["Random starting trees were used.", [["Random starting trees", "TREATMENT", 0, 21]]], ["A total of 10 million generations of Markov chains were run.", [["A total of 10 million generations of Markov chains", "TREATMENT", 0, 50], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Trees were saved every 100 generations, resulting in 100,000 trees in the initial samples.", [["samples", "ANATOMY", 82, 89]]], ["The burn-in (number of initial trees that were discarded) was set to 25,000.", [["burn", "DISEASE", 4, 8], ["The burn", "PROBLEM", 0, 8], ["burn", "OBSERVATION", 4, 8]]], ["A majority-rule consensus tree was generated from the remaining samples (75,000 trees), and the percentage of samples recovering any particular clade represented the clade's posterior probability.Phylogenetic analysis ::: Materials and methodsThe best-fit model of GTR + I + G was selected for Bayesian analysis by the program of Modeltest 3.7 using Akaike information criterion.", [["samples", "ANATOMY", 110, 117], ["Phylogenetic analysis", "TEST", 196, 217], ["GTR", "TEST", 265, 268], ["Bayesian analysis", "TEST", 294, 311], ["Modeltest", "TEST", 330, 339]]], ["In the analyses, 2,000,000 generations of Markov chains were run.", [["Markov chains", "TREATMENT", 42, 55]]], ["Trees were saved every 100 generations, yielding initial samples with a total size of 20,000.", [["samples", "ANATOMY", 57, 64], ["a total size", "TEST", 70, 82], ["size", "OBSERVATION_MODIFIER", 78, 82]]], ["Majority rule consensus trees, constructed from the 15,000 remaining trees, were used to determine the posterior probabilities of each node.Recombination detection ::: Materials and methodsGenetic recombination was evaluated by the recombination detection program (RDP) 3.0 and the genetic algorithms for recombination detection (GARD) program to predict the putative cross-over region and single breakpoint position.", [["node", "ANATOMY", 135, 139], ["node", "MULTI-TISSUE_STRUCTURE", 135, 139], ["the genetic algorithms", "TEST", 278, 300], ["posterior", "ANATOMY_MODIFIER", 103, 112], ["each", "OBSERVATION_MODIFIER", 130, 134], ["node", "OBSERVATION", 135, 139], ["breakpoint position", "OBSERVATION", 397, 416]]], ["Detailed information was provided in our previous study (Kuo et al., 2010).Positive selection analysis ::: Materials and methodsBased on BI analysis of the 24 IBVs, variable selective pressures were evaluated at individual codon positions of the TW N protein.", [["TW N protein", "PROTEIN", 246, 258], ["BI analysis", "TEST", 137, 148], ["the 24 IBVs", "TREATMENT", 152, 163], ["variable selective pressures", "TREATMENT", 165, 193], ["selective", "OBSERVATION_MODIFIER", 174, 183], ["pressures", "OBSERVATION_MODIFIER", 184, 193]]], ["We applied paired models of variable dN/dS distribution among amino acid sites, including M3 (discrete) versus M0 (one ratio), M2a (positive selection) versus M1a (nearly neutral) and M8 (beta and dN/dS) versus M7 (beta), in the codon-based phylogenetic models (CODEML) program within phylogenetic analysis by maximum likelihood (PAML) 4.", [["amino acid", "CHEMICAL", 62, 72], ["amino acid", "CHEMICAL", 62, 72], ["amino acid", "AMINO_ACID", 62, 72], ["M8 (beta", "GENE_OR_GENE_PRODUCT", 184, 192], ["M7 (beta", "GENE_OR_GENE_PRODUCT", 211, 219], ["M3", "PROTEIN", 90, 92], ["M2a", "PROTEIN", 127, 130], ["M1a", "PROTEIN", 159, 162], ["M8", "PROTEIN", 184, 186], ["beta", "PROTEIN", 188, 192], ["M7 (beta)", "PROTEIN", 211, 220], ["variable dN/dS distribution among amino acid sites", "PROBLEM", 28, 78], ["M1a", "TEST", 159, 162], ["M8", "TEST", 184, 186], ["beta", "TEST", 188, 192], ["and dN/dS)", "PROBLEM", 193, 203], ["M7", "TEST", 211, 213], ["the codon", "TEST", 225, 234], ["phylogenetic analysis", "TEST", 285, 306]]], ["The likelihood ratio test statistic was calculated as twice the log likelihood (L) difference between the two models and labeled as 2 (L1\u2212L0) in Table 1.", [["The likelihood ratio test statistic", "TEST", 0, 35]]], ["The value was compared with a chi-square test with one degree of freedom (d.f.), which is equal to the difference in the number of free parameters between the compared models.Homology modeling of three-dimensional protein structure ::: Materials and methodsA homology model of the NTD of the IBV N protein (TP/64) was built using the automated mode of the SWISS-MODEL program (Arnold et al., 2006).", [["IBV", "ORGANISM", 292, 295], ["NTD", "PROTEIN", 281, 284], ["IBV N protein", "PROTEIN", 292, 305], ["TP", "PROTEIN", 307, 309], ["The value", "TEST", 0, 9], ["a chi-square test", "TEST", 28, 45], ["Homology modeling", "TEST", 175, 192], ["the IBV N protein", "TREATMENT", 288, 305], ["equal", "OBSERVATION_MODIFIER", 90, 95], ["free parameters", "OBSERVATION", 131, 146]]], ["We used the crystal structure of the NTD of the IBV Beaudette strain (PDB No. 2BTL) as a template to construct a plausible conformation.", [["IBV", "ORGANISM", 48, 51], ["NTD", "PROTEIN", 37, 40], ["2BTL", "PROTEIN", 78, 82], ["IBV Beaudette strain (PDB No. 2BTL", "SPECIES", 48, 82], ["the IBV Beaudette strain", "TREATMENT", 44, 68], ["a template", "TREATMENT", 87, 97]]], ["The deduced models and template were superimposed, showing the overall structure with root mean square deviations of \u223c1.35 \u00c5.", [["The deduced models and template", "PROBLEM", 0, 31], ["overall", "OBSERVATION_MODIFIER", 63, 70], ["structure", "OBSERVATION_MODIFIER", 71, 80], ["root", "OBSERVATION_MODIFIER", 86, 90], ["mean", "OBSERVATION_MODIFIER", 91, 95], ["square deviations", "OBSERVATION", 96, 113]]], ["Model fidelity was confirmed using the PROCHECK and Adaptive Poisson\u2013Boltzmann Solver modules to examine the main-chain torsion angles and electrostatic distribution, respectively (Laskowski et al., 1993).Site-directed mutagenesis ::: Materials and methodsThe IBV N gene was cloned into pET-28a(+) (Merck-Novagen, USA) via BamH I and Xho I sites to synthesize a recombinant IBV N protein with a histidine tag.", [["histidine", "CHEMICAL", 395, 404], ["histidine", "CHEMICAL", 395, 404], ["IBV", "ORGANISM", 260, 263], ["pET-28a", "GENE_OR_GENE_PRODUCT", 287, 294], ["Merck-Novagen", "GENE_OR_GENE_PRODUCT", 299, 312], ["USA", "GENE_OR_GENE_PRODUCT", 314, 317], ["BamH I", "GENE_OR_GENE_PRODUCT", 323, 329], ["Xho I", "GENE_OR_GENE_PRODUCT", 334, 339], ["IBV", "ORGANISM", 374, 377], ["IBV N gene", "DNA", 260, 270], ["pET", "PROTEIN", 287, 290], ["BamH I and Xho I sites", "DNA", 323, 345], ["recombinant IBV N protein", "PROTEIN", 362, 387], ["histidine tag", "PROTEIN", 395, 408], ["IBV", "SPECIES", 260, 263], ["IBV", "SPECIES", 374, 377], ["the PROCHECK", "TREATMENT", 35, 47], ["Adaptive Poisson\u2013Boltzmann Solver modules", "TREATMENT", 52, 93], ["The IBV N gene", "TREATMENT", 256, 270], ["pET", "TEST", 287, 290], ["a recombinant IBV N protein", "TREATMENT", 360, 387], ["a histidine tag", "TREATMENT", 393, 408], ["main", "OBSERVATION_MODIFIER", 109, 113], ["chain torsion", "ANATOMY", 114, 127], ["angles", "ANATOMY_MODIFIER", 128, 134], ["electrostatic distribution", "OBSERVATION", 139, 165]]], ["Mutagenesis of N gene was performed according to the instructions provided with the QuikChange site-directed mutagenesis kit (Stratagene, USA).", [["N gene", "DNA", 15, 21], ["QuikChange site", "DNA", 84, 99], ["Mutagenesis of N gene", "TREATMENT", 0, 21], ["the QuikChange site", "TREATMENT", 80, 99]]], ["The sense oligonucleotides used for mutagenesis are as follows: 5\u2032-GAT AAT GAA AAT CTT AAA CCA AGC CAG CAG CAT GG-3\u2032, Thr to Pro at aa 64; 5\u2032-CCT GAT AAT GAA AAT CTT AAA AAT AGC CAG CAG CAT GGA TAC TGG-3\u2032, Thr to Asn at aa 64; 5\u2032-GCT GCA AAG GGT GCT GAT GTT AAA TCT AGA TCT AAT C-3\u2032, Thr to Val at aa 123.", [["aa 123", "CHEMICAL", 298, 304], ["Thr", "CHEMICAL", 118, 121], ["Thr", "CHEMICAL", 206, 209], ["Asn", "CHEMICAL", 213, 216], ["Thr", "CHEMICAL", 284, 287], ["Val", "CHEMICAL", 291, 294], ["5\u2032-GAT", "SIMPLE_CHEMICAL", 64, 70], ["Asn", "AMINO_ACID", 213, 216], ["aa 123", "AMINO_ACID", 298, 304], ["aa 64; 5\u2032-CCT GAT AAT GAA AAT CTT AAA AAT AGC CAG CAG CAT", "DNA", 132, 189], ["aa 64; 5\u2032-GCT GCA AAG GGT GCT GAT GTT AAA TCT AGA TCT AAT C-3\u2032", "DNA", 220, 282], ["The sense oligonucleotides", "TREATMENT", 0, 26], ["mutagenesis", "TEST", 36, 47], ["GAA", "TEST", 75, 78], ["AAT", "TEST", 79, 82], ["CTT", "TEST", 83, 86], ["AAA", "TEST", 87, 90], ["CCA", "TEST", 91, 94], ["AGC", "TEST", 95, 98], ["CAG", "TEST", 99, 102], ["CAG", "TEST", 103, 106], ["CAT", "TEST", 107, 110], ["GG", "TEST", 111, 113], ["aa", "TEST", 132, 134], ["CCT", "TEST", 142, 145], ["GAT", "TEST", 146, 149], ["AAT", "TEST", 150, 153], ["GAA", "TEST", 154, 157], ["AAT", "TEST", 158, 161], ["CTT", "TEST", 162, 165], ["AAA", "TEST", 166, 169], ["AAT", "TEST", 170, 173], ["AGC", "TEST", 174, 177], ["CAG", "TEST", 178, 181], ["CAG", "TEST", 182, 185], ["CAT", "TEST", 186, 189], ["GGA", "TEST", 190, 193], ["TAC", "TEST", 194, 197], ["TGG", "TEST", 198, 201], ["GCT", "TEST", 230, 233], ["GCA", "TEST", 234, 237], ["AAG", "TEST", 238, 241], ["GGT", "TEST", 242, 245], ["GCT", "TEST", 246, 249], ["GAT", "TEST", 250, 253], ["GTT", "TEST", 254, 257], ["AAA", "TEST", 258, 261], ["TCT", "TEST", 262, 265], ["AGA", "TEST", 266, 269], ["TCT AAT C", "TEST", 270, 279]]], ["These mutants were confirmed by nucleotide sequencing.Protein expression and purification ::: Materials and methodsThe pET-28 plasmid containing the full-length N protein was transferred into E. coli BL21(DE3) competent cells (Merck-Novagen), and the transformed bacteria were selected and cultured at 37 \u00b0C in LB broth containing 25 \u03bcg/ml kanamycin.", [["cells", "ANATOMY", 220, 225], ["nucleotide", "CHEMICAL", 32, 42], ["kanamycin", "CHEMICAL", 340, 349], ["nucleotide", "CHEMICAL", 32, 42], ["kanamycin", "CHEMICAL", 340, 349], ["pET-28", "GENE_OR_GENE_PRODUCT", 119, 125], ["E. coli BL21", "ORGANISM", 192, 204], ["DE3", "GENE_OR_GENE_PRODUCT", 205, 208], ["cells", "CELL", 220, 225], ["Merck-Novagen", "ORGANISM", 227, 240], ["kanamycin", "SIMPLE_CHEMICAL", 340, 349], ["pET-28 plasmid", "DNA", 119, 133], ["N protein", "PROTEIN", 161, 170], ["E. coli BL21(DE3) competent cells", "CELL_LINE", 192, 225], ["E. coli BL21", "SPECIES", 192, 204], ["E. coli BL21", "SPECIES", 192, 204], ["DE3", "SPECIES", 205, 208], ["nucleotide sequencing", "TEST", 32, 53], ["The pET", "TEST", 115, 122], ["E. coli BL21", "TREATMENT", 192, 204], ["the transformed bacteria", "PROBLEM", 247, 271], ["kanamycin", "TREATMENT", 340, 349]]], ["N protein expression was induced by adding 1 mM IPTG for 4 h when the OD600 value reached 0.4\u20130.6.", [["IPTG", "CHEMICAL", 48, 52], ["IPTG", "CHEMICAL", 48, 52], ["N protein", "PROTEIN", 0, 9], ["1 mM IPTG", "TREATMENT", 43, 52], ["the OD600 value", "TEST", 66, 81], ["protein expression", "OBSERVATION", 2, 20]]], ["To prevent protein degradation, the induction condition was carried out at 25 \u00b0C and supplemented with cocktailed protease inhibitors (Sigma\u2013Aldrich).", [["Sigma\u2013Aldrich", "SIMPLE_CHEMICAL", 135, 148], ["protein degradation", "PROBLEM", 11, 30], ["the induction condition", "PROBLEM", 32, 55], ["cocktailed protease inhibitors", "TREATMENT", 103, 133], ["protein degradation", "OBSERVATION", 11, 30]]], ["The cells were collected, suspended in lysis buffer (50 mM sodium monobasic phosphate, 300 mM sodium chloride, 1 mM imidazole, 1 mg/ml lysozyme) with protease inhibitor and then sonicated.", [["cells", "ANATOMY", 4, 9], ["sodium monobasic phosphate", "CHEMICAL", 59, 85], ["sodium chloride", "CHEMICAL", 94, 109], ["imidazole", "CHEMICAL", 116, 125], ["sodium monobasic phosphate", "CHEMICAL", 59, 85], ["sodium chloride", "CHEMICAL", 94, 109], ["imidazole", "CHEMICAL", 116, 125], ["cells", "CELL", 4, 9], ["sodium monobasic phosphate", "SIMPLE_CHEMICAL", 59, 85], ["sodium chloride", "SIMPLE_CHEMICAL", 94, 109], ["imidazole", "SIMPLE_CHEMICAL", 116, 125], ["lysis buffer", "TREATMENT", 39, 51], ["50 mM sodium monobasic phosphate", "TREATMENT", 53, 85], ["300 mM sodium chloride", "TREATMENT", 87, 109], ["1 mM imidazole", "TREATMENT", 111, 125], ["protease inhibitor", "TREATMENT", 150, 168]]], ["The crude cell lysates were applied to resin affinity columns through a fast protein liquid chromatography (FPLC) system (AKTA prime plus, Amersham Pharmacia) with buffer containing 8 M urea.", [["cell lysates", "ANATOMY", 10, 22], ["urea", "CHEMICAL", 186, 190], ["urea", "CHEMICAL", 186, 190], ["cell lysates", "ORGANISM_SUBSTANCE", 10, 22], ["urea", "SIMPLE_CHEMICAL", 186, 190], ["The crude cell lysates", "TREATMENT", 0, 22], ["resin affinity columns", "TREATMENT", 39, 61], ["a fast protein liquid chromatography", "TEST", 70, 106], ["AKTA prime plus, Amersham Pharmacia", "TREATMENT", 122, 157], ["crude cell lysates", "OBSERVATION", 4, 22]]], ["Resin-prepacked columns (Amersham Pharmacia) were equilibrated with a buffer consisting of 0.1 M NaH2PO4, 0.01 M Tris\u2013HCl, 8 M urea, and 1 mM imidazole (pH 8.0) and then washed with a buffer consisting of 0.1 M NaH2PO4, 0.01 M Tris\u2013HCl, 8 M urea, and 10 mM imidazole (pH 6.3).", [["NaH2PO4", "CHEMICAL", 97, 104], ["Tris\u2013HCl", "CHEMICAL", 113, 121], ["urea", "CHEMICAL", 127, 131], ["imidazole", "CHEMICAL", 142, 151], ["NaH2PO4", "CHEMICAL", 211, 218], ["Tris\u2013HCl", "CHEMICAL", 227, 235], ["urea", "CHEMICAL", 241, 245], ["imidazole", "CHEMICAL", 257, 266], ["NaH2PO4", "CHEMICAL", 97, 104], ["Tris\u2013HCl", "CHEMICAL", 113, 121], ["urea", "CHEMICAL", 127, 131], ["imidazole", "CHEMICAL", 142, 151], ["NaH2PO4", "CHEMICAL", 211, 218], ["Tris\u2013HCl", "CHEMICAL", 227, 235], ["urea", "CHEMICAL", 241, 245], ["imidazole", "CHEMICAL", 257, 266], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 113, 121], ["urea", "SIMPLE_CHEMICAL", 127, 131], ["imidazole", "SIMPLE_CHEMICAL", 142, 151], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 227, 235], ["8 M urea", "SIMPLE_CHEMICAL", 237, 245], ["imidazole", "SIMPLE_CHEMICAL", 257, 266], ["Resin-prepacked columns (Amersham Pharmacia", "TREATMENT", 0, 43], ["a buffer", "TREATMENT", 68, 76], ["0.1 M NaH2PO4", "TREATMENT", 91, 104], ["0.01 M Tris\u2013HCl", "TREATMENT", 106, 121], ["8 M urea", "TREATMENT", 123, 131], ["1 mM imidazole", "TREATMENT", 137, 151], ["pH", "TEST", 153, 155], ["a buffer", "TREATMENT", 182, 190], ["pH", "TEST", 268, 270]]], ["N protein fractions were eluted with a buffer containing 0.1 M NaH2PO4, 0.01 M Tris\u2013HCl, 8 M urea, and 250 mM imidazole (pH 4.5) at a flow rate of 2.0 ml/min.", [["NaH2PO4", "CHEMICAL", 63, 70], ["Tris\u2013HCl", "CHEMICAL", 79, 87], ["urea", "CHEMICAL", 93, 97], ["imidazole", "CHEMICAL", 110, 119], ["NaH2PO4", "CHEMICAL", 63, 70], ["Tris\u2013HCl", "CHEMICAL", 79, 87], ["urea", "CHEMICAL", 93, 97], ["imidazole", "CHEMICAL", 110, 119], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 79, 87], ["urea", "SIMPLE_CHEMICAL", 93, 97], ["imidazole", "SIMPLE_CHEMICAL", 110, 119], ["N protein fractions", "TEST", 0, 19], ["a buffer", "TREATMENT", 37, 45], ["pH", "TEST", 121, 123], ["a flow rate", "TEST", 132, 143], ["protein fractions", "OBSERVATION", 2, 19]]], ["Purified proteins were further dialyzed and refolded with refolding buffer (50 mM Tris\u2013HCl, 50 mM NaCl, 0.4 M l-Arginine, 1 mM EDTA, 0.2 mM phenylmethanesulfonyl fluoride, 0.5 mM oxidized glutathione, 5 mM reduced glutathione, pH 8.0).", [["Tris\u2013HCl", "CHEMICAL", 82, 90], ["NaCl", "CHEMICAL", 98, 102], ["l-Arginine", "CHEMICAL", 110, 120], ["phenylmethanesulfonyl fluoride", "CHEMICAL", 140, 170], ["glutathione", "CHEMICAL", 188, 199], ["glutathione", "CHEMICAL", 214, 225], ["Tris\u2013HCl", "CHEMICAL", 82, 90], ["NaCl", "CHEMICAL", 98, 102], ["l-Arginine", "CHEMICAL", 110, 120], ["EDTA", "CHEMICAL", 127, 131], ["phenylmethanesulfonyl fluoride", "CHEMICAL", 140, 170], ["oxidized glutathione", "CHEMICAL", 179, 199], ["reduced glutathione", "CHEMICAL", 206, 225], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 82, 90], ["l-Arginine", "SIMPLE_CHEMICAL", 110, 120], ["EDTA", "SIMPLE_CHEMICAL", 127, 131], ["phenylmethanesulfonyl fluoride", "SIMPLE_CHEMICAL", 140, 170], ["glutathione", "SIMPLE_CHEMICAL", 188, 199], ["glutathione", "SIMPLE_CHEMICAL", 214, 225], ["Purified proteins", "PROBLEM", 0, 17], ["refolding buffer", "TREATMENT", 58, 74], ["NaCl", "TEST", 98, 102], ["Arginine", "TREATMENT", 112, 120], ["1 mM EDTA", "TREATMENT", 122, 131], ["mM phenylmethanesulfonyl fluoride", "TREATMENT", 137, 170], ["0.5 mM oxidized glutathione", "TREATMENT", 172, 199], ["5 mM reduced glutathione", "TREATMENT", 201, 225], ["pH", "TEST", 227, 229]]], ["Samples were slowly refolded at 4 \u00b0C for four days as the urea concentration was lowered from 4 M to 0 M using a dialysis membrane with a molecular cutoff 30\u201360 KDa (Millipore).", [["Samples", "ANATOMY", 0, 7], ["membrane", "ANATOMY", 122, 130], ["urea", "CHEMICAL", 58, 62], ["urea", "CHEMICAL", 58, 62], ["urea", "SIMPLE_CHEMICAL", 58, 62], ["membrane", "CELLULAR_COMPONENT", 122, 130], ["Samples", "TEST", 0, 7], ["the urea concentration", "TEST", 54, 76], ["a dialysis membrane", "TREATMENT", 111, 130]]], ["Concentrations of the purified N proteins were determined by the Bradford assay (Bio-Rad, USA).", [["N proteins", "PROTEIN", 31, 41], ["the purified N proteins", "PROBLEM", 18, 41], ["the Bradford assay", "TEST", 61, 79]]], ["In addition, the N proteins were examined by 10% SDS-PAGE and stained with Coomassie brilliant blue R250 (USB-Affymetrix).Surface plasmon resonance (SPR) analysis ::: Materials and methodsThe binding capacity of N proteins for viral RNA was performed on a BIAcore 3000A SPR instrument (Amersham Pharmacia) equipped with a research-grade SensorChip SA5.", [["Coomassie brilliant blue", "CHEMICAL", 75, 99], ["Coomassie brilliant blue R250", "SIMPLE_CHEMICAL", 75, 104], ["N proteins", "PROTEIN", 17, 27], ["USB", "PROTEIN", 106, 109], ["N proteins", "PROTEIN", 212, 222], ["viral RNA", "RNA", 227, 236], ["Coomassie brilliant blue R250", "SPECIES", 75, 104], ["the N proteins", "TEST", 13, 27], ["Coomassie brilliant blue", "TEST", 75, 99], ["USB", "TEST", 106, 109], ["Surface plasmon resonance", "TEST", 122, 147], ["The binding capacity", "PROBLEM", 188, 208], ["viral RNA", "PROBLEM", 227, 236], ["a BIAcore 3000A SPR instrument (Amersham Pharmacia", "TREATMENT", 254, 304], ["capacity", "OBSERVATION_MODIFIER", 200, 208], ["SensorChip SA5", "OBSERVATION", 337, 351]]], ["This apparatus measures binding capacity by monitoring changes in the refractive index of the sensor chip surface.", [["This apparatus measures binding capacity", "PROBLEM", 0, 40], ["monitoring changes", "TEST", 44, 62], ["capacity", "OBSERVATION_MODIFIER", 32, 40], ["refractive", "OBSERVATION_MODIFIER", 70, 80], ["index", "OBSERVATION_MODIFIER", 81, 86], ["sensor chip", "OBSERVATION", 94, 105], ["surface", "OBSERVATION_MODIFIER", 106, 113]]], ["These changes, recorded in resonance unites (RU), are assumed to be proportional to the mass of the molecules bound to the chip.", [["These changes", "PROBLEM", 0, 13], ["mass", "OBSERVATION", 88, 92]]], ["Oligomers of the repeated TRS sequence, 5\u2032-(CUUAACAA)4-3\u2032, were synthesized using an automated RNA synthesizer, labeled with biotin and purified by gel electrophoresis.", [["biotin", "CHEMICAL", 125, 131], ["biotin", "CHEMICAL", 125, 131], ["5\u2032-(CUUAACAA)4-3\u2032", "SIMPLE_CHEMICAL", 40, 57], ["biotin", "SIMPLE_CHEMICAL", 125, 131], ["TRS sequence", "DNA", 26, 38], ["the repeated TRS sequence", "TEST", 13, 38], ["CUUAACAA", "TEST", 44, 52], ["an automated RNA synthesizer", "TEST", 82, 110], ["biotin", "TREATMENT", 125, 131], ["gel electrophoresis", "TEST", 148, 167]]], ["The oligomer probes were manually immobilized to the streptavidin-coated biosensor chip.", [["streptavidin", "SIMPLE_CHEMICAL", 53, 65], ["streptavidin", "PROTEIN", 53, 65], ["The oligomer probes", "TREATMENT", 0, 19], ["the streptavidin-coated biosensor chip", "TREATMENT", 49, 87]]], ["The purified N proteins were dissolved in a solution consisting of 50 mM Tris\u2013HCl, 50 mM NaCl, 1 mM EDTA, 0.5 mM oxidized glutathione, and 5 mM reduced glutathione at pH 7.3.", [["Tris\u2013HCl", "CHEMICAL", 73, 81], ["NaCl", "CHEMICAL", 89, 93], ["glutathione", "CHEMICAL", 122, 133], ["glutathione", "CHEMICAL", 152, 163], ["Tris\u2013HCl", "CHEMICAL", 73, 81], ["NaCl", "CHEMICAL", 89, 93], ["EDTA", "CHEMICAL", 100, 104], ["oxidized glutathione", "CHEMICAL", 113, 133], ["reduced glutathione", "CHEMICAL", 144, 163], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 73, 81], ["EDTA", "SIMPLE_CHEMICAL", 100, 104], ["glutathione", "SIMPLE_CHEMICAL", 122, 133], ["glutathione", "SIMPLE_CHEMICAL", 152, 163], ["N proteins", "PROTEIN", 13, 23], ["The purified N proteins", "TREATMENT", 0, 23], ["a solution", "TREATMENT", 42, 52], ["1 mM EDTA", "TREATMENT", 95, 104], ["0.5 mM oxidized glutathione", "TREATMENT", 106, 133], ["5 mM reduced glutathione", "TREATMENT", 139, 163], ["pH", "TEST", 167, 169]]], ["The protein was applied to the chip surface at a flow rate of 30 \u03bcl/min for 140 s to reach equilibrium.", [["surface", "ANATOMY", 36, 43], ["The protein", "TREATMENT", 0, 11], ["a flow rate", "TEST", 47, 58]]], ["Before fitting to the 1:1 Langmuir model, binding data were corrected by subtracting the control to account for simple refractive index differences.", [["binding data", "TEST", 42, 54], ["simple refractive index differences", "PROBLEM", 112, 147], ["refractive index", "OBSERVATION", 119, 135]]], ["Sensorgrams depicting interactions between RNA and N proteins were obtained using BIA evaluation 3 software (version 3).Statistical analysis ::: Materials and methodsOne-way analysis of variance (ANOVA) was performed to determine significant differences in N protein RNA-binding capacity in three independent experiments.", [["N proteins", "PROTEIN", 51, 61], ["RNA and N proteins", "TEST", 43, 61], ["BIA evaluation", "TEST", 82, 96], ["methods", "TEST", 159, 166], ["variance (ANOVA)", "TEST", 186, 202], ["significant differences in N protein RNA", "PROBLEM", 230, 270], ["binding capacity", "PROBLEM", 271, 287]]], ["The Tukey's post hoc test was further used for multiple comparisons among the data collected for the wild type and variant N proteins.", [["N proteins", "PROTEIN", 123, 133], ["The Tukey's post hoc test", "TEST", 0, 25], ["the data", "TEST", 74, 82]]], ["Statistical significance was set at p< 0.05.Recombination in the N gene of TW IBVs ::: ResultsWe analyzed 72 IBV strains from Taiwan, China and US in this study.", [["N gene", "DNA", 65, 71], ["IBV", "SPECIES", 109, 112], ["China and US", "TEST", 134, 146], ["this study", "TEST", 150, 160]]], ["The available full-length S1 and N gene sequences were the criteria for recruiting these strains (Genbank, accessed on April 13th, 2011).", [["S1", "GENE_OR_GENE_PRODUCT", 26, 28], ["full-length S1 and N gene sequences", "DNA", 14, 49], ["recruiting these strains", "PROBLEM", 72, 96]]], ["Based on a minimum evolution (ME) analysis using MEGA 4.0, the phylogenetic topology of the full-length S1 gene revealed that the most tested TW IBVs are similar to the CH IBVs (Fig. 1A).", [["S1", "GENE_OR_GENE_PRODUCT", 104, 106], ["TW IBVs", "CANCER", 142, 149], ["full-length S1 gene", "DNA", 92, 111], ["MEGA", "TEST", 49, 53], ["the most tested TW IBVs", "PROBLEM", 126, 149]]], ["In contrast, analysis of the full-length N genes of the IBV strains by ME (Fig. 1A and B) and Baysian analyses (supplementary Fig. S1) demonstrated that the TW IBVs are phylogenetically closer to the US IBVs than to the CH IBVs (Fig. 1B), indicating phylogenetic incongruence between the results for the S1 and N genes.Recombination in the N gene of TW IBVs ::: ResultsTwenty-four strains with complete sequences for the N gene were randomly chosen from the three TW, US and CH viral pools and subjected to phylogenetic analysis on the N protein.", [["IBV", "ORGANISM", 56, 59], ["N genes", "DNA", 41, 48], ["S1", "PROTEIN", 131, 133], ["TW IBVs", "DNA", 157, 164], ["US IBVs", "DNA", 200, 207], ["CH IBVs", "DNA", 220, 227], ["S1 and N genes", "DNA", 304, 318], ["N gene", "DNA", 340, 346], ["N gene", "DNA", 421, 427], ["N protein", "PROTEIN", 536, 545], ["IBV", "SPECIES", 56, 59], ["analysis", "TEST", 13, 21], ["the IBV strains", "PROBLEM", 52, 67], ["Baysian analyses", "TEST", 94, 110], ["the TW IBVs", "PROBLEM", 153, 164], ["the CH IBVs", "TEST", 216, 227], ["phylogenetic incongruence", "PROBLEM", 250, 275], ["the N gene", "TREATMENT", 417, 427], ["CH viral pools", "PROBLEM", 475, 489], ["phylogenetic analysis", "TEST", 507, 528], ["the N protein", "TREATMENT", 532, 545], ["phylogenetic incongruence", "OBSERVATION", 250, 275]]], ["Putative sporadic recombinant strains, such as TW3374/05 and TW2992/02, are excluded to avoid misinterpretation of further analytic results.", [["Putative sporadic recombinant strains", "PROBLEM", 0, 37], ["sporadic", "OBSERVATION_MODIFIER", 9, 17], ["recombinant strains", "OBSERVATION", 18, 37]]], ["One candidate crossover region between the TW and US IBV strains is located between amino acid (aa) 1 and 124 of the N protein (Kuo et al., 2010), as predicted by the recombination detection program (RDP) (Martin and Rybicki, 2000) used in our previous study (Fig. 1C) (Kuo et al., 2010).", [["amino acid", "CHEMICAL", 84, 94], ["amino acid", "CHEMICAL", 84, 94], ["amino acid", "AMINO_ACID", 84, 94], ["N protein", "PROTEIN", 117, 126], ["US IBV", "SPECIES", 50, 56], ["IBV strains", "PROBLEM", 53, 64], ["amino acid", "TEST", 84, 94]]], ["The p values of the RDP and Bootscan algorithms for this recombination were 5.1 \u00d7 10\u22124 and 1.0 \u00d7 10\u22125, respectively (Kuo et al., 2010).Recombination in the N gene of TW IBVs ::: ResultsBecause aligning the N genes of severe acute respiratory syndrome (SARS) virus, human coronavirus-OC43 (HCoV-OC43) and MHV with IBV N sequences gives many gaps across these sequences, an ancestor strain as an outlier sequence was absent in Fig. 1A and B (data not shown).", [["acute respiratory syndrome", "DISEASE", 224, 250], ["SARS", "DISEASE", 252, 256], ["severe acute respiratory", "ORGANISM", 217, 241], ["human", "ORGANISM", 265, 270], ["coronavirus-OC43", "ORGANISM", 271, 287], ["HCoV-OC43", "ORGANISM", 289, 298], ["MHV", "ORGANISM", 304, 307], ["B", "GENE_OR_GENE_PRODUCT", 437, 438], ["N gene", "DNA", 156, 162], ["N genes", "DNA", 206, 213], ["IBV N sequences", "DNA", 313, 328], ["human", "SPECIES", 265, 270], ["coronavirus", "SPECIES", 271, 282], ["severe acute respiratory syndrome (SARS) virus", "SPECIES", 217, 263], ["human coronavirus-OC43 (HCoV-OC43", "SPECIES", 265, 298], ["MHV", "SPECIES", 304, 307], ["IBV", "SPECIES", 313, 316], ["The p values", "TEST", 0, 12], ["Bootscan algorithms", "TEST", 28, 47], ["this recombination", "TEST", 52, 70], ["severe acute respiratory syndrome", "PROBLEM", 217, 250], ["SARS) virus", "PROBLEM", 252, 263], ["human coronavirus", "TEST", 265, 282], ["OC43", "TEST", 283, 287], ["HCoV", "TEST", 289, 293], ["MHV", "TREATMENT", 304, 307], ["IBV N sequences", "TEST", 313, 328], ["many gaps across these sequences", "PROBLEM", 335, 367], ["an ancestor strain", "PROBLEM", 369, 387], ["an outlier sequence", "TEST", 391, 410], ["1A and B (data", "TEST", 430, 444], ["severe", "OBSERVATION_MODIFIER", 217, 223], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["respiratory syndrome", "OBSERVATION", 230, 250]]], ["To further confirm our hypothesis of RNA recombination, unrooted Bayesian inference (BI) algorithm was applied in this study (Fig. 1D and E).", [["RNA recombination", "PROBLEM", 37, 54], ["this study", "TEST", 114, 124]]], ["BI analysis revealed that the putative crossover region (Fig. 1D) in the TW N protein, but not the non-recombinant region (Fig. 1E), belongs to the monophyletic group of US N proteins.", [["TW N", "GENE_OR_GENE_PRODUCT", 73, 77], ["Fig. 1E", "GENE_OR_GENE_PRODUCT", 123, 130], ["US N proteins", "GENE_OR_GENE_PRODUCT", 170, 183], ["TW N protein", "PROTEIN", 73, 85], ["non-recombinant region", "PROTEIN", 99, 121], ["Fig. 1E", "PROTEIN", 123, 130], ["US N proteins", "PROTEIN", 170, 183], ["BI analysis", "TEST", 0, 11], ["the putative crossover region", "PROBLEM", 26, 55], ["the TW N protein", "TEST", 69, 85]]], ["Moreover, to demonstrate that the trees of Fig. 1D and E are representative, we included all the strains in Fig. 1B and constructed their Bayesian trees (Fig. S2) according to the two segments of N-terminal and C-terminal amino acid sequences of IBV N protein (Fig. 1C).", [["amino acid", "CHEMICAL", 222, 232], ["C", "CHEMICAL", 211, 212], ["amino acid", "CHEMICAL", 222, 232], ["1B", "GENE_OR_GENE_PRODUCT", 113, 115], ["amino acid", "AMINO_ACID", 222, 232], ["IBV N protein", "GENE_OR_GENE_PRODUCT", 246, 259], ["S2", "PROTEIN", 159, 161], ["N-terminal and C-terminal amino acid sequences", "PROTEIN", 196, 242], ["IBV N protein", "PROTEIN", 246, 259], ["N-terminal and C-terminal amino acid sequences", "TREATMENT", 196, 242], ["IBV N protein", "TREATMENT", 246, 259]]], ["The results in Fig. S2 illustrated similar topologies as those in Fig. 1D and E, strongly supporting the presence of RNA recombination between the TW and US IBVs in the N gene sequence (Fig. 1D and E and Fig. S2).Recombination in the N gene of TW IBVs ::: ResultsTo further clarify whether the phylogenetic incongruence is caused by different evolutionary rates in different parts of the N gene, a ML test that is not biased by evolutionary rate variation was applied to recheck the phylogenetic relationships (Holmes and Rambaut, 2004).", [["S2", "GENE_OR_GENE_PRODUCT", 20, 22], ["S2", "PROTEIN", 20, 22], ["TW and US IBVs", "DNA", 147, 161], ["N gene sequence", "DNA", 169, 184], ["S2", "PROTEIN", 209, 211], ["N gene", "DNA", 234, 240], ["N gene", "DNA", 388, 394], ["RNA recombination", "TREATMENT", 117, 134], ["the TW", "TEST", 143, 149], ["US IBVs", "TEST", 154, 161], ["the phylogenetic incongruence", "PROBLEM", 290, 319], ["a ML test", "TEST", 396, 405], ["similar topologies", "OBSERVATION", 35, 53]]], ["No significant difference was observed between the results from the BI and those from the ML test (supplementary Fig. S3), confirming that RNA recombination probably occurred between TW and US IBVs in the 5\u2032- terminal region of the N gene and that the phylogenetic incongruence was not caused by point mutation or variation in local evolutionary rates.Positive selection of the N gene in TW IBVs ::: ResultsAlthough the N protein is evolutionally conserved among IBVs, positive selection may occur at individual amino acid (aa) residues.", [["amino acid", "CHEMICAL", 512, 522], ["amino acid", "CHEMICAL", 512, 522], ["S3", "GENE_OR_GENE_PRODUCT", 118, 120], ["IBVs", "GENE_OR_GENE_PRODUCT", 463, 467], ["amino acid", "AMINO_ACID", 512, 522], ["5\u2032- terminal region", "DNA", 205, 224], ["N gene", "DNA", 232, 238], ["N gene", "DNA", 378, 384], ["N protein", "PROTEIN", 420, 429], ["the BI", "TEST", 64, 70], ["the ML test", "TEST", 86, 97], ["RNA recombination", "PROBLEM", 139, 156], ["US IBVs", "TEST", 190, 197], ["the phylogenetic incongruence", "PROBLEM", 248, 277], ["point mutation", "PROBLEM", 296, 310], ["the N protein", "TEST", 416, 429], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["RNA recombination", "OBSERVATION", 139, 156], ["terminal", "ANATOMY_MODIFIER", 209, 217], ["region", "ANATOMY_MODIFIER", 218, 224]]], ["To investigate this possibility, full-length N genes of the 24 IBVs (shown in Fig. 1D and E) were subjected to codon-based phylogenetic models (CODEML) within the phylogenetic analysis by maximum likelihood (PAML) programs (Yang, 2007).", [["IBVs", "CANCER", 63, 67], ["N genes", "DNA", 45, 52], ["IBVs", "DNA", 63, 67], ["the 24 IBVs", "TREATMENT", 56, 67], ["codon", "TEST", 111, 116], ["the phylogenetic analysis", "TEST", 159, 184]]], ["Based on Bayesian analyses, neutral and positive selection models were compared using likelihood ratio tests.Positive selection of the N gene in TW IBVs ::: ResultsThe neutral models (M0, M1a and M7), selection models with a proportion of selected codons (M2a and M8) and a model for dN/dS heterogeneity among aa residues (M3) were applied for tests of selective pressure on N protein residues.", [["N gene", "DNA", 135, 141], ["M8", "PROTEIN", 264, 266], ["N protein residues", "PROTEIN", 375, 393], ["Bayesian analyses", "TEST", 9, 26], ["positive selection models", "TEST", 40, 65], ["likelihood ratio tests", "TEST", 86, 108], ["M1a", "TEST", 188, 191], ["selection models", "TEST", 201, 217], ["selected codons (M2a and M8", "TREATMENT", 239, 266], ["dN/dS heterogeneity", "PROBLEM", 284, 303], ["aa residues", "PROBLEM", 310, 321], ["tests", "TEST", 344, 349], ["selective pressure on N protein residues", "TREATMENT", 353, 393], ["M1a", "ANATOMY", 188, 191], ["protein residues", "OBSERVATION", 377, 393]]], ["The log likelihood values (Ln in Table 1) indicated that positive selection models (M2a, M3, M8) fitted the tested region better than neutral models (M0, M1a, M7).", [["The log likelihood values", "TEST", 0, 25], ["positive selection models", "PROBLEM", 57, 82], ["M2a", "TEST", 84, 87], ["M1a", "TEST", 154, 157], ["positive selection", "OBSERVATION", 57, 75]]], ["The nested comparisons between neutral and positive models, including M0 versus M3 (M0/M3), M1a/M2a and M7/M8, confirm the better fitness of positive models, suggesting that positive selection occurs at certain sites during the evolution of the TW N protein (p< 0.001 in these three comparisons, chi-square test) (Table 1).", [["M1a", "PROTEIN", 92, 95], ["M7", "PROTEIN", 104, 106], ["M8", "CELL_LINE", 107, 109], ["TW N protein", "PROTEIN", 245, 257], ["The nested comparisons", "TEST", 0, 22], ["M1a/M2a", "TEST", 92, 99], ["positive selection", "PROBLEM", 174, 192], ["the TW N protein", "TEST", 241, 257], ["chi-square test", "TEST", 296, 311], ["M1a", "ANATOMY", 92, 95], ["M2a", "ANATOMY", 96, 99], ["positive selection", "OBSERVATION", 174, 192]]], ["Both aa 64 and aa 123 of the TW N protein were consistently highlighted by positive selection models (M2a, M3, M8) as putative selection sites with high posterior probability values (pa and pb values of both sites >0.95 in M3 and M8 models, respectively) (Table 1).Positive selection of the N gene in TW IBVs ::: ResultsThe detail profile of these two positively selected sites of all tested IBVs in this study was summarized in Table 2.", [["TW N protein", "GENE_OR_GENE_PRODUCT", 29, 41], ["IBVs", "CANCER", 392, 396], ["TW N protein", "PROTEIN", 29, 41], ["N gene", "DNA", 291, 297], ["aa", "TEST", 15, 17], ["the TW N protein", "TEST", 25, 41], ["M2a", "TEST", 102, 105], ["high posterior probability values", "PROBLEM", 148, 181], ["pa and pb values", "TEST", 183, 199], ["sites", "TEST", 208, 213], ["all tested IBVs", "TEST", 381, 396], ["this study", "TEST", 400, 410], ["high", "OBSERVATION_MODIFIER", 148, 152], ["posterior", "OBSERVATION_MODIFIER", 153, 162], ["probability values", "OBSERVATION", 163, 181]]], ["Using the available database of fully sequenced N proteins (72 IBV strains), we determined that Thr residues are present at the aa 64 and 123 positions in 80.8% (21/26) and 65.4% (17/26) of the TW IBV strains, respectively (Table 2).", [["Thr", "CHEMICAL", 96, 99], ["TW IBV", "ORGANISM", 194, 200], ["N proteins", "PROTEIN", 48, 58], ["TW IBV", "SPECIES", 194, 200], ["IBV strains", "TEST", 63, 74], ["Thr residues", "PROBLEM", 96, 108], ["the TW IBV strains", "TEST", 190, 208]]], ["However, Thr residues are present at the aa 64 and 123 positions in only 46.7% (7/15) and 33.3% (5/15) of the US IBV strains, respectively.", [["Thr", "CHEMICAL", 9, 12], ["Thr", "AMINO_ACID", 9, 12], ["IBV", "ORGANISM", 113, 116], ["US IBV", "SPECIES", 110, 116], ["Thr residues", "PROBLEM", 9, 21], ["the US IBV strains", "TEST", 106, 124], ["Thr residues", "OBSERVATION", 9, 21], ["IBV strains", "OBSERVATION", 113, 124]]], ["In the CH IBVs, the prevalence of Thr residues at these two positions is further reduced to 29.0% (9/31) and 22.6% (7/31), respectively.", [["Thr", "CHEMICAL", 34, 37], ["Thr residues", "AMINO_ACID", 34, 46], ["Thr residues", "PROBLEM", 34, 46], ["Thr residues", "OBSERVATION", 34, 46], ["two", "OBSERVATION_MODIFIER", 56, 59], ["positions", "OBSERVATION_MODIFIER", 60, 69], ["reduced", "OBSERVATION_MODIFIER", 81, 88], ["29.0%", "OBSERVATION_MODIFIER", 92, 97]]], ["This information supports the CODEML prediction that both positions have undergone positive selection in TW IBVs.Positive selection of the N gene in TW IBVs ::: ResultsTo further demonstrate the result of positively selected residues in Table 1 (24 IBV strains), 58 IBV strains in Table 2 were recruited and few strains with partial sequences were excluded for CODEML analysis.", [["IBV", "ORGANISM", 266, 269], ["CODEML", "DNA", 30, 36], ["N gene", "DNA", 139, 145], ["IBV", "SPECIES", 266, 269], ["positive selection in TW IBVs", "TREATMENT", 83, 112], ["positively selected residues in Table", "PROBLEM", 205, 242], ["IBV strains", "TEST", 249, 260], ["58 IBV strains in Table 2", "PROBLEM", 263, 288], ["partial sequences", "TEST", 325, 342], ["CODEML analysis", "TEST", 361, 376], ["positive selection", "OBSERVATION", 83, 101]]], ["As shown in Table S2, both aa sites at 64 and 123 are predicted to be positively selected using M8 model (Probability > 0.95), strengthening the finding of the occurrence of positive selection at aa 64 and aa 123 of N protein among TW IBVs.Positive selection of the N gene in TW IBVs ::: ResultsNotably, the selected sites are located within the putative crossover region of the N protein in the TW IBVs (Fig. 1C), linking the RNA recombination with the positive selection events.", [["N protein", "PROTEIN", 216, 225], ["N gene", "DNA", 266, 272], ["N protein", "PROTEIN", 379, 388], ["TW IBVs", "PROTEIN", 396, 403], ["Probability", "TEST", 106, 117], ["positive selection", "PROBLEM", 174, 192], ["aa", "TEST", 196, 198], ["aa", "TEST", 206, 208], ["N protein", "TEST", 216, 225], ["TW IBVs", "TREATMENT", 232, 239], ["the TW IBVs", "TREATMENT", 392, 403], ["the positive selection events", "PROBLEM", 450, 479], ["S2", "ANATOMY_MODIFIER", 18, 20], ["N protein", "OBSERVATION", 379, 388], ["RNA recombination", "OBSERVATION", 427, 444], ["positive selection", "OBSERVATION", 454, 472]]], ["This observation also reflects the notion that particular residues of TW IBV recombinants have evolved under positive selection pressure in vaccinated flocks.", [["TW IBV", "ORGANISM", 70, 76], ["TW IBV", "SPECIES", 70, 76], ["This observation", "TEST", 0, 16], ["TW IBV recombinants", "TREATMENT", 70, 89], ["vaccinated flocks", "PROBLEM", 140, 157], ["positive selection pressure", "OBSERVATION", 109, 136], ["vaccinated flocks", "OBSERVATION", 140, 157]]], ["In addition, the putative positively selected residues are located in the NTD, suggesting that viral progeny with strong RNA-binding affinities may have been selected during the adaptive evolution of IBV in Taiwan.Stereography of the positively selected residues in the N protein ::: ResultsThe NTD of the IBV N protein participates in the binding to viral RNA and the formation of the RNP complex.", [["NTD", "GENE_OR_GENE_PRODUCT", 74, 77], ["IBV", "ORGANISM", 200, 203], ["IBV", "ORGANISM", 306, 309], ["RNP", "CELLULAR_COMPONENT", 386, 389], ["NTD", "PROTEIN", 74, 77], ["N protein", "PROTEIN", 270, 279], ["NTD", "PROTEIN", 295, 298], ["IBV N protein", "PROTEIN", 306, 319], ["viral RNA", "RNA", 351, 360], ["RNP complex", "PROTEIN", 386, 397], ["IBV", "SPECIES", 200, 203], ["IBV", "SPECIES", 306, 309], ["the putative positively selected residues", "PROBLEM", 13, 54], ["viral progeny", "PROBLEM", 95, 108], ["strong RNA-binding affinities", "PROBLEM", 114, 143], ["the IBV N protein", "TREATMENT", 302, 319], ["viral RNA", "PROBLEM", 351, 360], ["suggesting that", "UNCERTAINTY", 79, 94], ["viral progeny", "OBSERVATION", 95, 108], ["IBV", "OBSERVATION", 200, 203], ["viral RNA", "OBSERVATION", 351, 360], ["RNP complex", "OBSERVATION", 386, 397]]], ["The crystal structure of the NTD, based on the Beaudette strain, shows a U-shaped conformation composed of a five-stranded antiparallel \u03b2 sheet with positively charged amino acids clustered throughout the groove (Fan et al., 2005).", [["amino acids", "CHEMICAL", 168, 179], ["amino acids", "CHEMICAL", 168, 179], ["amino acids", "AMINO_ACID", 168, 179], ["NTD", "PROTEIN", 29, 32], ["five-stranded antiparallel \u03b2 sheet", "PROTEIN", 109, 143], ["the NTD", "PROBLEM", 25, 32], ["a U-shaped conformation", "PROBLEM", 71, 94], ["stranded antiparallel \u03b2 sheet", "TREATMENT", 114, 143], ["positively charged amino acids", "TREATMENT", 149, 179], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["structure", "OBSERVATION_MODIFIER", 12, 21], ["NTD", "OBSERVATION", 29, 32]]], ["Flexible loops and turns are around the inner core of the \u03b2 sheet of the NTD.", [["inner core", "ANATOMY", 40, 50], ["\u03b2 sheet", "PROTEIN", 58, 65], ["NTD", "PROTEIN", 73, 76], ["Flexible loops and turns", "PROBLEM", 0, 24], ["loops", "OBSERVATION", 9, 14], ["NTD", "OBSERVATION", 73, 76]]], ["The positively selected sites, aa 64 and 123, are located in the external \u03b1 turn and loop, respectively (arrow heads, Fig. 2A).", [["aa 64 and 123", "DNA", 31, 44], ["external", "ANATOMY_MODIFIER", 65, 73], ["loop", "OBSERVATION_MODIFIER", 85, 89]]], ["Notably, neither site is close to the RNA-binding groove (arrow, Fig. 2A).", [["neither site", "PROBLEM", 9, 21], ["groove", "OBSERVATION_MODIFIER", 50, 56]]], ["The locations of these two residues indicate that they do not directly participate in viral RNA binding.", [["viral RNA", "RNA", 86, 95], ["viral RNA binding", "PROBLEM", 86, 103]]], ["Software predictions by RNABindR (Terribilini et al., 2007), including Ensemble, PSSMSeq and PSSMStruct algorithms, also support this observation (data not shown).Stereography of the positively selected residues in the N protein ::: ResultsRegarding the aa 64 position, Pro is present in the Beaudette model strain, and Thr is present in the TW TP/64 strain.", [["Thr", "CHEMICAL", 320, 323], ["Thr", "AMINO_ACID", 320, 323], ["N protein", "PROTEIN", 219, 228], ["this observation", "TEST", 129, 145], ["64 strain", "OBSERVATION", 348, 357]]], ["Interestingly, replacing Pro with Thr at residue 64 transforms the \u03b1-turn conformation into a looped structure after protein modeling (Fig. 2B), indicating the structural flexibility of this NTD residue.", [["Pro", "CHEMICAL", 25, 28], ["Thr", "CHEMICAL", 34, 37], ["Pro", "CHEMICAL", 25, 28], ["Thr", "CHEMICAL", 34, 37], ["Thr", "AMINO_ACID", 34, 37], ["residue 64", "AMINO_ACID", 41, 51], ["\u03b1-turn conformation", "PROTEIN", 67, 86], ["Thr at residue", "TREATMENT", 34, 48], ["this NTD residue", "PROBLEM", 186, 202], ["structural flexibility", "OBSERVATION", 160, 182]]], ["This result also suggests that the epitope character of this region of the TW IBV N protein may be vulnerable to alteration under immunological pressure.", [["TW IBV", "ORGANISM", 75, 81], ["TW IBV N protein", "PROTEIN", 75, 91], ["TW IBV", "SPECIES", 75, 81], ["the epitope character", "PROBLEM", 31, 52], ["the TW IBV N protein", "TEST", 71, 91], ["immunological pressure", "TEST", 130, 152], ["immunological pressure", "OBSERVATION", 130, 152]]], ["For the other selected site, aa 123, where a Thr is present in the TW TP/64 strain and a Val is present in the Beaudette strain, no obvious conformational change was noted after homology modeling.", [["Thr", "CHEMICAL", 45, 48], ["Val", "CHEMICAL", 89, 92], ["aa 123", "AMINO_ACID", 29, 35], ["Thr", "AMINO_ACID", 45, 48], ["TP", "GENE_OR_GENE_PRODUCT", 70, 72], ["a Thr", "TREATMENT", 43, 48], ["obvious conformational change", "PROBLEM", 132, 161], ["Thr", "OBSERVATION", 45, 48], ["64 strain", "OBSERVATION", 73, 82], ["no obvious", "UNCERTAINTY", 129, 139]]], ["Nevertheless, a single mutational change from a hydrophilic amino acid (Thr) to a hydrophobic one (Val) could modulate the surface charge of the protein and its efficiency at forming high-order oligomers (Fan et al., 2005).Functional test of the positively selected sites ::: ResultsTo investigate the importance of the selected amino acid residues, the TW TP/64 strain, which was the first IBV strain to be identified in Taiwan in 1964, was chosen to represent wild type TW IBV and subjected to an analysis of RNA-binding activity.", [["surface", "ANATOMY", 123, 130], ["amino acid", "CHEMICAL", 60, 70], ["Thr", "CHEMICAL", 72, 75], ["Val", "CHEMICAL", 99, 102], ["amino acid", "CHEMICAL", 329, 339], ["amino acid", "CHEMICAL", 60, 70], ["Thr", "CHEMICAL", 72, 75], ["Val", "CHEMICAL", 99, 102], ["amino acid", "CHEMICAL", 329, 339], ["amino acid", "AMINO_ACID", 60, 70], ["Thr", "AMINO_ACID", 72, 75], ["amino acid", "AMINO_ACID", 329, 339], ["TP", "GENE_OR_GENE_PRODUCT", 357, 359], ["IBV", "ORGANISM", 391, 394], ["TW IBV", "ORGANISM", 472, 478], ["IBV", "SPECIES", 391, 394], ["TW IBV", "SPECIES", 472, 478], ["a single mutational change", "PROBLEM", 14, 40], ["a hydrophilic amino acid (Thr", "TREATMENT", 46, 75], ["the selected amino acid residues", "TREATMENT", 316, 348], ["the TW TP/64 strain", "PROBLEM", 350, 369], ["the first IBV strain", "PROBLEM", 381, 401], ["wild type TW IBV", "PROBLEM", 462, 478], ["an analysis", "TEST", 496, 507], ["surface", "OBSERVATION_MODIFIER", 123, 130]]], ["The TP/64 strain shares high genetic similarity to most TW IBV isolates (Fig. 1A and B and Table 2).", [["TP", "GENE_OR_GENE_PRODUCT", 4, 6], ["TW IBV", "ORGANISM", 56, 62], ["TW IBV", "SPECIES", 56, 62], ["The TP/64 strain", "TEST", 0, 16], ["high genetic similarity", "PROBLEM", 24, 47], ["IBV isolates", "TEST", 59, 71]]], ["Three N protein mutants, including T64P (ACA to CCA, Thr to Pro), T64N (ACA to AAT, Thr to Asp), and T123V (ACT to GTT, Thr to Val), were generated by site-directed mutagenesis and confirmed by sequencing (Fig. 3A).", [["Thr", "CHEMICAL", 53, 56], ["Pro", "CHEMICAL", 60, 63], ["Thr", "CHEMICAL", 84, 87], ["Asp", "CHEMICAL", 91, 94], ["Thr", "CHEMICAL", 120, 123], ["Val", "CHEMICAL", 127, 130], ["T64N (ACA to AAT, Thr to Asp", "GENE_OR_GENE_PRODUCT", 66, 94], ["ACT to GTT, Thr to Val", "GENE_OR_GENE_PRODUCT", 108, 130], ["N protein mutants", "PROTEIN", 6, 23], ["T64P", "PROTEIN", 35, 39], ["ACA", "PROTEIN", 41, 44], ["CCA", "PROTEIN", 48, 51], ["T64N", "PROTEIN", 66, 70], ["ACA", "PROTEIN", 72, 75], ["AAT", "PROTEIN", 79, 82], ["T123V", "PROTEIN", 101, 106], ["ACT", "PROTEIN", 108, 111], ["Three N protein mutants", "TEST", 0, 23], ["CCA", "TEST", 48, 51], ["Pro", "TEST", 60, 63], ["T64N", "TEST", 66, 70], ["ACA", "TEST", 72, 75], ["AAT", "TEST", 79, 82], ["Asp", "TEST", 91, 94], ["T123V", "TEST", 101, 106], ["GTT", "TREATMENT", 115, 118], ["protein mutants", "OBSERVATION", 8, 23]]], ["The production of full-length N protein of TP/64 (arrow head in Fig. 3B) was successfully induced by adding isopropyl \u03b2-d-1-thiogalactopyranoside (IPTG) in E. coli (Fig. 3B).", [["head", "ANATOMY", 56, 60], ["isopropyl \u03b2-d-1-thiogalactopyranoside", "CHEMICAL", 108, 145], ["IPTG", "CHEMICAL", 147, 151], ["isopropyl \u03b2-d-1-thiogalactopyranoside", "CHEMICAL", 108, 145], ["IPTG", "CHEMICAL", 147, 151], ["TP/64", "GENE_OR_GENE_PRODUCT", 43, 48], ["head", "ORGANISM_SUBDIVISION", 56, 60], ["isopropyl \u03b2-d-1-thiogalactopyranoside", "SIMPLE_CHEMICAL", 108, 145], ["IPTG", "SIMPLE_CHEMICAL", 147, 151], ["E. coli", "ORGANISM", 156, 163], ["Fig. 3B", "ORGANISM", 165, 172], ["N protein", "PROTEIN", 30, 39], ["TP", "PROTEIN", 43, 45], ["E. coli", "SPECIES", 156, 163], ["E. coli", "SPECIES", 156, 163], ["TP", "TEST", 43, 45], ["isopropyl \u03b2-d-1", "TREATMENT", 108, 123], ["thiogalactopyranoside (IPTG", "TREATMENT", 124, 151], ["E. coli", "PROBLEM", 156, 163], ["coli", "ANATOMY", 159, 163]]], ["The N protein of TP/64 (wild type, WT) and the mutant N proteins (T64P, T64N, T123V) were purified by Ni-column and further examined by the staining with Coomassie blue in SDS-PAGE (Fig. 3C).", [["Coomassie blue", "CHEMICAL", 154, 168], ["TP/64", "GENE_OR_GENE_PRODUCT", 17, 22], ["wild type, WT)", "ORGANISM", 24, 38], ["Coomassie", "SIMPLE_CHEMICAL", 154, 163], ["N protein", "PROTEIN", 4, 13], ["TP", "PROTEIN", 17, 19], ["64", "PROTEIN", 20, 22], ["WT", "PROTEIN", 35, 37], ["mutant N proteins", "PROTEIN", 47, 64], ["T64P", "PROTEIN", 66, 70], ["T64N", "PROTEIN", 72, 76], ["T123V", "PROTEIN", 78, 83], ["The N protein", "TEST", 0, 13], ["TP", "TEST", 17, 19], ["the mutant N proteins", "TEST", 43, 64], ["T64P", "TEST", 66, 70], ["T64N", "TEST", 72, 76], ["T123V", "TEST", 78, 83], ["Coomassie blue", "TEST", 154, 168]]], ["The detected size of full-length N protein was around 57 KDa (Fig. 3B and C), higher than the theoretical prediction (45 KDa).", [["full-length N protein", "PROTEIN", 21, 42], ["57 KDa", "PROTEIN", 54, 60], ["Fig. 3B and C", "PROTEIN", 62, 75], ["full-length N protein", "TEST", 21, 42], ["KDa", "TEST", 57, 60], ["C", "TEST", 74, 75], ["the theoretical prediction", "TEST", 90, 116], ["size", "OBSERVATION_MODIFIER", 13, 17]]], ["The upper shift of band location of expressed N protein might be caused by the intrinsic charged aa components of the N protein but not post-translational modification in E. coli due to the same detected molecular weight (MW) of N protein produced by an in vitro transcription and translation system (Fig. S4).", [["E. coli", "ORGANISM", 171, 178], ["N protein", "PROTEIN", 46, 55], ["N protein", "PROTEIN", 118, 127], ["N protein", "PROTEIN", 229, 238], ["E. coli", "SPECIES", 171, 178], ["E. coli", "SPECIES", 171, 178], ["expressed N protein", "PROBLEM", 36, 55], ["the intrinsic charged aa components", "PROBLEM", 75, 110], ["the N protein", "PROBLEM", 114, 127], ["post-translational modification", "PROBLEM", 136, 167], ["E. coli", "PROBLEM", 171, 178], ["upper shift", "OBSERVATION_MODIFIER", 4, 15]]], ["In addition, this upper shift of the N protein in SDS-PAGE were reported in a previous IBV N protein study (Yu et al., 2010) and other coronaviral N proteins (Hurst et al., 2009, Hurst et al., 2010).Functional test of the positively selected sites ::: ResultsThe RNA-binding capacity of the N protein was determined by surface plasmon resonance (SPR) analysis.", [["SDS-PAGE", "GENE_OR_GENE_PRODUCT", 50, 58], ["N protein", "PROTEIN", 37, 46], ["coronaviral N proteins", "PROTEIN", 135, 157], ["N protein", "PROTEIN", 291, 300], ["IBV", "SPECIES", 87, 90], ["this upper shift", "PROBLEM", 13, 29], ["the N protein in SDS", "TEST", 33, 53], ["a previous IBV N protein study", "TEST", 76, 106], ["The RNA", "TEST", 259, 266], ["the N protein", "TEST", 287, 300], ["surface plasmon resonance", "TEST", 319, 344], ["upper shift", "OBSERVATION_MODIFIER", 18, 29], ["binding capacity", "OBSERVATION_MODIFIER", 267, 283]]], ["Previous studies showed that the coronaviral N protein has a high affinity for the TRS sequence (Grossoehme et al., 2009).", [["coronaviral N", "GENE_OR_GENE_PRODUCT", 33, 46], ["coronaviral N protein", "PROTEIN", 33, 54], ["TRS sequence", "DNA", 83, 95], ["Previous studies", "TEST", 0, 16], ["the coronaviral N protein", "TEST", 29, 54], ["the TRS sequence", "TEST", 79, 95]]], ["A repeated TRS sequence has been used as a probe in the SPR experiments to measure the interaction of the N protein with viral RNA (Huang et al., 2009, Nelson et al., 2000).", [["TRS sequence", "DNA", 11, 23], ["N protein", "PROTEIN", 106, 115], ["viral RNA", "RNA", 121, 130], ["A repeated TRS sequence", "TEST", 0, 23]]], ["The applied viral RNA probe consisted of repeated IBV TRS sequences, 5\u2032-(CUUAACAA)4-3\u2032 and was biotin-labeled.", [["biotin", "CHEMICAL", 95, 101], ["biotin", "CHEMICAL", 95, 101], ["biotin", "SIMPLE_CHEMICAL", 95, 101], ["IBV TRS sequences", "DNA", 50, 67], ["IBV", "SPECIES", 50, 53], ["The applied viral RNA probe", "TREATMENT", 0, 27], ["repeated IBV TRS sequences", "TEST", 41, 67], ["biotin", "TEST", 95, 101]]], ["One hundred resonance units (RU) were immobilized onto a streptavidin-coated biosensor chip for detecting the binding capacity of purified IBV N proteins.", [["streptavidin", "SIMPLE_CHEMICAL", 57, 69], ["IBV", "ORGANISM", 139, 142], ["purified IBV N proteins", "PROTEIN", 130, 153], ["IBV", "SPECIES", 139, 142], ["a streptavidin-coated biosensor chip", "TREATMENT", 55, 91], ["the binding capacity", "PROBLEM", 106, 126], ["IBV N proteins", "TREATMENT", 139, 153]]], ["Compared to the wild type N protein, all three mutants showed significantly reduced TRS-binding capacity at 0.1 and 0.5 \u03bcM protein concentrations (Fig. 4A\u2013C,) (p< 0.01, one-way ANOVA, Tukey's post hoc analysis).", [["wild type N protein", "PROTEIN", 16, 35], ["the wild type N protein", "TEST", 12, 35], ["significantly reduced TRS", "PROBLEM", 62, 87], ["binding capacity", "TEST", 88, 104], ["protein concentrations", "TEST", 123, 145], ["Fig. 4A\u2013C", "TEST", 147, 156], ["Tukey's post hoc analysis", "TEST", 184, 209]]], ["When the protein concentrations were elevated from 0.05 \u03bcM to 0.5 \u03bcM, proportional increases in their RNA-binding capacities were detected (Fig. 4C).", [["the protein concentrations", "TEST", 5, 31], ["proportional increases in their RNA-binding capacities", "PROBLEM", 70, 124], ["increases", "OBSERVATION_MODIFIER", 83, 92]]], ["The T64P variant, which mimicked the 64 aa position of US Beaudette strain, showed about half the RNA-binding capacity of the wild type TW N protein (Fig. 4C) (p< 0.01, one-way ANOVA, Tukey's post hoc analysis).", [["T64P", "GENE_OR_GENE_PRODUCT", 4, 8], ["T64P variant", "PROTEIN", 4, 16], ["wild type TW N protein", "PROTEIN", 126, 148], ["US Beaudette strain", "TEST", 55, 74], ["Tukey's post hoc analysis", "TEST", 184, 209]]], ["Likewise, the T64N and T123V variants, which represented the most common configurations of aa 64 and aa 123 in the CH N protein (52.2% and 91.3%, respectively) (Table 2), showed only 30\u201340% of the RNA-binding capacity of the TW TP/64 strain (Fig. 4C) (p< 0.01, one-way ANOVA, Tukey's post hoc analysis).", [["T64N", "GENE_OR_GENE_PRODUCT", 14, 18], ["T123V", "GENE_OR_GENE_PRODUCT", 23, 28], ["T64N and T123V variants", "DNA", 14, 37], ["CH N protein", "PROTEIN", 115, 127], ["aa", "TEST", 91, 93], ["aa", "TEST", 101, 103], ["the CH N protein", "TEST", 111, 127], ["the RNA", "TEST", 193, 200], ["binding capacity", "TEST", 201, 217], ["the TW TP", "TEST", 221, 230], ["p", "TEST", 252, 253], ["Tukey's post hoc analysis", "TEST", 276, 301]]], ["The ANOVA analyses also revealed that the RNA-binding activity between the pairs of mutants (T64P, T64N and T123V) has no significant difference.", [["The ANOVA analyses", "TEST", 0, 18], ["the RNA", "TEST", 38, 45], ["significant difference", "PROBLEM", 122, 144], ["no", "UNCERTAINTY", 119, 121], ["significant", "OBSERVATION_MODIFIER", 122, 133], ["difference", "OBSERVATION", 134, 144]]], ["Taken together, these results indicate that both aa 64 and 123 are critical for 5\u2032-(CUUAACAA)4-3\u2032 binding, and the modulation of these two residues may affect the binding affinity of the N protein for viral genomic or subgenomic RNA.DiscussionWhile the IBV N protein has generally been conserved and negatively selected during viral evolution, we have identified two positively selected sites at aa 64 and 123 in the N protein of IBVs.", [["IBV", "ORGANISM", 253, 256], ["IBVs", "GENE_OR_GENE_PRODUCT", 430, 434], ["N protein", "PROTEIN", 187, 196], ["viral genomic or subgenomic RNA", "RNA", 201, 232], ["IBV N protein", "PROTEIN", 253, 266], ["N protein", "PROTEIN", 417, 426], ["IBVs", "PROTEIN", 430, 434], ["IBV", "SPECIES", 253, 256], ["these two residues", "PROBLEM", 129, 147], ["viral genomic or subgenomic RNA", "PROBLEM", 201, 232], ["the IBV N protein", "TEST", 249, 266], ["IBVs", "TREATMENT", 430, 434], ["subgenomic RNA", "OBSERVATION", 218, 232]]], ["These two residues are located in the putative recombinant region of the NTD domain and are critical for binding to TRS repeats.", [["putative recombinant region", "PROTEIN", 38, 65], ["NTD domain", "PROTEIN", 73, 83], ["TRS repeats", "DNA", 116, 127], ["These two residues", "PROBLEM", 0, 18], ["TRS repeats", "TEST", 116, 127], ["two", "OBSERVATION_MODIFIER", 6, 9], ["residues", "OBSERVATION", 10, 18], ["recombinant", "OBSERVATION_MODIFIER", 47, 58], ["NTD", "OBSERVATION", 73, 76]]], ["To our knowledge, this is the first report on viral evolution linking an RNA recombination event with positive selection.", [["RNA recombination", "OBSERVATION", 73, 90]]], ["This study also provides the first functional assay to illustrate the importance of positively selected sites in the N protein for coronaviral RNA binding.DiscussionSporadic genetic recombination in the sequences of interests will change branch lengths and the topology of phylogenetic tree (Yang et al., 2000).", [["N protein", "PROTEIN", 117, 126], ["coronaviral RNA", "RNA", 131, 146], ["This study", "TEST", 0, 10], ["coronaviral RNA binding", "PROBLEM", 131, 154]]], ["These two parameters are assumed to be constant across the tested sequences for the analyses of CODEML, especially when the positive selection is evaluated by branch-site method based on a likelihood ratio test (Scheffler et al., 2006).", [["a likelihood ratio test", "TEST", 187, 210]]], ["To avoid false result of the positive selection in this study, the possible recombinant IBV strains, such as TW3374/05, TW2992/02, TW3381/06 and TW3382/06, are excluded (Fig. 1A and B) and the selected strains are chosen from the population in a same clade.", [["IBV", "ORGANISM", 88, 91], ["B", "GENE_OR_GENE_PRODUCT", 182, 183], ["IBV", "SPECIES", 88, 91], ["the positive selection", "PROBLEM", 25, 47], ["this study", "TEST", 51, 61], ["recombinant IBV strains", "PROBLEM", 76, 99], ["the selected strains", "PROBLEM", 189, 209], ["possible", "UNCERTAINTY", 67, 75]]], ["In addition, the candidate of positive selected sites (Table 1) is evaluated by a codon-substitution model but not a branch-site likelihood model.", [["positive selected sites", "DNA", 30, 53], ["a codon-substitution model", "TREATMENT", 80, 106], ["branch", "ANATOMY_MODIFIER", 117, 123]]], ["Finally, the fidelity of the mathematic prediction by CODEML is further validated by the experimental function assay, demonstrating that the positively selected sites are critical for the viral RNA-binding activity.DiscussionIn addition to forming part of the RNP, the coronaviral N protein participates in the formation of the replication\u2013transcriptional complex.", [["RNP", "ANATOMY", 260, 263], ["RNP", "CELLULAR_COMPONENT", 260, 263], ["CODEML", "DNA", 54, 60], ["viral RNA", "RNA", 188, 197], ["RNP", "PROTEIN", 260, 263], ["coronaviral N protein", "PROTEIN", 269, 290], ["replication\u2013transcriptional complex", "PROTEIN", 328, 363], ["the experimental function assay", "TEST", 85, 116], ["the viral RNA", "PROBLEM", 184, 197], ["the coronaviral N protein", "TREATMENT", 265, 290], ["viral RNA", "OBSERVATION", 188, 197]]], ["Specifically, the N protein's NTD binds to the TRS of the leading sequence and regulates TRS-cTRS (complementary TRS) helical unwinding (Grossoehme et al., 2009), suggesting its critical role in genomic duplication and subgenomic expression.", [["NTD", "GENE_OR_GENE_PRODUCT", 30, 33], ["N protein", "PROTEIN", 18, 27], ["NTD", "PROTEIN", 30, 33], ["TRS", "DNA", 47, 50], ["TRS", "DNA", 89, 92], ["cTRS", "DNA", 93, 97], ["the N protein", "TEST", 14, 27], ["TRS", "TEST", 89, 92], ["genomic duplication", "PROBLEM", 195, 214], ["genomic duplication", "OBSERVATION", 195, 214], ["subgenomic expression", "OBSERVATION", 219, 240]]], ["In this study, we showed that substituting either of the positively selected residues with the amino acid present in most CH IBVs dramatically reduced the binding capacity of the N protein for synthetic TRS repeats (Fig. 4).", [["amino acid", "CHEMICAL", 95, 105], ["amino acid", "CHEMICAL", 95, 105], ["CH", "CHEMICAL", 122, 124], ["amino acid", "AMINO_ACID", 95, 105], ["N protein", "PROTEIN", 179, 188], ["synthetic TRS repeats", "DNA", 193, 214], ["this study", "TEST", 3, 13], ["the positively selected residues", "PROBLEM", 53, 85], ["the amino acid", "TEST", 91, 105], ["the binding capacity", "PROBLEM", 151, 171], ["synthetic TRS repeats", "TEST", 193, 214], ["binding capacity", "OBSERVATION", 155, 171]]], ["Although neither selected site is located in the RNA-binding groove of the NTD, the modified residues may alter the secondary structure or surface charge distribution of the N protein and consequently affect RNA\u2013NTD interactions.", [["surface", "ANATOMY", 139, 146], ["NTD", "PROTEIN", 75, 78], ["N protein", "PROTEIN", 174, 183], ["the modified residues", "TREATMENT", 80, 101], ["the N protein", "TREATMENT", 170, 183], ["groove", "OBSERVATION_MODIFIER", 61, 67], ["NTD", "OBSERVATION", 75, 78], ["secondary structure", "OBSERVATION", 116, 135], ["surface", "OBSERVATION_MODIFIER", 139, 146], ["charge", "OBSERVATION", 147, 153]]], ["Here, phylogenetic evaluation of viral proteins not only helps us to reconstruct the evolutionary paths of viral species but also provides new insights into functional residues in viral proteins.DiscussionDuring viral propagation, variants with enhanced cellular tropism, viral transmission or replicative advantage show enhanced fitness in infected hosts (Domingo and Holland, 1997).", [["cellular", "ANATOMY", 254, 262], ["cellular", "CELL", 254, 262], ["viral proteins", "PROTEIN", 33, 47], ["viral proteins", "PROTEIN", 180, 194], ["phylogenetic evaluation", "TEST", 6, 29], ["viral proteins", "PROBLEM", 33, 47], ["viral species", "PROBLEM", 107, 120], ["functional residues in viral proteins", "PROBLEM", 157, 194], ["enhanced cellular tropism", "PROBLEM", 245, 270], ["viral transmission", "TREATMENT", 272, 290], ["viral species", "OBSERVATION", 107, 120], ["functional residues", "OBSERVATION", 157, 176], ["viral proteins", "OBSERVATION", 180, 194], ["cellular tropism", "OBSERVATION", 254, 270]]], ["Amino acid mutations in human immunodeficiency virus (HIV) gag (Banke et al., 2009) and pol genes (Huang et al., 2002), which are mainly involved in genomic duplication, were positively selected in patients and conferred fitness under the pressure of anti-HIV drug treatment.", [["Amino acid", "CHEMICAL", 0, 10], ["human immunodeficiency virus (HIV) gag", "DISEASE", 24, 62], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["human immunodeficiency virus", "ORGANISM", 24, 52], ["HIV", "ORGANISM", 54, 57], ["gag", "ORGANISM", 59, 62], ["pol", "GENE_OR_GENE_PRODUCT", 88, 91], ["patients", "ORGANISM", 198, 206], ["pol genes", "DNA", 88, 97], ["human immunodeficiency virus", "SPECIES", 24, 52], ["patients", "SPECIES", 198, 206], ["human immunodeficiency virus", "SPECIES", 24, 52], ["HIV", "SPECIES", 54, 57], ["Amino acid mutations", "TEST", 0, 20], ["human immunodeficiency virus", "PROBLEM", 24, 52], ["anti-HIV drug treatment", "TREATMENT", 251, 274], ["acid mutations", "OBSERVATION", 6, 20], ["genomic duplication", "OBSERVATION", 149, 168], ["anti-HIV drug", "OBSERVATION", 251, 264]]], ["In addition, positively selected residues in capsid proteins have been reported in rabbit hemorrhagic disease virus (Esteves et al., 2008), hepatitis C virus (Kurbanov et al., 2010) and foot-and mouth disease virus (Haydon et al., 2001).", [["rabbit hemorrhagic disease", "DISEASE", 83, 109], ["hepatitis C", "DISEASE", 140, 151], ["foot-and mouth disease", "DISEASE", 186, 208], ["rabbit hemorrhagic disease virus", "ORGANISM", 83, 115], ["hepatitis C virus", "ORGANISM", 140, 157], ["foot-and mouth disease virus", "ORGANISM", 186, 214], ["capsid proteins", "PROTEIN", 45, 60], ["rabbit", "SPECIES", 83, 89], ["hepatitis C virus", "SPECIES", 140, 157], ["foot-and mouth disease virus", "SPECIES", 186, 214], ["rabbit hemorrhagic disease virus", "SPECIES", 83, 115], ["hepatitis C virus", "SPECIES", 140, 157], ["foot-and mouth disease virus", "SPECIES", 186, 214], ["positively selected residues in capsid proteins", "PROBLEM", 13, 60], ["rabbit hemorrhagic disease virus", "PROBLEM", 83, 115], ["hepatitis C virus", "PROBLEM", 140, 157], ["mouth disease virus", "PROBLEM", 195, 214], ["capsid proteins", "OBSERVATION", 45, 60], ["foot", "ANATOMY", 186, 190], ["mouth", "ANATOMY", 195, 200]]], ["In this study, SPR binding assays of point-mutant IBV N proteins demonstrated that the positively selected residues in the TW IBV N protein may improve binding efficiency for viral TRS repeats.", [["point-mutant IBV N proteins", "PROTEIN", 37, 64], ["TW IBV N protein", "PROTEIN", 123, 139], ["viral TRS repeats", "DNA", 175, 192], ["IBV", "SPECIES", 126, 129], ["this study", "TEST", 3, 13], ["SPR binding assays", "TEST", 15, 33], ["mutant IBV N proteins", "PROBLEM", 43, 64], ["the positively selected residues", "PROBLEM", 83, 115], ["the TW IBV N protein", "TREATMENT", 119, 139], ["binding efficiency", "PROBLEM", 152, 170], ["viral TRS repeats", "PROBLEM", 175, 192]]], ["Sophisticated approaches using viral replicons or recombinant infectious clone should further illuminate the detailed roles of these selected sites in coronaviral propagation.DiscussionGiven that vaccine-based immunization imposes strong selective pressure on viral evolution, we did not rule out the possibility that the avian immune system has reshaped the recombinant N protein of TW IBV through positive selection.", [["coronaviral", "ANATOMY", 151, 162], ["clone", "CELL", 73, 78], ["avian", "ORGANISM", 322, 327], ["TW IBV", "ORGANISM", 384, 390], ["viral replicons", "DNA", 31, 46], ["recombinant N protein", "PROTEIN", 359, 380], ["TW IBV", "SPECIES", 384, 390], ["Sophisticated approaches", "TREATMENT", 0, 24], ["viral replicons", "TREATMENT", 31, 46], ["recombinant infectious clone", "TREATMENT", 50, 78], ["vaccine-based immunization", "TREATMENT", 196, 222], ["the avian immune system", "PROBLEM", 318, 341], ["viral replicons", "OBSERVATION", 31, 46], ["coronaviral propagation", "OBSERVATION", 151, 174]]], ["Both S and N proteins are known to be major antigenic determinants of IBV (Cavanagh, 2003).", [["IBV", "ORGANISM", 70, 73], ["S and N proteins", "PROTEIN", 5, 21], ["IBV", "SPECIES", 70, 73], ["IBV", "PROBLEM", 70, 73], ["IBV", "OBSERVATION", 70, 73]]], ["Administration of N proteins via intraperitoneal injection can elicit protective adaptive immunity against an IBV challenge (Cavanagh, 2003).", [["intraperitoneal", "ANATOMY", 33, 48], ["N proteins", "GENE_OR_GENE_PRODUCT", 18, 28], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 48], ["N proteins", "PROTEIN", 18, 28], ["IBV", "SPECIES", 110, 113], ["N proteins via intraperitoneal injection", "TREATMENT", 18, 58], ["protective adaptive immunity", "TREATMENT", 70, 98], ["an IBV challenge", "TREATMENT", 107, 123]]], ["We speculate that the TW IBV, sharing epitopes in the NTD of the N protein with the US-serotype IBV because of an RNA recombination event, may have become more vulnerable to attack by the adaptive immune system in fowl vaccinated against the Connecticut or other US-like IBV strains.", [["TW IBV", "ORGANISM", 22, 28], ["US-serotype IBV", "ORGANISM", 84, 99], ["immune system", "ANATOMICAL_SYSTEM", 197, 210], ["fowl", "ORGANISM", 214, 218], ["US-like", "ORGANISM", 263, 270], ["IBV", "ORGANISM", 271, 274], ["epitopes", "PROTEIN", 38, 46], ["NTD", "PROTEIN", 54, 57], ["N protein", "PROTEIN", 65, 74], ["TW IBV", "SPECIES", 22, 28], ["IBV", "SPECIES", 96, 99], ["fowl", "SPECIES", 214, 218], ["IBV", "SPECIES", 271, 274], ["the TW IBV", "TREATMENT", 18, 28], ["the N protein", "TREATMENT", 61, 74], ["the US", "TEST", 80, 86], ["serotype IBV", "TREATMENT", 87, 99], ["an RNA recombination event", "PROBLEM", 111, 137], ["other US", "TEST", 257, 265], ["IBV strains", "PROBLEM", 271, 282], ["RNA recombination", "OBSERVATION", 114, 131], ["IBV strains", "OBSERVATION", 271, 282]]], ["To counteract this adverse effect, it is possible that residues in the \u03b1-turn (aa 63\u201367) and surrounding peptides located in an externally exposed loop (or a turn) have been positively selected to attenuate antigenic recognition by host B lymphocytes.", [["B lymphocytes", "ANATOMY", 237, 250], ["aa 63\u201367", "CHEMICAL", 79, 87], ["B lymphocytes", "CELL", 237, 250], ["\u03b1-turn", "PROTEIN", 71, 77], ["host B lymphocytes", "CELL_TYPE", 232, 250], ["surrounding peptides", "PROBLEM", 93, 113], ["an externally exposed loop", "TREATMENT", 125, 151], ["loop", "OBSERVATION", 147, 151]]], ["This speculation is supported by the fact that almost all the test TW IBVs were isolated from vaccinated flocks and were under immune selection pressure.", [["IBVs", "GENE_OR_GENE_PRODUCT", 70, 74], ["the test TW IBVs", "TEST", 58, 74], ["vaccinated flocks", "PROBLEM", 94, 111]]], ["In addition, a recent study on MHV infection, which emphasized that epitope-escape coronaviral strains can be quickly selected by genetic deletion or mutation under strong immunological pressure (Chua et al., 2004).", [["MHV infection", "DISEASE", 31, 44], ["MHV", "ORGANISM", 31, 34], ["MHV", "SPECIES", 31, 34], ["a recent study", "TEST", 13, 27], ["MHV infection", "PROBLEM", 31, 44], ["epitope-escape coronaviral strains", "PROBLEM", 68, 102], ["mutation", "PROBLEM", 150, 158], ["infection", "OBSERVATION", 35, 44]]], ["In addition, it has been suggested that the \u03b1-turn region (aa 63\u201367) may form an antigenic epitope in the IBV N protein (Ignjatovic and Sapats, 2005).", [["\u03b1-turn region", "PROTEIN", 44, 57], ["antigenic epitope", "PROTEIN", 81, 98], ["IBV N protein", "PROTEIN", 106, 119], ["IBV", "SPECIES", 106, 109], ["an antigenic epitope", "PROBLEM", 78, 98]]], ["Future works will aim to determine whether the mutations at aa 64 and 123 of the N protein in adapted strains result in altered epitope determinants and consequently provide competitive benefits for quasispecies in hosts by allowing the selected TW strains to escape immune surveillance.DiscussionTaken together, our data support the conclusion that positive selection has occurred in specific residues of the recombinant IBV N protein.", [["IBV N protein", "GENE_OR_GENE_PRODUCT", 422, 435], ["N protein", "PROTEIN", 81, 90], ["epitope determinants", "PROTEIN", 128, 148], ["recombinant IBV N protein", "PROTEIN", 410, 435], ["IBV", "SPECIES", 422, 425], ["the mutations", "PROBLEM", 43, 56], ["the N protein", "TREATMENT", 77, 90], ["adapted strains", "PROBLEM", 94, 109], ["altered epitope determinants", "PROBLEM", 120, 148], ["quasispecies in hosts", "PROBLEM", 199, 220], ["the selected TW strains", "PROBLEM", 233, 256], ["immune surveillance", "TEST", 267, 286], ["positive selection", "PROBLEM", 350, 368], ["the recombinant IBV N protein", "TREATMENT", 406, 435]]], ["This selection may promote the viral fitness in infected hosts, at least in part, by modulating the RNA-binding capacity of the N protein's NTD.", [["N protein", "PROTEIN", 128, 137], ["NTD", "PROTEIN", 140, 143], ["This selection", "TREATMENT", 0, 14], ["the viral fitness in infected hosts", "PROBLEM", 27, 62], ["the RNA", "TEST", 96, 103], ["the N protein", "TEST", 124, 137], ["viral fitness", "OBSERVATION", 31, 44], ["infected", "OBSERVATION", 48, 56]]], ["Diagram illustrating the proposed evolution of IBV in Taiwan is provided in Fig. 5.", [["IBV", "ORGANISM", 47, 50], ["IBV", "SPECIES", 47, 50], ["IBV", "PROBLEM", 47, 50], ["IBV", "OBSERVATION", 47, 50]]], ["Further investigation is required to illustrate the details that how the recombinant configuration of the N gene in the original founder was maintained and consequently fixed in the current TW IBV population.", [["N gene", "DNA", 106, 112], ["IBV", "SPECIES", 193, 196], ["Further investigation", "TEST", 0, 21]]]], "PMC7233673": [["Health care systems around the world face extreme challenges during the pandemic of SARS-CoV-2.", [["SARS", "DISEASE", 84, 88], ["SARS-CoV-2", "ORGANISM", 84, 94], ["SARS-CoV", "SPECIES", 84, 92]]], ["It has been reported that up to 20% of the patients develop an acute respiratory distress syndrome (ARDS) and approximately 12% require mechanical ventilation.", [["respiratory", "ANATOMY", 69, 80], ["acute respiratory distress syndrome", "DISEASE", 63, 98], ["ARDS", "DISEASE", 100, 104], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["an acute respiratory distress syndrome", "PROBLEM", 60, 98], ["ARDS)", "PROBLEM", 100, 105], ["mechanical ventilation", "TREATMENT", 136, 158], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["respiratory distress", "OBSERVATION", 69, 89], ["mechanical ventilation", "OBSERVATION", 136, 158]]], ["In many countries, this may lead to a rapid shortage of intensive care (ICU) ventilators.", [["ventilators", "TREATMENT", 77, 88]]], ["As such, a stepwise approach and triage utilizing all available types of ventilators might be necessary.", [["a stepwise approach", "TREATMENT", 9, 28], ["triage", "TEST", 33, 39], ["ventilators", "TREATMENT", 73, 84]]], ["As uncertainties of the correct sequence of ventilator utilization seem to exist, we aim to provide a quick overview of the possibilities and shed some light on recently discussed ideas.", [["ventilator utilization", "TREATMENT", 44, 66]]]], "93230653241118f412fbf58f3bcb5b6e980c1935": [["Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor BlockersTo the Editor: The COVID-19 pandemic has resulted in a debate over potential risks vs benefits of certain pharmaceuticals -\"angiotensin-converting enzyme inhibitors\" (ACEIs) and \"angiotensin-receptor blockers\" (ARBs).", [["Angiotensin", "CHEMICAL", 0, 11], ["Inflammation", "DISEASE", 54, 66], ["Angiotensin", "CHEMICAL", 109, 120], ["Angiotensin", "CHEMICAL", 154, 165], ["angiotensin", "CHEMICAL", 307, 318], ["angiotensin", "CHEMICAL", 362, 373], ["Angiotensin-Converting Enzyme 2", "GENE_OR_GENE_PRODUCT", 0, 31], ["Angiotensin-Converting Enzyme", "GENE_OR_GENE_PRODUCT", 109, 138], ["angiotensin-converting enzyme inhibitors", "SIMPLE_CHEMICAL", 307, 347], ["ACEIs", "SIMPLE_CHEMICAL", 350, 355], ["angiotensin-receptor blockers", "SIMPLE_CHEMICAL", 362, 391], ["ARBs", "SIMPLE_CHEMICAL", 394, 398], ["Angiotensin", "TREATMENT", 0, 11], ["Converting Enzyme", "TEST", 12, 29], ["Inflammation", "PROBLEM", 54, 66], ["Prescribed Angiotensin", "TREATMENT", 98, 120], ["Converting Enzyme Inhibitors", "TREATMENT", 121, 149], ["Angiotensin-Receptor Blockers", "TREATMENT", 154, 183], ["The COVID", "TREATMENT", 198, 207], ["certain pharmaceuticals", "TREATMENT", 281, 304], ["angiotensin", "TREATMENT", 307, 318], ["converting enzyme inhibitors", "TREATMENT", 319, 347], ["ACEIs", "TREATMENT", 350, 355], ["angiotensin-receptor blockers", "TREATMENT", 362, 391], ["ARBs", "TREATMENT", 394, 398], ["Inflammation", "OBSERVATION", 54, 66]]], ["A recent letter to the editor, published online on March 23 in the Journal of Travel Medicine 1 outlined a hypothesis stating that use of ACEIs and ARBs may increase the risk of severe disease in COVID-19 patients.", [["ACEIs", "CHEMICAL", 138, 143], ["ARBs", "CHEMICAL", 148, 152], ["ACEIs", "SIMPLE_CHEMICAL", 138, 143], ["ARBs", "SIMPLE_CHEMICAL", 148, 152], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["ACEIs", "TREATMENT", 138, 143], ["ARBs", "TREATMENT", 148, 152], ["severe disease in COVID", "PROBLEM", 178, 201], ["severe", "OBSERVATION_MODIFIER", 178, 184], ["disease", "OBSERVATION", 185, 192]]], ["Data showed that intravenous infusion of ACEIs and ARBs to experimental animals increased the numbers of angiotensinconverting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation.", [["intravenous", "ANATOMY", 17, 28], ["cardiopulmonary", "ANATOMY", 160, 175], ["ACEIs", "CHEMICAL", 41, 46], ["ARBs", "CHEMICAL", 51, 55], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 17, 28], ["ACEIs", "SIMPLE_CHEMICAL", 41, 46], ["ARBs", "SIMPLE_CHEMICAL", 51, 55], ["angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 105, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 137, 141], ["angiotensinconverting enzyme 2 (ACE2) receptors", "PROTEIN", 105, 152], ["intravenous infusion", "TREATMENT", 17, 37], ["ACEIs", "TREATMENT", 41, 46], ["ARBs", "TREATMENT", 51, 55], ["experimental animals", "PROBLEM", 59, 79], ["angiotensinconverting enzyme", "TEST", 105, 133], ["cardiopulmonary circulation", "ANATOMY", 160, 187]]], ["It is acknowledged that ACE2 receptors are widely dispersed, including lung alveolar epithelial cells, gastrointestinal tract enterocytes, the vascular system, the nasopharynx, kidney, and brain.", [["lung alveolar epithelial cells", "ANATOMY", 71, 101], ["gastrointestinal tract enterocytes", "ANATOMY", 103, 137], ["vascular system", "ANATOMY", 143, 158], ["nasopharynx", "ANATOMY", 164, 175], ["kidney", "ANATOMY", 177, 183], ["brain", "ANATOMY", 189, 194], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["lung alveolar epithelial cells", "CELL", 71, 101], ["gastrointestinal tract enterocytes", "MULTI-TISSUE_STRUCTURE", 103, 137], ["vascular system", "MULTI-TISSUE_STRUCTURE", 143, 158], ["nasopharynx", "ORGAN", 164, 175], ["kidney", "ORGAN", 177, 183], ["brain", "ORGAN", 189, 194], ["ACE2 receptors", "PROTEIN", 24, 38], ["lung alveolar epithelial cells", "CELL_TYPE", 71, 101], ["ACE2 receptors", "TREATMENT", 24, 38], ["lung alveolar epithelial cells", "PROBLEM", 71, 101], ["gastrointestinal tract enterocytes, the vascular system, the nasopharynx, kidney, and brain", "PROBLEM", 103, 194], ["widely", "OBSERVATION_MODIFIER", 43, 49], ["dispersed", "OBSERVATION_MODIFIER", 50, 59], ["lung", "ANATOMY", 71, 75], ["alveolar", "ANATOMY_MODIFIER", 76, 84], ["epithelial cells", "OBSERVATION", 85, 101], ["gastrointestinal tract", "ANATOMY", 103, 125], ["vascular system", "ANATOMY", 143, 158], ["nasopharynx", "ANATOMY", 164, 175], ["kidney", "ANATOMY", 177, 183], ["brain", "ANATOMY", 189, 194]]], ["2 (2) Based on that preclinical data, recognizing that ACE2 receptors are binding sites for COVID-19 entry into the body, an increased number of ACE2 receptors was hypothesized to heighten the risk for severe pulmonary disease, by increasing the number of binding sites available to the virus.", [["body", "ANATOMY", 116, 120], ["pulmonary", "ANATOMY", 209, 218], ["pulmonary disease", "DISEASE", 209, 226], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["COVID-19", "GENE_OR_GENE_PRODUCT", 92, 100], ["body", "ORGANISM_SUBDIVISION", 116, 120], ["ACE2", "GENE_OR_GENE_PRODUCT", 145, 149], ["pulmonary", "ORGAN", 209, 218], ["ACE2 receptors", "PROTEIN", 55, 69], ["ACE2 receptors", "PROTEIN", 145, 159], ["ACE2 receptors", "TREATMENT", 55, 69], ["binding sites", "PROBLEM", 74, 87], ["COVID", "TEST", 92, 97], ["ACE2 receptors", "TREATMENT", 145, 159], ["severe pulmonary disease", "PROBLEM", 202, 226], ["binding sites", "PROBLEM", 256, 269], ["the virus", "PROBLEM", 283, 292], ["body", "ANATOMY", 116, 120], ["increased", "OBSERVATION_MODIFIER", 125, 134], ["number", "OBSERVATION_MODIFIER", 135, 141], ["severe", "OBSERVATION_MODIFIER", 202, 208], ["pulmonary", "ANATOMY", 209, 218], ["disease", "OBSERVATION", 219, 226]]], ["Though that conclusion is persuasive at first glance, the data and recommendations presented in the accompanying article by Sanchis-Gomar et al, 3and the recent NEJM article byVaduganathan et al, 4 are more compelling.", [["the recent NEJM article byVaduganathan et al", "TREATMENT", 150, 194]]], ["Further analysis of the ACE2 mechanisms supports the hypothesis that ACEIs and ARBs are more likely to benefit than harm patients infected with COVID-19.", [["ACEIs", "CHEMICAL", 69, 74], ["ARBs", "CHEMICAL", 79, 83], ["COVID-19", "CHEMICAL", 144, 152], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["ACEIs", "SIMPLE_CHEMICAL", 69, 74], ["ARBs", "SIMPLE_CHEMICAL", 79, 83], ["patients", "ORGANISM", 121, 129], ["ACE2", "PROTEIN", 24, 28], ["patients", "SPECIES", 121, 129], ["Further analysis", "TEST", 0, 16], ["the ACE2 mechanisms", "TREATMENT", 20, 39], ["ACEIs", "TREATMENT", 69, 74], ["ARBs", "TREATMENT", 79, 83], ["COVID", "TEST", 144, 149]]], ["COVID-19 binds viral S protein to ACE2, reducing receptor expression, enabling viral and cell membrane fusion and viralreplication, with the potential for inflammatory tissue damage, and the severe inflammatory response, a cytokine storm.and the recent NEJM article byAt infection onset, an initial inflammatory response is triggered with the production of Angiotensin II (Ang II), via Renin-Angiotensin-Aldosterone System (RAAS) activation (nicely reviewed in the article).", [["cell membrane", "ANATOMY", 89, 102], ["tissue", "ANATOMY", 168, 174], ["tissue damage", "DISEASE", 168, 181], ["infection", "DISEASE", 271, 280], ["Angiotensin II", "CHEMICAL", 357, 371], ["Ang II", "CHEMICAL", 373, 379], ["Renin-Angiotensin-Aldosterone", "CHEMICAL", 386, 415], ["Aldosterone", "CHEMICAL", 404, 415], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["cell membrane", "CELLULAR_COMPONENT", 89, 102], ["tissue", "TISSUE", 168, 174], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 357, 371], ["Ang II", "GENE_OR_GENE_PRODUCT", 373, 379], ["Renin-Angiotensin-Aldosterone System", "GENE_OR_GENE_PRODUCT", 386, 422], ["RAAS", "GENE_OR_GENE_PRODUCT", 424, 428], ["COVID-19", "PROTEIN", 0, 8], ["viral S protein", "PROTEIN", 15, 30], ["ACE2", "PROTEIN", 34, 38], ["cytokine", "PROTEIN", 223, 231], ["Angiotensin II", "PROTEIN", 357, 371], ["Ang II", "PROTEIN", 373, 379], ["COVID", "TEST", 0, 5], ["viral S protein", "TREATMENT", 15, 30], ["ACE2", "TEST", 34, 38], ["reducing receptor expression", "TREATMENT", 40, 68], ["enabling viral and cell membrane fusion", "TREATMENT", 70, 109], ["viralreplication", "TREATMENT", 114, 130], ["inflammatory tissue damage", "PROBLEM", 155, 181], ["the severe inflammatory response", "PROBLEM", 187, 219], ["a cytokine storm", "PROBLEM", 221, 237], ["the recent NEJM article byAt infection", "PROBLEM", 242, 280], ["an initial inflammatory response", "PROBLEM", 288, 320], ["Angiotensin II (Ang II)", "TREATMENT", 357, 380], ["Renin-Angiotensin-Aldosterone System (RAAS) activation", "TREATMENT", 386, 440], ["cell membrane fusion", "OBSERVATION", 89, 109], ["inflammatory tissue", "OBSERVATION", 155, 174], ["severe", "OBSERVATION_MODIFIER", 191, 197], ["inflammatory", "OBSERVATION_MODIFIER", 198, 210], ["cytokine storm", "OBSERVATION", 223, 237], ["infection", "OBSERVATION", 271, 280], ["inflammatory", "OBSERVATION", 299, 311]]], ["This inflammatory response is normally moderated by the activation of ACE2 receptors.", [["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["ACE2 receptors", "PROTEIN", 70, 84], ["This inflammatory response", "PROBLEM", 0, 26], ["ACE2 receptors", "TREATMENT", 70, 84], ["inflammatory", "OBSERVATION", 5, 17]]], ["ACE2 is a key player in minimizing and reversing the inflammatory response, by converting Angiotensin II to angiotensin 1-7 (Ang 1-7), which after binding to the Mas receptor (MasR), results in a wide array of anti-inflammatory actions.", [["Angiotensin II", "CHEMICAL", 90, 104], ["angiotensin 1-7", "CHEMICAL", 108, 123], ["Ang 1-7", "CHEMICAL", 125, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 90, 104], ["angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 108, 123], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 125, 132], ["Mas receptor", "GENE_OR_GENE_PRODUCT", 162, 174], ["MasR", "GENE_OR_GENE_PRODUCT", 176, 180], ["ACE2", "PROTEIN", 0, 4], ["Angiotensin II", "PROTEIN", 90, 104], ["Mas receptor", "PROTEIN", 162, 174], ["MasR", "PROTEIN", 176, 180], ["the inflammatory response", "PROBLEM", 49, 74], ["Angiotensin II to angiotensin", "TREATMENT", 90, 119], ["anti-inflammatory actions", "TREATMENT", 210, 235], ["inflammatory response", "OBSERVATION", 53, 74]]], ["5 The inflammatory state is a critical organismal response to an invader, but ultimately healing requires inflammation resolution, a process blocked by COVID-19's binding to and disabling ACE2 receptors, leading to unrelenting inflammation.and the recent NEJM article byThe proposal that increased numbers of ACE2 receptors, due to ACEIs and ARBs, would signal an increase in viral binding and severe disease is unsupported by clinical data.", [["inflammation", "DISEASE", 106, 118], ["COVID-19's", "CHEMICAL", 152, 162], ["inflammation", "DISEASE", 227, 239], ["COVID-19's", "GENE_OR_GENE_PRODUCT", 152, 162], ["ACE2", "GENE_OR_GENE_PRODUCT", 188, 192], ["ACE2", "GENE_OR_GENE_PRODUCT", 309, 313], ["ARBs", "GENE_OR_GENE_PRODUCT", 342, 346], ["COVID", "PROTEIN", 152, 157], ["ACE2 receptors", "PROTEIN", 188, 202], ["ACE2 receptors", "PROTEIN", 309, 323], ["The inflammatory state", "PROBLEM", 2, 24], ["an invader", "PROBLEM", 62, 72], ["inflammation resolution", "PROBLEM", 106, 129], ["disabling ACE2 receptors", "PROBLEM", 178, 202], ["unrelenting inflammation", "PROBLEM", 215, 239], ["ACE2 receptors", "TREATMENT", 309, 323], ["ACEIs", "TREATMENT", 332, 337], ["ARBs", "TREATMENT", 342, 346], ["an increase in viral binding", "PROBLEM", 361, 389], ["severe disease", "PROBLEM", 394, 408], ["inflammatory", "OBSERVATION", 6, 18], ["organismal response", "OBSERVATION", 39, 58], ["invader", "OBSERVATION_MODIFIER", 65, 72], ["healing", "OBSERVATION_MODIFIER", 89, 96], ["inflammation", "OBSERVATION_MODIFIER", 106, 118], ["resolution", "OBSERVATION_MODIFIER", 119, 129], ["unrelenting", "OBSERVATION_MODIFIER", 215, 226], ["inflammation", "OBSERVATION", 227, 239], ["increased", "OBSERVATION_MODIFIER", 288, 297], ["increase", "OBSERVATION_MODIFIER", 364, 372], ["viral binding", "OBSERVATION", 376, 389], ["severe", "OBSERVATION_MODIFIER", 394, 400], ["disease", "OBSERVATION", 401, 408]]], ["The alternative view, that the presence of more functional ACE2 receptors could facilitate inflammation resolution by increasing production of anti-inflammatory Ang 1-7 is reasonable.", [["inflammation", "DISEASE", 91, 103], ["Ang", "CHEMICAL", 161, 164], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 161, 168], ["ACE2 receptors", "PROTEIN", 59, 73], ["The alternative view", "TEST", 0, 20], ["more functional ACE2 receptors", "PROBLEM", 43, 73], ["inflammation resolution", "PROBLEM", 91, 114], ["anti-inflammatory Ang", "TREATMENT", 143, 164], ["inflammation", "OBSERVATION", 91, 103]]], ["More Ang 1-7 would promote and support healthy vascular, pulmonary, myocardial, and renal function and suppress inflammatory cytokine production.", [["vascular", "ANATOMY", 47, 55], ["pulmonary", "ANATOMY", 57, 66], ["myocardial", "ANATOMY", 68, 78], ["renal", "ANATOMY", 84, 89], ["Ang", "CHEMICAL", 5, 8], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 5, 12], ["vascular", "MULTI-TISSUE_STRUCTURE", 47, 55], ["pulmonary", "MULTI-TISSUE_STRUCTURE", 57, 66], ["myocardial", "MULTI-TISSUE_STRUCTURE", 68, 78], ["renal", "ORGAN", 84, 89], ["Ang 1-7", "PROTEIN", 5, 12], ["cytokine", "PROTEIN", 125, 133], ["inflammatory cytokine production", "PROBLEM", 112, 144], ["vascular", "ANATOMY", 47, 55], ["pulmonary", "ANATOMY", 57, 66], ["myocardial", "ANATOMY", 68, 78], ["renal", "ANATOMY", 84, 89], ["inflammatory", "OBSERVATION_MODIFIER", 112, 124]]], ["If ACEIs and ARBs increase functional ACE2 receptors, the activation of anti-inflammatory pathways may save lives.and the recent NEJM article byPending more research on this topic, and lacking evidence of harm to patients infected by COVID-19 while taking ACEIs and ARBs, the discontinuation of these medications is unjustified and could result in more negative outcomes.5.Turner To the Editor: The COVID-19 pandemic has resulted in a debate over potential risks vs benefits of certain pharmaceuticalsangiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs).", [["angiotensin-receptor blockers", "CHEMICAL", 554, 583], ["ACEIs", "SIMPLE_CHEMICAL", 3, 8], ["ARBs", "SIMPLE_CHEMICAL", 13, 17], ["ACE2 receptors", "GENE_OR_GENE_PRODUCT", 38, 52], ["patients", "ORGANISM", 213, 221], ["ACEIs", "SIMPLE_CHEMICAL", 256, 261], ["ARBs", "SIMPLE_CHEMICAL", 266, 270], ["pharmaceuticalsangiotensin-converting enzyme inhibitors", "SIMPLE_CHEMICAL", 486, 541], ["ACEIs", "SIMPLE_CHEMICAL", 543, 548], ["angiotensin-receptor blockers", "SIMPLE_CHEMICAL", 554, 583], ["ARBs", "SIMPLE_CHEMICAL", 585, 589], ["ACE2 receptors", "PROTEIN", 38, 52], ["patients", "SPECIES", 213, 221], ["ACEIs", "TREATMENT", 3, 8], ["ARBs", "TREATMENT", 13, 17], ["functional ACE2 receptors", "TREATMENT", 27, 52], ["anti-inflammatory pathways", "TREATMENT", 72, 98], ["COVID", "TEST", 234, 239], ["ACEIs", "TREATMENT", 256, 261], ["ARBs", "TREATMENT", 266, 270], ["these medications", "TREATMENT", 295, 312], ["The COVID", "TREATMENT", 395, 404], ["certain pharmaceuticalsangiotensin", "TREATMENT", 478, 512], ["converting enzyme inhibitors", "TREATMENT", 513, 541], ["ACEIs", "TREATMENT", 543, 548], ["angiotensin-receptor blockers", "TREATMENT", 554, 583], ["ARBs", "TREATMENT", 585, 589]]], ["A recent letter to the editor, published online on March 23 in the Journal of Travel Medicine 1 outlined a hypothesis stating that use of ACEIs and ARBs may increase the risk of severe disease in COVID-19 patients.", [["ACEIs", "CHEMICAL", 138, 143], ["ARBs", "CHEMICAL", 148, 152], ["ACEIs", "SIMPLE_CHEMICAL", 138, 143], ["ARBs", "SIMPLE_CHEMICAL", 148, 152], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["ACEIs", "TREATMENT", 138, 143], ["ARBs", "TREATMENT", 148, 152], ["severe disease in COVID", "PROBLEM", 178, 201], ["severe", "OBSERVATION_MODIFIER", 178, 184], ["disease", "OBSERVATION", 185, 192]]], ["Data showed that intravenous infusion of ACEIs and ARBs to experimental animals increased the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation.", [["intravenous", "ANATOMY", 17, 28], ["cardiopulmonary", "ANATOMY", 161, 176], ["ACEIs", "CHEMICAL", 41, 46], ["ARBs", "CHEMICAL", 51, 55], ["angiotensin", "CHEMICAL", 105, 116], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 17, 28], ["ACEIs", "SIMPLE_CHEMICAL", 41, 46], ["ARBs", "SIMPLE_CHEMICAL", 51, 55], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 105, 136], ["ACE2", "GENE_OR_GENE_PRODUCT", 138, 142], ["angiotensin-converting enzyme 2 (ACE2) receptors", "PROTEIN", 105, 153], ["intravenous infusion", "TREATMENT", 17, 37], ["ACEIs", "TREATMENT", 41, 46], ["ARBs", "TREATMENT", 51, 55], ["experimental animals", "PROBLEM", 59, 79], ["angiotensin", "TEST", 105, 116], ["cardiopulmonary circulation", "ANATOMY", 161, 188]]], ["It is acknowledged that ACE2 receptors are widely dispersed, including lung alveolar epithelial cells, gastrointestinal tract enterocytes, the vascular system, the nasopharynx, kidney, and brain.", [["lung alveolar epithelial cells", "ANATOMY", 71, 101], ["gastrointestinal tract enterocytes", "ANATOMY", 103, 137], ["vascular system", "ANATOMY", 143, 158], ["nasopharynx", "ANATOMY", 164, 175], ["kidney", "ANATOMY", 177, 183], ["brain", "ANATOMY", 189, 194], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["lung alveolar epithelial cells", "CELL", 71, 101], ["gastrointestinal tract enterocytes", "MULTI-TISSUE_STRUCTURE", 103, 137], ["vascular system", "MULTI-TISSUE_STRUCTURE", 143, 158], ["nasopharynx", "ORGAN", 164, 175], ["kidney", "ORGAN", 177, 183], ["brain", "ORGAN", 189, 194], ["ACE2 receptors", "PROTEIN", 24, 38], ["lung alveolar epithelial cells", "CELL_TYPE", 71, 101], ["ACE2 receptors", "TREATMENT", 24, 38], ["lung alveolar epithelial cells", "PROBLEM", 71, 101], ["gastrointestinal tract enterocytes, the vascular system, the nasopharynx, kidney, and brain", "PROBLEM", 103, 194], ["widely", "OBSERVATION_MODIFIER", 43, 49], ["dispersed", "OBSERVATION_MODIFIER", 50, 59], ["lung", "ANATOMY", 71, 75], ["alveolar", "ANATOMY_MODIFIER", 76, 84], ["epithelial cells", "OBSERVATION", 85, 101], ["gastrointestinal tract", "ANATOMY", 103, 125], ["vascular system", "ANATOMY", 143, 158], ["nasopharynx", "ANATOMY", 164, 175], ["kidney", "ANATOMY", 177, 183], ["brain", "ANATOMY", 189, 194]]], ["2 Based on that preclinical data, recognizing that ACE2 receptors are binding sites for COVID-19 entry into the body, an increased number of ACE2 receptors was hypothesized to heighten the risk for severe pulmonary disease, by increasing the number of binding sites available to the virus.", [["body", "ANATOMY", 112, 116], ["pulmonary", "ANATOMY", 205, 214], ["pulmonary disease", "DISEASE", 205, 222], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["COVID-19", "GENE_OR_GENE_PRODUCT", 88, 96], ["body", "ORGANISM_SUBDIVISION", 112, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 141, 145], ["pulmonary", "ORGAN", 205, 214], ["ACE2 receptors", "PROTEIN", 51, 65], ["ACE2 receptors", "PROTEIN", 141, 155], ["preclinical data", "TEST", 16, 32], ["ACE2 receptors", "TREATMENT", 51, 65], ["binding sites", "PROBLEM", 70, 83], ["COVID", "TEST", 88, 93], ["ACE2 receptors", "TREATMENT", 141, 155], ["severe pulmonary disease", "PROBLEM", 198, 222], ["binding sites", "PROBLEM", 252, 265], ["the virus", "PROBLEM", 279, 288], ["body", "ANATOMY", 112, 116], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["number", "OBSERVATION_MODIFIER", 131, 137], ["severe", "OBSERVATION_MODIFIER", 198, 204], ["pulmonary", "ANATOMY", 205, 214], ["disease", "OBSERVATION", 215, 222]]], ["Further analysis of the ACE2 mechanisms supports the hypothesis that ACEIs and ARBs are more likely to benefit than harm patients infected with COVID-19.", [["ACEIs", "CHEMICAL", 69, 74], ["ARBs", "CHEMICAL", 79, 83], ["COVID-19", "CHEMICAL", 144, 152], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["ACEIs", "SIMPLE_CHEMICAL", 69, 74], ["ARBs", "SIMPLE_CHEMICAL", 79, 83], ["patients", "ORGANISM", 121, 129], ["ACE2", "PROTEIN", 24, 28], ["patients", "SPECIES", 121, 129], ["Further analysis", "TEST", 0, 16], ["the ACE2 mechanisms", "TREATMENT", 20, 39], ["ACEIs", "TREATMENT", 69, 74], ["ARBs", "TREATMENT", 79, 83], ["COVID", "TEST", 144, 149]]], ["COVID-19 binds viral S protein to ACE2, reducing receptor expression, enabling viral and cell membrane fusion and viral replication, with the potential for inflammatory tissue damage, and the severe inflammatory response, a cytokine storm.5.At the onset of infection, an initial inflammatory response is triggered with the production of Angiotensin II (Ang II), via Renin-Angiotensin-Aldosterone System (RAAS) activation (nicely reviewed in the article).", [["cell membrane", "ANATOMY", 89, 102], ["tissue", "ANATOMY", 169, 175], ["tissue damage", "DISEASE", 169, 182], ["infection", "DISEASE", 257, 266], ["Angiotensin II", "CHEMICAL", 337, 351], ["Ang II", "CHEMICAL", 353, 359], ["Renin-Angiotensin-Aldosterone", "CHEMICAL", 366, 395], ["Aldosterone", "CHEMICAL", 384, 395], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["cell membrane", "CELLULAR_COMPONENT", 89, 102], ["tissue", "TISSUE", 169, 175], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 337, 351], ["Ang II", "GENE_OR_GENE_PRODUCT", 353, 359], ["Renin-Angiotensin-Aldosterone System", "GENE_OR_GENE_PRODUCT", 366, 402], ["RAAS", "GENE_OR_GENE_PRODUCT", 404, 408], ["COVID-19", "PROTEIN", 0, 8], ["viral S protein", "PROTEIN", 15, 30], ["ACE2", "PROTEIN", 34, 38], ["cytokine", "PROTEIN", 224, 232], ["Angiotensin II", "PROTEIN", 337, 351], ["Ang II", "PROTEIN", 353, 359], ["COVID", "TEST", 0, 5], ["viral S protein", "TREATMENT", 15, 30], ["ACE2", "TEST", 34, 38], ["reducing receptor expression", "TREATMENT", 40, 68], ["enabling viral and cell membrane fusion", "TREATMENT", 70, 109], ["viral replication", "TREATMENT", 114, 131], ["inflammatory tissue damage", "PROBLEM", 156, 182], ["the severe inflammatory response", "PROBLEM", 188, 220], ["a cytokine storm", "PROBLEM", 222, 238], ["infection", "PROBLEM", 257, 266], ["an initial inflammatory response", "PROBLEM", 268, 300], ["Angiotensin II (Ang II)", "TREATMENT", 337, 360], ["Renin-Angiotensin-Aldosterone System (RAAS) activation", "TREATMENT", 366, 420], ["cell membrane fusion", "OBSERVATION", 89, 109], ["viral replication", "OBSERVATION", 114, 131], ["inflammatory tissue", "OBSERVATION", 156, 175], ["severe", "OBSERVATION_MODIFIER", 192, 198], ["inflammatory", "OBSERVATION_MODIFIER", 199, 211], ["cytokine storm", "OBSERVATION", 224, 238], ["infection", "OBSERVATION", 257, 266], ["inflammatory", "OBSERVATION", 279, 291]]], ["This inflammatory response is normally moderated by the activation of ACE2 receptors.", [["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["ACE2 receptors", "PROTEIN", 70, 84], ["This inflammatory response", "PROBLEM", 0, 26], ["ACE2 receptors", "TREATMENT", 70, 84], ["inflammatory", "OBSERVATION", 5, 17]]], ["ACE2 is a key player in minimizing and reversing the inflammatory response, by converting Angiotensin II to angiotensin 1-7 (Ang 1-7), which after binding to the Mas receptor (MasR), results in a wide array of anti-inflammatory actions.", [["Angiotensin II", "CHEMICAL", 90, 104], ["angiotensin 1-7", "CHEMICAL", 108, 123], ["Ang 1-7", "CHEMICAL", 125, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 90, 104], ["angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 108, 123], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 125, 132], ["Mas receptor", "GENE_OR_GENE_PRODUCT", 162, 174], ["MasR", "GENE_OR_GENE_PRODUCT", 176, 180], ["ACE2", "PROTEIN", 0, 4], ["Angiotensin II", "PROTEIN", 90, 104], ["Mas receptor", "PROTEIN", 162, 174], ["MasR", "PROTEIN", 176, 180], ["the inflammatory response", "PROBLEM", 49, 74], ["Angiotensin II to angiotensin", "TREATMENT", 90, 119], ["anti-inflammatory actions", "TREATMENT", 210, 235], ["inflammatory response", "OBSERVATION", 53, 74]]], ["5 The inflammatory state is a critical organismal response to an invader, but ultimately healing requires inflammation resolution, a process blocked by COVID-19's binding to and disabling ACE2 receptors, leading to unrelenting inflammation.5.The proposal that increased numbers of ACE2 receptors, due to ACEIs and ARBs, would signal an increase in viral binding and severe disease is unsupported by clinical data.", [["inflammation", "DISEASE", 106, 118], ["COVID-19's", "CHEMICAL", 152, 162], ["inflammation", "DISEASE", 227, 239], ["COVID-19's", "GENE_OR_GENE_PRODUCT", 152, 162], ["ACE2", "GENE_OR_GENE_PRODUCT", 188, 192], ["ACE2", "GENE_OR_GENE_PRODUCT", 281, 285], ["ARBs", "GENE_OR_GENE_PRODUCT", 314, 318], ["COVID", "PROTEIN", 152, 157], ["ACE2 receptors", "PROTEIN", 188, 202], ["ACE2 receptors", "PROTEIN", 281, 295], ["The inflammatory state", "PROBLEM", 2, 24], ["an invader", "PROBLEM", 62, 72], ["inflammation resolution", "PROBLEM", 106, 129], ["disabling ACE2 receptors", "PROBLEM", 178, 202], ["unrelenting inflammation", "PROBLEM", 215, 239], ["ACE2 receptors", "TREATMENT", 281, 295], ["ACEIs", "TREATMENT", 304, 309], ["ARBs", "TREATMENT", 314, 318], ["an increase in viral binding", "PROBLEM", 333, 361], ["severe disease", "PROBLEM", 366, 380], ["inflammatory", "OBSERVATION", 6, 18], ["organismal response", "OBSERVATION", 39, 58], ["invader", "OBSERVATION_MODIFIER", 65, 72], ["healing", "OBSERVATION_MODIFIER", 89, 96], ["inflammation", "OBSERVATION_MODIFIER", 106, 118], ["resolution", "OBSERVATION_MODIFIER", 119, 129], ["unrelenting", "OBSERVATION_MODIFIER", 215, 226], ["inflammation", "OBSERVATION", 227, 239], ["increased", "OBSERVATION_MODIFIER", 260, 269], ["numbers", "OBSERVATION_MODIFIER", 270, 277], ["increase", "OBSERVATION_MODIFIER", 336, 344], ["viral binding", "OBSERVATION", 348, 361], ["severe", "OBSERVATION_MODIFIER", 366, 372], ["disease", "OBSERVATION", 373, 380]]], ["The alternative view, that the presence of more functional ACE2 receptors could facilitate inflammation resolution by increasing production of anti-inflammatory Ang 1-7 is reasonable.", [["inflammation", "DISEASE", 91, 103], ["Ang", "CHEMICAL", 161, 164], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 161, 168], ["ACE2 receptors", "PROTEIN", 59, 73], ["The alternative view", "TEST", 0, 20], ["more functional ACE2 receptors", "PROBLEM", 43, 73], ["inflammation resolution", "PROBLEM", 91, 114], ["anti-inflammatory Ang", "TREATMENT", 143, 164], ["inflammation", "OBSERVATION", 91, 103]]], ["More Ang 1-7 would promote and support healthy vascular, pulmonary, myocardial, and renal function and suppress inflammatory cytokine production.", [["vascular", "ANATOMY", 47, 55], ["pulmonary", "ANATOMY", 57, 66], ["myocardial", "ANATOMY", 68, 78], ["renal", "ANATOMY", 84, 89], ["Ang", "CHEMICAL", 5, 8], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 5, 12], ["vascular", "MULTI-TISSUE_STRUCTURE", 47, 55], ["pulmonary", "MULTI-TISSUE_STRUCTURE", 57, 66], ["myocardial", "MULTI-TISSUE_STRUCTURE", 68, 78], ["renal", "ORGAN", 84, 89], ["Ang 1-7", "PROTEIN", 5, 12], ["cytokine", "PROTEIN", 125, 133], ["inflammatory cytokine production", "PROBLEM", 112, 144], ["vascular", "ANATOMY", 47, 55], ["pulmonary", "ANATOMY", 57, 66], ["myocardial", "ANATOMY", 68, 78], ["renal", "ANATOMY", 84, 89], ["inflammatory", "OBSERVATION_MODIFIER", 112, 124]]], ["If ACEIs and ARBs increase functional ACE2 receptors, the activation of anti-inflammatory pathways may save lives.5.Pending more research on this topic, and lacking evidence of harm to patients infected by COVID-19 while taking ACEIs and ARBs, the discontinuation of these medications is unjustified and could result in more negative outcomes.2.Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus.", [["ACEIs", "CHEMICAL", 228, 233], ["SARS coronavirus", "DISEASE", 476, 492], ["ACEIs", "SIMPLE_CHEMICAL", 3, 8], ["ARBs", "SIMPLE_CHEMICAL", 13, 17], ["ACE2 receptors", "GENE_OR_GENE_PRODUCT", 38, 52], ["patients", "ORGANISM", 185, 193], ["ACEIs", "SIMPLE_CHEMICAL", 228, 233], ["ARBs", "SIMPLE_CHEMICAL", 238, 242], ["Tissue", "TISSUE", 411, 417], ["ACE2", "GENE_OR_GENE_PRODUCT", 434, 438], ["SARS coronavirus", "ORGANISM", 476, 492], ["ACE2 receptors", "PROTEIN", 38, 52], ["ACE2 protein", "PROTEIN", 434, 446], ["patients", "SPECIES", 185, 193], ["SARS coronavirus", "SPECIES", 476, 492], ["ACEIs", "TREATMENT", 3, 8], ["ARBs", "TREATMENT", 13, 17], ["functional ACE2 receptors", "TREATMENT", 27, 52], ["anti-inflammatory pathways", "TREATMENT", 72, 98], ["COVID", "TEST", 206, 211], ["ACEIs", "TREATMENT", 228, 233], ["ARBs", "TREATMENT", 238, 242], ["these medications", "TREATMENT", 267, 284], ["ACE2 protein", "PROBLEM", 434, 446], ["SARS coronavirus", "PROBLEM", 476, 492], ["GJ", "ANATOMY", 395, 397]]], ["A first step in understanding SARS pathogenesis.", [["SARS", "DISEASE", 30, 34], ["SARS pathogenesis", "PROBLEM", 30, 47]]], ["2004; 203(2):631-637.3.Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensinconverting enzyme 2 and anti-hypertensives (angiotensin receptor blockers and angiotensin converting enzyme inhibitors) in coronavirus disease 2019 (COVID-19) .", [["angiotensin", "CHEMICAL", 140, 151], ["angiotensin", "CHEMICAL", 174, 185], ["coronavirus disease", "DISEASE", 219, 238], ["Angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 85, 115], ["anti-hypertensives", "SIMPLE_CHEMICAL", 120, 138], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 140, 169], ["angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 174, 203], ["coronavirus", "ORGANISM", 219, 230], ["Sanchis", "TEST", 23, 30], ["Perez", "TEST", 50, 55], ["enzyme", "TEST", 107, 113], ["anti-hypertensives (angiotensin receptor blockers", "TREATMENT", 120, 169], ["angiotensin converting enzyme inhibitors", "TREATMENT", 174, 214], ["coronavirus disease", "PROBLEM", 219, 238], ["COVID", "TEST", 245, 250]]], ["Mayo Clin Proc.", [["Mayo Clin Proc", "TREATMENT", 0, 14]]], ["2020;95(6):xx-xx.4.Vaduganathan5.Turner To the Editor: We thank Dr. Gersh for her interest and comments on our manuscript, as well as for taking the time to express her concerns on this subject.", [["Vaduganathan5", "CHEMICAL", 19, 32], ["Vaduganathan5", "SIMPLE_CHEMICAL", 19, 32], ["Vaduganathan5", "TREATMENT", 19, 32]]], ["We agree with Dr. Gersh that discontinuation of anti-hypertensives angiotensinconverting enzyme (ACE) inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of hypertension (HTN) is unjustified at this moment due to the lack of evidence on negative effects of these drugs in patients with coronavirus disease 2019 (COVID-19).", [["anti-hypertensives angiotensinconverting enzyme (ACE) inhibitors", "CHEMICAL", 48, 112], ["ACEIs", "CHEMICAL", 114, 119], ["angiotensin receptor blockers", "CHEMICAL", 124, 153], ["ARBs", "CHEMICAL", 155, 159], ["hypertension", "DISEASE", 182, 194], ["HTN", "DISEASE", 196, 199], ["coronavirus disease", "DISEASE", 311, 330], ["anti-hypertensives angiotensinconverting enzyme", "GENE_OR_GENE_PRODUCT", 48, 95], ["ACE", "GENE_OR_GENE_PRODUCT", 97, 100], ["ACEIs", "SIMPLE_CHEMICAL", 114, 119], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 124, 153], ["ARBs", "SIMPLE_CHEMICAL", 155, 159], ["patients", "ORGANISM", 297, 305], ["patients", "SPECIES", 297, 305], ["anti-hypertensives angiotensinconverting enzyme (ACE) inhibitors", "TREATMENT", 48, 112], ["ACEIs", "TREATMENT", 114, 119], ["angiotensin receptor blockers", "TREATMENT", 124, 153], ["ARBs", "TREATMENT", 155, 159], ["hypertension", "PROBLEM", 182, 194], ["HTN", "PROBLEM", 196, 199], ["these drugs", "TREATMENT", 282, 293], ["coronavirus disease", "PROBLEM", 311, 330], ["COVID", "TEST", 337, 342], ["hypertension", "OBSERVATION", 182, 194]]], ["However, in recent weeks, several important articles have been published, shedding new light in reference to the potential interplay of ACEIs and ARBs with COVID-19.", [["COVID-19", "CHEMICAL", 156, 164], ["ACEIs", "SIMPLE_CHEMICAL", 136, 141], ["ARBs", "SIMPLE_CHEMICAL", 146, 150], ["ACEIs", "TREATMENT", 136, 141], ["ARBs", "TREATMENT", 146, 150], ["COVID", "TEST", 156, 161]]], ["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus which causes COVID-19, penetrates the cells primarily through ACE2, its natural receptor at cell surface.", [["cells", "ANATOMY", 110, 115], ["cell surface", "ANATOMY", 164, 176], ["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["COVID-19", "CHEMICAL", 85, 93], ["Severe acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 47], ["SARS-CoV-2", "ORGANISM", 49, 59], ["cells", "CELL", 110, 115], ["ACE2", "GENE_OR_GENE_PRODUCT", 134, 138], ["cell surface", "CELLULAR_COMPONENT", 164, 176], ["ACE2", "PROTEIN", 134, 138], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV-2", "SPECIES", 49, 59], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["SARS-CoV", "TEST", 49, 57], ["the virus", "PROBLEM", 62, 71], ["COVID", "TEST", 85, 90], ["ACE2", "TEST", 134, 138], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["virus", "OBSERVATION", 66, 71], ["surface", "OBSERVATION_MODIFIER", 169, 176]]], ["Whether ACEIs and ARB administration would increase ACE2 levels or expression remains mostly speculative, as does whether increased ACE2 expression is beneficial or detrimental in COVID-19.", [["ACEIs", "CHEMICAL", 8, 13], ["ARB", "CHEMICAL", 18, 21], ["COVID-19", "CHEMICAL", 180, 188], ["ACEIs", "SIMPLE_CHEMICAL", 8, 13], ["ARB", "SIMPLE_CHEMICAL", 18, 21], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 132, 136], ["ACE2", "PROTEIN", 52, 56], ["ACE2", "PROTEIN", 132, 136], ["ACEIs", "TREATMENT", 8, 13], ["ARB administration", "TREATMENT", 18, 36], ["ACE2 levels", "TEST", 52, 63], ["increased ACE2 expression", "PROBLEM", 122, 147], ["COVID", "TEST", 180, 185]]], ["As noted by Dr. Gersh, Diaz argued that as ACE2 levels increase after intravenous infusion of ACEIs and ARBs in animal models, taking ACEIs or ARBs may aggravate the infection severity in COVID-19 patients.", [["intravenous", "ANATOMY", 70, 81], ["ACEIs", "CHEMICAL", 94, 99], ["ARBs", "CHEMICAL", 104, 108], ["ACEIs", "CHEMICAL", 134, 139], ["ARBs", "CHEMICAL", 143, 147], ["infection", "DISEASE", 166, 175], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 81], ["ACEIs", "SIMPLE_CHEMICAL", 94, 99], ["ARBs", "SIMPLE_CHEMICAL", 104, 108], ["ACEIs", "SIMPLE_CHEMICAL", 134, 139], ["ARBs", "SIMPLE_CHEMICAL", 143, 147], ["patients", "ORGANISM", 197, 205], ["ACE2", "PROTEIN", 43, 47], ["patients", "SPECIES", 197, 205], ["ACE2 levels", "TEST", 43, 54], ["intravenous infusion", "TREATMENT", 70, 90], ["ACEIs", "TREATMENT", 94, 99], ["ARBs", "TREATMENT", 104, 108], ["ACEIs", "TREATMENT", 134, 139], ["ARBs", "TREATMENT", 143, 147], ["the infection severity", "PROBLEM", 162, 184], ["infection", "OBSERVATION", 166, 175]]], ["1 However, not all studies conducted in animals clearly shown increased ACE2 levels in response to ACEI/ARB administration.", [["ACEI", "CHEMICAL", 99, 103], ["ARB", "CHEMICAL", 104, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["ACEI", "SIMPLE_CHEMICAL", 99, 103], ["ARB", "SIMPLE_CHEMICAL", 104, 107], ["ACE2", "PROTEIN", 72, 76], ["all studies", "TEST", 15, 26], ["increased ACE2 levels", "PROBLEM", 62, 83], ["ACEI", "TREATMENT", 99, 103], ["ARB administration", "TREATMENT", 104, 122]]], ["2 Importantly, investigations analyzing changes in plasma or tissue ACE2 levels in humans are limited.", [["plasma", "ANATOMY", 51, 57], ["tissue", "ANATOMY", 61, 67], ["plasma", "ORGANISM_SUBSTANCE", 51, 57], ["tissue", "TISSUE", 61, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["humans", "ORGANISM", 83, 89], ["ACE2", "PROTEIN", 68, 72], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 83, 89], ["investigations analyzing changes in plasma or tissue ACE2 levels", "TEST", 15, 79]]], ["In fact, two studies in patients with atrial fibrillation or coronary heart disease found no differences in plasma ACE2 levels between those taking ACEIs or ARBs versus those not taking these medications.", [["atrial", "ANATOMY", 38, 44], ["coronary", "ANATOMY", 61, 69], ["heart", "ANATOMY", 70, 75], ["plasma", "ANATOMY", 108, 114], ["atrial fibrillation", "DISEASE", 38, 57], ["coronary heart disease", "DISEASE", 61, 83], ["ACEIs", "CHEMICAL", 148, 153], ["ARBs", "CHEMICAL", 157, 161], ["patients", "ORGANISM", 24, 32], ["atrial", "MULTI-TISSUE_STRUCTURE", 38, 44], ["heart", "ORGAN", 70, 75], ["plasma", "ORGANISM_SUBSTANCE", 108, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 115, 119], ["ACEIs", "SIMPLE_CHEMICAL", 148, 153], ["ARBs", "SIMPLE_CHEMICAL", 157, 161], ["ACE2", "PROTEIN", 115, 119], ["patients", "SPECIES", 24, 32], ["two studies", "TEST", 9, 20], ["atrial fibrillation", "PROBLEM", 38, 57], ["coronary heart disease", "PROBLEM", 61, 83], ["plasma ACE2 levels", "TEST", 108, 126], ["ACEIs", "TREATMENT", 148, 153], ["ARBs", "TREATMENT", 157, 161], ["these medications", "TREATMENT", 186, 203], ["atrial", "ANATOMY", 38, 44], ["fibrillation", "OBSERVATION", 45, 57], ["coronary heart", "ANATOMY", 61, 75], ["disease", "OBSERVATION", 76, 83]]], ["3, 4 Nonetheless, plasma levels may not reflect tissue ACE2 expression, and vice versa, and this topic requires further investigation.5.The role of ACE2 expression in COVID-19 morbidity and mortality is still unknown.", [["plasma", "ANATOMY", 18, 24], ["tissue", "ANATOMY", 48, 54], ["plasma", "ORGANISM_SUBSTANCE", 18, 24], ["tissue", "TISSUE", 48, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["ACE2", "PROTEIN", 55, 59], ["ACE2", "PROTEIN", 148, 152], ["plasma levels", "TEST", 18, 31], ["tissue ACE2 expression", "PROBLEM", 48, 70], ["further investigation", "TEST", 112, 133], ["COVID", "TEST", 167, 172], ["may not reflect", "UNCERTAINTY", 32, 47], ["ACE2 expression", "OBSERVATION", 55, 70]]], ["As hypertension is a clear risk factor for COVID-19, 5 Dr. Gersh noted that many such patients are likely to be on ACEIs or ARBs, and, as such, these anti-HTN medications may be directly connected with infection severity.", [["hypertension", "DISEASE", 3, 15], ["infection", "DISEASE", 202, 211], ["patients", "ORGANISM", 86, 94], ["ACEIs", "SIMPLE_CHEMICAL", 115, 120], ["ARBs", "SIMPLE_CHEMICAL", 124, 128], ["anti-HTN", "SIMPLE_CHEMICAL", 150, 158], ["patients", "SPECIES", 86, 94], ["hypertension", "PROBLEM", 3, 15], ["COVID", "TEST", 43, 48], ["ACEIs", "TREATMENT", 115, 120], ["ARBs", "TREATMENT", 124, 128], ["these anti-HTN medications", "TREATMENT", 144, 170], ["infection severity", "PROBLEM", 202, 220], ["hypertension", "OBSERVATION", 3, 15], ["infection", "OBSERVATION", 202, 211]]], ["However, although a relatively high percentage of COVID-19 patients hospitalized have HTN, the percentage of HTN in adults is similar worldwide, increasing with age.", [["HTN", "DISEASE", 86, 89], ["HTN", "DISEASE", 109, 112], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["HTN", "PROBLEM", 86, 89], ["HTN", "PROBLEM", 109, 112], ["relatively", "OBSERVATION_MODIFIER", 20, 30], ["high", "OBSERVATION_MODIFIER", 31, 35], ["HTN", "OBSERVATION", 109, 112], ["similar", "OBSERVATION_MODIFIER", 126, 133], ["worldwide", "OBSERVATION_MODIFIER", 134, 143]]], ["In patients with COVID-19, the odds of disease severity with HTN was found in meta-regression to be associated with advancing age.", [["HTN", "DISEASE", 61, 64], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["COVID", "TEST", 17, 22], ["disease severity", "PROBLEM", 39, 55], ["HTN", "PROBLEM", 61, 64], ["disease", "OBSERVATION", 39, 46], ["HTN", "OBSERVATION", 61, 64]]], ["5 As Marin has also stated, an epidemiological association based simply on prevalence of HTN and ACEI/ARBs in COVID-19 is inappropriate.", [["HTN", "DISEASE", 89, 92], ["ACEI/ARBs", "CHEMICAL", 97, 106], ["ACEI", "SIMPLE_CHEMICAL", 97, 101], ["HTN", "PROBLEM", 89, 92], ["ACEI", "TREATMENT", 97, 101], ["ARBs", "TREATMENT", 102, 106], ["COVID", "TEST", 110, 115]]], ["6 Moreover, it has been previously reported that ACE2 expression is reduced in HTN animal models and, historically, HTN has not affect outcomes of other coronavirus infections.", [["HTN", "DISEASE", 79, 82], ["HTN", "DISEASE", 116, 119], ["coronavirus infections", "DISEASE", 153, 175], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["coronavirus", "ORGANISM", 153, 164], ["ACE2", "PROTEIN", 49, 53], ["HTN animal models", "PROBLEM", 79, 96], ["HTN", "PROBLEM", 116, 119], ["other coronavirus infections", "PROBLEM", 147, 175], ["reduced", "OBSERVATION_MODIFIER", 68, 75], ["coronavirus", "OBSERVATION_MODIFIER", 153, 164], ["infections", "OBSERVATION", 165, 175]]], ["7 Most concerning is the fact that Marin pointed out that many patients from South America, Central America and Spain have abruptly interrupted their treatments with ACEIs or ARBs over these hypothetical concerns, which might may be as equally dangerous to the patient as COVID-19 itself.", [["COVID-19", "CHEMICAL", 272, 280], ["patients", "ORGANISM", 63, 71], ["patient", "ORGANISM", 261, 268], ["patients", "SPECIES", 63, 71], ["patient", "SPECIES", 261, 268], ["ACEIs", "TREATMENT", 166, 171], ["ARBs", "TREATMENT", 175, 179], ["COVID", "TEST", 272, 277]]], ["Mehra et al. 8 analyzed the factors associated with increased risk of in-hospital death in 8,910 COVID-19 patients included in an observational database of 169 worldwide hospitals.", [["death", "DISEASE", 82, 87], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["increased", "OBSERVATION_MODIFIER", 52, 61]]], ["Among those factors, the authors found that ACEIs were independently associated with a significant 67% reduction in mortality in a subgroup with hypertension, whereas ARBs were associated with an insignificant 23% higher mortality.", [["hypertension", "DISEASE", 145, 157], ["ACEIs", "SIMPLE_CHEMICAL", 44, 49], ["ACEIs", "TREATMENT", 44, 49], ["a significant 67% reduction in mortality", "PROBLEM", 85, 125], ["hypertension", "PROBLEM", 145, 157], ["ARBs", "TEST", 167, 171], ["an insignificant 23% higher mortality", "PROBLEM", 193, 230], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["reduction", "OBSERVATION_MODIFIER", 103, 112], ["hypertension", "OBSERVATION", 145, 157]]], ["8 Taking ACEIs or statins were associated with higher rates of survival after hospital discharge, while taking ARBs had no effect.", [["ACEIs", "CHEMICAL", 9, 14], ["statins", "CHEMICAL", 18, 25], ["ARBs", "CHEMICAL", 111, 115], ["statins", "CHEMICAL", 18, 25], ["statins", "SIMPLE_CHEMICAL", 18, 25], ["ACEIs", "TREATMENT", 9, 14], ["statins", "TREATMENT", 18, 25], ["ARBs", "TREATMENT", 111, 115]]], ["Additionally, there was no increased risk of in-hospital death associated with either ACEIs (2.1% vs. 6.1%; odds ratio, 0.33; 95% CI, 0.20 to 0.54) or ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, 0.87 to 1.74).", [["death", "DISEASE", 57, 62], ["ACEIs", "CHEMICAL", 86, 91], ["in-hospital death", "PROBLEM", 45, 62], ["ACEIs", "TEST", 86, 91], ["odds ratio", "TEST", 108, 118], ["CI", "TEST", 130, 132], ["ARBs", "TEST", 151, 155], ["odds ratio", "TEST", 172, 182], ["CI", "TEST", 194, 196], ["no", "UNCERTAINTY", 24, 26], ["increased", "OBSERVATION_MODIFIER", 27, 36]]], ["Likewise, Mancia et al. 9 carried out a case-control study involving 6,272 confirmed COVID-19 patients from the Lombardy region of Italy.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["a case-control study", "TEST", 38, 58], ["COVID", "TEST", 85, 90]]], ["They compared COVID-19 patients with 30,759 controls matched by age, sex, and municipality of residence.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["COVID", "TEST", 14, 19]]], ["Neither ACEIs , nor ARBs, were associated with increased probability of being infected by SARS-CoV-2 in multivariate logistic-regression analysis.", [["ACEIs", "CHEMICAL", 8, 13], ["SARS", "DISEASE", 90, 94], ["ACEIs", "SIMPLE_CHEMICAL", 8, 13], ["ARBs", "SIMPLE_CHEMICAL", 20, 24], ["SARS-CoV", "SPECIES", 90, 98], ["ACEIs", "TEST", 8, 13], ["ARBs", "TEST", 20, 24], ["SARS", "TEST", 90, 94], ["CoV", "TEST", 95, 98], ["multivariate logistic", "TEST", 104, 125], ["regression analysis", "TEST", 126, 145], ["ACEIs", "OBSERVATION", 8, 13], ["infected", "OBSERVATION", 78, 86]]], ["Moreover, no association was observed between these drugs and SARS-CoV-2 infection severity.", [["SARS", "DISEASE", 62, 66], ["infection", "DISEASE", 73, 82], ["CoV-2", "ORGANISM", 67, 72], ["SARS-CoV", "SPECIES", 62, 70], ["these drugs", "TREATMENT", 46, 57], ["SARS", "PROBLEM", 62, 66], ["CoV-2 infection severity", "PROBLEM", 67, 91], ["infection", "OBSERVATION", 73, 82]]], ["Reynolds et al. 10 analyzed the data of 5,894 COVID-19 patients (tested positive) from the New York University (NYU) Langone Health electronic health record, 1,002 with severe disease (ICU admission, mechanical ventilation, or death).", [["death", "DISEASE", 227, 232], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["the data", "TEST", 28, 36], ["COVID", "TEST", 46, 51], ["severe disease", "PROBLEM", 169, 183], ["mechanical ventilation", "TREATMENT", 200, 222], ["death", "PROBLEM", 227, 232], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["disease", "OBSERVATION", 176, 183]]], ["Through a Bayesian approach, no association between taking ACEIs or ARBs and positive test result or COVID-19 severity could be found.5.In a retrospective, single-center case series of the 1178 COVID-19 patients with HTN hospitalized at the Central Hospital of Wuhan, China (January 15 to March 15, 2020), Li et al. 11 studied the association between ACEIs/ARB and severity of illness and mortality.", [["ACEIs", "CHEMICAL", 59, 64], ["HTN", "DISEASE", 217, 220], ["ARB", "CHEMICAL", 357, 360], ["illness", "DISEASE", 377, 384], ["ARBs", "SIMPLE_CHEMICAL", 68, 72], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["a Bayesian approach", "TREATMENT", 8, 27], ["ACEIs", "TREATMENT", 59, 64], ["ARBs", "TREATMENT", 68, 72], ["positive test result", "TEST", 77, 97], ["COVID", "TEST", 101, 106], ["HTN", "PROBLEM", 217, 220], ["ACEIs", "TREATMENT", 351, 356], ["ARB", "TREATMENT", 357, 360], ["illness", "PROBLEM", 377, 384], ["mortality", "PROBLEM", 389, 398]]], ["There were no differences between the percentage of patients with HTN taking ACEIS/ARB with severe and non-severe infections (32.9% vs 30.7%; p=0.645), or between non-survivors and survivors (27.3%vs 33.0%; p=0.34).", [["HTN", "DISEASE", 66, 69], ["ACEIS", "CHEMICAL", 77, 82], ["ARB", "CHEMICAL", 83, 86], ["infections", "DISEASE", 114, 124], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["HTN", "PROBLEM", 66, 69], ["ACEIS", "TREATMENT", 77, 82], ["ARB", "TREATMENT", 83, 86], ["severe and non-severe infections", "PROBLEM", 92, 124], ["p", "TEST", 142, 143], ["survivors", "TEST", 181, 190], ["p", "TEST", 207, 208], ["no", "UNCERTAINTY", 11, 13], ["non-severe", "OBSERVATION_MODIFIER", 103, 113], ["infections", "OBSERVATION", 114, 124]]], ["Unlike the Mehra et al. 8 data, which suggested more benefits with ACEIs, no differences were observed between patients taking ACEIs and those taking ARBs.", [["ACEIs", "CHEMICAL", 127, 132], ["ARBs", "CHEMICAL", 150, 154], ["ACEIs", "SIMPLE_CHEMICAL", 67, 72], ["patients", "ORGANISM", 111, 119], ["ACEIs", "SIMPLE_CHEMICAL", 127, 132], ["patients", "SPECIES", 111, 119], ["ACEIs", "TREATMENT", 67, 72], ["ACEIs", "TREATMENT", 127, 132], ["ARBs", "TREATMENT", 150, 154]]], ["These authors concluded that neither ACEIs nor ARBs may be associated with severity or mortality of COVID-19 patients.", [["ACEIs", "CHEMICAL", 37, 42], ["ARBs", "CHEMICAL", 47, 51], ["ACEIs", "SIMPLE_CHEMICAL", 37, 42], ["ARBs", "SIMPLE_CHEMICAL", 47, 51], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["ACEIs", "TREATMENT", 37, 42], ["ARBs", "TREATMENT", 47, 51], ["severity", "PROBLEM", 75, 83], ["COVID", "TEST", 100, 105]]], ["8 In a retrospective, multicenter study including 1128 adult COVID-19 Chinese patients with HTN, 188 taking ACEIs/ARBs and 940 without these agents, Zhang et al. 12 reported that unadjusted mortality rate was lower in the ACEIs/ARBs group versus the non-ACEIs/ARBs group (3.7% vs. 9.8%; p=0.01).", [["HTN", "DISEASE", 92, 95], ["ACEIs/ARBs", "CHEMICAL", 108, 118], ["ACEIs/ARBs", "CHEMICAL", 222, 232], ["non-ACEIs/ARBs", "CHEMICAL", 250, 264], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["multicenter study", "TEST", 22, 39], ["adult COVID", "TEST", 55, 66], ["HTN", "PROBLEM", 92, 95], ["ACEIs", "TREATMENT", 108, 113], ["ARBs", "TREATMENT", 114, 118], ["these agents", "TREATMENT", 135, 147], ["mortality rate", "TEST", 190, 204], ["the ACEIs", "TEST", 218, 227], ["ARBs", "TEST", 228, 232], ["the non-ACEIs", "TEST", 246, 259], ["ARBs", "TEST", 260, 264], ["p", "TEST", 287, 288]]], ["After adjusting for age, gender, comorbidities, and in-hospital medications, the risk for allcause mortality was still lower in the ACEIs/ARBs group versus the non-ACEIs/ARBs group (adjusted hazard ratio, 0.42; 95% CI, 0.19-0.92; p=0.03).", [["ACEIs", "CHEMICAL", 132, 137], ["ARBs", "CHEMICAL", 138, 142], ["ARBs", "CHEMICAL", 170, 174], ["comorbidities", "PROBLEM", 33, 46], ["medications", "TREATMENT", 64, 75], ["allcause mortality", "PROBLEM", 90, 108], ["the ACEIs", "TEST", 128, 137], ["ARBs", "TEST", 138, 142], ["the non-ACEIs", "TEST", 156, 169], ["ARBs", "TEST", 170, 174], ["hazard ratio", "TEST", 191, 203], ["CI", "TEST", 215, 217], ["p", "TEST", 230, 231]]], ["Their results also demonstrated lower risk of COVID-19 mortality in patients who received ACEIs/ARBs versus those who did not (adjusted hazard ratio, 0.37; 95% CI, 0.15-0.89; P = 0.03) in a propensity score-matched analysis followed by adjusting imbalanced variables in mixed-effect Cox model.", [["ACEIs/ARBs", "CHEMICAL", 90, 100], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["COVID", "TEST", 46, 51], ["ACEIs", "TREATMENT", 90, 95], ["ARBs", "TREATMENT", 96, 100], ["CI", "TEST", 160, 162], ["P", "TEST", 175, 176], ["a propensity score", "TEST", 188, 206], ["matched analysis", "TEST", 207, 223], ["imbalanced variables", "PROBLEM", 246, 266]]], ["Moreover, compared to other anti-HTN drugs, ACEIs/ARBs were associated with lower mortality (adjusted hazard ratio, 0.30; 95%CI, 0.12-0.70; P = 0.01) in COVID-19.", [["ACEIs/ARBs", "CHEMICAL", 44, 54], ["anti-HTN", "SIMPLE_CHEMICAL", 28, 36], ["ACEIs", "SIMPLE_CHEMICAL", 44, 49], ["ARBs", "SIMPLE_CHEMICAL", 50, 54], ["other anti-HTN drugs", "TREATMENT", 22, 42], ["ACEIs", "TREATMENT", 44, 49], ["ARBs", "TREATMENT", 50, 54], ["lower mortality", "PROBLEM", 76, 91], ["hazard ratio", "TEST", 102, 114], ["CI", "TEST", 125, 127], ["P", "TEST", 140, 141], ["COVID", "TEST", 153, 158]]], ["Therefore, what can be reasonably concluded from the recently published large single and multi-center studies from multiple countries, is that there is no significant risk of disease severity or mortality associated with ACEI/ARB, with some even suggesting potential benefits in patient with COIVD-19.5.The mechanism behind any potential benefit of ACEI and ARB in COVID-19 is still enigmatic.", [["ACEI", "CHEMICAL", 221, 225], ["ARB", "CHEMICAL", 226, 229], ["ACEI", "CHEMICAL", 349, 353], ["ARB", "CHEMICAL", 358, 361], ["COVID-19", "CHEMICAL", 365, 373], ["ACEI", "SIMPLE_CHEMICAL", 221, 225], ["ARB", "SIMPLE_CHEMICAL", 226, 229], ["patient", "ORGANISM", 279, 286], ["ACEI", "SIMPLE_CHEMICAL", 349, 353], ["ARB", "SIMPLE_CHEMICAL", 358, 361], ["patient", "SPECIES", 279, 286], ["multi-center studies", "TEST", 89, 109], ["disease severity", "PROBLEM", 175, 191], ["ACEI", "TREATMENT", 221, 225], ["ARB", "TREATMENT", 226, 229], ["COIVD", "TEST", 292, 297], ["ACEI", "TREATMENT", 349, 353], ["ARB", "TREATMENT", 358, 361], ["COVID", "TEST", 365, 370], ["large", "OBSERVATION_MODIFIER", 72, 77], ["no significant", "UNCERTAINTY", 152, 166], ["disease", "OBSERVATION", 175, 182]]], ["Differences in inflammatory and immune biomarkers has been reported in COVID-19 patients taking ACEI and ARBs.", [["ACEI", "CHEMICAL", 96, 100], ["patients", "ORGANISM", 80, 88], ["ACEI", "SIMPLE_CHEMICAL", 96, 100], ["ARBs", "SIMPLE_CHEMICAL", 105, 109], ["patients", "SPECIES", 80, 88], ["immune biomarkers", "TEST", 32, 49], ["COVID", "TEST", 71, 76], ["ACEI", "TREATMENT", 96, 100], ["ARBs", "TREATMENT", 105, 109], ["inflammatory", "OBSERVATION_MODIFIER", 15, 27]]], ["Meng et al. 13 found a reduced rate of severe COVID-19 disease and lower levels of interleukin-6, increased CD3 and CD8 T-cell in peripheral blood, and decreased peak viral loads compared to those using other anti-HTN medication.", [["CD8 T-cell", "ANATOMY", 116, 126], ["peripheral blood", "ANATOMY", 130, 146], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 83, 96], ["CD3", "GENE_OR_GENE_PRODUCT", 108, 111], ["CD8", "GENE_OR_GENE_PRODUCT", 116, 119], ["peripheral blood", "ORGANISM_SUBSTANCE", 130, 146], ["anti-HTN", "SIMPLE_CHEMICAL", 209, 217], ["interleukin-6", "PROTEIN", 83, 96], ["CD3", "PROTEIN", 108, 111], ["CD8", "PROTEIN", 116, 119], ["Meng et al.", "TEST", 0, 11], ["a reduced rate of severe COVID-19 disease", "PROBLEM", 21, 62], ["interleukin", "TEST", 83, 94], ["increased CD3", "PROBLEM", 98, 111], ["peripheral blood", "TEST", 130, 146], ["decreased peak viral loads", "PROBLEM", 152, 178], ["other anti-HTN medication", "TREATMENT", 203, 228], ["reduced", "OBSERVATION_MODIFIER", 23, 30], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["peripheral", "ANATOMY_MODIFIER", 130, 140], ["blood", "ANATOMY", 141, 146], ["decreased", "OBSERVATION_MODIFIER", 152, 161], ["peak viral loads", "OBSERVATION", 162, 178]]], ["Moreover, Yang et al. reported that COVID-19 patients with HTN taking ACEI and ARBs had significantly lower C reactive protein and procalcitonin, as well as decreased rate of critical illness and death.", [["HTN", "DISEASE", 59, 62], ["ACEI", "CHEMICAL", 70, 74], ["ARBs", "CHEMICAL", 79, 83], ["illness", "DISEASE", 184, 191], ["death", "DISEASE", 196, 201], ["patients", "ORGANISM", 45, 53], ["ARBs", "SIMPLE_CHEMICAL", 79, 83], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 108, 126], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 131, 144], ["C reactive protein", "PROTEIN", 108, 126], ["procalcitonin", "PROTEIN", 131, 144], ["patients", "SPECIES", 45, 53], ["HTN", "PROBLEM", 59, 62], ["ACEI", "TREATMENT", 70, 74], ["ARBs", "TREATMENT", 79, 83], ["significantly lower C reactive protein", "PROBLEM", 88, 126], ["procalcitonin", "TEST", 131, 144], ["critical illness", "PROBLEM", 175, 191], ["death", "PROBLEM", 196, 201], ["reactive protein", "OBSERVATION", 110, 126]]], ["14 ARBs may also exert beneficial effects in patients with sepsis, pneumonia and influenza.", [["ARBs", "CHEMICAL", 3, 7], ["sepsis", "DISEASE", 59, 65], ["pneumonia", "DISEASE", 67, 76], ["influenza", "DISEASE", 81, 90], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["ARBs", "TREATMENT", 3, 7], ["sepsis", "PROBLEM", 59, 65], ["pneumonia", "PROBLEM", 67, 76], ["influenza", "PROBLEM", 81, 90], ["sepsis", "OBSERVATION", 59, 65], ["pneumonia", "OBSERVATION", 67, 76], ["influenza", "OBSERVATION", 81, 90]]], ["Moreover, a combination of statin and ARBs appeared to substantially reduce mortality during the recent Ebola outbreak dramatically, 15 similar to the reduction in mortality noted by Mehra et al. 8 with ACEIs/statin therapy in COVID-19.", [["statin", "CHEMICAL", 27, 33], ["ARBs", "CHEMICAL", 38, 42], ["Ebola", "DISEASE", 104, 109], ["ACEIs", "CHEMICAL", 203, 208], ["statin", "CHEMICAL", 209, 215], ["statin", "CHEMICAL", 27, 33], ["statin", "CHEMICAL", 209, 215], ["statin", "SIMPLE_CHEMICAL", 27, 33], ["ARBs", "SIMPLE_CHEMICAL", 38, 42], ["Ebola", "ORGANISM", 104, 109], ["ACEIs", "SIMPLE_CHEMICAL", 203, 208], ["statin", "SIMPLE_CHEMICAL", 209, 215], ["statin", "TREATMENT", 27, 33], ["ARBs", "TREATMENT", 38, 42], ["ACEIs", "TREATMENT", 203, 208], ["statin therapy", "TREATMENT", 209, 223], ["Ebola", "OBSERVATION_MODIFIER", 104, 109], ["reduction", "OBSERVATION_MODIFIER", 151, 160]]], ["It has been suggested that higher doses of ARBs may protect COVID-19 patients from acute lung injury (ALI) via two complementary mechanisms: (i) by blocking excessive angiotensin II binding promoting vasoconstriction, inflammation, and oxidative damage; ii) by up-regulating ACE2 and increasing angiotensin 1-7 production.", [["lung", "ANATOMY", 89, 93], ["ARBs", "CHEMICAL", 43, 47], ["acute lung injury", "DISEASE", 83, 100], ["ALI", "DISEASE", 102, 105], ["angiotensin II", "CHEMICAL", 167, 181], ["inflammation", "DISEASE", 218, 230], ["angiotensin 1-7", "CHEMICAL", 295, 310], ["ARBs", "SIMPLE_CHEMICAL", 43, 47], ["patients", "ORGANISM", 69, 77], ["lung", "ORGAN", 89, 93], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 167, 181], ["ACE2", "GENE_OR_GENE_PRODUCT", 275, 279], ["angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 295, 310], ["angiotensin II", "PROTEIN", 167, 181], ["ACE2", "PROTEIN", 275, 279], ["patients", "SPECIES", 69, 77], ["ARBs", "TREATMENT", 43, 47], ["COVID", "TEST", 60, 65], ["acute lung injury", "PROBLEM", 83, 100], ["blocking excessive angiotensin II binding", "PROBLEM", 148, 189], ["vasoconstriction", "PROBLEM", 200, 216], ["inflammation", "PROBLEM", 218, 230], ["oxidative damage", "PROBLEM", 236, 252], ["ACE2", "TEST", 275, 279], ["increasing angiotensin", "PROBLEM", 284, 306], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["lung", "ANATOMY", 89, 93], ["injury", "OBSERVATION", 94, 100], ["inflammation", "OBSERVATION", 218, 230], ["oxidative damage", "OBSERVATION", 236, 252]]], ["16 In fact, trials using Losartan to reduce ALI in COVID-19 are currently underway in the United States.", [["Losartan", "CHEMICAL", 25, 33], ["ALI", "DISEASE", 44, 47], ["Losartan", "CHEMICAL", 25, 33], ["Losartan", "SIMPLE_CHEMICAL", 25, 33], ["Losartan", "TREATMENT", 25, 33], ["ALI", "PROBLEM", 44, 47]]], ["Interestingly, ACEI were reported by Mehra et al. 8 to reduce mortality, while a similar effect could not be noted for ARBs.", [["ACEI", "CHEMICAL", 15, 19], ["ACEI", "SIMPLE_CHEMICAL", 15, 19], ["ACEI", "TREATMENT", 15, 19], ["ARBs", "PROBLEM", 119, 123]]], ["This warrants immediate further investigation.", [["immediate further investigation", "TEST", 14, 45]]], ["We hypothesize that ACEI may not only attenuate the increase in angiotensin II, but via reduced endothelial dysfunction and decreased expression of tissue plasminogen activator-1 and increase tissue plasminogen activator levels (tPA) due to decreased bradykinin breakdown, may mitigate the reported COVID-19 associated coagulopathy; such coagulopathy may drive ALI and multiple organ dysfunction.", [["endothelial", "ANATOMY", 96, 107], ["organ", "ANATOMY", 378, 383], ["ACEI", "CHEMICAL", 20, 24], ["angiotensin II", "CHEMICAL", 64, 78], ["bradykinin", "CHEMICAL", 251, 261], ["coagulopathy", "DISEASE", 319, 331], ["coagulopathy", "DISEASE", 338, 350], ["ALI", "DISEASE", 361, 364], ["organ dysfunction", "DISEASE", 378, 395], ["bradykinin", "CHEMICAL", 251, 261], ["COVID-19", "CHEMICAL", 299, 307], ["ACEI", "SIMPLE_CHEMICAL", 20, 24], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 64, 78], ["endothelial", "CELL", 96, 107], ["tissue plasminogen activator-1", "GENE_OR_GENE_PRODUCT", 148, 178], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 192, 220], ["PA", "GENE_OR_GENE_PRODUCT", 230, 232], ["bradykinin", "SIMPLE_CHEMICAL", 251, 261], ["organ", "ORGAN", 378, 383], ["angiotensin II", "PROTEIN", 64, 78], ["tissue plasminogen activator-1", "PROTEIN", 148, 178], ["tissue plasminogen", "PROTEIN", 192, 210], ["ACEI", "TREATMENT", 20, 24], ["the increase in angiotensin II", "PROBLEM", 48, 78], ["reduced endothelial dysfunction", "PROBLEM", 88, 119], ["tissue plasminogen activator", "TREATMENT", 148, 176], ["tissue plasminogen activator levels", "TEST", 192, 227], ["tPA", "TEST", 229, 232], ["decreased bradykinin breakdown", "PROBLEM", 241, 271], ["the reported COVID-19 associated coagulopathy", "PROBLEM", 286, 331], ["such coagulopathy", "PROBLEM", 333, 350], ["ALI", "PROBLEM", 361, 364], ["multiple organ dysfunction", "PROBLEM", 369, 395], ["increase", "OBSERVATION_MODIFIER", 52, 60], ["angiotensin II", "OBSERVATION", 64, 78], ["endothelial dysfunction", "OBSERVATION", 96, 119], ["decreased", "OBSERVATION_MODIFIER", 241, 250], ["bradykinin breakdown", "OBSERVATION", 251, 271], ["coagulopathy", "OBSERVATION", 319, 331], ["organ", "ANATOMY", 378, 383], ["dysfunction", "OBSERVATION", 384, 395]]], ["17 As the COVID-19 pandemic continues, the cardiovascular health of patients must not be neglected at the expense of outbreak.", [["cardiovascular", "ANATOMY", 43, 57], ["cardiovascular", "ANATOMICAL_SYSTEM", 43, 57], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["the COVID", "TEST", 6, 15], ["pandemic", "PROBLEM", 19, 27]]], ["ACEIs and ARBs improve outcomes and increase survival in multiple cardiovascular diseases.", [["cardiovascular", "ANATOMY", 66, 80], ["ACEIs", "CHEMICAL", 0, 5], ["ARBs", "CHEMICAL", 10, 14], ["cardiovascular diseases", "DISEASE", 66, 89], ["ACEIs", "SIMPLE_CHEMICAL", 0, 5], ["ARBs", "SIMPLE_CHEMICAL", 10, 14], ["cardiovascular", "ANATOMICAL_SYSTEM", 66, 80], ["ACEIs", "TREATMENT", 0, 5], ["ARBs", "TREATMENT", 10, 14], ["multiple cardiovascular diseases", "PROBLEM", 57, 89], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["survival", "OBSERVATION_MODIFIER", 45, 53], ["multiple", "OBSERVATION_MODIFIER", 57, 65], ["cardiovascular diseases", "OBSERVATION", 66, 89]]], ["While further investigation in prospective studies is warranted, the preponderance of current data and evidence makes it highly unlikely that the use of ACEIs/ARBs may be associated with increased severity or mortality risk.", [["ACEIs/ARBs", "CHEMICAL", 153, 163], ["ACEIs", "SIMPLE_CHEMICAL", 153, 158], ["ARBs", "SIMPLE_CHEMICAL", 159, 163], ["further investigation", "TEST", 6, 27], ["prospective studies", "TEST", 31, 50], ["ACEIs", "TREATMENT", 153, 158], ["ARBs", "TREATMENT", 159, 163], ["increased severity", "PROBLEM", 187, 205], ["mortality risk", "PROBLEM", 209, 223]]], ["In summary, the newly reported data supports current guidelines and health professional recommendations for continuation of ACEI/ARBs for treating HTN during the COVID-19 pandemic.", [["ACEI/ARBs", "CHEMICAL", 124, 133], ["HTN", "DISEASE", 147, 150], ["ACEI", "SIMPLE_CHEMICAL", 124, 128], ["ARBs", "SIMPLE_CHEMICAL", 129, 133], ["ACEI", "TREATMENT", 124, 128], ["ARBs", "TREATMENT", 129, 133], ["HTN", "PROBLEM", 147, 150], ["the COVID", "TEST", 158, 167], ["pandemic", "PROBLEM", 171, 179]]]], "50c48a9c7b8190be25d3a1d12a0e1ce2234bc29b": [["Urticaria-Angioedema SyndromeUrticaria and angioedema comprise a unique syndrome, with the two frequently associated.", [["Urticaria", "DISEASE", 0, 9], ["Angioedema SyndromeUrticaria", "DISEASE", 10, 38], ["angioedema", "DISEASE", 43, 53], ["Urticaria", "PROBLEM", 0, 9], ["Angioedema SyndromeUrticaria", "PROBLEM", 10, 38], ["angioedema", "PROBLEM", 43, 53], ["a unique syndrome", "PROBLEM", 63, 80], ["Angioedema", "OBSERVATION", 10, 20], ["angioedema", "OBSERVATION", 43, 53]]], ["Angioedema may be isolated: when associated with urticaria it is commonly underdiagnosed.", [["Angioedema", "DISEASE", 0, 10], ["urticaria", "DISEASE", 49, 58], ["Angioedema", "PROBLEM", 0, 10], ["urticaria", "PROBLEM", 49, 58]]], ["Such disorders are well known to pediatricians and allergists and often are a manifestation of type I IgE-mediated reaction.times/yearIdiopathic urticaria, usually chronic: most cases are thus considered since no precipitating cause can be identified after having excluded all potential causes of urticaria (70%-80% of cases) [18, 37] Prevalence Pediatric urticaria is credited with a 2%-5% prevalence [60] , with a total value of 3.9% (Figs.", [["Idiopathic urticaria", "DISEASE", 134, 154], ["urticaria", "DISEASE", 297, 306], ["urticaria", "DISEASE", 356, 365], ["type I IgE", "GENE_OR_GENE_PRODUCT", 95, 105], ["IgE", "PROTEIN", 102, 105], ["Such disorders", "PROBLEM", 0, 14], ["type I IgE-mediated reaction", "PROBLEM", 95, 123], ["Idiopathic urticaria", "PROBLEM", 134, 154], ["urticaria", "PROBLEM", 297, 306], ["a total value", "TEST", 414, 427], ["Idiopathic", "OBSERVATION_MODIFIER", 134, 144], ["urticaria", "OBSERVATION", 145, 154], ["urticaria", "OBSERVATION", 297, 306]]], ["Isolated angioedema is present in up to 9.6% of allergic children [60] .", [["angioedema", "DISEASE", 9, 19], ["allergic", "DISEASE", 48, 56], ["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65], ["Isolated angioedema", "PROBLEM", 0, 19], ["angioedema", "OBSERVATION", 9, 19]]], ["Higher incidences are found in cohort studies.", [["Higher incidences", "PROBLEM", 0, 17], ["cohort studies", "TEST", 31, 45]]], ["Urticaria was seen in 28 (49%) and angioedema in 34 children aged 1-3 years (60%) [144] .", [["Urticaria", "DISEASE", 0, 9], ["angioedema", "DISEASE", 35, 45], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["Urticaria", "PROBLEM", 0, 9], ["angioedema", "PROBLEM", 35, 45], ["angioedema", "OBSERVATION", 35, 45]]], ["Urticaria was associated with angioedema in 38.6% of children [29] .", [["Urticaria", "DISEASE", 0, 9], ["angioedema", "DISEASE", 30, 40], ["children", "ORGANISM", 53, 61], ["children", "SPECIES", 53, 61], ["Urticaria", "PROBLEM", 0, 9], ["angioedema", "PROBLEM", 30, 40], ["angioedema", "OBSERVATION", 30, 40]]], ["Urticaria manifested mostly in male children (59.8%), mainly of preschool and school age rather than the under-1-year age group [13] .", [["Urticaria", "DISEASE", 0, 9], ["children", "ORGANISM", 36, 44], ["children", "SPECIES", 36, 44], ["Urticaria", "PROBLEM", 0, 9]]], ["Acute urticaria may have an even higher prevalence (91.7%) [13] than that seen in AD: probably its frequency is underestimated since often, above all when caused by foods, a specialist is not consulted, the parents or the patients having recognized the evident cause-effect correlation (Chap.", [["urticaria", "DISEASE", 6, 15], ["AD", "DISEASE", 82, 84], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 222, 230], ["Acute urticaria", "PROBLEM", 0, 15], ["urticaria", "OBSERVATION", 6, 15]]], ["Table 8 .1 [37, 42, 45, 117] shows the division into hereditary and acquired types, further subdivided into types that are apparently primary and secondary to other disorders.Etiopathogenesis Genetic FactorsA genetic influence was demonstrated in 56 children with urticaria-angioedema subjected to challenge with additives: the 25 children with positive challenge showed a positivity, with statistically significant differences, of family (64.2%) and personal history (80%) and elevated IgE levels (40%) [59] .", [["hereditary", "DISEASE", 53, 63], ["urticaria-angioedema", "DISEASE", 264, 284], ["children", "ORGANISM", 250, 258], ["children", "ORGANISM", 331, 339], ["IgE", "GENE_OR_GENE_PRODUCT", 487, 490], ["IgE", "PROTEIN", 487, 490], ["children", "SPECIES", 250, 258], ["children", "SPECIES", 331, 339], ["other disorders", "PROBLEM", 159, 174], ["urticaria", "PROBLEM", 264, 273], ["angioedema", "PROBLEM", 274, 284], ["elevated IgE levels", "PROBLEM", 478, 497], ["hereditary", "OBSERVATION", 53, 63]]], ["A 67% rate of food urticaria occurred in atopic children [67, 90] .", [["food urticaria", "DISEASE", 14, 28], ["atopic", "DISEASE", 41, 47], ["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["food urticaria", "PROBLEM", 14, 28], ["food urticaria", "OBSERVATION", 14, 28]]], ["Children are more likely than controls to have a personal or family history (FH) of atopy (FHA) [169] .", [["FH", "DISEASE", 77, 79], ["atopy", "DISEASE", 84, 89], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["As a consequence, children affected by IgE-mediated atopic disease are more at risk of urticarial manifestations compared to the general population; likewise dermographism and aquagenic urticaria are significantly more frequent in atopic children than in nonatopic children [60] .", [["atopic disease", "DISEASE", 52, 66], ["urticaria", "DISEASE", 186, 195], ["atopic", "DISEASE", 231, 237], ["children", "ORGANISM", 18, 26], ["IgE", "GENE_OR_GENE_PRODUCT", 39, 42], ["children", "ORGANISM", 238, 246], ["IgE", "PROTEIN", 39, 42], ["children", "SPECIES", 18, 26], ["children", "SPECIES", 238, 246], ["children", "SPECIES", 265, 273], ["atopic disease", "PROBLEM", 52, 66], ["urticarial manifestations", "PROBLEM", 87, 112], ["aquagenic urticaria", "PROBLEM", 176, 195], ["atopic disease", "OBSERVATION", 52, 66], ["urticarial", "OBSERVATION", 87, 97], ["urticaria", "OBSERVATION", 186, 195]]], ["Recently, Muckle-Wells syndrome and familial cold urticaria, two rare autosomal dominant disorders, both localized on chromosomal region 1q44 [50] have been found to be associated with mutations, all located in exon 3 of the CIAS1 gene [62] .Pathogenic MechanismsSeveral pathogenic mechanisms are operative in urticaria, either immunological or nonimmunological (Table 8 .1), which may be involved in acquired types of this syndrome.Pathogenic MechanismsThe urticaria-angioedema caused by an immunological pathogenesis include [44] : \u2211 IgE-mediated urticaria:Pathogenic Mechanisms-Foods, inhalants, insect bites, etc.Immunological MechanismsSeveral pathogenetic mechanisms may involve types I-III immune reactions [45, 175] .Immunological MechanismsType I mechanism is fulfilled once specific IgE is bound to basophils or skin mast cells.", [["chromosomal", "ANATOMY", 118, 129], ["basophils", "ANATOMY", 809, 818], ["skin mast cells", "ANATOMY", 822, 837], ["Muckle-Wells syndrome", "DISEASE", 10, 31], ["familial cold urticaria", "DISEASE", 36, 59], ["autosomal dominant disorders", "DISEASE", 70, 98], ["urticaria", "DISEASE", 310, 319], ["urticaria-angioedema", "DISEASE", 458, 478], ["urticaria", "DISEASE", 549, 558], ["insect bites", "DISEASE", 599, 611], ["chromosomal", "CELLULAR_COMPONENT", 118, 129], ["exon 3", "CELLULAR_COMPONENT", 211, 217], ["CIAS1", "GENE_OR_GENE_PRODUCT", 225, 230], ["[44]", "SIMPLE_CHEMICAL", 527, 531], ["IgE", "GENE_OR_GENE_PRODUCT", 536, 539], ["types I-III", "GENE_OR_GENE_PRODUCT", 685, 696], ["Type I", "GENE_OR_GENE_PRODUCT", 749, 755], ["IgE", "GENE_OR_GENE_PRODUCT", 793, 796], ["basophils", "CELL", 809, 818], ["skin mast cells", "CELL", 822, 837], ["exon 3", "DNA", 211, 217], ["CIAS1 gene", "DNA", 225, 235], ["IgE", "PROTEIN", 536, 539], ["IgE", "PROTEIN", 793, 796], ["basophils", "CELL_TYPE", 809, 818], ["skin mast cells", "CELL_TYPE", 822, 837], ["Muckle-Wells syndrome", "PROBLEM", 10, 31], ["familial cold urticaria", "PROBLEM", 36, 59], ["two rare autosomal dominant disorders", "PROBLEM", 61, 98], ["mutations", "PROBLEM", 185, 194], ["Pathogenic MechanismsSeveral pathogenic mechanisms", "PROBLEM", 242, 292], ["urticaria", "PROBLEM", 310, 319], ["this syndrome", "PROBLEM", 419, 432], ["Pathogenic Mechanisms", "PROBLEM", 433, 454], ["The urticaria-angioedema", "PROBLEM", 454, 478], ["an immunological pathogenesis", "PROBLEM", 489, 518], ["IgE-mediated urticaria", "PROBLEM", 536, 558], ["Immunological MechanismsSeveral pathogenetic mechanisms", "PROBLEM", 617, 672], ["Type I mechanism", "PROBLEM", 749, 765], ["skin mast cells", "PROBLEM", 822, 837], ["Wells syndrome", "OBSERVATION", 17, 31], ["familial", "OBSERVATION_MODIFIER", 36, 44], ["cold urticaria", "OBSERVATION", 45, 59], ["autosomal", "OBSERVATION_MODIFIER", 70, 79], ["dominant", "OBSERVATION_MODIFIER", 80, 88], ["disorders", "OBSERVATION", 89, 98], ["urticaria", "OBSERVATION", 458, 467], ["urticaria", "OBSERVATION", 549, 558], ["skin", "ANATOMY", 822, 826], ["mast cells", "OBSERVATION", 827, 837]]], ["Contact with allergens leads to consequent degranulation, mediator release and development of typical skin and mucosal lesions.", [["skin", "ANATOMY", 102, 106], ["mucosal lesions", "ANATOMY", 111, 126], ["skin", "ORGAN", 102, 106], ["mucosal lesions", "PATHOLOGICAL_FORMATION", 111, 126], ["consequent degranulation", "PROBLEM", 32, 56], ["mediator release", "TREATMENT", 58, 74], ["typical skin and mucosal lesions", "PROBLEM", 94, 126], ["typical", "OBSERVATION_MODIFIER", 94, 101], ["skin", "ANATOMY", 102, 106], ["mucosal", "ANATOMY", 111, 118], ["lesions", "OBSERVATION", 119, 126]]], ["This IgE-mediated mechanism is operative on reactions to foods such as cow's milk (CM), egg, fish, wheat, parasites (helminths), some protozoa, insect venom, pollens, pet dander [53, 103] , b-lactamine metabolites, insulin, enzymes, sera [227] and latex [112] .", [["milk", "ANATOMY", 77, 81], ["CM", "ANATOMY", 83, 85], ["egg", "ANATOMY", 88, 91], ["venom", "ANATOMY", 151, 156], ["sera", "ANATOMY", 233, 237], ["b-lactamine", "CHEMICAL", 190, 201], ["b-lactamine", "CHEMICAL", 190, 201], ["IgE", "GENE_OR_GENE_PRODUCT", 5, 8], ["milk", "ORGANISM_SUBSTANCE", 77, 81], ["CM", "ORGANISM_SUBSTANCE", 83, 85], ["egg", "ORGANISM_SUBSTANCE", 88, 91], ["fish", "ORGANISM_SUBDIVISION", 93, 97], ["wheat", "ORGANISM_SUBDIVISION", 99, 104], ["venom", "ORGANISM_SUBSTANCE", 151, 156], ["pollens", "ORGANISM_SUBDIVISION", 158, 165], ["53, 103]", "SIMPLE_CHEMICAL", 179, 187], ["b-lactamine", "SIMPLE_CHEMICAL", 190, 201], ["insulin", "GENE_OR_GENE_PRODUCT", 215, 222], ["sera", "ORGANISM_SUBSTANCE", 233, 237], ["IgE", "PROTEIN", 5, 8], ["insulin", "PROTEIN", 215, 222], ["enzymes", "PROTEIN", 224, 231], ["cow", "SPECIES", 71, 74], ["milk", "SPECIES", 77, 81], ["wheat", "SPECIES", 99, 104], ["pet dander", "SPECIES", 167, 177], ["cow", "SPECIES", 71, 74], ["wheat", "SPECIES", 99, 104], ["pet dander", "SPECIES", 167, 177], ["some protozoa", "PROBLEM", 129, 142], ["pet dander", "TEST", 167, 177], ["b-lactamine metabolites", "TEST", 190, 213], ["insulin", "TREATMENT", 215, 222], ["enzymes", "TEST", 224, 231], ["sera", "TEST", 233, 237], ["latex", "TEST", 248, 253], ["egg", "ANATOMY", 88, 91], ["fish", "ANATOMY", 93, 97], ["venom", "ANATOMY", 151, 156]]], ["T-cell expression of cutaneous lymphocyte antigen (CLA), a unique skin-homing receptor, was selectively up-regulated in patients with CM-induced urticaria and may play an important role in the pathogenesis of this disease [28] .Immunological MechanismsType II mechanism involves complement-fixing IgG or IgM antibodies, complement activates C3a, C4a, and C5a components capable of directly activating mast cell degranulation.", [["T-cell", "ANATOMY", 0, 6], ["cutaneous lymphocyte", "ANATOMY", 21, 41], ["skin", "ANATOMY", 66, 70], ["mast cell", "ANATOMY", 401, 410], ["CM", "DISEASE", 134, 136], ["urticaria", "DISEASE", 145, 154], ["T-cell", "CELL", 0, 6], ["cutaneous lymphocyte antigen", "GENE_OR_GENE_PRODUCT", 21, 49], ["CLA", "GENE_OR_GENE_PRODUCT", 51, 54], ["skin", "ORGAN", 66, 70], ["patients", "ORGANISM", 120, 128], ["IgG", "GENE_OR_GENE_PRODUCT", 297, 300], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 304, 318], ["C3a", "GENE_OR_GENE_PRODUCT", 341, 344], ["C4a", "GENE_OR_GENE_PRODUCT", 346, 349], ["C5a", "GENE_OR_GENE_PRODUCT", 355, 358], ["mast cell", "CELL", 401, 410], ["cutaneous lymphocyte antigen", "PROTEIN", 21, 49], ["CLA", "PROTEIN", 51, 54], ["skin-homing receptor", "PROTEIN", 66, 86], ["IgG", "PROTEIN", 297, 300], ["IgM antibodies", "PROTEIN", 304, 318], ["C3a", "PROTEIN", 341, 344], ["C4a", "PROTEIN", 346, 349], ["C5a components", "PROTEIN", 355, 369], ["patients", "SPECIES", 120, 128], ["cutaneous lymphocyte antigen", "TEST", 21, 49], ["homing receptor", "TREATMENT", 71, 86], ["urticaria", "PROBLEM", 145, 154], ["this disease", "PROBLEM", 209, 221], ["Type II mechanism", "PROBLEM", 252, 269], ["complement", "TEST", 279, 289], ["fixing IgG", "PROBLEM", 290, 300], ["IgM antibodies", "PROBLEM", 304, 318], ["C3a", "TEST", 341, 344], ["C4a", "TEST", 346, 349], ["activating mast cell degranulation", "PROBLEM", 390, 424], ["cutaneous", "ANATOMY", 21, 30], ["lymphocyte", "OBSERVATION", 31, 41], ["skin", "ANATOMY", 66, 70], ["urticaria", "OBSERVATION", 145, 154], ["mast cell degranulation", "OBSERVATION", 401, 424]]], ["Known examples are the hemolytic reactions after blood transfusions (due to incompatible groups) and immunoglobulins (mainly IgA) and sulfamide administration [227] .", [["blood", "ANATOMY", 49, 54], ["hemolytic", "DISEASE", 23, 32], ["sulfamide", "CHEMICAL", 134, 143], ["sulfamide", "CHEMICAL", 134, 143], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 101, 116], ["IgA", "GENE_OR_GENE_PRODUCT", 125, 128], ["sulfamide", "SIMPLE_CHEMICAL", 134, 143], ["immunoglobulins", "PROTEIN", 101, 116], ["IgA", "PROTEIN", 125, 128], ["the hemolytic reactions", "PROBLEM", 19, 42], ["blood transfusions", "TREATMENT", 49, 67], ["immunoglobulins", "TREATMENT", 101, 116], ["sulfamide administration", "TREATMENT", 134, 158], ["hemolytic", "OBSERVATION_MODIFIER", 23, 32]]], ["This mechanism has been found in physical urticaria such as cold-induced, cholinergic and dermographic types [53] .", [["urticaria", "DISEASE", 42, 51], ["physical urticaria", "PROBLEM", 33, 51], ["urticaria", "OBSERVATION", 42, 51]]], ["Type III mechanism is manifest via an interplay between CIC, activated complement and kinins and the anaphylotoxin system, which is seen with serum sickness.", [["serum", "ANATOMY", 142, 147], ["serum sickness", "DISEASE", 142, 156], ["Type III", "GENE_OR_GENE_PRODUCT", 0, 8], ["CIC", "GENE_OR_GENE_PRODUCT", 56, 59], ["kinins", "GENE_OR_GENE_PRODUCT", 86, 92], ["anaphylotoxin", "GENE_OR_GENE_PRODUCT", 101, 114], ["serum", "ORGANISM_SUBSTANCE", 142, 147], ["CIC", "PROTEIN", 56, 59], ["Type III mechanism", "PROBLEM", 0, 18], ["activated complement and kinins and the anaphylotoxin system", "PROBLEM", 61, 121], ["serum sickness", "PROBLEM", 142, 156]]], ["This mechanism is observed in childhood infections [7] , urticarial vasculitis, Sch\u00f6nlein-Henoch syndrome (SHS), panarteritis nodosa, cryoglobulinemia, hereditary complement deficiencies, autoimmunity etc. [53] .", [["infections", "DISEASE", 40, 50], ["urticarial vasculitis", "DISEASE", 57, 78], ["Sch\u00f6nlein-Henoch syndrome", "DISEASE", 80, 105], ["SHS", "DISEASE", 107, 110], ["panarteritis nodosa", "DISEASE", 113, 132], ["cryoglobulinemia", "DISEASE", 134, 150], ["hereditary complement deficiencies", "DISEASE", 152, 186], ["autoimmunity", "DISEASE", 188, 200], ["childhood infections", "PROBLEM", 30, 50], ["urticarial vasculitis", "PROBLEM", 57, 78], ["Sch\u00f6nlein-Henoch syndrome", "PROBLEM", 80, 105], ["panarteritis nodosa", "PROBLEM", 113, 132], ["cryoglobulinemia", "PROBLEM", 134, 150], ["hereditary complement deficiencies", "PROBLEM", 152, 186], ["autoimmunity etc", "PROBLEM", 188, 204], ["infections", "OBSERVATION", 40, 50], ["urticarial", "OBSERVATION_MODIFIER", 57, 67], ["vasculitis", "OBSERVATION", 68, 78], ["Henoch syndrome", "OBSERVATION", 90, 105], ["nodosa", "OBSERVATION", 126, 132], ["cryoglobulinemia", "OBSERVATION", 134, 150], ["hereditary", "OBSERVATION_MODIFIER", 152, 162], ["complement deficiencies", "OBSERVATION", 163, 186]]], ["Such a pathogenic mechanism has been considered in food-induced reactions, since elimination of CM from the diet of a patient with angioedema and bronchospasm resulted in CIC disappearance, and reintroduction of CM caused a return to previous CIC levels within 24 h[119] .", [["CM", "DISEASE", 96, 98], ["angioedema", "DISEASE", 131, 141], ["bronchospasm", "DISEASE", 146, 158], ["CM", "DISEASE", 212, 214], ["patient", "ORGANISM", 118, 125], ["CIC", "PATHOLOGICAL_FORMATION", 171, 174], ["CIC", "PROTEIN", 243, 246], ["patient", "SPECIES", 118, 125], ["a pathogenic mechanism", "PROBLEM", 5, 27], ["angioedema", "PROBLEM", 131, 141], ["bronchospasm", "PROBLEM", 146, 158], ["CIC disappearance", "PROBLEM", 171, 188], ["previous CIC levels", "TEST", 234, 253], ["bronchospasm", "OBSERVATION", 146, 158]]], ["These II and III types are objectively rare in children.Immunological MechanismsSeveral investigators consider that a type IV mechanism may be operative via IL 3 and IL 5 generation, which are capable of acting on both mast cell degranulation and eosinophil recruitment, thus explaining some types of chronic urticaria [37] , especially eotaxin-driven allergic acute urticaria [95] .Immunological MechanismsThe skin is particularly rich in mast cells.", [["mast cell", "ANATOMY", 219, 228], ["eosinophil", "ANATOMY", 247, 257], ["skin", "ANATOMY", 411, 415], ["mast cells", "ANATOMY", 440, 450], ["urticaria", "DISEASE", 309, 318], ["allergic acute urticaria", "DISEASE", 352, 376], ["children", "ORGANISM", 47, 55], ["IL 3", "GENE_OR_GENE_PRODUCT", 157, 161], ["IL 5", "GENE_OR_GENE_PRODUCT", 166, 170], ["mast cell", "CELL", 219, 228], ["eosinophil", "CELL", 247, 257], ["eotaxin", "GENE_OR_GENE_PRODUCT", 337, 344], ["skin", "ORGAN", 411, 415], ["mast cells", "CELL", 440, 450], ["IL 3", "PROTEIN", 157, 161], ["eotaxin", "PROTEIN", 337, 344], ["mast cells", "CELL_TYPE", 440, 450], ["children", "SPECIES", 47, 55], ["a type IV mechanism", "TREATMENT", 116, 135], ["operative via IL", "TREATMENT", 143, 159], ["both mast cell degranulation", "TREATMENT", 214, 242], ["eosinophil recruitment", "TREATMENT", 247, 269], ["chronic urticaria", "PROBLEM", 301, 318], ["eotaxin", "TREATMENT", 337, 344], ["allergic acute urticaria", "PROBLEM", 352, 376], ["III types", "OBSERVATION_MODIFIER", 13, 22], ["mast cell degranulation", "OBSERVATION", 219, 242], ["eosinophil recruitment", "OBSERVATION", 247, 269], ["chronic", "OBSERVATION_MODIFIER", 301, 308], ["urticaria", "OBSERVATION", 309, 318], ["acute", "OBSERVATION_MODIFIER", 361, 366], ["urticaria", "OBSERVATION", 367, 376], ["skin", "ANATOMY", 411, 415], ["mast cells", "OBSERVATION", 440, 450]]], ["7 we described their origin in bone marrow and subsequent migration into the skin aided by chemoattractants and adhesion molecules [37] .", [["bone marrow", "ANATOMY", 31, 42], ["skin", "ANATOMY", 77, 81], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 31, 42], ["skin", "ORGAN", 77, 81], ["chemoattractants", "PROTEIN", 91, 107], ["adhesion molecules", "PROTEIN", 112, 130], ["bone marrow", "PROBLEM", 31, 42], ["adhesion molecules", "TEST", 112, 130], ["origin", "ANATOMY_MODIFIER", 21, 27], ["bone", "ANATOMY", 31, 35], ["marrow", "OBSERVATION", 36, 42], ["migration", "OBSERVATION_MODIFIER", 58, 67], ["skin", "ANATOMY", 77, 81]]], ["In immediate-type hypersensitivity, mast cell activation is triggered by allergen cross-linkage of high-affinity IgE receptors (FceRI) borne on their cytoplasmic membrane and on peripheral blood basophils.", [["mast cell", "ANATOMY", 36, 45], ["cytoplasmic membrane", "ANATOMY", 150, 170], ["peripheral blood basophils", "ANATOMY", 178, 204], ["hypersensitivity", "DISEASE", 18, 34], ["mast cell", "CELL", 36, 45], ["IgE receptors", "GENE_OR_GENE_PRODUCT", 113, 126], ["FceRI", "GENE_OR_GENE_PRODUCT", 128, 133], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 150, 170], ["peripheral blood basophils", "ORGANISM_SUBSTANCE", 178, 204], ["high-affinity IgE receptors", "PROTEIN", 99, 126], ["FceRI", "PROTEIN", 128, 133], ["peripheral blood basophils", "CELL_TYPE", 178, 204], ["type hypersensitivity", "PROBLEM", 13, 34], ["mast cell activation", "PROBLEM", 36, 56], ["peripheral blood basophils", "TEST", 178, 204], ["-type", "OBSERVATION_MODIFIER", 12, 17], ["hypersensitivity", "OBSERVATION_MODIFIER", 18, 34], ["mast cell activation", "OBSERVATION", 36, 56], ["cytoplasmic membrane", "OBSERVATION", 150, 170], ["peripheral", "ANATOMY_MODIFIER", 178, 188], ["blood basophils", "ANATOMY", 189, 204]]], ["Mast cells may be activated by specific allergens or by HRFs (histamine release factors) [46] or chemokines, produced by peripheral blood mononuclear cells (PBMCs) that are part of the cell infiltrate causing skin inflammatory lesions.", [["Mast cells", "ANATOMY", 0, 10], ["peripheral blood mononuclear cells", "ANATOMY", 121, 155], ["PBMCs", "ANATOMY", 157, 162], ["cell", "ANATOMY", 185, 189], ["skin inflammatory lesions", "ANATOMY", 209, 234], ["histamine", "CHEMICAL", 62, 71], ["histamine", "CHEMICAL", 62, 71], ["Mast cells", "CELL", 0, 10], ["HRFs", "GENE_OR_GENE_PRODUCT", 56, 60], ["histamine release factors) [46]", "GENE_OR_GENE_PRODUCT", 62, 93], ["peripheral blood mononuclear cells", "CELL", 121, 155], ["PBMCs", "CELL", 157, 162], ["cell", "CELL", 185, 189], ["skin inflammatory lesions", "PATHOLOGICAL_FORMATION", 209, 234], ["Mast cells", "CELL_TYPE", 0, 10], ["HRFs", "PROTEIN", 56, 60], ["histamine release factors", "PROTEIN", 62, 87], ["chemokines", "PROTEIN", 97, 107], ["peripheral blood mononuclear cells", "CELL_TYPE", 121, 155], ["PBMCs", "CELL_TYPE", 157, 162], ["Mast cells", "PROBLEM", 0, 10], ["histamine release factors", "TEST", 62, 87], ["peripheral blood mononuclear cells", "PROBLEM", 121, 155], ["the cell infiltrate", "PROBLEM", 181, 200], ["skin inflammatory lesions", "PROBLEM", 209, 234], ["peripheral", "ANATOMY_MODIFIER", 121, 131], ["blood", "ANATOMY", 132, 137], ["mononuclear cells", "OBSERVATION", 138, 155], ["cell", "ANATOMY", 185, 189], ["infiltrate", "OBSERVATION", 190, 200], ["skin", "ANATOMY", 209, 213], ["inflammatory", "OBSERVATION_MODIFIER", 214, 226], ["lesions", "OBSERVATION", 227, 234]]], ["Cutaneous mast cells are tryptase and chymase-containing mast cells (TC) ( Table 1 .27) and contain in the granules both types of proteases, tryptase and kinase [194] , which are able to induce further degranulation [53] .", [["Cutaneous mast cells", "ANATOMY", 0, 20], ["mast cells", "ANATOMY", 57, 67], ["TC", "ANATOMY", 69, 71], ["granules", "ANATOMY", 107, 115], ["Cutaneous mast cells", "CELL", 0, 20], ["tryptase", "GENE_OR_GENE_PRODUCT", 25, 33], ["chymase", "GENE_OR_GENE_PRODUCT", 38, 45], ["mast cells", "CELL", 57, 67], ["TC", "CELL", 69, 71], ["granules", "CELLULAR_COMPONENT", 107, 115], ["tryptase", "GENE_OR_GENE_PRODUCT", 141, 149], ["kinase [194]", "GENE_OR_GENE_PRODUCT", 154, 166], ["Cutaneous mast cells", "CELL_TYPE", 0, 20], ["tryptase", "PROTEIN", 25, 33], ["chymase", "PROTEIN", 38, 45], ["mast cells", "CELL_TYPE", 57, 67], ["TC", "CELL_TYPE", 69, 71], ["proteases", "PROTEIN", 130, 139], ["tryptase", "PROTEIN", 141, 149], ["Cutaneous mast cells", "TEST", 0, 20], ["tryptase", "TEST", 25, 33], ["chymase", "TEST", 38, 45], ["mast cells", "TEST", 57, 67], ["Table", "TEST", 75, 80], ["tryptase and kinase", "TEST", 141, 160], ["mast cells", "OBSERVATION", 10, 20], ["chymase", "ANATOMY", 38, 45], ["mast cells", "OBSERVATION", 57, 67]]], ["Tryptase in particular can be viewed as a marker of mast cell activation, since its concentration in lesional skin increases proportionately to histamine concentration [103] .", [["mast cell", "ANATOMY", 52, 61], ["lesional skin", "ANATOMY", 101, 114], ["Tryptase", "CHEMICAL", 0, 8], ["histamine", "CHEMICAL", 144, 153], ["histamine", "CHEMICAL", 144, 153], ["Tryptase", "SIMPLE_CHEMICAL", 0, 8], ["mast cell", "CELL", 52, 61], ["skin", "ORGAN", 110, 114], ["histamine", "SIMPLE_CHEMICAL", 144, 153], ["Tryptase", "PROTEIN", 0, 8], ["mast cell activation", "PROBLEM", 52, 72], ["histamine concentration", "TEST", 144, 167], ["mast cell activation", "OBSERVATION", 52, 72], ["skin", "ANATOMY", 110, 114]]], ["Leukocyte emigration is regulated by vasoactive and chemotactic mediators released from mast cells, inducing a sequential up-regulation of endothelial adhesion molecules (CD62P, CD62E, CD54 = ICAM-1, and CD106 = VCAM), b2-integrins on leukocytes, and ILs on endothelial, epithelial, and infiltrating cells [91] .", [["Leukocyte", "ANATOMY", 0, 9], ["mast cells", "ANATOMY", 88, 98], ["endothelial", "ANATOMY", 139, 150], ["leukocytes", "ANATOMY", 235, 245], ["endothelial", "ANATOMY", 258, 269], ["epithelial", "ANATOMY", 271, 281], ["infiltrating cells", "ANATOMY", 287, 305], ["Leukocyte", "CELL", 0, 9], ["mast cells", "CELL", 88, 98], ["endothelial adhesion molecules", "GENE_OR_GENE_PRODUCT", 139, 169], ["CD62P", "GENE_OR_GENE_PRODUCT", 171, 176], ["CD62E", "GENE_OR_GENE_PRODUCT", 178, 183], ["CD54", "GENE_OR_GENE_PRODUCT", 185, 189], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 192, 198], ["CD106 = VCAM", "GENE_OR_GENE_PRODUCT", 204, 216], ["b2-integrins", "GENE_OR_GENE_PRODUCT", 219, 231], ["leukocytes", "CELL", 235, 245], ["ILs", "GENE_OR_GENE_PRODUCT", 251, 254], ["endothelial", "CELL", 258, 269], ["epithelial", "CELL", 271, 281], ["cells", "CELL", 300, 305], ["chemotactic mediators", "PROTEIN", 52, 73], ["mast cells", "CELL_TYPE", 88, 98], ["endothelial adhesion molecules", "PROTEIN", 139, 169], ["CD62P", "PROTEIN", 171, 176], ["CD62E", "PROTEIN", 178, 183], ["CD54", "PROTEIN", 185, 189], ["ICAM", "PROTEIN", 192, 196], ["CD106", "PROTEIN", 204, 209], ["VCAM", "PROTEIN", 212, 216], ["b2", "PROTEIN", 219, 221], ["integrins", "PROTEIN", 222, 231], ["leukocytes", "CELL_TYPE", 235, 245], ["ILs", "PROTEIN", 251, 254], ["endothelial, epithelial, and infiltrating cells", "CELL_TYPE", 258, 305], ["Leukocyte emigration", "TEST", 0, 20], ["vasoactive and chemotactic mediators", "TREATMENT", 37, 73], ["mast cells", "PROBLEM", 88, 98], ["endothelial adhesion molecules", "PROBLEM", 139, 169], ["CD62P", "TEST", 171, 176], ["CD62E", "TEST", 178, 183], ["CD54", "TEST", 185, 189], ["ICAM", "TEST", 192, 196], ["CD106", "TEST", 204, 209], ["VCAM", "TEST", 212, 216], ["b2", "TEST", 219, 221], ["leukocytes", "TEST", 235, 245], ["ILs", "PROBLEM", 251, 254], ["epithelial, and infiltrating cells", "PROBLEM", 271, 305], ["mast cells", "OBSERVATION", 88, 98], ["endothelial", "ANATOMY", 139, 150], ["leukocytes", "ANATOMY", 235, 245], ["endothelial", "ANATOMY", 258, 269], ["epithelial", "ANATOMY", 271, 281], ["infiltrating cells", "OBSERVATION", 287, 305]]], ["In chronic/ idiopathic forms, T lymphocytes (50%) are characteristically found with perivascular distribution, monocytes (20%), mast cells (10%) and no B lymphocytes [103] .", [["T lymphocytes", "ANATOMY", 30, 43], ["perivascular", "ANATOMY", 84, 96], ["monocytes", "ANATOMY", 111, 120], ["mast cells", "ANATOMY", 128, 138], ["B lymphocytes", "ANATOMY", 152, 165], ["T lymphocytes", "CELL", 30, 43], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 96], ["monocytes", "CELL", 111, 120], ["mast cells", "CELL", 128, 138], ["B lymphocytes", "CELL", 152, 165], ["T lymphocytes", "CELL_TYPE", 30, 43], ["monocytes", "CELL_TYPE", 111, 120], ["mast cells", "CELL_TYPE", 128, 138], ["B lymphocytes", "CELL_TYPE", 152, 165], ["chronic/ idiopathic forms", "PROBLEM", 3, 28], ["T lymphocytes", "TEST", 30, 43], ["perivascular distribution", "TEST", 84, 109], ["monocytes", "TEST", 111, 120], ["mast cells", "TEST", 128, 138], ["B lymphocytes", "PROBLEM", 152, 165], ["chronic", "OBSERVATION_MODIFIER", 3, 10], ["idiopathic", "OBSERVATION", 12, 22], ["lymphocytes", "ANATOMY", 32, 43], ["perivascular", "ANATOMY_MODIFIER", 84, 96], ["monocytes", "ANATOMY", 111, 120], ["mast cells", "OBSERVATION", 128, 138], ["no", "UNCERTAINTY", 149, 151], ["lymphocytes", "ANATOMY", 154, 165]]], ["CD4 prevails over CD8 [19] .", [["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 18, 21], ["CD4", "PROTEIN", 0, 3], ["CD8", "PROTEIN", 18, 21]]], ["One hypothesis postulates that there is a predominance of activated CD4, as seen in delayed pressure urticaria (DPU) [103] .", [["delayed pressure urticaria", "DISEASE", 84, 110], ["CD4", "GENE_OR_GENE_PRODUCT", 68, 71], ["CD4", "PROTEIN", 68, 71], ["activated CD4", "PROBLEM", 58, 71], ["delayed pressure urticaria", "PROBLEM", 84, 110], ["predominance", "OBSERVATION_MODIFIER", 42, 54], ["activated CD4", "OBSERVATION", 58, 71], ["pressure urticaria", "OBSERVATION", 92, 110]]], ["However, a more likely hypothesis shows no evidence of CD4 activation, although it confirms the unbalanced CD4/CD8 ratio [19] .", [["CD4", "GENE_OR_GENE_PRODUCT", 55, 58], ["CD4", "GENE_OR_GENE_PRODUCT", 107, 110], ["CD8", "GENE_OR_GENE_PRODUCT", 111, 114], ["CD4", "PROTEIN", 55, 58], ["CD4", "PROTEIN", 107, 110], ["CD8", "PROTEIN", 111, 114], ["CD4 activation", "PROBLEM", 55, 69], ["no evidence of", "UNCERTAINTY", 40, 54], ["CD4 activation", "OBSERVATION", 55, 69]]], ["CD62E has been found in both groups of patients, but CD54 only in DPU patients [19] .", [["CD62E", "GENE_OR_GENE_PRODUCT", 0, 5], ["patients", "ORGANISM", 39, 47], ["CD54", "GENE_OR_GENE_PRODUCT", 53, 57], ["DPU", "ORGANISM", 66, 69], ["patients", "ORGANISM", 70, 78], ["CD62E", "PROTEIN", 0, 5], ["CD54", "PROTEIN", 53, 57], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 70, 78], ["CD54", "TEST", 53, 57], ["both groups", "OBSERVATION_MODIFIER", 24, 35]]], ["Both CD62E and CD54 act as T-lymphocyte adhesion receptors and their increase found in DPU patients may reflect the inflammatory nature of this disorder [19] .Immunological MechanismsIn chronic urticaria, IgG Aabs (autoantibodies) directed against IgE in function of anti-IgE and/or anti-vasodilatory phase) a local axon reflex with dilation of small perilesional arteries, a neurogenic response of the short-circuit type, sending a stimulus back to the cutaneous nerve endings of the involved area.", [["T-lymphocyte", "ANATOMY", 27, 39], ["DPU", "ANATOMY", 87, 90], ["axon", "ANATOMY", 316, 320], ["perilesional arteries", "ANATOMY", 351, 372], ["cutaneous nerve endings", "ANATOMY", 454, 477], ["area", "ANATOMY", 494, 498], ["chronic urticaria", "DISEASE", 186, 203], ["CD62E", "GENE_OR_GENE_PRODUCT", 5, 10], ["CD54", "GENE_OR_GENE_PRODUCT", 15, 19], ["T-lymphocyte adhesion receptors", "GENE_OR_GENE_PRODUCT", 27, 58], ["DPU", "ORGANISM", 87, 90], ["patients", "ORGANISM", 91, 99], ["IgG Aabs (autoantibodies) directed against IgE", "GENE_OR_GENE_PRODUCT", 205, 251], ["anti-IgE", "GENE_OR_GENE_PRODUCT", 267, 275], ["perilesional arteries", "MULTI-TISSUE_STRUCTURE", 351, 372], ["cutaneous nerve endings", "MULTI-TISSUE_STRUCTURE", 454, 477], ["CD62E", "PROTEIN", 5, 10], ["CD54", "PROTEIN", 15, 19], ["T-lymphocyte adhesion receptors", "PROTEIN", 27, 58], ["IgG Aabs", "PROTEIN", 205, 213], ["autoantibodies", "PROTEIN", 215, 229], ["IgE", "PROTEIN", 248, 251], ["anti-IgE", "PROTEIN", 267, 275], ["patients", "SPECIES", 91, 99], ["Both CD62E", "TEST", 0, 10], ["CD54 act", "TEST", 15, 23], ["T-lymphocyte adhesion receptors", "TREATMENT", 27, 58], ["this disorder", "PROBLEM", 139, 152], ["Immunological MechanismsIn chronic urticaria", "PROBLEM", 159, 203], ["IgG Aabs (autoantibodies)", "TREATMENT", 205, 230], ["anti-IgE", "TREATMENT", 267, 275], ["anti-vasodilatory phase", "TREATMENT", 283, 306], ["a local axon reflex", "TEST", 308, 327], ["dilation of small perilesional arteries", "PROBLEM", 333, 372], ["a neurogenic response", "PROBLEM", 374, 395], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["may reflect", "UNCERTAINTY", 100, 111], ["inflammatory", "OBSERVATION_MODIFIER", 116, 128], ["chronic", "OBSERVATION_MODIFIER", 186, 193], ["urticaria", "OBSERVATION", 194, 203], ["dilation", "OBSERVATION", 333, 341], ["small", "OBSERVATION_MODIFIER", 345, 350], ["perilesional arteries", "ANATOMY", 351, 372], ["neurogenic response", "OBSERVATION", 376, 395], ["short", "OBSERVATION_MODIFIER", 403, 408], ["cutaneous nerve", "ANATOMY", 454, 469]]], ["The increased vascular permeability leads to activation of the plasma kinin-forming system and production of bradykinin, which is especially important in hereditary angioedema.", [["vascular", "ANATOMY", 14, 22], ["plasma", "ANATOMY", 63, 69], ["bradykinin", "CHEMICAL", 109, 119], ["hereditary angioedema", "DISEASE", 154, 175], ["bradykinin", "CHEMICAL", 109, 119], ["vascular", "MULTI-TISSUE_STRUCTURE", 14, 22], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["kinin", "GENE_OR_GENE_PRODUCT", 70, 75], ["bradykinin", "GENE_OR_GENE_PRODUCT", 109, 119], ["The increased vascular permeability", "PROBLEM", 0, 35], ["the plasma kinin", "TEST", 59, 75], ["bradykinin", "PROBLEM", 109, 119], ["hereditary angioedema", "PROBLEM", 154, 175], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["vascular", "ANATOMY", 14, 22], ["permeability leads", "OBSERVATION", 23, 41], ["bradykinin", "OBSERVATION", 109, 119], ["hereditary", "OBSERVATION_MODIFIER", 154, 164], ["angioedema", "OBSERVATION", 165, 175]]], ["Likely the histamine-mediated stimulation of neural sensorial fibers provokes the release of substance P (SP) and of tachykinins with histamine-release action, with consequent amplification of symptoms [103] .", [["neural sensorial fibers", "ANATOMY", 45, 68], ["histamine", "CHEMICAL", 11, 20], ["histamine", "CHEMICAL", 134, 143], ["histamine", "CHEMICAL", 11, 20], ["histamine", "CHEMICAL", 134, 143], ["histamine", "SIMPLE_CHEMICAL", 11, 20], ["sensorial fibers", "MULTI-TISSUE_STRUCTURE", 52, 68], ["substance P", "SIMPLE_CHEMICAL", 93, 104], ["SP", "SIMPLE_CHEMICAL", 106, 108], ["tachykinins", "GENE_OR_GENE_PRODUCT", 117, 128], ["histamine", "SIMPLE_CHEMICAL", 134, 143], ["the histamine-mediated stimulation of neural sensorial fibers", "TREATMENT", 7, 68], ["tachykinins", "PROBLEM", 117, 128], ["histamine-release action", "TREATMENT", 134, 158], ["symptoms", "PROBLEM", 193, 201]]], ["Additional mediators important in the pathogenesis are both PG (prostaglandins) and LT (leukotrienes), deriving from arachidonic acid metabolism, PGD 2 is active in mastocytosis, LTB 4 and LTC 4 in pressure urticaria, LTB 4 and PAF in cold, heat, and cholinergic urticaria [103] .", [["PG", "CHEMICAL", 60, 62], ["prostaglandins", "CHEMICAL", 64, 78], ["leukotrienes", "CHEMICAL", 88, 100], ["arachidonic acid", "CHEMICAL", 117, 133], ["mastocytosis", "DISEASE", 165, 177], ["urticaria", "DISEASE", 207, 216], ["PAF", "CHEMICAL", 228, 231], ["urticaria", "DISEASE", 263, 272], ["prostaglandins", "CHEMICAL", 64, 78], ["arachidonic acid", "CHEMICAL", 117, 133], ["PG", "SIMPLE_CHEMICAL", 60, 62], ["prostaglandins", "SIMPLE_CHEMICAL", 64, 78], ["LT", "SIMPLE_CHEMICAL", 84, 86], ["leukotrienes", "SIMPLE_CHEMICAL", 88, 100], ["arachidonic acid", "SIMPLE_CHEMICAL", 117, 133], ["PGD 2", "GENE_OR_GENE_PRODUCT", 146, 151], ["mastocytosis", "PATHOLOGICAL_FORMATION", 165, 177], ["LTB 4", "GENE_OR_GENE_PRODUCT", 218, 223], ["PAF", "SIMPLE_CHEMICAL", 228, 231], ["PAF", "PROTEIN", 228, 231], ["Additional mediators", "TREATMENT", 0, 20], ["PG (prostaglandins)", "TREATMENT", 60, 79], ["LT (leukotrienes)", "TREATMENT", 84, 101], ["arachidonic acid metabolism", "PROBLEM", 117, 144], ["active in mastocytosis", "PROBLEM", 155, 177], ["LTB", "TEST", 179, 182], ["LTC", "TEST", 189, 192], ["pressure urticaria", "PROBLEM", 198, 216], ["LTB", "TEST", 218, 221], ["PAF", "PROBLEM", 228, 231], ["cold", "PROBLEM", 235, 239], ["cholinergic urticaria", "PROBLEM", 251, 272], ["LT", "ANATOMY", 84, 86], ["active", "OBSERVATION_MODIFIER", 155, 161], ["mastocytosis", "OBSERVATION", 165, 177], ["pressure urticaria", "OBSERVATION", 198, 216], ["LTB", "ANATOMY", 218, 221], ["heat", "ANATOMY", 241, 245]]], ["With the advent of LT-receptor antagonists, the LTC 4 contribution to chronic urticaria symptoms is more evident [103] .Immunological MechanismsIn other urticarial types, the immunological mechanism is not always identified: allergens may be produced in solar urticaria, both in serum and epidermis, triggered by solar ray exposure, which in aquagenic urticaria in contact with water become soluble in the corneum layer, and diffuse to dermal mast cells.", [["serum", "ANATOMY", 279, 284], ["epidermis", "ANATOMY", 289, 298], ["corneum layer", "ANATOMY", 406, 419], ["dermal mast cells", "ANATOMY", 436, 453], ["urticaria", "DISEASE", 78, 87], ["urticarial", "DISEASE", 153, 163], ["urticaria", "DISEASE", 260, 269], ["urticaria", "DISEASE", 352, 361], ["LT-receptor antagonists", "GENE_OR_GENE_PRODUCT", 19, 42], ["serum", "ORGANISM_SUBSTANCE", 279, 284], ["epidermis", "ORGAN", 289, 298], ["corneum layer", "TISSUE", 406, 419], ["dermal mast cells", "CELL", 436, 453], ["LT", "PROTEIN", 19, 21], ["dermal mast cells", "CELL_TYPE", 436, 453], ["LT-receptor antagonists", "TREATMENT", 19, 42], ["the LTC", "TREATMENT", 44, 51], ["chronic urticaria symptoms", "PROBLEM", 70, 96], ["allergens", "PROBLEM", 225, 234], ["solar urticaria", "PROBLEM", 254, 269], ["solar ray exposure", "PROBLEM", 313, 331], ["aquagenic urticaria", "PROBLEM", 342, 361], ["diffuse to dermal mast cells", "PROBLEM", 425, 453], ["chronic", "OBSERVATION_MODIFIER", 70, 77], ["urticaria", "OBSERVATION", 78, 87], ["urticarial types", "OBSERVATION", 153, 169], ["solar urticaria", "OBSERVATION", 254, 269], ["epidermis", "ANATOMY", 289, 298], ["urticaria", "OBSERVATION", 352, 361], ["corneum layer", "ANATOMY", 406, 419], ["diffuse", "OBSERVATION_MODIFIER", 425, 432], ["dermal mast cells", "OBSERVATION", 436, 453]]], ["Cryoglobulins, cold hemolysins and cryofibrinogen are observed in some cases of cold urticaria [60] .Immunological MechanismsSerotonin chemotactic factors, kinins, derivatives of tissue and plasma kininogen with an inflammatory action, tenfold more pronounced than that of histamine and MIF (monocyte-macrophage migration inhibiting factor), and 15-HETE (15-hydroxyeicosatetraenoic acid) in LPRs may also participate in the wheal formation process [37] .Immunological MechanismsFceRI have been detected.", [["tissue", "ANATOMY", 179, 185], ["plasma", "ANATOMY", 190, 196], ["wheal", "ANATOMY", 424, 429], ["urticaria", "DISEASE", 85, 94], ["histamine", "CHEMICAL", 273, 282], ["15-HETE", "CHEMICAL", 346, 353], ["15-hydroxyeicosatetraenoic acid", "CHEMICAL", 355, 386], ["histamine", "CHEMICAL", 273, 282], ["15-HETE", "CHEMICAL", 346, 353], ["15-hydroxyeicosatetraenoic acid", "CHEMICAL", 355, 386], ["Cryoglobulins", "GENE_OR_GENE_PRODUCT", 0, 13], ["hemolysins", "GENE_OR_GENE_PRODUCT", 20, 30], ["cryofibrinogen", "SIMPLE_CHEMICAL", 35, 49], ["MechanismsSerotonin chemotactic factors", "GENE_OR_GENE_PRODUCT", 115, 154], ["kinins", "GENE_OR_GENE_PRODUCT", 156, 162], ["tissue", "TISSUE", 179, 185], ["plasma", "ORGANISM_SUBSTANCE", 190, 196], ["kininogen", "GENE_OR_GENE_PRODUCT", 197, 206], ["histamine", "SIMPLE_CHEMICAL", 273, 282], ["MIF", "GENE_OR_GENE_PRODUCT", 287, 290], ["monocyte-macrophage migration inhibiting factor", "GENE_OR_GENE_PRODUCT", 292, 339], ["15-HETE", "SIMPLE_CHEMICAL", 346, 353], ["15-hydroxyeicosatetraenoic acid", "SIMPLE_CHEMICAL", 355, 386], ["LPRs", "SIMPLE_CHEMICAL", 391, 395], ["wheal", "PATHOLOGICAL_FORMATION", 424, 429], ["Cryoglobulins", "PROTEIN", 0, 13], ["cold hemolysins", "PROTEIN", 15, 30], ["Immunological MechanismsSerotonin chemotactic factors", "PROTEIN", 101, 154], ["plasma kininogen", "PROTEIN", 190, 206], ["MIF", "PROTEIN", 287, 290], ["macrophage migration inhibiting factor", "PROTEIN", 301, 339], ["MechanismsFceRI", "PROTEIN", 468, 483], ["Cryoglobulins", "TEST", 0, 13], ["cold hemolysins", "TEST", 15, 30], ["cryofibrinogen", "TREATMENT", 35, 49], ["cold urticaria", "PROBLEM", 80, 94], ["Immunological MechanismsSerotonin chemotactic factors", "PROBLEM", 101, 154], ["derivatives of tissue", "PROBLEM", 164, 185], ["plasma kininogen", "TEST", 190, 206], ["an inflammatory action", "PROBLEM", 212, 234], ["histamine", "TEST", 273, 282], ["MIF", "TEST", 287, 290], ["monocyte", "TEST", 292, 300], ["HETE", "TEST", 349, 353], ["the wheal formation process", "PROBLEM", 420, 447], ["Immunological MechanismsFceRI", "PROBLEM", 454, 483], ["cold hemolysins", "OBSERVATION_MODIFIER", 15, 30], ["cold urticaria", "OBSERVATION", 80, 94], ["inflammatory", "OBSERVATION", 215, 227]]], ["These Aabs selectively directed against the receptor a subunit are of the IgG 1 or IgG 3 subclass and effectively fix complement and in the absence of IgE induce basophil and mast cell histamine release in both instances [92] .", [["basophil", "ANATOMY", 162, 170], ["mast cell", "ANATOMY", 175, 184], ["histamine", "CHEMICAL", 185, 194], ["histamine", "CHEMICAL", 185, 194], ["Aabs", "GENE_OR_GENE_PRODUCT", 6, 10], ["IgG 1", "GENE_OR_GENE_PRODUCT", 74, 79], ["IgG 3", "GENE_OR_GENE_PRODUCT", 83, 88], ["IgE", "GENE_OR_GENE_PRODUCT", 151, 154], ["basophil", "CELL", 162, 170], ["mast cell", "CELL", 175, 184], ["histamine", "SIMPLE_CHEMICAL", 185, 194], ["Aabs", "PROTEIN", 6, 10], ["IgG 1", "PROTEIN", 74, 79], ["IgG 3 subclass", "PROTEIN", 83, 97], ["IgE", "PROTEIN", 151, 154], ["the IgG", "TEST", 70, 77], ["IgE induce basophil", "TREATMENT", 151, 170], ["mast cell histamine release", "TREATMENT", 175, 202], ["mast cell", "OBSERVATION", 175, 184]]], ["The number of mast cells is not significantly different compared to controls, so the histamine increase may be due to circulating basophils recruited into skin lesions [194] .", [["mast cells", "ANATOMY", 14, 24], ["basophils", "ANATOMY", 130, 139], ["skin lesions", "ANATOMY", 155, 167], ["histamine", "CHEMICAL", 85, 94], ["histamine", "CHEMICAL", 85, 94], ["mast cells", "CELL", 14, 24], ["histamine", "SIMPLE_CHEMICAL", 85, 94], ["basophils", "CELL", 130, 139], ["skin", "ORGAN", 155, 159], ["mast cells", "CELL_TYPE", 14, 24], ["circulating basophils", "CELL_TYPE", 118, 139], ["mast cells", "PROBLEM", 14, 24], ["the histamine increase", "PROBLEM", 81, 103], ["circulating basophils", "PROBLEM", 118, 139], ["skin lesions", "PROBLEM", 155, 167], ["mast cells", "OBSERVATION", 14, 24], ["not significantly different", "OBSERVATION_MODIFIER", 28, 55], ["may be due to", "UNCERTAINTY", 104, 117], ["circulating basophils", "OBSERVATION", 118, 139], ["skin", "ANATOMY", 155, 159], ["lesions", "OBSERVATION", 160, 167]]], ["Moreover, the serum of \u226460% of patients reacting with basophils of healthy donors stimulated in vitro basophil releasability [88, 89, 92] .", [["serum", "ANATOMY", 14, 19], ["basophils", "ANATOMY", 54, 63], ["basophil", "ANATOMY", 102, 110], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["patients", "ORGANISM", 31, 39], ["basophils", "CELL", 54, 63], ["donors", "ORGANISM", 75, 81], ["basophil", "CELL", 102, 110], ["basophils", "CELL_TYPE", 54, 63], ["patients", "SPECIES", 31, 39], ["the serum", "TEST", 10, 19], ["vitro basophil releasability", "TEST", 96, 124]]], ["Consequently, cross-linkage of Aab IgG to FceRI is a pathogenic mechanism peculiar to chronic urticaria, which operates by stimulating or facilitating metachromatic cell degranulation [88] with consequent histamine release [67] .", [["metachromatic cell", "ANATOMY", 151, 169], ["urticaria", "DISEASE", 94, 103], ["histamine", "CHEMICAL", 205, 214], ["histamine", "CHEMICAL", 205, 214], ["Aab IgG", "GENE_OR_GENE_PRODUCT", 31, 38], ["FceRI", "GENE_OR_GENE_PRODUCT", 42, 47], ["metachromatic cell", "CELL", 151, 169], ["histamine", "SIMPLE_CHEMICAL", 205, 214], ["Aab IgG", "PROTEIN", 31, 38], ["FceRI", "PROTEIN", 42, 47], ["Aab IgG", "TREATMENT", 31, 38], ["a pathogenic mechanism", "PROBLEM", 51, 73], ["chronic urticaria", "PROBLEM", 86, 103], ["metachromatic cell degranulation", "PROBLEM", 151, 183], ["consequent histamine release", "TREATMENT", 194, 222], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["urticaria", "OBSERVATION", 94, 103], ["metachromatic cell degranulation", "OBSERVATION", 151, 183]]], ["Such Aabs could correspond to HRFs with molecular weight (MW) >100 kD, equally provided with IgG anti-IgE Aabs able to interact with IgE [252] .", [["Aabs", "ANATOMY", 5, 9], ["Aabs", "GENE_OR_GENE_PRODUCT", 5, 9], ["IgG anti-IgE", "GENE_OR_GENE_PRODUCT", 93, 105], ["IgE", "GENE_OR_GENE_PRODUCT", 133, 136], ["Aabs", "PROTEIN", 5, 9], ["HRFs", "PROTEIN", 30, 34], ["IgG anti", "PROTEIN", 93, 101], ["IgE", "PROTEIN", 102, 105], ["Aabs", "PROTEIN", 106, 110], ["IgE", "PROTEIN", 133, 136], ["HRFs", "TEST", 30, 34], ["molecular weight", "TEST", 40, 56], ["IgG anti", "TREATMENT", 93, 101]]], ["These data explain why some patients suffer from severe and ongoing symptoms [89] .", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["severe and ongoing symptoms", "PROBLEM", 49, 76], ["severe", "OBSERVATION_MODIFIER", 49, 55]]], ["Basophil histamine release plays a significantly pathogenic role because basophils, when stimulated with anti-IgE that interact with IgE present on basophils, release less histamine [249] , even if the levels are variable between subjects [88, 252] .", [["Basophil", "ANATOMY", 0, 8], ["basophils", "ANATOMY", 73, 82], ["basophils", "ANATOMY", 148, 157], ["histamine", "CHEMICAL", 9, 18], ["histamine", "CHEMICAL", 172, 181], ["histamine", "CHEMICAL", 9, 18], ["histamine", "CHEMICAL", 172, 181], ["Basophil histamine", "GENE_OR_GENE_PRODUCT", 0, 18], ["basophils", "CELL", 73, 82], ["anti-IgE", "GENE_OR_GENE_PRODUCT", 105, 113], ["IgE", "GENE_OR_GENE_PRODUCT", 133, 136], ["basophils", "CELL", 148, 157], ["basophils", "CELL_TYPE", 73, 82], ["anti-IgE", "PROTEIN", 105, 113], ["IgE", "PROTEIN", 133, 136], ["basophils", "CELL_TYPE", 148, 157], ["Basophil histamine release", "TREATMENT", 0, 26], ["anti-IgE", "TREATMENT", 105, 113], ["basophils", "TREATMENT", 148, 157], ["the levels", "TEST", 198, 208]]], ["The easy basophil degranulability acts as an opening key to the gaps between endothelial cells, which allows allergen and CIC to break into the perivascular tissue [225] .", [["basophil", "ANATOMY", 9, 17], ["endothelial cells", "ANATOMY", 77, 94], ["perivascular tissue", "ANATOMY", 144, 163], ["basophil", "CELL", 9, 17], ["endothelial cells", "CELL", 77, 94], ["CIC", "GENE_OR_GENE_PRODUCT", 122, 125], ["perivascular tissue", "TISSUE", 144, 163], ["endothelial cells", "CELL_TYPE", 77, 94], ["CIC", "PROTEIN", 122, 125], ["endothelial cells", "PROBLEM", 77, 94], ["CIC", "TREATMENT", 122, 125], ["basophil degranulability", "OBSERVATION", 9, 33], ["endothelial cells", "ANATOMY", 77, 94], ["perivascular tissue", "ANATOMY", 144, 163]]], ["The skin histamine content and its releasability are increased in vivo during active disease and in remission.", [["skin", "ANATOMY", 4, 8], ["histamine", "CHEMICAL", 9, 18], ["histamine", "CHEMICAL", 9, 18], ["skin", "ORGAN", 4, 8], ["The skin histamine content", "TREATMENT", 0, 26], ["active disease", "PROBLEM", 78, 92], ["skin", "ANATOMY", 4, 8], ["histamine content", "OBSERVATION", 9, 26], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["active", "OBSERVATION_MODIFIER", 78, 84], ["disease", "OBSERVATION", 85, 92]]], ["Mast cell release following an allergen challenge is not different between patients with chronic urticaria and normal controls [67] .", [["Mast cell", "ANATOMY", 0, 9], ["urticaria", "DISEASE", 97, 106], ["Mast cell", "CELL", 0, 9], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["Mast cell release", "TREATMENT", 0, 17], ["an allergen challenge", "TREATMENT", 28, 49], ["chronic urticaria", "PROBLEM", 89, 106], ["chronic", "OBSERVATION_MODIFIER", 89, 96], ["urticaria", "OBSERVATION", 97, 106]]], ["Therefore, the histamine level increment could depend on a transient functional imbalance more than on an intrinsic mast cell defect [194] .", [["mast cell", "ANATOMY", 116, 125], ["histamine", "CHEMICAL", 15, 24], ["histamine", "CHEMICAL", 15, 24], ["histamine", "SIMPLE_CHEMICAL", 15, 24], ["mast cell", "CELL", 116, 125], ["the histamine level increment", "PROBLEM", 11, 40], ["a transient functional imbalance", "PROBLEM", 57, 89], ["an intrinsic mast cell defect", "PROBLEM", 103, 132], ["mast cell defect", "OBSERVATION", 116, 132]]], ["To reconcile apparently conflicting data, we should admit that histamine may derive from mast cell nonimmunological stimulation.Immunological MechanismsAlthough eosinophils are not the most prominent cell type found in urticarial lesions, several eosinophil-derived mediators, including EDN (eosinophil-derived neurotoxin) and MBP (major basic protein) have been detected in late-phase reactions (LPR) in chronic urticaria between 2 and 5 h after allergen challenge [251] .", [["mast cell", "ANATOMY", 89, 98], ["eosinophils", "ANATOMY", 161, 172], ["cell", "ANATOMY", 200, 204], ["urticarial lesions", "ANATOMY", 219, 237], ["eosinophil", "ANATOMY", 247, 257], ["histamine", "CHEMICAL", 63, 72], ["urticarial lesions", "DISEASE", 219, 237], ["urticaria", "DISEASE", 413, 422], ["histamine", "CHEMICAL", 63, 72], ["histamine", "SIMPLE_CHEMICAL", 63, 72], ["mast cell", "CELL", 89, 98], ["eosinophils", "CELL", 161, 172], ["cell type", "CELL", 200, 209], ["urticarial lesions", "PATHOLOGICAL_FORMATION", 219, 237], ["eosinophil", "CELL", 247, 257], ["EDN", "GENE_OR_GENE_PRODUCT", 287, 290], ["eosinophil-derived neurotoxin", "GENE_OR_GENE_PRODUCT", 292, 321], ["MBP", "GENE_OR_GENE_PRODUCT", 327, 330], ["Immunological MechanismsAlthough eosinophils", "CELL_TYPE", 128, 172], ["eosinophil", "CELL_TYPE", 247, 257], ["EDN", "PROTEIN", 287, 290], ["eosinophil", "CELL_TYPE", 292, 302], ["MBP", "PROTEIN", 327, 330], ["major basic protein", "PROTEIN", 332, 351], ["histamine", "TREATMENT", 63, 72], ["mast cell nonimmunological stimulation", "TREATMENT", 89, 127], ["urticarial lesions", "PROBLEM", 219, 237], ["several eosinophil", "TEST", 239, 257], ["EDN", "TEST", 287, 290], ["eosinophil", "TEST", 292, 302], ["neurotoxin", "TEST", 311, 321], ["MBP", "TEST", 327, 330], ["chronic urticaria", "PROBLEM", 405, 422], ["mast cell", "OBSERVATION", 89, 98], ["most prominent", "OBSERVATION_MODIFIER", 185, 199], ["cell type", "OBSERVATION", 200, 209], ["urticarial", "ANATOMY", 219, 229], ["lesions", "OBSERVATION", 230, 237], ["chronic", "OBSERVATION_MODIFIER", 405, 412], ["urticaria", "OBSERVATION", 413, 422]]], ["These cationic proteins have been shown to elicit wheal and flare when directly injected into the skin.", [["skin", "ANATOMY", 98, 102], ["wheal", "PATHOLOGICAL_FORMATION", 50, 55], ["skin", "ORGAN", 98, 102], ["cationic proteins", "PROTEIN", 6, 23], ["These cationic proteins", "TREATMENT", 0, 23], ["flare", "PROBLEM", 60, 65], ["flare", "OBSERVATION", 60, 65], ["skin", "ANATOMY", 98, 102]]], ["Eosinophils may also comprise a part of the inflammatory cell infiltrate, along with neutrophils, in DPU and solar urticaria [121] .", [["Eosinophils", "ANATOMY", 0, 11], ["inflammatory cell", "ANATOMY", 44, 61], ["neutrophils", "ANATOMY", 85, 96], ["urticaria", "DISEASE", 115, 124], ["Eosinophils", "CELL", 0, 11], ["inflammatory cell", "CELL", 44, 61], ["neutrophils", "CELL", 85, 96], ["Eosinophils", "CELL_TYPE", 0, 11], ["neutrophils", "CELL_TYPE", 85, 96], ["Eosinophils", "TEST", 0, 11], ["the inflammatory cell infiltrate", "PROBLEM", 40, 72], ["neutrophils", "TEST", 85, 96], ["solar urticaria", "PROBLEM", 109, 124], ["inflammatory", "OBSERVATION_MODIFIER", 44, 56], ["cell", "OBSERVATION", 57, 61], ["infiltrate", "OBSERVATION", 62, 72], ["solar urticaria", "OBSERVATION", 109, 124]]], ["Moreover, eosinophils are major LTC 4 producers in allergic inflammation [103] .Immunological MechanismsHistamine plays a central role in urticarial lesions by increasing vascular permeability and intensely itching wheals on clinical grounds [231] .", [["eosinophils", "ANATOMY", 10, 21], ["urticarial lesions", "ANATOMY", 138, 156], ["vascular", "ANATOMY", 171, 179], ["allergic inflammation", "DISEASE", 51, 72], ["MechanismsHistamine", "CHEMICAL", 94, 113], ["eosinophils", "CELL", 10, 21], ["MechanismsHistamine", "GENE_OR_GENE_PRODUCT", 94, 113], ["urticarial lesions", "PATHOLOGICAL_FORMATION", 138, 156], ["vascular", "MULTI-TISSUE_STRUCTURE", 171, 179], ["eosinophils", "CELL_TYPE", 10, 21], ["eosinophils", "TEST", 10, 21], ["allergic inflammation", "PROBLEM", 51, 72], ["urticarial lesions", "PROBLEM", 138, 156], ["increasing vascular permeability", "PROBLEM", 160, 192], ["intensely itching wheals", "PROBLEM", 197, 221], ["eosinophils", "OBSERVATION", 10, 21], ["allergic inflammation", "OBSERVATION", 51, 72], ["central", "OBSERVATION_MODIFIER", 122, 129], ["urticarial", "OBSERVATION_MODIFIER", 138, 148], ["lesions", "OBSERVATION", 149, 156], ["increasing", "OBSERVATION_MODIFIER", 160, 170], ["vascular", "ANATOMY", 171, 179], ["permeability", "OBSERVATION_MODIFIER", 180, 192]]], ["The classic Lewis triple responses (Fig. 8.3) , produced by subcutaneous histamine injection or by gentle stroking with a smooth object, are paradigmatic of what occurs in urticaria linear erythema; flare and wheal are due, respectively, to vasodilatory (H 1 and H 2 action) and vasopermeability (H 1 action) histamine action, to which is added (for the Immunohistopathology Urticaria is histologically characterized by dilation of venules and capillaries, tissular edema and a predominant perivascular infiltrate, of variable composition and intensity.", [["subcutaneous", "ANATOMY", 60, 72], ["smooth object", "ANATOMY", 122, 135], ["venules", "ANATOMY", 432, 439], ["capillaries", "ANATOMY", 444, 455], ["tissular edema", "ANATOMY", 457, 471], ["perivascular infiltrate", "ANATOMY", 490, 513], ["histamine", "CHEMICAL", 73, 82], ["urticaria", "DISEASE", 172, 181], ["erythema", "DISEASE", 189, 197], ["histamine", "CHEMICAL", 309, 318], ["Urticaria", "DISEASE", 375, 384], ["tissular edema", "DISEASE", 457, 471], ["histamine", "CHEMICAL", 73, 82], ["histamine", "CHEMICAL", 309, 318], ["histamine", "SIMPLE_CHEMICAL", 73, 82], ["H 1", "GENE_OR_GENE_PRODUCT", 255, 258], ["H 2", "GENE_OR_GENE_PRODUCT", 263, 266], ["H 1", "GENE_OR_GENE_PRODUCT", 297, 300], ["histamine", "SIMPLE_CHEMICAL", 309, 318], ["venules", "MULTI-TISSUE_STRUCTURE", 432, 439], ["capillaries", "TISSUE", 444, 455], ["tissular edema", "PATHOLOGICAL_FORMATION", 457, 471], ["perivascular infiltrate", "TISSUE", 490, 513], ["Fig.", "TEST", 36, 40], ["subcutaneous histamine injection", "TREATMENT", 60, 92], ["urticaria linear erythema", "PROBLEM", 172, 197], ["flare and wheal", "PROBLEM", 199, 214], ["vasopermeability (H 1 action", "TREATMENT", 279, 307], ["histamine action", "TREATMENT", 309, 325], ["the Immunohistopathology Urticaria", "PROBLEM", 350, 384], ["dilation of venules and capillaries", "PROBLEM", 420, 455], ["tissular edema", "PROBLEM", 457, 471], ["a predominant perivascular infiltrate", "PROBLEM", 476, 513], ["smooth object", "OBSERVATION", 122, 135], ["urticaria", "OBSERVATION_MODIFIER", 172, 181], ["linear", "OBSERVATION_MODIFIER", 182, 188], ["erythema", "OBSERVATION", 189, 197], ["flare", "OBSERVATION", 199, 204], ["dilation", "OBSERVATION", 420, 428], ["venules", "ANATOMY", 432, 439], ["capillaries", "ANATOMY", 444, 455], ["tissular", "ANATOMY", 457, 465], ["edema", "OBSERVATION", 466, 471], ["predominant", "OBSERVATION_MODIFIER", 478, 489], ["perivascular", "ANATOMY_MODIFIER", 490, 502], ["infiltrate", "OBSERVATION", 503, 513], ["variable composition", "OBSERVATION_MODIFIER", 518, 538], ["intensity", "OBSERVATION_MODIFIER", 543, 552]]], ["The histological peculiarity of urticarial wheals is common to all types, independently of etiology; mast cells and related mediators are the cornerstone of the lesions [166] .", [["urticarial wheals", "ANATOMY", 32, 49], ["mast cells", "ANATOMY", 101, 111], ["lesions", "ANATOMY", 161, 168], ["urticarial wheals", "DISEASE", 32, 49], ["mast cells", "CELL", 101, 111], ["lesions", "PATHOLOGICAL_FORMATION", 161, 168], ["mast cells", "CELL_TYPE", 101, 111], ["urticarial wheals", "PROBLEM", 32, 49], ["mast cells", "PROBLEM", 101, 111], ["urticarial", "OBSERVATION_MODIFIER", 32, 42], ["wheals", "OBSERVATION", 43, 49], ["all types", "OBSERVATION_MODIFIER", 63, 72], ["mast cells", "OBSERVATION", 101, 111], ["lesions", "OBSERVATION", 161, 168]]], ["The more evident alteration is the dermal edema with vascular turgor, secondary to an increased size of endothelial cells: edema and infiltrate preferentially involve the dermal deeper strata, extending in certain cases to subcutaneous tissues, where flushing and itching stimuli are lacking because of the scarcity of capillary bed and nerve endings.", [["dermal edema", "ANATOMY", 35, 47], ["vascular", "ANATOMY", 53, 61], ["endothelial cells", "ANATOMY", 104, 121], ["edema", "ANATOMY", 123, 128], ["dermal", "ANATOMY", 171, 177], ["subcutaneous tissues", "ANATOMY", 223, 243], ["capillary bed", "ANATOMY", 319, 332], ["nerve endings", "ANATOMY", 337, 350], ["edema", "DISEASE", 42, 47], ["edema", "DISEASE", 123, 128], ["flushing", "DISEASE", 251, 259], ["itching", "DISEASE", 264, 271], ["dermal edema", "PATHOLOGICAL_FORMATION", 35, 47], ["vascular", "MULTI-TISSUE_STRUCTURE", 53, 61], ["endothelial cells", "CELL", 104, 121], ["edema", "PATHOLOGICAL_FORMATION", 123, 128], ["dermal", "TISSUE", 171, 177], ["subcutaneous tissues", "TISSUE", 223, 243], ["capillary bed", "TISSUE", 319, 332], ["nerve endings", "MULTI-TISSUE_STRUCTURE", 337, 350], ["endothelial cells", "CELL_TYPE", 104, 121], ["the dermal edema", "PROBLEM", 31, 47], ["vascular turgor", "PROBLEM", 53, 68], ["an increased size of endothelial cells", "PROBLEM", 83, 121], ["edema", "PROBLEM", 123, 128], ["infiltrate", "PROBLEM", 133, 143], ["the dermal deeper strata", "PROBLEM", 167, 191], ["flushing", "PROBLEM", 251, 259], ["itching stimuli", "PROBLEM", 264, 279], ["more evident", "OBSERVATION_MODIFIER", 4, 16], ["alteration", "OBSERVATION", 17, 27], ["dermal", "OBSERVATION_MODIFIER", 35, 41], ["edema", "OBSERVATION", 42, 47], ["vascular", "ANATOMY", 53, 61], ["turgor", "OBSERVATION", 62, 68], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["size", "OBSERVATION_MODIFIER", 96, 100], ["endothelial cells", "OBSERVATION", 104, 121], ["edema", "OBSERVATION", 123, 128], ["infiltrate", "OBSERVATION", 133, 143], ["dermal", "OBSERVATION_MODIFIER", 171, 177], ["deeper", "OBSERVATION_MODIFIER", 178, 184], ["strata", "OBSERVATION_MODIFIER", 185, 191], ["subcutaneous tissues", "ANATOMY", 223, 243], ["flushing", "OBSERVATION_MODIFIER", 251, 259], ["itching", "OBSERVATION", 264, 271], ["capillary bed", "ANATOMY", 319, 332], ["nerve", "ANATOMY", 337, 342]]], ["The perivascular cell infiltrate is represented, especially in chronic forms, by T-activated lymphocytes, monocytes, eosinophils and mast cells; the clear-cut prevalence of neutrophils is characteristic.", [["perivascular cell", "ANATOMY", 4, 21], ["lymphocytes", "ANATOMY", 93, 104], ["monocytes", "ANATOMY", 106, 115], ["eosinophils", "ANATOMY", 117, 128], ["mast cells", "ANATOMY", 133, 143], ["neutrophils", "ANATOMY", 173, 184], ["perivascular cell", "CELL", 4, 21], ["T", "CELL", 81, 82], ["lymphocytes", "CELL", 93, 104], ["monocytes", "CELL", 106, 115], ["eosinophils", "CELL", 117, 128], ["mast cells", "CELL", 133, 143], ["neutrophils", "CELL", 173, 184], ["T-activated lymphocytes", "CELL_TYPE", 81, 104], ["monocytes", "CELL_TYPE", 106, 115], ["eosinophils", "CELL_TYPE", 117, 128], ["mast cells", "CELL_TYPE", 133, 143], ["neutrophils", "CELL_TYPE", 173, 184], ["The perivascular cell infiltrate", "PROBLEM", 0, 32], ["T-activated lymphocytes", "TEST", 81, 104], ["monocytes", "TEST", 106, 115], ["eosinophils", "TEST", 117, 128], ["mast cells", "TEST", 133, 143], ["perivascular cell", "OBSERVATION", 4, 21], ["infiltrate", "OBSERVATION", 22, 32], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["mast cells", "OBSERVATION", 133, 143], ["clear", "OBSERVATION_MODIFIER", 149, 154], ["-cut", "OBSERVATION_MODIFIER", 154, 158], ["neutrophils", "OBSERVATION", 173, 184]]], ["Activated T cells are predominant compared to all other cells, followed by mast cells and both B lymphocytes; NK cells are absent [117] .", [["T cells", "ANATOMY", 10, 17], ["cells", "ANATOMY", 56, 61], ["mast cells", "ANATOMY", 75, 85], ["B lymphocytes", "ANATOMY", 95, 108], ["NK cells", "ANATOMY", 110, 118], ["T cells", "CELL", 10, 17], ["cells", "CELL", 56, 61], ["mast cells", "CELL", 75, 85], ["B lymphocytes", "CELL", 95, 108], ["NK cells", "CELL", 110, 118], ["Activated T cells", "CELL_TYPE", 0, 17], ["mast cells", "CELL_TYPE", 75, 85], ["B lymphocytes", "CELL_TYPE", 95, 108], ["NK cells", "CELL_TYPE", 110, 118], ["Activated T cells", "PROBLEM", 0, 17], ["mast cells", "TEST", 75, 85], ["both B lymphocytes", "TEST", 90, 108], ["NK cells", "TEST", 110, 118], ["mast cells", "OBSERVATION", 75, 85], ["lymphocytes", "ANATOMY", 97, 108], ["NK cells", "OBSERVATION", 110, 118]]], ["Since this pathology involves the vascular compartment, the etiological agents more frequently responsible are internally transported.", [["vascular compartment", "ANATOMY", 34, 54], ["vascular compartment", "MULTI-TISSUE_STRUCTURE", 34, 54], ["vascular compartment", "ANATOMY", 34, 54]]], ["In immune processes persistent for >30 min, numerous leukocytes are active, among which neutrophils are disposed between the walls of capillary and post-capillary venules which, if their number increases, may lead to urticarial vasculitis more frequently associated with chronic forms [89] .", [["leukocytes", "ANATOMY", 53, 63], ["neutrophils", "ANATOMY", 88, 99], ["walls", "ANATOMY", 125, 130], ["capillary", "ANATOMY", 134, 143], ["post-capillary venules", "ANATOMY", 148, 170], ["vasculitis", "DISEASE", 228, 238], ["leukocytes", "CELL", 53, 63], ["neutrophils", "CELL", 88, 99], ["capillary", "TISSUE", 134, 143], ["post-capillary venules", "TISSUE", 148, 170], ["leukocytes", "CELL_TYPE", 53, 63], ["neutrophils", "CELL_TYPE", 88, 99], ["numerous leukocytes", "PROBLEM", 44, 63], ["urticarial vasculitis", "PROBLEM", 217, 238], ["persistent", "OBSERVATION_MODIFIER", 20, 30], ["numerous", "OBSERVATION_MODIFIER", 44, 52], ["leukocytes", "OBSERVATION", 53, 63], ["active", "OBSERVATION_MODIFIER", 68, 74], ["walls", "ANATOMY_MODIFIER", 125, 130], ["capillary", "ANATOMY_MODIFIER", 134, 143], ["post-capillary venules", "ANATOMY", 148, 170], ["urticarial", "OBSERVATION_MODIFIER", 217, 227], ["vasculitis", "OBSERVATION", 228, 238]]], ["Eosinophils are seen more rarely, and perivascular infiltrations by lymphocytes expressing the CD4 phenotype are frequently detected [19] .", [["Eosinophils", "ANATOMY", 0, 11], ["perivascular infiltrations", "ANATOMY", 38, 64], ["lymphocytes", "ANATOMY", 68, 79], ["Eosinophils", "CELL", 0, 11], ["perivascular infiltrations", "CELLULAR_COMPONENT", 38, 64], ["lymphocytes", "CELL", 68, 79], ["CD4", "GENE_OR_GENE_PRODUCT", 95, 98], ["Eosinophils", "CELL_TYPE", 0, 11], ["lymphocytes", "CELL_TYPE", 68, 79], ["CD4", "PROTEIN", 95, 98], ["Eosinophils", "TEST", 0, 11], ["perivascular infiltrations", "PROBLEM", 38, 64], ["the CD4 phenotype", "TEST", 91, 108], ["more rarely", "OBSERVATION_MODIFIER", 21, 32], ["perivascular", "ANATOMY_MODIFIER", 38, 50], ["infiltrations", "OBSERVATION", 51, 64], ["lymphocytes", "ANATOMY", 68, 79], ["CD4 phenotype", "OBSERVATION", 95, 108]]], ["Histopathological evidence in chronic lesions is similar to what is seen in AD and ACD LPRs: vasoactive mediators and chemotactic factors recruit PBMCs, neutrophils, and eosinophils into the cutaneous microenvironment; inflammatory cells in turn stimulate mast cells to dismiss HRFs [46] .", [["chronic lesions", "ANATOMY", 30, 45], ["PBMCs", "ANATOMY", 146, 151], ["neutrophils", "ANATOMY", 153, 164], ["eosinophils", "ANATOMY", 170, 181], ["cutaneous", "ANATOMY", 191, 200], ["inflammatory cells", "ANATOMY", 219, 237], ["mast cells", "ANATOMY", 256, 266], ["AD", "DISEASE", 76, 78], ["chronic lesions", "PATHOLOGICAL_FORMATION", 30, 45], ["PBMCs", "CELL", 146, 151], ["neutrophils", "CELL", 153, 164], ["eosinophils", "CELL", 170, 181], ["inflammatory cells", "CELL", 219, 237], ["mast cells", "CELL", 256, 266], ["vasoactive mediators", "PROTEIN", 93, 113], ["chemotactic factors", "PROTEIN", 118, 137], ["PBMCs", "CELL_TYPE", 146, 151], ["neutrophils", "CELL_TYPE", 153, 164], ["eosinophils", "CELL_TYPE", 170, 181], ["inflammatory cells", "CELL_TYPE", 219, 237], ["mast cells", "CELL_TYPE", 256, 266], ["chronic lesions", "PROBLEM", 30, 45], ["vasoactive mediators", "TREATMENT", 93, 113], ["chemotactic factors", "TEST", 118, 137], ["PBMCs", "TEST", 146, 151], ["neutrophils", "TEST", 153, 164], ["eosinophils", "TEST", 170, 181], ["inflammatory cells", "PROBLEM", 219, 237], ["mast cells", "PROBLEM", 256, 266], ["HRFs", "TEST", 278, 282], ["chronic", "OBSERVATION_MODIFIER", 30, 37], ["lesions", "OBSERVATION", 38, 45], ["cutaneous", "ANATOMY", 191, 200], ["inflammatory cells", "OBSERVATION", 219, 237], ["mast cells", "OBSERVATION", 256, 266]]], ["It is tempting to speculate whether the initial stimulus comes from activated T cells or from mast cells [19, 103] .Nonimmunological MechanismsSeveral naturally occurring and exogenous nonimmunological compounds have histamine-releasing action via nonspecific mast cell activation.", [["T cells", "ANATOMY", 78, 85], ["mast cells", "ANATOMY", 94, 104], ["mast cell", "ANATOMY", 260, 269], ["histamine", "CHEMICAL", 217, 226], ["histamine", "CHEMICAL", 217, 226], ["T cells", "CELL", 78, 85], ["mast cells", "CELL", 94, 104], ["histamine", "SIMPLE_CHEMICAL", 217, 226], ["mast cell", "CELL", 260, 269], ["activated T cells", "CELL_TYPE", 68, 85], ["mast cells", "CELL_TYPE", 94, 104], ["the initial stimulus", "PROBLEM", 36, 56], ["activated T cells", "PROBLEM", 68, 85], ["mast cells", "TEST", 94, 104], ["exogenous nonimmunological compounds", "TREATMENT", 175, 211], ["histamine", "TREATMENT", 217, 226], ["nonspecific mast cell activation", "PROBLEM", 248, 280], ["mast cells", "OBSERVATION", 94, 104], ["nonspecific", "OBSERVATION_MODIFIER", 248, 259], ["mast cell activation", "OBSERVATION", 260, 280]]], ["These compounds include (Table 8 .1) ASA (acetylsalicylic acid), which, in common with NSAIDs (nonsteroidal anti-inflammatory drugs), generally inhibits the cyclooxygenase pathway, resulting in derailment of the arachidonic acid pathway towards LT production ( Fig. 1.57) .", [["ASA", "CHEMICAL", 37, 40], ["acetylsalicylic acid", "CHEMICAL", 42, 62], ["NSAIDs", "CHEMICAL", 87, 93], ["arachidonic acid", "CHEMICAL", 212, 228], ["ASA", "CHEMICAL", 37, 40], ["acetylsalicylic acid", "CHEMICAL", 42, 62], ["arachidonic acid", "CHEMICAL", 212, 228], ["(Table 8 .1) ASA", "SIMPLE_CHEMICAL", 24, 40], ["acetylsalicylic acid", "SIMPLE_CHEMICAL", 42, 62], ["NSAIDs", "SIMPLE_CHEMICAL", 87, 93], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 95, 131], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 157, 171], ["arachidonic acid", "SIMPLE_CHEMICAL", 212, 228], ["LT", "SIMPLE_CHEMICAL", 245, 247], ["cyclooxygenase", "PROTEIN", 157, 171], ["LT", "PROTEIN", 245, 247], ["ASA (acetylsalicylic acid", "TREATMENT", 37, 62], ["NSAIDs (nonsteroidal anti-inflammatory drugs", "TREATMENT", 87, 131], ["the cyclooxygenase pathway", "TREATMENT", 153, 179], ["the arachidonic acid pathway", "TEST", 208, 236], ["arachidonic acid", "OBSERVATION", 212, 228]]], ["These drugs have a short half-life; thus possible plasma increments are sporadically detected, unlike in patients with mastocytosis or urticaria pigmentosa, who are primarily susceptible because of an increased skin mast cell population [61] .", [["plasma", "ANATOMY", 50, 56], ["skin mast cell", "ANATOMY", 211, 225], ["mastocytosis", "DISEASE", 119, 131], ["urticaria pigmentosa", "DISEASE", 135, 155], ["plasma", "ORGANISM_SUBSTANCE", 50, 56], ["patients", "ORGANISM", 105, 113], ["skin mast cell", "CELL", 211, 225], ["patients", "SPECIES", 105, 113], ["These drugs", "TREATMENT", 0, 11], ["plasma increments", "PROBLEM", 50, 67], ["mastocytosis", "PROBLEM", 119, 131], ["urticaria pigmentosa", "PROBLEM", 135, 155], ["an increased skin mast cell population", "PROBLEM", 198, 236], ["mastocytosis", "OBSERVATION", 119, 131], ["urticaria pigmentosa", "OBSERVATION", 135, 155], ["increased", "OBSERVATION_MODIFIER", 201, 210], ["skin", "ANATOMY", 211, 215], ["mast cell population", "OBSERVATION", 216, 236]]], ["Nonimmunological activation has been demonstrated in several types of idiopathic, heat-and cold-induced, cholinergic, etc. urticaria [60] , which respond to H 1 anti-histamines in the absence of allergens [44] .", [["urticaria", "DISEASE", 123, 132], ["H 1 anti-histamines", "CHEMICAL", 157, 176], ["H 1", "CHEMICAL", 157, 160], ["H 1 anti-histamines", "SIMPLE_CHEMICAL", 157, 176], ["Nonimmunological activation", "PROBLEM", 0, 27], ["idiopathic, heat", "PROBLEM", 70, 86], ["urticaria", "PROBLEM", 123, 132], ["several types", "OBSERVATION_MODIFIER", 53, 66], ["idiopathic", "OBSERVATION", 70, 80]]], ["Urticaria may be caused by a host of agents, including detergents, foods, and endogenous peptides such as endorphins, neuropeptides or tachykinins [131] ; but compound 48/80 and codeine cause histamine release only in the skin mast cell [45] .", [["skin mast cell", "ANATOMY", 222, 236], ["Urticaria", "DISEASE", 0, 9], ["compound 48/80", "CHEMICAL", 159, 173], ["codeine", "CHEMICAL", 178, 185], ["histamine", "CHEMICAL", 192, 201], ["codeine", "CHEMICAL", 178, 185], ["histamine", "CHEMICAL", 192, 201], ["endorphins", "GENE_OR_GENE_PRODUCT", 106, 116], ["neuropeptides", "GENE_OR_GENE_PRODUCT", 118, 131], ["tachykinins [131]", "SIMPLE_CHEMICAL", 135, 152], ["compound 48/80", "SIMPLE_CHEMICAL", 159, 173], ["codeine", "SIMPLE_CHEMICAL", 178, 185], ["histamine", "SIMPLE_CHEMICAL", 192, 201], ["skin mast cell", "CELL", 222, 236], ["skin mast cell", "CELL_TYPE", 222, 236], ["Urticaria", "PROBLEM", 0, 9], ["detergents", "TREATMENT", 55, 65], ["endogenous peptides", "PROBLEM", 78, 97], ["endorphins", "PROBLEM", 106, 116], ["tachykinins", "PROBLEM", 135, 146], ["codeine", "TREATMENT", 178, 185], ["histamine release", "PROBLEM", 192, 209], ["skin", "ANATOMY", 222, 226], ["mast cell", "OBSERVATION", 227, 236]]], ["Likewise, physical stimuli may act on peripheral skin nociceptors, thus inducing neuropeptide release.", [["skin", "ANATOMY", 49, 53], ["skin", "ORGAN", 49, 53], ["neuropeptide", "GENE_OR_GENE_PRODUCT", 81, 93], ["physical stimuli", "TEST", 10, 26], ["peripheral skin nociceptors", "TREATMENT", 38, 65], ["skin nociceptors", "ANATOMY", 49, 65]]], ["Experimental evidence demonstrates that SP has a vaso-permeabilizing effect on epithelial cells.", [["epithelial cells", "ANATOMY", 79, 95], ["SP", "CHEMICAL", 40, 42], ["SP", "SIMPLE_CHEMICAL", 40, 42], ["epithelial cells", "CELL", 79, 95], ["SP", "PROTEIN", 40, 42], ["epithelial cells", "CELL_TYPE", 79, 95], ["a vaso", "TREATMENT", 47, 53], ["epithelial cells", "PROBLEM", 79, 95], ["epithelial cells", "OBSERVATION", 79, 95]]], ["Tachykinin release into the skin may explain the functional aspects of several types of physical urticaria and the lack of response to anti-histamines and corticosteroids (CSs) [225] .Nonimmunological MechanismsNonimmunological mechanisms activating mast cells should be re-examined in light of the new acquisitions on neuropeptides, and interactions between the peptidergic nervous system and immunocompetent leukocytes, thus suggesting that mast cells fall in the neuroimmunological axis.", [["skin", "ANATOMY", 28, 32], ["mast cells", "ANATOMY", 250, 260], ["peptidergic nervous system", "ANATOMY", 363, 389], ["leukocytes", "ANATOMY", 410, 420], ["mast cells", "ANATOMY", 443, 453], ["Tachykinin", "CHEMICAL", 0, 10], ["urticaria", "DISEASE", 97, 106], ["anti-histamines", "CHEMICAL", 135, 150], ["corticosteroids", "CHEMICAL", 155, 170], ["Tachykinin", "CHEMICAL", 0, 10], ["anti-histamines", "CHEMICAL", 135, 150], ["corticosteroids", "CHEMICAL", 155, 170], ["Tachykinin", "GENE_OR_GENE_PRODUCT", 0, 10], ["skin", "ORGAN", 28, 32], ["anti-histamines", "SIMPLE_CHEMICAL", 135, 150], ["corticosteroids", "SIMPLE_CHEMICAL", 155, 170], ["mast cells", "CELL", 250, 260], ["peptidergic nervous system", "ANATOMICAL_SYSTEM", 363, 389], ["leukocytes", "CELL", 410, 420], ["mast cells", "CELL", 443, 453], ["mast cells", "CELL_TYPE", 250, 260], ["immunocompetent leukocytes", "CELL_TYPE", 394, 420], ["mast cells", "CELL_TYPE", 443, 453], ["Tachykinin release into the skin", "PROBLEM", 0, 32], ["physical urticaria", "PROBLEM", 88, 106], ["anti-histamines", "TREATMENT", 135, 150], ["corticosteroids", "TREATMENT", 155, 170], ["activating mast cells", "PROBLEM", 239, 260], ["the new acquisitions on neuropeptides", "PROBLEM", 295, 332], ["immunocompetent leukocytes", "PROBLEM", 394, 420], ["mast cells fall", "PROBLEM", 443, 458], ["skin", "ANATOMY", 28, 32], ["urticaria", "OBSERVATION", 97, 106], ["mast cells", "OBSERVATION", 250, 260], ["peptidergic nervous", "ANATOMY", 363, 382], ["immunocompetent leukocytes", "OBSERVATION", 394, 420], ["mast cells", "OBSERVATION", 443, 453], ["neuroimmunological axis", "ANATOMY", 466, 489]]], ["SP, NKA (neurokinin A) and CGRP (calcitonin gene-related peptide), via a retrograde axon reflex stimulating mast cells to release histamine (Chap.", [["axon", "ANATOMY", 84, 88], ["mast cells", "ANATOMY", 108, 118], ["CGRP", "CHEMICAL", 27, 31], ["calcitonin gene-related peptide", "CHEMICAL", 33, 64], ["histamine", "CHEMICAL", 130, 139], ["histamine", "CHEMICAL", 130, 139], ["SP", "GENE_OR_GENE_PRODUCT", 0, 2], ["NKA", "GENE_OR_GENE_PRODUCT", 4, 7], ["neurokinin A", "GENE_OR_GENE_PRODUCT", 9, 21], ["CGRP", "GENE_OR_GENE_PRODUCT", 27, 31], ["calcitonin gene-related peptide", "GENE_OR_GENE_PRODUCT", 33, 64], ["mast cells", "CELL", 108, 118], ["histamine", "SIMPLE_CHEMICAL", 130, 139], ["SP", "PROTEIN", 0, 2], ["mast cells", "CELL_TYPE", 108, 118], ["NKA", "PROBLEM", 4, 7], ["CGRP (calcitonin gene", "TREATMENT", 27, 48], ["a retrograde axon reflex stimulating mast cells", "TREATMENT", 71, 118], ["mast cells", "OBSERVATION", 108, 118]]], ["10), act moreover on blood vessels.", [["blood vessels", "ANATOMY", 21, 34], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 21, 34], ["blood vessels", "ANATOMY", 21, 34]]], ["Alternatively the reflex may originate from mast cells, by leading to a tachykinin antidromic stimulation [115] .", [["mast cells", "ANATOMY", 44, 54], ["tachykinin", "CHEMICAL", 72, 82], ["mast cells", "CELL", 44, 54], ["mast cells", "CELL_TYPE", 44, 54], ["the reflex", "TEST", 14, 24], ["mast cells", "PROBLEM", 44, 54], ["a tachykinin antidromic stimulation", "TREATMENT", 70, 105], ["mast cells", "OBSERVATION", 44, 54]]], ["Abnormalities of skin mast cell responses to neuropeptides may underlie pathological manifestations in several types of cutaneous urticaria, for example in patients affected with cold or heat urticaria, in areas devoid of tachykinins following application of capsaicin (stimulating SP release from sensorial termination and provoking an equal increase in vascular permeability), vascular responses to thermal challenge are reduced.", [["skin mast cell", "ANATOMY", 17, 31], ["cutaneous urticaria", "ANATOMY", 120, 139], ["vascular", "ANATOMY", 355, 363], ["vascular", "ANATOMY", 379, 387], ["cutaneous urticaria", "DISEASE", 120, 139], ["urticaria", "DISEASE", 192, 201], ["capsaicin", "CHEMICAL", 259, 268], ["capsaicin", "CHEMICAL", 259, 268], ["skin mast cell", "CELL", 17, 31], ["patients", "ORGANISM", 156, 164], ["tachykinins", "GENE_OR_GENE_PRODUCT", 222, 233], ["capsaicin", "SIMPLE_CHEMICAL", 259, 268], ["SP", "SIMPLE_CHEMICAL", 282, 284], ["vascular", "MULTI-TISSUE_STRUCTURE", 355, 363], ["vascular", "MULTI-TISSUE_STRUCTURE", 379, 387], ["SP", "PROTEIN", 282, 284], ["patients", "SPECIES", 156, 164], ["Abnormalities of skin mast cell responses", "PROBLEM", 0, 41], ["pathological manifestations", "PROBLEM", 72, 99], ["cutaneous urticaria", "PROBLEM", 120, 139], ["cold or heat urticaria", "PROBLEM", 179, 201], ["tachykinins", "PROBLEM", 222, 233], ["capsaicin (stimulating SP release", "TREATMENT", 259, 292], ["sensorial termination", "TREATMENT", 298, 319], ["an equal increase in vascular permeability", "PROBLEM", 334, 376], ["thermal challenge", "TREATMENT", 401, 418], ["skin", "ANATOMY", 17, 21], ["mast cell", "OBSERVATION", 22, 31], ["several types", "OBSERVATION_MODIFIER", 103, 116], ["cutaneous", "ANATOMY", 120, 129], ["urticaria", "OBSERVATION", 130, 139], ["urticaria", "OBSERVATION", 192, 201], ["equal", "OBSERVATION_MODIFIER", 337, 342], ["increase", "OBSERVATION_MODIFIER", 343, 351], ["vascular permeability", "ANATOMY", 355, 376], ["vascular", "ANATOMY", 379, 387]]], ["Similarly, patients with chronic urticaria show an increase in cutaneous symptoms in response to codeine.As a consequence, such mechanisms activating mast cells nonimmunologically may have great weight from a physiopathological point of view [166] , probably in several cases of chronic urticaria.Pathogenesis of Hereditary AngioedemaHereditary angioedema includes [155] : \u2211 Genetic deficiency of C1 inhibitor (C1-INH) -Hereditary angioedema type I and type II -Five other genetic syndromes \u2211 Acquired formsPathogenesis of Hereditary AngioedemaThe gene for human C1-INH is localized to chromosome 11q11-q13.1 [204] .Pathogenesis of Hereditary AngioedemaHereditary angioedema is inherited as an autosomal dominant trait with incomplete penetrance and is relatively uncommon (0.1%).", [["cutaneous", "ANATOMY", 63, 72], ["mast cells", "ANATOMY", 150, 160], ["chronic urticaria", "DISEASE", 25, 42], ["codeine", "CHEMICAL", 97, 104], ["chronic urticaria", "DISEASE", 279, 296], ["Hereditary AngioedemaHereditary angioedema", "DISEASE", 313, 355], ["C1-INH", "CHEMICAL", 411, 417], ["Hereditary angioedema", "DISEASE", 420, 441], ["Hereditary Angioedema", "DISEASE", 523, 544], ["Hereditary AngioedemaHereditary angioedema", "DISEASE", 632, 674], ["autosomal dominant trait", "DISEASE", 694, 718], ["codeine", "CHEMICAL", 97, 104], ["[155] : \u2211", "CHEMICAL", 365, 374], ["C1-INH", "CHEMICAL", 411, 417], ["patients", "ORGANISM", 11, 19], ["cutaneous", "ORGANISM_SUBDIVISION", 63, 72], ["codeine", "SIMPLE_CHEMICAL", 97, 104], ["mast cells", "CELL", 150, 160], ["[155]", "SIMPLE_CHEMICAL", 365, 370], ["human", "ORGANISM", 557, 562], ["C1-INH", "GENE_OR_GENE_PRODUCT", 563, 569], ["mast cells", "CELL_TYPE", 150, 160], ["human C1-INH", "DNA", 557, 569], ["chromosome 11q11", "DNA", 586, 602], ["patients", "SPECIES", 11, 19], ["human", "SPECIES", 557, 562], ["human", "SPECIES", 557, 562], ["chronic urticaria", "PROBLEM", 25, 42], ["cutaneous symptoms", "PROBLEM", 63, 81], ["codeine", "TREATMENT", 97, 104], ["such mechanisms activating mast cells", "PROBLEM", 123, 160], ["chronic urticaria", "PROBLEM", 279, 296], ["Hereditary AngioedemaHereditary angioedema", "PROBLEM", 313, 355], ["Genetic deficiency of C1 inhibitor", "PROBLEM", 375, 409], ["C1-INH)", "PROBLEM", 411, 418], ["Hereditary angioedema type I", "PROBLEM", 420, 448], ["type II", "PROBLEM", 453, 460], ["Five other genetic syndromes", "PROBLEM", 462, 490], ["Hereditary Angioedema", "PROBLEM", 523, 544], ["human C1-INH", "TREATMENT", 557, 569], ["Hereditary AngioedemaHereditary angioedema", "PROBLEM", 632, 674], ["an autosomal dominant trait", "PROBLEM", 691, 718], ["incomplete penetrance", "PROBLEM", 724, 745], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["urticaria", "OBSERVATION", 33, 42], ["increase", "OBSERVATION_MODIFIER", 51, 59], ["cutaneous", "ANATOMY", 63, 72], ["symptoms", "OBSERVATION", 73, 81], ["mast cells", "OBSERVATION", 150, 160], ["chronic", "OBSERVATION_MODIFIER", 279, 286], ["urticaria", "OBSERVATION", 287, 296], ["Hereditary", "OBSERVATION_MODIFIER", 313, 323], ["AngioedemaHereditary angioedema", "OBSERVATION", 324, 355], ["deficiency", "OBSERVATION", 383, 393], ["C1", "ANATOMY", 397, 399], ["angioedema", "OBSERVATION", 431, 441], ["Hereditary", "OBSERVATION_MODIFIER", 523, 533], ["Angioedema", "OBSERVATION", 534, 544], ["Hereditary", "OBSERVATION_MODIFIER", 632, 642], ["AngioedemaHereditary angioedema", "OBSERVATION", 643, 674], ["autosomal", "OBSERVATION_MODIFIER", 694, 703], ["dominant", "OBSERVATION_MODIFIER", 704, 712], ["trait", "OBSERVATION_MODIFIER", 713, 718], ["incomplete", "OBSERVATION_MODIFIER", 724, 734], ["penetrance", "OBSERVATION", 735, 745], ["relatively", "OBSERVATION_MODIFIER", 753, 763], ["uncommon", "OBSERVATION_MODIFIER", 764, 772]]], ["Type I (85% of patients) results from a complement esterase inhibitor deficiency (C1-INH), with MW of 104 kD, produced in liver, monocytes, megakaryoblasts, fibroblasts and placental cells, acting as a regulator of coagulative, fibrinolytic, inflammatory processes, etc. Owing to C1-INH deficiency, based on T-lymphocyte activation with production of interleukins (IL 1 and IL 2 R) [168] .", [["liver", "ANATOMY", 122, 127], ["monocytes", "ANATOMY", 129, 138], ["megakaryoblasts", "ANATOMY", 140, 155], ["fibroblasts", "ANATOMY", 157, 168], ["placental cells", "ANATOMY", 173, 188], ["coagulative", "ANATOMY", 215, 226], ["T-lymphocyte", "ANATOMY", 308, 320], ["Type I", "DISEASE", 0, 6], ["C1-INH", "CHEMICAL", 82, 88], ["C1-INH", "CHEMICAL", 280, 286], ["C1-INH", "CHEMICAL", 82, 88], ["C1-INH", "CHEMICAL", 280, 286], ["patients", "ORGANISM", 15, 23], ["complement esterase", "GENE_OR_GENE_PRODUCT", 40, 59], ["C1-INH", "GENE_OR_GENE_PRODUCT", 82, 88], ["liver", "ORGAN", 122, 127], ["monocytes", "CELL", 129, 138], ["megakaryoblasts", "CELL", 140, 155], ["fibroblasts", "CELL", 157, 168], ["placental cells", "CELL", 173, 188], ["C1-INH", "GENE_OR_GENE_PRODUCT", 280, 286], ["T-lymphocyte", "CELL", 308, 320], ["interleukins", "GENE_OR_GENE_PRODUCT", 351, 363], ["IL 1", "GENE_OR_GENE_PRODUCT", 365, 369], ["IL 2 R", "GENE_OR_GENE_PRODUCT", 374, 380], ["complement esterase", "PROTEIN", 40, 59], ["MW", "PROTEIN", 96, 98], ["monocytes", "CELL_TYPE", 129, 138], ["megakaryoblasts", "CELL_TYPE", 140, 155], ["fibroblasts", "CELL_TYPE", 157, 168], ["placental cells", "CELL_TYPE", 173, 188], ["interleukins", "PROTEIN", 351, 363], ["IL 1 and IL 2 R", "PROTEIN", 365, 380], ["patients", "SPECIES", 15, 23], ["Type I", "PROBLEM", 0, 6], ["a complement esterase inhibitor deficiency", "PROBLEM", 38, 80], ["megakaryoblasts", "PROBLEM", 140, 155], ["fibroblasts and placental cells", "PROBLEM", 157, 188], ["inflammatory processes", "PROBLEM", 242, 264], ["C1-INH deficiency", "PROBLEM", 280, 297], ["interleukins (IL", "TREATMENT", 351, 367], ["liver", "ANATOMY", 122, 127], ["monocytes", "ANATOMY", 129, 138], ["placental cells", "OBSERVATION", 173, 188], ["coagulative", "OBSERVATION_MODIFIER", 215, 226], ["inflammatory", "OBSERVATION", 242, 254], ["C1", "ANATOMY", 280, 282]]], ["An adolescent had similar symptoms and an IL 5 elevation [8] .An increased IL 6 production could be related to blood monocytes and endothelial cells stimulated by an eosinophil mediator [208] .Pathogenesis of Hereditary AngioedemaVibratory angioedema described within the physical urticaria is also hereditary.Acquired C1-INH DeficiencyType I acquired C1-INH deficiency (35 cases) has been shown in patients with lymphoproliferative disease, especially B cell-mediated, such as chronic lymphocytic leukemia, macroglobulinemia, essential cryoglobulinemia, or lymphocytic lymphoma.", [["blood monocytes", "ANATOMY", 111, 126], ["endothelial cells", "ANATOMY", 131, 148], ["eosinophil", "ANATOMY", 166, 176], ["B cell", "ANATOMY", 453, 459], ["chronic lymphocytic leukemia", "ANATOMY", 478, 506], ["lymphocytic lymphoma", "ANATOMY", 558, 578], ["Hereditary AngioedemaVibratory angioedema", "DISEASE", 209, 250], ["urticaria", "DISEASE", 281, 290], ["hereditary", "DISEASE", 299, 309], ["C1-INH", "CHEMICAL", 352, 358], ["lymphoproliferative disease", "DISEASE", 413, 440], ["chronic lymphocytic leukemia", "DISEASE", 478, 506], ["macroglobulinemia", "DISEASE", 508, 525], ["essential cryoglobulinemia", "DISEASE", 527, 553], ["lymphocytic lymphoma", "DISEASE", 558, 578], ["IL 6", "GENE_OR_GENE_PRODUCT", 75, 79], ["blood monocytes", "CELL", 111, 126], ["endothelial cells", "CELL", 131, 148], ["eosinophil", "CELL", 166, 176], ["C1-INH", "GENE_OR_GENE_PRODUCT", 352, 358], ["patients", "ORGANISM", 399, 407], ["B cell", "CELL", 453, 459], ["chronic lymphocytic leukemia", "CANCER", 478, 506], ["macroglobulinemia", "CANCER", 508, 525], ["lymphocytic lymphoma", "CANCER", 558, 578], ["IL 6", "PROTEIN", 75, 79], ["blood monocytes", "CELL_TYPE", 111, 126], ["endothelial cells", "CELL_TYPE", 131, 148], ["patients", "SPECIES", 399, 407], ["similar symptoms", "PROBLEM", 18, 34], ["an IL 5 elevation", "TREATMENT", 39, 56], ["An increased IL 6 production", "PROBLEM", 62, 90], ["blood monocytes", "TEST", 111, 126], ["endothelial cells", "TEST", 131, 148], ["an eosinophil mediator", "TEST", 163, 185], ["Hereditary AngioedemaVibratory angioedema", "PROBLEM", 209, 250], ["the physical urticaria", "PROBLEM", 268, 290], ["hereditary", "PROBLEM", 299, 309], ["Acquired C1-INH Deficiency", "PROBLEM", 310, 336], ["Type I acquired C1-INH deficiency", "PROBLEM", 336, 369], ["lymphoproliferative disease", "PROBLEM", 413, 440], ["chronic lymphocytic leukemia", "PROBLEM", 478, 506], ["macroglobulinemia", "PROBLEM", 508, 525], ["essential cryoglobulinemia", "PROBLEM", 527, 553], ["lymphocytic lymphoma", "PROBLEM", 558, 578], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["IL 6", "OBSERVATION", 75, 79], ["Hereditary", "OBSERVATION_MODIFIER", 209, 219], ["AngioedemaVibratory angioedema", "OBSERVATION", 220, 250], ["C1", "ANATOMY", 319, 321], ["INH Deficiency", "OBSERVATION", 322, 336], ["C1", "ANATOMY", 352, 354], ["lymphoproliferative disease", "OBSERVATION", 413, 440], ["chronic", "OBSERVATION_MODIFIER", 478, 485], ["lymphocytic leukemia", "OBSERVATION", 486, 506], ["macroglobulinemia", "OBSERVATION", 508, 525], ["essential", "OBSERVATION_MODIFIER", 527, 536], ["cryoglobulinemia", "OBSERVATION", 537, 553], ["lymphocytic lymphoma", "OBSERVATION", 558, 578]]], ["These patients may have a nonfunctioning C1-INH, and extremely low C3 levels, or by C1-INH consumption at a higher level than that of re-synthesis.", [["C1-INH", "CHEMICAL", 84, 90], ["C1-INH", "CHEMICAL", 84, 90], ["patients", "ORGANISM", 6, 14], ["C1-INH", "SIMPLE_CHEMICAL", 41, 47], ["C3", "GENE_OR_GENE_PRODUCT", 67, 69], ["C1-INH", "SIMPLE_CHEMICAL", 84, 90], ["C3", "PROTEIN", 67, 69], ["patients", "SPECIES", 6, 14], ["a nonfunctioning C1-INH, and extremely low C3 levels", "PROBLEM", 24, 76], ["C1-INH consumption", "PROBLEM", 84, 102], ["nonfunctioning", "OBSERVATION", 26, 40], ["low C3", "OBSERVATION_MODIFIER", 63, 69]]], ["This is caused by an excessive C1 activation, with consequent C1 reduced serum levels, either via particular CIC (idiotype-anti-idiotope), which appear to fix C1q, or via anti-C1-INH Aabs, which block the normal activity of C1 inhibitor.", [["serum", "ANATOMY", 73, 78], ["INH", "CHEMICAL", 179, 182], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["CIC", "GENE_OR_GENE_PRODUCT", 109, 112], ["idiotype-anti-idiotope", "GENE_OR_GENE_PRODUCT", 114, 136], ["C1q", "GENE_OR_GENE_PRODUCT", 159, 162], ["anti-C1-INH Aabs", "GENE_OR_GENE_PRODUCT", 171, 187], ["C1", "GENE_OR_GENE_PRODUCT", 224, 226], ["C1", "PROTEIN", 62, 64], ["CIC", "PROTEIN", 109, 112], ["idiotype", "PROTEIN", 114, 122], ["C1q", "PROTEIN", 159, 162], ["anti-C1", "PROTEIN", 171, 178], ["C1 inhibitor", "PROTEIN", 224, 236], ["an excessive C1 activation", "PROBLEM", 18, 44], ["consequent C1 reduced serum levels", "PROBLEM", 51, 85], ["C1q", "TEST", 159, 162], ["anti-C1", "TEST", 171, 178], ["INH Aabs", "TEST", 179, 187], ["C1 inhibitor", "TREATMENT", 224, 236], ["excessive", "OBSERVATION_MODIFIER", 21, 30], ["C1 activation", "OBSERVATION", 31, 44], ["normal activity", "OBSERVATION", 205, 220]]], ["The clinical manifestations are shared with those of hereditary forms [155] .Acquired C1-INH DeficiencyType II acquired C1-INH deficiency with C1-INH deficiency and IgA/IgG 1 Aabs directed at C1-INH: the resulting C1-INH functional block could lead to an uncontrolled activation.Acquired C1-INH DeficiencyRare cases not belonging to either type may be recorded [155] .", [["C1-INH", "CHEMICAL", 86, 92], ["INH", "CHEMICAL", 123, 126], ["C1-INH", "CHEMICAL", 143, 149], ["C1-INH", "CHEMICAL", 192, 198], ["C1-INH", "CHEMICAL", 86, 92], ["C1-INH", "CHEMICAL", 288, 294], ["C1-INH", "GENE_OR_GENE_PRODUCT", 120, 126], ["C1-INH", "GENE_OR_GENE_PRODUCT", 143, 149], ["IgA", "GENE_OR_GENE_PRODUCT", 165, 168], ["IgG 1 Aabs", "GENE_OR_GENE_PRODUCT", 169, 179], ["C1-INH", "GENE_OR_GENE_PRODUCT", 192, 198], ["C1-INH", "GENE_OR_GENE_PRODUCT", 214, 220], ["C1", "PROTEIN", 143, 145], ["IgA", "PROTEIN", 165, 168], ["IgG 1 Aabs", "PROTEIN", 169, 179], ["C1", "PROTEIN", 192, 194], ["C1", "PROTEIN", 214, 216], ["hereditary forms", "PROBLEM", 53, 69], ["Acquired C1-INH Deficiency", "PROBLEM", 77, 103], ["Type II acquired C1-INH deficiency", "PROBLEM", 103, 137], ["C1-INH deficiency", "PROBLEM", 143, 160], ["IgA/IgG", "TEST", 165, 172], ["Aabs", "TEST", 175, 179], ["the resulting C1-INH functional block", "PROBLEM", 200, 237], ["an uncontrolled activation", "PROBLEM", 252, 278], ["Acquired C1-INH DeficiencyRare cases", "PROBLEM", 279, 315], ["C1", "ANATOMY", 86, 88], ["INH Deficiency", "OBSERVATION", 89, 103], ["C1", "ANATOMY", 120, 122], ["INH deficiency", "OBSERVATION", 123, 137], ["C1", "ANATOMY", 143, 145], ["C1", "ANATOMY", 214, 216], ["uncontrolled", "OBSERVATION_MODIFIER", 255, 267], ["activation", "OBSERVATION", 268, 278]]], ["Briefly, these deficiencies depend on anti-C1-INH Aabs interfering with normal interactions between C1-INH and proteases, thus increasing C1-INH catabolism.", [["INH", "CHEMICAL", 46, 49], ["INH", "CHEMICAL", 141, 144], ["INH", "CHEMICAL", 46, 49], ["C1-INH", "CHEMICAL", 138, 144], ["anti-C1-INH Aabs", "SIMPLE_CHEMICAL", 38, 54], ["C1-INH", "GENE_OR_GENE_PRODUCT", 100, 106], ["C1-INH", "SIMPLE_CHEMICAL", 138, 144], ["anti-C1", "PROTEIN", 38, 45], ["C1", "PROTEIN", 100, 102], ["proteases", "PROTEIN", 111, 120], ["C1", "PROTEIN", 138, 140], ["these deficiencies", "PROBLEM", 9, 27], ["anti-C1", "TEST", 38, 45], ["proteases", "PROBLEM", 111, 120], ["increasing C1-INH catabolism", "PROBLEM", 127, 155]]], ["Moreover, there is the risk that some patients may be associated with autoimmune disease, including LES, autoimmune hemolytic anemia, diabetes mellitus, rheumatoid arthritis, etc. [250] .Pathogenesis of UrticariaPossible types of urticaria [60, 156] Foods are common causes of urticaria in children, the mechanisms are immunological of type I [90] , or non-IgE-mediated, or aspecific.", [["autoimmune disease", "DISEASE", 70, 88], ["autoimmune hemolytic anemia", "DISEASE", 105, 132], ["diabetes mellitus", "DISEASE", 134, 151], ["rheumatoid arthritis", "DISEASE", 153, 173], ["urticaria", "DISEASE", 230, 239], ["urticaria", "DISEASE", 277, 286], ["patients", "ORGANISM", 38, 46], ["Foods", "ORGANISM_SUBSTANCE", 250, 255], ["children", "ORGANISM", 290, 298], ["type I [90]", "GENE_OR_GENE_PRODUCT", 336, 347], ["non-IgE", "GENE_OR_GENE_PRODUCT", 353, 360], ["patients", "SPECIES", 38, 46], ["children", "SPECIES", 290, 298], ["autoimmune disease", "PROBLEM", 70, 88], ["LES, autoimmune hemolytic anemia", "PROBLEM", 100, 132], ["diabetes mellitus", "PROBLEM", 134, 151], ["rheumatoid arthritis", "PROBLEM", 153, 173], ["urticaria", "PROBLEM", 230, 239], ["urticaria", "PROBLEM", 277, 286], ["may be associated with", "UNCERTAINTY", 47, 69], ["autoimmune", "OBSERVATION", 70, 80], ["autoimmune hemolytic anemia", "OBSERVATION", 105, 132], ["diabetes mellitus", "OBSERVATION", 134, 151], ["rheumatoid arthritis", "OBSERVATION", 153, 173], ["UrticariaPossible types", "OBSERVATION_MODIFIER", 203, 226], ["urticaria", "OBSERVATION", 230, 239], ["urticaria", "OBSERVATION", 277, 286]]], ["There is insufficient proof to confirm a CIC role in urticaria syndrome.", [["urticaria syndrome", "DISEASE", 53, 71], ["urticaria syndrome", "PROBLEM", 53, 71], ["urticaria syndrome", "OBSERVATION", 53, 71]]], ["Glycoproteins with MW of 10-50 kD are often responsible, since they resist enzyme digestion and heat denaturation.", [["MW", "PROTEIN", 19, 21], ["Glycoproteins", "TREATMENT", 0, 13], ["heat denaturation", "PROBLEM", 96, 113], ["heat denaturation", "OBSERVATION", 96, 113]]], ["The complement is also activated after minimal stimuli, often of a traumatic nature, with formation of C3a and C5a, activation of kinin-like C2 factor, and secretion of more chemical mediators, associated with angioedema onset.", [["traumatic", "DISEASE", 67, 76], ["angioedema", "DISEASE", 210, 220], ["C3a", "GENE_OR_GENE_PRODUCT", 103, 106], ["C5a", "GENE_OR_GENE_PRODUCT", 111, 114], ["kinin-like C2 factor", "GENE_OR_GENE_PRODUCT", 130, 150], ["C3a", "PROTEIN", 103, 106], ["C5a", "PROTEIN", 111, 114], ["kinin", "PROTEIN", 130, 135], ["C2 factor", "PROTEIN", 141, 150], ["a traumatic nature", "PROBLEM", 65, 83], ["C3a and C5a", "PROBLEM", 103, 114], ["kinin-like C2 factor", "PROBLEM", 130, 150], ["angioedema onset", "PROBLEM", 210, 226], ["traumatic", "OBSERVATION", 67, 76], ["C3a", "ANATOMY", 103, 106], ["angioedema", "OBSERVATION", 210, 220]]], ["In Type II (10%-15% of patients), C1-INH levels are normal, since the deficiency is functional.", [["Type II", "DISEASE", 3, 10], ["C1-INH", "CHEMICAL", 34, 40], ["Type II", "CANCER", 3, 10], ["patients", "ORGANISM", 23, 31], ["C1-INH", "GENE_OR_GENE_PRODUCT", 34, 40], ["C1", "PROTEIN", 34, 36], ["patients", "SPECIES", 23, 31], ["C1-INH levels", "TEST", 34, 47], ["the deficiency", "PROBLEM", 66, 80], ["normal", "OBSERVATION", 52, 58]]], ["More precisely, in Type I patients, C1-INH-deficient production results from one chromosome 11 gene, which is defined as unproductive; in Type II patients, a gene mutation leads to a functionally inactive C1-INH (MW = 96 kD): therefore the product of a solely normal gene is insufficient to ensure a C1-INH adequate concentration [155] .", [["INH", "CHEMICAL", 39, 42], ["INH", "CHEMICAL", 303, 306], ["C1-INH", "CHEMICAL", 300, 306], ["patients", "ORGANISM", 26, 34], ["C1-INH", "GENE_OR_GENE_PRODUCT", 36, 42], ["chromosome 11", "CELLULAR_COMPONENT", 81, 94], ["patients", "ORGANISM", 146, 154], ["C1-INH", "GENE_OR_GENE_PRODUCT", 205, 211], ["C1-INH", "GENE_OR_GENE_PRODUCT", 300, 306], ["chromosome 11 gene", "DNA", 81, 99], ["C1", "PROTEIN", 205, 207], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 146, 154], ["a gene mutation", "PROBLEM", 156, 171], ["unproductive", "OBSERVATION_MODIFIER", 121, 133]]], ["Consequently, in both cases C2 and C4 are reduced, the C4d/C4 ratio is elevated, and Clq and C3 levels are normal [250] .", [["C4", "GENE_OR_GENE_PRODUCT", 35, 37], ["C4d", "GENE_OR_GENE_PRODUCT", 55, 58], ["C4", "GENE_OR_GENE_PRODUCT", 59, 61], ["Clq", "GENE_OR_GENE_PRODUCT", 85, 88], ["C3", "GENE_OR_GENE_PRODUCT", 93, 95], ["C2", "PROTEIN", 28, 30], ["C4d", "PROTEIN", 55, 58], ["C4", "PROTEIN", 59, 61], ["Clq", "PROTEIN", 85, 88], ["C3", "PROTEIN", 93, 95], ["the C4d/C4 ratio", "TEST", 51, 67], ["elevated", "PROBLEM", 71, 79], ["Clq and C3 levels", "TEST", 85, 102], ["C2", "ANATOMY_MODIFIER", 28, 30], ["C4", "ANATOMY_MODIFIER", 35, 37], ["reduced", "OBSERVATION_MODIFIER", 42, 49], ["C4", "ANATOMY_MODIFIER", 59, 61], ["elevated", "OBSERVATION_MODIFIER", 71, 79], ["normal", "OBSERVATION", 107, 113]]], ["A type III has been recently described in women with normal C1-inhibitor protein, C1-inhibitor function, and C4 levels [35] .Pathogenesis of UrticariaTwenty-one children with hereditary angioedema had Type I and five suffered from Type II [70] .", [["hereditary angioedema", "DISEASE", 175, 196], ["Type I", "DISEASE", 201, 207], ["women", "ORGANISM", 42, 47], ["C1", "GENE_OR_GENE_PRODUCT", 82, 84], ["children", "ORGANISM", 161, 169], ["C1", "PROTEIN", 60, 62], ["C1", "PROTEIN", 82, 84], ["C4", "PROTEIN", 109, 111], ["women", "SPECIES", 42, 47], ["children", "SPECIES", 161, 169], ["A type III", "PROBLEM", 0, 10], ["C4 levels", "TEST", 109, 118], ["hereditary angioedema", "PROBLEM", 175, 196], ["Type I", "PROBLEM", 201, 207], ["type III", "OBSERVATION_MODIFIER", 2, 10], ["angioedema", "OBSERVATION", 186, 196]]], ["In 11 members of a family, the mean age at onset of symptoms was 11 years [247] .", [["symptoms", "PROBLEM", 52, 60]]], ["In children <10, intestinal colic and edema of the extremities are the most frequent manifestations [69] .", [["intestinal", "ANATOMY", 17, 27], ["edema", "ANATOMY", 38, 43], ["extremities", "ANATOMY", 51, 62], ["intestinal colic", "DISEASE", 17, 33], ["edema of the extremities", "DISEASE", 38, 62], ["children", "ORGANISM", 3, 11], ["intestinal colic", "PATHOLOGICAL_FORMATION", 17, 33], ["edema", "PATHOLOGICAL_FORMATION", 38, 43], ["extremities", "ORGANISM_SUBDIVISION", 51, 62], ["children", "SPECIES", 3, 11], ["intestinal colic", "PROBLEM", 17, 33], ["edema of the extremities", "PROBLEM", 38, 62], ["intestinal colic", "ANATOMY", 17, 33], ["edema", "OBSERVATION", 38, 43], ["extremities", "ANATOMY", 51, 62]]], ["Edema formation primarily afflicted subcutaneous tissues.", [["Edema", "ANATOMY", 0, 5], ["subcutaneous tissues", "ANATOMY", 36, 56], ["Edema", "DISEASE", 0, 5], ["Edema", "PATHOLOGICAL_FORMATION", 0, 5], ["subcutaneous tissues", "TISSUE", 36, 56], ["Edema formation", "PROBLEM", 0, 15], ["subcutaneous tissues", "ANATOMY", 36, 56]]], ["Mechanical trauma was identified as a precipitating factor in 80% of children [70] .", [["Mechanical trauma", "DISEASE", 0, 17], ["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77], ["Mechanical trauma", "PROBLEM", 0, 17], ["trauma", "OBSERVATION", 11, 17]]], ["A 10-year-old child died from laryngeal asphyxia, and an 8-year-old had membrano-proliferative glomerulonephritis [69] .", [["laryngeal", "ANATOMY", 30, 39], ["laryngeal asphyxia", "DISEASE", 30, 48], ["glomerulonephritis", "DISEASE", 95, 113], ["child", "ORGANISM", 14, 19], ["laryngeal", "ORGAN", 30, 39], ["laryngeal asphyxia", "PROBLEM", 30, 48], ["membrano-proliferative glomerulonephritis", "PROBLEM", 72, 113], ["laryngeal", "ANATOMY", 30, 39], ["asphyxia", "OBSERVATION", 40, 48], ["proliferative", "OBSERVATION_MODIFIER", 81, 94], ["glomerulonephritis", "OBSERVATION", 95, 113]]], ["C1-INH deficiency is evident when C1-INH concentrations fall under 15%-20% of normal and occurs frequently in patients with reduced inhibitor activity, in whom the lacking control of complement C1-esterase enzyme activity, and of activated Hageman factor, plasmin and kallikrein, lead to release of vascular permeability factors [60] .Pathogenesis of UrticariaThe additional five genetic syndromes are as follows [166] : \u2211 Familial deficiency of C3b inactivator, autosomal recessive; the alternative pathway is activated with production of anaphylotoxins. \u2211 Familial deficiency of carboxypeptidase-N, inactivator enzyme of anaphylotoxins and kinins. \u2211 Muckle-Wells syndrome, autosomal dominant, with painful urticarial dermatitis, deafness of the perceptive type and renal amyloidosis. \u2211 Melkersson-Rosenthal syndrome, with chronic orofacial noninflammatory tumefaction (tapiroid face), usually limited to lips, characteristic fissured tongue and relapsing facial palsies.", [["vascular", "ANATOMY", 299, 307], ["renal", "ANATOMY", 767, 772], ["orofacial", "ANATOMY", 832, 841], ["face", "ANATOMY", 880, 884], ["lips", "ANATOMY", 906, 910], ["tongue", "ANATOMY", 936, 942], ["facial", "ANATOMY", 957, 963], ["C1-INH", "CHEMICAL", 0, 6], ["C1-INH", "CHEMICAL", 34, 40], ["Urticaria", "DISEASE", 351, 360], ["Familial deficiency", "DISEASE", 423, 442], ["autosomal recessive", "DISEASE", 463, 482], ["Muckle-Wells syndrome", "DISEASE", 652, 673], ["autosomal dominant", "DISEASE", 675, 693], ["urticarial dermatitis", "DISEASE", 708, 729], ["deafness of the perceptive type", "DISEASE", 731, 762], ["renal amyloidosis", "DISEASE", 767, 784], ["Melkersson-Rosenthal syndrome", "DISEASE", 788, 817], ["orofacial noninflammatory tumefaction", "DISEASE", 832, 869], ["facial palsies", "DISEASE", 957, 971], ["C1-INH", "CHEMICAL", 0, 6], ["C1-INH", "CHEMICAL", 34, 40], ["C1-INH", "GENE_OR_GENE_PRODUCT", 0, 6], ["C1-INH", "SIMPLE_CHEMICAL", 34, 40], ["patients", "ORGANISM", 110, 118], ["complement C1-esterase enzyme", "GENE_OR_GENE_PRODUCT", 183, 212], ["Hageman factor", "GENE_OR_GENE_PRODUCT", 240, 254], ["plasmin", "GENE_OR_GENE_PRODUCT", 256, 263], ["kallikrein", "GENE_OR_GENE_PRODUCT", 268, 278], ["vascular", "MULTI-TISSUE_STRUCTURE", 299, 307], ["C3b inactivator", "GENE_OR_GENE_PRODUCT", 446, 461], ["anaphylotoxins", "GENE_OR_GENE_PRODUCT", 540, 554], ["carboxypeptidase-N", "GENE_OR_GENE_PRODUCT", 581, 599], ["anaphylotoxins", "GENE_OR_GENE_PRODUCT", 623, 637], ["kinins", "GENE_OR_GENE_PRODUCT", 642, 648], ["renal", "ORGAN", 767, 772], ["lips", "ORGANISM_SUBDIVISION", 906, 910], ["tongue", "ORGAN", 936, 942], ["facial", "ORGAN", 957, 963], ["complement C1", "PROTEIN", 183, 196], ["esterase enzyme", "PROTEIN", 197, 212], ["Hageman factor", "PROTEIN", 240, 254], ["plasmin", "PROTEIN", 256, 263], ["kallikrein", "PROTEIN", 268, 278], ["vascular permeability factors", "PROTEIN", 299, 328], ["C3b inactivator", "PROTEIN", 446, 461], ["anaphylotoxins", "PROTEIN", 540, 554], ["carboxypeptidase-N", "PROTEIN", 581, 599], ["inactivator enzyme", "PROTEIN", 601, 619], ["anaphylotoxins", "PROTEIN", 623, 637], ["patients", "SPECIES", 110, 118], ["C1-INH deficiency", "PROBLEM", 0, 17], ["INH concentrations", "PROBLEM", 37, 55], ["reduced inhibitor activity", "PROBLEM", 124, 150], ["activated Hageman factor", "PROBLEM", 230, 254], ["plasmin and kallikrein", "TREATMENT", 256, 278], ["vascular permeability factors", "PROBLEM", 299, 328], ["Urticaria", "PROBLEM", 351, 360], ["Familial deficiency of C3b inactivator", "PROBLEM", 423, 461], ["autosomal recessive", "PROBLEM", 463, 482], ["anaphylotoxins", "TREATMENT", 540, 554], ["Familial deficiency of carboxypeptidase", "PROBLEM", 558, 597], ["inactivator enzyme of anaphylotoxins", "PROBLEM", 601, 637], ["kinins", "PROBLEM", 642, 648], ["Muckle-Wells syndrome", "PROBLEM", 652, 673], ["autosomal dominant", "PROBLEM", 675, 693], ["painful urticarial dermatitis", "PROBLEM", 700, 729], ["deafness", "PROBLEM", 731, 739], ["the perceptive type", "PROBLEM", 743, 762], ["renal amyloidosis", "PROBLEM", 767, 784], ["Rosenthal syndrome", "PROBLEM", 799, 817], ["chronic orofacial noninflammatory tumefaction", "PROBLEM", 824, 869], ["characteristic fissured tongue", "PROBLEM", 912, 942], ["relapsing facial palsies", "PROBLEM", 947, 971], ["INH deficiency", "OBSERVATION", 3, 17], ["normal", "OBSERVATION", 78, 84], ["vascular", "ANATOMY", 299, 307], ["Urticaria", "OBSERVATION", 351, 360], ["C3b inactivator", "OBSERVATION", 446, 461], ["Wells syndrome", "OBSERVATION", 659, 673], ["autosomal", "OBSERVATION_MODIFIER", 675, 684], ["dominant", "OBSERVATION_MODIFIER", 685, 693], ["painful", "OBSERVATION_MODIFIER", 700, 707], ["urticarial dermatitis", "OBSERVATION", 708, 729], ["deafness", "OBSERVATION", 731, 739], ["perceptive type", "OBSERVATION_MODIFIER", 747, 762], ["renal", "ANATOMY", 767, 772], ["amyloidosis", "OBSERVATION", 773, 784], ["Rosenthal syndrome", "OBSERVATION", 799, 817], ["chronic", "OBSERVATION_MODIFIER", 824, 831], ["orofacial", "ANATOMY", 832, 841], ["noninflammatory", "OBSERVATION_MODIFIER", 842, 857], ["tumefaction", "OBSERVATION", 858, 869], ["lips", "ANATOMY", 906, 910], ["fissured", "OBSERVATION_MODIFIER", 927, 935], ["tongue", "ANATOMY", 936, 942], ["relapsing", "OBSERVATION_MODIFIER", 947, 956], ["facial", "ANATOMY", 957, 963], ["palsies", "OBSERVATION", 964, 971]]], ["Several patients reported with this autosomal dominant syndrome have no FH of the disease [142, 202] .", [["autosomal dominant syndrome", "DISEASE", 36, 63], ["FH of the disease", "DISEASE", 72, 89], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["this autosomal dominant syndrome", "PROBLEM", 31, 63], ["the disease", "PROBLEM", 78, 89], ["dominant", "OBSERVATION_MODIFIER", 46, 54], ["syndrome", "OBSERVATION", 55, 63], ["no", "UNCERTAINTY", 69, 71]]], ["Additives might be implicated in the pathogenesis [202] . \u2211 Episodic angioedema (from 1 week to 1 month) associated with eosinophilia, periodic attacks of fever, myalgia and oliguria; 8 out of 12 patients were aged between 2.5 and 18 [168] .", [["Episodic angioedema", "DISEASE", 60, 79], ["eosinophilia", "DISEASE", 121, 133], ["fever", "DISEASE", 155, 160], ["myalgia", "DISEASE", 162, 169], ["oliguria", "DISEASE", 174, 182], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["Episodic angioedema", "PROBLEM", 60, 79], ["eosinophilia", "PROBLEM", 121, 133], ["periodic attacks", "PROBLEM", 135, 151], ["fever", "PROBLEM", 155, 160], ["myalgia", "PROBLEM", 162, 169], ["oliguria", "PROBLEM", 174, 182], ["angioedema", "OBSERVATION", 69, 79], ["eosinophilia", "OBSERVATION", 121, 133], ["periodic", "OBSERVATION_MODIFIER", 135, 143], ["attacks", "OBSERVATION_MODIFIER", 144, 151], ["fever", "OBSERVATION", 155, 160], ["oliguria", "OBSERVATION", 174, 182]]], ["Eosinophilia is usually associated with an increase in IgE and/or IgM levels; the pathogenesis is foods most frequently implicated are fish (mostly cod), seafood >CM and dairy products >peanuts and nuts >egg >fruits, etc., in some cases with IgE-mediated (55%) or aspecific mechanisms (75%) [90] , and acute urticaria provoked by caresses after peanut contact (Table 7 .22).", [["peanuts", "ANATOMY", 186, 193], ["egg", "ANATOMY", 204, 207], ["fruits", "ANATOMY", 209, 215], ["Eosinophilia", "DISEASE", 0, 12], ["CM", "DISEASE", 163, 165], ["urticaria", "DISEASE", 308, 317], ["IgE", "GENE_OR_GENE_PRODUCT", 55, 58], ["IgM", "GENE_OR_GENE_PRODUCT", 66, 69], ["fish", "ORGANISM_SUBDIVISION", 135, 139], ["peanuts", "ORGANISM_SUBDIVISION", 186, 193], ["nuts", "ORGANISM_SUBDIVISION", 198, 202], ["egg", "ORGANISM_SUBSTANCE", 204, 207], ["fruits", "ORGANISM_SUBDIVISION", 209, 215], ["IgE", "GENE_OR_GENE_PRODUCT", 242, 245], ["IgE", "PROTEIN", 55, 58], ["IgM", "PROTEIN", 66, 69], ["IgE", "PROTEIN", 242, 245], ["peanuts", "SPECIES", 186, 193], ["peanuts", "SPECIES", 186, 193], ["Eosinophilia", "PROBLEM", 0, 12], ["an increase in IgE and/or IgM levels", "PROBLEM", 40, 76], ["dairy products", "TREATMENT", 170, 184], ["nuts", "TEST", 198, 202], ["IgE", "TEST", 242, 245], ["acute urticaria", "PROBLEM", 302, 317], ["usually associated with", "UNCERTAINTY", 16, 39], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["acute", "OBSERVATION_MODIFIER", 302, 307], ["urticaria", "OBSERVATION", 308, 317]]], ["In pediatric cohorts, urticaria was secondary to foods from 11% [144] to 57% [90] of cases.", [["urticaria", "DISEASE", 22, 31], ["urticaria", "PROBLEM", 22, 31]]], ["In young infants, CM and egg play a role [184] , with cases of urticaria and shock by CM, peach and wheat at 4-6 months of life [90] .", [["egg", "ANATOMY", 25, 28], ["CM", "DISEASE", 18, 20], ["urticaria", "DISEASE", 63, 72], ["shock", "DISEASE", 77, 82], ["CM", "DISEASE", 86, 88], ["infants", "ORGANISM", 9, 16], ["egg", "ORGANISM_SUBSTANCE", 25, 28], ["peach", "ORGANISM_SUBDIVISION", 90, 95], ["infants", "SPECIES", 9, 16], ["wheat", "SPECIES", 100, 105], ["peach", "SPECIES", 90, 95], ["urticaria", "PROBLEM", 63, 72], ["shock", "PROBLEM", 77, 82], ["urticaria", "OBSERVATION", 63, 72]]], ["A wheat allergic boy experienced systemic urticaria and angioedema within 40 min after the ingestion of 9 g of packed rice crackers contaminated by 1.50 mg/g of wheat [137] .", [["allergic", "DISEASE", 8, 16], ["systemic urticaria", "DISEASE", 33, 51], ["angioedema", "DISEASE", 56, 66], ["9 g of packed rice crackers", "CHEMICAL", 104, 131], ["wheat", "SPECIES", 2, 7], ["boy", "SPECIES", 17, 20], ["rice", "SPECIES", 118, 122], ["wheat", "SPECIES", 161, 166], ["rice", "SPECIES", 118, 122], ["A wheat allergic", "PROBLEM", 0, 16], ["systemic urticaria", "PROBLEM", 33, 51], ["angioedema", "PROBLEM", 56, 66], ["packed rice crackers", "TREATMENT", 111, 131], ["allergic", "OBSERVATION_MODIFIER", 8, 16], ["systemic", "OBSERVATION_MODIFIER", 33, 41], ["urticaria", "OBSERVATION", 42, 51], ["angioedema", "OBSERVATION", 56, 66]]], ["Two children seen by us showed severe urticaria while touching or eating a peach.", [["urticaria", "DISEASE", 38, 47], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["severe urticaria", "PROBLEM", 31, 47], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["urticaria", "OBSERVATION", 38, 47]]], ["The mother of one boy had urticaria by maize, pollens, and fruit in general.", [["fruit", "ANATOMY", 59, 64], ["urticaria", "DISEASE", 26, 35], ["boy", "ORGANISM", 18, 21], ["pollens", "ORGANISM_SUBDIVISION", 46, 53], ["boy", "SPECIES", 18, 21], ["maize", "SPECIES", 39, 44], ["maize", "SPECIES", 39, 44], ["urticaria", "PROBLEM", 26, 35]]], ["A drop of CM fell on the foot of a 10-month-old child and a generalized urticaria was spread to the whole leg.", [["foot", "ANATOMY", 25, 29], ["leg", "ANATOMY", 106, 109], ["CM", "DISEASE", 10, 12], ["urticaria", "DISEASE", 72, 81], ["foot", "ORGANISM_SUBDIVISION", 25, 29], ["child", "ORGANISM", 48, 53], ["leg", "ORGANISM_SUBDIVISION", 106, 109], ["A drop of CM", "PROBLEM", 0, 12], ["a generalized urticaria", "PROBLEM", 58, 81], ["drop", "OBSERVATION_MODIFIER", 2, 6], ["of CM", "OBSERVATION_MODIFIER", 7, 12], ["foot", "ANATOMY", 25, 29], ["generalized", "OBSERVATION_MODIFIER", 60, 71], ["urticaria", "OBSERVATION", 72, 81], ["leg", "ANATOMY", 106, 109]]], ["In two pediatric cohorts, urticaria was caused by CM in 18%-26% [40, 60] , peanuts in 63.6%, tomato in 37.3% and egg white in 26.2% of cases [60] .", [["urticaria", "DISEASE", 26, 35], ["CM", "DISEASE", 50, 52], ["peanuts", "ORGANISM_SUBDIVISION", 75, 82], ["tomato", "ORGANISM_SUBDIVISION", 93, 99], ["peanuts", "SPECIES", 75, 82], ["tomato", "SPECIES", 93, 99], ["peanuts", "SPECIES", 75, 82], ["tomato", "SPECIES", 93, 99], ["urticaria", "PROBLEM", 26, 35], ["CM", "TEST", 50, 52], ["peanuts", "TEST", 75, 82], ["tomato", "TEST", 93, 99], ["egg white", "TEST", 113, 122], ["cases", "TEST", 135, 140], ["urticaria", "OBSERVATION", 26, 35]]], ["In 67% of 100 children, the foods were implicated in this frequency order: eggs and nuts, fruit, CM, vegetables, fish and shellfish [67] .", [["eggs", "ANATOMY", 75, 79], ["nuts", "ANATOMY", 84, 88], ["fruit", "ANATOMY", 90, 95], ["CM", "ANATOMY", 97, 99], ["vegetables", "ANATOMY", 101, 111], ["CM", "DISEASE", 97, 99], ["children", "ORGANISM", 14, 22], ["nuts", "ORGANISM_SUBDIVISION", 84, 88], ["fruit", "ORGANISM_SUBDIVISION", 90, 95], ["vegetables", "ORGANISM_SUBDIVISION", 101, 111], ["fish", "ORGANISM_SUBDIVISION", 113, 117], ["children", "SPECIES", 14, 22]]], ["Fish often induces IgE-mediated urticaria-angioedema in children (60%-92% of cases) [41, 49, 164] ; urticaria on the face and arms in one boy following hand immersion in water used to wash codfish and in another after handling a raw peach, complicated the latter by glottis edema [184] , have also been noted.", [["face", "ANATOMY", 117, 121], ["hand", "ANATOMY", 152, 156], ["glottis", "ANATOMY", 266, 273], ["urticaria", "DISEASE", 32, 41], ["angioedema", "DISEASE", 42, 52], ["urticaria", "DISEASE", 100, 109], ["edema", "DISEASE", 274, 279], ["IgE", "GENE_OR_GENE_PRODUCT", 19, 22], ["children", "ORGANISM", 56, 64], ["face", "ORGANISM_SUBDIVISION", 117, 121], ["boy", "ORGANISM", 138, 141], ["hand", "ORGANISM_SUBDIVISION", 152, 156], ["IgE", "PROTEIN", 19, 22], ["children", "SPECIES", 56, 64], ["boy", "SPECIES", 138, 141], ["peach", "SPECIES", 233, 238], ["IgE-mediated urticaria", "PROBLEM", 19, 41], ["angioedema", "PROBLEM", 42, 52], ["urticaria on the face and arms", "PROBLEM", 100, 130], ["glottis edema", "PROBLEM", 266, 279], ["urticaria", "OBSERVATION", 32, 41], ["angioedema", "OBSERVATION", 42, 52], ["urticaria", "OBSERVATION", 100, 109], ["face", "ANATOMY", 117, 121], ["arms", "ANATOMY", 126, 130], ["glottis", "ANATOMY", 266, 273], ["edema", "OBSERVATION", 274, 279]]], ["As in our cases [41] , if a fish-allergic child with AD eats a few milligrams of fish, he does not show worsening AD but persisting angioedema despite an elimination diet ( Fig. 8.4 ).", [["fish-allergic", "DISEASE", 28, 41], ["AD", "DISEASE", 53, 55], ["AD", "DISEASE", 114, 116], ["angioedema", "DISEASE", 132, 142], ["fish", "ORGANISM", 28, 32], ["fish", "ORGANISM", 81, 85], ["worsening AD", "PROBLEM", 104, 116], ["persisting angioedema", "PROBLEM", 121, 142]]], ["Fish provoked urticaria in 23.8% and urticaria-angioedema in 33.3% of 21 children by inhalation of airborne particles [49] .", [["urticaria", "DISEASE", 14, 23], ["urticaria", "DISEASE", 37, 46], ["angioedema", "DISEASE", 47, 57], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["Fish provoked urticaria", "PROBLEM", 0, 23], ["urticaria", "PROBLEM", 37, 46], ["angioedema", "PROBLEM", 47, 57], ["urticaria", "OBSERVATION", 14, 23], ["urticaria", "OBSERVATION", 37, 46], ["angioedema", "OBSERVATION", 47, 57]]], ["An uncommon case was elicited by a hemostatic sponge of bovine fibrin used in tooth extraction [242] .", [["tooth", "ANATOMY", 78, 83], ["bovine", "ORGANISM", 56, 62], ["fibrin", "GENE_OR_GENE_PRODUCT", 63, 69], ["tooth", "ORGAN", 78, 83], ["bovine", "SPECIES", 56, 62], ["a hemostatic sponge of bovine fibrin", "TREATMENT", 33, 69], ["tooth extraction", "TREATMENT", 78, 94], ["bovine fibrin", "OBSERVATION", 56, 69]]], ["Immediate reactions have been reported after contact with apple, endive, lettuce, flour, garlic, honey, lamb, pear, potato, turkey, and wheat [184] (Table 8.1) .Pathogenesis of UrticariaInhalant allergens may occasion urticaria since they cross-react with food allergens (Table 1 .73), or by direct skin contact: above all, exposure to inhalant allergens in children with AD may cause lesion flare-ups, preceded by urticarial lesions (Chap.", [["flour", "ANATOMY", 82, 87], ["skin", "ANATOMY", 299, 303], ["lesion", "ANATOMY", 385, 391], ["urticarial lesions", "ANATOMY", 415, 433], ["apple, endive, lettuce, flour, garlic, honey, lamb, pear, potato, turkey", "CHEMICAL", 58, 130], ["urticaria", "DISEASE", 218, 227], ["inhalant allergens", "DISEASE", 336, 354], ["AD", "DISEASE", 372, 374], ["urticarial lesions", "DISEASE", 415, 433], ["lettuce", "ORGANISM_SUBDIVISION", 73, 80], ["flour", "ORGANISM_SUBDIVISION", 82, 87], ["garlic", "SIMPLE_CHEMICAL", 89, 95], ["honey", "ORGANISM_SUBDIVISION", 97, 102], ["lamb", "ORGANISM_SUBDIVISION", 104, 108], ["pear", "ORGANISM_SUBDIVISION", 110, 114], ["potato", "ORGANISM_SUBDIVISION", 116, 122], ["turkey", "ORGANISM_SUBDIVISION", 124, 130], ["skin", "ORGAN", 299, 303], ["children", "ORGANISM", 358, 366], ["urticarial lesions", "PATHOLOGICAL_FORMATION", 415, 433], ["apple", "SPECIES", 58, 63], ["lettuce", "SPECIES", 73, 80], ["flour", "SPECIES", 82, 87], ["garlic", "SPECIES", 89, 95], ["honey", "SPECIES", 97, 102], ["lamb", "SPECIES", 104, 108], ["pear", "SPECIES", 110, 114], ["potato", "SPECIES", 116, 122], ["turkey", "SPECIES", 124, 130], ["wheat", "SPECIES", 136, 141], ["children", "SPECIES", 358, 366], ["apple", "SPECIES", 58, 63], ["lettuce", "SPECIES", 73, 80], ["lamb", "SPECIES", 104, 108], ["potato", "SPECIES", 116, 122], ["turkey", "SPECIES", 124, 130], ["Immediate reactions", "PROBLEM", 0, 19], ["UrticariaInhalant allergens", "PROBLEM", 177, 204], ["occasion urticaria", "PROBLEM", 209, 227], ["lesion flare", "PROBLEM", 385, 397], ["urticarial lesions", "PROBLEM", 415, 433], ["skin", "ANATOMY", 299, 303], ["lesion", "OBSERVATION", 385, 391], ["urticarial", "ANATOMY", 415, 425], ["lesions", "OBSERVATION", 426, 433]]], ["There might be a reduction at the threshold by which release of mast cell products can be induced (priming effect) during hay fever season.", [["mast cell", "ANATOMY", 64, 73], ["fever", "DISEASE", 126, 131], ["mast cell", "CELL", 64, 73], ["a reduction at the threshold", "PROBLEM", 15, 43], ["mast cell products", "TREATMENT", 64, 82], ["reduction", "OBSERVATION_MODIFIER", 17, 26], ["mast cell products", "OBSERVATION", 64, 82]]], ["Grass pollens cross-react with peanut and tomato: in a pediatric study [60] : skin prick tests (SPTs) were positive to grasses more frequently than to Der p.", [["skin", "ANATOMY", 78, 82], ["peanut", "ORGANISM_SUBSTANCE", 31, 37], ["tomato", "ORGANISM_SUBDIVISION", 42, 48], ["skin", "ORGAN", 78, 82], ["peanut", "SPECIES", 31, 37], ["tomato", "SPECIES", 42, 48], ["tomato", "SPECIES", 42, 48], ["Der p.", "SPECIES", 151, 157], ["a pediatric study", "TEST", 53, 70], ["skin prick tests", "TEST", 78, 94], ["skin", "ANATOMY", 78, 82]]], ["A case similar to peanuts was angioedema, which occurred after stroking a cat ( Fig. 8.2 ).", [["angioedema", "DISEASE", 30, 40], ["peanuts", "ORGANISM_SUBDIVISION", 18, 25], ["peanuts", "SPECIES", 18, 25], ["angioedema", "PROBLEM", 30, 40], ["stroking a cat ( Fig.", "TEST", 63, 84], ["angioedema", "OBSERVATION", 30, 40]]], ["Urticaria associated with other conditions such as urticaria associated with AD may reach an elevated prevalence in children (Chaps.", [["Urticaria", "DISEASE", 0, 9], ["urticaria", "DISEASE", 51, 60], ["AD", "DISEASE", 77, 79], ["children", "ORGANISM", 116, 124], ["children", "SPECIES", 116, 124], ["Urticaria", "PROBLEM", 0, 9], ["other conditions", "PROBLEM", 26, 42], ["urticaria", "PROBLEM", 51, 60]]], ["5 and 7).Pathogenesis of UrticariaInsect bites and stings cause acute urticaria.", [["UrticariaInsect bites", "DISEASE", 25, 46], ["stings", "DISEASE", 51, 57], ["urticaria", "DISEASE", 70, 79], ["UrticariaInsect bites", "PROBLEM", 25, 46], ["stings", "PROBLEM", 51, 57], ["acute urticaria", "PROBLEM", 64, 79], ["UrticariaInsect bites", "OBSERVATION", 25, 46], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["urticaria", "OBSERVATION", 70, 79]]], ["Urticarial reactions can be part of a systemic reaction to Hymenoptera stings heralding potentially fatal anaphylactic reactions on subsequent stings.Complement-Mediated UrticariaComplement may be activated in different ways in urticaria [45, 157] (Table 8.1) .Complement-Mediated UrticariaClassic pathway activation via aggregated immunoglobulins such as IgG and IgM in CICs, and the same mechanism may be active to a varying degree in other forms of urticaria, as well as in cases of myeloma or dermomyositis, etc.Complement-Mediated UrticariaAlternative pathway activation might result from venoms, antigens, radiological contrast media, complex carbohydrates (agar, dextran, polyvinylpyrrolidone, zymosan), polysaccharides and lipopolysaccharides (LPS) of the cell wall of Gram+ and Gram-organisms.", [["Urticarial", "ANATOMY", 0, 10], ["CICs", "ANATOMY", 371, 375], ["myeloma", "ANATOMY", 486, 493], ["cell wall", "ANATOMY", 764, 773], ["Hymenoptera stings", "DISEASE", 59, 77], ["anaphylactic reactions", "DISEASE", 106, 128], ["urticaria", "DISEASE", 228, 237], ["urticaria", "DISEASE", 452, 461], ["myeloma", "DISEASE", 486, 493], ["dermomyositis", "DISEASE", 497, 510], ["dextran", "CHEMICAL", 670, 677], ["polyvinylpyrrolidone", "CHEMICAL", 679, 699], ["zymosan", "CHEMICAL", 701, 708], ["lipopolysaccharides", "CHEMICAL", 731, 750], ["LPS", "CHEMICAL", 752, 755], ["carbohydrates", "CHEMICAL", 649, 662], ["polyvinylpyrrolidone", "CHEMICAL", 679, 699], ["Complement", "GENE_OR_GENE_PRODUCT", 150, 160], ["Complement", "GENE_OR_GENE_PRODUCT", 261, 271], ["UrticariaClassic", "GENE_OR_GENE_PRODUCT", 281, 297], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 332, 347], ["IgG", "GENE_OR_GENE_PRODUCT", 356, 359], ["IgM", "GENE_OR_GENE_PRODUCT", 364, 367], ["CICs", "CELL", 371, 375], ["myeloma", "CANCER", 486, 493], ["Complement", "GENE_OR_GENE_PRODUCT", 516, 526], ["UrticariaAlternative", "SIMPLE_CHEMICAL", 536, 556], ["dextran", "SIMPLE_CHEMICAL", 670, 677], ["polyvinylpyrrolidone", "SIMPLE_CHEMICAL", 679, 699], ["zymosan", "SIMPLE_CHEMICAL", 701, 708], ["polysaccharides", "SIMPLE_CHEMICAL", 711, 726], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 731, 750], ["LPS", "SIMPLE_CHEMICAL", 752, 755], ["cell wall", "CELL", 764, 773], ["immunoglobulins", "PROTEIN", 332, 347], ["IgG", "PROTEIN", 356, 359], ["IgM", "PROTEIN", 364, 367], ["CICs", "CELL_TYPE", 371, 375], ["antigens", "PROTEIN", 602, 610], ["Urticarial reactions", "PROBLEM", 0, 20], ["a systemic reaction", "PROBLEM", 36, 55], ["Hymenoptera stings", "PROBLEM", 59, 77], ["fatal anaphylactic reactions", "PROBLEM", 100, 128], ["urticaria", "PROBLEM", 228, 237], ["Mediated UrticariaClassic pathway activation", "PROBLEM", 272, 316], ["aggregated immunoglobulins", "PROBLEM", 321, 347], ["IgG", "TEST", 356, 359], ["IgM in CICs", "TEST", 364, 375], ["urticaria", "PROBLEM", 452, 461], ["myeloma", "PROBLEM", 486, 493], ["dermomyositis", "PROBLEM", 497, 510], ["venoms", "PROBLEM", 594, 600], ["radiological contrast media", "TREATMENT", 612, 639], ["complex carbohydrates (agar", "TREATMENT", 641, 668], ["dextran", "TREATMENT", 670, 677], ["polyvinylpyrrolidone", "TREATMENT", 679, 699], ["zymosan", "TREATMENT", 701, 708], ["polysaccharides", "TREATMENT", 711, 726], ["lipopolysaccharides (LPS", "TREATMENT", 731, 755], ["the cell wall of Gram", "TEST", 760, 781], ["Gram-organisms", "PROBLEM", 787, 801], ["systemic", "OBSERVATION_MODIFIER", 38, 46], ["reaction", "OBSERVATION", 47, 55], ["fatal", "OBSERVATION_MODIFIER", 100, 105], ["anaphylactic", "OBSERVATION", 106, 118], ["urticaria", "OBSERVATION", 452, 461], ["myeloma", "OBSERVATION", 486, 493], ["dermomyositis", "OBSERVATION", 497, 510], ["cell wall", "ANATOMY", 764, 773]]], ["Moreover, activated complement C3a, C4a, and C5a anaphylotoxins are capable of triggering mast cell histamine release, thus playing the pivotal role of possible mediators of urticaria [45] .", [["mast cell", "ANATOMY", 90, 99], ["histamine", "CHEMICAL", 100, 109], ["urticaria", "DISEASE", 174, 183], ["histamine", "CHEMICAL", 100, 109], ["C3a", "GENE_OR_GENE_PRODUCT", 31, 34], ["C4a", "GENE_OR_GENE_PRODUCT", 36, 39], ["C5a", "GENE_OR_GENE_PRODUCT", 45, 48], ["mast cell", "CELL", 90, 99], ["C3a", "PROTEIN", 31, 34], ["C4a", "PROTEIN", 36, 39], ["C5a anaphylotoxins", "PROTEIN", 45, 63], ["activated complement C3a", "TEST", 10, 34], ["C4a", "TEST", 36, 39], ["C5a anaphylotoxins", "TREATMENT", 45, 63], ["mast cell histamine release", "TREATMENT", 90, 117], ["urticaria", "PROBLEM", 174, 183], ["mast cell", "OBSERVATION", 90, 99]]], ["Infection, either associated or not with drug intake, was the cause in 46 children (81%).", [["Infection", "DISEASE", 0, 9], ["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["Infection", "PROBLEM", 0, 9]]], ["The organisms were enterovirus (50%), parvovirus B19 (20%), Epstein-Barr (15%), and mycoplasma (15%) [29] .Complement-Mediated UrticariaIn conclusion, a cause was suspected in 28 out of 52 children (54%) such as a viral illness (19%), antibiotics (15%), or a combination (35%) [169] .", [["enterovirus", "DISEASE", 19, 30], ["parvovirus B19", "DISEASE", 38, 52], ["mycoplasma", "DISEASE", 84, 94], ["viral illness", "DISEASE", 214, 227], ["enterovirus", "ORGANISM", 19, 30], ["parvovirus B19", "ORGANISM", 38, 52], ["Epstein-Barr", "ORGANISM", 60, 72], ["children", "ORGANISM", 189, 197], ["parvovirus B19", "SPECIES", 38, 52], ["children", "SPECIES", 189, 197], ["parvovirus B19", "SPECIES", 38, 52], ["The organisms", "TEST", 0, 13], ["enterovirus", "TEST", 19, 30], ["parvovirus B19", "TEST", 38, 52], ["Epstein", "TEST", 60, 67], ["mycoplasma", "TEST", 84, 94], ["a viral illness", "PROBLEM", 212, 227], ["antibiotics", "TREATMENT", 235, 246], ["mycoplasma", "ANATOMY", 84, 94]]], ["Even if the pathogenic mechanisms appear to be numerous, conflicting with clinical monomorphism, they may actually be related to a few vasoactive factors that play a role of potential mediators [175] .Clinical PresentationUrticaria ( Fig. 8.1 ) is a skin eruption characterized by raised, erythematous wheals, with defined or serpiginous borders, irregular form (usually oval), color varying from pink or reddish to whitish, surrounded by normal skin or by a bright-red flare, and with variable form, seat extension and duration.", [["skin", "ANATOMY", 250, 254], ["erythematous wheals", "ANATOMY", 289, 308], ["skin", "ANATOMY", 446, 450], ["skin eruption", "DISEASE", 250, 263], ["skin", "ORGAN", 250, 254], ["skin", "ORGAN", 446, 450], ["vasoactive factors", "PROTEIN", 135, 153], ["the pathogenic mechanisms", "PROBLEM", 8, 33], ["a few vasoactive factors", "PROBLEM", 129, 153], ["Clinical PresentationUrticaria ( Fig.", "TEST", 201, 238], ["a skin eruption", "PROBLEM", 248, 263], ["erythematous wheals", "PROBLEM", 289, 308], ["serpiginous borders", "PROBLEM", 326, 345], ["irregular form", "PROBLEM", 347, 361], ["a bright-red flare", "PROBLEM", 457, 475], ["skin", "ANATOMY", 250, 254], ["eruption", "OBSERVATION", 255, 263], ["erythematous", "OBSERVATION_MODIFIER", 289, 301], ["wheals", "OBSERVATION", 302, 308], ["serpiginous", "OBSERVATION_MODIFIER", 326, 337], ["irregular", "OBSERVATION_MODIFIER", 347, 356], ["varying", "OBSERVATION_MODIFIER", 384, 391], ["pink", "OBSERVATION_MODIFIER", 397, 401], ["reddish", "OBSERVATION_MODIFIER", 405, 412], ["whitish", "OBSERVATION_MODIFIER", 416, 423], ["normal", "OBSERVATION", 439, 445], ["skin", "ANATOMY", 446, 450], ["bright", "OBSERVATION_MODIFIER", 459, 465], ["-red", "OBSERVATION_MODIFIER", 465, 469], ["flare", "OBSERVATION", 470, 475]]], ["These lesions, accompanied by intense itching, are fleeting and resolve completely within 24 h of onset, especially after Hymenoptera stings, without leaving any trace, even if new elements may follow while the old ones clear.", [["lesions", "ANATOMY", 6, 13], ["itching", "DISEASE", 38, 45], ["Hymenoptera stings", "DISEASE", 122, 140], ["lesions", "PATHOLOGICAL_FORMATION", 6, 13], ["These lesions", "PROBLEM", 0, 13], ["intense itching", "PROBLEM", 30, 45], ["lesions", "OBSERVATION", 6, 13], ["intense", "OBSERVATION_MODIFIER", 30, 37], ["itching", "OBSERVATION", 38, 45], ["fleeting", "OBSERVATION_MODIFIER", 51, 59], ["clear", "OBSERVATION", 220, 225]]], ["Lesions lasting longer should raise suspicion for the diagnosis of vasculitis presenting as urticarial lesions Wheals vary in size (from 1-2 mm to 1-2 cm) and number and in some cases undergo a coalescence involving very large areas (giant urticaria) up to 10 cm in diameter and assuming the aspect of a geographical map.", [["urticarial lesions", "ANATOMY", 92, 110], ["vasculitis", "DISEASE", 67, 77], ["urticarial lesions", "DISEASE", 92, 110], ["urticaria", "DISEASE", 240, 249], ["urticarial lesions", "PATHOLOGICAL_FORMATION", 92, 110], ["Lesions", "PROBLEM", 0, 7], ["vasculitis", "PROBLEM", 67, 77], ["urticarial lesions", "PROBLEM", 92, 110], ["Wheals vary in size", "PROBLEM", 111, 130], ["a coalescence", "PROBLEM", 192, 205], ["very large areas (giant urticaria", "PROBLEM", 216, 249], ["vasculitis", "OBSERVATION", 67, 77], ["urticarial", "OBSERVATION_MODIFIER", 92, 102], ["lesions", "OBSERVATION", 103, 110], ["vary", "OBSERVATION_MODIFIER", 118, 122], ["size", "OBSERVATION_MODIFIER", 126, 130], ["coalescence", "OBSERVATION", 194, 205], ["very", "OBSERVATION_MODIFIER", 216, 220], ["large", "OBSERVATION_MODIFIER", 221, 226], ["areas", "OBSERVATION_MODIFIER", 227, 232], ["giant", "OBSERVATION_MODIFIER", 234, 239], ["urticaria", "OBSERVATION", 240, 249], ["10 cm", "OBSERVATION_MODIFIER", 257, 262]]], ["Urticaria may be generalized or localized and in the latter case the lesions affect preferentially the trunk and limbs, but also the palms and soles, the face and scalp.", [["lesions", "ANATOMY", 69, 76], ["trunk", "ANATOMY", 103, 108], ["limbs", "ANATOMY", 113, 118], ["palms", "ANATOMY", 133, 138], ["soles", "ANATOMY", 143, 148], ["face", "ANATOMY", 154, 158], ["scalp", "ANATOMY", 163, 168], ["Urticaria", "DISEASE", 0, 9], ["lesions", "CANCER", 69, 76], ["trunk", "ORGANISM_SUBDIVISION", 103, 108], ["limbs", "ORGANISM_SUBDIVISION", 113, 118], ["palms", "ORGANISM_SUBDIVISION", 133, 138], ["soles", "ORGANISM_SUBDIVISION", 143, 148], ["face", "ORGANISM_SUBDIVISION", 154, 158], ["scalp", "ORGAN", 163, 168], ["Urticaria", "PROBLEM", 0, 9], ["may be", "UNCERTAINTY", 10, 16], ["generalized", "OBSERVATION_MODIFIER", 17, 28], ["lesions", "OBSERVATION", 69, 76], ["trunk", "ANATOMY", 103, 108], ["limbs", "ANATOMY", 113, 118], ["palms", "ANATOMY", 133, 138], ["soles", "ANATOMY_MODIFIER", 143, 148], ["face", "ANATOMY", 154, 158], ["scalp", "ANATOMY", 163, 168]]], ["An important characteristic is that the color typically blanches with pressure; this simple test is helpful to differentiate an erythema from a skin hemorrhage [117] .Clinical PresentationAcute allergic urticaria is an IgE-mediated allergic reaction associated with systemic anaphylaxis.", [["blanches", "ANATOMY", 56, 64], ["erythema", "ANATOMY", 128, 136], ["skin", "ANATOMY", 144, 148], ["erythema", "DISEASE", 128, 136], ["skin hemorrhage", "DISEASE", 144, 159], ["allergic urticaria", "DISEASE", 194, 212], ["allergic reaction", "DISEASE", 232, 249], ["anaphylaxis", "DISEASE", 275, 286], ["skin", "ORGAN", 144, 148], ["IgE", "GENE_OR_GENE_PRODUCT", 219, 222], ["IgE", "PROTEIN", 219, 222], ["pressure", "PROBLEM", 70, 78], ["this simple test", "TEST", 80, 96], ["an erythema", "PROBLEM", 125, 136], ["a skin hemorrhage", "PROBLEM", 142, 159], ["Clinical PresentationAcute allergic urticaria", "PROBLEM", 167, 212], ["an IgE-mediated allergic reaction", "PROBLEM", 216, 249], ["systemic anaphylaxis", "PROBLEM", 266, 286], ["pressure", "OBSERVATION_MODIFIER", 70, 78], ["erythema", "OBSERVATION", 128, 136], ["skin", "ANATOMY", 144, 148], ["hemorrhage", "OBSERVATION", 149, 159], ["allergic urticaria", "OBSERVATION", 194, 212], ["allergic reaction", "OBSERVATION", 232, 249], ["systemic", "OBSERVATION_MODIFIER", 266, 274], ["anaphylaxis", "OBSERVATION", 275, 286]]], ["It is extremely common, possibly affecting about 10%-20% of the general population.", [["extremely", "OBSERVATION_MODIFIER", 6, 15], ["common", "OBSERVATION", 16, 22]]], ["Most frequently, this a self-limited disorder [103] .", [["a self-limited disorder", "PROBLEM", 22, 45]]], ["However, excluding drug reactions and insect stings, acute allergic urticaria comprises 2%-6% of the total number of urticaria cases seen in a dermatology clinic [117] .", [["insect stings", "DISEASE", 38, 51], ["allergic urticaria", "DISEASE", 59, 77], ["urticaria", "DISEASE", 117, 126], ["drug reactions", "PROBLEM", 19, 33], ["insect stings", "PROBLEM", 38, 51], ["acute allergic urticaria", "PROBLEM", 53, 77], ["urticaria cases", "PROBLEM", 117, 132], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["allergic urticaria", "OBSERVATION", 59, 77], ["urticaria", "OBSERVATION", 117, 126]]], ["This is an eosinophil-driven disease, as demonstrated by a study on 19 infants and children aged from 9 months to 8 years and recruited from the emergency room while presenting with acute attacks of wheals and itching, accompanied by angioedema in seven subjects.", [["eosinophil", "ANATOMY", 11, 21], ["wheals", "DISEASE", 199, 205], ["itching", "DISEASE", 210, 217], ["angioedema", "DISEASE", 234, 244], ["eosinophil", "CELL", 11, 21], ["infants", "ORGANISM", 71, 78], ["children", "ORGANISM", 83, 91], ["infants", "SPECIES", 71, 78], ["children", "SPECIES", 83, 91], ["an eosinophil-driven disease", "PROBLEM", 8, 36], ["a study", "TEST", 57, 64], ["acute attacks of wheals", "PROBLEM", 182, 205], ["itching", "PROBLEM", 210, 217], ["angioedema", "PROBLEM", 234, 244], ["eosinophil", "OBSERVATION", 11, 21], ["acute", "OBSERVATION_MODIFIER", 182, 187], ["attacks", "OBSERVATION", 188, 195], ["wheals", "OBSERVATION", 199, 205], ["itching", "OBSERVATION", 210, 217], ["angioedema", "OBSERVATION", 234, 244]]], ["Total serum IgE levels were above the highest normal for their age.", [["serum", "ANATOMY", 6, 11], ["serum", "ORGANISM_SUBSTANCE", 6, 11], ["IgE", "GENE_OR_GENE_PRODUCT", 12, 15], ["IgE", "PROTEIN", 12, 15], ["Total serum IgE levels", "TEST", 0, 22]]], ["The eotaxin values were significantly higher than the controls' corresponding values.", [["eotaxin", "GENE_OR_GENE_PRODUCT", 4, 11], ["eotaxin", "PROTEIN", 4, 11], ["The eotaxin values", "TEST", 0, 18]]], ["As a potent eosinophil selective chemoattractant, eotaxin is a chemokine that promotes the selective recruitment of eosinophils, the major effec-Urticaria Induced by Drugs and/or Presumed Arachidonic Acid Metabolism Abnormalities and/or AdditivesThe whole spectrum of drugs are the most common causes of urticaria by pseudoallergic mechanisms in 29.8% [13] and in 22% of children [90] .", [["eosinophil", "ANATOMY", 12, 22], ["eosinophils", "ANATOMY", 116, 127], ["Urticaria", "DISEASE", 145, 154], ["Arachidonic Acid", "CHEMICAL", 188, 204], ["urticaria", "DISEASE", 304, 313], ["Arachidonic Acid", "CHEMICAL", 188, 204], ["eosinophil", "CELL", 12, 22], ["eotaxin", "GENE_OR_GENE_PRODUCT", 50, 57], ["eosinophils", "CELL", 116, 127], ["Arachidonic Acid", "SIMPLE_CHEMICAL", 188, 204], ["children", "ORGANISM", 371, 379], ["eosinophil selective chemoattractant", "PROTEIN", 12, 48], ["eotaxin", "PROTEIN", 50, 57], ["chemokine", "PROTEIN", 63, 72], ["eosinophils", "CELL_TYPE", 116, 127], ["children", "SPECIES", 371, 379], ["a potent eosinophil selective chemoattractant", "TREATMENT", 3, 48], ["eotaxin", "TREATMENT", 50, 57], ["a chemokine", "TREATMENT", 61, 72], ["the selective recruitment of eosinophils", "TREATMENT", 87, 127], ["Urticaria", "PROBLEM", 145, 154], ["Drugs", "TREATMENT", 166, 171], ["Arachidonic Acid Metabolism Abnormalities", "PROBLEM", 188, 229], ["The whole spectrum of drugs", "TREATMENT", 246, 273], ["urticaria", "PROBLEM", 304, 313], ["Urticaria", "OBSERVATION", 145, 154], ["Presumed", "UNCERTAINTY", 179, 187], ["Arachidonic Acid Metabolism", "OBSERVATION", 188, 215], ["urticaria", "OBSERVATION", 304, 313]]], ["ASA is the most usual and best studied drug that acts directly and even provokes relapses in subjects with chronic urticaria secondary to different causes.", [["ASA", "CHEMICAL", 0, 3], ["urticaria", "DISEASE", 115, 124], ["ASA", "CHEMICAL", 0, 3], ["ASA", "SIMPLE_CHEMICAL", 0, 3], ["ASA", "TREATMENT", 0, 3], ["chronic urticaria", "PROBLEM", 107, 124], ["different causes", "PROBLEM", 138, 154], ["chronic", "OBSERVATION_MODIFIER", 107, 114], ["urticaria", "OBSERVATION", 115, 124]]], ["ASA was the most frequently used antipyretic [53.8%) [13] .", [["ASA", "CHEMICAL", 0, 3], ["ASA", "CHEMICAL", 0, 3], ["ASA", "SIMPLE_CHEMICAL", 0, 3], ["ASA", "TREATMENT", 0, 3], ["antipyretic", "TREATMENT", 33, 44]]], ["ASA also cross-reacts with NSAIDs in ASA-sensitive patients suffering from clinical manifestations following NSAID treatment, in addition to colorings and preservatives [59] .", [["NSAIDs", "CHEMICAL", 27, 33], ["ASA", "CHEMICAL", 37, 40], ["ASA", "CHEMICAL", 0, 3], ["ASA", "CHEMICAL", 37, 40], ["ASA", "SIMPLE_CHEMICAL", 0, 3], ["NSAIDs", "SIMPLE_CHEMICAL", 27, 33], ["ASA", "SIMPLE_CHEMICAL", 37, 40], ["patients", "ORGANISM", 51, 59], ["NSAID", "SIMPLE_CHEMICAL", 109, 114], ["patients", "SPECIES", 51, 59], ["ASA", "TREATMENT", 0, 3], ["NSAIDs", "TREATMENT", 27, 33], ["ASA", "TREATMENT", 37, 40], ["clinical manifestations", "PROBLEM", 75, 98], ["NSAID treatment", "TREATMENT", 109, 124]]], ["Other causative drugs were antibiotics (60.9%) [13] or 47.7% [29] , antipyretics (35.1%), or a combination of antibiotics and antipyretics (16.2%) [13] .", [["Other causative drugs", "TREATMENT", 0, 21], ["antibiotics", "TREATMENT", 27, 38], ["antipyretics", "TREATMENT", 68, 80], ["antibiotics", "TREATMENT", 110, 121], ["antipyretics", "TREATMENT", 126, 138]]], ["Contaminant penicillin derivatives in CM or poultry meat routinely penicillin-treated may cause immediate allergic reactions or chronic urticaria [156] , prevalently in highly sensitized subjects [157] ; gastrointestinal symptoms are frequently elicited, but the food challenge test (FCT) is rarely positive [156] .Urticaria Induced by Drugs and/or Presumed Arachidonic Acid Metabolism Abnormalities and/or AdditivesThe additives (Chap.", [["gastrointestinal", "ANATOMY", 204, 220], ["penicillin", "CHEMICAL", 12, 22], ["CM", "DISEASE", 38, 40], ["penicillin", "CHEMICAL", 67, 77], ["allergic reactions", "DISEASE", 106, 124], ["urticaria", "DISEASE", 136, 145], ["gastrointestinal symptoms", "DISEASE", 204, 229], ["Urticaria", "DISEASE", 315, 324], ["Arachidonic Acid", "CHEMICAL", 358, 374], ["penicillin", "CHEMICAL", 12, 22], ["penicillin", "CHEMICAL", 67, 77], ["Arachidonic Acid", "CHEMICAL", 358, 374], ["penicillin derivatives", "SIMPLE_CHEMICAL", 12, 34], ["CM", "CELL", 38, 40], ["penicillin", "SIMPLE_CHEMICAL", 67, 77], ["gastrointestinal", "ORGAN", 204, 220], ["Arachidonic Acid", "SIMPLE_CHEMICAL", 358, 374], ["poultry", "SPECIES", 44, 51], ["poultry", "SPECIES", 44, 51], ["Contaminant penicillin derivatives", "TREATMENT", 0, 34], ["poultry meat", "TREATMENT", 44, 56], ["penicillin", "TREATMENT", 67, 77], ["immediate allergic reactions", "PROBLEM", 96, 124], ["chronic urticaria", "PROBLEM", 128, 145], ["gastrointestinal symptoms", "PROBLEM", 204, 229], ["the food challenge test", "TEST", 259, 282], ["Urticaria", "PROBLEM", 315, 324], ["Drugs", "TREATMENT", 336, 341], ["Arachidonic Acid Metabolism Abnormalities", "PROBLEM", 358, 399], ["chronic", "OBSERVATION_MODIFIER", 128, 135], ["urticaria", "OBSERVATION", 136, 145], ["gastrointestinal", "ANATOMY", 204, 220], ["Presumed", "UNCERTAINTY", 349, 357], ["Arachidonic Acid Metabolism", "OBSERVATION", 358, 385]]], ["10) most often incriminated are as follows [59] : E102 (70%), E110 (64.2%), E127 (35.7%), E160b (60.7%), E211 (57.1%), aspartame (48.2%) and ASA (12.6%).", [["aspartame", "CHEMICAL", 119, 128], ["ASA", "CHEMICAL", 141, 144], ["aspartame", "CHEMICAL", 119, 128], ["ASA", "CHEMICAL", 141, 144], ["aspartame", "SIMPLE_CHEMICAL", 119, 128], ["E110", "TEST", 62, 66], ["E127", "TEST", 76, 80], ["E160b", "TEST", 90, 95], ["E211", "TEST", 105, 109], ["aspartame", "TEST", 119, 128], ["ASA", "TEST", 141, 144]]], ["A cause-effect ratio is more evident in chronic urticaria, that is 30%-50% [60] .", [["urticaria", "DISEASE", 48, 57], ["effect ratio", "PROBLEM", 8, 20], ["chronic urticaria", "PROBLEM", 40, 57], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["urticaria", "OBSERVATION", 48, 57]]], ["The pertinent role in children is unknown, since the related FCTs have rarely been done.Pseudoallergic UrticariaSeveral histamine-releaser foods, if ingested in sufficient amount, have the ability to act on mast cells by an aspecific mechanism, thus inducing urticarial reactions also in nonsensitized subjects.", [["mast cells", "ANATOMY", 207, 217], ["histamine", "CHEMICAL", 120, 129], ["histamine", "CHEMICAL", 120, 129], ["children", "ORGANISM", 22, 30], ["FCTs", "CANCER", 61, 65], ["mast cells", "CELL", 207, 217], ["mast cells", "CELL_TYPE", 207, 217], ["children", "SPECIES", 22, 30], ["the related FCTs", "PROBLEM", 49, 65], ["Pseudoallergic UrticariaSeveral histamine", "TREATMENT", 88, 129], ["mast cells", "TREATMENT", 207, 217], ["urticarial reactions", "PROBLEM", 259, 279]]], ["In both cases (immunological and nonimmunological mechanisms), the symptoms are practically overlapping, but a nonimmunological response is best defined as a pseudoallergic reaction [18, 60] .", [["the symptoms", "PROBLEM", 63, 75], ["a pseudoallergic reaction", "PROBLEM", 156, 181]]], ["Urticaria provoked by additives contained in prepared foods is a frequent finding among children consulting in our department.Infection-Induced UrticariaUrticaria may occur during parasite and infectious disorders, especially in chronic urticaria [159] .", [["Urticaria", "DISEASE", 0, 9], ["UrticariaUrticaria", "CHEMICAL", 144, 162], ["infectious disorders", "DISEASE", 193, 213], ["chronic urticaria", "DISEASE", 229, 246], ["children", "ORGANISM", 88, 96], ["children", "SPECIES", 88, 96], ["Urticaria", "PROBLEM", 0, 9], ["Infection", "PROBLEM", 126, 135], ["Induced UrticariaUrticaria", "PROBLEM", 136, 162], ["infectious disorders", "PROBLEM", 193, 213], ["chronic urticaria", "PROBLEM", 229, 246], ["infectious", "OBSERVATION_MODIFIER", 193, 203], ["chronic", "OBSERVATION_MODIFIER", 229, 236], ["urticaria", "OBSERVATION", 237, 246]]], ["Among infections with helminths, oxyuriasis, and ascariasis are most diffused in infancy [175] .", [["infections", "DISEASE", 6, 16], ["helminths", "DISEASE", 22, 31], ["oxyuriasis", "DISEASE", 33, 43], ["ascariasis", "DISEASE", 49, 59], ["Among infections", "PROBLEM", 0, 16], ["helminths", "PROBLEM", 22, 31], ["oxyuriasis", "PROBLEM", 33, 43], ["ascariasis", "PROBLEM", 49, 59], ["infections", "OBSERVATION", 6, 16], ["ascariasis", "OBSERVATION", 49, 59], ["diffused", "OBSERVATION_MODIFIER", 69, 77]]], ["The underlying mechanisms are uncertain, such as urticaria in the prodromes of hepatitis B and infectious mononucleosis (IMN), either spontaneously or following ampicillin treatment [227] .", [["urticaria", "DISEASE", 49, 58], ["hepatitis B", "DISEASE", 79, 90], ["infectious mononucleosis", "DISEASE", 95, 119], ["IMN", "DISEASE", 121, 124], ["ampicillin", "CHEMICAL", 161, 171], ["ampicillin", "CHEMICAL", 161, 171], ["hepatitis B", "ORGANISM", 79, 90], ["IMN", "CANCER", 121, 124], ["ampicillin", "SIMPLE_CHEMICAL", 161, 171], ["hepatitis B", "SPECIES", 79, 90], ["urticaria", "PROBLEM", 49, 58], ["hepatitis B", "PROBLEM", 79, 90], ["infectious mononucleosis", "PROBLEM", 95, 119], ["ampicillin treatment", "TREATMENT", 161, 181], ["urticaria", "OBSERVATION", 49, 58], ["hepatitis", "OBSERVATION", 79, 88], ["infectious", "OBSERVATION_MODIFIER", 95, 105]]], ["Urticaria has been associated with enterovirus, cytomegalovirus (CMV), and other infections, but clinically these infections are not unlike those of different tor cells in allergic inflammation.", [["tor cells", "ANATOMY", 159, 168], ["Urticaria", "DISEASE", 0, 9], ["enterovirus, cytomegalovirus (CMV), and other infections", "DISEASE", 35, 91], ["infections", "DISEASE", 114, 124], ["allergic inflammation", "DISEASE", 172, 193], ["enterovirus", "ORGANISM", 35, 46], ["cytomegalovirus", "ORGANISM", 48, 63], ["CMV", "ORGANISM", 65, 68], ["tor cells", "CELL", 159, 168], ["tor cells", "CELL_TYPE", 159, 168], ["CMV", "SPECIES", 65, 68], ["Urticaria", "PROBLEM", 0, 9], ["enterovirus", "PROBLEM", 35, 46], ["cytomegalovirus (CMV)", "PROBLEM", 48, 69], ["other infections", "PROBLEM", 75, 91], ["these infections", "PROBLEM", 108, 124], ["allergic inflammation", "PROBLEM", 172, 193], ["associated with", "UNCERTAINTY", 19, 34], ["enterovirus", "OBSERVATION", 35, 46], ["cytomegalovirus", "OBSERVATION", 48, 63], ["infections", "OBSERVATION", 81, 91], ["infections", "OBSERVATION", 114, 124], ["allergic inflammation", "OBSERVATION", 172, 193]]], ["Eotaxin is thus implied in the causation of the tissue eosinophilia that characterizes allergic acute urticaria and may also be a biomarker of lesional activity [95] .Infection-Induced UrticariaAngioedema (Figs.", [["tissue", "ANATOMY", 48, 54], ["lesional", "ANATOMY", 143, 151], ["Eotaxin", "CHEMICAL", 0, 7], ["eosinophilia", "DISEASE", 55, 67], ["allergic acute urticaria", "DISEASE", 87, 111], ["UrticariaAngioedema", "DISEASE", 185, 204], ["Eotaxin", "GENE_OR_GENE_PRODUCT", 0, 7], ["tissue", "TISSUE", 48, 54], ["Eotaxin", "PROTEIN", 0, 7], ["Eotaxin", "TREATMENT", 0, 7], ["the tissue eosinophilia", "PROBLEM", 44, 67], ["allergic acute urticaria", "PROBLEM", 87, 111], ["Infection", "PROBLEM", 167, 176], ["Induced UrticariaAngioedema", "PROBLEM", 177, 204], ["tissue", "ANATOMY", 48, 54], ["eosinophilia", "OBSERVATION", 55, 67], ["allergic", "OBSERVATION_MODIFIER", 87, 95], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["urticaria", "OBSERVATION", 102, 111], ["may also be", "UNCERTAINTY", 116, 127]]], ["8.2, 8.4 ) is sometimes referred to as angioneurotic edema, coined by Osler who did not refer to neurosis at this time [158] .", [["angioneurotic edema", "ANATOMY", 39, 58], ["edema", "DISEASE", 53, 58], ["neurosis", "DISEASE", 97, 105], ["edema", "PATHOLOGICAL_FORMATION", 53, 58], ["angioneurotic edema", "PROBLEM", 39, 58], ["neurosis", "PROBLEM", 97, 105], ["edema", "OBSERVATION", 53, 58]]], ["Isolated angioedema is rather rare at the pediatric age, is more often a symptom of a generalized anaphylactic manifestation, as when it is caused by an insect sting [175] .", [["angioedema", "DISEASE", 9, 19], ["anaphylactic manifestation", "DISEASE", 98, 124], ["Isolated angioedema", "PROBLEM", 0, 19], ["a generalized anaphylactic manifestation", "PROBLEM", 84, 124], ["angioedema", "OBSERVATION", 9, 19], ["more often", "OBSERVATION_MODIFIER", 60, 70], ["generalized", "OBSERVATION_MODIFIER", 86, 97], ["anaphylactic manifestation", "OBSERVATION", 98, 124]]], ["In 26 children, pedigree analysis revealed 19 patients with afflicted relatives, and clinical manifestations of the disease first occurred at 2.5-12 years of age [69] .", [["children", "ORGANISM", 6, 14], ["patients", "ORGANISM", 46, 54], ["children", "SPECIES", 6, 14], ["patients", "SPECIES", 46, 54], ["pedigree analysis", "TEST", 16, 33], ["the disease", "PROBLEM", 112, 123]]], ["Angioedema was caused by food in 40% (Fig. 5.12 ), insect bites in 30%, infection in 20%, and an antibiotic in 10% of children [187] .", [["Angioedema", "DISEASE", 0, 10], ["insect bites", "DISEASE", 51, 63], ["infection", "DISEASE", 72, 81], ["children", "ORGANISM", 118, 126], ["children", "SPECIES", 118, 126], ["Angioedema", "PROBLEM", 0, 10], ["infection", "PROBLEM", 72, 81], ["an antibiotic", "TREATMENT", 94, 107]]], ["The swelling involves deeper skin layers with fewer mast cells and nerve endings, and is thus painless and nonpruritic.", [["skin layers", "ANATOMY", 29, 40], ["mast cells", "ANATOMY", 52, 62], ["nerve endings", "ANATOMY", 67, 80], ["swelling", "DISEASE", 4, 12], ["skin layers", "TISSUE", 29, 40], ["mast cells", "CELL", 52, 62], ["nerve endings", "TISSUE", 67, 80], ["mast cells", "CELL_TYPE", 52, 62], ["The swelling", "PROBLEM", 0, 12], ["deeper skin layers", "PROBLEM", 22, 40], ["fewer mast cells and nerve endings", "PROBLEM", 46, 80], ["painless", "PROBLEM", 94, 102], ["nonpruritic", "PROBLEM", 107, 118], ["swelling", "OBSERVATION", 4, 12], ["deeper", "ANATOMY_MODIFIER", 22, 28], ["skin", "ANATOMY", 29, 33], ["layers", "ANATOMY_MODIFIER", 34, 40], ["fewer", "OBSERVATION_MODIFIER", 46, 51], ["mast cells", "OBSERVATION", 52, 62], ["nerve", "ANATOMY", 67, 72], ["painless", "OBSERVATION_MODIFIER", 94, 102]]], ["It is characterized by gradual onset of circumscribed bouts of edema, localized in subcutaneous tissue, skin and mucosa, more evident in the face, lids, lips, tongue, upper airways, gastrointestinal mucosa and less in the limbs, involving the mucosa to varying degrees and discomfort, accompanied by extreme weakness.", [["edema", "ANATOMY", 63, 68], ["subcutaneous tissue", "ANATOMY", 83, 102], ["skin", "ANATOMY", 104, 108], ["mucosa", "ANATOMY", 113, 119], ["face", "ANATOMY", 141, 145], ["lids", "ANATOMY", 147, 151], ["lips", "ANATOMY", 153, 157], ["tongue", "ANATOMY", 159, 165], ["upper airways", "ANATOMY", 167, 180], ["gastrointestinal mucosa", "ANATOMY", 182, 205], ["limbs", "ANATOMY", 222, 227], ["mucosa", "ANATOMY", 243, 249], ["edema", "DISEASE", 63, 68], ["edema", "PATHOLOGICAL_FORMATION", 63, 68], ["subcutaneous tissue", "TISSUE", 83, 102], ["skin", "ORGAN", 104, 108], ["mucosa", "MULTI-TISSUE_STRUCTURE", 113, 119], ["face", "ORGANISM_SUBDIVISION", 141, 145], ["lids", "ORGANISM_SUBDIVISION", 147, 151], ["lips", "ORGANISM_SUBDIVISION", 153, 157], ["tongue", "ORGAN", 159, 165], ["upper airways", "MULTI-TISSUE_STRUCTURE", 167, 180], ["gastrointestinal mucosa", "MULTI-TISSUE_STRUCTURE", 182, 205], ["limbs", "ORGANISM_SUBDIVISION", 222, 227], ["mucosa", "MULTI-TISSUE_STRUCTURE", 243, 249], ["edema", "PROBLEM", 63, 68], ["lips, tongue, upper airways, gastrointestinal mucosa and less in the limbs", "PROBLEM", 153, 227], ["discomfort", "PROBLEM", 273, 283], ["extreme weakness", "PROBLEM", 300, 316], ["gradual", "OBSERVATION_MODIFIER", 23, 30], ["onset", "OBSERVATION_MODIFIER", 31, 36], ["circumscribed", "OBSERVATION_MODIFIER", 40, 53], ["bouts", "OBSERVATION_MODIFIER", 54, 59], ["edema", "OBSERVATION", 63, 68], ["subcutaneous tissue", "ANATOMY", 83, 102], ["skin", "ANATOMY", 104, 108], ["mucosa", "ANATOMY", 113, 119], ["face", "ANATOMY", 141, 145], ["lids", "ANATOMY", 147, 151], ["lips", "ANATOMY", 153, 157], ["tongue", "ANATOMY", 159, 165], ["upper", "ANATOMY_MODIFIER", 167, 172], ["airways", "ANATOMY", 173, 180], ["gastrointestinal mucosa", "ANATOMY", 182, 205], ["less", "OBSERVATION_MODIFIER", 210, 214], ["limbs", "ANATOMY", 222, 227], ["mucosa", "ANATOMY", 243, 249], ["varying degrees", "OBSERVATION_MODIFIER", 253, 268], ["discomfort", "OBSERVATION", 273, 283], ["extreme", "OBSERVATION_MODIFIER", 300, 307], ["weakness", "OBSERVATION", 308, 316]]], ["Incidence of angioedema of the head or neck, most often facial was 80%, tenderness or pain 40%, dyspnea 30%, dysphagia (including drooling and spitting) 30%, and hoarseness 10% [187] .", [["head", "ANATOMY", 31, 35], ["neck", "ANATOMY", 39, 43], ["facial", "ANATOMY", 56, 62], ["angioedema of the head or neck", "DISEASE", 13, 43], ["tenderness", "DISEASE", 72, 82], ["pain", "DISEASE", 86, 90], ["dyspnea", "DISEASE", 96, 103], ["dysphagia", "DISEASE", 109, 118], ["drooling", "DISEASE", 130, 138], ["hoarseness", "DISEASE", 162, 172], ["head", "ORGANISM_SUBDIVISION", 31, 35], ["neck", "ORGAN", 39, 43], ["facial", "ORGAN", 56, 62], ["angioedema of the head or neck", "PROBLEM", 13, 43], ["tenderness", "PROBLEM", 72, 82], ["pain", "PROBLEM", 86, 90], ["dyspnea", "PROBLEM", 96, 103], ["dysphagia", "PROBLEM", 109, 118], ["drooling", "PROBLEM", 130, 138], ["spitting", "PROBLEM", 143, 151], ["hoarseness", "PROBLEM", 162, 172], ["angioedema", "OBSERVATION", 13, 23], ["head", "ANATOMY", 31, 35], ["neck", "ANATOMY", 39, 43], ["tenderness", "OBSERVATION", 72, 82], ["dysphagia", "OBSERVATION", 109, 118]]], ["The clinical manifestations, self-limited and present in two-thirds of cases in patients up to 13 years of age, are usually preceded by local trauma, also mild, such as local inflammation, minor surgery, dental extraction, fatigue, and emotional stress, sometimes without an apparent cause [60] .", [["trauma", "DISEASE", 142, 148], ["inflammation", "DISEASE", 175, 187], ["fatigue", "DISEASE", 223, 230], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["local trauma", "PROBLEM", 136, 148], ["local inflammation", "PROBLEM", 169, 187], ["minor surgery", "TREATMENT", 189, 202], ["dental extraction", "TREATMENT", 204, 221], ["fatigue", "PROBLEM", 223, 230], ["emotional stress", "PROBLEM", 236, 252], ["local", "OBSERVATION_MODIFIER", 136, 141], ["trauma", "OBSERVATION", 142, 148], ["mild", "OBSERVATION_MODIFIER", 155, 159], ["local", "OBSERVATION_MODIFIER", 169, 174], ["inflammation", "OBSERVATION", 175, 187], ["minor", "OBSERVATION_MODIFIER", 189, 194], ["surgery", "OBSERVATION", 195, 202]]], ["It is characterized by recurrent attacks of self-limiting angioedema affecting the face, limbs, gastrointestinal system and upper airways [247] .", [["face", "ANATOMY", 83, 87], ["limbs", "ANATOMY", 89, 94], ["gastrointestinal system", "ANATOMY", 96, 119], ["upper airways", "ANATOMY", 124, 137], ["angioedema", "DISEASE", 58, 68], ["face", "ORGANISM_SUBDIVISION", 83, 87], ["limbs", "ORGANISM_SUBDIVISION", 89, 94], ["gastrointestinal system", "ANATOMICAL_SYSTEM", 96, 119], ["upper airways", "ORGANISM_SUBDIVISION", 124, 137], ["recurrent attacks", "PROBLEM", 23, 40], ["self-limiting angioedema affecting the face, limbs, gastrointestinal system and upper airways", "PROBLEM", 44, 137], ["recurrent", "OBSERVATION_MODIFIER", 23, 32], ["attacks", "OBSERVATION_MODIFIER", 33, 40], ["self-limiting", "OBSERVATION_MODIFIER", 44, 57], ["angioedema", "OBSERVATION", 58, 68], ["face", "ANATOMY", 83, 87], ["limbs", "ANATOMY", 89, 94], ["gastrointestinal system", "ANATOMY", 96, 119], ["upper", "ANATOMY_MODIFIER", 124, 129], ["airways", "ANATOMY", 130, 137]]], ["Additional symptoms are erythematous rashes, pleuritic pains, urinary retention and seizures or hemiparesis, sometimes simulating a cerebral edema.", [["pleuritic", "ANATOMY", 45, 54], ["urinary", "ANATOMY", 62, 69], ["cerebral", "ANATOMY", 132, 140], ["rashes", "DISEASE", 37, 43], ["pleuritic pains", "DISEASE", 45, 60], ["urinary retention", "DISEASE", 62, 79], ["seizures", "DISEASE", 84, 92], ["hemiparesis", "DISEASE", 96, 107], ["cerebral edema", "DISEASE", 132, 146], ["urinary", "ORGANISM_SUBDIVISION", 62, 69], ["cerebral edema", "PATHOLOGICAL_FORMATION", 132, 146], ["Additional symptoms", "PROBLEM", 0, 19], ["erythematous rashes", "PROBLEM", 24, 43], ["pleuritic pains", "PROBLEM", 45, 60], ["urinary retention", "PROBLEM", 62, 79], ["seizures", "PROBLEM", 84, 92], ["hemiparesis", "PROBLEM", 96, 107], ["a cerebral edema", "PROBLEM", 130, 146], ["erythematous", "OBSERVATION_MODIFIER", 24, 36], ["pleuritic", "ANATOMY", 45, 54], ["urinary", "ANATOMY", 62, 69], ["retention", "OBSERVATION", 70, 79], ["seizures", "OBSERVATION", 84, 92], ["hemiparesis", "OBSERVATION", 96, 107], ["cerebral", "ANATOMY", 132, 140], ["edema", "OBSERVATION", 141, 146]]], ["The swelling progresses over hours, commonly increasing over 12-72 h and then subsiding over 1-3 days, leaving a normal-appearing skin [155] .", [["skin", "ANATOMY", 130, 134], ["swelling", "DISEASE", 4, 12], ["skin", "ORGAN", 130, 134], ["The swelling", "PROBLEM", 0, 12], ["swelling", "OBSERVATION", 4, 12], ["normal", "OBSERVATION", 113, 119], ["skin", "ANATOMY", 130, 134]]], ["The frequency may vary from a single episode over the entire life to weekly recurrences.Infection-Induced UrticariaGastrointestinal exacerbations may cause vomiting, watery diarrhea, colicky abdominal pain and guarding, but in the absence of fever and leukocytosis there is instead enteritis [103] .", [["abdominal", "ANATOMY", 191, 200], ["UrticariaGastrointestinal exacerbations", "DISEASE", 106, 145], ["vomiting", "DISEASE", 156, 164], ["watery diarrhea", "DISEASE", 166, 181], ["abdominal pain", "DISEASE", 191, 205], ["fever", "DISEASE", 242, 247], ["leukocytosis", "DISEASE", 252, 264], ["enteritis", "DISEASE", 282, 291], ["abdominal", "ORGANISM_SUBDIVISION", 191, 200], ["a single episode", "PROBLEM", 28, 44], ["Infection", "PROBLEM", 88, 97], ["UrticariaGastrointestinal exacerbations", "PROBLEM", 106, 145], ["vomiting", "PROBLEM", 156, 164], ["watery diarrhea", "PROBLEM", 166, 181], ["colicky abdominal pain", "PROBLEM", 183, 205], ["guarding", "PROBLEM", 210, 218], ["fever", "PROBLEM", 242, 247], ["leukocytosis", "PROBLEM", 252, 264], ["enteritis", "PROBLEM", 282, 291], ["UrticariaGastrointestinal exacerbations", "OBSERVATION", 106, 145], ["colicky", "OBSERVATION_MODIFIER", 183, 190], ["abdominal", "ANATOMY", 191, 200], ["pain", "OBSERVATION", 201, 205], ["guarding", "OBSERVATION", 210, 218], ["fever", "OBSERVATION", 242, 247], ["leukocytosis", "OBSERVATION", 252, 264], ["enteritis", "OBSERVATION", 282, 291]]], ["When the intestinal mucosa is involved, an occlusive syndrome may occur with subintrant colic and other symptoms mimicking an acute surgical emergency, sometimes resulting in unnecessary exploratory laparotomies and even appendicectomy [237] , regardless of signs of peritoneal irritation.", [["intestinal mucosa", "ANATOMY", 9, 26], ["peritoneal", "ANATOMY", 267, 277], ["occlusive syndrome", "DISEASE", 43, 61], ["colic", "DISEASE", 88, 93], ["peritoneal irritation", "DISEASE", 267, 288], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 9, 26], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 267, 277], ["an occlusive syndrome", "PROBLEM", 40, 61], ["subintrant colic", "PROBLEM", 77, 93], ["other symptoms", "PROBLEM", 98, 112], ["an acute surgical emergency", "PROBLEM", 123, 150], ["unnecessary exploratory laparotomies", "TREATMENT", 175, 211], ["appendicectomy", "TREATMENT", 221, 235], ["peritoneal irritation", "PROBLEM", 267, 288], ["intestinal mucosa", "ANATOMY", 9, 26], ["occlusive", "OBSERVATION_MODIFIER", 43, 52], ["syndrome", "OBSERVATION", 53, 61], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["surgical", "OBSERVATION", 132, 140], ["laparotomies", "OBSERVATION", 199, 211], ["appendicectomy", "OBSERVATION", 221, 235], ["peritoneal", "ANATOMY", 267, 277], ["irritation", "OBSERVATION", 278, 288]]], ["Extravascular fluid leakage to gut edema can lead to hypotension and hemoconcentration [155] .", [["Extravascular fluid", "ANATOMY", 0, 19], ["gut edema", "ANATOMY", 31, 40], ["edema", "DISEASE", 35, 40], ["hypotension", "DISEASE", 53, 64], ["hemoconcentration", "DISEASE", 69, 86], ["fluid", "ORGANISM_SUBSTANCE", 14, 19], ["gut edema", "PATHOLOGICAL_FORMATION", 31, 40], ["Extravascular fluid leakage", "PROBLEM", 0, 27], ["gut edema", "PROBLEM", 31, 40], ["hypotension", "PROBLEM", 53, 64], ["hemoconcentration", "PROBLEM", 69, 86], ["fluid leakage", "OBSERVATION", 14, 27], ["gut", "ANATOMY", 31, 34], ["edema", "OBSERVATION", 35, 40], ["hypotension", "OBSERVATION", 53, 64]]], ["The most severe complication is laryngeal edema, which, when not treated quickly and aggressively, can be lethal; the laryngeal involvement provokes death by asphyxia [169] .", [["laryngeal", "ANATOMY", 32, 41], ["laryngeal", "ANATOMY", 118, 127], ["laryngeal edema", "DISEASE", 32, 47], ["death", "DISEASE", 149, 154], ["asphyxia", "DISEASE", 158, 166], ["laryngeal edema", "PATHOLOGICAL_FORMATION", 32, 47], ["laryngeal", "ORGAN", 118, 127], ["The most severe complication", "PROBLEM", 0, 28], ["laryngeal edema", "PROBLEM", 32, 47], ["asphyxia", "PROBLEM", 158, 166], ["most", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["complication", "OBSERVATION", 16, 28], ["laryngeal", "ANATOMY", 32, 41], ["edema", "OBSERVATION", 42, 47], ["laryngeal", "ANATOMY", 118, 127]]], ["Usually an asphyxial crisis is not suddenly precipitated, because in certain cases the attack, before the real appearance of swelling, is preceded by dysphagia, dysphonia and other prodromic signs such as subjective sensation of pharyngeal prickling, pruritus or burning.", [["pharyngeal", "ANATOMY", 229, 239], ["swelling", "DISEASE", 125, 133], ["dysphagia", "DISEASE", 150, 159], ["dysphonia", "DISEASE", 161, 170], ["pharyngeal prickling", "DISEASE", 229, 249], ["pruritus", "DISEASE", 251, 259], ["pharyngeal", "ORGANISM_SUBDIVISION", 229, 239], ["an asphyxial crisis", "PROBLEM", 8, 27], ["swelling", "PROBLEM", 125, 133], ["dysphagia", "PROBLEM", 150, 159], ["dysphonia", "PROBLEM", 161, 170], ["other prodromic signs", "PROBLEM", 175, 196], ["pharyngeal prickling", "PROBLEM", 229, 249], ["pruritus", "PROBLEM", 251, 259], ["burning", "PROBLEM", 263, 270], ["asphyxial crisis", "OBSERVATION", 11, 27], ["swelling", "OBSERVATION", 125, 133], ["dysphonia", "OBSERVATION", 161, 170], ["pharyngeal", "ANATOMY", 229, 239], ["prickling", "OBSERVATION", 240, 249]]], ["Subsequently a sensation of painful tension precedes the edema.", [["edema", "ANATOMY", 57, 62], ["edema", "DISEASE", 57, 62], ["edema", "PATHOLOGICAL_FORMATION", 57, 62], ["painful tension", "PROBLEM", 28, 43], ["the edema", "PROBLEM", 53, 62], ["painful", "OBSERVATION_MODIFIER", 28, 35], ["tension", "OBSERVATION", 36, 43], ["edema", "OBSERVATION", 57, 62]]], ["These are warning symptoms allowing the timely institution of medical therapy, thus eluding tracheostomy [103] .", [["warning symptoms", "PROBLEM", 10, 26], ["medical therapy", "TREATMENT", 62, 77], ["tracheostomy", "TREATMENT", 92, 104]]], ["In these patients, oral surgery represents a particular danger since edema can easily progress to upper airway obstruction.", [["oral", "ANATOMY", 19, 23], ["edema", "ANATOMY", 69, 74], ["upper airway", "ANATOMY", 98, 110], ["edema", "DISEASE", 69, 74], ["airway obstruction", "DISEASE", 104, 122], ["patients", "ORGANISM", 9, 17], ["oral", "ORGANISM_SUBDIVISION", 19, 23], ["edema", "PATHOLOGICAL_FORMATION", 69, 74], ["upper airway", "ORGANISM_SUBDIVISION", 98, 110], ["obstruction", "PATHOLOGICAL_FORMATION", 111, 122], ["patients", "SPECIES", 9, 17], ["oral surgery", "TREATMENT", 19, 31], ["edema", "PROBLEM", 69, 74], ["upper airway obstruction", "PROBLEM", 98, 122], ["upper", "ANATOMY_MODIFIER", 98, 103], ["airway", "ANATOMY", 104, 110], ["obstruction", "OBSERVATION", 111, 122]]], ["Trauma precipitates facial and airway edema via dental manipulation or adenotonsillectomy.", [["facial", "ANATOMY", 20, 26], ["airway", "ANATOMY", 31, 37], ["Trauma", "DISEASE", 0, 6], ["airway edema", "DISEASE", 31, 43], ["airway edema", "PATHOLOGICAL_FORMATION", 31, 43], ["Trauma", "PROBLEM", 0, 6], ["facial and airway edema", "PROBLEM", 20, 43], ["dental manipulation", "TREATMENT", 48, 67], ["adenotonsillectomy", "TREATMENT", 71, 89], ["facial", "ANATOMY", 20, 26], ["airway", "ANATOMY", 31, 37], ["edema", "OBSERVATION", 38, 43], ["adenotonsillectomy", "OBSERVATION", 71, 89]]], ["Normal activity such as writing and/or computer typing are causes precipitating hand edema.", [["hand", "ANATOMY", 80, 84], ["edema", "DISEASE", 85, 90], ["hand", "ORGANISM_SUBDIVISION", 80, 84], ["edema", "PATHOLOGICAL_FORMATION", 85, 90], ["computer typing", "TEST", 39, 54], ["precipitating hand edema", "PROBLEM", 66, 90], ["activity", "OBSERVATION_MODIFIER", 7, 15], ["edema", "OBSERVATION", 85, 90]]], ["In rare cases, symptoms can be triggered by infections [237] .Physical UrticariaPhysical urticaria can be subdivided into thermal, mechanical and cholinergic urticaria, with an 8% incidence in children [90] .", [["infections", "DISEASE", 44, 54], ["UrticariaPhysical urticaria", "DISEASE", 71, 98], ["urticaria", "DISEASE", 158, 167], ["children", "ORGANISM", 193, 201], ["children", "SPECIES", 193, 201], ["symptoms", "PROBLEM", 15, 23], ["infections", "PROBLEM", 44, 54], ["Physical UrticariaPhysical urticaria", "PROBLEM", 62, 98], ["mechanical and cholinergic urticaria", "PROBLEM", 131, 167], ["cholinergic urticaria", "OBSERVATION", 146, 167]]], ["In some patients more than one type of physical urticaria may be present (Table 8 .1, Fig. 8 .5) [42] .Physical UrticariaEIA syndrome with a family tendency, is rather rare and differs from other physical urticaria due to its sporadic occurrence.", [["urticaria", "DISEASE", 48, 57], ["UrticariaEIA syndrome", "DISEASE", 112, 133], ["urticaria", "DISEASE", 205, 214], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["physical urticaria", "PROBLEM", 39, 57], ["Physical UrticariaEIA syndrome", "PROBLEM", 103, 133], ["a family tendency", "PROBLEM", 139, 156], ["other physical urticaria", "PROBLEM", 190, 214], ["its sporadic occurrence", "PROBLEM", 222, 245], ["urticaria", "OBSERVATION", 48, 57], ["UrticariaEIA syndrome", "OBSERVATION", 112, 133]]], ["Four clinical phases have been proposed: (1) the prodromal manifestations are cutaneous (pruritus, warmth, flushing and fatigue), (2) early symptoms include urticaria and angioedema, (3) the full-phase symptoms are respiratory and gastrointestinal and (4) as in phase 1, and less often shock [183] .", [["cutaneous", "ANATOMY", 78, 87], ["respiratory", "ANATOMY", 215, 226], ["gastrointestinal", "ANATOMY", 231, 247], ["pruritus", "DISEASE", 89, 97], ["flushing", "DISEASE", 107, 115], ["fatigue", "DISEASE", 120, 127], ["urticaria", "DISEASE", 157, 166], ["angioedema", "DISEASE", 171, 181], ["shock", "DISEASE", 286, 291], ["gastrointestinal", "ORGAN", 231, 247], ["the prodromal manifestations", "PROBLEM", 45, 73], ["cutaneous (pruritus", "PROBLEM", 78, 97], ["warmth", "PROBLEM", 99, 105], ["flushing", "PROBLEM", 107, 115], ["fatigue", "PROBLEM", 120, 127], ["early symptoms", "PROBLEM", 134, 148], ["urticaria", "PROBLEM", 157, 166], ["angioedema", "PROBLEM", 171, 181], ["the full-phase symptoms", "PROBLEM", 187, 210], ["cutaneous", "ANATOMY", 78, 87], ["urticaria", "OBSERVATION", 157, 166], ["angioedema", "OBSERVATION", 171, 181], ["gastrointestinal", "ANATOMY", 231, 247]]], ["Occasionally the symptoms occur without a break.", [["the symptoms", "PROBLEM", 13, 25]]], ["Triggering factors are cold and certain foods and drugs [42] .", [["Triggering factors", "PROBLEM", 0, 18], ["cold", "PROBLEM", 23, 27]]], ["Three clinical forms have been described: one is EIA occurring after jogging started within 2 h of any meal (postprandial EIA), another form occurs only following a specific food ingestion, and the third when no food is identified [190] .", [["EIA", "PROBLEM", 49, 52], ["postprandial EIA", "TEST", 109, 125]]], ["High histamine concentrations and mast cell degranulation were detected in skin biopsies [190] (see Chap.", [["mast cell", "ANATOMY", 34, 43], ["skin biopsies", "ANATOMY", 75, 88], ["histamine", "CHEMICAL", 5, 14], ["histamine", "CHEMICAL", 5, 14], ["histamine", "SIMPLE_CHEMICAL", 5, 14], ["mast cell", "CELL", 34, 43], ["skin biopsies", "TISSUE", 75, 88], ["High histamine concentrations", "PROBLEM", 0, 29], ["mast cell degranulation", "PROBLEM", 34, 57], ["skin biopsies", "TEST", 75, 88], ["histamine concentrations", "OBSERVATION", 5, 29], ["mast cell degranulation", "OBSERVATION", 34, 57], ["skin", "ANATOMY", 75, 79]]], ["20). after 6-24 h or more after pressure has been applied for a period as short as 2-3 min.", [["pressure", "TREATMENT", 32, 40]]], ["Pressure areas are diffused and result from prolonged sitting on a nonupholstered seat; wearing tight clothing and straps, watches, belts; wearing tight shoes; or walking, jogging, and climbing ladders.", [["Pressure areas", "PROBLEM", 0, 14], ["a nonupholstered seat", "TREATMENT", 65, 86], ["tight clothing and straps", "TREATMENT", 96, 121], ["diffused", "OBSERVATION_MODIFIER", 19, 27]]], ["Swelling of the soles of the feet may limit ambulation and become progressively disabling.", [["soles", "ANATOMY", 16, 21], ["feet", "ANATOMY", 29, 33], ["soles", "ORGANISM_SUBDIVISION", 16, 21], ["feet", "ORGAN", 29, 33], ["Swelling of the soles of the feet", "PROBLEM", 0, 33], ["progressively disabling", "PROBLEM", 66, 89], ["soles", "ANATOMY_MODIFIER", 16, 21], ["feet", "ANATOMY", 29, 33], ["progressively", "OBSERVATION_MODIFIER", 66, 79], ["disabling", "OBSERVATION", 80, 89]]], ["The typical lesion is painful as it is deep-seated and edematous [183] .", [["lesion", "ANATOMY", 12, 18], ["The typical lesion", "PROBLEM", 0, 18], ["painful", "PROBLEM", 22, 29], ["edematous", "PROBLEM", 55, 64], ["typical", "OBSERVATION_MODIFIER", 4, 11], ["lesion", "OBSERVATION", 12, 18], ["painful", "OBSERVATION_MODIFIER", 22, 29], ["deep", "OBSERVATION_MODIFIER", 39, 43], ["edematous", "OBSERVATION", 55, 64]]], ["The trunk, buttocks, feet and hands are the regions affected in 95%-98% of cases [64] .", [["trunk", "ANATOMY", 4, 9], ["buttocks", "ANATOMY", 11, 19], ["feet", "ANATOMY", 21, 25], ["trunk", "ORGANISM_SUBDIVISION", 4, 9], ["buttocks", "ORGANISM_SUBDIVISION", 11, 19], ["feet", "ORGANISM_SUBDIVISION", 21, 25], ["hands", "ORGANISM_SUBDIVISION", 30, 35], ["cases", "TEST", 75, 80], ["trunk", "ANATOMY", 4, 9], ["buttocks", "ANATOMY", 11, 19], ["feet", "ANATOMY", 21, 25], ["hands", "ANATOMY", 30, 35]]], ["Skin biopsies reveal signs of vasculitis with neutrophils in the lower dermis and subcutaneous tissue 4-5 h after peak swelling, then lymphocyte infiltrate after 24-48 h, thus denoting a cellmediated immunity (CMI), with tissue eosinophilia but not in the bloodstream [225] .", [["Skin biopsies", "ANATOMY", 0, 13], ["neutrophils", "ANATOMY", 46, 57], ["lower dermis", "ANATOMY", 65, 77], ["subcutaneous tissue", "ANATOMY", 82, 101], ["lymphocyte", "ANATOMY", 134, 144], ["tissue", "ANATOMY", 221, 227], ["bloodstream", "ANATOMY", 256, 267], ["vasculitis", "DISEASE", 30, 40], ["swelling", "DISEASE", 119, 127], ["eosinophilia", "DISEASE", 228, 240], ["Skin biopsies", "MULTI-TISSUE_STRUCTURE", 0, 13], ["neutrophils", "CELL", 46, 57], ["lower dermis", "TISSUE", 65, 77], ["subcutaneous tissue", "TISSUE", 82, 101], ["lymphocyte", "CELL", 134, 144], ["tissue", "TISSUE", 221, 227], ["neutrophils", "CELL_TYPE", 46, 57], ["Skin biopsies", "TEST", 0, 13], ["vasculitis", "PROBLEM", 30, 40], ["neutrophils in the lower dermis", "PROBLEM", 46, 77], ["peak swelling", "PROBLEM", 114, 127], ["lymphocyte infiltrate", "PROBLEM", 134, 155], ["a cellmediated immunity (CMI", "PROBLEM", 185, 213], ["tissue eosinophilia", "PROBLEM", 221, 240], ["signs of", "UNCERTAINTY", 21, 29], ["vasculitis", "OBSERVATION", 30, 40], ["neutrophils", "OBSERVATION", 46, 57], ["lower", "ANATOMY_MODIFIER", 65, 70], ["dermis", "ANATOMY", 71, 77], ["subcutaneous tissue", "ANATOMY", 82, 101], ["swelling", "OBSERVATION", 119, 127], ["lymphocyte infiltrate", "OBSERVATION", 134, 155], ["tissue", "ANATOMY", 221, 227], ["eosinophilia", "OBSERVATION", 228, 240]]], ["A mechanism elicited by histamine probably coexists, with participation of axonal reflexes and neuropeptide involvement as SP [156] .", [["axonal", "ANATOMY", 75, 81], ["histamine", "CHEMICAL", 24, 33], ["histamine", "CHEMICAL", 24, 33], ["histamine", "SIMPLE_CHEMICAL", 24, 33], ["axonal reflexes", "TEST", 75, 90]]], ["The increased IL 1 levels may contribute to leukocyte recruitment and systemic symptoms such as fever and malaise [117] .", [["leukocyte", "ANATOMY", 44, 53], ["fever", "DISEASE", 96, 101], ["IL 1", "GENE_OR_GENE_PRODUCT", 14, 18], ["leukocyte", "CELL", 44, 53], ["IL 1", "PROTEIN", 14, 18], ["The increased IL 1 levels", "TREATMENT", 0, 25], ["leukocyte recruitment", "PROBLEM", 44, 65], ["systemic symptoms", "PROBLEM", 70, 87], ["fever", "PROBLEM", 96, 101], ["malaise", "PROBLEM", 106, 113], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["may contribute to", "UNCERTAINTY", 26, 43], ["leukocyte recruitment", "OBSERVATION", 44, 65]]], ["Up-regulation of adhesion molecules CD62E and CD106 has led to the hypothesis that vascular endothelial activation plays an early role in the lesion upsurge [19] .Physical UrticariaCold urticaria refers to a group of urticarial manifestations induced by exposure to the cold such as typical (primary, secondary) and atypical, familial immediate or delayed, and acquired systemic or localized:Physical UrticariaPrimary typical cold urticaria (idiopathic) is characterized by a rapid onset (2-5 min) after a local cooling induced by a blunt decrease, even of 1\u00b0C, of body T, with itching, burning, flushing and edema limited to coldexposed skin (face, limbs) occurring on skin rewarming even after 1 h [42] .", [["vascular endothelial", "ANATOMY", 83, 103], ["lesion", "ANATOMY", 142, 148], ["body", "ANATOMY", 565, 569], ["edema", "ANATOMY", 609, 614], ["skin", "ANATOMY", 638, 642], ["face", "ANATOMY", 644, 648], ["limbs", "ANATOMY", 650, 655], ["skin", "ANATOMY", 670, 674], ["UrticariaCold urticaria", "DISEASE", 172, 195], ["urticaria", "DISEASE", 431, 440], ["idiopathic", "DISEASE", 442, 452], ["itching", "DISEASE", 578, 585], ["flushing", "DISEASE", 596, 604], ["edema", "DISEASE", 609, 614], ["CD62E", "GENE_OR_GENE_PRODUCT", 36, 41], ["CD106", "GENE_OR_GENE_PRODUCT", 46, 51], ["vascular endothelial", "CELL", 83, 103], ["body T", "CELL", 565, 571], ["edema", "PATHOLOGICAL_FORMATION", 609, 614], ["skin", "ORGAN", 638, 642], ["face", "ORGANISM_SUBDIVISION", 644, 648], ["limbs", "ORGANISM_SUBDIVISION", 650, 655], ["skin", "ORGAN", 670, 674], ["adhesion molecules", "PROTEIN", 17, 35], ["CD62E", "PROTEIN", 36, 41], ["CD106", "PROTEIN", 46, 51], ["adhesion molecules CD62E", "TEST", 17, 41], ["CD106", "TREATMENT", 46, 51], ["vascular endothelial activation", "PROBLEM", 83, 114], ["Physical UrticariaCold urticaria", "PROBLEM", 163, 195], ["urticarial manifestations", "PROBLEM", 217, 242], ["typical cold urticaria (idiopathic)", "PROBLEM", 418, 453], ["a local cooling", "TREATMENT", 504, 519], ["a blunt decrease", "PROBLEM", 531, 547], ["body T", "PROBLEM", 565, 571], ["itching", "PROBLEM", 578, 585], ["burning", "PROBLEM", 587, 594], ["flushing", "PROBLEM", 596, 604], ["edema", "PROBLEM", 609, 614], ["skin rewarming", "TREATMENT", 670, 684], ["adhesion molecules", "OBSERVATION", 17, 35], ["vascular endothelial", "ANATOMY", 83, 103], ["early", "OBSERVATION_MODIFIER", 124, 129], ["lesion", "OBSERVATION", 142, 148], ["urticaria", "OBSERVATION", 186, 195], ["cold urticaria", "OBSERVATION", 426, 440], ["rapid", "OBSERVATION_MODIFIER", 476, 481], ["blunt", "OBSERVATION_MODIFIER", 533, 538], ["decrease", "OBSERVATION", 539, 547], ["itching", "OBSERVATION", 578, 585], ["edema", "OBSERVATION", 609, 614], ["skin", "ANATOMY", 638, 642], ["limbs", "ANATOMY", 650, 655], ["skin", "ANATOMY", 670, 674]]], ["An act of short duration is sufficient, such as holding cold objects or drinking cold beverages may produce hand or lip swelling, respectively.", [["hand", "ANATOMY", 108, 112], ["lip", "ANATOMY", 116, 119], ["lip swelling", "DISEASE", 116, 128], ["hand", "ORGANISM_SUBDIVISION", 108, 112], ["lip", "ORGANISM_SUBDIVISION", 116, 119], ["hand or lip swelling", "PROBLEM", 108, 128], ["short duration", "OBSERVATION_MODIFIER", 10, 24], ["lip", "ANATOMY", 116, 119], ["swelling", "OBSERVATION", 120, 128]]], ["Eating cold foods may also cause a glottis edema.", [["glottis", "ANATOMY", 35, 42], ["glottis edema", "DISEASE", 35, 48], ["glottis edema", "PATHOLOGICAL_FORMATION", 35, 48], ["a glottis edema", "PROBLEM", 33, 48], ["glottis", "ANATOMY", 35, 42], ["edema", "OBSERVATION", 43, 48]]], ["Total body exposure to cold such as showering or bathing in cold water, especially in open places with further cooling, may produce such widespread vasodilation that severe hypotension and collapse ensue, and in extreme cases even death by drowning for persons diving into cold waters, often labeled \"faintness\" [111, 233] .", [["body", "ANATOMY", 6, 10], ["hypotension", "DISEASE", 173, 184], ["death", "DISEASE", 231, 236], ["drowning", "DISEASE", 240, 248], ["body", "ORGANISM_SUBDIVISION", 6, 10], ["persons", "SPECIES", 253, 260], ["further cooling", "TREATMENT", 103, 118], ["severe hypotension", "PROBLEM", 166, 184], ["collapse", "PROBLEM", 189, 197], ["body", "OBSERVATION_MODIFIER", 6, 10], ["exposure", "OBSERVATION", 11, 19], ["cold", "OBSERVATION", 23, 27], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["hypotension", "OBSERVATION", 173, 184], ["collapse", "OBSERVATION", 189, 197]]], ["In children aged 12.6 years, atopy was present in 67% of cases, and girls more frequently had cold urticaria, other types of physical urticaria were present in 25% with no familial inheritance; 83% of children had localized and generalized symptoms [181] .", [["atopy", "DISEASE", 29, 34], ["cold urticaria", "DISEASE", 94, 108], ["physical urticaria", "DISEASE", 125, 143], ["familial inheritance", "DISEASE", 172, 192], ["children", "ORGANISM", 3, 11], ["children", "ORGANISM", 201, 209], ["children", "SPECIES", 3, 11], ["girls", "SPECIES", 68, 73], ["children", "SPECIES", 201, 209], ["cold urticaria", "PROBLEM", 94, 108], ["physical urticaria", "PROBLEM", 125, 143], ["familial inheritance", "PROBLEM", 172, 192], ["generalized symptoms", "PROBLEM", 228, 248], ["urticaria", "OBSERVATION", 99, 108], ["urticaria", "OBSERVATION", 134, 143]]], ["Among 30 children <18 years old, the age of onset was at \u00aa7 years, with a strikingly high rate of asthma (46.7%) and AR (50%), and a FHA of 89.3%; 33% had anaphylactic reactions [4] .Physical UrticariaSecondary typical cold urticaria is associated with cryoglobulinemia, cryofibrinogenemia, cold hemagglu-Dermographism or dermographic urticaria, meaning literally writing on the skin, is the commonest physical urticaria, which is seen in about 5%-10% of normal subjects without a sex predilection [103] .", [["skin", "ANATOMY", 379, 383], ["asthma", "DISEASE", 98, 104], ["anaphylactic reactions", "DISEASE", 155, 177], ["cold urticaria", "DISEASE", 219, 233], ["cryoglobulinemia", "DISEASE", 253, 269], ["cryofibrinogenemia", "DISEASE", 271, 289], ["urticaria", "DISEASE", 335, 344], ["urticaria", "DISEASE", 411, 420], ["children", "ORGANISM", 9, 17], ["skin", "ORGAN", 379, 383], ["children", "SPECIES", 9, 17], ["asthma", "PROBLEM", 98, 104], ["AR", "TEST", 117, 119], ["a FHA", "TEST", 131, 136], ["anaphylactic reactions", "PROBLEM", 155, 177], ["typical cold urticaria", "PROBLEM", 211, 233], ["cryoglobulinemia", "PROBLEM", 253, 269], ["cryofibrinogenemia", "PROBLEM", 271, 289], ["cold hemagglu", "PROBLEM", 291, 304], ["Dermographism", "PROBLEM", 305, 318], ["dermographic urticaria", "PROBLEM", 322, 344], ["the commonest physical urticaria", "PROBLEM", 388, 420], ["asthma", "OBSERVATION", 98, 104], ["cold urticaria", "OBSERVATION", 219, 233], ["cryoglobulinemia", "OBSERVATION", 253, 269], ["dermographic", "OBSERVATION_MODIFIER", 322, 334], ["urticaria", "OBSERVATION", 335, 344], ["skin", "ANATOMY", 379, 383], ["urticaria", "OBSERVATION", 411, 420]]], ["In 238 children aged 2-14 years, the prevalence was 24%, with a significant predominance of females (33%) over males (16%) [136] .", [["children", "ORGANISM", 7, 15], ["children", "SPECIES", 7, 15], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["predominance", "OBSERVATION_MODIFIER", 76, 88]]], ["Following the application of a linear pressure or a gentle friction, there is characteristically the production of a wheal (diameter >2 mm) and flare reaction.", [["a linear pressure", "TREATMENT", 29, 46], ["a gentle friction", "TREATMENT", 50, 67], ["a wheal (diameter", "PROBLEM", 115, 132], ["flare reaction", "PROBLEM", 144, 158], ["gentle friction", "OBSERVATION_MODIFIER", 52, 67], ["production", "OBSERVATION_MODIFIER", 101, 111], ["wheal", "OBSERVATION", 117, 122], ["flare", "OBSERVATION", 144, 149]]], ["If the skin is stroked with a wooden tongue-depressor, a fingernail, an instrument with blunted point (a key), or a retracted ball point pen [156] , within 2-3 min the usual white line secondary to reflex vasoconstriction is followed by pruritus, flushing and a linear edema, which occur exactly in the distribution of the stimulus [111, 175] .", [["skin", "ANATOMY", 7, 11], ["tongue", "ANATOMY", 37, 43], ["white line", "ANATOMY", 174, 184], ["edema", "ANATOMY", 269, 274], ["pruritus", "DISEASE", 237, 245], ["flushing", "DISEASE", 247, 255], ["edema", "DISEASE", 269, 274], ["skin", "ORGAN", 7, 11], ["tongue", "ORGAN", 37, 43], ["edema", "PATHOLOGICAL_FORMATION", 269, 274], ["depressor", "PROBLEM", 44, 53], ["reflex vasoconstriction", "PROBLEM", 198, 221], ["pruritus", "PROBLEM", 237, 245], ["flushing", "PROBLEM", 247, 255], ["a linear edema", "PROBLEM", 260, 274], ["skin", "ANATOMY", 7, 11], ["reflex vasoconstriction", "OBSERVATION", 198, 221], ["linear", "OBSERVATION_MODIFIER", 262, 268], ["edema", "OBSERVATION", 269, 274]]], ["A positive response occurring at a stroke pressure of 3.6 g/mm 2 of skin surface or less confirms the diagnosis.", [["skin surface", "ANATOMY", 68, 80], ["stroke", "DISEASE", 35, 41], ["skin", "ORGAN", 68, 72], ["A positive response", "PROBLEM", 0, 19], ["a stroke pressure", "TEST", 33, 50], ["skin surface", "TEST", 68, 80], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["response", "OBSERVATION_MODIFIER", 11, 19], ["skin", "ANATOMY", 68, 72], ["surface", "ANATOMY_MODIFIER", 73, 80]]], ["Less obvious triggers are pressure from clothes or leaning against a chair [117] .", [["pressure from clothes", "PROBLEM", 26, 47], ["pressure", "OBSERVATION_MODIFIER", 26, 34]]], ["Three types of dermographism have been reported according to the chronology of the wheal and flare reaction, following a stimulus application: Symptoms are more common on the trunk and limbs and are differentiated by the classic triple response because minimal stimuli lead to extreme responses.", [["trunk", "ANATOMY", 175, 180], ["limbs", "ANATOMY", 185, 190], ["trunk", "ORGANISM_SUBDIVISION", 175, 180], ["limbs", "ORGANISM_SUBDIVISION", 185, 190], ["flare reaction", "PROBLEM", 93, 107], ["a stimulus application", "TREATMENT", 119, 141], ["Symptoms", "PROBLEM", 143, 151], ["flare", "OBSERVATION", 93, 98], ["more common", "OBSERVATION_MODIFIER", 156, 167], ["trunk", "ANATOMY", 175, 180], ["limbs", "ANATOMY", 185, 190]]], ["Many subjects are carriers of a mild dermographism, while a wheal response to the mechanical skin stimulus is less frequent.An association between skin and bronchial hyperreactivity (BHR) has been suggested in children with dermographism [136] .", [["skin", "ANATOMY", 93, 97], ["skin", "ANATOMY", 147, 151], ["bronchial", "ANATOMY", 156, 165], ["dermographism", "DISEASE", 37, 50], ["skin and bronchial hyperreactivity", "DISEASE", 147, 181], ["skin", "ORGAN", 93, 97], ["skin", "ORGAN", 147, 151], ["bronchial", "MULTI-TISSUE_STRUCTURE", 156, 165], ["children", "ORGANISM", 210, 218], ["children", "SPECIES", 210, 218], ["a mild dermographism", "PROBLEM", 30, 50], ["a wheal response", "PROBLEM", 58, 74], ["the mechanical skin stimulus", "TEST", 78, 106], ["An association between skin and bronchial hyperreactivity (BHR)", "PROBLEM", 124, 187], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["dermographism", "OBSERVATION", 37, 50], ["skin", "ANATOMY", 93, 97], ["skin", "ANATOMY", 147, 151], ["bronchial", "ANATOMY", 156, 165], ["hyperreactivity", "OBSERVATION", 166, 181]]], ["In about 70% of patients, a passive antibody-mediated transfer (Prausnitz-K\u00fcstner reaction) has been documented, which underlies an IgEmediated reaction, along with findings of mast cell degranulation histamine release [183] or mechanisms involving IgM antibodies [117] .", [["mast cell", "ANATOMY", 177, 186], ["histamine", "CHEMICAL", 201, 210], ["histamine", "CHEMICAL", 201, 210], ["patients", "ORGANISM", 16, 24], ["mast cell", "CELL", 177, 186], ["histamine", "SIMPLE_CHEMICAL", 201, 210], ["IgM", "GENE_OR_GENE_PRODUCT", 249, 252], ["IgM antibodies", "PROTEIN", 249, 263], ["patients", "SPECIES", 16, 24], ["a passive antibody", "TEST", 26, 44], ["Prausnitz", "TEST", 64, 73], ["an IgEmediated reaction", "PROBLEM", 129, 152], ["mast cell degranulation histamine release", "PROBLEM", 177, 218], ["IgM antibodies", "TEST", 249, 263], ["mast cell degranulation", "OBSERVATION", 177, 200]]], ["Variant types of dermographism have been described [67, 183, 233] :Physical Urticariaconstitutional, its onset is often in infancy and duration may be lifelong.Physical Urticariaacquired primitive, with a sudden onset and a duration of 1-2 years.Physical Urticariaacquired secondary, associated with cutaneous mastocytosis, upon challenge with penicillin or insect sting, or in patients with hyperthyroidism, scabies, etc.Physical Urticariacold-dependent, the classic wheal is produced only during skin cooling, but not if the skin is stroked when skin temperature (T) is normal.Physical Urticariadelayed form, causes burning and pain instead of pruritic symptoms.Physical UrticariaPressure urticaria, initially classified as a rare familial variant of dermographism.", [["cutaneous", "ANATOMY", 300, 309], ["skin", "ANATOMY", 498, 502], ["skin", "ANATOMY", 527, 531], ["skin", "ANATOMY", 548, 552], ["mastocytosis", "DISEASE", 310, 322], ["penicillin", "CHEMICAL", 344, 354], ["insect sting", "DISEASE", 358, 370], ["hyperthyroidism", "DISEASE", 392, 407], ["scabies", "DISEASE", 409, 416], ["pain", "DISEASE", 630, 634], ["pruritic", "DISEASE", 646, 654], ["UrticariaPressure urticaria", "DISEASE", 673, 700], ["penicillin", "CHEMICAL", 344, 354], ["penicillin", "SIMPLE_CHEMICAL", 344, 354], ["patients", "ORGANISM", 378, 386], ["wheal", "PATHOLOGICAL_FORMATION", 468, 473], ["skin", "ORGAN", 498, 502], ["skin", "ORGAN", 527, 531], ["skin", "ORGAN", 548, 552], ["patients", "SPECIES", 378, 386], ["dermographism", "PROBLEM", 17, 30], ["cutaneous mastocytosis", "PROBLEM", 300, 322], ["penicillin", "TREATMENT", 344, 354], ["insect sting", "PROBLEM", 358, 370], ["hyperthyroidism", "PROBLEM", 392, 407], ["scabies", "PROBLEM", 409, 416], ["the classic wheal", "PROBLEM", 456, 473], ["skin cooling", "TREATMENT", 498, 510], ["burning", "PROBLEM", 618, 625], ["pain", "PROBLEM", 630, 634], ["pruritic symptoms", "PROBLEM", 646, 663], ["Physical UrticariaPressure urticaria", "PROBLEM", 664, 700], ["a rare familial variant of dermographism", "PROBLEM", 726, 766], ["cutaneous", "ANATOMY", 300, 309], ["mastocytosis", "OBSERVATION", 310, 322], ["hyperthyroidism", "OBSERVATION", 392, 407], ["scabies", "OBSERVATION", 409, 416], ["dependent", "OBSERVATION_MODIFIER", 445, 454], ["skin", "ANATOMY", 498, 502], ["cooling", "OBSERVATION", 503, 510], ["skin", "ANATOMY", 527, 531], ["normal", "OBSERVATION", 572, 578], ["urticaria", "OBSERVATION", 691, 700]]], ["DPU appears commonly tinins and hemolysins; complement deficiencies; urticarial vasculitis; viral infections (IMN); insect stings or drugs (griseofulvin, penicillin) [175] .Physical UrticariaAtypical cold urticaria has varying manifestations and syndromes: 1.", [["DPU", "CHEMICAL", 0, 3], ["urticarial vasculitis", "DISEASE", 69, 90], ["viral infections", "DISEASE", 92, 108], ["IMN", "DISEASE", 110, 113], ["insect stings", "DISEASE", 116, 129], ["griseofulvin", "CHEMICAL", 140, 152], ["penicillin", "CHEMICAL", 154, 164], ["urticaria", "DISEASE", 205, 214], ["griseofulvin", "CHEMICAL", 140, 152], ["penicillin", "CHEMICAL", 154, 164], ["DPU", "GENE_OR_GENE_PRODUCT", 0, 3], ["griseofulvin", "SIMPLE_CHEMICAL", 140, 152], ["penicillin", "SIMPLE_CHEMICAL", 154, 164], ["hemolysins", "PROBLEM", 32, 42], ["complement deficiencies", "PROBLEM", 44, 67], ["urticarial vasculitis", "PROBLEM", 69, 90], ["viral infections (IMN)", "PROBLEM", 92, 114], ["insect stings", "PROBLEM", 116, 129], ["drugs (griseofulvin, penicillin)", "TREATMENT", 133, 165], ["Physical UrticariaAtypical cold urticaria", "PROBLEM", 173, 214], ["varying manifestations", "PROBLEM", 219, 241], ["urticarial", "OBSERVATION_MODIFIER", 69, 79], ["vasculitis", "OBSERVATION", 80, 90], ["viral infections", "OBSERVATION", 92, 108]]], ["Systemic or generalized cold urticaria has systemic symptoms characterized by giant urticaria and negative ice cube test [110] (ICT).", [["urticaria", "DISEASE", 29, 38], ["giant urticaria", "DISEASE", 78, 93], ["generalized cold urticaria", "PROBLEM", 12, 38], ["systemic symptoms", "PROBLEM", 43, 60], ["giant urticaria", "PROBLEM", 78, 93], ["ice cube test", "TEST", 107, 120], ["generalized", "OBSERVATION_MODIFIER", 12, 23], ["cold", "OBSERVATION_MODIFIER", 24, 28], ["urticaria", "OBSERVATION", 29, 38], ["giant", "OBSERVATION_MODIFIER", 78, 83], ["urticaria", "OBSERVATION", 84, 93]]], ["Two rare familial types of cold urticaria (20 cases) plus four large North American families [93] , both with autosomal dominant trait: in the immediate type mapped to chromosome 1q44, burning papules or macules appear after 30 min to 4 h associated with chills, fever, arthralgias and neutrophil leukocytosis.", [["chromosome 1q44", "ANATOMY", 168, 183], ["papules", "ANATOMY", 193, 200], ["macules", "ANATOMY", 204, 211], ["neutrophil", "ANATOMY", 286, 296], ["cold urticaria", "DISEASE", 27, 41], ["autosomal dominant trait", "DISEASE", 110, 134], ["papules", "DISEASE", 193, 200], ["macules", "DISEASE", 204, 211], ["chills", "DISEASE", 255, 261], ["fever", "DISEASE", 263, 268], ["arthralgias", "DISEASE", 270, 281], ["leukocytosis", "DISEASE", 297, 309], ["chromosome 1q44", "CELLULAR_COMPONENT", 168, 183], ["papules", "PATHOLOGICAL_FORMATION", 193, 200], ["macules", "PATHOLOGICAL_FORMATION", 204, 211], ["neutrophil", "CELL", 286, 296], ["chromosome 1q44", "DNA", 168, 183], ["cold urticaria", "PROBLEM", 27, 41], ["autosomal dominant trait", "PROBLEM", 110, 134], ["burning papules", "PROBLEM", 185, 200], ["macules", "PROBLEM", 204, 211], ["chills", "PROBLEM", 255, 261], ["fever", "PROBLEM", 263, 268], ["arthralgias", "PROBLEM", 270, 281], ["neutrophil leukocytosis", "PROBLEM", 286, 309], ["familial types", "OBSERVATION_MODIFIER", 9, 23], ["cold urticaria", "OBSERVATION_MODIFIER", 27, 41], ["dominant trait", "OBSERVATION", 120, 134], ["macules", "OBSERVATION", 204, 211], ["chills", "OBSERVATION", 255, 261], ["arthralgias", "OBSERVATION", 270, 281], ["neutrophil leukocytosis", "OBSERVATION", 286, 309]]], ["In the delayed type, they occur in the skin area of cold exposure after 9-18 h, accompanied by burning with absence of pruritus.", [["skin area", "ANATOMY", 39, 48], ["pruritus", "DISEASE", 119, 127], ["skin", "ORGAN", 39, 43], ["pruritus", "PROBLEM", 119, 127], ["delayed type", "OBSERVATION_MODIFIER", 7, 19], ["skin", "ANATOMY", 39, 43], ["pruritus", "OBSERVATION", 119, 127]]], ["In several cases, histological features include mast cell degranulation and an increase in blood histamine levels following cold exposure.", [["mast cell", "ANATOMY", 48, 57], ["blood", "ANATOMY", 91, 96], ["histamine", "CHEMICAL", 97, 106], ["histamine", "CHEMICAL", 97, 106], ["mast cell", "CELL", 48, 57], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["histamine", "SIMPLE_CHEMICAL", 97, 106], ["mast cell degranulation", "PROBLEM", 48, 71], ["an increase in blood histamine levels", "PROBLEM", 76, 113], ["cold exposure", "PROBLEM", 124, 137], ["mast cell degranulation", "OBSERVATION", 48, 71], ["increase", "OBSERVATION_MODIFIER", 79, 87]]], ["In other cases, the IgE-mediated reaction is passively transferred [100, 233] .", [["IgE", "GENE_OR_GENE_PRODUCT", 20, 23], ["IgE", "PROTEIN", 20, 23], ["the IgE-mediated reaction", "PROBLEM", 16, 41]]], ["This syndrome is associated with the CIAS1 gene [62, 93] .Physical UrticariaAcquired cold urticaria manifestations and syndromes: 1.", [["urticaria", "DISEASE", 90, 99], ["CIAS1", "GENE_OR_GENE_PRODUCT", 37, 42], ["CIAS1 gene", "DNA", 37, 47], ["This syndrome", "PROBLEM", 0, 13], ["Physical UrticariaAcquired cold urticaria manifestations", "PROBLEM", 58, 114]]], ["Cold-induced cholinergic urticaria and cold-dependent dermographism, appearing after cold exposure.", [["urticaria", "DISEASE", 25, 34], ["cholinergic urticaria", "PROBLEM", 13, 34], ["cold-dependent dermographism", "PROBLEM", 39, 67], ["cholinergic urticaria", "OBSERVATION", 13, 34], ["dependent", "OBSERVATION_MODIFIER", 44, 53], ["dermographism", "OBSERVATION", 54, 67]]], ["These forms are linked to both delayed cold urticaria and systemic types by ICT negativity [233] .", [["urticaria", "DISEASE", 44, 53], ["delayed cold urticaria", "PROBLEM", 31, 53], ["ICT negativity", "TEST", 76, 90], ["delayed", "OBSERVATION_MODIFIER", 31, 38], ["cold urticaria", "OBSERVATION", 39, 53]]], ["Localized cold urticaria affects certain areas of the body after cold contact under specific predisposing conditions mostly related to cold injuries or insect stings [111] .Physical UrticariaIn most of these syndromes, the most closely studied pathogenic aspect is the participation of histamine; TNF-a-induced mast cell release is relevant, which could be implicated in shock-like clinical manifestations [209] .Physical UrticariaSolar urticaria (1%-4% of urticaria cases), rare in children [240] and familial cases, affects both sexes, usually when they are <30 [141] .", [["body", "ANATOMY", 54, 58], ["mast cell", "ANATOMY", 311, 320], ["cold urticaria", "DISEASE", 10, 24], ["injuries", "DISEASE", 140, 148], ["insect stings", "DISEASE", 152, 165], ["histamine", "CHEMICAL", 286, 295], ["shock", "DISEASE", 371, 376], ["UrticariaSolar urticaria", "DISEASE", 422, 446], ["urticaria", "DISEASE", 457, 466], ["histamine", "CHEMICAL", 286, 295], ["body", "ORGANISM_SUBDIVISION", 54, 58], ["histamine", "SIMPLE_CHEMICAL", 286, 295], ["TNF-a-", "GENE_OR_GENE_PRODUCT", 297, 303], ["mast cell", "CELL", 311, 320], ["children", "ORGANISM", 483, 491], ["TNF", "PROTEIN", 297, 300], ["children", "SPECIES", 483, 491], ["Localized cold urticaria", "PROBLEM", 0, 24], ["cold injuries", "PROBLEM", 135, 148], ["insect stings", "PROBLEM", 152, 165], ["these syndromes", "PROBLEM", 202, 217], ["histamine", "TREATMENT", 286, 295], ["TNF", "TEST", 297, 300], ["a-induced mast cell release", "PROBLEM", 301, 328], ["shock", "PROBLEM", 371, 376], ["Physical UrticariaSolar urticaria", "PROBLEM", 413, 446], ["urticaria cases", "PROBLEM", 457, 472], ["cold", "OBSERVATION_MODIFIER", 10, 14], ["urticaria", "OBSERVATION", 15, 24], ["body", "ANATOMY", 54, 58], ["mast cell", "OBSERVATION", 311, 320], ["UrticariaSolar urticaria", "OBSERVATION", 422, 446]]], ["Within 30 s to 3 min after skin exposure to sun or UV (ultraviolet) spectrum light, patients note erythema preceded by, or immediately followed by, pruritus and then wheals (5-10 mm, persisting for 15 min to 3 h, less if patients take shelter in a shaded place [42] .", [["skin", "ANATOMY", 27, 31], ["erythema", "DISEASE", 98, 106], ["pruritus", "DISEASE", 148, 156], ["skin", "ORGAN", 27, 31], ["patients", "ORGANISM", 84, 92], ["erythema", "PATHOLOGICAL_FORMATION", 98, 106], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 221, 229], ["UV (ultraviolet)", "TREATMENT", 51, 67], ["erythema", "PROBLEM", 98, 106], ["pruritus", "PROBLEM", 148, 156], ["skin", "ANATOMY", 27, 31], ["erythema", "OBSERVATION", 98, 106]]], ["Patients complain of itchy, pricking, tingling, or burning lesions.", [["lesions", "ANATOMY", 59, 66], ["itchy", "DISEASE", 21, 26], ["pricking", "DISEASE", 28, 36], ["Patients", "ORGANISM", 0, 8], ["lesions", "PATHOLOGICAL_FORMATION", 59, 66], ["Patients", "SPECIES", 0, 8], ["itchy", "PROBLEM", 21, 26], ["pricking", "PROBLEM", 28, 36], ["tingling", "PROBLEM", 38, 46], ["burning lesions", "PROBLEM", 51, 66], ["itchy", "OBSERVATION", 21, 26], ["burning", "OBSERVATION_MODIFIER", 51, 58], ["lesions", "OBSERVATION", 59, 66]]], ["If a sufficiently large area of skin is exposed, systemic symptoms up to anaphylaxis may occur [183] .", [["skin", "ANATOMY", 32, 36], ["anaphylaxis", "DISEASE", 73, 84], ["skin", "ORGAN", 32, 36], ["systemic symptoms", "PROBLEM", 49, 66], ["anaphylaxis", "PROBLEM", 73, 84], ["large", "OBSERVATION_MODIFIER", 18, 23], ["area", "OBSERVATION_MODIFIER", 24, 28], ["skin", "ANATOMY", 32, 36]]], ["In about 25% of cases, it is associated with dermographic urticaria or with a history of AD [141] .", [["urticaria", "DISEASE", 58, 67], ["AD", "DISEASE", 89, 91], ["dermographic urticaria", "PROBLEM", 45, 67]]], ["A rare delayed form is characterized by a 17-to 72-h time-lag for lesion onset [111] .", [["lesion", "ANATOMY", 66, 72], ["lesion onset", "PROBLEM", 66, 78], ["lesion", "OBSERVATION", 66, 72]]], ["An axon-induced flare encircles the area with changing borders beyond the involved sites [111] .", [["area", "ANATOMY", 36, 40], ["An axon-induced flare", "PROBLEM", 0, 21], ["axon-induced", "OBSERVATION_MODIFIER", 3, 15], ["flare", "OBSERVATION", 16, 21], ["area", "OBSERVATION_MODIFIER", 36, 40]]], ["This disorder has been classified into six different types depending on the wavelengths of light to which patients react: only types I and IV can be passively transferred and may be antibodymediated.", [["disorder", "DISEASE", 5, 13], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["This disorder", "PROBLEM", 0, 13], ["six different types", "OBSERVATION_MODIFIER", 39, 58]]], ["In type VI, or erythropoietic protoporphyria, protoporphyrin IX acts as a photosensitizer activated by sun rays with a wavelength of 400 nm [197] .", [["erythropoietic protoporphyria", "DISEASE", 15, 44], ["protoporphyrin IX", "CHEMICAL", 46, 63], ["protoporphyrin IX", "GENE_OR_GENE_PRODUCT", 46, 63], ["protoporphyrin IX", "PROTEIN", 46, 63], ["type VI", "PROBLEM", 3, 10], ["erythropoietic protoporphyria", "PROBLEM", 15, 44], ["protoporphyrin IX acts", "TREATMENT", 46, 68], ["a photosensitizer", "TREATMENT", 72, 89], ["type VI", "OBSERVATION_MODIFIER", 3, 10], ["erythropoietic protoporphyria", "OBSERVATION", 15, 44]]], ["Skin biop-sies show neutrophils and eosinophils within a time-lag of 5 min to 2 h, replaced by PBMCs after 24 h [151] and eosinophils degranulate in skin lesions with MBP deposition [121] .Physical UrticariaContact urticaria with erythematous and wheal-like eruptions is aroused 30-60 min after normal skin exposure to the offending substance, most often induced by nettles and certain vegetables (see \"Phytodermatitis\"), some coelenterates such as jellyfish, as well as drugs, foods, cosmetics, fragrances (cinnamic aldehyde), chemical substances (disinfectants and bleaching), cat, dog, horse hair (in order of frequency), etc. [103] .", [["Skin biop-sies", "ANATOMY", 0, 14], ["neutrophils", "ANATOMY", 20, 31], ["eosinophils", "ANATOMY", 36, 47], ["PBMCs", "ANATOMY", 95, 100], ["eosinophils", "ANATOMY", 122, 133], ["skin lesions", "ANATOMY", 149, 161], ["erythematous", "ANATOMY", 230, 242], ["wheal", "ANATOMY", 247, 252], ["skin", "ANATOMY", 302, 306], ["vegetables", "ANATOMY", 386, 396], ["hair", "ANATOMY", 595, 599], ["urticaria", "DISEASE", 215, 224], ["erythematous", "DISEASE", 230, 242], ["eruptions", "DISEASE", 258, 267], ["cinnamic aldehyde", "CHEMICAL", 508, 525], ["cinnamic aldehyde", "CHEMICAL", 508, 525], ["Skin", "ORGAN", 0, 4], ["neutrophils", "CELL", 20, 31], ["eosinophils", "CELL", 36, 47], ["PBMCs", "CELL", 95, 100], ["eosinophils", "CELL", 122, 133], ["skin lesions", "PATHOLOGICAL_FORMATION", 149, 161], ["MBP", "GENE_OR_GENE_PRODUCT", 167, 170], ["skin", "ORGAN", 302, 306], ["vegetables", "ORGANISM_SUBDIVISION", 386, 396], ["cinnamic aldehyde", "SIMPLE_CHEMICAL", 508, 525], ["cat", "ORGANISM_SUBDIVISION", 579, 582], ["dog", "ORGANISM_SUBDIVISION", 584, 587], ["horse hair", "MULTI-TISSUE_STRUCTURE", 589, 599], ["neutrophils", "CELL_TYPE", 20, 31], ["eosinophils", "CELL_TYPE", 36, 47], ["PBMCs", "CELL_TYPE", 95, 100], ["eosinophils", "CELL_TYPE", 122, 133], ["MBP", "PROTEIN", 167, 170], ["cat", "SPECIES", 579, 582], ["dog", "SPECIES", 584, 587], ["horse", "SPECIES", 589, 594], ["Skin biop", "TEST", 0, 9], ["neutrophils", "TEST", 20, 31], ["eosinophils", "TEST", 36, 47], ["eosinophils degranulate in skin lesions", "PROBLEM", 122, 161], ["MBP deposition", "TEST", 167, 181], ["Physical UrticariaContact urticaria", "PROBLEM", 189, 224], ["erythematous and wheal-like eruptions", "PROBLEM", 230, 267], ["neutrophils", "OBSERVATION", 20, 31], ["eosinophils degranulate", "OBSERVATION", 122, 145], ["skin", "ANATOMY", 149, 153], ["lesions", "OBSERVATION", 154, 161], ["MBP deposition", "OBSERVATION", 167, 181], ["urticaria", "OBSERVATION", 215, 224], ["erythematous", "OBSERVATION_MODIFIER", 230, 242], ["skin", "ANATOMY", 302, 306]]], ["Contact can be achieved via airborne agents, including grass pollen, as in sensitized children walking outdoors during days or in places with notable pollination, or playing in the grass, etc., or indirectly via toy contamination with pollens.", [["children", "ORGANISM", 86, 94], ["children", "SPECIES", 86, 94]]], ["Food allergens include egg, CM, tomato, chicken, honey, peanut butter, sunflower seeds, and cooked chick-peas [1, 115] , also during their manipulation by children affected with oral allergy syndrome (OAS).", [["egg", "ANATOMY", 23, 26], ["honey", "ANATOMY", 49, 54], ["seeds", "ANATOMY", 81, 86], ["oral", "ANATOMY", 178, 182], ["oral allergy syndrome", "DISEASE", 178, 199], ["OAS", "DISEASE", 201, 204], ["egg", "ORGANISM_SUBSTANCE", 23, 26], ["tomato", "ORGANISM_SUBDIVISION", 32, 38], ["chicken", "ORGANISM", 40, 47], ["honey", "ORGANISM_SUBDIVISION", 49, 54], ["peanut butter", "ORGANISM", 56, 69], ["chick", "ORGANISM", 99, 104], ["children", "ORGANISM", 155, 163], ["oral", "ORGANISM_SUBDIVISION", 178, 182], ["tomato", "SPECIES", 32, 38], ["chicken", "SPECIES", 40, 47], ["honey", "SPECIES", 49, 54], ["peanut", "SPECIES", 56, 62], ["butter", "SPECIES", 63, 69], ["sunflower", "SPECIES", 71, 80], ["chick", "SPECIES", 99, 104], ["peas", "SPECIES", 105, 109], ["children", "SPECIES", 155, 163], ["tomato", "SPECIES", 32, 38], ["chicken", "SPECIES", 40, 47], ["honey", "SPECIES", 49, 54], ["peanut", "SPECIES", 56, 62], ["oral allergy syndrome", "PROBLEM", 178, 199]]], ["Symptoms are usually elicited within 30-60 min; cases with onset delayed up to 6 h have been reported.Physical UrticariaThere are four clinical forms [117] : \u2211 Contact urticaria, localized, the most frequent, usually caused by foods and pet danders. \u2211 Contact urticaria with angioedema, also with systemic manifestations, often formaldehyde-induced. \u2211 Contact urticaria with asthma, sometimes associated with gastrointestinal and oculorhinitic disorders. the onset is triggered by cephalosporins, various vegetables and processionary caterpillars, whose urticating hairs caused toxic-irritative effects on both skin and mucosa by direct contact as in 60/653 children (9.18%) with 4 IgE-mediated cases (6.7%) [222] , and on the airways by aerodispersion (allergen Tha p 1, Table 1 .74). \u2211 Contact urticaria with anaphylactic shock, a severe reaction often associated with penicillin, neomycin, bacitracin, etc.Physical UrticariaA delayed type of contact urticaria is limited to some families.Physical UrticariaContact urticaria can be categorized into three groups from the pathogenetic point of view [115] : \u2211 Immunological contact urticaria, almost always IgEmediated: Table 8 .2 [115] . \u2211 Nonimmunological contact urticaria, mostly triggered by preservatives or additives employed the world over (Table 8 .2). \u2211 Urticaria characterized by an undefined mechanism including OAS and protein contact dermatitis; see, respectively, Chap.", [["gastrointestinal", "ANATOMY", 409, 425], ["vegetables", "ANATOMY", 505, 515], ["hairs", "ANATOMY", 565, 570], ["skin", "ANATOMY", 611, 615], ["mucosa", "ANATOMY", 620, 626], ["airways", "ANATOMY", 727, 734], ["Contact urticaria", "DISEASE", 160, 177], ["urticaria", "DISEASE", 260, 269], ["angioedema", "DISEASE", 275, 285], ["formaldehyde", "CHEMICAL", 328, 340], ["urticaria", "DISEASE", 360, 369], ["asthma", "DISEASE", 375, 381], ["gastrointestinal and oculorhinitic disorders", "DISEASE", 409, 453], ["cephalosporins", "CHEMICAL", 481, 495], ["urticaria", "DISEASE", 796, 805], ["anaphylactic shock", "DISEASE", 811, 829], ["penicillin", "CHEMICAL", 871, 881], ["neomycin", "CHEMICAL", 883, 891], ["bacitracin", "CHEMICAL", 893, 903], ["urticaria", "DISEASE", 953, 962], ["urticaria", "DISEASE", 1017, 1026], ["Immunological contact urticaria", "DISEASE", 1110, 1141], ["urticaria", "DISEASE", 1216, 1225], ["Urticaria", "DISEASE", 1314, 1323], ["dermatitis", "DISEASE", 1398, 1408], ["formaldehyde", "CHEMICAL", 328, 340], ["cephalosporins", "CHEMICAL", 481, 495], ["penicillin", "CHEMICAL", 871, 881], ["neomycin", "CHEMICAL", 883, 891], ["bacitracin", "CHEMICAL", 893, 903], ["formaldehyde", "SIMPLE_CHEMICAL", 328, 340], ["gastrointestinal", "ORGANISM_SUBDIVISION", 409, 425], ["cephalosporins", "SIMPLE_CHEMICAL", 481, 495], ["vegetables", "ORGANISM_SUBDIVISION", 505, 515], ["hairs", "ORGAN", 565, 570], ["skin", "ORGAN", 611, 615], ["mucosa", "MULTI-TISSUE_STRUCTURE", 620, 626], ["children", "ORGANISM", 658, 666], ["IgE", "GENE_OR_GENE_PRODUCT", 682, 685], ["airways", "MULTI-TISSUE_STRUCTURE", 727, 734], ["penicillin", "SIMPLE_CHEMICAL", 871, 881], ["neomycin", "SIMPLE_CHEMICAL", 883, 891], ["bacitracin", "SIMPLE_CHEMICAL", 893, 903], ["IgE", "PROTEIN", 682, 685], ["children", "SPECIES", 658, 666], ["Symptoms", "PROBLEM", 0, 8], ["Contact urticaria", "PROBLEM", 160, 177], ["Contact urticaria", "PROBLEM", 252, 269], ["angioedema", "PROBLEM", 275, 285], ["systemic manifestations", "PROBLEM", 297, 320], ["Contact urticaria", "PROBLEM", 352, 369], ["asthma", "PROBLEM", 375, 381], ["gastrointestinal and oculorhinitic disorders", "PROBLEM", 409, 453], ["cephalosporins", "TREATMENT", 481, 495], ["processionary caterpillars", "PROBLEM", 520, 546], ["toxic-irritative effects", "PROBLEM", 578, 602], ["4 IgE-mediated cases", "TREATMENT", 680, 700], ["Contact urticaria", "PROBLEM", 788, 805], ["anaphylactic shock", "PROBLEM", 811, 829], ["a severe reaction", "PROBLEM", 831, 848], ["penicillin", "TREATMENT", 871, 881], ["neomycin", "TREATMENT", 883, 891], ["bacitracin", "TREATMENT", 893, 903], ["etc", "TREATMENT", 905, 908], ["contact urticaria", "PROBLEM", 945, 962], ["Physical UrticariaContact urticaria", "PROBLEM", 991, 1026], ["Immunological contact urticaria", "PROBLEM", 1110, 1141], ["Nonimmunological contact urticaria", "PROBLEM", 1191, 1225], ["Urticaria", "PROBLEM", 1314, 1323], ["an undefined mechanism", "PROBLEM", 1341, 1363], ["OAS", "PROBLEM", 1374, 1377], ["protein contact dermatitis", "PROBLEM", 1382, 1408], ["urticaria", "OBSERVATION", 168, 177], ["most frequent", "OBSERVATION_MODIFIER", 194, 207], ["urticaria", "OBSERVATION", 260, 269], ["angioedema", "OBSERVATION", 275, 285], ["urticaria", "OBSERVATION", 360, 369], ["asthma", "OBSERVATION", 375, 381], ["gastrointestinal", "ANATOMY", 409, 425], ["toxic", "OBSERVATION_MODIFIER", 578, 583], ["irritative effects", "OBSERVATION", 584, 602], ["skin", "ANATOMY", 611, 615], ["mucosa", "ANATOMY", 620, 626], ["airways", "ANATOMY", 727, 734], ["urticaria", "OBSERVATION", 796, 805], ["anaphylactic shock", "OBSERVATION", 811, 829], ["severe", "OBSERVATION_MODIFIER", 833, 839], ["reaction", "OBSERVATION", 840, 848], ["Urticaria", "OBSERVATION", 1314, 1323], ["protein contact dermatitis", "OBSERVATION", 1382, 1408]]], ["9 and the second part of this chapter. \u2211 Vibratory angioedema, a hereditary disorder more commonly transmitted as an autosomal dominant condition, arising in children and persisting into adult age, decreasing progressively in severity [42] .", [["angioedema", "DISEASE", 51, 61], ["hereditary disorder", "DISEASE", 65, 84], ["autosomal dominant condition", "DISEASE", 117, 145], ["children", "ORGANISM", 158, 166], ["children", "SPECIES", 158, 166], ["Vibratory angioedema", "PROBLEM", 41, 61], ["a hereditary disorder", "PROBLEM", 63, 84], ["an autosomal dominant condition", "PROBLEM", 114, 145], ["angioedema", "OBSERVATION", 51, 61], ["hereditary", "OBSERVATION_MODIFIER", 65, 75], ["disorder", "OBSERVATION", 76, 84], ["dominant", "OBSERVATION_MODIFIER", 127, 135], ["condition", "OBSERVATION", 136, 145]]], ["Patients complain of pruritus, erythema, edema and wheals of 5-10 mm, within minutes in response to the application to the skin of an even gentle vibratory stimulus and lasting up to 24 h, depending on the stimulus and body sur-forelimbs, occur from 2-3 min to 30 min after exposure to water [156] .", [["edema", "ANATOMY", 41, 46], ["skin", "ANATOMY", 123, 127], ["body sur-forelimbs", "ANATOMY", 219, 237], ["pruritus", "DISEASE", 21, 29], ["erythema", "DISEASE", 31, 39], ["edema", "DISEASE", 41, 46], ["Patients", "ORGANISM", 0, 8], ["erythema", "PATHOLOGICAL_FORMATION", 31, 39], ["edema", "PATHOLOGICAL_FORMATION", 41, 46], ["skin", "ORGAN", 123, 127], ["body", "ORGANISM_SUBDIVISION", 219, 223], ["Patients", "SPECIES", 0, 8], ["pruritus", "PROBLEM", 21, 29], ["erythema", "PROBLEM", 31, 39], ["edema", "PROBLEM", 41, 46], ["wheals", "PROBLEM", 51, 57], ["pruritus", "OBSERVATION", 21, 29], ["erythema", "OBSERVATION", 31, 39], ["edema", "OBSERVATION", 41, 46], ["wheals", "OBSERVATION_MODIFIER", 51, 57], ["5-10 mm", "OBSERVATION_MODIFIER", 61, 68], ["skin", "ANATOMY", 123, 127]]], ["On immersion, seven babies became pale, hypotonic, still and unreactive [146] .", [["babies", "ORGANISM", 20, 26], ["pale", "PROBLEM", 34, 38], ["hypotonic", "PROBLEM", 40, 49], ["pale", "OBSERVATION", 34, 38], ["hypotonic", "OBSERVATION", 40, 49], ["unreactive", "OBSERVATION", 61, 71]]], ["The lesions may subside after 30 min [156] ; however, recovery took a few seconds after withdrawal from the bath and stimulation [146] .", [["lesions", "ANATOMY", 4, 11], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["The lesions", "PROBLEM", 0, 11], ["withdrawal", "PROBLEM", 88, 98], ["the bath and stimulation", "TREATMENT", 104, 128], ["lesions", "OBSERVATION", 4, 11]]], ["Biopsy specimens of the lesions reveal mast cell degranulation and hyperhistaminemia; also a cholinergic mechanism seems to play a role [183] .", [["Biopsy specimens", "ANATOMY", 0, 16], ["lesions", "ANATOMY", 24, 31], ["mast cell", "ANATOMY", 39, 48], ["hyperhistaminemia", "DISEASE", 67, 84], ["Biopsy specimens", "CANCER", 0, 16], ["lesions", "PATHOLOGICAL_FORMATION", 24, 31], ["mast cell", "CELL", 39, 48], ["Biopsy specimens", "TEST", 0, 16], ["the lesions", "PROBLEM", 20, 31], ["mast cell degranulation", "PROBLEM", 39, 62], ["hyperhistaminemia", "PROBLEM", 67, 84], ["a cholinergic mechanism", "PROBLEM", 91, 114], ["lesions", "OBSERVATION", 24, 31], ["mast cell degranulation", "OBSERVATION", 39, 62]]], ["The sex ratio is unfavorable to females (2:1) at puberty or pre-puberty age [238] . \u2211 Cholinergic or thermolytic urticaria, also known as generalized heat urticaria, along with dermographism is the most common physical urticaria (5%-7% of all urticaria forms), prevalently affecting adolescents and young adults.", [["thermolytic urticaria", "DISEASE", 101, 122], ["heat urticaria", "DISEASE", 150, 164], ["urticaria", "DISEASE", 219, 228], ["urticaria", "DISEASE", 243, 252], ["adolescents", "SPECIES", 283, 294], ["Cholinergic", "PROBLEM", 86, 97], ["thermolytic urticaria", "PROBLEM", 101, 122], ["generalized heat urticaria", "PROBLEM", 138, 164], ["physical urticaria", "PROBLEM", 210, 228], ["all urticaria forms", "PROBLEM", 239, 258], ["unfavorable", "OBSERVATION_MODIFIER", 17, 28], ["urticaria", "OBSERVATION", 113, 122], ["urticaria", "OBSERVATION", 155, 164], ["urticaria", "OBSERVATION", 219, 228]]], ["Prodromic signs may face area involved.", [["Prodromic signs", "PROBLEM", 0, 15]]], ["If the stimulus is appropriately intense a systemic reaction may occur, inciting stimuli are motorcycling, toweling, massaging, and the like.", [["a systemic reaction", "PROBLEM", 41, 60], ["inciting stimuli", "PROBLEM", 72, 88], ["motorcycling", "PROBLEM", 93, 105], ["toweling", "PROBLEM", 107, 115], ["massaging", "PROBLEM", 117, 126]]], ["A form with delayed onset (4-8 h) and one acquired idiopathic form have been reported [42, 103, 111] . \u2211 Aquagenic urticaria is another rare form: 15 pediatric cases have been recorded [129, 146, 163, 236] .Age ranges from 2-15 months [146] to 7 years [163] ; eight children had associated symptomatic dermographism [146, 163] .", [["urticaria", "DISEASE", 115, 124], ["children", "ORGANISM", 266, 274], ["children", "SPECIES", 266, 274], ["delayed onset", "PROBLEM", 12, 25], ["one acquired idiopathic form", "PROBLEM", 38, 66], ["Aquagenic urticaria", "PROBLEM", 105, 124], ["associated symptomatic dermographism", "PROBLEM", 279, 315], ["idiopathic", "OBSERVATION", 51, 61]]], ["A familial tendency has been observed in 11 families [146, 183] , in one family over three generations in association with familial lactose intolerance [213] .", [["lactose intolerance", "DISEASE", 132, 151], ["lactose", "CHEMICAL", 132, 139], ["lactose", "SIMPLE_CHEMICAL", 132, 139], ["A familial tendency", "PROBLEM", 0, 19], ["familial lactose intolerance", "PROBLEM", 123, 151]]], ["Affected individuals develop pinpoint wheals after skin contact with water, snow, or more or less intense perspiration, regardless of the T [183] .", [["skin", "ANATOMY", 51, 55], ["individuals", "ORGANISM", 9, 20], ["skin", "ORGAN", 51, 55], ["Affected individuals", "PROBLEM", 0, 20], ["pinpoint wheals", "PROBLEM", 29, 44], ["pinpoint", "OBSERVATION_MODIFIER", 29, 37], ["wheals", "OBSERVATION", 38, 44], ["skin", "ANATOMY", 51, 55]]], ["The lesions (pruritic wheals of 1-3 mm) predominate on the trunk and, less often on 551 Urticaria-Angioedema Syndrome arise within 2-30 min of the triggering event, consisting of pruritus, tingling, warmth, or burning of the skin [183] .", [["lesions", "ANATOMY", 4, 11], ["trunk", "ANATOMY", 59, 64], ["skin", "ANATOMY", 225, 229], ["Urticaria", "DISEASE", 88, 97], ["Angioedema Syndrome", "DISEASE", 98, 117], ["pruritus", "DISEASE", 179, 187], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["trunk", "ORGANISM_SUBDIVISION", 59, 64], ["skin", "ORGAN", 225, 229], ["The lesions (pruritic wheals", "PROBLEM", 0, 28], ["Urticaria", "PROBLEM", 88, 97], ["Angioedema Syndrome", "PROBLEM", 98, 117], ["pruritus", "PROBLEM", 179, 187], ["tingling", "PROBLEM", 189, 197], ["warmth", "PROBLEM", 199, 205], ["burning of the skin", "PROBLEM", 210, 229], ["lesions", "OBSERVATION", 4, 11], ["pruritic", "OBSERVATION_MODIFIER", 13, 21], ["1-3 mm", "OBSERVATION_MODIFIER", 32, 38], ["trunk", "ANATOMY", 59, 64], ["less", "OBSERVATION_MODIFIER", 70, 74], ["Angioedema", "OBSERVATION", 98, 108], ["pruritus", "OBSERVATION", 179, 187], ["skin", "ANATOMY", 225, 229]]], ["The ensuing cutaneous manifestations are erythematous and wheal-like, 1-3 mm in diameter, with surrounding bright red flares.", [["cutaneous", "ANATOMY", 12, 21], ["The ensuing cutaneous manifestations", "PROBLEM", 0, 36], ["erythematous", "PROBLEM", 41, 53], ["wheal", "TEST", 58, 63], ["surrounding bright red flares", "PROBLEM", 95, 124], ["cutaneous", "OBSERVATION_MODIFIER", 12, 21], ["erythematous", "OBSERVATION_MODIFIER", 41, 53], ["wheal", "OBSERVATION_MODIFIER", 58, 63], ["1-3 mm", "OBSERVATION_MODIFIER", 70, 76], ["diameter", "OBSERVATION_MODIFIER", 80, 88], ["surrounding", "OBSERVATION_MODIFIER", 95, 106], ["bright", "OBSERVATION_MODIFIER", 107, 113], ["red flares", "OBSERVATION", 114, 124]]], ["These may become confluent to form intensely itching papular wheals, which appear abruptly after variations in ambient T or changes in body T following fever, intense sweating after vigorous exercise, hot showers or sauna, intense transient emotional stimuli, often accompanied by symptoms of cholinergic stimulation, such as lacrimation, salivation and diarrhea, with the involved area returning to normal after about 1 h [117, 175, 183] .", [["body", "ANATOMY", 135, 139], ["fever", "DISEASE", 152, 157], ["salivation", "DISEASE", 339, 349], ["diarrhea", "DISEASE", 354, 362], ["papular wheals", "PATHOLOGICAL_FORMATION", 53, 67], ["intensely itching papular wheals", "PROBLEM", 35, 67], ["fever", "PROBLEM", 152, 157], ["intense sweating", "PROBLEM", 159, 175], ["vigorous exercise", "TREATMENT", 182, 199], ["intense transient emotional stimuli", "PROBLEM", 223, 258], ["symptoms", "PROBLEM", 281, 289], ["cholinergic stimulation", "PROBLEM", 293, 316], ["lacrimation, salivation", "PROBLEM", 326, 349], ["diarrhea", "PROBLEM", 354, 362], ["confluent", "OBSERVATION_MODIFIER", 17, 26], ["intensely", "OBSERVATION_MODIFIER", 35, 44], ["itching", "OBSERVATION_MODIFIER", 45, 52], ["papular", "OBSERVATION_MODIFIER", 53, 60], ["wheals", "OBSERVATION", 61, 67], ["abruptly", "OBSERVATION_MODIFIER", 82, 90], ["body", "ANATOMY", 135, 139], ["cholinergic stimulation", "OBSERVATION", 293, 316]]], ["In severely ill patients, systemic symptoms such as angioedema and cardiovascular, respiratory or gastrointestinal signs may be associated with anaphylaxis [156] .", [["cardiovascular", "ANATOMY", 67, 81], ["respiratory", "ANATOMY", 83, 94], ["gastrointestinal", "ANATOMY", 98, 114], ["severely ill", "DISEASE", 3, 15], ["angioedema", "DISEASE", 52, 62], ["cardiovascular, respiratory or gastrointestinal signs", "DISEASE", 67, 120], ["anaphylaxis", "DISEASE", 144, 155], ["patients", "ORGANISM", 16, 24], ["gastrointestinal", "ORGAN", 98, 114], ["patients", "SPECIES", 16, 24], ["systemic symptoms", "PROBLEM", 26, 43], ["angioedema", "PROBLEM", 52, 62], ["cardiovascular, respiratory or gastrointestinal signs", "PROBLEM", 67, 120], ["anaphylaxis", "PROBLEM", 144, 155], ["severely", "OBSERVATION_MODIFIER", 3, 11], ["ill", "OBSERVATION_MODIFIER", 12, 15], ["respiratory", "ANATOMY", 83, 94], ["gastrointestinal", "ANATOMY", 98, 114]]], ["A similar picture can be produced in affected individuals by acetylcholine: it is postulated that pathogenic mechanisms are based on body T increase and the following skin exposure to a warm stimulus can affect the higher nerve centers [197] .", [["body", "ANATOMY", 133, 137], ["skin", "ANATOMY", 167, 171], ["nerve centers", "ANATOMY", 222, 235], ["acetylcholine", "CHEMICAL", 61, 74], ["acetylcholine", "CHEMICAL", 61, 74], ["acetylcholine", "SIMPLE_CHEMICAL", 61, 74], ["body T", "CELL", 133, 139], ["skin", "ORGAN", 167, 171], ["pathogenic mechanisms", "PROBLEM", 98, 119], ["body T increase", "PROBLEM", 133, 148], ["a warm stimulus", "TEST", 184, 199], ["skin", "ANATOMY", 167, 171]]], ["Thus, acetylcholine release may be evoked along peripheral nerve endings, also inducing histamine release, probably by a direct action of cholinergic receptors on mast cells [197] . \u2211 Cholinergic cold urticaria occurs when systemic cold contact produces a form similar to cold urticaria [4, 181] . \u2211 Localized heat urticaria, also rare (18 cases) is apparent with immediate urticarial reactions within 5 min after heat application, for example warm water [54] at a T of 43\u00b0C and lasting about 1 h, with increased plasma histamine levels [42] .", [["peripheral nerve endings", "ANATOMY", 48, 72], ["mast cells", "ANATOMY", 163, 173], ["plasma", "ANATOMY", 513, 519], ["acetylcholine", "CHEMICAL", 6, 19], ["histamine", "CHEMICAL", 88, 97], ["urticaria", "DISEASE", 201, 210], ["urticaria", "DISEASE", 277, 286], ["urticaria", "DISEASE", 315, 324], ["histamine", "CHEMICAL", 520, 529], ["acetylcholine", "CHEMICAL", 6, 19], ["histamine", "CHEMICAL", 88, 97], ["histamine", "CHEMICAL", 520, 529], ["acetylcholine", "SIMPLE_CHEMICAL", 6, 19], ["peripheral nerve endings", "MULTI-TISSUE_STRUCTURE", 48, 72], ["histamine", "SIMPLE_CHEMICAL", 88, 97], ["mast cells", "CELL", 163, 173], ["plasma", "ORGANISM_SUBSTANCE", 513, 519], ["histamine", "SIMPLE_CHEMICAL", 520, 529], ["cholinergic receptors", "PROTEIN", 138, 159], ["mast cells", "CELL_TYPE", 163, 173], ["acetylcholine release", "TREATMENT", 6, 27], ["histamine release", "TREATMENT", 88, 105], ["Cholinergic cold urticaria", "PROBLEM", 184, 210], ["systemic cold contact", "PROBLEM", 223, 244], ["cold urticaria", "PROBLEM", 272, 286], ["Localized heat urticaria", "PROBLEM", 300, 324], ["immediate urticarial reactions", "PROBLEM", 364, 394], ["heat application", "TREATMENT", 414, 430], ["increased plasma histamine levels", "TEST", 503, 536], ["peripheral", "ANATOMY_MODIFIER", 48, 58], ["nerve", "ANATOMY", 59, 64], ["mast cells", "OBSERVATION", 163, 173], ["urticaria", "OBSERVATION", 201, 210], ["heat", "OBSERVATION_MODIFIER", 310, 314], ["urticaria", "OBSERVATION", 315, 324], ["urticarial", "OBSERVATION", 374, 384]]], ["A 5-year-old girl developed sudden-onset episodes of pruritus (after 3 min of heat exposure), redness, and local skin swelling, which resolved within 90 min.", [["skin", "ANATOMY", 113, 117], ["pruritus", "DISEASE", 53, 61], ["redness", "DISEASE", 94, 101], ["skin swelling", "DISEASE", 113, 126], ["girl", "ORGANISM", 13, 17], ["skin", "ORGAN", 113, 117], ["girl", "SPECIES", 13, 17], ["pruritus", "PROBLEM", 53, 61], ["heat exposure", "PROBLEM", 78, 91], ["redness", "PROBLEM", 94, 101], ["local skin swelling", "PROBLEM", 107, 126], ["pruritus", "OBSERVATION", 53, 61], ["redness", "OBSERVATION", 94, 101], ["local", "OBSERVATION_MODIFIER", 107, 112], ["skin", "ANATOMY", 113, 117], ["swelling", "OBSERVATION", 118, 126]]], ["Histamine increased at 3 min after heat challenge and then declined [134] .", [["Histamine", "CHEMICAL", 0, 9], ["Histamine", "CHEMICAL", 0, 9], ["Histamine", "SIMPLE_CHEMICAL", 0, 9], ["Histamine", "TREATMENT", 0, 9], ["heat challenge", "TEST", 35, 49], ["increased", "OBSERVATION_MODIFIER", 10, 19]]], ["A delayed familial localized heat urticaria is very rare; lesions appear 6-18 h after exposure to localized thermal stimuli and last 12-24 h [111] .Physical UrticariaThe mother of a child seen by us experiences urticaria to both cold and warm objects or even the weather.Chronic UrticariaChronic urticaria is defined as persisting or recurrent urticaria lasting >6 weeks, which may be presently considered the most frequent cause of urticaria [18] .", [["lesions", "ANATOMY", 58, 65], ["urticaria", "DISEASE", 34, 43], ["Urticaria", "DISEASE", 157, 166], ["urticaria", "DISEASE", 211, 220], ["UrticariaChronic urticaria", "DISEASE", 279, 305], ["urticaria", "DISEASE", 344, 353], ["urticaria", "DISEASE", 433, 442], ["lesions", "PATHOLOGICAL_FORMATION", 58, 65], ["child", "ORGANISM", 182, 187], ["child", "SPECIES", 182, 187], ["A delayed familial localized heat urticaria", "PROBLEM", 0, 43], ["lesions", "PROBLEM", 58, 65], ["localized thermal stimuli", "TEST", 98, 123], ["Physical Urticaria", "PROBLEM", 148, 166], ["urticaria", "PROBLEM", 211, 220], ["Chronic UrticariaChronic urticaria", "PROBLEM", 271, 305], ["recurrent urticaria", "PROBLEM", 334, 353], ["urticaria", "PROBLEM", 433, 442], ["heat urticaria", "OBSERVATION", 29, 43], ["lesions", "OBSERVATION", 58, 65], ["Urticaria", "OBSERVATION", 157, 166], ["UrticariaChronic", "OBSERVATION_MODIFIER", 279, 295], ["urticaria", "OBSERVATION", 296, 305], ["persisting", "OBSERVATION_MODIFIER", 320, 330], ["recurrent", "OBSERVATION_MODIFIER", 334, 343], ["urticaria", "OBSERVATION", 344, 353], ["urticaria", "OBSERVATION", 433, 442]]], ["In follow-ups, several cases may progress from acute to chronic urticaria, for example 12 (30%) of 40 children in one study [144] .", [["urticaria", "DISEASE", 64, 73], ["children", "ORGANISM", 102, 110], ["children", "SPECIES", 102, 110], ["chronic urticaria", "PROBLEM", 56, 73], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["urticaria", "OBSERVATION", 64, 73]]], ["In three studies on 366 children aged 1-14 [18, 201, 229] , several causes were ascertained, summarized in Table 8 .3 [18, 229] , including physical forms (cholinergic, dermographic, cold and pressure urticaria), infections (parasites and/or streptococci), foods (CM, egg, fish, nuts), food additives (tartrazine, salicylates), aeroallergens (pollens, cat dander) and drugs (penicillin, phenobarbital).", [["egg", "ANATOMY", 268, 271], ["nuts", "ANATOMY", 279, 283], ["urticaria", "DISEASE", 201, 210], ["infections", "DISEASE", 213, 223], ["CM", "DISEASE", 264, 266], ["tartrazine", "CHEMICAL", 302, 312], ["penicillin", "CHEMICAL", 375, 385], ["phenobarbital", "CHEMICAL", 387, 400], ["tartrazine", "CHEMICAL", 302, 312], ["salicylates", "CHEMICAL", 314, 325], ["penicillin", "CHEMICAL", 375, 385], ["phenobarbital", "CHEMICAL", 387, 400], ["children", "ORGANISM", 24, 32], ["egg", "ORGANISM_SUBDIVISION", 268, 271], ["fish", "ORGANISM_SUBDIVISION", 273, 277], ["nuts", "ORGANISM_SUBDIVISION", 279, 283], ["tartrazine", "SIMPLE_CHEMICAL", 302, 312], ["salicylates", "SIMPLE_CHEMICAL", 314, 325], ["pollens", "ORGANISM_SUBDIVISION", 343, 350], ["cat", "ORGANISM", 352, 355], ["dander", "ORGANISM_SUBDIVISION", 356, 362], ["penicillin", "SIMPLE_CHEMICAL", 375, 385], ["phenobarbital", "SIMPLE_CHEMICAL", 387, 400], ["children", "SPECIES", 24, 32], ["cat", "SPECIES", 352, 355], ["cat dander", "SPECIES", 352, 362], ["cholinergic, dermographic, cold and pressure urticaria", "PROBLEM", 156, 210], ["infections", "PROBLEM", 213, 223], ["parasites", "PROBLEM", 225, 234], ["streptococci", "PROBLEM", 242, 254], ["tartrazine", "TREATMENT", 302, 312], ["salicylates", "TREATMENT", 314, 325], ["aeroallergens", "PROBLEM", 328, 341], ["drugs", "TREATMENT", 368, 373], ["penicillin", "TREATMENT", 375, 385], ["phenobarbital", "TREATMENT", 387, 400], ["infections", "OBSERVATION", 213, 223]]], ["In 75% of children, urticaria was attributed to pseudoallergens such as coloring agents, preservatives, saccharin/cyclamate and monosodium glutamate [65] .", [["urticaria", "DISEASE", 20, 29], ["pseudoallergens", "DISEASE", 48, 63], ["saccharin", "CHEMICAL", 104, 113], ["cyclamate", "CHEMICAL", 114, 123], ["monosodium glutamate", "CHEMICAL", 128, 148], ["saccharin", "CHEMICAL", 104, 113], ["cyclamate", "CHEMICAL", 114, 123], ["monosodium glutamate", "CHEMICAL", 128, 148], ["children", "ORGANISM", 10, 18], ["saccharin", "SIMPLE_CHEMICAL", 104, 113], ["cyclamate", "SIMPLE_CHEMICAL", 114, 123], ["monosodium glutamate", "SIMPLE_CHEMICAL", 128, 148], ["children", "SPECIES", 10, 18], ["urticaria", "PROBLEM", 20, 29], ["pseudoallergens", "PROBLEM", 48, 63], ["coloring agents", "TREATMENT", 72, 87], ["preservatives", "TREATMENT", 89, 102], ["saccharin/cyclamate", "TREATMENT", 104, 123], ["monosodium glutamate", "TREATMENT", 128, 148]]], ["In 43 children with additive sensitivity (32 also with angioedema), both SPTs and FCTs were positive in 2%-28% of cases [201] .", [["angioedema", "DISEASE", 55, 65], ["children", "ORGANISM", 6, 14], ["children", "SPECIES", 6, 14], ["angioedema", "PROBLEM", 55, 65], ["both SPTs", "TEST", 68, 77], ["FCTs", "TEST", 82, 86]]], ["We stress the cases provoked by yeast extract (Chap.", [["extract", "ANATOMY", 38, 45], ["yeast", "SPECIES", 32, 37], ["yeast", "SPECIES", 32, 37]]], ["10) and penicillin [157] .", [["penicillin", "CHEMICAL", 8, 18], ["penicillin", "CHEMICAL", 8, 18], ["penicillin", "SIMPLE_CHEMICAL", 8, 18], ["penicillin", "TREATMENT", 8, 18]]], ["In 132 children, in most cases the cause remained unknown (63.6%) [13] .", [["children", "ORGANISM", 7, 15], ["children", "SPECIES", 7, 15]]], ["Chronic idiopathic urticaria syndrome applies to many patients without an easily identifiable cause; however, frequently these patients suffer from a chronic disease [89] .", [["idiopathic urticaria syndrome", "DISEASE", 8, 37], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 127, 135], ["Chronic idiopathic urticaria syndrome", "PROBLEM", 0, 37], ["a chronic disease", "PROBLEM", 148, 165], ["idiopathic", "OBSERVATION_MODIFIER", 8, 18], ["urticaria syndrome", "OBSERVATION", 19, 37], ["chronic", "OBSERVATION_MODIFIER", 150, 157], ["disease", "OBSERVATION", 158, 165]]], ["Recently, two youngsters were reported, one with positive autoimmune markers, the other with juvenile rheumatoid arthritis (JRA), thus opening the door to autoimmunity in the pathogenesis of chronic urticaria [54] .Chronic UrticariaHistopathological features show that the preponderant cell types are CD4 + T cells predominant over CD8 + T cells, and that mast cells degranulate [19] , thus being considered the primary effector cells in chronic urticaria with a significant increase in number [19] .", [["cell", "ANATOMY", 286, 290], ["CD4 + T cells", "ANATOMY", 301, 314], ["CD8 + T cells", "ANATOMY", 332, 345], ["mast cells", "ANATOMY", 356, 366], ["primary effector cells", "ANATOMY", 412, 434], ["juvenile rheumatoid arthritis", "DISEASE", 93, 122], ["JRA", "DISEASE", 124, 127], ["autoimmunity", "DISEASE", 155, 167], ["chronic urticaria", "DISEASE", 191, 208], ["urticaria", "DISEASE", 446, 455], ["cell", "CELL", 286, 290], ["CD4", "GENE_OR_GENE_PRODUCT", 301, 304], ["CD8", "GENE_OR_GENE_PRODUCT", 332, 335], ["mast cells", "CELL", 356, 366], ["cells", "CELL", 429, 434], ["CD4", "PROTEIN", 301, 304], ["T cells", "CELL_TYPE", 307, 314], ["CD8 + T cells", "CELL_TYPE", 332, 345], ["mast cells", "CELL_TYPE", 356, 366], ["primary effector cells", "CELL_TYPE", 412, 434], ["positive autoimmune markers", "PROBLEM", 49, 76], ["juvenile rheumatoid arthritis", "PROBLEM", 93, 122], ["autoimmunity", "PROBLEM", 155, 167], ["chronic urticaria", "PROBLEM", 191, 208], ["Chronic UrticariaHistopathological features", "PROBLEM", 215, 258], ["T cells", "PROBLEM", 307, 314], ["T cells", "PROBLEM", 338, 345], ["mast cells degranulate", "PROBLEM", 356, 378], ["chronic urticaria", "PROBLEM", 438, 455], ["autoimmune markers", "OBSERVATION", 58, 76], ["juvenile", "OBSERVATION_MODIFIER", 93, 101], ["rheumatoid arthritis", "OBSERVATION", 102, 122], ["chronic", "OBSERVATION_MODIFIER", 191, 198], ["urticaria", "OBSERVATION", 199, 208], ["preponderant", "OBSERVATION_MODIFIER", 273, 285], ["cell types", "OBSERVATION", 286, 296], ["mast cells degranulate", "OBSERVATION", 356, 378], ["effector cells", "OBSERVATION", 420, 434], ["chronic", "OBSERVATION_MODIFIER", 438, 445], ["urticaria", "OBSERVATION", 446, 455], ["significant", "OBSERVATION_MODIFIER", 463, 474], ["increase", "OBSERVATION_MODIFIER", 475, 483]]], ["Significantly increased are intradermal CD3 + , CD4 + , CD8 + , and CD25 + T cells, as well as eosinophils, neutrophils, basophils, and macrophages.", [["intradermal CD3 + , CD4 + , CD8 +", "ANATOMY", 28, 61], ["CD25 + T cells", "ANATOMY", 68, 82], ["eosinophils", "ANATOMY", 95, 106], ["neutrophils", "ANATOMY", 108, 119], ["basophils", "ANATOMY", 121, 130], ["macrophages", "ANATOMY", 136, 147], ["CD3", "GENE_OR_GENE_PRODUCT", 40, 43], ["CD4", "GENE_OR_GENE_PRODUCT", 48, 51], ["CD8", "GENE_OR_GENE_PRODUCT", 56, 59], ["CD25", "GENE_OR_GENE_PRODUCT", 68, 72], ["eosinophils", "CELL", 95, 106], ["neutrophils", "CELL", 108, 119], ["basophils", "CELL", 121, 130], ["macrophages", "CELL", 136, 147], ["CD3", "PROTEIN", 40, 43], ["CD4", "PROTEIN", 48, 51], ["CD8", "PROTEIN", 56, 59], ["CD25", "PROTEIN", 68, 72], ["T cells", "CELL_TYPE", 75, 82], ["eosinophils", "CELL_TYPE", 95, 106], ["neutrophils", "CELL_TYPE", 108, 119], ["basophils", "CELL_TYPE", 121, 130], ["macrophages", "CELL_TYPE", 136, 147], ["intradermal CD3", "TEST", 28, 43], ["CD4", "TEST", 48, 51], ["CD8", "TEST", 56, 59], ["CD25", "TEST", 68, 72], ["eosinophils", "TEST", 95, 106], ["neutrophils", "TEST", 108, 119], ["basophils", "TEST", 121, 130], ["macrophages", "TEST", 136, 147], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["intradermal CD3", "OBSERVATION", 28, 43], ["basophils", "ANATOMY", 121, 130], ["macrophages", "ANATOMY", 136, 147]]], ["T cells from these patients are characterized by a Th0 cytokine profile, with significant increases of IL 4 and IL 5 mRNA and cells positive for IFN-g.", [["T cells", "ANATOMY", 0, 7], ["cells", "ANATOMY", 126, 131], ["T cells", "CELL", 0, 7], ["patients", "ORGANISM", 19, 27], ["IL 4", "GENE_OR_GENE_PRODUCT", 103, 107], ["IL 5", "GENE_OR_GENE_PRODUCT", 112, 116], ["cells", "CELL", 126, 131], ["T cells", "CELL_TYPE", 0, 7], ["Th0 cytokine", "PROTEIN", 51, 63], ["IL 4 and IL 5 mRNA", "RNA", 103, 121], ["IFN", "PROTEIN", 145, 148], ["patients", "SPECIES", 19, 27], ["a Th0 cytokine profile", "TEST", 49, 71], ["significant increases of IL", "PROBLEM", 78, 105], ["cells", "TEST", 126, 131], ["IFN", "TEST", 145, 148], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["increases", "OBSERVATION_MODIFIER", 90, 99]]], ["A pattern distinct from that seen in the allergen-induced LPR, where IFN-g is absent [248] .", [["IFN-g", "GENE_OR_GENE_PRODUCT", 69, 74], ["IFN", "PROTEIN", 69, 72], ["A pattern distinct", "PROBLEM", 0, 18], ["IFN", "TEST", 69, 72], ["pattern", "OBSERVATION_MODIFIER", 2, 9], ["distinct", "OBSERVATION_MODIFIER", 10, 18]]], ["An increased histamine release may be induced by nonspecific mast cell activation.", [["mast cell", "ANATOMY", 61, 70], ["histamine", "CHEMICAL", 13, 22], ["histamine", "CHEMICAL", 13, 22], ["histamine", "SIMPLE_CHEMICAL", 13, 22], ["mast cell", "CELL", 61, 70], ["An increased histamine release", "PROBLEM", 0, 30], ["nonspecific mast cell activation", "PROBLEM", 49, 81], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["histamine release", "OBSERVATION", 13, 30], ["may be", "UNCERTAINTY", 31, 37], ["nonspecific", "OBSERVATION_MODIFIER", 49, 60], ["mast cell activation", "OBSERVATION", 61, 81]]], ["It is unlikely that the histamine release is secondary to peripheral blood basophils [45] .", [["peripheral blood basophils", "ANATOMY", 58, 84], ["histamine", "CHEMICAL", 24, 33], ["histamine", "CHEMICAL", 24, 33], ["histamine", "SIMPLE_CHEMICAL", 24, 33], ["blood basophils", "ORGANISM_SUBSTANCE", 69, 84], ["peripheral blood basophils", "CELL_TYPE", 58, 84], ["the histamine release", "PROBLEM", 20, 41], ["peripheral blood basophils", "TEST", 58, 84], ["unlikely", "UNCERTAINTY", 6, 14]]], ["Actually, basophils of these patients have a decreased releasability; thus mast cells as the source of spontaneously released histamine in these patients is further substantiated by increased tryptase levels in blister fluid [45] .", [["basophils", "ANATOMY", 10, 19], ["mast cells", "ANATOMY", 75, 85], ["blister fluid", "ANATOMY", 211, 224], ["histamine", "CHEMICAL", 126, 135], ["histamine", "CHEMICAL", 126, 135], ["basophils", "CELL", 10, 19], ["patients", "ORGANISM", 29, 37], ["mast cells", "CELL", 75, 85], ["histamine", "SIMPLE_CHEMICAL", 126, 135], ["patients", "ORGANISM", 145, 153], ["tryptase", "GENE_OR_GENE_PRODUCT", 192, 200], ["blister fluid", "ORGANISM_SUBSTANCE", 211, 224], ["basophils", "CELL_TYPE", 10, 19], ["mast cells", "CELL_TYPE", 75, 85], ["tryptase", "PROTEIN", 192, 200], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 145, 153], ["a decreased releasability", "PROBLEM", 43, 68], ["mast cells", "PROBLEM", 75, 85], ["increased tryptase levels in blister fluid", "PROBLEM", 182, 224], ["decreased", "OBSERVATION_MODIFIER", 45, 54], ["mast cells", "OBSERVATION", 75, 85], ["increased", "OBSERVATION_MODIFIER", 182, 191], ["tryptase", "OBSERVATION", 192, 200]]], ["On skin biopsies, there is evidence of neutrophils within capillary and post-capillary venular walls, but not of structural damage [89] .", [["skin biopsies", "ANATOMY", 3, 16], ["neutrophils", "ANATOMY", 39, 50], ["capillary", "ANATOMY", 58, 67], ["post-capillary venular walls", "ANATOMY", 72, 100], ["skin biopsies", "MULTI-TISSUE_STRUCTURE", 3, 16], ["neutrophils", "CELL", 39, 50], ["capillary", "TISSUE", 58, 67], ["post-capillary venular walls", "TISSUE", 72, 100], ["neutrophils", "CELL_TYPE", 39, 50], ["skin biopsies", "TEST", 3, 16], ["neutrophils", "PROBLEM", 39, 50], ["structural damage", "PROBLEM", 113, 130], ["skin", "ANATOMY", 3, 7], ["biopsies", "OBSERVATION", 8, 16], ["evidence of", "UNCERTAINTY", 27, 38], ["neutrophils", "OBSERVATION", 39, 50], ["capillary", "ANATOMY_MODIFIER", 58, 67], ["post-capillary venular", "ANATOMY", 72, 94], ["walls", "ANATOMY_MODIFIER", 95, 100], ["not of", "UNCERTAINTY", 106, 112]]], ["Spontaneous wheals show expression of CD62E and CD50 on vascular endothelial cells and of CD106 on perivascular cells [89] .CHAPTER 8Other Allergic Skin DisordersPsychogenic UrticariaPsychogenic factors may exacerbate symptoms of urticaria-angioedema due to diverse causes; however, it is insufficiently understood whether they are primary or associated with other unidentified factors.Psychogenic UrticariaWhen hereditary angioedema is suspected, the history should be complete (FH may be negative in 20% of cases), especially investigating previous recurrent episodes of edema.", [["wheals", "ANATOMY", 12, 18], ["vascular endothelial cells", "ANATOMY", 56, 82], ["perivascular cells", "ANATOMY", 99, 117], ["edema", "ANATOMY", 573, 578], ["Allergic", "DISEASE", 139, 147], ["Skin Disorders", "DISEASE", 148, 162], ["urticaria", "DISEASE", 230, 239], ["angioedema", "DISEASE", 240, 250], ["hereditary angioedema", "DISEASE", 412, 433], ["FH", "DISEASE", 480, 482], ["edema", "DISEASE", 573, 578], ["wheals", "CANCER", 12, 18], ["CD62E", "GENE_OR_GENE_PRODUCT", 38, 43], ["CD50", "GENE_OR_GENE_PRODUCT", 48, 52], ["vascular endothelial cells", "CELL", 56, 82], ["CD106", "GENE_OR_GENE_PRODUCT", 90, 95], ["perivascular cells", "CELL", 99, 117], ["edema", "PATHOLOGICAL_FORMATION", 573, 578], ["CD62E", "PROTEIN", 38, 43], ["CD50", "PROTEIN", 48, 52], ["vascular endothelial cells", "CELL_TYPE", 56, 82], ["CD106", "PROTEIN", 90, 95], ["perivascular cells", "CELL_TYPE", 99, 117], ["Spontaneous wheals", "PROBLEM", 0, 18], ["CD62E", "TEST", 38, 43], ["vascular endothelial cells", "TEST", 56, 82], ["perivascular cells", "TEST", 99, 117], ["Allergic Skin Disorders", "PROBLEM", 139, 162], ["Psychogenic UrticariaPsychogenic factors", "PROBLEM", 162, 202], ["symptoms", "PROBLEM", 218, 226], ["urticaria", "PROBLEM", 230, 239], ["angioedema", "PROBLEM", 240, 250], ["diverse causes", "PROBLEM", 258, 272], ["Psychogenic UrticariaWhen hereditary angioedema", "PROBLEM", 386, 433], ["edema", "PROBLEM", 573, 578], ["vascular endothelial", "ANATOMY", 56, 76], ["perivascular cells", "ANATOMY", 99, 117], ["Allergic", "OBSERVATION_MODIFIER", 139, 147], ["Skin", "ANATOMY", 148, 152], ["urticaria", "OBSERVATION", 230, 239], ["hereditary", "OBSERVATION_MODIFIER", 412, 422], ["angioedema", "OBSERVATION", 423, 433], ["edema", "OBSERVATION", 573, 578]]], ["Diagnosis is made by studying the complement components (C4, C3 and C2) and C1-INH levels (algorithm): \u2211 In asymptomatic periods, the C4 level is decreased and the C2 level is normal; during the attacks the C4 level usually cannot be measured, C2 levels are reduced, C3 turnover is enhanced, and CH50 (50% hemolytic complement) may be reduced. \u2211 C1-INH immunochemical assay: the levels are reduced in 85% of cases; in the remaining 15% the levels are normal or increased, so that functional studies with enzymatic and immunochemical tests should be done [155] . \u2211 If C4 and C1-INH are very low, then C1-INH antigenic protein assay should be done to distinguish type I (low levels) from type II (normal) antigen, despite low functional protein [35] .Psychogenic UrticariaIn one family, C1-INH levels were undetectable or low in some patients and CH50 was undetectable in all of the patients.", [["hemolytic", "DISEASE", 306, 315], ["\u2211 C1-INH", "CHEMICAL", 344, 352], ["C1-INH", "CHEMICAL", 785, 791], ["C1-INH", "CHEMICAL", 574, 580], ["C1-INH", "GENE_OR_GENE_PRODUCT", 76, 82], ["C4", "GENE_OR_GENE_PRODUCT", 134, 136], ["C2", "GENE_OR_GENE_PRODUCT", 164, 166], ["C2", "GENE_OR_GENE_PRODUCT", 244, 246], ["C3", "GENE_OR_GENE_PRODUCT", 267, 269], ["CH50", "GENE_OR_GENE_PRODUCT", 296, 300], ["C4", "GENE_OR_GENE_PRODUCT", 567, 569], ["C1-INH", "GENE_OR_GENE_PRODUCT", 574, 580], ["C1-INH", "GENE_OR_GENE_PRODUCT", 600, 606], ["type II (normal) antigen", "GENE_OR_GENE_PRODUCT", 686, 710], ["C1-INH", "GENE_OR_GENE_PRODUCT", 785, 791], ["patients", "ORGANISM", 832, 840], ["CH50", "GENE_OR_GENE_PRODUCT", 845, 849], ["patients", "ORGANISM", 881, 889], ["C4", "PROTEIN", 57, 59], ["C3", "PROTEIN", 61, 63], ["C2", "PROTEIN", 68, 70], ["C1", "PROTEIN", 76, 78], ["C4", "PROTEIN", 134, 136], ["C2", "PROTEIN", 164, 166], ["C4", "PROTEIN", 207, 209], ["C2", "PROTEIN", 244, 246], ["C3", "PROTEIN", 267, 269], ["CH50", "PROTEIN", 296, 300], ["C4", "PROTEIN", 567, 569], ["C1", "PROTEIN", 574, 576], ["C1", "PROTEIN", 600, 602], ["type II (normal) antigen", "PROTEIN", 686, 710], ["CH50", "PROTEIN", 845, 849], ["patients", "SPECIES", 832, 840], ["patients", "SPECIES", 881, 889], ["the complement components (C4, C3 and C2) and C1-INH levels", "TEST", 30, 89], ["CH50", "TEST", 296, 300], ["hemolytic complement", "TEST", 306, 326], ["C1-INH immunochemical assay", "TEST", 346, 373], ["the levels", "TEST", 375, 385], ["functional studies", "TEST", 480, 498], ["immunochemical tests", "TEST", 518, 538], ["C4 and C1-INH", "TEST", 567, 580], ["very low", "PROBLEM", 585, 593], ["C1-INH antigenic protein assay", "TEST", 600, 630], ["type I (low levels) from type II (normal) antigen", "PROBLEM", 661, 710], ["low functional protein", "PROBLEM", 720, 742], ["C1-INH levels", "TEST", 785, 798], ["CH50", "TEST", 845, 849], ["C2", "ANATOMY", 68, 70], ["C1", "ANATOMY", 76, 78], ["asymptomatic", "OBSERVATION_MODIFIER", 108, 120], ["periods", "OBSERVATION_MODIFIER", 121, 128], ["C4", "ANATOMY_MODIFIER", 134, 136], ["decreased", "OBSERVATION_MODIFIER", 146, 155], ["C2", "ANATOMY", 164, 166], ["normal", "OBSERVATION", 176, 182], ["C4", "ANATOMY_MODIFIER", 207, 209], ["cannot be", "UNCERTAINTY", 224, 233], ["reduced", "OBSERVATION_MODIFIER", 258, 265], ["C3", "OBSERVATION_MODIFIER", 267, 269], ["enhanced", "OBSERVATION_MODIFIER", 282, 290], ["may be", "UNCERTAINTY", 328, 334], ["reduced", "OBSERVATION_MODIFIER", 335, 342], ["C1", "ANATOMY", 346, 348], ["reduced", "OBSERVATION_MODIFIER", 390, 397], ["normal", "OBSERVATION", 451, 457], ["increased", "OBSERVATION_MODIFIER", 461, 470], ["C1", "ANATOMY", 574, 576], ["low", "OBSERVATION_MODIFIER", 820, 823]]], ["The C4 level was low, and in a 10-year-old boy diagnosis was based on low C1-INH, CH50 and C4, in addition to his FH [247] .Psychogenic UrticariaDiagnosis has been successfully made at birth using cord blood and by examining C1-INH functionality [230] .Psychogenic UrticariaDiagnosis of urticaria (Table 8 .4) first requires a distinction between acute and chronic urticaria [44] : \u2211 Genetic factors, atopy \u2211 Aspect of the lesions \u2211 Triggering causes \u2211 Clinical manifestations \u2211 Duration of clinical manifestations \u2211 Associated symptomsPsychogenic UrticariaThe child's lifestyle should be investigated, particularly food preferences and potential, continuous or occasional drug intake, as well as information on additives, inhalants, recent infections, stress, work, and hobbies [175] .", [["cord blood", "ANATOMY", 197, 207], ["lesions", "ANATOMY", 423, 430], ["UrticariaDiagnosis", "DISEASE", 136, 154], ["C1-INH", "CHEMICAL", 225, 231], ["urticaria", "DISEASE", 287, 296], ["urticaria", "DISEASE", 365, 374], ["Psychogenic Urticaria", "DISEASE", 536, 557], ["infections", "DISEASE", 741, 751], ["C1-INH", "CHEMICAL", 225, 231], ["C4", "GENE_OR_GENE_PRODUCT", 4, 6], ["boy", "ORGANISM", 43, 46], ["cord blood", "ORGANISM_SUBSTANCE", 197, 207], ["lesions", "PATHOLOGICAL_FORMATION", 423, 430], ["child", "ORGANISM", 561, 566], ["C4", "PROTEIN", 4, 6], ["C1", "PROTEIN", 74, 76], ["CH50", "PROTEIN", 82, 86], ["C4", "PROTEIN", 91, 93], ["boy", "SPECIES", 43, 46], ["child", "SPECIES", 561, 566], ["The C4 level", "TEST", 0, 12], ["low C1-INH, CH50 and C4", "PROBLEM", 70, 93], ["Psychogenic UrticariaDiagnosis", "PROBLEM", 124, 154], ["cord blood", "TEST", 197, 207], ["Psychogenic UrticariaDiagnosis of urticaria", "PROBLEM", 253, 296], ["acute and chronic urticaria", "PROBLEM", 347, 374], ["Genetic factors", "PROBLEM", 384, 399], ["the lesions", "PROBLEM", 419, 430], ["Clinical manifestations", "PROBLEM", 453, 476], ["clinical manifestations", "PROBLEM", 491, 514], ["Associated symptoms", "PROBLEM", 517, 536], ["Psychogenic Urticaria", "PROBLEM", 536, 557], ["recent infections", "PROBLEM", 734, 751], ["C4", "OBSERVATION_MODIFIER", 4, 6], ["low", "OBSERVATION_MODIFIER", 17, 20], ["C4", "ANATOMY", 91, 93], ["urticaria", "OBSERVATION", 287, 296], ["acute", "OBSERVATION_MODIFIER", 347, 352], ["chronic", "OBSERVATION_MODIFIER", 357, 364], ["urticaria", "OBSERVATION", 365, 374], ["lesions", "OBSERVATION", 423, 430], ["infections", "OBSERVATION", 741, 751]]], ["It should be ascertained whether or not [44] : \u2211 It is a clear-cut type of urticaria \u2211 There is a pathogenic mechanism correlated with what has been ingested, inhaled, or injected 554 CHAPTER 8 Other Allergic Skin Disorders FPTs ensure conclusive evidence to be looked for only in children who have a history of previous food-induced anaphylactic shock.", [["Skin", "ANATOMY", 209, 213], ["urticaria", "DISEASE", 75, 84], ["Allergic Skin Disorders", "DISEASE", 200, 223], ["anaphylactic shock", "DISEASE", 334, 352], ["[44] : \u2211", "CHEMICAL", 40, 48], ["Skin", "ORGAN", 209, 213], ["children", "ORGANISM", 281, 289], ["children", "SPECIES", 281, 289], ["urticaria", "PROBLEM", 75, 84], ["a pathogenic mechanism", "PROBLEM", 96, 118], ["Other Allergic Skin Disorders", "PROBLEM", 194, 223], ["anaphylactic shock", "PROBLEM", 334, 352], ["clear", "OBSERVATION_MODIFIER", 57, 62], ["urticaria", "OBSERVATION", 75, 84], ["Skin", "ANATOMY", 209, 213], ["anaphylactic shock", "OBSERVATION", 334, 352]]], ["A possible therapeutic elimination diet is discussed in Chap.", [["therapeutic elimination diet", "TREATMENT", 11, 39], ["possible", "UNCERTAINTY", 2, 10], ["therapeutic", "OBSERVATION_MODIFIER", 11, 22], ["elimination", "OBSERVATION", 23, 34]]], ["9 .Psychogenic UrticariaIn additive-induced urticaria, countless food dyes and preservatives are suspected [59] .", [["urticaria", "DISEASE", 44, 53], ["Psychogenic UrticariaIn additive", "PROBLEM", 3, 35], ["induced urticaria", "PROBLEM", 36, 53], ["urticaria", "OBSERVATION", 44, 53]]], ["An elimination diet such as the one we prescribe should exclude ASA, benzoic acid and dyes (Table 8 .5), frequently prescribed to the children seen in our department: a positive result validates the search for causative additives.", [["ASA, benzoic acid", "CHEMICAL", 64, 81], ["ASA", "CHEMICAL", 64, 67], ["benzoic acid", "CHEMICAL", 69, 81], ["ASA", "SIMPLE_CHEMICAL", 64, 67], ["benzoic acid", "SIMPLE_CHEMICAL", 69, 81], ["dyes", "SIMPLE_CHEMICAL", 86, 90], ["children", "ORGANISM", 134, 142], ["children", "SPECIES", 134, 142], ["An elimination diet", "TREATMENT", 0, 19], ["ASA", "TREATMENT", 64, 67], ["benzoic acid and dyes", "TREATMENT", 69, 90]]], ["A diet free of ASA and other pertinent additives is similarly helpful in children with drug-induced urticaria [227] .", [["ASA", "CHEMICAL", 15, 18], ["urticaria", "DISEASE", 100, 109], ["ASA", "CHEMICAL", 15, 18], ["ASA", "SIMPLE_CHEMICAL", 15, 18], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["ASA", "TREATMENT", 15, 18], ["other pertinent additives", "TREATMENT", 23, 48], ["induced urticaria", "PROBLEM", 92, 109]]], ["In our department we have noted that almost all children improve by eliminating all prepared foods, with no exception.Psychogenic UrticariaIn the case of pseudoallergic urticaria, the abovementioned causes should be chosen among nonimmunological mechanisms.", [["pseudoallergic urticaria", "DISEASE", 154, 178], ["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["Psychogenic", "PROBLEM", 118, 129], ["pseudoallergic urticaria", "PROBLEM", 154, 178], ["pseudoallergic urticaria", "OBSERVATION", 154, 178]]], ["When aeroallergens are suspected, interventions for allergen avoidance should be scheduled.", [["aeroallergens", "PROBLEM", 5, 18], ["allergen avoidance", "TREATMENT", 52, 70]]], ["Total serum IgE levels could increase, with a possible peripheral eosinophilia [117] .Physical Urticaria\u2211 EIA: it is important to assemble a circumstantial history.", [["serum", "ANATOMY", 6, 11], ["peripheral eosinophilia", "DISEASE", 55, 78], ["serum", "ORGANISM_SUBSTANCE", 6, 11], ["IgE", "GENE_OR_GENE_PRODUCT", 12, 15], ["IgE", "PROTEIN", 12, 15], ["Total serum IgE levels", "TEST", 0, 22], ["peripheral eosinophilia", "PROBLEM", 55, 78], ["possible", "UNCERTAINTY", 46, 54], ["peripheral", "ANATOMY_MODIFIER", 55, 65], ["eosinophilia", "OBSERVATION", 66, 78]]], ["Then the patient is invited to run in place or on a treadmill for at least 5-10 min.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16]]], ["Positive responses follow the four phases, sometimes a differential diagnosis with cholinergic urticaria may be necessary [190] . \u2211 Dermographism: by gentle stroking of the skin, in normal responses an immediate blanching followed by a red flare for 10 min is detected, in simple forms a linear wheal and flare appear lasting 10-15 min and in symptomatic forms there are pruritus with linear wheal and flare lasting 30 min to 3 h.", [["skin", "ANATOMY", 173, 177], ["urticaria", "DISEASE", 95, 104], ["pruritus", "DISEASE", 371, 379], ["skin", "ORGAN", 173, 177], ["cholinergic urticaria", "PROBLEM", 83, 104], ["a red flare", "PROBLEM", 234, 245], ["a linear wheal", "PROBLEM", 286, 300], ["flare", "PROBLEM", 305, 310], ["pruritus", "PROBLEM", 371, 379], ["linear wheal", "PROBLEM", 385, 397], ["flare", "PROBLEM", 402, 407], ["gentle", "OBSERVATION_MODIFIER", 150, 156], ["stroking", "OBSERVATION", 157, 165], ["skin", "ANATOMY", 173, 177], ["normal", "OBSERVATION", 182, 188], ["immediate", "OBSERVATION_MODIFIER", 202, 211], ["blanching", "OBSERVATION_MODIFIER", 212, 221], ["flare", "OBSERVATION", 240, 245], ["linear", "OBSERVATION_MODIFIER", 288, 294], ["wheal", "OBSERVATION", 295, 300], ["flare", "OBSERVATION", 305, 310], ["pruritus", "OBSERVATION", 371, 379], ["linear", "OBSERVATION_MODIFIER", 385, 391], ["wheal", "OBSERVATION", 392, 397], ["flare", "OBSERVATION", 402, 407]]], ["In the delayed variant, the wheal decreases within 20-30 min, recurs in the same site by 3-8 h and persists for 24-48 h.", [["site", "ANATOMY", 81, 85], ["wheal", "PATHOLOGICAL_FORMATION", 28, 33], ["the wheal", "PROBLEM", 24, 33], ["delayed variant", "OBSERVATION", 7, 22], ["wheal", "OBSERVATION_MODIFIER", 28, 33], ["decreases", "OBSERVATION_MODIFIER", 34, 43]]], ["The diagnosis is confirmed by using the dermographometer ( Fig. 8.7) , which is pressed on the skin and a typical response occurs at the pressure of 3.6 g/mm 2 = 3.5\u00a510 5 Pa [117] .Physical Urticaria\u2211 There is a contact reaction (difficult to discern if AD coexists) \u2211 There is an association with a systemic disease \u2211 There are infectious episodes, past or present For food-induced urticaria, a possible approach involves: \u2211 When the reactions occur <2-3 times/week, it is useful and economic to record the ingested foods in a diary, a practice which focuses the attention of both the family and the child on food factors. \u2211 When the manifestations recur with greater frequency or daily, a diagnostic elimination diet is prescribed, also to detect occult, clinically relevant allergens present in many different foodstuffs.", [["skin", "ANATOMY", 95, 99], ["Urticaria", "DISEASE", 190, 199], ["AD", "DISEASE", 254, 256], ["urticaria", "DISEASE", 383, 392], ["skin", "ORGAN", 95, 99], ["the dermographometer ( Fig.", "TREATMENT", 36, 63], ["the pressure", "TEST", 133, 145], ["Physical Urticaria", "PROBLEM", 181, 199], ["a contact reaction", "PROBLEM", 210, 228], ["a systemic disease", "PROBLEM", 298, 316], ["infectious episodes", "PROBLEM", 329, 348], ["induced urticaria", "PROBLEM", 375, 392], ["a diagnostic elimination diet", "TREATMENT", 689, 718], ["clinically relevant allergens", "PROBLEM", 757, 786], ["skin", "ANATOMY", 95, 99], ["Urticaria", "OBSERVATION", 190, 199], ["contact reaction", "OBSERVATION", 212, 228], ["systemic", "OBSERVATION_MODIFIER", 300, 308], ["disease", "OBSERVATION", 309, 316], ["infectious", "OBSERVATION_MODIFIER", 329, 339], ["urticaria", "OBSERVATION", 383, 392]]], ["A positive result indicates the opportunity to continue with SPTs or RAST, but 555 Urticaria-Angioedema Syndrome \u2211 Pressure urticaria: hanging a 6-10 kg weight across the shoulder or thigh for 10-15 min will produce painful swelling at the pressure site after 4-8 h.", [["shoulder", "ANATOMY", 171, 179], ["thigh", "ANATOMY", 183, 188], ["Urticaria", "DISEASE", 83, 92], ["Angioedema", "DISEASE", 93, 103], ["Pressure urticaria", "DISEASE", 115, 133], ["swelling", "DISEASE", 224, 232], ["shoulder", "ORGANISM_SUBDIVISION", 171, 179], ["thigh", "ORGANISM_SUBDIVISION", 183, 188], ["SPTs", "TEST", 61, 65], ["RAST", "TEST", 69, 73], ["Urticaria", "PROBLEM", 83, 92], ["Angioedema Syndrome", "PROBLEM", 93, 112], ["Pressure urticaria", "PROBLEM", 115, 133], ["painful swelling at the pressure site", "PROBLEM", 216, 253], ["Pressure urticaria", "OBSERVATION", 115, 133], ["shoulder", "ANATOMY", 171, 179], ["thigh", "ANATOMY", 183, 188], ["painful", "OBSERVATION_MODIFIER", 216, 223], ["swelling", "OBSERVATION", 224, 232]]], ["In younger children the pressure is adjusted according to age.", [["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19]]], ["In delayed pressure urticaria, the dermographometer is set at 9.75\u00a510 5 Pa (99.4 g/mm 2 ) and held firmly against the skin of the back for varying numbers of seconds [117] . \u2211 Cold urticaria: \u2211 In the localized form, diagnosis is confirmed by placing an ice cube at 1\u00b0C on forearm skin for 10-20 min, then rewarming the skin until it returns to a normal T: within 5-20 min an edema appears matching the cube basis ( Fig. 8.8) .A negative test (and for systemic cold urticaria) is repeated by having the patient stand for 10-20 min in a cooled room at a T of 4\u00b0C [110] .", [["skin", "ANATOMY", 118, 122], ["forearm skin", "ANATOMY", 273, 285], ["skin", "ANATOMY", 320, 324], ["edema", "ANATOMY", 376, 381], ["urticaria", "DISEASE", 20, 29], ["urticaria", "DISEASE", 181, 190], ["edema", "DISEASE", 376, 381], ["urticaria", "DISEASE", 466, 475], ["skin", "ORGAN", 118, 122], ["C", "GENE_OR_GENE_PRODUCT", 268, 269], ["forearm", "TISSUE", 273, 280], ["skin", "ORGAN", 281, 285], ["skin", "ORGAN", 320, 324], ["edema", "PATHOLOGICAL_FORMATION", 376, 381], ["patient", "ORGANISM", 503, 510], ["patient", "SPECIES", 503, 510], ["delayed pressure urticaria", "PROBLEM", 3, 29], ["the dermographometer", "TEST", 31, 51], ["Pa", "TEST", 72, 74], ["Cold urticaria", "PROBLEM", 176, 190], ["an ice cube", "TREATMENT", 251, 262], ["an edema", "PROBLEM", 373, 381], ["A negative test", "TEST", 427, 442], ["systemic cold urticaria", "PROBLEM", 452, 475], ["delayed", "OBSERVATION_MODIFIER", 3, 10], ["pressure urticaria", "OBSERVATION", 11, 29], ["skin", "ANATOMY", 118, 122], ["back", "ANATOMY", 130, 134], ["urticaria", "OBSERVATION", 181, 190], ["forearm", "ANATOMY", 273, 280], ["skin", "ANATOMY", 281, 285], ["skin", "ANATOMY", 320, 324], ["normal", "OBSERVATION", 347, 353], ["edema", "OBSERVATION", 376, 381], ["negative", "OBSERVATION", 429, 437]]], ["By the end of the test, characteristic wheals and flares develop, especially on the trunk and proximal aspects of the limbs, or giant urticaria [110] in 92% of cases [181] .", [["trunk", "ANATOMY", 84, 89], ["limbs", "ANATOMY", 118, 123], ["giant urticaria", "DISEASE", 128, 143], ["trunk", "ORGANISM_SUBDIVISION", 84, 89], ["limbs", "ORGANISM_SUBDIVISION", 118, 123], ["the test", "TEST", 14, 22], ["characteristic wheals", "PROBLEM", 24, 45], ["flares", "PROBLEM", 50, 56], ["giant urticaria", "PROBLEM", 128, 143], ["wheals", "OBSERVATION", 39, 45], ["flares", "OBSERVATION", 50, 56], ["trunk", "ANATOMY", 84, 89], ["proximal", "ANATOMY_MODIFIER", 94, 102], ["limbs", "ANATOMY", 118, 123], ["giant", "OBSERVATION_MODIFIER", 128, 133], ["urticaria", "OBSERVATION", 134, 143]]], ["Children with negative ICT at 10 min had similar symptoms and response to antihistamines as patients with positive ICT.", [["Children", "ORGANISM", 0, 8], ["patients", "ORGANISM", 92, 100], ["Children", "SPECIES", 0, 8], ["patients", "SPECIES", 92, 100], ["similar symptoms", "PROBLEM", 41, 57], ["antihistamines", "TREATMENT", 74, 88]]], ["All children with cold urticaria and their parents should be cautioned regarding the risk of anaphylaxis [4] .", [["cold urticaria", "DISEASE", 18, 32], ["anaphylaxis", "DISEASE", 93, 104], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["cold urticaria", "PROBLEM", 18, 32], ["anaphylaxis", "PROBLEM", 93, 104]]], ["In selected cases it is necessary to test both cryoglobulins and cryofibrinogen [156] .Physical Urticaria\u2211 In systemic cold urticaria, the ICT is negative and the cooled room test positive.", [["cryofibrinogen", "CHEMICAL", 65, 79], ["Urticaria", "DISEASE", 96, 105], ["systemic cold urticaria", "DISEASE", 110, 133], ["cryofibrinogen", "CHEMICAL", 65, 79], ["cryoglobulins", "GENE_OR_GENE_PRODUCT", 47, 60], ["cryofibrinogen", "SIMPLE_CHEMICAL", 65, 79], ["cryoglobulins", "PROTEIN", 47, 60], ["cryoglobulins", "TEST", 47, 60], ["cryofibrinogen", "TEST", 65, 79], ["Physical Urticaria", "PROBLEM", 87, 105], ["systemic cold urticaria", "PROBLEM", 110, 133], ["the ICT", "TEST", 135, 142], ["the cooled room test", "TEST", 159, 179], ["Urticaria", "OBSERVATION", 96, 105], ["systemic", "OBSERVATION_MODIFIER", 110, 118], ["cold urticaria", "OBSERVATION", 119, 133], ["negative", "OBSERVATION", 146, 154]]], ["Levels of both histamine and PGD 2 are increased [140, 156] .", [["histamine", "CHEMICAL", 15, 24], ["histamine", "CHEMICAL", 15, 24], ["histamine", "SIMPLE_CHEMICAL", 15, 24], ["PGD 2", "GENE_OR_GENE_PRODUCT", 29, 34], ["Levels", "TEST", 0, 6], ["both histamine", "TREATMENT", 10, 24], ["PGD", "TEST", 29, 32]]], ["Measuring blood histamine levels after a negative ICT appears to be a sensitive way to diagnose patients without risk of anaphylaxis during generalized cold exposure [140] . \u2211 The prevalence of secondary cold urticaria is 1%; however, we recommend the related screening. \u2211 Solar urticaria: a small skin area of 1\u00a51 cm for 1-2 min is exposed to a source of monochromatic light of various wavelengths for 10 min at a distance of 10 cm.", [["blood", "ANATOMY", 10, 15], ["skin area", "ANATOMY", 298, 307], ["histamine", "CHEMICAL", 16, 25], ["anaphylaxis", "DISEASE", 121, 132], ["cold urticaria", "DISEASE", 204, 218], ["urticaria", "DISEASE", 279, 288], ["histamine", "CHEMICAL", 16, 25], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["histamine", "SIMPLE_CHEMICAL", 16, 25], ["patients", "ORGANISM", 96, 104], ["skin", "ORGAN", 298, 302], ["patients", "SPECIES", 96, 104], ["Measuring blood histamine levels", "TEST", 0, 32], ["anaphylaxis", "PROBLEM", 121, 132], ["generalized cold exposure", "PROBLEM", 140, 165], ["secondary cold urticaria", "PROBLEM", 194, 218], ["the related screening", "TEST", 248, 269], ["Solar urticaria", "PROBLEM", 273, 288], ["a small skin area", "PROBLEM", 290, 307], ["anaphylaxis", "OBSERVATION", 121, 132], ["secondary", "OBSERVATION_MODIFIER", 194, 203], ["cold", "OBSERVATION_MODIFIER", 204, 208], ["urticaria", "OBSERVATION", 209, 218], ["urticaria", "OBSERVATION", 279, 288], ["small", "OBSERVATION_MODIFIER", 292, 297], ["skin", "ANATOMY", 298, 302], ["area", "OBSERVATION_MODIFIER", 303, 307], ["1\u00a51 cm", "OBSERVATION_MODIFIER", 311, 317], ["10 cm", "OBSERVATION_MODIFIER", 427, 432]]], ["If the result is negative the exposure time-lag is increased.", [["negative", "OBSERVATION", 17, 25], ["increased", "OBSERVATION_MODIFIER", 51, 60]]], ["Fluorescent tubes, carbon arc, etc., in combination with emission of a broad wavelength spectrum, employing different filters to ascertain which one provokes urticaria [111, 183] , are used.", [["urticaria", "DISEASE", 158, 167], ["carbon", "CHEMICAL", 19, 25], ["Fluorescent tubes", "TREATMENT", 0, 17], ["carbon arc", "TREATMENT", 19, 29], ["a broad wavelength spectrum", "TREATMENT", 69, 96], ["employing different filters", "TREATMENT", 98, 125], ["urticaria", "PROBLEM", 158, 167], ["tubes", "OBSERVATION", 12, 17], ["carbon arc", "OBSERVATION", 19, 29]]], ["A differential diagnosis from erythropoietic protoporphyria requires measuring protoporphyrin and coproporphyrin levels [240] . \u2211 Contact urticaria: an accurate history and SPTs may disclose some offending agents such as topical drugs, diverse chemical substances, cosmetics, vegetable substances, pet danders, etc. The rub test may confirm the diagnosis, that is the suspected item is rubbed gently on normal skin, and inspected for signs of a reaction at 60 min [117] . \u2211 Vibratory angioedema: symptoms may be reproduced by gently stimulating the medial aspect of the forearm with a laboratory vortex for 4-5 min or laying a finger-pad on a common tube mixer for 10 min.", [["vegetable", "ANATOMY", 276, 285], ["skin", "ANATOMY", 410, 414], ["medial aspect", "ANATOMY", 549, 562], ["forearm", "ANATOMY", 570, 577], ["erythropoietic protoporphyria", "DISEASE", 30, 59], ["coproporphyrin", "CHEMICAL", 98, 112], ["urticaria", "DISEASE", 138, 147], ["angioedema", "DISEASE", 484, 494], ["protoporphyrin", "CHEMICAL", 79, 93], ["coproporphyrin", "CHEMICAL", 98, 112], ["protoporphyrin", "SIMPLE_CHEMICAL", 79, 93], ["coproporphyrin", "SIMPLE_CHEMICAL", 98, 112], ["vegetable", "ORGANISM_SUBDIVISION", 276, 285], ["skin", "ORGAN", 410, 414], ["forearm", "ORGANISM_SUBDIVISION", 570, 577], ["tube", "TISSUE", 650, 654], ["protoporphyrin", "PROTEIN", 79, 93], ["erythropoietic protoporphyria", "PROBLEM", 30, 59], ["protoporphyrin and coproporphyrin levels", "TEST", 79, 119], ["topical drugs", "TREATMENT", 221, 234], ["diverse chemical substances", "TREATMENT", 236, 263], ["cosmetics", "TREATMENT", 265, 274], ["The rub test", "TEST", 316, 328], ["a reaction", "PROBLEM", 443, 453], ["Vibratory angioedema", "PROBLEM", 474, 494], ["symptoms", "PROBLEM", 496, 504], ["a common tube mixer", "TREATMENT", 641, 660], ["erythropoietic protoporphyria", "OBSERVATION", 30, 59], ["skin", "ANATOMY", 410, 414], ["angioedema", "OBSERVATION", 484, 494], ["medial", "ANATOMY_MODIFIER", 549, 555], ["forearm", "ANATOMY", 570, 577], ["pad", "ANATOMY", 634, 637]]], ["Positive responders should develop a pruritic circumferential edema, which distinguishes the condition from delayed dermographism and delayed pressure urticaria [42, 111] (Fig. 8.9 ). \u2211 Aquagenic urticaria: challenge tests are performed using tap water compresses at 35\u00b0C or any other T applied to the upper body for 5-30 min.", [["upper body", "ANATOMY", 302, 312], ["edema", "DISEASE", 62, 67], ["urticaria", "DISEASE", 151, 160], ["urticaria", "DISEASE", 196, 205], ["edema", "PATHOLOGICAL_FORMATION", 62, 67], ["upper body", "ORGANISM_SUBDIVISION", 302, 312], ["a pruritic circumferential edema", "PROBLEM", 35, 67], ["delayed dermographism", "PROBLEM", 108, 129], ["delayed pressure urticaria", "PROBLEM", 134, 160], ["Fig.", "TEST", 172, 176], ["Aquagenic urticaria", "PROBLEM", 186, 205], ["challenge tests", "TEST", 207, 222], ["tap water compresses", "TREATMENT", 243, 263], ["pruritic", "OBSERVATION_MODIFIER", 37, 45], ["circumferential", "OBSERVATION_MODIFIER", 46, 61], ["edema", "OBSERVATION", 62, 67], ["urticaria", "OBSERVATION", 196, 205], ["upper", "ANATOMY_MODIFIER", 302, 307], ["body", "ANATOMY", 308, 312]]], ["The condition responded to treatment with UV-B and oral antihistamines [163] . \u2211 Cholinergic urticaria: to reproduce the eruption, exercise such as jogging on the spot, running on a treadmill in a plastic occlusive suit, running up and down stairs with warm clothes or with an exercise bicycle should be continued until it provokes an increase in perspiration, or by half-body immersion in a hot bath (42\u00b0C) to raise body T. In case of a negative response, an intradermal test is done using 0.05 ml of methacholine chloride at 0.02% or carbachol at 0.002%, which in positive tests induce a localized whealing surrounded by flushing within 20 min.", [["oral", "ANATOMY", 51, 55], ["body", "ANATOMY", 372, 376], ["body", "ANATOMY", 417, 421], ["UV-B", "CHEMICAL", 42, 46], ["urticaria", "DISEASE", 93, 102], ["eruption", "DISEASE", 121, 129], ["methacholine chloride", "CHEMICAL", 502, 523], ["carbachol", "CHEMICAL", 536, 545], ["methacholine chloride", "CHEMICAL", 502, 523], ["carbachol", "CHEMICAL", 536, 545], ["UV-B", "SIMPLE_CHEMICAL", 42, 46], ["oral", "ORGANISM_SUBDIVISION", 51, 55], ["body", "ORGANISM_SUBDIVISION", 372, 376], ["methacholine chloride", "SIMPLE_CHEMICAL", 502, 523], ["carbachol", "SIMPLE_CHEMICAL", 536, 545], ["treatment", "TREATMENT", 27, 36], ["UV", "TREATMENT", 42, 44], ["B", "TREATMENT", 45, 46], ["oral antihistamines", "TREATMENT", 51, 70], ["Cholinergic urticaria", "PROBLEM", 81, 102], ["the eruption", "PROBLEM", 117, 129], ["a plastic occlusive suit", "TREATMENT", 195, 219], ["warm clothes", "TREATMENT", 253, 265], ["an exercise bicycle", "TREATMENT", 274, 293], ["an increase in perspiration", "PROBLEM", 332, 359], ["a hot bath", "TREATMENT", 390, 400], ["an intradermal test", "TEST", 457, 476], ["methacholine chloride", "TREATMENT", 502, 523], ["carbachol", "TREATMENT", 536, 545], ["positive tests", "TEST", 566, 580], ["increase", "OBSERVATION_MODIFIER", 335, 343], ["perspiration", "OBSERVATION", 347, 359], ["flushing", "OBSERVATION", 623, 631]]], ["The test is positive in 33%-50% of patients.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["The test", "TEST", 0, 8], ["positive", "OBSERVATION_MODIFIER", 12, 20]]], ["However, it is rarely a reproducible test [44, 183] . \u2211 Localized heat urticaria: a heated cylinder with water heated to 50-55\u00b0C is applied to the skin for 5 min [42] .Physical UrticariaChronic Urticaria.", [["skin", "ANATOMY", 147, 151], ["urticaria", "DISEASE", 71, 80], ["UrticariaChronic Urticaria", "DISEASE", 177, 203], ["skin", "ORGAN", 147, 151], ["Localized heat urticaria", "PROBLEM", 56, 80], ["a heated cylinder with water", "TREATMENT", 82, 110], ["Physical UrticariaChronic Urticaria", "PROBLEM", 168, 203], ["heat", "OBSERVATION_MODIFIER", 66, 70], ["urticaria", "OBSERVATION", 71, 80], ["skin", "ANATOMY", 147, 151], ["UrticariaChronic Urticaria", "OBSERVATION", 177, 203]]], ["Patients are investigated according to the above-mentioned epidemiological data.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Following this evaluation, the diagnosis is by exclusion, apart CHAPTER 8 intestinal tract and clinically, by congestion, migraine and hypotension secondary to histamine release [166] .", [["intestinal tract", "ANATOMY", 74, 90], ["congestion", "DISEASE", 110, 120], ["migraine", "DISEASE", 122, 130], ["hypotension", "DISEASE", 135, 146], ["histamine", "CHEMICAL", 160, 169], ["histamine", "CHEMICAL", 160, 169], ["intestinal tract", "ORGANISM_SUBDIVISION", 74, 90], ["histamine", "SIMPLE_CHEMICAL", 160, 169], ["this evaluation", "TEST", 10, 25], ["congestion", "PROBLEM", 110, 120], ["migraine", "PROBLEM", 122, 130], ["hypotension", "PROBLEM", 135, 146], ["histamine release", "PROBLEM", 160, 177], ["intestinal tract", "ANATOMY", 74, 90], ["congestion", "OBSERVATION", 110, 120]]], ["Urticaria as a sign of systemic disease: urticaria may be the only sign of infections caused by bacteria, viruses, yeasts, and molds.", [["Urticaria", "DISEASE", 0, 9], ["systemic disease", "DISEASE", 23, 39], ["urticaria", "DISEASE", 41, 50], ["infections", "DISEASE", 75, 85], ["Urticaria", "PROBLEM", 0, 9], ["systemic disease", "PROBLEM", 23, 39], ["urticaria", "PROBLEM", 41, 50], ["infections", "PROBLEM", 75, 85], ["bacteria", "PROBLEM", 96, 104], ["viruses", "PROBLEM", 106, 113], ["yeasts", "PROBLEM", 115, 121], ["molds", "PROBLEM", 127, 132], ["sign of", "UNCERTAINTY", 15, 22], ["systemic", "OBSERVATION_MODIFIER", 23, 31], ["disease", "OBSERVATION", 32, 39], ["urticaria", "OBSERVATION", 41, 50], ["infections", "OBSERVATION", 75, 85], ["bacteria", "OBSERVATION", 96, 104]]], ["Several parasitic infections are causative agents in urticaria and eosinophilia, such as infestations by Ancylostoma, Ascaris, Echinococcus, Fasciola, Filaria, Schistosoma, Strongyloides, Toxocara, Trichinella, etc. Urticaria may be associated with malignancy, endocrine disorders (hyperthyroidism, hypothyroidism), and autoimmune disease.TreatmentSpecific management consists in the removal of all offending agents, stimuli, or allergens, and the drug management of possible predisposing or concurrent factors (infections, infestations, etc.), or ongoing problems.", [["endocrine", "ANATOMY", 261, 270], ["parasitic infections", "DISEASE", 8, 28], ["urticaria", "DISEASE", 53, 62], ["eosinophilia", "DISEASE", 67, 79], ["Ancylostoma, Ascaris, Echinococcus, Fasciola, Filaria, Schistosoma, Strongyloides, Toxocara", "DISEASE", 105, 196], ["Urticaria", "DISEASE", 216, 225], ["malignancy", "DISEASE", 249, 259], ["endocrine disorders", "DISEASE", 261, 280], ["hyperthyroidism", "DISEASE", 282, 297], ["hypothyroidism", "DISEASE", 299, 313], ["autoimmune disease", "DISEASE", 320, 338], ["infections", "DISEASE", 512, 522], ["infestations", "DISEASE", 524, 536], ["Ancylostoma", "ORGANISM", 105, 116], ["Ascaris, Echinococcus", "ORGANISM", 118, 139], ["Fasciola, Filaria", "ORGANISM", 141, 158], ["Schistosoma, Strongyloides", "ORGANISM", 160, 186], ["Toxocara", "ORGANISM", 188, 196], ["Trichinella", "ORGANISM", 198, 209], ["Fasciola", "SPECIES", 141, 149], ["Schistosoma", "SPECIES", 160, 171], ["Several parasitic infections", "PROBLEM", 0, 28], ["urticaria", "PROBLEM", 53, 62], ["eosinophilia", "PROBLEM", 67, 79], ["infestations", "PROBLEM", 89, 101], ["Ancylostoma", "PROBLEM", 105, 116], ["Ascaris", "PROBLEM", 118, 125], ["Echinococcus", "PROBLEM", 127, 139], ["Fasciola", "PROBLEM", 141, 149], ["Filaria", "PROBLEM", 151, 158], ["Schistosoma", "TREATMENT", 160, 171], ["Strongyloides", "TREATMENT", 173, 186], ["Toxocara", "TREATMENT", 188, 196], ["Trichinella", "PROBLEM", 198, 209], ["Urticaria", "PROBLEM", 216, 225], ["malignancy", "PROBLEM", 249, 259], ["endocrine disorders", "PROBLEM", 261, 280], ["hyperthyroidism", "PROBLEM", 282, 297], ["hypothyroidism", "PROBLEM", 299, 313], ["autoimmune disease", "PROBLEM", 320, 338], ["TreatmentSpecific management", "TREATMENT", 339, 367], ["the removal", "TREATMENT", 380, 391], ["all offending agents", "TREATMENT", 395, 415], ["allergens", "PROBLEM", 429, 438], ["the drug management", "TREATMENT", 444, 463], ["concurrent factors (infections", "PROBLEM", 492, 522], ["infestations", "PROBLEM", 524, 536], ["ongoing problems", "PROBLEM", 548, 564], ["parasitic", "OBSERVATION_MODIFIER", 8, 17], ["infections", "OBSERVATION", 18, 28], ["urticaria", "OBSERVATION", 53, 62], ["eosinophilia", "OBSERVATION", 67, 79], ["Ancylostoma", "OBSERVATION", 105, 116], ["Echinococcus", "OBSERVATION_MODIFIER", 127, 139], ["Fasciola", "ANATOMY", 141, 149], ["Filaria", "ANATOMY", 151, 158], ["Schistosoma", "ANATOMY", 160, 171], ["Strongyloides", "OBSERVATION", 173, 186], ["may be associated with", "UNCERTAINTY", 226, 248], ["malignancy", "OBSERVATION", 249, 259], ["hyperthyroidism", "OBSERVATION", 282, 297], ["hypothyroidism", "OBSERVATION", 299, 313], ["autoimmune disease", "OBSERVATION", 320, 338]]], ["A truly specific management is not as yet available, since the etiopathogenetic mechanisms underlying urticaria are largely unknown.A stimulating prospective involves the histamine releasing IgG Aab neutralization by means of soluble FceRI-a [92] .TreatmentAn aspecific or second-line management includes the following: \u2211 New-generation nonsedating H 1 antihistamines, alone or combined with H 2 , are the mainstay of symptomatic management, such as chronic urticaria [192] , efficaciously controlled in particular by cetirizine [10] , levocetirizine and cimetidine associated with hydroxyzine [192] .", [["urticaria", "DISEASE", 102, 111], ["histamine", "CHEMICAL", 171, 180], ["H 1 antihistamines", "CHEMICAL", 349, 367], ["urticaria", "DISEASE", 458, 467], ["cetirizine", "CHEMICAL", 518, 528], ["levocetirizine", "CHEMICAL", 536, 550], ["cimetidine", "CHEMICAL", 555, 565], ["hydroxyzine", "CHEMICAL", 582, 593], ["histamine", "CHEMICAL", 171, 180], ["H 1", "CHEMICAL", 349, 352], ["H 2", "CHEMICAL", 392, 395], ["cetirizine", "CHEMICAL", 518, 528], ["levocetirizine", "CHEMICAL", 536, 550], ["cimetidine", "CHEMICAL", 555, 565], ["hydroxyzine", "CHEMICAL", 582, 593], ["histamine", "SIMPLE_CHEMICAL", 171, 180], ["IgG", "GENE_OR_GENE_PRODUCT", 191, 194], ["FceRI", "GENE_OR_GENE_PRODUCT", 234, 239], ["H 1 antihistamines", "SIMPLE_CHEMICAL", 349, 367], ["cetirizine", "SIMPLE_CHEMICAL", 518, 528], ["levocetirizine", "SIMPLE_CHEMICAL", 536, 550], ["cimetidine", "SIMPLE_CHEMICAL", 555, 565], ["hydroxyzine", "SIMPLE_CHEMICAL", 582, 593], ["IgG Aab", "PROTEIN", 191, 198], ["FceRI", "PROTEIN", 234, 239], ["urticaria", "PROBLEM", 102, 111], ["A stimulating prospective", "TREATMENT", 132, 157], ["the histamine", "TREATMENT", 167, 180], ["TreatmentAn aspecific", "PROBLEM", 248, 269], ["second-line management", "TREATMENT", 273, 295], ["New-generation nonsedating H 1 antihistamines", "TREATMENT", 322, 367], ["symptomatic management", "TREATMENT", 418, 440], ["chronic urticaria", "PROBLEM", 450, 467], ["cetirizine", "TREATMENT", 518, 528], ["levocetirizine", "TREATMENT", 536, 550], ["cimetidine", "TREATMENT", 555, 565], ["hydroxyzine", "TREATMENT", 582, 593], ["urticaria", "OBSERVATION", 102, 111]]], ["Cetirizine and levocetirizine dosage schedules are shown in Table 7 .", [["Cetirizine", "CHEMICAL", 0, 10], ["levocetirizine", "CHEMICAL", 15, 29], ["Cetirizine", "CHEMICAL", 0, 10], ["levocetirizine", "CHEMICAL", 15, 29], ["Cetirizine", "SIMPLE_CHEMICAL", 0, 10], ["levocetirizine", "SIMPLE_CHEMICAL", 15, 29], ["Cetirizine", "TREATMENT", 0, 10], ["levocetirizine dosage schedules", "TREATMENT", 15, 46]]], ["19 . \u2211 In a double-blind (DB) study, 31 children aged 2-6 years (mean 3.85) with idiopathic chronic urticaria were treated with cetirizine at a dosage of 5 mg daily, which showed a significantly more rapid resolution of symptoms and itching compared with 31 children treated for the same length of time with oxatomide, at a dosage of 25 mg daily [113] . \u2211 Membrane stabilizers such as ketotifen (Chap.", [["Membrane", "ANATOMY", 356, 364], ["idiopathic chronic urticaria", "DISEASE", 81, 109], ["cetirizine", "CHEMICAL", 128, 138], ["itching", "DISEASE", 233, 240], ["oxatomide", "CHEMICAL", 308, 317], ["ketotifen", "CHEMICAL", 385, 394], ["cetirizine", "CHEMICAL", 128, 138], ["oxatomide", "CHEMICAL", 308, 317], ["ketotifen", "CHEMICAL", 385, 394], ["children", "ORGANISM", 40, 48], ["cetirizine", "SIMPLE_CHEMICAL", 128, 138], ["children", "ORGANISM", 258, 266], ["oxatomide", "SIMPLE_CHEMICAL", 308, 317], ["ketotifen", "SIMPLE_CHEMICAL", 385, 394], ["children", "SPECIES", 40, 48], ["children", "SPECIES", 258, 266], ["idiopathic chronic urticaria", "PROBLEM", 81, 109], ["cetirizine", "TREATMENT", 128, 138], ["symptoms", "PROBLEM", 220, 228], ["itching", "PROBLEM", 233, 240], ["oxatomide", "TREATMENT", 308, 317], ["Membrane stabilizers", "TREATMENT", 356, 376], ["ketotifen (Chap", "TREATMENT", 385, 400], ["idiopathic", "OBSERVATION_MODIFIER", 81, 91], ["chronic", "OBSERVATION_MODIFIER", 92, 99], ["urticaria", "OBSERVATION", 100, 109]]], ["7), which has been found useful in cold-induced and cholinergic urticaria and dermographism after the demonstration that the drug inhibits histamine release at a specific challenge [103] .", [["urticaria", "DISEASE", 64, 73], ["histamine", "CHEMICAL", 139, 148], ["histamine", "CHEMICAL", 139, 148], ["histamine", "SIMPLE_CHEMICAL", 139, 148], ["cholinergic urticaria", "PROBLEM", 52, 73], ["dermographism", "PROBLEM", 78, 91], ["the drug inhibits histamine release", "TREATMENT", 121, 156], ["cholinergic urticaria", "OBSERVATION", 52, 73]]], ["Similarly, ketotifen was effective in urticaria refractory to antihistamines and in chronic urticaria [101] . \u2211 In more severe cases and/or those resistant to other therapies, systemic CSs are required for transient relief [103] . \u2211 For pediatric cases of extreme severity, a resort to Epi-pen may be suggested [4] .TreatmentA child aged 10 was treated with e aminocaproic acid plus montelukast plus ranitidine.", [["ketotifen", "CHEMICAL", 11, 20], ["urticaria", "DISEASE", 38, 47], ["antihistamines", "CHEMICAL", 62, 76], ["urticaria", "DISEASE", 92, 101], ["Epi-pen", "CHEMICAL", 286, 293], ["aminocaproic acid", "CHEMICAL", 360, 377], ["montelukast", "CHEMICAL", 383, 394], ["ranitidine", "CHEMICAL", 400, 410], ["ketotifen", "CHEMICAL", 11, 20], ["aminocaproic acid", "CHEMICAL", 360, 377], ["montelukast", "CHEMICAL", 383, 394], ["ranitidine", "CHEMICAL", 400, 410], ["ketotifen", "SIMPLE_CHEMICAL", 11, 20], ["e aminocaproic acid", "SIMPLE_CHEMICAL", 358, 377], ["montelukast", "SIMPLE_CHEMICAL", 383, 394], ["ranitidine", "SIMPLE_CHEMICAL", 400, 410], ["ketotifen", "TREATMENT", 11, 20], ["urticaria", "PROBLEM", 38, 47], ["antihistamines", "TREATMENT", 62, 76], ["chronic urticaria", "PROBLEM", 84, 101], ["other therapies", "TREATMENT", 159, 174], ["systemic CSs", "TREATMENT", 176, 188], ["transient relief", "PROBLEM", 206, 222], ["extreme severity", "PROBLEM", 256, 272], ["Epi-pen", "TREATMENT", 286, 293], ["e aminocaproic acid", "TREATMENT", 358, 377], ["montelukast", "TREATMENT", 383, 394], ["ranitidine", "TREATMENT", 400, 410], ["chronic", "OBSERVATION_MODIFIER", 84, 91], ["urticaria", "OBSERVATION", 92, 101], ["severe", "OBSERVATION_MODIFIER", 120, 126]]], ["This regimen induced a full remission of urticaria in about 48 h.", [["urticaria", "DISEASE", 41, 50], ["This regimen", "TREATMENT", 0, 12], ["urticaria", "PROBLEM", 41, 50], ["urticaria", "OBSERVATION", 41, 50]]], ["The treatment was gradually tapered in the subsequent months, and after \u00aa13 months, the boy still remains completely symptom-free [228] . from cases clearly connected with foods [99] .", [["boy", "ORGANISM", 88, 91], ["The treatment", "TREATMENT", 0, 13], ["tapered", "OBSERVATION_MODIFIER", 28, 35]]], ["Neither laboratory data nor SPTs to foods are of value in adults in whom up to 90% of cases remain unassessed [159] , whereas the contrary is true in children, both for foods [18, 229] and additives [18, 201, 229] .", [["children", "ORGANISM", 150, 158], ["children", "SPECIES", 150, 158], ["laboratory data", "TEST", 8, 23]]], ["In a 6-year-old boy with a 3-month history of recurrent, severe angioedema episodes a diagnosis of autoreactive chronic urticaria (ACU) was made after an autologous serum skin test (ASST) [10] .Differential DiagnosisThe differential diagnosis [45] includes the following disorders: \u2211 Exanthematous infections in children and EBV, CMV, coxsackie, rotavirus infections, certain infestations by parasites and microbial infections. \u2211 Papular urticaria, provoked by insect bites in exposed areas, is characterized by pruritic papules and wheals, with immediate or delayed onset, expressing immunological mechanisms of type I or IV, respectively.", [["serum skin", "ANATOMY", 165, 175], ["papules", "ANATOMY", 521, 528], ["angioedema", "DISEASE", 64, 74], ["autoreactive chronic urticaria", "DISEASE", 99, 129], ["Exanthematous infections", "DISEASE", 284, 308], ["rotavirus infections", "DISEASE", 346, 366], ["infestations", "DISEASE", 376, 388], ["microbial infections", "DISEASE", 406, 426], ["Papular urticaria", "DISEASE", 430, 447], ["insect bites", "DISEASE", 461, 473], ["papules", "DISEASE", 521, 528], ["boy", "ORGANISM", 16, 19], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["skin", "ORGAN", 171, 175], ["children", "ORGANISM", 312, 320], ["EBV", "ORGANISM", 325, 328], ["CMV", "ORGANISM", 330, 333], ["coxsackie", "ORGANISM", 335, 344], ["rotavirus", "ORGANISM", 346, 355], ["papules", "PATHOLOGICAL_FORMATION", 521, 528], ["type I", "GENE_OR_GENE_PRODUCT", 613, 619], ["boy", "SPECIES", 16, 19], ["children", "SPECIES", 312, 320], ["EBV", "SPECIES", 325, 328], ["CMV", "SPECIES", 330, 333], ["rotavirus", "SPECIES", 346, 355], ["recurrent, severe angioedema episodes", "PROBLEM", 46, 83], ["autoreactive chronic urticaria", "PROBLEM", 99, 129], ["an autologous serum skin test", "TEST", 151, 180], ["Exanthematous infections", "PROBLEM", 284, 308], ["EBV", "PROBLEM", 325, 328], ["CMV", "PROBLEM", 330, 333], ["coxsackie", "PROBLEM", 335, 344], ["rotavirus infections", "PROBLEM", 346, 366], ["certain infestations", "PROBLEM", 368, 388], ["parasites", "PROBLEM", 392, 401], ["microbial infections", "PROBLEM", 406, 426], ["Papular urticaria", "PROBLEM", 430, 447], ["pruritic papules", "PROBLEM", 512, 528], ["wheals", "PROBLEM", 533, 539], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["angioedema", "OBSERVATION", 64, 74], ["autoreactive", "OBSERVATION_MODIFIER", 99, 111], ["chronic", "OBSERVATION_MODIFIER", 112, 119], ["urticaria", "OBSERVATION", 120, 129], ["Exanthematous", "OBSERVATION_MODIFIER", 284, 297], ["infections", "OBSERVATION", 298, 308], ["microbial", "OBSERVATION_MODIFIER", 406, 415], ["infections", "OBSERVATION", 416, 426], ["Papular", "OBSERVATION_MODIFIER", 430, 437], ["urticaria", "OBSERVATION", 438, 447], ["insect bites", "OBSERVATION_MODIFIER", 461, 473], ["pruritic", "OBSERVATION_MODIFIER", 512, 520], ["papules", "OBSERVATION", 521, 528]]], ["The lesions are often located on the lower limbs and tend to persist longer than urticarial lesions, most frequently seen in young children [103] . \u2211 Erythema multiforme, a self-limited disorder, typically characterized by pruritic urticarial lesions, wholly similar to urticaria in the earlier stages, which last longer and may have a targetoid aspect evolving into bullous lesions.", [["lesions", "ANATOMY", 4, 11], ["lower limbs", "ANATOMY", 37, 48], ["urticarial lesions", "ANATOMY", 81, 99], ["Erythema multiforme", "ANATOMY", 150, 169], ["urticarial lesions", "ANATOMY", 232, 250], ["bullous lesions", "ANATOMY", 367, 382], ["urticarial lesions", "DISEASE", 81, 99], ["Erythema multiforme", "DISEASE", 150, 169], ["self-limited disorder", "DISEASE", 173, 194], ["urticarial lesions", "DISEASE", 232, 250], ["urticaria", "DISEASE", 270, 279], ["bullous lesions", "DISEASE", 367, 382], ["lesions", "CANCER", 4, 11], ["lower limbs", "ORGANISM_SUBDIVISION", 37, 48], ["urticarial lesions", "PATHOLOGICAL_FORMATION", 81, 99], ["children", "ORGANISM", 131, 139], ["pruritic", "PATHOLOGICAL_FORMATION", 223, 231], ["urticarial lesions", "PATHOLOGICAL_FORMATION", 232, 250], ["bullous lesions", "PATHOLOGICAL_FORMATION", 367, 382], ["children", "SPECIES", 131, 139], ["The lesions", "PROBLEM", 0, 11], ["urticarial lesions", "PROBLEM", 81, 99], ["Erythema multiforme", "PROBLEM", 150, 169], ["a self-limited disorder", "PROBLEM", 171, 194], ["pruritic urticarial lesions", "PROBLEM", 223, 250], ["urticaria", "PROBLEM", 270, 279], ["bullous lesions", "PROBLEM", 367, 382], ["lesions", "OBSERVATION", 4, 11], ["lower", "ANATOMY_MODIFIER", 37, 42], ["limbs", "ANATOMY", 43, 48], ["urticarial", "OBSERVATION_MODIFIER", 81, 91], ["lesions", "OBSERVATION", 92, 99], ["most frequently", "OBSERVATION_MODIFIER", 101, 116], ["Erythema", "OBSERVATION", 150, 158], ["self-limited", "OBSERVATION_MODIFIER", 173, 185], ["pruritic", "OBSERVATION_MODIFIER", 223, 231], ["urticarial", "OBSERVATION_MODIFIER", 232, 242], ["lesions", "OBSERVATION", 243, 250], ["urticaria", "OBSERVATION", 270, 279], ["earlier stages", "OBSERVATION_MODIFIER", 287, 301], ["bullous", "OBSERVATION_MODIFIER", 367, 374], ["lesions", "OBSERVATION", 375, 382]]], ["It is more often located on the dorsal surfaces of both hands and feet, frequently misdiagnosed as urticaria. \u2211 Dermatitis herpetiformis is seen in children aged 3-7 years.", [["dorsal surfaces", "ANATOMY", 32, 47], ["hands", "ANATOMY", 56, 61], ["feet", "ANATOMY", 66, 70], ["urticaria", "DISEASE", 99, 108], ["Dermatitis herpetiformis", "DISEASE", 112, 136], ["dorsal surfaces", "MULTI-TISSUE_STRUCTURE", 32, 47], ["hands", "ORGANISM_SUBDIVISION", 56, 61], ["feet", "ORGANISM_SUBDIVISION", 66, 70], ["children", "ORGANISM", 148, 156], ["children", "SPECIES", 148, 156], ["urticaria", "PROBLEM", 99, 108], ["Dermatitis herpetiformis", "PROBLEM", 112, 136], ["more often", "OBSERVATION_MODIFIER", 6, 16], ["dorsal", "ANATOMY_MODIFIER", 32, 38], ["surfaces", "ANATOMY_MODIFIER", 39, 47], ["both", "ANATOMY_MODIFIER", 51, 55], ["hands", "ANATOMY", 56, 61], ["feet", "ANATOMY", 66, 70], ["urticaria", "OBSERVATION", 99, 108], ["herpetiformis", "OBSERVATION", 123, 136]]], ["The early lesions have an evident urticarial component.", [["lesions", "ANATOMY", 10, 17], ["lesions", "CANCER", 10, 17], ["The early lesions", "PROBLEM", 0, 17], ["an evident urticarial component", "PROBLEM", 23, 54], ["early", "OBSERVATION_MODIFIER", 4, 9], ["lesions", "OBSERVATION", 10, 17], ["evident", "OBSERVATION_MODIFIER", 26, 33], ["urticarial", "OBSERVATION_MODIFIER", 34, 44], ["component", "OBSERVATION_MODIFIER", 45, 54]]], ["Sites of predilection are the shoulders, elbows, knees and buttocks, often confused with cholinergic urticaria. \u2211 Urticaria pigmentosa is a localized mastocytosis occurring in infants and children before the age of 10, with most cases developing in the 1st year of life [12] .", [["shoulders", "ANATOMY", 30, 39], ["elbows", "ANATOMY", 41, 47], ["knees", "ANATOMY", 49, 54], ["buttocks", "ANATOMY", 59, 67], ["urticaria", "DISEASE", 101, 110], ["Urticaria pigmentosa", "DISEASE", 114, 134], ["mastocytosis", "DISEASE", 150, 162], ["shoulders", "ORGANISM_SUBDIVISION", 30, 39], ["elbows", "ORGANISM_SUBDIVISION", 41, 47], ["knees", "ORGANISM_SUBDIVISION", 49, 54], ["buttocks", "ORGANISM_SUBDIVISION", 59, 67], ["mastocytosis", "CANCER", 150, 162], ["infants", "ORGANISM", 176, 183], ["children", "ORGANISM", 188, 196], ["infants", "SPECIES", 176, 183], ["children", "SPECIES", 188, 196], ["predilection are the shoulders, elbows, knees and buttocks", "PROBLEM", 9, 67], ["confused", "PROBLEM", 75, 83], ["cholinergic urticaria", "PROBLEM", 89, 110], ["Urticaria pigmentosa", "PROBLEM", 114, 134], ["a localized mastocytosis", "PROBLEM", 138, 162], ["predilection", "OBSERVATION", 9, 21], ["shoulders", "ANATOMY", 30, 39], ["elbows", "ANATOMY", 41, 47], ["knees", "ANATOMY", 49, 54], ["buttocks", "ANATOMY", 59, 67], ["cholinergic urticaria", "OBSERVATION", 89, 110], ["Urticaria pigmentosa", "OBSERVATION", 114, 134], ["localized", "OBSERVATION_MODIFIER", 140, 149], ["mastocytosis", "OBSERVATION", 150, 162]]], ["Individual macules or papules, and nodular, lichenoid or plaque-like lesions range in color from pink to salmon, and in size from a few mm to several cm, which, when stroked, form a linear pruritic wheal, Darier's sign, the hallmark for clinical diagnosis.", [["macules", "ANATOMY", 11, 18], ["papules", "ANATOMY", 22, 29], ["nodular", "ANATOMY", 35, 42], ["lichenoid", "ANATOMY", 44, 53], ["plaque", "ANATOMY", 57, 63], ["lesions", "ANATOMY", 69, 76], ["papules", "DISEASE", 22, 29], ["plaque", "DISEASE", 57, 63], ["Darier's sign", "DISEASE", 205, 218], ["macules", "PATHOLOGICAL_FORMATION", 11, 18], ["papules", "PATHOLOGICAL_FORMATION", 22, 29], ["plaque-like lesions", "PATHOLOGICAL_FORMATION", 57, 76], ["Individual macules", "PROBLEM", 0, 18], ["papules", "PROBLEM", 22, 29], ["nodular, lichenoid or plaque-like lesions", "PROBLEM", 35, 76], ["a linear pruritic wheal", "PROBLEM", 180, 203], ["Darier's sign", "TEST", 205, 218], ["macules", "OBSERVATION", 11, 18], ["papules", "OBSERVATION", 22, 29], ["nodular", "OBSERVATION_MODIFIER", 35, 42], ["lichenoid", "OBSERVATION_MODIFIER", 44, 53], ["plaque", "OBSERVATION", 57, 63], ["lesions", "OBSERVATION", 69, 76], ["color", "OBSERVATION_MODIFIER", 86, 91], ["pink", "OBSERVATION_MODIFIER", 97, 101], ["to salmon", "OBSERVATION_MODIFIER", 102, 111], ["size", "OBSERVATION_MODIFIER", 120, 124], ["few mm", "OBSERVATION_MODIFIER", 132, 138], ["several cm", "OBSERVATION_MODIFIER", 142, 152], ["linear", "OBSERVATION_MODIFIER", 182, 188], ["pruritic", "OBSERVATION_MODIFIER", 189, 197]]], ["The condition usually fades at puberty; a skin biopsy may confirm the diagnosis [45, 61] . \u2211 Juvenile urticaria pigmentosa occurs at birth or in the 1st months of life and takes the form of a solitary nodule 1-5 cm in diameter (mastocytoma), most often on the back of the hand, wrist, neck, or the lesions may present as disseminated macule, plaques, or bullae, ranging in color from red-brown to yellow-tan.", [["skin", "ANATOMY", 42, 46], ["solitary nodule", "ANATOMY", 192, 207], ["mastocytoma", "ANATOMY", 228, 239], ["back", "ANATOMY", 260, 264], ["hand", "ANATOMY", 272, 276], ["wrist", "ANATOMY", 278, 283], ["neck", "ANATOMY", 285, 289], ["lesions", "ANATOMY", 298, 305], ["macule", "ANATOMY", 334, 340], ["plaques", "ANATOMY", 342, 349], ["bullae", "ANATOMY", 354, 360], ["urticaria pigmentosa", "DISEASE", 102, 122], ["mastocytoma", "DISEASE", 228, 239], ["plaques", "DISEASE", 342, 349], ["bullae", "DISEASE", 354, 360], ["skin", "ORGAN", 42, 46], ["solitary nodule", "CANCER", 192, 207], ["mastocytoma", "CANCER", 228, 239], ["back", "ORGANISM_SUBDIVISION", 260, 264], ["hand", "ORGANISM_SUBDIVISION", 272, 276], ["wrist", "ORGANISM_SUBDIVISION", 278, 283], ["neck", "ORGANISM_SUBDIVISION", 285, 289], ["lesions", "PATHOLOGICAL_FORMATION", 298, 305], ["macule", "CANCER", 334, 340], ["plaques", "PATHOLOGICAL_FORMATION", 342, 349], ["bullae", "PATHOLOGICAL_FORMATION", 354, 360], ["a skin biopsy", "TEST", 40, 53], ["Juvenile urticaria pigmentosa", "PROBLEM", 93, 122], ["a solitary nodule", "PROBLEM", 190, 207], ["mastocytoma", "PROBLEM", 228, 239], ["the lesions", "PROBLEM", 294, 305], ["plaques", "PROBLEM", 342, 349], ["bullae", "PROBLEM", 354, 360], ["skin", "ANATOMY", 42, 46], ["urticaria pigmentosa", "OBSERVATION", 102, 122], ["solitary", "OBSERVATION_MODIFIER", 192, 200], ["nodule", "OBSERVATION", 201, 207], ["1-5 cm", "OBSERVATION_MODIFIER", 208, 214], ["mastocytoma", "OBSERVATION", 228, 239], ["back", "ANATOMY", 260, 264], ["hand", "ANATOMY", 272, 276], ["wrist", "ANATOMY", 278, 283], ["neck", "ANATOMY", 285, 289], ["lesions", "OBSERVATION", 298, 305], ["disseminated", "OBSERVATION_MODIFIER", 321, 333], ["macule", "OBSERVATION", 334, 340], ["plaques", "OBSERVATION", 342, 349], ["bullae", "OBSERVATION", 354, 360], ["ranging", "OBSERVATION_MODIFIER", 362, 369], ["red", "OBSERVATION_MODIFIER", 384, 387], ["brown to yellow-tan", "OBSERVATION_MODIFIER", 388, 407]]], ["It most commonly fades at puberty. \u2211 Systemic mastocytosis is similar to urticaria pigmentosa, but uncommon and more severe.", [["mastocytosis", "DISEASE", 46, 58], ["urticaria pigmentosa", "DISEASE", 73, 93], ["Systemic mastocytosis", "PROBLEM", 37, 58], ["urticaria pigmentosa", "PROBLEM", 73, 93], ["Systemic", "OBSERVATION_MODIFIER", 37, 45], ["mastocytosis", "OBSERVATION", 46, 58], ["urticaria pigmentosa", "OBSERVATION", 73, 93], ["uncommon", "OBSERVATION_MODIFIER", 99, 107], ["more severe", "OBSERVATION_MODIFIER", 112, 123]]], ["It is characterized by onset in the first few months of life and mast cell accumulation in the dermis, bone marrow and gastro-Angioedema.", [["mast cell", "ANATOMY", 65, 74], ["dermis", "ANATOMY", 95, 101], ["bone marrow", "ANATOMY", 103, 114], ["Angioedema", "DISEASE", 126, 136], ["mast cell", "CELL", 65, 74], ["dermis", "TISSUE", 95, 101], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 103, 114], ["gastro-Angioedema", "CANCER", 119, 136], ["mast cell accumulation in the dermis", "PROBLEM", 65, 101], ["bone marrow", "PROBLEM", 103, 114], ["Angioedema", "PROBLEM", 126, 136], ["onset", "OBSERVATION_MODIFIER", 23, 28], ["mast cell accumulation", "OBSERVATION", 65, 87], ["dermis", "ANATOMY", 95, 101], ["bone marrow", "ANATOMY", 103, 114], ["gastro", "ANATOMY", 119, 125], ["Angioedema", "OBSERVATION", 126, 136]]], ["The above-mentioned therapeutic options may be followed.", [["therapeutic options", "TREATMENT", 20, 39]]], ["In children with the hereditary form, danazol has been demonstrated to be effective at the recommended dose of 20-30 mg/kg/day, with a maximal dose of 600 mg/day [15] for 5 days before and 2 days after the event [35] .", [["danazol", "CHEMICAL", 38, 45], ["danazol", "CHEMICAL", 38, 45], ["children", "ORGANISM", 3, 11], ["danazol", "SIMPLE_CHEMICAL", 38, 45], ["children", "SPECIES", 3, 11], ["danazol", "TREATMENT", 38, 45]]], ["Therapy improved serum complement parameters significantly and reduced the frequency and severity of clinical manifestations [70] .", [["serum", "ANATOMY", 17, 22], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["Therapy", "TREATMENT", 0, 7], ["serum complement parameters", "TEST", 17, 44], ["clinical manifestations", "PROBLEM", 101, 124]]], ["Doses of 0.5 g/day of e aminocaproic acid (EACA) and 1-2 g/day of tranexamic acid are prescribed to prevent episodes in children as needed [35, 69, 70] .", [["e aminocaproic acid", "CHEMICAL", 22, 41], ["EACA", "CHEMICAL", 43, 47], ["tranexamic acid", "CHEMICAL", 66, 81], ["aminocaproic acid", "CHEMICAL", 24, 41], ["EACA", "CHEMICAL", 43, 47], ["tranexamic acid", "CHEMICAL", 66, 81], ["e aminocaproic acid", "SIMPLE_CHEMICAL", 22, 41], ["EACA", "SIMPLE_CHEMICAL", 43, 47], ["tranexamic acid", "SIMPLE_CHEMICAL", 66, 81], ["children", "ORGANISM", 120, 128], ["children", "SPECIES", 120, 128], ["e aminocaproic acid (EACA)", "TREATMENT", 22, 48], ["tranexamic acid", "TREATMENT", 66, 81]]], ["Acute, lifethreatening edematous attacks are treated by the administration of C1-INH concentrate, which achieves the resolution of the edema within several hours [35, 70] .", [["edematous", "ANATOMY", 23, 32], ["edema", "ANATOMY", 135, 140], ["C1-INH", "CHEMICAL", 78, 84], ["edema", "DISEASE", 135, 140], ["C1-INH", "CHEMICAL", 78, 84], ["C1-INH", "SIMPLE_CHEMICAL", 78, 84], ["edema", "PATHOLOGICAL_FORMATION", 135, 140], ["Acute, lifethreatening edematous attacks", "PROBLEM", 0, 40], ["C1-INH concentrate", "TREATMENT", 78, 96], ["the edema", "PROBLEM", 131, 140], ["edematous", "OBSERVATION_MODIFIER", 23, 32], ["attacks", "OBSERVATION", 33, 40], ["resolution", "OBSERVATION_MODIFIER", 117, 127], ["edema", "OBSERVATION", 135, 140]]], ["Undesirable adverse effects can be avoided and the child's quality of life enhanced dramatically by administering the lowest effective drug dose [70] .", [["Undesirable adverse effects", "PROBLEM", 0, 27], ["the lowest effective drug dose", "TREATMENT", 114, 144]]], ["In C1-INH deficiency, both primitive and acquired experimental treatment procedures are under study [155] .", [["C1-INH", "CHEMICAL", 3, 9], ["C1-INH", "CHEMICAL", 3, 9], ["C1-INH", "GENE_OR_GENE_PRODUCT", 3, 9], ["C1-INH deficiency", "PROBLEM", 3, 20], ["C1", "ANATOMY", 3, 5], ["INH deficiency", "OBSERVATION", 6, 20]]], ["In cases of laryngeal edema, a tracheotomy will be indispensable.", [["laryngeal edema", "ANATOMY", 12, 27], ["laryngeal edema", "DISEASE", 12, 27], ["laryngeal edema", "PATHOLOGICAL_FORMATION", 12, 27], ["laryngeal edema", "PROBLEM", 12, 27], ["a tracheotomy", "TREATMENT", 29, 42], ["laryngeal", "ANATOMY", 12, 21], ["edema", "OBSERVATION", 22, 27], ["tracheotomy", "OBSERVATION", 31, 42]]], ["Patients may die as a result of laryngeal edema before a diagnosis is established [247] .", [["laryngeal", "ANATOMY", 32, 41], ["laryngeal edema", "DISEASE", 32, 47], ["Patients", "ORGANISM", 0, 8], ["laryngeal edema", "PATHOLOGICAL_FORMATION", 32, 47], ["Patients", "SPECIES", 0, 8], ["laryngeal edema", "PROBLEM", 32, 47], ["laryngeal", "ANATOMY", 32, 41], ["edema", "OBSERVATION", 42, 47]]], ["Adequate prophylaxis and follow-up care can spare pediatric patients from edematous attacks.Differential DiagnosisIn some patients with Melkersson-Rosenthal syndrome, a remission was obtained with an avoidance diet free of tartrazine and Na benzoate [161] , but not in others [142] .", [["Melkersson-Rosenthal syndrome", "DISEASE", 136, 165], ["tartrazine", "CHEMICAL", 223, 233], ["Na benzoate", "CHEMICAL", 238, 249], ["tartrazine", "CHEMICAL", 223, 233], ["Na benzoate", "CHEMICAL", 238, 249], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 122, 130], ["tartrazine", "SIMPLE_CHEMICAL", 223, 233], ["Na benzoate", "SIMPLE_CHEMICAL", 238, 249], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 122, 130], ["edematous attacks", "PROBLEM", 74, 91], ["Melkersson", "PROBLEM", 136, 146], ["Rosenthal syndrome", "PROBLEM", 147, 165], ["tartrazine", "TREATMENT", 223, 233], ["Na benzoate", "TREATMENT", 238, 249], ["prophylaxis", "OBSERVATION", 9, 20], ["edematous", "OBSERVATION", 74, 83], ["Rosenthal syndrome", "OBSERVATION", 147, 165]]], ["Clofazimine, 100 mg, administered orally 4 times weekly for 3-11 months was shown to be effective in several patients [202] .PreventionA paradigmatic example of preventive management is the elimination of stimuli triggering urticaria episodes: \u2211 In cold urticaria, cold desensitization by repeated skin exposure to cold until it becomes refractory to challenge has been recommended in motivated patients.", [["skin", "ANATOMY", 298, 302], ["Clofazimine", "CHEMICAL", 0, 11], ["urticaria", "DISEASE", 224, 233], ["urticaria", "DISEASE", 254, 263], ["Clofazimine", "CHEMICAL", 0, 11], ["Clofazimine", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 109, 117], ["skin", "ORGAN", 298, 302], ["patients", "ORGANISM", 395, 403], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 395, 403], ["Clofazimine", "TREATMENT", 0, 11], ["preventive management", "TREATMENT", 161, 182], ["urticaria episodes", "PROBLEM", 224, 242], ["cold urticaria", "PROBLEM", 249, 263], ["cold desensitization", "TREATMENT", 265, 285], ["repeated skin exposure", "TREATMENT", 289, 311], ["cold urticaria", "OBSERVATION", 249, 263], ["skin", "ANATOMY", 298, 302]]], ["A cardinal objective is the prevention of shock reactions during aquatic exposures, including traveling by boat or motor boat, water-skiing and other exposures to cold which lower the body T [233] .", [["body", "ANATOMY", 184, 188], ["shock", "DISEASE", 42, 47], ["shock reactions", "PROBLEM", 42, 57], ["shock", "OBSERVATION", 42, 47], ["body", "ANATOMY", 184, 188]]], ["In a child with cold urticaria seen by us, protection by a large hat and a scarf was unsuccessful. \u2211 Patients with cholinergic or generalized heat urticaria should protect the upper part of their body from excessive heating; also these patients may have recourse to a desensitization with warm baths by gradually increasing water T [44] . \u2211 In solar urticaria ordinary window glass 3 mm thick will absorb most UV radiation <3,200 \u00c5.", [["body", "ANATOMY", 196, 200], ["cold urticaria", "DISEASE", 16, 30], ["urticaria", "DISEASE", 147, 156], ["urticaria", "DISEASE", 350, 359], ["Patients", "ORGANISM", 101, 109], ["upper part", "ORGANISM_SUBDIVISION", 176, 186], ["body", "ORGANISM_SUBDIVISION", 196, 200], ["patients", "ORGANISM", 236, 244], ["child", "SPECIES", 5, 10], ["Patients", "SPECIES", 101, 109], ["patients", "SPECIES", 236, 244], ["cold urticaria", "PROBLEM", 16, 30], ["a scarf", "TREATMENT", 73, 80], ["generalized heat urticaria", "PROBLEM", 130, 156], ["excessive heating", "TREATMENT", 206, 223], ["a desensitization", "TREATMENT", 266, 283], ["warm baths", "TREATMENT", 289, 299], ["most UV radiation", "TREATMENT", 405, 422], ["urticaria", "OBSERVATION", 21, 30], ["urticaria", "OBSERVATION", 147, 156], ["upper", "ANATOMY_MODIFIER", 176, 181], ["solar urticaria", "OBSERVATION", 344, 359], ["glass 3 mm", "OBSERVATION_MODIFIER", 376, 386]]], ["Protective garments to cover the skin should be used.", [["skin", "ANATOMY", 33, 37], ["skin", "ORGAN", 33, 37], ["Protective garments", "TREATMENT", 0, 19], ["garments", "OBSERVATION", 11, 19], ["skin", "ANATOMY", 33, 37]]], ["Oral b-carotene was useful for type VI of solar urticaria.", [["Oral", "ANATOMY", 0, 4], ["b-carotene", "CHEMICAL", 5, 15], ["solar urticaria", "DISEASE", 42, 57], ["b-carotene", "CHEMICAL", 5, 15], ["Oral b-carotene", "SIMPLE_CHEMICAL", 0, 15], ["Oral b-carotene", "TREATMENT", 0, 15], ["solar urticaria", "PROBLEM", 42, 57], ["solar urticaria", "OBSERVATION", 42, 57]]], ["Types I-V can be prevented, at least in part, by antihistamines or by PUVA therapy [141] . \u2211 Subjects with EIA should select activities requiring a more modest effort, avoid ingestion of foods and drugs (ASA and NSAID) in the 4-6 h before a planned activity, and carry out physical activity possibly with a partner.", [["PUVA", "CHEMICAL", 70, 74], ["ASA", "CHEMICAL", 204, 207], ["Types I-V", "GENE_OR_GENE_PRODUCT", 0, 9], ["antihistamines", "SIMPLE_CHEMICAL", 49, 63], ["PUVA", "SIMPLE_CHEMICAL", 70, 74], ["antihistamines", "TREATMENT", 49, 63], ["PUVA therapy", "TREATMENT", 70, 82], ["EIA", "TREATMENT", 107, 110], ["drugs", "TREATMENT", 197, 202], ["ASA", "TREATMENT", 204, 207], ["NSAID", "TREATMENT", 212, 217]]], ["Moreover, they should recognize the prodromal signs, to slow down to a minimum or stop exercising [190] .", [["the prodromal signs", "PROBLEM", 32, 51]]], ["An epinephrine kit (Epi-pen) and medical identification bracelet is mandatory.PreventionIn a prospective, DB, parallel-group study of urticaria prevention in 817 children with AD who were 12-24 months of age at study entry, acute urticaria occurred in 5.8% of the children treated with cetirizine, 0.25 mg/kg, and in 16.2% of the placebo-treated children [191] .Allergic Contact DermatitisACD is one of the most frequent skin disorders and the prototype of a delayed type of CMI hypersensitivity reaction: any part of the skin that comes into contact with a relevant sensitizing allergen may be vulnerable.", [["skin", "ANATOMY", 421, 425], ["skin", "ANATOMY", 522, 526], ["epinephrine", "CHEMICAL", 3, 14], ["Epi-pen", "CHEMICAL", 20, 27], ["urticaria", "DISEASE", 134, 143], ["AD", "DISEASE", 176, 178], ["acute urticaria", "DISEASE", 224, 239], ["cetirizine", "CHEMICAL", 286, 296], ["Allergic Contact DermatitisACD", "DISEASE", 362, 392], ["skin disorders", "DISEASE", 421, 435], ["hypersensitivity", "DISEASE", 479, 495], ["epinephrine", "CHEMICAL", 3, 14], ["cetirizine", "CHEMICAL", 286, 296], ["epinephrine", "SIMPLE_CHEMICAL", 3, 14], ["children", "ORGANISM", 162, 170], ["children", "ORGANISM", 264, 272], ["cetirizine", "SIMPLE_CHEMICAL", 286, 296], ["children", "ORGANISM", 346, 354], ["skin", "ORGAN", 421, 425], ["skin", "ORGAN", 522, 526], ["children", "SPECIES", 162, 170], ["children", "SPECIES", 264, 272], ["children", "SPECIES", 346, 354], ["An epinephrine kit (Epi-pen)", "TREATMENT", 0, 28], ["medical identification bracelet", "TREATMENT", 33, 64], ["urticaria", "PROBLEM", 134, 143], ["acute urticaria", "PROBLEM", 224, 239], ["cetirizine", "TREATMENT", 286, 296], ["Allergic", "PROBLEM", 362, 370], ["frequent skin disorders", "PROBLEM", 412, 435], ["CMI hypersensitivity reaction", "PROBLEM", 475, 504], ["urticaria", "OBSERVATION", 134, 143], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["urticaria", "OBSERVATION", 230, 239], ["one of the most frequent", "OBSERVATION_MODIFIER", 396, 420], ["skin", "ANATOMY", 421, 425], ["disorders", "OBSERVATION", 426, 435], ["skin", "ANATOMY", 522, 526]]], ["Characteristically, ACD is at first limited to the skin site exposed to the allergen, but the reaction may then spread to other locations.", [["skin site", "ANATOMY", 51, 60], ["ACD", "DISEASE", 20, 23], ["skin", "ORGAN", 51, 55], ["the skin site", "PROBLEM", 47, 60], ["the reaction", "PROBLEM", 90, 102], ["ACD", "OBSERVATION", 20, 23], ["skin", "ANATOMY", 51, 55]]], ["The allergen is brought into skin contact in many ways such as compression, friction, transpiration, humidity and warmth.", [["skin", "ANATOMY", 29, 33], ["skin", "ORGAN", 29, 33], ["warmth", "PROBLEM", 114, 120], ["skin", "ANATOMY", 29, 33], ["compression", "OBSERVATION", 63, 74]]], ["Lesion severity and persistence are dictated by several factors such as MW, chemical potency, concentration and dose of the allergenic stimuli, site of contact, the frequency, duration and intensity of exposure, and especially the patient's degree of sensitization [82] .DefinitionDermatitis of variable intensity, due to lymphocytes previously sensitized by antigens making contact with exogenous haptens, mostly chemical haptens, at variance with AD, in which allergens arrive by the hematic route.", [["lymphocytes", "ANATOMY", 322, 333], ["AD", "DISEASE", 449, 451], ["patient", "ORGANISM", 231, 238], ["lymphocytes", "CELL", 322, 333], ["lymphocytes", "CELL_TYPE", 322, 333], ["antigens", "PROTEIN", 359, 367], ["patient", "SPECIES", 231, 238], ["Lesion severity", "PROBLEM", 0, 15], ["the allergenic stimuli", "TREATMENT", 120, 142], ["sensitization", "PROBLEM", 251, 264], ["variable intensity", "PROBLEM", 295, 313], ["lymphocytes", "PROBLEM", 322, 333], ["persistence", "OBSERVATION_MODIFIER", 20, 31], ["allergenic stimuli", "OBSERVATION", 124, 142], ["variable intensity", "OBSERVATION_MODIFIER", 295, 313]]], ["In this reaction, after the first epicutaneous allergen sensitization, Langerhans cells (LCs) take allergens up and migrate from the skin to draining lymph nodes and activate naive T cells in the context of HLA class I or II.", [["Langerhans cells", "ANATOMY", 71, 87], ["LCs", "ANATOMY", 89, 92], ["skin", "ANATOMY", 133, 137], ["lymph nodes", "ANATOMY", 150, 161], ["T cells", "ANATOMY", 181, 188], ["Langerhans cells", "CELL", 71, 87], ["LCs", "CELL", 89, 92], ["skin", "ORGAN", 133, 137], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 150, 161], ["T cells", "CELL", 181, 188], ["HLA class I", "GENE_OR_GENE_PRODUCT", 207, 218], ["Langerhans cells", "CELL_TYPE", 71, 87], ["LCs", "CELL_TYPE", 89, 92], ["naive T cells", "CELL_TYPE", 175, 188], ["HLA class I or II", "PROTEIN", 207, 224], ["this reaction", "PROBLEM", 3, 16], ["the first epicutaneous allergen sensitization", "TREATMENT", 24, 69], ["Langerhans cells (LCs)", "TREATMENT", 71, 93], ["allergens", "PROBLEM", 99, 108], ["draining lymph nodes", "PROBLEM", 141, 161], ["skin", "ANATOMY", 133, 137], ["draining", "OBSERVATION_MODIFIER", 141, 149], ["lymph nodes", "OBSERVATION", 150, 161]]], ["Clinical manifestations vary from a transient erythema to edematous papules with vesiculous and occasionally bullous outcome; itching is ACD's distinctive symptom, manifesting with variable intensity [107] .PrevalencePediatric ACD is a much more frequent disease than previously reported (Table 5 .9).", [["erythema", "ANATOMY", 46, 54], ["edematous papules", "ANATOMY", 58, 75], ["erythema", "DISEASE", 46, 54], ["papules", "DISEASE", 68, 75], ["itching", "DISEASE", 126, 133], ["ACD", "DISEASE", 137, 140], ["ACD", "DISEASE", 227, 230], ["erythema", "PATHOLOGICAL_FORMATION", 46, 54], ["edematous papules", "PATHOLOGICAL_FORMATION", 58, 75], ["Clinical manifestations", "PROBLEM", 0, 23], ["a transient erythema to edematous papules", "PROBLEM", 34, 75], ["vesiculous", "PROBLEM", 81, 91], ["occasionally bullous outcome", "PROBLEM", 96, 124], ["itching", "PROBLEM", 126, 133], ["ACD's distinctive symptom", "PROBLEM", 137, 162], ["PrevalencePediatric ACD", "TREATMENT", 207, 230], ["a much more frequent disease", "PROBLEM", 234, 262], ["transient", "OBSERVATION_MODIFIER", 36, 45], ["erythema", "OBSERVATION", 46, 54], ["edematous", "OBSERVATION_MODIFIER", 58, 67], ["papules", "OBSERVATION", 68, 75], ["occasionally", "OBSERVATION_MODIFIER", 96, 108], ["bullous", "OBSERVATION_MODIFIER", 109, 116]]], ["Epidemiological studies supply an ever-growing body of data pushing out the boundaries of the disease, including prematures [76] , a 1-week-old neonate with ACD to the epoxy resin in his vinyl identification band, and a 7-month-old infant who developed nickel dermatitis to the snaps in his sleepwear [75] .", [["ACD", "DISEASE", 157, 160], ["nickel dermatitis", "DISEASE", 253, 270], ["epoxy", "CHEMICAL", 168, 173], ["vinyl", "CHEMICAL", 187, 192], ["nickel", "CHEMICAL", 253, 259], ["neonate", "ORGANISM", 144, 151], ["infant", "ORGANISM", 232, 238], ["infant", "SPECIES", 232, 238], ["Epidemiological studies", "TEST", 0, 23], ["the disease", "PROBLEM", 90, 101], ["the epoxy resin", "TREATMENT", 164, 179], ["nickel dermatitis", "PROBLEM", 253, 270], ["disease", "OBSERVATION", 94, 101], ["nickel dermatitis", "OBSERVATION", 253, 270]]], ["Children as young as 6 months of age may be sensitized to contact allergens with a prevalence of sen-finding of two monozygous girls with contact allergy, thus suggesting a genetically determined selection process during development of the peripheral T-cell system [206] .Histopathological AspectsIn the acute forms, within 6 h from allergen exposure, perivascular infiltration of lymphocytes and monocytes are seen in the highest dermal layers.", [["peripheral T-cell", "ANATOMY", 240, 257], ["perivascular", "ANATOMY", 352, 364], ["lymphocytes", "ANATOMY", 381, 392], ["monocytes", "ANATOMY", 397, 406], ["dermal layers", "ANATOMY", 431, 444], ["allergy", "DISEASE", 146, 153], ["Children", "ORGANISM", 0, 8], ["peripheral T-cell", "CELL", 240, 257], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 352, 364], ["lymphocytes", "CELL", 381, 392], ["monocytes", "CELL", 397, 406], ["dermal layers", "TISSUE", 431, 444], ["lymphocytes", "CELL_TYPE", 381, 392], ["monocytes", "CELL_TYPE", 397, 406], ["Children", "SPECIES", 0, 8], ["girls", "SPECIES", 127, 132], ["contact allergy", "PROBLEM", 138, 153], ["perivascular infiltration of lymphocytes and monocytes", "PROBLEM", 352, 406], ["peripheral", "ANATOMY_MODIFIER", 240, 250], ["acute", "OBSERVATION_MODIFIER", 304, 309], ["perivascular", "ANATOMY_MODIFIER", 352, 364], ["infiltration", "OBSERVATION", 365, 377], ["lymphocytes", "OBSERVATION", 381, 392], ["monocytes", "OBSERVATION", 397, 406], ["highest", "OBSERVATION_MODIFIER", 423, 430], ["dermal", "OBSERVATION_MODIFIER", 431, 437], ["layers", "OBSERVATION_MODIFIER", 438, 444]]], ["Subsequently an intracellular and intercellular edema develops in the epidermis, thus causing spongiosis.", [["intracellular", "ANATOMY", 16, 29], ["intercellular edema", "ANATOMY", 34, 53], ["epidermis", "ANATOMY", 70, 79], ["edema", "DISEASE", 48, 53], ["spongiosis", "DISEASE", 94, 104], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 16, 29], ["intercellular", "CELLULAR_COMPONENT", 34, 47], ["edema", "PATHOLOGICAL_FORMATION", 48, 53], ["epidermis", "TISSUE", 70, 79], ["spongiosis", "PATHOLOGICAL_FORMATION", 94, 104], ["an intracellular and intercellular edema", "PROBLEM", 13, 53], ["the epidermis", "PROBLEM", 66, 79], ["spongiosis", "PROBLEM", 94, 104], ["intracellular", "OBSERVATION_MODIFIER", 16, 29], ["intercellular", "OBSERVATION_MODIFIER", 34, 47], ["edema", "OBSERVATION", 48, 53], ["epidermis", "ANATOMY", 70, 79], ["causing", "UNCERTAINTY", 86, 93], ["spongiosis", "OBSERVATION", 94, 104]]], ["Chronic lesions are characterized instead by hyperkeratosis, and in the dermal superficial layers by a dense monocyte and basophil infiltration [107, 138] .Immunological AspectsThough humoral immunity may participate in ACD pathogenesis, this depends above all on allergen-specific T cell activation stimulated by chemical substances of low MW, which are haptens and therefore need to link with proteins called carriers in the skin before they become antigenic and acquire immunogenicity (Fig. 8.10 ) sitization as high as 24.5% [38] ; 43% of children aged 8 (median) suffered from ACD of the delayed type to metals and the like and 6.6% of them to patch-test diagnosed foods, increased up to 20% by an open FCT [154] .", [["lesions", "ANATOMY", 8, 15], ["dermal superficial layers", "ANATOMY", 72, 97], ["monocyte", "ANATOMY", 109, 117], ["basophil", "ANATOMY", 122, 130], ["T cell", "ANATOMY", 282, 288], ["skin", "ANATOMY", 427, 431], ["hyperkeratosis", "DISEASE", 45, 59], ["ACD", "DISEASE", 220, 223], ["ACD", "DISEASE", 582, 585], ["lesions", "PATHOLOGICAL_FORMATION", 8, 15], ["dermal superficial layers", "TISSUE", 72, 97], ["monocyte", "CELL", 109, 117], ["basophil", "CELL", 122, 130], ["T cell", "CELL", 282, 288], ["skin", "ORGAN", 427, 431], ["children", "ORGANISM", 543, 551], ["children", "SPECIES", 543, 551], ["Chronic lesions", "PROBLEM", 0, 15], ["hyperkeratosis", "PROBLEM", 45, 59], ["a dense monocyte and basophil infiltration", "PROBLEM", 101, 143], ["ACD pathogenesis", "PROBLEM", 220, 236], ["an open FCT", "TEST", 700, 711], ["lesions", "OBSERVATION", 8, 15], ["hyperkeratosis", "OBSERVATION", 45, 59], ["dermal", "ANATOMY_MODIFIER", 72, 78], ["superficial", "ANATOMY_MODIFIER", 79, 90], ["layers", "ANATOMY_MODIFIER", 91, 97], ["dense", "OBSERVATION_MODIFIER", 103, 108], ["monocyte", "OBSERVATION_MODIFIER", 109, 117], ["basophil infiltration", "OBSERVATION", 122, 143], ["low MW", "OBSERVATION_MODIFIER", 337, 343], ["skin", "ANATOMY", 427, 431]]], ["The development of contact allergy and ACD increases with age [145, 185] In children aged 3-14, the following positivities were found: 38.8% preservatives, 25% topical drugs and 11%-16.6% fragrances and perfumes [56, 212] .", [["allergy", "DISEASE", 27, 34], ["ACD", "DISEASE", 39, 42], ["children", "ORGANISM", 76, 84], ["children", "SPECIES", 76, 84], ["contact allergy", "PROBLEM", 19, 34], ["preservatives", "TEST", 141, 154], ["topical drugs", "TEST", 160, 173], ["perfumes", "TEST", 203, 211], ["contact allergy", "OBSERVATION", 19, 34]]], ["Also, occupational ACD incidence is increased (21.2%) in boys and girls helping their parents in domestic work [7] or work outside the home [85, 199] .", [["ACD", "DISEASE", 19, 22], ["boys", "SPECIES", 57, 61], ["girls", "SPECIES", 66, 71], ["increased", "OBSERVATION_MODIFIER", 36, 45]]], ["These data also complete the ACD natural history in Table 5 .9.Etiopathogenesis Genetic FactorsSeveral textbooks assert that ACD is not linked to atopy.", [["ACD", "DISEASE", 125, 128], ["atopy", "DISEASE", 146, 151]]], ["On the contrary, atopic sensitization in children and teenagers ranges from 16.7% to 32.6% [7, 56, 85, 199, 212, 214] , with peaks of 50% [63] , with positive FH between 20.7% [199] and 42.1% [80] .", [["atopic sensitization", "DISEASE", 17, 37], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["atopic sensitization", "TEST", 17, 37], ["peaks", "TEST", 125, 130]]], ["As discussed earlier, a large share of children with AD are also affected with ACD, with a prevalence between 16 antigen macrophage [20] .", [["AD", "DISEASE", 53, 55], ["ACD", "DISEASE", 79, 82], ["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47], ["AD", "PROBLEM", 53, 55], ["large", "OBSERVATION_MODIFIER", 24, 29]]], ["These circumstances result in a cascade of inflammatory events leading to the development of dermatitis or, after a diagnostic FCT, to a hypersensitivity reaction [20] .", [["dermatitis", "DISEASE", 93, 103], ["hypersensitivity", "DISEASE", 137, 153], ["inflammatory events", "PROBLEM", 43, 62], ["dermatitis", "PROBLEM", 93, 103], ["a diagnostic FCT", "TEST", 114, 130], ["a hypersensitivity reaction", "PROBLEM", 135, 162], ["inflammatory", "OBSERVATION", 43, 55], ["dermatitis", "OBSERVATION", 93, 103]]], ["ACD can thus be classified as a delayed type of hypersensitivity (DTH) reaction, in other words, a stage of hypersensitivity associated with an increased number of allergen-specific T cells able to invade the peripheral tissues [105] .", [["T cells", "ANATOMY", 182, 189], ["peripheral tissues", "ANATOMY", 209, 227], ["ACD", "DISEASE", 0, 3], ["hypersensitivity", "DISEASE", 48, 64], ["DTH", "DISEASE", 66, 69], ["hypersensitivity", "DISEASE", 108, 124], ["T cells", "CELL", 182, 189], ["peripheral tissues", "TISSUE", 209, 227], ["allergen-specific T cells", "CELL_TYPE", 164, 189], ["hypersensitivity (DTH) reaction", "PROBLEM", 48, 79], ["hypersensitivity", "PROBLEM", 108, 124], ["an increased number of allergen", "PROBLEM", 141, 172], ["specific T cells", "PROBLEM", 173, 189], ["increased", "OBSERVATION_MODIFIER", 144, 153], ["peripheral tissues", "ANATOMY", 209, 227]]], ["The series of immune events that induce ACD implies the interaction, at an undetermined site, between T lymphocytes and epidermal CD1 + LCs (Figs.", [["site", "ANATOMY", 88, 92], ["T lymphocytes", "ANATOMY", 102, 115], ["epidermal CD1 + LCs", "ANATOMY", 120, 139], ["ACD", "DISEASE", 40, 43], ["ACD", "GENE_OR_GENE_PRODUCT", 40, 43], ["T lymphocytes", "CELL", 102, 115], ["T lymphocytes", "CELL_TYPE", 102, 115], ["epidermal CD1 + LCs", "CELL_TYPE", 120, 139], ["immune events", "PROBLEM", 14, 27], ["ACD", "PROBLEM", 40, 43], ["lymphocytes", "ANATOMY", 104, 115]]], ["2), functionally immunocompetent (CD1 + /IgE + ) cells.", [["CD1 + /IgE + ) cells", "ANATOMY", 34, 54], ["CD1", "GENE_OR_GENE_PRODUCT", 34, 37], ["IgE", "GENE_OR_GENE_PRODUCT", 41, 44], ["IgE", "PROTEIN", 41, 44], ["immunocompetent", "OBSERVATION", 17, 32]]], ["Early and important participants in the induction of ADC, LCs act as APCs in the initiation of a type IV immune reaction [207] .", [["LCs", "ANATOMY", 58, 61], ["APCs", "ANATOMY", 69, 73], ["LCs", "CELL", 58, 61], ["APCs", "CELL", 69, 73], ["LCs", "CELL_TYPE", 58, 61], ["APCs", "CELL_TYPE", 69, 73], ["participants", "SPECIES", 20, 32], ["a type IV immune reaction", "PROBLEM", 95, 120]]], ["Mobilization of dendritic cells (DCs) occurs in response to local generation of proinflammatory ILs such as IL 1 and TNF-a.", [["dendritic cells", "ANATOMY", 16, 31], ["DCs", "ANATOMY", 33, 36], ["dendritic cells", "CELL", 16, 31], ["DCs", "CELL", 33, 36], ["ILs", "GENE_OR_GENE_PRODUCT", 96, 99], ["IL 1", "GENE_OR_GENE_PRODUCT", 108, 112], ["TNF-a.", "GENE_OR_GENE_PRODUCT", 117, 123], ["dendritic cells", "CELL_TYPE", 16, 31], ["DCs", "CELL_TYPE", 33, 36], ["proinflammatory ILs", "PROTEIN", 80, 99], ["IL 1", "PROTEIN", 108, 112], ["TNF", "PROTEIN", 117, 120], ["Mobilization of dendritic cells (DCs)", "TREATMENT", 0, 37], ["local generation of proinflammatory ILs", "TREATMENT", 60, 99], ["dendritic cells", "OBSERVATION", 16, 31]]], ["Activated DCs express high levels of CCR7, HLA antigens, and costimulatory molecules (CD40, CD80, CD86) [33] .", [["DCs", "ANATOMY", 10, 13], ["DCs", "CELL", 10, 13], ["CCR7", "GENE_OR_GENE_PRODUCT", 37, 41], ["HLA antigens", "GENE_OR_GENE_PRODUCT", 43, 55], ["CD40", "GENE_OR_GENE_PRODUCT", 86, 90], ["CD80", "GENE_OR_GENE_PRODUCT", 92, 96], ["CD86", "GENE_OR_GENE_PRODUCT", 98, 102], ["Activated DCs", "CELL_TYPE", 0, 13], ["CCR7", "PROTEIN", 37, 41], ["HLA antigens", "PROTEIN", 43, 55], ["costimulatory molecules", "PROTEIN", 61, 84], ["CD40", "PROTEIN", 86, 90], ["CD80", "PROTEIN", 92, 96], ["CD86", "PROTEIN", 98, 102], ["HLA antigens", "TEST", 43, 55], ["CCR7", "ANATOMY", 37, 41]]], ["Sensitizing allergens contacting the skin activate T lymphocytes.", [["skin", "ANATOMY", 37, 41], ["T lymphocytes", "ANATOMY", 51, 64], ["skin", "ORGAN", 37, 41], ["T lymphocytes", "CELL", 51, 64], ["T lymphocytes", "CELL_TYPE", 51, 64], ["Sensitizing allergens", "PROBLEM", 0, 21], ["skin", "ANATOMY", 37, 41]]], ["To a subsequent cutaneous contact the duo hapten + carrier is taken up, processed and expressed on the surface of LCs bearing class II HLA-DR molecules [23] .", [["cutaneous", "ANATOMY", 16, 25], ["surface", "ANATOMY", 103, 110], ["LCs", "ANATOMY", 114, 117], ["surface", "CELLULAR_COMPONENT", 103, 110], ["LCs", "CELL", 114, 117], ["class II HLA-DR molecules", "GENE_OR_GENE_PRODUCT", 126, 151], ["LCs", "CELL_TYPE", 114, 117], ["class II HLA-DR molecules", "PROTEIN", 126, 151]]], ["After the allergen-HLA complex presentation, LCs migrate out of the epidermis into the dermis and then into draining lymphatics and on to regional satellite lymph nodes.", [["LCs", "ANATOMY", 45, 48], ["epidermis", "ANATOMY", 68, 77], ["dermis", "ANATOMY", 87, 93], ["lymphatics", "ANATOMY", 117, 127], ["satellite lymph nodes", "ANATOMY", 147, 168], ["LCs", "CELL", 45, 48], ["epidermis", "TISSUE", 68, 77], ["dermis", "TISSUE", 87, 93], ["lymphatics", "MULTI-TISSUE_STRUCTURE", 117, 127], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 157, 168], ["HLA complex", "PROTEIN", 19, 30], ["LCs", "CELL_TYPE", 45, 48], ["epidermis", "ANATOMY", 68, 77], ["dermis", "ANATOMY", 87, 93], ["draining", "ANATOMY_MODIFIER", 108, 116], ["lymphatics", "ANATOMY", 117, 127], ["regional", "OBSERVATION_MODIFIER", 138, 146], ["satellite", "OBSERVATION_MODIFIER", 147, 156], ["lymph nodes", "OBSERVATION", 157, 168]]], ["Within 4-6 h of hapten application, LCs congregate in T-dependent zones; within 18-24 h a great number of LCs are in the draining lymph nodes to present the processed antigen and transfer the sensitization to a large repertoire of specifically sensitized CD4 T lymphocytes bearing CD3 receptors that undergo proliferation and clonal expansion [207] .", [["LCs", "ANATOMY", 36, 39], ["LCs", "ANATOMY", 106, 109], ["lymph nodes", "ANATOMY", 130, 141], ["CD4 T lymphocytes", "ANATOMY", 255, 272], ["LCs", "CELL", 36, 39], ["T", "CELL", 54, 55], ["LCs", "CELL", 106, 109], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 130, 141], ["CD4 T lymphocytes", "CELL", 255, 272], ["CD3", "GENE_OR_GENE_PRODUCT", 281, 284], ["LCs", "CELL_TYPE", 36, 39], ["LCs", "CELL_TYPE", 106, 109], ["CD4 T lymphocytes", "CELL_TYPE", 255, 272], ["CD3 receptors", "PROTEIN", 281, 294], ["hapten application", "TREATMENT", 16, 34], ["the draining lymph nodes", "PROBLEM", 117, 141], ["sensitized CD4 T lymphocytes bearing CD3 receptors", "TREATMENT", 244, 294], ["proliferation", "PROBLEM", 308, 321], ["clonal expansion", "PROBLEM", 326, 342], ["LCs", "OBSERVATION", 106, 109], ["draining", "ANATOMY", 121, 129], ["lymph nodes", "OBSERVATION", 130, 141], ["proliferation", "OBSERVATION_MODIFIER", 308, 321], ["clonal", "OBSERVATION_MODIFIER", 326, 332], ["expansion", "OBSERVATION_MODIFIER", 333, 342]]], ["The antigens interacting with HLA molecules emit the first signal for lymphocyte activation, and the second signal is represented by IL 1 produced by keratinocytes and LCs with the primary function of activating T lymphocytes.", [["lymphocyte", "ANATOMY", 70, 80], ["keratinocytes", "ANATOMY", 150, 163], ["LCs", "ANATOMY", 168, 171], ["T lymphocytes", "ANATOMY", 212, 225], ["lymphocyte", "CELL", 70, 80], ["IL 1", "GENE_OR_GENE_PRODUCT", 133, 137], ["keratinocytes", "CELL", 150, 163], ["LCs", "CELL", 168, 171], ["T lymphocytes", "CELL", 212, 225], ["HLA molecules", "PROTEIN", 30, 43], ["IL 1", "PROTEIN", 133, 137], ["keratinocytes", "CELL_TYPE", 150, 163], ["LCs", "CELL_TYPE", 168, 171], ["activating T lymphocytes", "CELL_TYPE", 201, 225], ["lymphocyte activation", "TEST", 70, 91]]], ["This results in the clonal proliferation of antigenspecific memory T cells with the phenotype of CD4 + , CD45RO, CD45RA, which yield a number of ILs, including IL 2 and IFN-g [207] .", [["antigenspecific memory T cells", "ANATOMY", 44, 74], ["CD4 + , CD45RO", "ANATOMY", 97, 111], ["clonal", "CELL", 20, 26], ["antigenspecific memory T cells", "CELL", 44, 74], ["CD4", "GENE_OR_GENE_PRODUCT", 97, 100], ["CD45RO", "GENE_OR_GENE_PRODUCT", 105, 111], ["CD45RA", "GENE_OR_GENE_PRODUCT", 113, 119], ["ILs", "GENE_OR_GENE_PRODUCT", 145, 148], ["IL 2", "GENE_OR_GENE_PRODUCT", 160, 164], ["IFN", "GENE_OR_GENE_PRODUCT", 169, 172], ["antigenspecific memory T cells", "CELL_TYPE", 44, 74], ["CD4", "PROTEIN", 97, 100], ["CD45RO", "PROTEIN", 105, 111], ["CD45RA", "PROTEIN", 113, 119], ["ILs", "PROTEIN", 145, 148], ["IL 2", "PROTEIN", 160, 164], ["IFN", "PROTEIN", 169, 172], ["the clonal proliferation", "PROBLEM", 16, 40], ["CD4", "TEST", 97, 100], ["CD45RO", "TEST", 105, 111], ["IL", "TEST", 160, 162], ["IFN", "TEST", 169, 172], ["clonal proliferation", "OBSERVATION", 20, 40], ["antigenspecific memory T cells", "OBSERVATION", 44, 74]]], ["The coincident presence of both ILs corroborates the conclusion that they are the product of CD4 Th1 specific for contact antigens, in parallel with the delayed reaction of AD [105] .", [["AD", "DISEASE", 173, 175], ["ILs", "GENE_OR_GENE_PRODUCT", 32, 35], ["CD4", "GENE_OR_GENE_PRODUCT", 93, 96], ["ILs", "PROTEIN", 32, 35], ["CD4 Th1", "PROTEIN", 93, 100], ["contact antigens", "PROTEIN", 114, 130], ["contact antigens", "PROBLEM", 114, 130], ["the delayed reaction", "PROBLEM", 149, 169], ["both ILs", "OBSERVATION", 27, 35]]], ["Keratinocytes with their HLA-DR antigens and CD54 (Fig. 8.11 ) act as target cells for activated T cells, and the inflammatory IL they produce attract PBMCs in an allergen-nonspecific way [20] .", [["Keratinocytes", "ANATOMY", 0, 13], ["cells", "ANATOMY", 77, 82], ["T cells", "ANATOMY", 97, 104], ["PBMCs", "ANATOMY", 151, 156], ["Keratinocytes", "CELL", 0, 13], ["HLA-DR antigens", "GENE_OR_GENE_PRODUCT", 25, 40], ["CD54", "GENE_OR_GENE_PRODUCT", 45, 49], ["cells", "CELL", 77, 82], ["T cells", "CELL", 97, 104], ["IL", "GENE_OR_GENE_PRODUCT", 127, 129], ["PBMCs", "CELL", 151, 156], ["Keratinocytes", "CELL_TYPE", 0, 13], ["HLA-DR antigens", "PROTEIN", 25, 40], ["CD54", "PROTEIN", 45, 49], ["Fig. 8.11", "PROTEIN", 51, 60], ["target cells", "CELL_TYPE", 70, 82], ["activated T cells", "CELL_TYPE", 87, 104], ["inflammatory IL", "PROTEIN", 114, 129], ["PBMCs", "CELL_TYPE", 151, 156], ["Keratinocytes", "TEST", 0, 13], ["their HLA", "TEST", 19, 28], ["DR antigens", "TEST", 29, 40], ["CD54", "TEST", 45, 49], ["Fig.", "TEST", 51, 55], ["activated T cells", "PROBLEM", 87, 104], ["the inflammatory IL", "TREATMENT", 110, 129], ["inflammatory", "OBSERVATION_MODIFIER", 114, 126]]], ["During the induction phase, the CD4 infiltrated in the dermis proliferate and differentiate into effector cells and release Th1-like ILs (Table 1.", [["CD4", "ANATOMY", 32, 35], ["dermis", "ANATOMY", 55, 61], ["effector cells", "ANATOMY", 97, 111], ["CD4", "GENE_OR_GENE_PRODUCT", 32, 35], ["dermis", "TISSUE", 55, 61], ["cells", "CELL", 106, 111], ["CD4", "PROTEIN", 32, 35], ["effector cells", "CELL_TYPE", 97, 111], ["ILs", "PROTEIN", 133, 136], ["the CD4 infiltrated", "PROBLEM", 28, 47], ["CD4 infiltrated", "OBSERVATION", 32, 47], ["dermis", "ANATOMY", 55, 61], ["effector cells", "OBSERVATION", 97, 111]]], ["10), capable of inducing capillary vasodilation and permeability increase, thus leading to the allergic skin inflammation [207] .", [["capillary", "ANATOMY", 25, 34], ["skin", "ANATOMY", 104, 108], ["allergic skin inflammation", "DISEASE", 95, 121], ["capillary", "TISSUE", 25, 34], ["skin", "ORGAN", 104, 108], ["capillary vasodilation", "PROBLEM", 25, 47], ["permeability increase", "PROBLEM", 52, 73], ["the allergic skin inflammation", "PROBLEM", 91, 121], ["capillary vasodilation", "OBSERVATION", 25, 47], ["permeability increase", "OBSERVATION", 52, 73], ["allergic", "OBSERVATION_MODIFIER", 95, 103], ["skin", "ANATOMY", 104, 108], ["inflammation", "OBSERVATION", 109, 121]]], ["Th1 T cells dominate and amplify the generation of cytotoxic allergen-specific CD8 lymphocytes (CTLs), which leads in the final analysis to cutaneous lesions.", [["Th1 T cells", "ANATOMY", 0, 11], ["CD8 lymphocytes", "ANATOMY", 79, 94], ["CTLs", "ANATOMY", 96, 100], ["cutaneous lesions", "ANATOMY", 140, 157], ["Th1 T cells", "CELL", 0, 11], ["CD8 lymphocytes", "CELL", 79, 94], ["CTLs", "CELL", 96, 100], ["cutaneous lesions", "CANCER", 140, 157], ["Th1 T cells", "CELL_TYPE", 0, 11], ["cytotoxic allergen-specific CD8 lymphocytes", "CELL_TYPE", 51, 94], ["CTLs", "CELL_TYPE", 96, 100], ["Th1 T cells", "TEST", 0, 11], ["cytotoxic allergen", "TEST", 51, 69], ["the final analysis", "TEST", 118, 136], ["cutaneous lesions", "PROBLEM", 140, 157], ["cytotoxic allergen", "OBSERVATION", 51, 69], ["CD8 lymphocytes", "OBSERVATION", 79, 94], ["cutaneous", "ANATOMY", 140, 149], ["lesions", "OBSERVATION", 150, 157]]], ["As seen from studies on the animal model, both mediate type IV immune responses, Th1 with class II HLA, and CTLs with class I HLA.", [["class II HLA", "GENE_OR_GENE_PRODUCT", 90, 102], ["class I HLA", "GENE_OR_GENE_PRODUCT", 118, 129], ["class II HLA", "PROTEIN", 90, 102], ["CTLs", "CELL_TYPE", 108, 112], ["class I HLA", "PROTEIN", 118, 129]]], ["Suppressor CD8 T cells are subsequently generated, although in a lesser number, thus achieving a balance between sensitization and tolerance, orchestrated by a complex suppressor circuit acting on both afferent and efferent pathways of the DTH reaction [23] .", [["Suppressor CD8 T cells", "ANATOMY", 0, 22], ["afferent", "ANATOMY", 202, 210], ["CD8", "GENE_OR_GENE_PRODUCT", 11, 14], ["DTH", "GENE_OR_GENE_PRODUCT", 240, 243], ["Suppressor CD8 T cells", "CELL_TYPE", 0, 22], ["Suppressor CD8 T cells", "TEST", 0, 22], ["a complex suppressor circuit", "TREATMENT", 158, 186], ["the DTH reaction", "PROBLEM", 236, 252]]], ["Looked at in more detail, whether sensitization has an effect either on Th1 or Th2 activity depends on the exposure intensity and LC integrity; however, there is no numerical difference between the different T-cell subpopulations in the various phases so far delineated [211] .", [["T-cell", "ANATOMY", 208, 214], ["Th1", "GENE_OR_GENE_PRODUCT", 72, 75], ["Th2", "GENE_OR_GENE_PRODUCT", 79, 82], ["T-cell", "CELL", 208, 214], ["T-cell subpopulations", "CELL_TYPE", 208, 229], ["the exposure intensity", "TEST", 103, 125], ["LC integrity", "TEST", 130, 142], ["numerical difference", "PROBLEM", 165, 185], ["no", "UNCERTAINTY", 162, 164], ["cell subpopulations", "OBSERVATION", 210, 229]]], ["Intercellular connections are ensured by b1-b3 integrins (Tables 1.45-1.47), which allow cells to migrate into the skin, and IFN-g-stimulated endothelial cells express CD54, more adhesion molecules and class II molecules [251] .", [["Intercellular", "ANATOMY", 0, 13], ["cells", "ANATOMY", 89, 94], ["skin", "ANATOMY", 115, 119], ["endothelial cells", "ANATOMY", 142, 159], ["Intercellular", "CELL", 0, 13], ["b1-b3 integrins", "GENE_OR_GENE_PRODUCT", 41, 56], ["cells", "CELL", 89, 94], ["skin", "ORGAN", 115, 119], ["IFN-g", "GENE_OR_GENE_PRODUCT", 125, 130], ["endothelial cells", "CELL", 142, 159], ["CD54", "GENE_OR_GENE_PRODUCT", 168, 172], ["b1", "PROTEIN", 41, 43], ["b3 integrins", "PROTEIN", 44, 56], ["IFN-g-stimulated endothelial cells", "CELL_LINE", 125, 159], ["CD54", "PROTEIN", 168, 172], ["adhesion molecules", "PROTEIN", 179, 197], ["class II molecules", "PROTEIN", 202, 220], ["IFN", "TEST", 125, 128], ["CD54", "TEST", 168, 172], ["skin", "ANATOMY", 115, 119]]], ["This leads to preferential PBMC migration from the bloodstream to the inflamed skin lesions, and circulating T cells, by expressing their ligands such as CD11a/CD18 and CLA, recognize CD54 on endothelial cell and keratinocyte surface membranes activated by IL 1 and can bind these cells [20, 251] .", [["PBMC", "ANATOMY", 27, 31], ["bloodstream", "ANATOMY", 51, 62], ["skin lesions", "ANATOMY", 79, 91], ["T cells", "ANATOMY", 109, 116], ["endothelial cell", "ANATOMY", 192, 208], ["keratinocyte surface membranes", "ANATOMY", 213, 243], ["cells", "ANATOMY", 281, 286], ["PBMC", "CELL", 27, 31], ["skin lesions", "PATHOLOGICAL_FORMATION", 79, 91], ["T cells", "CELL", 109, 116], ["CD11a", "GENE_OR_GENE_PRODUCT", 154, 159], ["CD18", "GENE_OR_GENE_PRODUCT", 160, 164], ["CLA", "SIMPLE_CHEMICAL", 169, 172], ["CD54", "GENE_OR_GENE_PRODUCT", 184, 188], ["endothelial cell", "CELL", 192, 208], ["keratinocyte surface membranes", "CELLULAR_COMPONENT", 213, 243], ["IL 1", "GENE_OR_GENE_PRODUCT", 257, 261], ["cells", "CELL", 281, 286], ["PBMC", "CELL_TYPE", 27, 31], ["circulating T cells", "CELL_TYPE", 97, 116], ["CD11a", "PROTEIN", 154, 159], ["CD18", "PROTEIN", 160, 164], ["CLA", "PROTEIN", 169, 172], ["CD54", "PROTEIN", 184, 188], ["endothelial cell", "CELL_TYPE", 192, 208], ["IL 1", "PROTEIN", 257, 261], ["preferential PBMC migration", "PROBLEM", 14, 41], ["the inflamed skin lesions", "PROBLEM", 66, 91], ["circulating T cells", "PROBLEM", 97, 116], ["CD11a/CD18", "TEST", 154, 164], ["CLA", "TEST", 169, 172], ["endothelial cell", "TEST", 192, 208], ["keratinocyte surface membranes", "TREATMENT", 213, 243], ["preferential PBMC migration", "OBSERVATION", 14, 41], ["bloodstream", "OBSERVATION_MODIFIER", 51, 62], ["inflamed", "OBSERVATION_MODIFIER", 70, 78], ["skin", "ANATOMY", 79, 83], ["lesions", "OBSERVATION", 84, 91], ["CLA", "ANATOMY", 169, 172], ["CD54", "OBSERVATION", 184, 188], ["endothelial cell", "OBSERVATION", 192, 208]]], ["Moreover, PBMCs of patients with ACD presenting antigens to autologous T cells can stimulate the proliferation of the two different subsets, CD45RO + and CD45RA + , potentially recognized by two different epitopes.", [["PBMCs", "ANATOMY", 10, 15], ["T cells", "ANATOMY", 71, 78], ["PBMCs", "CELL", 10, 15], ["patients", "ORGANISM", 19, 27], ["T cells", "CELL", 71, 78], ["CD45RO", "GENE_OR_GENE_PRODUCT", 141, 147], ["CD45", "GENE_OR_GENE_PRODUCT", 154, 158], ["PBMCs", "CELL_TYPE", 10, 15], ["autologous T cells", "CELL_TYPE", 60, 78], ["CD45RO", "PROTEIN", 141, 147], ["CD45", "PROTEIN", 154, 158], ["epitopes", "PROTEIN", 205, 213], ["patients", "SPECIES", 19, 27], ["ACD", "PROBLEM", 33, 36], ["autologous T cells", "TREATMENT", 60, 78], ["CD45RO", "TEST", 141, 147], ["CD45RA", "TEST", 154, 160]]], ["However, CD3 + , CD45RA and CD8 T cell responses are absent [23] .", [["CD3 + , CD45RA", "ANATOMY", 9, 23], ["CD8 T cell", "ANATOMY", 28, 38], ["CD3", "GENE_OR_GENE_PRODUCT", 9, 12], ["CD45RA", "GENE_OR_GENE_PRODUCT", 17, 23], ["CD8", "GENE_OR_GENE_PRODUCT", 28, 31], ["CD3", "PROTEIN", 9, 12], ["CD3", "TEST", 9, 12], ["CD45RA", "TEST", 17, 23], ["CD8 T cell responses", "TEST", 28, 48]]], ["CD45RO + CD4 + T cells stimulated by antigens reach the maximal expression at 96 h (Fig. 8.12 ), thus suggesting that they are able to induce immediate cutaneous reactions in patch test sites [23] .", [["CD45RO + CD4 + T cells", "ANATOMY", 0, 22], ["cutaneous", "ANATOMY", 152, 161], ["CD45RO", "GENE_OR_GENE_PRODUCT", 0, 6], ["CD4", "GENE_OR_GENE_PRODUCT", 9, 12], ["CD45RO", "PROTEIN", 0, 6], ["CD4", "PROTEIN", 9, 12], ["T cells", "CELL_TYPE", 15, 22], ["antigens", "PROTEIN", 37, 45], ["CD45RO", "TEST", 0, 6], ["CD4 + T cells", "TREATMENT", 9, 22], ["immediate cutaneous reactions", "PROBLEM", 142, 171]]], ["DTH, thus terminating the response, which is instead up-regulated by its inhibition [71] .", [["DTH", "GENE_OR_GENE_PRODUCT", 0, 3], ["DTH", "PROTEIN", 0, 3]]], ["TNF-a stimulated with UVB propitiates the reaction by its proinflammatory and vasodilatory effects, but may be critical in inhibiting the migration of epidermal LCs [104] , which produce few ILs [128] .", [["epidermal LCs", "ANATOMY", 151, 164], ["UVB", "CHEMICAL", 22, 25], ["TNF", "GENE_OR_GENE_PRODUCT", 0, 3], ["UVB", "SIMPLE_CHEMICAL", 22, 25], ["TNF", "PROTEIN", 0, 3], ["epidermal LCs", "CELL_TYPE", 151, 164], ["ILs", "PROTEIN", 191, 194], ["TNF", "TEST", 0, 3], ["UVB", "TREATMENT", 22, 25], ["the reaction", "PROBLEM", 38, 50]]], ["Chemokines such as RANTES and MIP-1b may recruit a higher level of T lymphocytes, with a further increase in local mediators [203] .", [["T lymphocytes", "ANATOMY", 67, 80], ["RANTES", "GENE_OR_GENE_PRODUCT", 19, 25], ["MIP-1b", "GENE_OR_GENE_PRODUCT", 30, 36], ["T lymphocytes", "CELL", 67, 80], ["Chemokines", "PROTEIN", 0, 10], ["RANTES", "PROTEIN", 19, 25], ["MIP-1b", "PROTEIN", 30, 36], ["T lymphocytes", "CELL_TYPE", 67, 80], ["Chemokines", "TEST", 0, 10], ["RANTES", "TEST", 19, 25], ["MIP", "TEST", 30, 33], ["increase", "OBSERVATION_MODIFIER", 97, 105]]], ["A distinctive type of reaction involves Ni.", [["Ni.", "CHEMICAL", 40, 43], ["A distinctive type of reaction", "PROBLEM", 0, 30], ["reaction", "OBSERVATION", 22, 30]]], ["Ni-specific T lymphocyte clones recognize the antigen only on the cell surface of LCs in association with HLA class II molecules, whereas they were unable to recognize Ni when presented by monocytes.", [["T lymphocyte clones", "ANATOMY", 12, 31], ["cell surface", "ANATOMY", 66, 78], ["LCs", "ANATOMY", 82, 85], ["monocytes", "ANATOMY", 189, 198], ["Ni", "CHEMICAL", 168, 170], ["Ni", "CHEMICAL", 168, 170], ["T lymphocyte clones", "CELL", 12, 31], ["cell surface", "CELLULAR_COMPONENT", 66, 78], ["LCs", "CELL", 82, 85], ["HLA class II", "GENE_OR_GENE_PRODUCT", 106, 118], ["Ni", "GENE_OR_GENE_PRODUCT", 168, 170], ["monocytes", "CELL", 189, 198], ["Ni-specific T lymphocyte clones", "CELL_LINE", 0, 31], ["LCs", "CELL_TYPE", 82, 85], ["HLA class II molecules", "PROTEIN", 106, 128], ["Ni", "PROTEIN", 168, 170], ["monocytes", "CELL_TYPE", 189, 198], ["Ni-specific T lymphocyte clones", "TEST", 0, 31], ["HLA class II molecules", "PROBLEM", 106, 128], ["lymphocyte clones", "OBSERVATION", 14, 31], ["LCs", "OBSERVATION", 82, 85]]], ["Therefore, there may be a direct and non-HLA-restricted recognition by T-cell clones; thus Ni might interact directly on the T cell surface structure, with consequent activation and proliferation of these T cells.", [["T-cell clones", "ANATOMY", 71, 84], ["T cell surface", "ANATOMY", 125, 139], ["T cells", "ANATOMY", 205, 212], ["Ni", "CHEMICAL", 91, 93], ["Ni", "CHEMICAL", 91, 93], ["T-cell clones", "CELL", 71, 84], ["Ni", "GENE_OR_GENE_PRODUCT", 91, 93], ["T cell", "CELL", 125, 131], ["T cells", "CELL", 205, 212], ["T-cell clones", "CELL_LINE", 71, 84], ["Ni", "PROTEIN", 91, 93], ["T cells", "CELL_TYPE", 205, 212], ["a direct and non-HLA", "PROBLEM", 24, 44], ["consequent activation and proliferation of these T cells", "PROBLEM", 156, 212]]], ["Since HLA class II molecules are polymorphous and contain mostly three subtypes, all heterozygotic subjects inherit two different alleles for each of these three subtypes, so Ni may be associated with up to six different HLA class II determinants presented by APC, although it is difficult to identify the precise determinant involved [105] .", [["Ni", "CHEMICAL", 175, 177], ["Ni", "CHEMICAL", 175, 177], ["HLA class II", "GENE_OR_GENE_PRODUCT", 6, 18], ["Ni", "GENE_OR_GENE_PRODUCT", 175, 177], ["APC", "GENE_OR_GENE_PRODUCT", 260, 263], ["HLA class II molecules", "PROTEIN", 6, 28], ["Ni", "PROTEIN", 175, 177], ["HLA class II determinants", "PROTEIN", 221, 246], ["APC", "CELL_TYPE", 260, 263], ["polymorphous", "PROBLEM", 33, 45], ["polymorphous", "OBSERVATION_MODIFIER", 33, 45], ["mostly", "OBSERVATION_MODIFIER", 58, 64], ["three subtypes", "OBSERVATION_MODIFIER", 65, 79], ["APC", "OBSERVATION", 260, 263]]], ["See in the next section that oral Ni administration may have important suppressive effects in the recipients [76] .Etiological AgentsA plethora of compounds hold a top position as ACD causative agents, some, such as dinitrochlorobenzene (DNCB), exercising their action indiscriminately, while others are much more selective.", [["oral", "ANATOMY", 29, 33], ["Ni", "CHEMICAL", 34, 36], ["dinitrochlorobenzene", "CHEMICAL", 216, 236], ["DNCB", "CHEMICAL", 238, 242], ["Ni", "CHEMICAL", 34, 36], ["dinitrochlorobenzene", "CHEMICAL", 216, 236], ["DNCB", "CHEMICAL", 238, 242], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["Ni", "SIMPLE_CHEMICAL", 34, 36], ["dinitrochlorobenzene", "SIMPLE_CHEMICAL", 216, 236], ["DNCB", "SIMPLE_CHEMICAL", 238, 242], ["oral Ni administration", "TREATMENT", 29, 51], ["a top position", "TREATMENT", 162, 176], ["ACD causative agents", "TREATMENT", 180, 200], ["dinitrochlorobenzene (DNCB)", "TREATMENT", 216, 243]]], ["The more frequently induced substances are summarized in Table 8 .8 [7, 56, 57, 63, 85, 131, 149, 199, 212] , and Table 8 .9 [20, 131] shows the sources of sensitization as related to their topography.", [["Table", "TEST", 114, 119], ["sensitization", "PROBLEM", 156, 169]]], ["On the drug panorama, we give concise indications since Chap.", [["Chap", "PROTEIN", 56, 60]]], ["19 discusses the topic at length, and latex dermatitis is analyzed below.", [["latex dermatitis", "DISEASE", 38, 54], ["latex dermatitis", "PROBLEM", 38, 54], ["latex dermatitis", "OBSERVATION", 38, 54]]], ["We examine the technomarketing particularities related to the most diffused haptens [7, 52, 57, 80, 131, 138, 173, 227] .Etiological AgentsMetachromatic cells are involved in ACD: the cellular infiltrate can contain up to 10% basophils and 40% mast cells, activated by IL released by T lymphocytes, and they amplify the reaction by dilating capillaries [107] .", [["AgentsMetachromatic cells", "ANATOMY", 133, 158], ["cellular infiltrate", "ANATOMY", 184, 203], ["basophils", "ANATOMY", 226, 235], ["mast cells", "ANATOMY", 244, 254], ["T lymphocytes", "ANATOMY", 284, 297], ["capillaries", "ANATOMY", 341, 352], ["AgentsMetachromatic cells", "CELL", 133, 158], ["ACD", "PATHOLOGICAL_FORMATION", 175, 178], ["cellular", "CELL", 184, 192], ["basophils", "CELL", 226, 235], ["mast cells", "CELL", 244, 254], ["IL", "GENE_OR_GENE_PRODUCT", 269, 271], ["T lymphocytes", "CELL", 284, 297], ["capillaries", "TISSUE", 341, 352], ["Etiological AgentsMetachromatic cells", "CELL_TYPE", 121, 158], ["basophils", "CELL_TYPE", 226, 235], ["mast cells", "CELL_TYPE", 244, 254], ["IL", "PROTEIN", 269, 271], ["T lymphocytes", "CELL_TYPE", 284, 297], ["Etiological AgentsMetachromatic cells", "PROBLEM", 121, 158], ["the cellular infiltrate", "PROBLEM", 180, 203], ["basophils", "TEST", 226, 235], ["40% mast cells", "PROBLEM", 240, 254], ["AgentsMetachromatic cells", "OBSERVATION", 133, 158], ["cellular", "OBSERVATION_MODIFIER", 184, 192], ["infiltrate", "OBSERVATION", 193, 203], ["mast cells", "OBSERVATION", 244, 254]]], ["Basophils principally are seen transiently: at 48-72 h large numbers of basophils are seen within the skin blood vessels, but their exact role is far from elucidated [107] .", [["Basophils", "ANATOMY", 0, 9], ["basophils", "ANATOMY", 72, 81], ["skin blood vessels", "ANATOMY", 102, 120], ["Basophils", "GENE_OR_GENE_PRODUCT", 0, 9], ["basophils", "CELL", 72, 81], ["skin blood vessels", "MULTI-TISSUE_STRUCTURE", 102, 120], ["Basophils", "CELL_TYPE", 0, 9], ["basophils", "CELL_TYPE", 72, 81], ["Basophils", "TEST", 0, 9], ["large numbers of basophils", "PROBLEM", 55, 81], ["large", "OBSERVATION_MODIFIER", 55, 60], ["numbers", "OBSERVATION_MODIFIER", 61, 68], ["basophils", "OBSERVATION", 72, 81], ["skin", "ANATOMY", 102, 106], ["blood vessels", "ANATOMY", 107, 120]]], ["Macrophages invade both dermis and epidermis also at 48 h, and contribute to calming the reaction by producing either PGE, which inhibit IL 1 , IL 2 and NK cells, or LTB 4 inducing T CD8 cells, which further progressively calm the reaction.", [["Macrophages", "ANATOMY", 0, 11], ["dermis", "ANATOMY", 24, 30], ["epidermis", "ANATOMY", 35, 44], ["NK cells", "ANATOMY", 153, 161], ["T CD8 cells", "ANATOMY", 181, 192], ["PGE", "CHEMICAL", 118, 121], ["PGE", "CHEMICAL", 118, 121], ["Macrophages", "CELL", 0, 11], ["dermis", "TISSUE", 24, 30], ["epidermis", "ORGAN", 35, 44], ["PGE", "SIMPLE_CHEMICAL", 118, 121], ["IL 1", "GENE_OR_GENE_PRODUCT", 137, 141], ["IL 2", "GENE_OR_GENE_PRODUCT", 144, 148], ["NK cells", "CELL", 153, 161], ["LTB 4", "GENE_OR_GENE_PRODUCT", 166, 171], ["T CD8 cells", "CELL", 181, 192], ["Macrophages", "CELL_TYPE", 0, 11], ["IL 1", "PROTEIN", 137, 141], ["NK cells", "CELL_TYPE", 153, 161], ["LTB 4", "PROTEIN", 166, 171], ["T CD8 cells", "CELL_TYPE", 181, 192], ["Macrophages", "PROBLEM", 0, 11], ["calming the reaction", "PROBLEM", 77, 97], ["NK cells", "TEST", 153, 161], ["LTB", "PROBLEM", 166, 169], ["T CD8 cells", "PROBLEM", 181, 192], ["the reaction", "PROBLEM", 227, 239], ["dermis", "ANATOMY", 24, 30], ["epidermis", "ANATOMY", 35, 44], ["CD8 cells", "OBSERVATION", 183, 192]]], ["Therefore both hapten size and its capacity to steadily bind a carrier protein appear to be important factors in immunogenicity [107] .Etiological AgentsTables 8.6 [58, 128] and 8.7 [104] show the production of ILs by keratinocytes and LCs [82, 128] and by nickel (Ni)-specific T lymphocyte clones in an ACD response.", [["keratinocytes", "ANATOMY", 218, 231], ["LCs", "ANATOMY", 236, 239], ["T lymphocyte clones", "ANATOMY", 278, 297], ["nickel", "CHEMICAL", 257, 263], ["Ni", "CHEMICAL", 265, 267], ["nickel", "CHEMICAL", 257, 263], ["Ni", "CHEMICAL", 265, 267], ["ILs", "GENE_OR_GENE_PRODUCT", 211, 214], ["keratinocytes", "CELL", 218, 231], ["LCs", "CELL", 236, 239], ["nickel (Ni)", "SIMPLE_CHEMICAL", 257, 268], ["T lymphocyte clones", "CELL", 278, 297], ["carrier protein", "PROTEIN", 63, 78], ["ILs", "PROTEIN", 211, 214], ["keratinocytes", "CELL_TYPE", 218, 231], ["LCs", "CELL_TYPE", 236, 239], ["nickel (Ni)-specific T lymphocyte clones", "CELL_LINE", 257, 297], ["both hapten size", "TREATMENT", 10, 26], ["its capacity", "PROBLEM", 31, 43], ["a carrier protein", "PROBLEM", 61, 78], ["Etiological AgentsTables", "TEST", 135, 159], ["keratinocytes", "TEST", 218, 231], ["LCs", "TEST", 236, 239], ["nickel", "TEST", 257, 263], ["Ni", "TEST", 265, 267], ["specific T lymphocyte clones", "PROBLEM", 269, 297], ["hapten", "OBSERVATION_MODIFIER", 15, 21], ["size", "OBSERVATION_MODIFIER", 22, 26], ["lymphocyte clones", "OBSERVATION", 280, 297], ["ACD response", "OBSERVATION", 304, 316]]], ["It is surprising how many ILs are produced by keratinocytes: Ni-sensitive patients produce both IL 4 and IL 5 ,but the nonallergic patients have elevated levels of IFN-g.", [["keratinocytes", "ANATOMY", 46, 59], ["nonallergic", "DISEASE", 119, 130], ["ILs", "GENE_OR_GENE_PRODUCT", 26, 29], ["keratinocytes", "CELL", 46, 59], ["patients", "ORGANISM", 74, 82], ["IL 4", "GENE_OR_GENE_PRODUCT", 96, 100], ["IL 5", "GENE_OR_GENE_PRODUCT", 105, 109], ["patients", "ORGANISM", 131, 139], ["ILs", "PROTEIN", 26, 29], ["keratinocytes", "CELL_TYPE", 46, 59], ["IL 4", "PROTEIN", 96, 100], ["IL 5", "PROTEIN", 105, 109], ["IFN", "PROTEIN", 164, 167], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 131, 139], ["elevated levels of IFN", "PROBLEM", 145, 167], ["elevated", "OBSERVATION", 145, 153]]], ["A recent study [82] showed that IL 1a ,and IL 1b are among the several ILs produced in the skin after contact by an immunizing agent, which potentially primes the synthesis of more chemotactic ILs involved in ACD and IL 10 [71, 128] , which instead inhibits the reaction.", [["skin", "ANATOMY", 91, 95], ["IL 1a", "GENE_OR_GENE_PRODUCT", 32, 37], ["IL 1b", "GENE_OR_GENE_PRODUCT", 43, 48], ["ILs", "GENE_OR_GENE_PRODUCT", 71, 74], ["skin", "ORGAN", 91, 95], ["ILs", "GENE_OR_GENE_PRODUCT", 193, 196], ["ACD", "GENE_OR_GENE_PRODUCT", 209, 212], ["IL 10", "GENE_OR_GENE_PRODUCT", 217, 222], ["IL 1a", "PROTEIN", 32, 37], ["IL 1b", "PROTEIN", 43, 48], ["ILs", "PROTEIN", 71, 74], ["chemotactic ILs", "PROTEIN", 181, 196], ["A recent study", "TEST", 0, 14], ["IL 1a", "TREATMENT", 32, 37], ["IL 1b", "TREATMENT", 43, 48], ["an immunizing agent", "TREATMENT", 113, 132], ["chemotactic ILs", "TREATMENT", 181, 196], ["the reaction", "PROBLEM", 258, 270], ["skin", "ANATOMY", 91, 95]]], ["In particular the keratinocyte-produced IL 10 may down-regulate 561 Allergic Contact Dermatitis TGF-a \u00b1 ?Etiological AgentsTGF-b \u00b1 ?Etiological AgentsData from [58, 128] .", [["keratinocyte", "ANATOMY", 18, 30], ["Dermatitis", "DISEASE", 85, 95], ["keratinocyte", "CELL", 18, 30], ["IL 10", "GENE_OR_GENE_PRODUCT", 40, 45], ["TGF", "GENE_OR_GENE_PRODUCT", 96, 99], ["AgentsTGF", "GENE_OR_GENE_PRODUCT", 117, 126], ["IL 10", "PROTEIN", 40, 45], ["TGF", "PROTEIN", 96, 99], ["AgentsTGF", "PROTEIN", 117, 126], ["-b", "PROTEIN", 126, 128], ["TGF", "TEST", 96, 99], ["keratinocyte", "ANATOMY", 18, 30]]], ["Balsam of Peru: vegetal fragrance containing principally benzylbenzoate, benzoic acid, cinnamyl alcohol, eugenol and vanillin.", [["Balsam of Peru: vegetal fragrance", "CHEMICAL", 0, 33], ["benzylbenzoate", "CHEMICAL", 57, 71], ["benzoic acid", "CHEMICAL", 73, 85], ["cinnamyl alcohol", "CHEMICAL", 87, 103], ["eugenol", "CHEMICAL", 105, 112], ["vanillin", "CHEMICAL", 117, 125], ["benzylbenzoate", "CHEMICAL", 57, 71], ["benzoic acid", "CHEMICAL", 73, 85], ["cinnamyl alcohol", "CHEMICAL", 87, 103], ["eugenol", "CHEMICAL", 105, 112], ["vanillin", "CHEMICAL", 117, 125], ["benzylbenzoate", "SIMPLE_CHEMICAL", 57, 71], ["benzoic acid", "SIMPLE_CHEMICAL", 73, 85], ["cinnamyl alcohol", "SIMPLE_CHEMICAL", 87, 103], ["eugenol", "SIMPLE_CHEMICAL", 105, 112], ["vanillin", "SIMPLE_CHEMICAL", 117, 125], ["benzylbenzoate", "TREATMENT", 57, 71], ["benzoic acid", "TREATMENT", 73, 85], ["eugenol", "TREATMENT", 105, 112], ["vanillin", "TREATMENT", 117, 125], ["vegetal fragrance", "OBSERVATION", 16, 33]]], ["It is used in: \u2211 Emollients, medical creams and ointments, powders, tinctures, suppositories, healing preparations and for burns (due to antiseptic and/or keratoplasty actions) \u2211 Straps and paints due to its adhesive action \u2211 Perfumes and cosmetics (after-shave lotions, brilliantine, creams, face powders, deodorants, infantile cosmetics, lipsticks, lotions, perfumes, soaps, toothpastes, etc.) as fragrance \u2211 Tobaccos \u2211 Drugs (balsamics, cough syrups, emollient lozenges, topical drugs); liquid cement for dentists \u2211 Foods (as aromatizing in food industry) such as aperitifs, baked goods, bitters, chewing gums, candies, chocolates, cola, cocktails, ice creams, orange squash, p\u00e2t\u00e9 de foie gras, sauces, vanilla, products containing 562 CHAPTER 8 Other Allergic Skin Disorders Fig. 8.13 .", [["burns", "DISEASE", 123, 128], ["brilliantine", "CHEMICAL", 271, 283], ["infantile cosmetics", "DISEASE", 319, 338], ["lipsticks", "DISEASE", 340, 349], ["cough syrups", "DISEASE", 440, 452], ["emollient lozenges", "CHEMICAL", 454, 472], ["chewing gums, candies, chocolates, cola, cocktails, ice creams, orange squash", "CHEMICAL", 600, 677], ["Allergic Skin Disorders", "DISEASE", 755, 778], ["ointments", "SIMPLE_CHEMICAL", 48, 57], ["gums", "ORGANISM_SUBDIVISION", 608, 612], ["candies", "ORGANISM_SUBDIVISION", 614, 621], ["cola", "ORGANISM_SUBDIVISION", 635, 639], ["vanilla", "ORGANISM_SUBDIVISION", 706, 713], ["orange squash", "SPECIES", 664, 677], ["Emollients", "TREATMENT", 17, 27], ["medical creams", "TREATMENT", 29, 43], ["ointments", "TREATMENT", 48, 57], ["powders", "TREATMENT", 59, 66], ["tinctures", "TREATMENT", 68, 77], ["suppositories", "TREATMENT", 79, 92], ["healing preparations", "TREATMENT", 94, 114], ["burns", "PROBLEM", 123, 128], ["antiseptic", "TREATMENT", 137, 147], ["keratoplasty actions)", "TREATMENT", 155, 176], ["Straps", "TREATMENT", 179, 185], ["paints", "TREATMENT", 190, 196], ["its adhesive action", "TREATMENT", 204, 223], ["lotions", "TREATMENT", 262, 269], ["brilliantine", "TREATMENT", 271, 283], ["creams", "TREATMENT", 285, 291], ["face powders", "TREATMENT", 293, 305], ["deodorants", "TREATMENT", 307, 317], ["infantile cosmetics", "TREATMENT", 319, 338], ["lipsticks", "TREATMENT", 340, 349], ["lotions", "TREATMENT", 351, 358], ["toothpastes", "TREATMENT", 377, 388], ["cough syrups", "TREATMENT", 440, 452], ["emollient lozenges", "TREATMENT", 454, 472], ["topical drugs", "TREATMENT", 474, 487], ["liquid cement", "TREATMENT", 490, 503], ["ice creams", "TREATMENT", 652, 662], ["Allergic Skin Disorders Fig", "PROBLEM", 755, 782], ["Skin", "ANATOMY", 764, 768], ["Disorders Fig", "OBSERVATION", 769, 782]]], ["ACD provoked by resin \u2211 Perfumes, bath salts, soaps, shaving-creams, toothpastes \u2211 Insecticides \u2211 Expectorants by mouth, antirheumatic and rubefacient liniments Parabens mix: substances with antioxidant, antifermentative and fungicidal power, found in cosmetics, drugs and foods as preservatives; are present in: \u2211 Preservatives found in many dermological creams, pastes, face powders, cosmetics, sun-creams, toothpastes, cleansing milk and creams, hair lotions, lipsticks, soaps citrus peels (orange jam, cakes with candied fruits, etc.), confectionery products with spices, perfumed teas Colophony (Fig. 8.13 ): a resin obtained from different conifer species, one of its derivatives is turpentine oil.", [["mouth", "ANATOMY", 114, 119], ["milk", "ANATOMY", 432, 436], ["hair", "ANATOMY", 449, 453], ["lipsticks", "ANATOMY", 463, 472], ["peels", "ANATOMY", 487, 492], ["fruits", "ANATOMY", 525, 531], ["oil", "ANATOMY", 700, 703], ["ACD", "DISEASE", 0, 3], ["lipsticks, soaps citrus peels", "CHEMICAL", 463, 492], ["perfumed teas Colophony", "CHEMICAL", 576, 599], ["turpentine", "CHEMICAL", 689, 699], ["mouth", "ORGANISM_SUBDIVISION", 114, 119], ["milk", "ORGANISM_SUBSTANCE", 432, 436], ["hair lotions", "MULTI-TISSUE_STRUCTURE", 449, 461], ["peels", "TISSUE", 487, 492], ["fruits", "ORGANISM_SUBDIVISION", 525, 531], ["turpentine", "SIMPLE_CHEMICAL", 689, 699], ["oil", "ORGANISM_SUBSTANCE", 700, 703], ["ACD", "TREATMENT", 0, 3], ["resin \u2211 Perfumes", "TREATMENT", 16, 32], ["bath salts", "TREATMENT", 34, 44], ["soaps", "TREATMENT", 46, 51], ["shaving", "TREATMENT", 53, 60], ["creams", "TREATMENT", 61, 67], ["toothpastes", "TREATMENT", 69, 80], ["Insecticides", "TREATMENT", 83, 95], ["antirheumatic and rubefacient liniments", "TREATMENT", 121, 160], ["antioxidant", "TREATMENT", 191, 202], ["fungicidal power", "TREATMENT", 225, 241], ["Preservatives", "TREATMENT", 315, 328], ["many dermological creams", "TREATMENT", 338, 362], ["pastes", "TREATMENT", 364, 370], ["face powders", "TREATMENT", 372, 384], ["cosmetics", "TREATMENT", 386, 395], ["sun-creams", "TREATMENT", 397, 407], ["toothpastes", "TREATMENT", 409, 420], ["cleansing milk", "TREATMENT", 422, 436], ["creams", "TREATMENT", 441, 447], ["hair lotions", "TREATMENT", 449, 461], ["lipsticks", "TREATMENT", 463, 472], ["soaps citrus peels", "TREATMENT", 474, 492], ["a resin", "TREATMENT", 614, 621], ["turpentine oil", "TREATMENT", 689, 703], ["mouth", "ANATOMY", 114, 119]]], ["It is found in: \u2211 Electric insulators, pharmaceuticals, soldering materials, such as patches, plasters, and products of common use, including soaps and cosmetics, in addition to adhesives, depilatories, dressings, mastics, nail polish, shoe wax, stickers, tape, varnishes, watercolors; cleaning compounds (furniture and floors), lacquers, surface coating, paints, paper boxes, resins, and printing inks Turpentine: oils, resins and varnish solvents, is found in: 563 Allergic Contact Dermatitis ) is one of the most common sensitizers in our environment contained in nickel-plated manufactured products of common use such as: \u2211 Coins (euro cents), door handles, drawing-pins, earrings, inks, keys, lighters, metallic parts of watch-straps, needles, paper-clips, pencils, pins, safety-pins, scissors, spectacle frames, thimbles, tweezers, utensils, watchcases, etc. \u2211 Identification bracelets (maternity wards), particular groups of patients, also allergic children. \u2211 Dental prostheses, orthodontic instruments, and lowweight gold alloyed with Ni used in dentistry.Etiological Agents\u2211 Clothes accessories such as bobby-pins, buckles, buttons, clips, fasteners, clothing and hair clasps, shoe laces, safety-pins, zippers. \u2211 Costume jewelry since nickel-plating precedes goldplating (bracelets, earrings, jewelry of white and yellow gold, medals, etc.); some children may be exquisitely sensitive to even Ni traces found in gold jewelry. \u2211 Colorings for cosmetics, for example eye-shadows. \u2211 Curling instruments for eyelashes and hair. \u2211 Door handles, handles of electric appliances, stainless steel pots or enameled pots (especially in blue or green), as well as pottery, insecticides, plastics. \u2211 Dyes, metallic paint, mordents, paints, shoe waxes, wallpapers. \u2211 Young children and girls have a high risk of sensitization at the time of ear, nose, and tongue piercing and subsequently [130] (the Italian press reported on March 12, 2003 the case of a 24-year-old who probably died of a fulminating hepatitis after a tongue-piercing). \u2211 Ni can contaminate foods cooked in chipped pots or pickled in metallic containers or cans. \u2211 Can be found in raw and canned foods, for some of which we give the Ni content in mg/hg [173] : lentils 310, white beans 285, rye 270, peas 225, cocoa and chocolate 220, peanuts 160, raspberry 40, herrings 30, jam 25, potatoes 25, white wine 10, CM and derivatives 5, as well as asparagus, beer, butter, carrots, Brussels sprouts, cabbages, corn flour and whole meal, hazel nuts, margarine, mushrooms, onions, oysters, pears (also cooked), popcorn, raisins, rhubarb, soy, spinach, strawberry, tea, tomatoes, walnuts, yeast (artificial), etc., in addition to traces in cleansing tools. \u2211 It is known that sweating may release Ni ions from metallic objects.", [["surface", "ANATOMY", 339, 346], ["hair", "ANATOMY", 1174, 1178], ["eyelashes", "ANATOMY", 1514, 1523], ["hair", "ANATOMY", 1528, 1532], ["ear", "ANATOMY", 1837, 1840], ["nose", "ANATOMY", 1842, 1846], ["tongue", "ANATOMY", 1852, 1858], ["tongue", "ANATOMY", 2016, 2022], ["sprouts", "ANATOMY", 2451, 2458], ["cabbages", "ANATOMY", 2460, 2468], ["nuts", "ANATOMY", 2503, 2507], ["mushrooms", "ANATOMY", 2520, 2529], ["tea", "ANATOMY", 2622, 2625], ["tomatoes", "ANATOMY", 2627, 2635], ["walnuts", "ANATOMY", 2637, 2644], ["shoe wax, stickers, tape, varnishes, watercolors", "CHEMICAL", 236, 284], ["Turpentine", "CHEMICAL", 403, 413], ["oils, resins and varnish solvents", "CHEMICAL", 415, 448], ["Allergic Contact Dermatitis", "DISEASE", 467, 494], ["nickel", "CHEMICAL", 567, 573], ["allergic", "DISEASE", 947, 955], ["Ni", "CHEMICAL", 1044, 1046], ["Costume jewelry", "CHEMICAL", 1223, 1238], ["nickel", "CHEMICAL", 1245, 1251], ["Ni", "CHEMICAL", 1403, 1405], ["hepatitis", "DISEASE", 1998, 2007], ["Ni", "CHEMICAL", 2036, 2038], ["Ni", "CHEMICAL", 2197, 2199], ["white beans 285, rye 270, peas 225, cocoa and chocolate 220, peanuts 160, raspberry 40, herrings 30, jam 25, potatoes 25, white wine 10, CM and derivatives 5, as well as asparagus, beer, butter, carrots, Brussels sprouts, cabbages, corn flour", "CHEMICAL", 2238, 2480], ["hazel nuts, margarine, mushrooms, onions, oysters, pears (also cooked), popcorn, raisins, rhubarb, soy, spinach, strawberry, tea, tomatoes, walnuts", "CHEMICAL", 2497, 2644], ["Ni", "CHEMICAL", 2754, 2756], ["varnish", "CHEMICAL", 432, 439], ["nickel", "CHEMICAL", 567, 573], ["Ni", "CHEMICAL", 1044, 1046], ["nickel", "CHEMICAL", 1245, 1251], ["Ni", "CHEMICAL", 1403, 1405], ["Ni", "CHEMICAL", 2036, 2038], ["Ni", "CHEMICAL", 2197, 2199], ["Ni", "CHEMICAL", 2754, 2756], ["Turpentine", "SIMPLE_CHEMICAL", 403, 413], ["oils", "TISSUE", 415, 419], ["varnish solvents", "SIMPLE_CHEMICAL", 432, 448], ["patients", "ORGANISM", 932, 940], ["children", "ORGANISM", 956, 964], ["children", "ORGANISM", 1357, 1365], ["eyelashes", "PATHOLOGICAL_FORMATION", 1514, 1523], ["hair", "ORGAN", 1528, 1532], ["Dyes", "SIMPLE_CHEMICAL", 1697, 1701], ["children", "ORGANISM", 1769, 1777], ["ear", "ORGAN", 1837, 1840], ["nose", "ORGANISM_SUBDIVISION", 1842, 1846], ["tongue", "ORGAN", 1852, 1858], ["tongue", "ORGANISM_SUBDIVISION", 2016, 2022], ["Ni", "SIMPLE_CHEMICAL", 2197, 2199], ["lentils", "ORGANISM", 2225, 2232], ["beans", "ORGANISM_SUBDIVISION", 2244, 2249], ["peas", "ORGANISM_SUBDIVISION", 2264, 2268], ["cocoa", "ORGANISM_SUBDIVISION", 2274, 2279], ["peanuts", "ORGANISM_SUBDIVISION", 2299, 2306], ["butter", "ORGANISM_SUBDIVISION", 2425, 2431], ["carrots", "ORGANISM_SUBDIVISION", 2433, 2440], ["sprouts", "TISSUE", 2451, 2458], ["nuts", "ORGANISM_SUBDIVISION", 2503, 2507], ["margarine", "ORGANISM_SUBDIVISION", 2509, 2518], ["raisins", "ORGANISM_SUBDIVISION", 2578, 2585], ["rhubarb", "ORGANISM_SUBDIVISION", 2587, 2594], ["soy", "ORGANISM_SUBDIVISION", 2596, 2599], ["spinach", "ORGANISM_SUBDIVISION", 2601, 2608], ["strawberry", "ORGANISM_SUBDIVISION", 2610, 2620], ["tea", "ORGANISM_SUBDIVISION", 2622, 2625], ["tomatoes", "ORGANISM_SUBDIVISION", 2627, 2635], ["walnuts", "ORGANISM_SUBDIVISION", 2637, 2644], ["Ni ions", "SIMPLE_CHEMICAL", 2754, 2761], ["patients", "SPECIES", 932, 940], ["children", "SPECIES", 956, 964], ["children", "SPECIES", 1357, 1365], ["children", "SPECIES", 1769, 1777], ["girls", "SPECIES", 1782, 1787], ["beans", "SPECIES", 2244, 2249], ["rye", "SPECIES", 2255, 2258], ["peas", "SPECIES", 2264, 2268], ["peanuts", "SPECIES", 2299, 2306], ["raspberry", "SPECIES", 2312, 2321], ["potatoes", "SPECIES", 2347, 2355], ["butter", "SPECIES", 2425, 2431], ["carrots", "SPECIES", 2433, 2440], ["corn", "SPECIES", 2470, 2474], ["margarine", "SPECIES", 2509, 2518], ["onions", "SPECIES", 2531, 2537], ["pears", "SPECIES", 2548, 2553], ["raisins", "SPECIES", 2578, 2585], ["rhubarb", "SPECIES", 2587, 2594], ["soy", "SPECIES", 2596, 2599], ["spinach", "SPECIES", 2601, 2608], ["strawberry", "SPECIES", 2610, 2620], ["tea", "SPECIES", 2622, 2625], ["tomatoes", "SPECIES", 2627, 2635], ["walnuts", "SPECIES", 2637, 2644], ["yeast", "SPECIES", 2646, 2651], ["white beans 285", "SPECIES", 2238, 2253], ["carrots", "SPECIES", 2433, 2440], ["corn", "SPECIES", 2470, 2474], ["strawberry", "SPECIES", 2610, 2620], ["tomatoes", "SPECIES", 2627, 2635], ["yeast", "SPECIES", 2646, 2651], ["Electric insulators", "TREATMENT", 18, 37], ["soldering materials", "TREATMENT", 56, 75], ["plasters", "TREATMENT", 94, 102], ["soaps", "TREATMENT", 142, 147], ["cosmetics", "TREATMENT", 152, 161], ["adhesives", "TREATMENT", 178, 187], ["depilatories", "TREATMENT", 189, 201], ["dressings", "TREATMENT", 203, 212], ["mastics", "TREATMENT", 214, 221], ["tape", "TREATMENT", 256, 260], ["varnishes", "TREATMENT", 262, 271], ["watercolors", "TREATMENT", 273, 284], ["lacquers", "TREATMENT", 329, 337], ["resins", "TREATMENT", 377, 383], ["resins and varnish solvents", "TREATMENT", 421, 448], ["Allergic Contact Dermatitis", "PROBLEM", 467, 494], ["watch-straps", "TREATMENT", 726, 738], ["needles", "TREATMENT", 740, 747], ["clips", "TREATMENT", 755, 760], ["pencils", "TREATMENT", 762, 769], ["pins", "TREATMENT", 771, 775], ["safety-pins", "TREATMENT", 777, 788], ["scissors", "TREATMENT", 790, 798], ["Dental prostheses", "TREATMENT", 968, 985], ["orthodontic instruments", "TREATMENT", 987, 1010], ["Etiological Agents", "TREATMENT", 1065, 1083], ["Clothes accessories", "TREATMENT", 1085, 1104], ["bobby-pins", "TREATMENT", 1113, 1123], ["clips", "TREATMENT", 1143, 1148], ["fasteners", "TREATMENT", 1150, 1159], ["clothing and hair clasps", "TREATMENT", 1161, 1185], ["shoe laces", "TREATMENT", 1187, 1197], ["zippers", "TREATMENT", 1212, 1219], ["nickel-plating", "TREATMENT", 1245, 1259], ["example eye-shadows", "PROBLEM", 1467, 1486], ["eyelashes", "PROBLEM", 1514, 1523], ["electric appliances", "TREATMENT", 1561, 1580], ["stainless steel pots or enameled pots", "PROBLEM", 1582, 1619], ["Dyes", "TREATMENT", 1697, 1701], ["a fulminating hepatitis", "PROBLEM", 1984, 2007], ["lentils", "TEST", 2225, 2232], ["white beans", "TEST", 2238, 2249], ["rye", "TEST", 2255, 2258], ["peas", "TEST", 2264, 2268], ["cocoa", "TEST", 2274, 2279], ["chocolate", "TEST", 2284, 2293], ["peanuts", "TEST", 2299, 2306], ["herrings", "TEST", 2326, 2334], ["potatoes", "TEST", 2347, 2355], ["derivatives", "TREATMENT", 2382, 2393], ["yeast", "PROBLEM", 2646, 2651], ["sweating", "PROBLEM", 2733, 2741], ["soldering materials", "OBSERVATION", 56, 75], ["nail", "ANATOMY", 223, 227], ["clips", "OBSERVATION", 755, 760], ["pins", "ANATOMY", 771, 775], ["prostheses", "OBSERVATION", 975, 985], ["pins", "OBSERVATION", 1119, 1123], ["clips", "OBSERVATION", 1143, 1148], ["hair clasps", "OBSERVATION", 1174, 1185], ["hair", "ANATOMY", 1528, 1532], ["metallic paint", "OBSERVATION", 1703, 1717], ["ear", "ANATOMY", 1837, 1840], ["nose", "ANATOMY", 1842, 1846], ["tongue", "ANATOMY", 1852, 1858], ["tongue", "ANATOMY", 2016, 2022], ["metallic containers", "OBSERVATION", 2098, 2117], ["strawberry", "ANATOMY", 2610, 2620], ["metallic objects", "OBSERVATION", 2767, 2783]]], ["The metallic containers for food preservation should no longer affect Ni content, since Ni contact is now avoided by means of an internal coating formed by a layer of acrylic or epoxy polymeric resins, as for enameled pots.", [["Ni", "CHEMICAL", 70, 72], ["Ni", "CHEMICAL", 88, 90], ["Ni", "CHEMICAL", 70, 72], ["Ni", "CHEMICAL", 88, 90], ["acrylic", "CHEMICAL", 167, 174], ["epoxy", "CHEMICAL", 178, 183], ["Ni", "SIMPLE_CHEMICAL", 70, 72], ["acrylic", "SIMPLE_CHEMICAL", 167, 174], ["The metallic containers", "TREATMENT", 0, 23], ["food preservation", "TREATMENT", 28, 45], ["an internal coating", "TREATMENT", 126, 145], ["a layer of acrylic or epoxy polymeric resins", "TREATMENT", 156, 200], ["enameled pots", "PROBLEM", 209, 222]]], ["Instead, wearing Ni-releasing orthodontic braces induces by immunosuppression tolerance to later Ni contact, provided that fitting of braces is absolutely not preceded by further Ni contacts, for example ear-piercing [130, 221] .", [["Ni", "CHEMICAL", 97, 99], ["Ni", "CHEMICAL", 179, 181], ["Ni", "CHEMICAL", 97, 99], ["Ni", "CHEMICAL", 179, 181], ["Ni-releasing orthodontic braces", "TREATMENT", 17, 48], ["braces", "TREATMENT", 134, 140]]], ["We stress that in Denmark the use of Ni has been banned since June 1989 in belts, buttons, frames for glasses, hair-clips and bobbypins, costume jewelry in general, watch-cases and related watch-straps, zippers, and any object touching the skin; violation of the ban carries a 1-year sentence of imprisonment.Etiological AgentsPotassium (K) bichromate: is employed: \u2211 In chromed alloy and manufactures. \u2211 In leather tanning. \u2211 As cloth dye, such as in military green fabric and billiard-and card-tables. \u2211 As anticorrosive in paints, oils and refrigerant fluids. \u2211 As a catalyst in acrylic resin synthesis.Etiological AgentsIt is contained in: \u2211 Objects of common use such as colored pencils and pens, fragrances and deodorants, magnetic tapes, match \u2211 Acaricides, antiparasitics, astringents for mouthwash and lotions, fertilizers, fungicides. \u2211 Foods in traces: beer, clams, edible mushrooms, lentils, mussels, oysters, shrimps.", [["hair", "ANATOMY", 111, 115], ["skin", "ANATOMY", 240, 244], ["oils", "ANATOMY", 534, 538], ["mushrooms", "ANATOMY", 884, 893], ["lentils", "ANATOMY", 895, 902], ["mussels", "ANATOMY", 904, 911], ["oysters", "ANATOMY", 913, 920], ["Ni", "CHEMICAL", 37, 39], ["AgentsPotassium", "CHEMICAL", 321, 336], ["K", "CHEMICAL", 338, 339], ["Ni", "CHEMICAL", 37, 39], ["AgentsPotassium", "CHEMICAL", 321, 336], ["acrylic resin", "CHEMICAL", 582, 595], ["skin", "ORGAN", 240, 244], ["acrylic resin", "SIMPLE_CHEMICAL", 582, 595], ["mussels", "ORGANISM_SUBDIVISION", 904, 911], ["glasses", "TREATMENT", 102, 109], ["clips", "TREATMENT", 116, 121], ["bobbypins", "TREATMENT", 126, 135], ["watch-straps", "TREATMENT", 189, 201], ["zippers", "TREATMENT", 203, 210], ["cloth dye", "TREATMENT", 430, 439], ["refrigerant fluids", "TREATMENT", 543, 561], ["a catalyst in acrylic resin synthesis", "TREATMENT", 568, 605], ["colored pencils and pens", "TREATMENT", 676, 700], ["deodorants", "TREATMENT", 717, 727], ["magnetic tapes", "TREATMENT", 729, 743], ["match \u2211 Acaricides", "TREATMENT", 745, 763], ["antiparasitics", "TREATMENT", 765, 779], ["astringents", "TREATMENT", 781, 792], ["mouthwash", "TREATMENT", 797, 806], ["lotions", "TREATMENT", 811, 818], ["fertilizers", "TREATMENT", 820, 831], ["fungicides", "TREATMENT", 833, 843], ["clips", "OBSERVATION", 116, 121], ["skin", "ANATOMY", 240, 244], ["leather tanning", "OBSERVATION", 408, 423], ["acrylic", "OBSERVATION", 582, 589], ["resin synthesis", "OBSERVATION", 590, 605]]], ["Paraphenylenediamine (PPDA): is employed in: \u2211 Color film developers, inexpensive fabrics and furs, lubricating oils, permanent black or dark hair dyes, dyed textiles, etc. \u2211 As an accelerator and antioxidant: rubber, catalyzers for resin synthesis. \u2211 Antioxidant in gasoline, oils, lubricating, printing inks and cartridges for printers (computer), reagents for photography, lithography and radiography. \u2211 Cross-reactivity with other substances of the para group such as local anesthetics (benzocaine, procaine, etc.), sulfonamide drugs, aniline dyes and PABA (paminobenzoic acid) used in sun screens (creams, lotions, ointments) and in several cosmetics, including eye shadows, lipsticks, hair balsams, nail varnishes, shampoos.", [["oils", "ANATOMY", 112, 116], ["hair", "ANATOMY", 142, 146], ["oils", "ANATOMY", 277, 281], ["eye", "ANATOMY", 667, 670], ["lipsticks", "ANATOMY", 680, 689], ["hair", "ANATOMY", 691, 695], ["nail", "ANATOMY", 705, 709], ["Paraphenylenediamine", "CHEMICAL", 0, 20], ["PPDA", "CHEMICAL", 22, 26], ["benzocaine", "CHEMICAL", 491, 501], ["procaine", "CHEMICAL", 503, 511], ["sulfonamide", "CHEMICAL", 520, 531], ["aniline dyes", "CHEMICAL", 539, 551], ["PABA", "CHEMICAL", 556, 560], ["paminobenzoic acid", "CHEMICAL", 562, 580], ["Paraphenylenediamine", "CHEMICAL", 0, 20], ["PPDA", "CHEMICAL", 22, 26], ["benzocaine", "CHEMICAL", 491, 501], ["procaine", "CHEMICAL", 503, 511], ["sulfonamide", "CHEMICAL", 520, 531], ["aniline", "CHEMICAL", 539, 546], ["PABA", "CHEMICAL", 556, 560], ["paminobenzoic acid", "CHEMICAL", 562, 580], ["Paraphenylenediamine", "SIMPLE_CHEMICAL", 0, 20], ["PPDA", "SIMPLE_CHEMICAL", 22, 26], ["resin", "SIMPLE_CHEMICAL", 233, 238], ["gasoline", "SIMPLE_CHEMICAL", 267, 275], ["benzocaine", "SIMPLE_CHEMICAL", 491, 501], ["procaine", "SIMPLE_CHEMICAL", 503, 511], ["sulfonamide drugs", "SIMPLE_CHEMICAL", 520, 537], ["aniline dyes", "SIMPLE_CHEMICAL", 539, 551], ["PABA", "SIMPLE_CHEMICAL", 556, 560], ["paminobenzoic acid", "SIMPLE_CHEMICAL", 562, 580], ["eye", "ORGAN", 667, 670], ["Color film", "TEST", 47, 57], ["inexpensive fabrics", "TREATMENT", 70, 89], ["lubricating oils", "TREATMENT", 100, 116], ["catalyzers", "TREATMENT", 218, 228], ["resin synthesis", "TREATMENT", 233, 248], ["Antioxidant in gasoline", "TREATMENT", 252, 275], ["photography", "TEST", 363, 374], ["lithography", "TEST", 376, 387], ["radiography", "TEST", 392, 403], ["the para group", "TREATMENT", 449, 463], ["local anesthetics", "TREATMENT", 472, 489], ["benzocaine", "TREATMENT", 491, 501], ["procaine", "TREATMENT", 503, 511], ["sulfonamide drugs", "TREATMENT", 520, 537], ["aniline dyes", "TREATMENT", 539, 551], ["PABA (paminobenzoic acid)", "TREATMENT", 556, 581], ["creams", "TREATMENT", 603, 609], ["lotions", "TREATMENT", 611, 618], ["ointments", "TREATMENT", 620, 629], ["eye shadows", "PROBLEM", 667, 678], ["lipsticks", "TREATMENT", 680, 689], ["eye", "ANATOMY", 667, 670], ["hair", "ANATOMY", 691, 695], ["nail", "ANATOMY", 705, 709]]], ["PPDA oxidizes rapidly in contact with atmospheric oxygen, but this reduces its allergenicity only slightly.Etiological AgentsEthylendiamine: stabilizer found in cosmetics and topical drugs (antihistamine ointments, eye drops, nose drops, lotions for itching eczema), in fungicides, insecticides, and preservatives in creams, as a catalyzer for resin synthesis, as well as in anticorrosive and antifreeze agents, solvents, etc. It can cross-react with aminophylline, hydroxyzine, prometazine, etc.Etiological AgentsFormaldehyde is a chemical widely used as a disinfectant, while formalin, a 27% aqueous solution, is used to treat allergens to produce allergoids.", [["eye", "ANATOMY", 215, 218], ["nose", "ANATOMY", 226, 230], ["PPDA", "CHEMICAL", 0, 4], ["oxygen", "CHEMICAL", 50, 56], ["Ethylendiamine", "CHEMICAL", 125, 139], ["antihistamine ointments", "CHEMICAL", 190, 213], ["itching eczema", "DISEASE", 250, 264], ["aminophylline", "CHEMICAL", 451, 464], ["hydroxyzine", "CHEMICAL", 466, 477], ["prometazine", "CHEMICAL", 479, 490], ["Formaldehyde", "CHEMICAL", 514, 526], ["formalin", "CHEMICAL", 578, 586], ["allergoids", "DISEASE", 650, 660], ["PPDA", "CHEMICAL", 0, 4], ["oxygen", "CHEMICAL", 50, 56], ["Ethylendiamine", "CHEMICAL", 125, 139], ["aminophylline", "CHEMICAL", 451, 464], ["hydroxyzine", "CHEMICAL", 466, 477], ["prometazine", "CHEMICAL", 479, 490], ["Formaldehyde", "CHEMICAL", 514, 526], ["formalin", "CHEMICAL", 578, 586], ["PPDA", "SIMPLE_CHEMICAL", 0, 4], ["oxygen", "SIMPLE_CHEMICAL", 50, 56], ["Ethylendiamine", "SIMPLE_CHEMICAL", 125, 139], ["eye", "ORGANISM_SUBDIVISION", 215, 218], ["nose", "ORGANISM_SUBDIVISION", 226, 230], ["resin", "SIMPLE_CHEMICAL", 344, 349], ["aminophylline", "SIMPLE_CHEMICAL", 451, 464], ["hydroxyzine", "SIMPLE_CHEMICAL", 466, 477], ["prometazine", "SIMPLE_CHEMICAL", 479, 490], ["Formaldehyde", "SIMPLE_CHEMICAL", 514, 526], ["formalin", "SIMPLE_CHEMICAL", 578, 586], ["atmospheric oxygen", "TREATMENT", 38, 56], ["stabilizer", "TREATMENT", 141, 151], ["cosmetics", "TREATMENT", 161, 170], ["topical drugs", "TREATMENT", 175, 188], ["antihistamine ointments", "TREATMENT", 190, 213], ["eye drops", "TREATMENT", 215, 224], ["nose drops", "TREATMENT", 226, 236], ["lotions", "TREATMENT", 238, 245], ["itching eczema", "PROBLEM", 250, 264], ["insecticides", "TREATMENT", 282, 294], ["preservatives", "TREATMENT", 300, 313], ["creams", "TREATMENT", 317, 323], ["resin synthesis", "TREATMENT", 344, 359], ["anticorrosive", "TREATMENT", 375, 388], ["antifreeze agents", "TREATMENT", 393, 410], ["solvents", "TREATMENT", 412, 420], ["aminophylline", "TREATMENT", 451, 464], ["hydroxyzine", "TREATMENT", 466, 477], ["prometazine", "TREATMENT", 479, 490], ["a 27% aqueous solution", "TREATMENT", 588, 610], ["allergens", "PROBLEM", 629, 638]]], ["Formaldehyde antigenicity was recognized as early as 1914 [116] .", [["Formaldehyde", "CHEMICAL", 0, 12], ["Formaldehyde", "CHEMICAL", 0, 12], ["Formaldehyde", "SIMPLE_CHEMICAL", 0, 12]]], ["It is found in: \u2211 Bactericides, denatured alcohol, fabric softeners, fungicides, oral disinfectants, preservatives, and in antitetanic vaccines. \u2211 Cosmetics in general, deodorizers, nail hardeners, permanent fluids, soaps, shampoos, toothpastes, etc. \u2211 Plastic packing (demopac) for foods prepared in advance, from which residual amounts are naturally released. \u2211 Enamels, glues, pastels, tanning agents, tempera painting, in dry-cleaning as a spot remover, in typography, etc. \u2211 Adhesive strips to apply wall-to-wall carpeting, textile finishes. \u2211 Insulating materials, plywood paneling and wrinkleresistant clothes.Etiological AgentsWe underline its hidden presence in carpets, cigarettes, insulators, paper tissues and serviettes, towels, and other paper products also for toilet or medical supplies, preservatives employed in the pharmaceutical and other industries, disinfectants also for housework, and as a monomer in butylphenol-formaldehyde resins used in adhesives, corsets, glues, leather goods, products to protect color fading in clothing articles and in underwear elastics or as sizing, crease-resistant and/or waterproof finishes.", [["oral", "ANATOMY", 81, 85], ["nail", "ANATOMY", 182, 186], ["Enamels", "ANATOMY", 364, 371], ["wall", "ANATOMY", 505, 509], ["wall", "ANATOMY", 513, 517], ["tissues", "ANATOMY", 710, 717], ["alcohol", "CHEMICAL", 42, 49], ["demopac", "CHEMICAL", 270, 277], ["Enamels", "DISEASE", 364, 371], ["butylphenol-formaldehyde resins", "CHEMICAL", 925, 956], ["alcohol", "CHEMICAL", 42, 49], ["butylphenol", "CHEMICAL", 925, 936], ["formaldehyde", "CHEMICAL", 937, 949], ["Bactericides", "SIMPLE_CHEMICAL", 18, 30], ["alcohol", "SIMPLE_CHEMICAL", 42, 49], ["fungicides", "SIMPLE_CHEMICAL", 69, 79], ["oral", "ORGANISM_SUBDIVISION", 81, 85], ["tissues", "TISSUE", 710, 717], ["butylphenol-formaldehyde resins", "SIMPLE_CHEMICAL", 925, 956], ["fabric softeners", "TREATMENT", 51, 67], ["fungicides", "TREATMENT", 69, 79], ["oral disinfectants", "TREATMENT", 81, 99], ["preservatives", "TREATMENT", 101, 114], ["antitetanic vaccines", "TREATMENT", 123, 143], ["deodorizers", "TREATMENT", 169, 180], ["nail hardeners", "TREATMENT", 182, 196], ["permanent fluids", "TREATMENT", 198, 214], ["soaps", "TREATMENT", 216, 221], ["shampoos", "TREATMENT", 223, 231], ["toothpastes", "TREATMENT", 233, 244], ["Plastic packing (demopac)", "TREATMENT", 253, 278], ["Adhesive strips", "TREATMENT", 480, 495], ["wall-to-wall carpeting", "TREATMENT", 505, 527], ["Insulating materials", "TREATMENT", 549, 569], ["wrinkleresistant clothes", "TREATMENT", 592, 616], ["a monomer in butylphenol-formaldehyde resins", "TREATMENT", 912, 956], ["adhesives", "TREATMENT", 965, 974], ["nail", "ANATOMY", 182, 186], ["packing", "OBSERVATION_MODIFIER", 261, 268]]], ["However, that contained in shampoos heads, paper money and wall-paper, shaving-creams and razor-blades. \u2211 Bleaches, cleansing creams, detergents in general, floor waxes and other products, porcelain, pots, shoe polish. \u2211 Leather objects, shoes. \u2211 Fixatives, inks, photographic chemicals. \u2211 Rubber objects and artificial flowers. \u2211 Foods in traces (apples, beer, bread, canned cereals, chocolate, eggs, frozen peas, mushrooms, onions, potatoes, plums, raisins, watercress, wholemeal).Etiological AgentsCobalt chloride (CoCl) is found in almost all bichromate materials, moreover: \u2211 In galvanized manufactured products. \u2211 As catalyzing in rubber synthesis, acrylic resins and polyesters. \u2211 As Ni impurities. \u2211 As an alloy in joint prostheses. \u2211 In adhesives, artists' paints, buttons, ceramic and plastic paints, coins, colored pencils, costume jewelry, eye shadows, inorganic pigments in inks, hair dyes, linseed oil-based paints, tattoo pigments, watch straps, wet cement, zippers. \u2211 In Ni-containing accouterments on clothing. \u2211 In anti-perspiration creams, flypaper. \u2211 In vitamin B 12 preparations and in mineral tablets. \u2211 In foods, namely apricots, beans, beer, beets, bread, cocoa, cabbages, chocolate, cloves, liver, nut, tea, wine [125] .Etiological AgentsChrome (Cr) in small amounts is present in cigarettes and in objects of common use: \u2211 Alloys for tooth prostheses, bleaches, cement, ceramic paints, detergents, flypaper, fireworks, floor wax, green felts, matches, military green fabric, pots, razor blades, safety matches, shaving creams, shoe polish, wood ashes and stain, wallpapers. \u2211 As a water and flour pollutant: small amounts are found in mineral waters. \u2211 In foods: apples, beer, cocoa, canned cereals, chocolate, eggs, fish, frozen peas, meat, mushrooms, onions, potatoes, plums, raisins, spices, tea, watercress, wholemeal, wine [125] .Etiological AgentsIn industry: \u2211 As fore-gilding of raw textiles and chrome-tanned leathers (also with Cu and tannins). \u2211 In typo-lithography: auto-implants, fixatives, inks, photographic chemicals, special papers. \u2211 In mechanics: anticorrosive oils and greases, antirust dyes, cooling mixtures for motors, metallic alloys, welding materials. \u2211 In galvanizing processes: aluminium coloring, chromium plating, electroplating, polishing. \u2211 In colors, enamels, dyeing, oil paints and distempers.Etiological AgentsCopper (Cu) is a minor sensitizer found in bronze, brass, and other alloy objects, also of common use: \u2211 Pots for polenta, coins, costume jewelry, electric materials, green eye shadow, intrauterine contraceptives. and liquid soaps is a rare cause of ACD since it is rapidly diluted and rinsed.Etiological AgentsMercury (Hg) includes different compounds, all cross-reacting between themselves, employed in medicine and cosmetics: \u2211 Mercurochrome, phenylmercuricborate, etc., are used as disinfectants for small wounds and in lipsticks. \u2211 Thimerosal is a topical antiseptic employed as an ingredient of germicides, cosmetics, eye shadows, preparations for dentists, eyewashes and nasal drops, contact lens cleaning and wetting solutions (Chap.", [["flowers", "ANATOMY", 320, 327], ["eggs", "ANATOMY", 396, 400], ["peas", "ANATOMY", 409, 413], ["mushrooms", "ANATOMY", 415, 424], ["onions", "ANATOMY", 426, 432], ["potatoes", "ANATOMY", 434, 442], ["plums", "ANATOMY", 444, 449], ["joint", "ANATOMY", 723, 728], ["eye", "ANATOMY", 852, 855], ["hair", "ANATOMY", 893, 897], ["beans", "ANATOMY", 1153, 1158], ["beets", "ANATOMY", 1166, 1171], ["bread", "ANATOMY", 1173, 1178], ["cocoa", "ANATOMY", 1180, 1185], ["cabbages", "ANATOMY", 1187, 1195], ["cloves", "ANATOMY", 1208, 1214], ["liver", "ANATOMY", 1216, 1221], ["tea", "ANATOMY", 1228, 1231], ["tooth", "ANATOMY", 1360, 1365], ["eggs", "ANATOMY", 1737, 1741], ["peas", "ANATOMY", 1756, 1760], ["meat", "ANATOMY", 1762, 1766], ["mushrooms", "ANATOMY", 1768, 1777], ["onions", "ANATOMY", 1779, 1785], ["potatoes", "ANATOMY", 1787, 1795], ["plums", "ANATOMY", 1797, 1802], ["tea", "ANATOMY", 1821, 1824], ["watercress", "ANATOMY", 1826, 1836], ["wholemeal", "ANATOMY", 1838, 1847], ["enamels", "ANATOMY", 2310, 2317], ["oil", "ANATOMY", 2327, 2330], ["eye", "ANATOMY", 2544, 2547], ["intrauterine", "ANATOMY", 2556, 2568], ["wounds", "ANATOMY", 2881, 2887], ["eye", "ANATOMY", 2995, 2998], ["nasal", "ANATOMY", 3049, 3054], ["lens", "ANATOMY", 3070, 3074], ["apples, beer, bread, canned cereals, chocolate, eggs, frozen peas, mushrooms, onions, potatoes, plums, raisins, watercress", "CHEMICAL", 348, 470], ["AgentsCobalt chloride", "CHEMICAL", 495, 516], ["CoCl", "CHEMICAL", 518, 522], ["acrylic resins", "CHEMICAL", 655, 669], ["Ni", "CHEMICAL", 691, 693], ["vitamin B", "CHEMICAL", 1074, 1083], ["apricots, beans, beer, beets, bread, cocoa, cabbages, chocolate, cloves, liver, nut, tea, wine", "CHEMICAL", 1143, 1237], ["Chrome", "CHEMICAL", 1263, 1269], ["Cr", "CHEMICAL", 1271, 1273], ["flypaper", "CHEMICAL", 1424, 1432], ["apples, beer, cocoa, canned cereals, chocolate, eggs, fish, frozen peas, meat, mushrooms, onions, potatoes, plums, raisins, spices, tea", "CHEMICAL", 1689, 1824], ["chrome", "CHEMICAL", 1930, 1936], ["Cu", "CHEMICAL", 1964, 1966], ["aluminium coloring", "CHEMICAL", 2232, 2250], ["chromium", "CHEMICAL", 2252, 2260], ["distempers", "DISEASE", 2342, 2352], ["AgentsCopper", "CHEMICAL", 2365, 2377], ["Cu", "CHEMICAL", 2379, 2381], ["intrauterine contraceptives", "CHEMICAL", 2556, 2583], ["ACD", "DISEASE", 2621, 2624], ["Hg", "CHEMICAL", 2691, 2693], ["Mercurochrome", "CHEMICAL", 2802, 2815], ["phenylmercuricborate", "CHEMICAL", 2817, 2837], ["Thimerosal", "CHEMICAL", 2908, 2918], ["AgentsCobalt chloride", "CHEMICAL", 495, 516], ["CoCl", "CHEMICAL", 518, 522], ["Ni", "CHEMICAL", 691, 693], ["vitamin B 12", "CHEMICAL", 1074, 1086], ["Cr", "CHEMICAL", 1271, 1273], ["chrome", "CHEMICAL", 1930, 1936], ["Cu", "CHEMICAL", 1964, 1966], ["tannins", "CHEMICAL", 1971, 1978], ["aluminium", "CHEMICAL", 2232, 2241], ["chromium", "CHEMICAL", 2252, 2260], ["AgentsCopper", "CHEMICAL", 2365, 2377], ["Cu", "CHEMICAL", 2379, 2381], ["AgentsMercury", "CHEMICAL", 2676, 2689], ["Hg", "CHEMICAL", 2691, 2693], ["phenylmercuricborate", "CHEMICAL", 2817, 2837], ["Thimerosal", "CHEMICAL", 2908, 2918], ["flowers", "ORGANISM_SUBDIVISION", 320, 327], ["apples", "ORGANISM_SUBDIVISION", 348, 354], ["bread", "ORGANISM_SUBDIVISION", 362, 367], ["cereals", "ORGANISM_SUBDIVISION", 376, 383], ["chocolate", "ORGANISM_SUBDIVISION", 385, 394], ["eggs", "ORGANISM_SUBDIVISION", 396, 400], ["peas", "ORGANISM_SUBDIVISION", 409, 413], ["mushrooms", "ORGANISM_SUBDIVISION", 415, 424], ["onions", "ORGANISM_SUBDIVISION", 426, 432], ["potatoes", "ORGANISM_SUBDIVISION", 434, 442], ["raisins", "ORGANISM_SUBDIVISION", 451, 458], ["AgentsCobalt chloride", "SIMPLE_CHEMICAL", 495, 516], ["CoCl", "SIMPLE_CHEMICAL", 518, 522], ["acrylic resins", "SIMPLE_CHEMICAL", 655, 669], ["Ni impurities", "SIMPLE_CHEMICAL", 691, 704], ["joint", "TISSUE", 723, 728], ["eye", "ORGAN", 852, 855], ["vitamin B 12", "SIMPLE_CHEMICAL", 1074, 1086], ["mineral tablets", "SIMPLE_CHEMICAL", 1107, 1122], ["beans", "ORGANISM_SUBDIVISION", 1153, 1158], ["beets", "ORGANISM_SUBDIVISION", 1166, 1171], ["bread", "ORGANISM_SUBDIVISION", 1173, 1178], ["cocoa", "ORGANISM_SUBDIVISION", 1180, 1185], ["chocolate", "ORGANISM_SUBDIVISION", 1197, 1206], ["liver", "ORGAN", 1216, 1221], ["nut", "ORGANISM_SUBDIVISION", 1223, 1226], ["tea", "ORGANISM_SUBDIVISION", 1228, 1231], ["Cr", "SIMPLE_CHEMICAL", 1271, 1273], ["tooth", "ORGAN", 1360, 1365], ["apples", "ORGANISM_SUBDIVISION", 1689, 1695], ["beer", "ORGANISM_SUBDIVISION", 1697, 1701], ["cocoa", "ORGANISM_SUBDIVISION", 1703, 1708], ["chocolate", "ORGANISM_SUBDIVISION", 1726, 1735], ["fish", "ORGANISM_SUBDIVISION", 1743, 1747], ["peas", "ORGANISM_SUBDIVISION", 1756, 1760], ["meat", "ORGANISM_SUBDIVISION", 1762, 1766], ["mushrooms", "ORGANISM_SUBDIVISION", 1768, 1777], ["onions", "ORGANISM_SUBDIVISION", 1779, 1785], ["potatoes", "ORGANISM_SUBDIVISION", 1787, 1795], ["raisins", "ORGANISM_SUBDIVISION", 1804, 1811], ["spices", "ORGANISM_SUBDIVISION", 1813, 1819], ["tea", "ORGANISM_SUBDIVISION", 1821, 1824], ["Cu", "SIMPLE_CHEMICAL", 1964, 1966], ["tannins", "SIMPLE_CHEMICAL", 1971, 1978], ["greases", "SIMPLE_CHEMICAL", 2115, 2122], ["antirust dyes", "SIMPLE_CHEMICAL", 2124, 2137], ["aluminium", "SIMPLE_CHEMICAL", 2232, 2241], ["chromium", "SIMPLE_CHEMICAL", 2252, 2260], ["oil", "ORGANISM_SUBSTANCE", 2327, 2330], ["AgentsCopper", "SIMPLE_CHEMICAL", 2365, 2377], ["bronze", "SIMPLE_CHEMICAL", 2414, 2420], ["eye", "ORGAN", 2544, 2547], ["AgentsMercury", "SIMPLE_CHEMICAL", 2676, 2689], ["Mercurochrome", "SIMPLE_CHEMICAL", 2802, 2815], ["phenylmercuricborate", "SIMPLE_CHEMICAL", 2817, 2837], ["wounds", "PATHOLOGICAL_FORMATION", 2881, 2887], ["Thimerosal", "SIMPLE_CHEMICAL", 2908, 2918], ["germicides", "SIMPLE_CHEMICAL", 2972, 2982], ["eye", "ORGAN", 2995, 2998], ["peas", "SPECIES", 409, 413], ["onions", "SPECIES", 426, 432], ["potatoes", "SPECIES", 434, 442], ["beans", "SPECIES", 1153, 1158], ["beets", "SPECIES", 1166, 1171], ["bread", "SPECIES", 1173, 1178], ["peas", "SPECIES", 1756, 1760], ["meat", "SPECIES", 1762, 1766], ["onions", "SPECIES", 1779, 1785], ["potatoes", "SPECIES", 1787, 1795], ["peas", "SPECIES", 409, 413], ["beets", "SPECIES", 1166, 1171], ["cocoa", "SPECIES", 1180, 1185], ["cocoa", "SPECIES", 1703, 1708], ["peas", "SPECIES", 1756, 1760], ["onions", "SPECIES", 1779, 1785], ["potatoes", "SPECIES", 1787, 1795], ["shaving-creams", "TREATMENT", 71, 85], ["razor-blades", "TREATMENT", 90, 102], ["Bleaches", "TREATMENT", 106, 114], ["cleansing creams", "TREATMENT", 116, 132], ["detergents", "TREATMENT", 134, 144], ["Fixatives", "TREATMENT", 247, 256], ["chocolate", "TREATMENT", 385, 394], ["Etiological AgentsCobalt chloride (CoCl)", "TREATMENT", 483, 523], ["galvanized manufactured products", "TREATMENT", 584, 616], ["rubber synthesis", "TREATMENT", 637, 653], ["acrylic resins", "TREATMENT", 655, 669], ["polyesters", "TREATMENT", 674, 684], ["an alloy in joint prostheses", "TREATMENT", 711, 739], ["ceramic and plastic paints", "TREATMENT", 783, 809], ["eye shadows", "PROBLEM", 852, 863], ["inorganic pigments", "TREATMENT", 865, 883], ["tattoo pigments", "TREATMENT", 930, 945], ["watch straps", "TREATMENT", 947, 959], ["wet cement", "TREATMENT", 961, 971], ["zippers", "TREATMENT", 973, 980], ["anti-perspiration creams", "TREATMENT", 1033, 1057], ["vitamin B 12 preparations", "TREATMENT", 1074, 1099], ["mineral tablets", "TREATMENT", 1107, 1122], ["Etiological AgentsChrome", "TREATMENT", 1245, 1269], ["Alloys", "TREATMENT", 1349, 1355], ["tooth prostheses", "TREATMENT", 1360, 1376], ["bleaches", "PROBLEM", 1378, 1386], ["cement, ceramic paints", "TREATMENT", 1388, 1410], ["razor blades", "TREATMENT", 1507, 1519], ["safety matches", "TREATMENT", 1521, 1535], ["shaving creams", "TREATMENT", 1537, 1551], ["small amounts", "PROBLEM", 1634, 1647], ["auto-implants", "TREATMENT", 2004, 2017], ["fixatives", "TREATMENT", 2019, 2028], ["anticorrosive oils", "TREATMENT", 2092, 2110], ["greases", "TREATMENT", 2115, 2122], ["antirust dyes", "TREATMENT", 2124, 2137], ["cooling mixtures", "TREATMENT", 2139, 2155], ["motors, metallic alloys, welding materials", "TREATMENT", 2160, 2202], ["aluminium coloring", "TREATMENT", 2232, 2250], ["chromium plating", "TREATMENT", 2252, 2268], ["electroplating", "TREATMENT", 2270, 2284], ["polishing", "TREATMENT", 2286, 2295], ["distempers", "PROBLEM", 2342, 2352], ["a minor sensitizer", "PROBLEM", 2386, 2404], ["electric materials", "TREATMENT", 2518, 2536], ["green eye shadow", "PROBLEM", 2538, 2554], ["intrauterine contraceptives", "TREATMENT", 2556, 2583], ["ACD", "PROBLEM", 2621, 2624], ["different compounds", "PROBLEM", 2704, 2723], ["Mercurochrome", "TREATMENT", 2802, 2815], ["phenylmercuricborate", "TREATMENT", 2817, 2837], ["small wounds", "PROBLEM", 2875, 2887], ["Thimerosal", "TREATMENT", 2908, 2918], ["a topical antiseptic", "TREATMENT", 2922, 2942], ["an ingredient of germicides", "TREATMENT", 2955, 2982], ["dentists", "TREATMENT", 3025, 3033], ["eyewashes", "TREATMENT", 3035, 3044], ["nasal drops", "TREATMENT", 3049, 3060], ["contact lens cleaning", "TREATMENT", 3062, 3083], ["wall", "ANATOMY", 59, 63], ["artificial flowers", "OBSERVATION", 309, 327], ["manufactured products", "OBSERVATION", 595, 616], ["rubber synthesis", "OBSERVATION", 637, 653], ["acrylic resins", "OBSERVATION", 655, 669], ["impurities", "OBSERVATION", 694, 704], ["joint", "ANATOMY", 723, 728], ["prostheses", "OBSERVATION", 729, 739], ["plastic paints", "OBSERVATION", 795, 809], ["eye", "ANATOMY", 852, 855], ["inorganic pigments", "OBSERVATION", 865, 883], ["cement", "OBSERVATION", 965, 971], ["liver", "ANATOMY", 1216, 1221], ["tooth", "ANATOMY", 1360, 1365], ["prostheses", "OBSERVATION", 1366, 1376], ["ceramic paints", "OBSERVATION", 1396, 1410], ["small amounts", "OBSERVATION_MODIFIER", 1634, 1647], ["mushrooms", "ANATOMY", 1768, 1777], ["alloy objects", "OBSERVATION", 2439, 2452], ["eye", "ANATOMY", 2544, 2547], ["liquid soaps", "OBSERVATION", 2589, 2601], ["ACD", "OBSERVATION", 2621, 2624], ["small", "OBSERVATION_MODIFIER", 2875, 2880], ["wounds", "OBSERVATION", 2881, 2887], ["eye", "ANATOMY", 2995, 2998], ["nasal", "ANATOMY", 3049, 3054]]], ["14), etc., as preservatives in pharmaceutical preparations, including vaccines and sera, and as a rubber accelerator. \u2211 Yellow oxide (HgO) is a topical antimicrobial employed for eye applications and as caustic, cicatrizant, etc. \u2211 Bichloride (HgCl 2 ) is employed in amalgam fillings, contraceptives, electric materials, lubricants, thermometers, etc. \u2211 It is also found in aniline colors, textiles, etc., for leather, felts, furs, wood preservation, in photography and printing.Etiological AgentsTopical medicaments \u2211 Benzocaine, a local anesthetic, can be found more or less commonly in medicaments reducing pain, itching, or stinging, cuts, burns, insect bites, rashes, sunburns, toothaches, and in hemorrhoidal preparations, cough syrups, throat lozenges (cross-reacts with PABA). \u2211 Neomycin is present in over-the-counter antibiotic creams, eyewashes, lotions, many skin, ear and nose products, medication powders, ointments and some types of measles vaccines (Chap.", [["sera", "ANATOMY", 83, 87], ["eye", "ANATOMY", 179, 182], ["wood", "ANATOMY", 433, 437], ["hemorrhoidal", "ANATOMY", 703, 715], ["throat", "ANATOMY", 744, 750], ["skin", "ANATOMY", 872, 876], ["ear", "ANATOMY", 878, 881], ["nose", "ANATOMY", 886, 890], ["Yellow oxide", "CHEMICAL", 120, 132], ["HgO", "CHEMICAL", 134, 137], ["\u2211 Bichloride", "CHEMICAL", 230, 242], ["HgCl 2", "CHEMICAL", 244, 250], ["Benzocaine", "CHEMICAL", 520, 530], ["pain", "DISEASE", 611, 615], ["itching", "DISEASE", 617, 624], ["burns", "DISEASE", 645, 650], ["insect bites", "DISEASE", 652, 664], ["rashes", "DISEASE", 666, 672], ["sunburns", "DISEASE", 674, 682], ["toothaches", "DISEASE", 684, 694], ["cough syrups", "DISEASE", 730, 742], ["PABA", "CHEMICAL", 779, 783], ["Neomycin", "CHEMICAL", 788, 796], ["Yellow oxide", "CHEMICAL", 120, 132], ["HgO", "CHEMICAL", 134, 137], ["\u2211 Bichloride", "CHEMICAL", 230, 242], ["HgCl 2", "CHEMICAL", 244, 250], ["aniline", "CHEMICAL", 375, 382], ["Benzocaine", "CHEMICAL", 520, 530], ["PABA", "CHEMICAL", 779, 783], ["Neomycin", "CHEMICAL", 788, 796], ["sera", "ORGANISM_SUBSTANCE", 83, 87], ["Yellow oxide", "SIMPLE_CHEMICAL", 120, 132], ["HgO", "SIMPLE_CHEMICAL", 134, 137], ["eye", "ORGAN", 179, 182], ["\u2211 Bichloride", "SIMPLE_CHEMICAL", 230, 242], ["HgCl 2", "SIMPLE_CHEMICAL", 244, 250], ["aniline", "SIMPLE_CHEMICAL", 375, 382], ["Benzocaine", "SIMPLE_CHEMICAL", 520, 530], ["throat", "ORGANISM_SUBDIVISION", 744, 750], ["PABA", "SIMPLE_CHEMICAL", 779, 783], ["Neomycin", "SIMPLE_CHEMICAL", 788, 796], ["skin", "ORGAN", 872, 876], ["ear", "ORGAN", 878, 881], ["pharmaceutical preparations", "TREATMENT", 31, 58], ["vaccines", "TREATMENT", 70, 78], ["sera", "TREATMENT", 83, 87], ["a rubber accelerator", "TREATMENT", 96, 116], ["a topical antimicrobial", "TREATMENT", 142, 165], ["eye applications", "TREATMENT", 179, 195], ["cicatrizant", "TREATMENT", 212, 223], ["contraceptives", "TREATMENT", 286, 300], ["electric materials", "TREATMENT", 302, 320], ["lubricants", "TREATMENT", 322, 332], ["Etiological AgentsTopical medicaments", "TREATMENT", 480, 517], ["Benzocaine", "TREATMENT", 520, 530], ["a local anesthetic", "TREATMENT", 532, 550], ["reducing pain", "PROBLEM", 602, 615], ["itching", "PROBLEM", 617, 624], ["stinging", "PROBLEM", 629, 637], ["burns", "PROBLEM", 645, 650], ["insect bites", "PROBLEM", 652, 664], ["rashes", "PROBLEM", 666, 672], ["sunburns", "PROBLEM", 674, 682], ["toothaches", "TREATMENT", 684, 694], ["hemorrhoidal preparations", "TREATMENT", 703, 728], ["cough syrups", "PROBLEM", 730, 742], ["throat lozenges", "PROBLEM", 744, 759], ["Neomycin", "TREATMENT", 788, 796], ["antibiotic creams", "TREATMENT", 828, 845], ["eyewashes", "TREATMENT", 847, 856], ["lotions", "TREATMENT", 858, 865], ["many skin, ear and nose products", "TREATMENT", 867, 899], ["medication powders", "TREATMENT", 901, 919], ["ointments", "TREATMENT", 921, 930], ["measles vaccines", "TREATMENT", 949, 965], ["aniline colors", "OBSERVATION", 375, 389], ["wood preservation", "OBSERVATION", 433, 450], ["hemorrhoidal", "ANATOMY", 703, 715], ["throat", "ANATOMY", 744, 750], ["skin", "ANATOMY", 872, 876], ["ear", "ANATOMY", 878, 881], ["nose", "ANATOMY", 886, 890]]], ["It is also a component of deodorants and toilet soaps.", [["deodorants and toilet soaps", "TREATMENT", 26, 53], ["component", "OBSERVATION_MODIFIER", 13, 22]]], ["Other aminoglycoside antibiotics such as gentamicin, kanamycin and streptomycin may cross-react.Etiological AgentsBenzalkonium chloride is a quaternary ammonium cationic detergent with manifold applications as a preoperative skin disinfectant, for disinfection of surgical instruments, and antimicrobial preservative in nasal sprays, ophthalmic medications, solutions for contact lenses (Chaps.", [["skin", "ANATOMY", 225, 229], ["nasal", "ANATOMY", 320, 325], ["aminoglycoside", "CHEMICAL", 6, 20], ["gentamicin", "CHEMICAL", 41, 51], ["kanamycin", "CHEMICAL", 53, 62], ["streptomycin", "CHEMICAL", 67, 79], ["Benzalkonium chloride", "CHEMICAL", 114, 135], ["quaternary ammonium", "CHEMICAL", 141, 160], ["aminoglycoside", "CHEMICAL", 6, 20], ["gentamicin", "CHEMICAL", 41, 51], ["kanamycin", "CHEMICAL", 53, 62], ["streptomycin", "CHEMICAL", 67, 79], ["Benzalkonium chloride", "CHEMICAL", 114, 135], ["quaternary ammonium", "CHEMICAL", 141, 160], ["aminoglycoside", "SIMPLE_CHEMICAL", 6, 20], ["gentamicin", "SIMPLE_CHEMICAL", 41, 51], ["kanamycin", "SIMPLE_CHEMICAL", 53, 62], ["streptomycin", "SIMPLE_CHEMICAL", 67, 79], ["Benzalkonium chloride", "SIMPLE_CHEMICAL", 114, 135], ["ammonium", "SIMPLE_CHEMICAL", 152, 160], ["skin", "ORGAN", 225, 229], ["Other aminoglycoside antibiotics", "TREATMENT", 0, 32], ["gentamicin", "TREATMENT", 41, 51], ["kanamycin", "TREATMENT", 53, 62], ["streptomycin", "TREATMENT", 67, 79], ["Etiological AgentsBenzalkonium chloride", "TREATMENT", 96, 135], ["a quaternary ammonium cationic detergent", "TREATMENT", 139, 179], ["manifold applications", "TREATMENT", 185, 206], ["a preoperative skin disinfectant", "TREATMENT", 210, 242], ["disinfection", "TREATMENT", 248, 260], ["surgical instruments", "TREATMENT", 264, 284], ["antimicrobial preservative", "TREATMENT", 290, 316], ["nasal sprays", "TREATMENT", 320, 332], ["ophthalmic medications", "TREATMENT", 334, 356], ["skin", "ANATOMY", 225, 229], ["surgical instruments", "OBSERVATION", 264, 284]]], ["However, it frequently induces irritant reactions and may cross-react with curariform preparations employed in general anesthesia (Chap.", [["irritant reactions", "PROBLEM", 31, 49], ["curariform preparations", "TREATMENT", 75, 98], ["general anesthesia", "TREATMENT", 111, 129]]], ["20).Etiological AgentsDisinfectants include (in addition to thimerosal and benzalkonium chloride): \u2211 Betadine, a skin disinfectant used for burn or wound dressings, etc. \u2211 Chlorhexidine hydrochloride, a topical disinfectant found in skin cleaners, gingival washes, cosmetics, deodorants, etc. \u2211 Dequalinium chloride, employed as benzalkonium chloride, is present in throat lozenges. \u2211 Menthol, alcohol extracted from peppermint, is perfuming and revulsive, used also as antipruritic in cosmetics and pharmaceutics or in inhaled medication for respiratory diseases.Etiological Agents\u2211 Gentian violet, coloring employed also as an antimycotic mostly in topical applications; however, it is sensitizing, and cross-reacts with bright green.Etiological AgentsFragrance mix is a frequent ingredient of after-shave lotions, beauty creams, cosmetics, soaps, sanitary napkins, shampoos, toiletries, toothpastes, and in household products such as deodorant sprays, detergents, polishes, and solvents.", [["skin", "ANATOMY", 113, 117], ["wound", "ANATOMY", 148, 153], ["skin", "ANATOMY", 233, 237], ["gingival", "ANATOMY", 248, 256], ["throat", "ANATOMY", 366, 372], ["respiratory", "ANATOMY", 543, 554], ["thimerosal", "CHEMICAL", 60, 70], ["benzalkonium chloride", "CHEMICAL", 75, 96], ["Betadine", "CHEMICAL", 101, 109], ["burn", "DISEASE", 140, 144], ["Chlorhexidine hydrochloride", "CHEMICAL", 172, 199], ["Dequalinium chloride", "CHEMICAL", 295, 315], ["benzalkonium chloride", "CHEMICAL", 329, 350], ["Menthol", "CHEMICAL", 385, 392], ["alcohol", "CHEMICAL", 394, 401], ["respiratory diseases", "DISEASE", 543, 563], ["Gentian violet", "CHEMICAL", 584, 598], ["thimerosal", "CHEMICAL", 60, 70], ["benzalkonium chloride", "CHEMICAL", 75, 96], ["Betadine", "CHEMICAL", 101, 109], ["Chlorhexidine hydrochloride", "CHEMICAL", 172, 199], ["Dequalinium chloride", "CHEMICAL", 295, 315], ["benzalkonium chloride", "CHEMICAL", 329, 350], ["Menthol", "CHEMICAL", 385, 392], ["alcohol", "CHEMICAL", 394, 401], ["Gentian violet", "CHEMICAL", 584, 598], ["thimerosal", "SIMPLE_CHEMICAL", 60, 70], ["benzalkonium chloride", "SIMPLE_CHEMICAL", 75, 96], ["Betadine", "SIMPLE_CHEMICAL", 101, 109], ["skin", "ORGAN", 113, 117], ["wound", "PATHOLOGICAL_FORMATION", 148, 153], ["Chlorhexidine", "SIMPLE_CHEMICAL", 172, 185], ["skin", "ORGAN", 233, 237], ["\u2211 Dequalinium chloride", "SIMPLE_CHEMICAL", 293, 315], ["benzalkonium chloride", "SIMPLE_CHEMICAL", 329, 350], ["throat", "ORGANISM_SUBDIVISION", 366, 372], ["Menthol", "SIMPLE_CHEMICAL", 385, 392], ["alcohol", "SIMPLE_CHEMICAL", 394, 401], ["thimerosal and benzalkonium chloride", "TREATMENT", 60, 96], ["Betadine", "TREATMENT", 101, 109], ["a skin disinfectant", "TREATMENT", 111, 130], ["burn", "PROBLEM", 140, 144], ["wound dressings", "TREATMENT", 148, 163], ["Chlorhexidine hydrochloride", "TREATMENT", 172, 199], ["a topical disinfectant", "TREATMENT", 201, 223], ["skin cleaners", "TREATMENT", 233, 246], ["gingival washes", "TREATMENT", 248, 263], ["cosmetics", "TREATMENT", 265, 274], ["deodorants", "TREATMENT", 276, 286], ["etc", "TREATMENT", 288, 291], ["Dequalinium chloride", "TREATMENT", 295, 315], ["benzalkonium chloride", "TREATMENT", 329, 350], ["pharmaceutics", "TREATMENT", 500, 513], ["inhaled medication", "TREATMENT", 520, 538], ["respiratory diseases", "PROBLEM", 543, 563], ["Etiological Agents", "TREATMENT", 564, 582], ["Gentian violet", "TREATMENT", 584, 598], ["an antimycotic", "TREATMENT", 626, 640], ["topical applications", "TREATMENT", 651, 671], ["bright green", "PROBLEM", 723, 735], ["lotions", "TREATMENT", 808, 815], ["beauty creams", "TREATMENT", 817, 830], ["cosmetics", "TREATMENT", 832, 841], ["soaps", "TREATMENT", 843, 848], ["sanitary napkins", "TREATMENT", 850, 866], ["shampoos", "TREATMENT", 868, 876], ["toothpastes", "TREATMENT", 890, 901], ["deodorant sprays", "TREATMENT", 937, 953], ["detergents", "TREATMENT", 955, 965], ["polishes", "TREATMENT", 967, 975], ["solvents", "TREATMENT", 981, 989], ["skin", "ANATOMY", 113, 117], ["disinfectant", "OBSERVATION", 118, 130], ["wound", "ANATOMY", 148, 153], ["dressings", "OBSERVATION", 154, 163], ["skin", "ANATOMY", 233, 237], ["cleaners", "OBSERVATION", 238, 246], ["gingival", "ANATOMY", 248, 256], ["throat", "ANATOMY", 366, 372], ["respiratory diseases", "OBSERVATION", 543, 563]]], ["It contains cinnamic alcohol, cinnamic aldehyde, eugenol, geraniol, etc. \u2211 Cinnamic alcohol is utilized as a fixative of mixtures based on jasmine, hyacinth, lilac, narcissus and rose perfumes, as deodorant at 12.5% solution in glycerin and in the soap industry. \u2211 Cinnamic aldehyde is used to give a cinnamon flavor to foods, drinks, pharmaceutical products (it is a valid anti-mold for syrups) and to formulate synthetic perfumes. \u2211 Geraniol is found in flavors used in foodstuffs and soaps, and is also used in the color composition in rose scale.Etiological AgentsRubber additives (accelerators, antioxidants): essentially thiurams and mercaptobenzothiazole (MBT) and benzothiazole bisulfide (BTS) and diphenylguanidine (DPG).", [["cinnamic alcohol", "CHEMICAL", 12, 28], ["cinnamic aldehyde", "CHEMICAL", 30, 47], ["eugenol", "CHEMICAL", 49, 56], ["geraniol", "CHEMICAL", 58, 66], ["Cinnamic alcohol", "CHEMICAL", 75, 91], ["jasmine", "CHEMICAL", 139, 146], ["hyacinth", "CHEMICAL", 148, 156], ["glycerin", "CHEMICAL", 228, 236], ["Cinnamic aldehyde", "CHEMICAL", 265, 282], ["Geraniol", "CHEMICAL", 435, 443], ["thiurams", "CHEMICAL", 627, 635], ["mercaptobenzothiazole", "CHEMICAL", 640, 661], ["MBT", "CHEMICAL", 663, 666], ["benzothiazole bisulfide", "CHEMICAL", 672, 695], ["BTS", "CHEMICAL", 697, 700], ["diphenylguanidine", "CHEMICAL", 706, 723], ["DPG", "CHEMICAL", 725, 728], ["cinnamic alcohol", "CHEMICAL", 12, 28], ["cinnamic aldehyde", "CHEMICAL", 30, 47], ["eugenol", "CHEMICAL", 49, 56], ["geraniol", "CHEMICAL", 58, 66], ["Cinnamic alcohol", "CHEMICAL", 75, 91], ["jasmine", "CHEMICAL", 139, 146], ["glycerin", "CHEMICAL", 228, 236], ["Cinnamic aldehyde", "CHEMICAL", 265, 282], ["Geraniol", "CHEMICAL", 435, 443], ["thiurams", "CHEMICAL", 627, 635], ["mercaptobenzothiazole", "CHEMICAL", 640, 661], ["MBT", "CHEMICAL", 663, 666], ["benzothiazole bisulfide", "CHEMICAL", 672, 695], ["BTS", "CHEMICAL", 697, 700], ["diphenylguanidine", "CHEMICAL", 706, 723], ["DPG", "CHEMICAL", 725, 728], ["cinnamic alcohol", "SIMPLE_CHEMICAL", 12, 28], ["cinnamic aldehyde", "SIMPLE_CHEMICAL", 30, 47], ["eugenol", "SIMPLE_CHEMICAL", 49, 56], ["geraniol", "SIMPLE_CHEMICAL", 58, 66], ["Cinnamic alcohol", "SIMPLE_CHEMICAL", 75, 91], ["jasmine", "SIMPLE_CHEMICAL", 139, 146], ["hyacinth", "SIMPLE_CHEMICAL", 148, 156], ["lilac", "SIMPLE_CHEMICAL", 158, 163], ["narcissus", "SIMPLE_CHEMICAL", 165, 174], ["glycerin", "SIMPLE_CHEMICAL", 228, 236], ["Cinnamic aldehyde", "SIMPLE_CHEMICAL", 265, 282], ["Geraniol", "SIMPLE_CHEMICAL", 435, 443], ["thiurams", "SIMPLE_CHEMICAL", 627, 635], ["mercaptobenzothiazole", "SIMPLE_CHEMICAL", 640, 661], ["MBT", "SIMPLE_CHEMICAL", 663, 666], ["benzothiazole bisulfide", "SIMPLE_CHEMICAL", 672, 695], ["BTS", "SIMPLE_CHEMICAL", 697, 700], ["diphenylguanidine", "SIMPLE_CHEMICAL", 706, 723], ["DPG", "SIMPLE_CHEMICAL", 725, 728], ["a fixative of mixtures", "TREATMENT", 107, 129], ["jasmine", "TREATMENT", 139, 146], ["hyacinth", "TREATMENT", 148, 156], ["lilac", "TREATMENT", 158, 163], ["narcissus", "TREATMENT", 165, 174], ["deodorant", "TREATMENT", 197, 206], ["glycerin", "TREATMENT", 228, 236], ["Cinnamic aldehyde", "TREATMENT", 265, 282], ["a cinnamon flavor", "TREATMENT", 299, 316], ["pharmaceutical products", "TREATMENT", 335, 358], ["a valid anti-mold for syrups", "TREATMENT", 366, 394], ["Geraniol", "TREATMENT", 435, 443], ["soaps", "TREATMENT", 487, 492], ["Etiological AgentsRubber additives (accelerators, antioxidants", "TREATMENT", 550, 612], ["essentially thiurams", "TREATMENT", 615, 635], ["mercaptobenzothiazole (MBT)", "TREATMENT", 640, 667], ["benzothiazole bisulfide (BTS)", "TREATMENT", 672, 701], ["diphenylguanidine (DPG)", "TREATMENT", 706, 729], ["cinnamic alcohol", "OBSERVATION", 12, 28], ["lilac", "ANATOMY", 158, 163]]], ["They are found in almost all rubber objects, including boots, galoshes, shoes (Fig. 8.16) , adhesives, brushes, condoms, elastic bands of all types, especially for undergarments, electric cords, gaskets, germicides, gloves for housework, physicians, and health care workers, inflatable mattresses, insulating tapes, oil, paints, rubber bands, rubber mattresses, soaps, shampoos, tool handles, etc. \u2211 MBT (mercaptobenzothiazole) is a preservative found in disinfectants, fungicides, bactericides (in foods, creams, soaps, sprays), a vulcanization accelerator, an anticorrosive agent in cutting oils such as antirust and antifreeze fluids, and in tires of black color, such as those of cars. \u2211 Thiurams have fungicide actions, and as bacteriostatics are used in foods, soaps, creams and sprays, and in antiparasitics and pesticides.Etiological AgentsDermatitis is characterized by macular erythema and papules due to vasodilation, vesicles or blebs related to intensity of allergic reactions and to the tendency to flood from the contact site.", [["cords", "ANATOMY", 188, 193], ["oil", "ANATOMY", 316, 319], ["oils", "ANATOMY", 593, 597], ["macular", "ANATOMY", 879, 886], ["papules", "ANATOMY", 900, 907], ["vesicles", "ANATOMY", 929, 937], ["blebs", "ANATOMY", 941, 946], ["\u2211 MBT", "CHEMICAL", 398, 403], ["mercaptobenzothiazole", "CHEMICAL", 405, 426], ["bactericides", "CHEMICAL", 482, 494], ["Thiurams", "CHEMICAL", 692, 700], ["AgentsDermatitis", "DISEASE", 842, 858], ["erythema", "DISEASE", 887, 895], ["papules", "DISEASE", 900, 907], ["allergic reactions", "DISEASE", 971, 989], ["MBT", "CHEMICAL", 400, 403], ["mercaptobenzothiazole", "CHEMICAL", 405, 426], ["oil", "ORGANISM_SUBSTANCE", 316, 319], ["\u2211", "SIMPLE_CHEMICAL", 398, 399], ["MBT", "SIMPLE_CHEMICAL", 400, 403], ["mercaptobenzothiazole", "SIMPLE_CHEMICAL", 405, 426], ["bactericides", "SIMPLE_CHEMICAL", 482, 494], ["Thiurams", "SIMPLE_CHEMICAL", 692, 700], ["macular erythema", "PATHOLOGICAL_FORMATION", 879, 895], ["papules", "PATHOLOGICAL_FORMATION", 900, 907], ["vesicles", "CELLULAR_COMPONENT", 929, 937], ["blebs", "CELLULAR_COMPONENT", 941, 946], ["boots", "TREATMENT", 55, 60], ["adhesives", "TREATMENT", 92, 101], ["brushes", "TREATMENT", 103, 110], ["condoms", "TREATMENT", 112, 119], ["inflatable mattresses", "TREATMENT", 275, 296], ["insulating tapes", "TREATMENT", 298, 314], ["rubber bands", "TREATMENT", 329, 341], ["rubber mattresses", "TREATMENT", 343, 360], ["soaps", "TREATMENT", 362, 367], ["MBT (mercaptobenzothiazole)", "TREATMENT", 400, 427], ["a preservative", "TREATMENT", 431, 445], ["fungicides", "TREATMENT", 470, 480], ["bactericides", "PROBLEM", 482, 494], ["creams", "TREATMENT", 506, 512], ["soaps", "TREATMENT", 514, 519], ["sprays", "TREATMENT", 521, 527], ["a vulcanization accelerator", "TREATMENT", 530, 557], ["an anticorrosive agent in cutting oils", "TREATMENT", 559, 597], ["antifreeze fluids", "TREATMENT", 619, 636], ["black color", "PROBLEM", 654, 665], ["fungicide actions", "TREATMENT", 706, 723], ["bacteriostatics", "TREATMENT", 732, 747], ["soaps", "TREATMENT", 767, 772], ["creams", "TREATMENT", 774, 780], ["sprays", "TREATMENT", 785, 791], ["Etiological AgentsDermatitis", "PROBLEM", 830, 858], ["macular erythema", "PROBLEM", 879, 895], ["papules", "PROBLEM", 900, 907], ["vasodilation", "PROBLEM", 915, 927], ["vesicles", "PROBLEM", 929, 937], ["blebs", "PROBLEM", 941, 946], ["allergic reactions", "PROBLEM", 971, 989], ["rubber objects", "OBSERVATION", 29, 43], ["elastic bands", "OBSERVATION_MODIFIER", 121, 134], ["all types", "OBSERVATION_MODIFIER", 138, 147], ["inflatable mattresses", "OBSERVATION", 275, 296], ["rubber bands", "OBSERVATION", 329, 341], ["rubber mattresses", "OBSERVATION", 343, 360], ["macular", "OBSERVATION_MODIFIER", 879, 886], ["erythema", "OBSERVATION", 887, 895], ["papules", "OBSERVATION", 900, 907], ["vasodilation", "OBSERVATION", 915, 927], ["blebs", "OBSERVATION", 941, 946], ["allergic", "OBSERVATION", 971, 979]]], ["The dermis shows perivascular leukocyte infiltration and edema.", [["dermis", "ANATOMY", 4, 10], ["perivascular leukocyte", "ANATOMY", 17, 39], ["edema", "ANATOMY", 57, 62], ["edema", "DISEASE", 57, 62], ["dermis", "TISSUE", 4, 10], ["perivascular leukocyte", "CELL", 17, 39], ["edema", "PATHOLOGICAL_FORMATION", 57, 62], ["perivascular leukocyte infiltration", "PROBLEM", 17, 52], ["edema", "PROBLEM", 57, 62], ["dermis", "ANATOMY", 4, 10], ["perivascular", "ANATOMY_MODIFIER", 17, 29], ["leukocyte infiltration", "OBSERVATION", 30, 52], ["edema", "OBSERVATION", 57, 62]]], ["In some parts, for example, the eyelids, penis and scrotum, both erythema and edema predominate on the vesicles: above all the edema may be particularly intense.", [["eyelids", "ANATOMY", 32, 39], ["penis", "ANATOMY", 41, 46], ["scrotum", "ANATOMY", 51, 58], ["erythema", "ANATOMY", 65, 73], ["edema", "ANATOMY", 78, 83], ["vesicles", "ANATOMY", 103, 111], ["edema", "ANATOMY", 127, 132], ["erythema", "DISEASE", 65, 73], ["edema", "DISEASE", 78, 83], ["edema", "DISEASE", 127, 132], ["eyelids", "ORGANISM_SUBDIVISION", 32, 39], ["penis", "ORGANISM_SUBDIVISION", 41, 46], ["scrotum", "ORGAN", 51, 58], ["edema", "PATHOLOGICAL_FORMATION", 78, 83], ["vesicles", "CELLULAR_COMPONENT", 103, 111], ["edema", "PATHOLOGICAL_FORMATION", 127, 132], ["the eyelids, penis and scrotum", "PROBLEM", 28, 58], ["both erythema", "PROBLEM", 60, 73], ["edema", "PROBLEM", 78, 83], ["the edema", "PROBLEM", 123, 132], ["eyelids", "ANATOMY", 32, 39], ["penis", "ANATOMY", 41, 46], ["scrotum", "ANATOMY", 51, 58], ["both", "OBSERVATION_MODIFIER", 60, 64], ["erythema", "OBSERVATION", 65, 73], ["edema", "OBSERVATION", 78, 83], ["vesicles", "ANATOMY", 103, 111], ["edema", "OBSERVATION", 127, 132], ["may be particularly", "UNCERTAINTY", 133, 152], ["intense", "OBSERVATION_MODIFIER", 153, 160]]], ["Lesions may remain circumscribed or, due to persisting exposure, spread even to far regions by an involuntary contact or in certain cases by self-contact.", [["Lesions", "PROBLEM", 0, 7], ["persisting exposure", "PROBLEM", 44, 63], ["circumscribed", "OBSERVATION", 19, 32], ["persisting", "OBSERVATION_MODIFIER", 44, 54], ["exposure", "OBSERVATION", 55, 63]]], ["By progression of the inflammatory reaction, the skin becomes hyperpigmented, small vesicles appear, which result in exudation, transudation, crusting and subsequent scaling.", [["skin", "ANATOMY", 49, 53], ["vesicles", "ANATOMY", 84, 92], ["crusting", "DISEASE", 142, 150], ["skin", "ORGAN", 49, 53], ["vesicles", "CELLULAR_COMPONENT", 84, 92], ["the inflammatory reaction", "PROBLEM", 18, 43], ["hyperpigmented", "PROBLEM", 62, 76], ["small vesicles", "PROBLEM", 78, 92], ["exudation", "PROBLEM", 117, 126], ["transudation", "PROBLEM", 128, 140], ["crusting", "PROBLEM", 142, 150], ["subsequent scaling", "PROBLEM", 155, 173], ["progression", "OBSERVATION_MODIFIER", 3, 14], ["inflammatory", "OBSERVATION_MODIFIER", 22, 34], ["reaction", "OBSERVATION", 35, 43], ["skin", "ANATOMY", 49, 53], ["hyperpigmented", "OBSERVATION", 62, 76], ["small", "OBSERVATION_MODIFIER", 78, 83], ["vesicles", "OBSERVATION", 84, 92], ["exudation", "OBSERVATION_MODIFIER", 117, 126], ["crusting", "OBSERVATION_MODIFIER", 142, 150], ["scaling", "OBSERVATION_MODIFIER", 166, 173]]], ["Itching is a symptom invariably present and mostly intense.", [["Itching", "DISEASE", 0, 7], ["Itching", "PROBLEM", 0, 7], ["a symptom", "PROBLEM", 11, 20], ["mostly", "OBSERVATION_MODIFIER", 44, 50], ["intense", "OBSERVATION_MODIFIER", 51, 58]]], ["The dermatitis may appear later, with different localizations, by hand transfer; palms and soles and scalp are frequently spared, due to either the greater thickness of the corneum layer or an increased barrier function [7] .Chronic FormIf allergen exposure persists, the skin undergoes an epidermal hyperplasia evolving into hyperkeratosis and acanthosis when the leukocyte infiltration spreads via the epidermis and basal or corneum layers, then to the features of long-standing AD, with lichenification, scaling, fissuring and crusts [7] .Chronic FormSystemic forms include pompholyx (vesiculous-bullous relapsing dermatitis, limited to fingers, palms or soles), the baboon syndrome (common involvement of the buttocks, accompanied by an eczema-like and symmetric eruption on the elbows, armpits, eyelids and lateral neck region) [138] , following ingestion or absorption of Ni, Cr, Co, due to metal prosthesis [7] or provoked by medications first applied topically and then ingested by mouth [227] .Types of ACDStudies on the prevalence of localization of ACD lesions in two pediatric case reports have recorded the lesions as follows: generalized in 15.8%-22.5% of cases, if localized: face 8.3%-8.9%, face and neck 42.3%, mouth 35%, limbs 35%, upper limbs 25.2%, hands 13.3%-45.9%, lower limbs 3.6%, feet 5.4%-20%, hands and feet 3.3%-8.9% [170, 185, 199] .", [["hand", "ANATOMY", 66, 70], ["palms", "ANATOMY", 81, 86], ["soles", "ANATOMY", 91, 96], ["scalp", "ANATOMY", 101, 106], ["corneum layer", "ANATOMY", 173, 186], ["barrier", "ANATOMY", 203, 210], ["skin", "ANATOMY", 272, 276], ["epidermal hyperplasia", "ANATOMY", 290, 311], ["hyperkeratosis", "ANATOMY", 326, 340], ["leukocyte", "ANATOMY", 365, 374], ["epidermis", "ANATOMY", 404, 413], ["basal", "ANATOMY", 418, 423], ["corneum layers", "ANATOMY", 427, 441], ["fingers", "ANATOMY", 640, 647], ["palms", "ANATOMY", 649, 654], ["soles", "ANATOMY", 658, 663], ["buttocks", "ANATOMY", 713, 721], ["elbows", "ANATOMY", 783, 789], ["armpits", "ANATOMY", 791, 798], ["eyelids", "ANATOMY", 800, 807], ["lateral neck region", "ANATOMY", 812, 831], ["mouth", "ANATOMY", 990, 995], ["ACD lesions", "ANATOMY", 1060, 1071], ["lesions", "ANATOMY", 1120, 1127], ["face", "ANATOMY", 1207, 1211], ["neck", "ANATOMY", 1216, 1220], ["mouth", "ANATOMY", 1228, 1233], ["limbs", "ANATOMY", 1239, 1244], ["upper limbs", "ANATOMY", 1250, 1261], ["lower limbs", "ANATOMY", 1288, 1299], ["dermatitis", "DISEASE", 4, 14], ["hyperplasia", "DISEASE", 300, 311], ["hyperkeratosis", "DISEASE", 326, 340], ["acanthosis", "DISEASE", 345, 355], ["AD", "DISEASE", 481, 483], ["bullous relapsing dermatitis", "DISEASE", 599, 627], ["baboon syndrome", "DISEASE", 670, 685], ["eczema", "DISEASE", 741, 747], ["eruption", "DISEASE", 767, 775], ["armpits", "DISEASE", 791, 798], ["Ni", "CHEMICAL", 878, 880], ["Cr", "CHEMICAL", 882, 884], ["Co", "CHEMICAL", 886, 888], ["ACD", "DISEASE", 1060, 1063], ["Ni", "CHEMICAL", 878, 880], ["Cr", "CHEMICAL", 882, 884], ["Co", "CHEMICAL", 886, 888], ["hand", "ORGANISM_SUBDIVISION", 66, 70], ["palms", "ORGANISM_SUBDIVISION", 81, 86], ["soles", "ORGANISM_SUBDIVISION", 91, 96], ["scalp", "ORGAN", 101, 106], ["corneum layer", "TISSUE", 173, 186], ["barrier", "TISSUE", 203, 210], ["skin", "ORGAN", 272, 276], ["epidermal hyperplasia", "PATHOLOGICAL_FORMATION", 290, 311], ["hyperkeratosis", "PATHOLOGICAL_FORMATION", 326, 340], ["leukocyte", "CELL", 365, 374], ["epidermis", "TISSUE", 404, 413], ["corneum layers", "TISSUE", 427, 441], ["fingers", "ORGANISM_SUBDIVISION", 640, 647], ["palms", "ORGANISM_SUBDIVISION", 649, 654], ["soles", "ORGANISM_SUBDIVISION", 658, 663], ["baboon", "ORGANISM", 670, 676], ["buttocks", "ORGANISM_SUBDIVISION", 713, 721], ["elbows", "ORGANISM_SUBDIVISION", 783, 789], ["eyelids", "ORGAN", 800, 807], ["Ni, Cr", "SIMPLE_CHEMICAL", 878, 884], ["Co", "SIMPLE_CHEMICAL", 886, 888], ["ACD lesions", "PATHOLOGICAL_FORMATION", 1060, 1071], ["lesions", "PATHOLOGICAL_FORMATION", 1120, 1127], ["limbs", "ORGANISM_SUBDIVISION", 1239, 1244], ["upper limbs", "ORGANISM_SUBDIVISION", 1250, 1261], ["lower limbs", "ORGANISM_SUBDIVISION", 1288, 1299], ["The dermatitis", "PROBLEM", 0, 14], ["palms and soles and scalp", "PROBLEM", 81, 106], ["an increased barrier function", "PROBLEM", 190, 219], ["Chronic FormIf allergen exposure", "PROBLEM", 225, 257], ["an epidermal hyperplasia", "PROBLEM", 287, 311], ["hyperkeratosis", "PROBLEM", 326, 340], ["acanthosis", "PROBLEM", 345, 355], ["the leukocyte infiltration", "PROBLEM", 361, 387], ["long-standing AD", "PROBLEM", 467, 483], ["lichenification", "PROBLEM", 490, 505], ["scaling", "PROBLEM", 507, 514], ["Chronic FormSystemic forms", "PROBLEM", 542, 568], ["pompholyx (vesiculous-bullous relapsing dermatitis", "PROBLEM", 577, 627], ["the baboon syndrome", "PROBLEM", 666, 685], ["common involvement of the buttocks", "PROBLEM", 687, 721], ["an eczema", "PROBLEM", 738, 747], ["symmetric eruption on the elbows, armpits, eyelids and lateral neck region", "PROBLEM", 757, 831], ["Cr", "TEST", 882, 884], ["metal prosthesis", "TREATMENT", 897, 913], ["medications", "TREATMENT", 933, 944], ["ACD lesions", "PROBLEM", 1060, 1071], ["the lesions", "PROBLEM", 1116, 1127], ["face", "TEST", 1191, 1195], ["face", "TEST", 1207, 1211], ["neck", "TEST", 1216, 1220], ["mouth", "TEST", 1228, 1233], ["limbs", "TEST", 1239, 1244], ["upper limbs", "TEST", 1250, 1261], ["hands", "TEST", 1269, 1274], ["lower limbs", "TEST", 1288, 1299], ["feet", "TEST", 1306, 1310], ["hands", "TEST", 1321, 1326], ["feet", "TEST", 1331, 1335], ["dermatitis", "OBSERVATION", 4, 14], ["soles", "ANATOMY", 91, 96], ["scalp", "ANATOMY", 101, 106], ["corneum", "ANATOMY", 173, 180], ["layer", "ANATOMY_MODIFIER", 181, 186], ["increased", "OBSERVATION_MODIFIER", 193, 202], ["barrier function", "OBSERVATION", 203, 219], ["allergen exposure", "OBSERVATION", 240, 257], ["skin", "ANATOMY", 272, 276], ["epidermal", "OBSERVATION_MODIFIER", 290, 299], ["hyperplasia", "OBSERVATION", 300, 311], ["hyperkeratosis", "OBSERVATION", 326, 340], ["acanthosis", "OBSERVATION", 345, 355], ["leukocyte infiltration", "OBSERVATION", 365, 387], ["epidermis", "ANATOMY", 404, 413], ["basal", "ANATOMY_MODIFIER", 418, 423], ["corneum layers", "ANATOMY", 427, 441], ["scaling", "OBSERVATION_MODIFIER", 507, 514], ["crusts", "OBSERVATION_MODIFIER", 530, 536], ["bullous", "OBSERVATION_MODIFIER", 599, 606], ["relapsing dermatitis", "OBSERVATION", 607, 627], ["palms", "ANATOMY", 649, 654], ["soles", "ANATOMY", 658, 663], ["baboon syndrome", "OBSERVATION", 670, 685], ["buttocks", "ANATOMY", 713, 721], ["eczema", "OBSERVATION", 741, 747], ["symmetric", "OBSERVATION_MODIFIER", 757, 766], ["eruption", "OBSERVATION", 767, 775], ["elbows", "ANATOMY", 783, 789], ["eyelids", "ANATOMY", 800, 807], ["lateral", "ANATOMY_MODIFIER", 812, 819], ["neck", "ANATOMY", 820, 824], ["metal prosthesis", "OBSERVATION", 897, 913], ["ACD", "ANATOMY", 1060, 1063], ["lesions", "OBSERVATION", 1064, 1071], ["lesions", "OBSERVATION", 1120, 1127], ["neck", "ANATOMY", 1216, 1220], ["mouth", "ANATOMY", 1228, 1233], ["limbs", "ANATOMY", 1239, 1244], ["upper limbs", "ANATOMY", 1250, 1261], ["lower limbs", "ANATOMY", 1288, 1299], ["feet", "ANATOMY", 1306, 1310], ["hands", "ANATOMY", 1321, 1326], ["feet", "ANATOMY", 1331, 1335]]], ["Other children had foot eczema in 27.7% of cases [7] more often than on their hands [214] and on the hands in 5%-6% of cases [63] .", [["foot eczema", "DISEASE", 19, 30], ["children", "ORGANISM", 6, 14], ["foot", "ORGANISM_SUBDIVISION", 19, 23], ["children", "SPECIES", 6, 14], ["foot eczema", "PROBLEM", 19, 30], ["foot", "ANATOMY", 19, 23], ["eczema", "OBSERVATION", 24, 30], ["hands", "ANATOMY", 101, 106]]], ["The 13 main types of ACD are as follows:Types of ACDDiaper dermatitis peaks at age 9-12 months.", [["ACD", "DISEASE", 21, 24], ["dermatitis", "DISEASE", 59, 69], ["ACDDiaper dermatitis", "PROBLEM", 49, 69], ["13 main", "OBSERVATION_MODIFIER", 4, 11], ["ACD", "OBSERVATION", 21, 24], ["ACDDiaper dermatitis", "OBSERVATION", 49, 69]]], ["The skin may become erythematous and scaly and in more severe cases exhibits a papulovesicular or bullous reaction, which extends to external genitalia and buttocks, usually sparing the genitocrural folds.", [["skin", "ANATOMY", 4, 8], ["scaly", "ANATOMY", 37, 42], ["papulovesicular", "ANATOMY", 79, 94], ["genitalia", "ANATOMY", 142, 151], ["buttocks", "ANATOMY", 156, 164], ["genitocrural folds", "ANATOMY", 186, 204], ["bullous reaction", "DISEASE", 98, 114], ["skin", "ORGAN", 4, 8], ["genitalia", "ORGAN", 142, 151], ["buttocks", "ORGANISM_SUBDIVISION", 156, 164], ["erythematous", "PROBLEM", 20, 32], ["scaly", "PROBLEM", 37, 42], ["a papulovesicular or bullous reaction", "PROBLEM", 77, 114], ["skin", "ANATOMY", 4, 8], ["may become", "UNCERTAINTY", 9, 19], ["erythematous", "OBSERVATION", 20, 32], ["scaly", "OBSERVATION", 37, 42], ["more severe", "OBSERVATION_MODIFIER", 50, 61], ["papulovesicular", "ANATOMY", 79, 94], ["bullous", "OBSERVATION_MODIFIER", 98, 105], ["reaction", "OBSERVATION", 106, 114], ["external genitalia", "ANATOMY", 133, 151], ["buttocks", "ANATOMY", 156, 164], ["genitocrural folds", "ANATOMY", 186, 204]]], ["The lesions may spread \u2211 DPG, a rubber vulcanization accelerator, is found in boots, elastic bands for undergarments, gloves, preservatives, and elasticized fabrics (with textile fibers interwoven with elastic), etc.Types of ACDEpoxypolymeric resins are found in adhesives, coatings, dental cements, glues, and in the inner coating of tins for preserved foods.Types of ACDNi sulfate reached the highest figures in two cohorts, from 14.9% [84] to 23.7%, with a peak incidence among children aged 1-3 years of 39% [179] .", [["lesions", "ANATOMY", 4, 11], ["DPG", "DISEASE", 25, 28], ["ACDNi sulfate", "CHEMICAL", 369, 382], ["DPG", "CHEMICAL", 25, 28], ["ACDNi sulfate", "CHEMICAL", 369, 382], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["DPG", "SIMPLE_CHEMICAL", 25, 28], ["ACDEpoxypolymeric resins", "SIMPLE_CHEMICAL", 225, 249], ["ACDNi sulfate", "SIMPLE_CHEMICAL", 369, 382], ["children", "ORGANISM", 481, 489], ["children", "SPECIES", 481, 489], ["The lesions", "PROBLEM", 0, 11], ["DPG", "PROBLEM", 25, 28], ["a rubber vulcanization accelerator", "TREATMENT", 30, 64], ["boots", "TREATMENT", 78, 83], ["elastic bands", "PROBLEM", 85, 98], ["undergarments", "PROBLEM", 103, 116], ["gloves", "TREATMENT", 118, 124], ["preservatives", "TREATMENT", 126, 139], ["elasticized fabrics", "TREATMENT", 145, 164], ["textile fibers interwoven", "TREATMENT", 171, 196], ["ACDEpoxypolymeric resins", "TREATMENT", 225, 249], ["adhesives", "TREATMENT", 263, 272], ["dental cements", "TREATMENT", 284, 298], ["glues", "TREATMENT", 300, 305], ["ACDNi sulfate", "TREATMENT", 369, 382], ["lesions", "OBSERVATION", 4, 11], ["rubber vulcanization accelerator", "OBSERVATION", 32, 64], ["boots", "ANATOMY", 78, 83], ["elastic bands", "OBSERVATION", 85, 98], ["ACDEpoxypolymeric resins", "OBSERVATION", 225, 249], ["dental cements", "OBSERVATION", 284, 298]]], ["Two children aged 4-6 elicited positive reactions to Ni sulfate contained in medication [47] , a 4-year-old girl to Cu present in toys, and a boy aged 11 to turpentine contained in pastels [80] .", [["Ni sulfate", "CHEMICAL", 53, 63], ["Cu", "CHEMICAL", 116, 118], ["turpentine", "CHEMICAL", 157, 167], ["Ni sulfate", "CHEMICAL", 53, 63], ["Cu", "CHEMICAL", 116, 118], ["children", "ORGANISM", 4, 12], ["Ni sulfate", "SIMPLE_CHEMICAL", 53, 63], ["girl", "ORGANISM", 108, 112], ["children", "SPECIES", 4, 12], ["girl", "SPECIES", 108, 112], ["boy", "SPECIES", 142, 145], ["positive reactions", "PROBLEM", 31, 49], ["Ni sulfate", "TREATMENT", 53, 63]]], ["Several waxes, rubber, spices and flavoring agents provoke contact urticaria and are summarized in the Appendix 8.1 [184] .Several causative agents of ACD can exacerbate clinical manifestations if ingested with foodstuffs [125]:Co: Absorption in the gastrointestinal tract appears to be particularly rapid, owing to sudden relapses after FCT.Several causative agents of ACD can exacerbate clinical manifestations if ingested with foodstuffs [125]:Cr: Even if we ingest 25-300 mg/day, Cr concentration in the organism is low, therefore the role of Cr contained in foodstuffs is controversial.Several causative agents of ACD can exacerbate clinical manifestations if ingested with foodstuffs [125]:Ni: High content in the above-mentioned foods.", [["gastrointestinal tract", "ANATOMY", 250, 272], ["waxes, rubber, spices", "CHEMICAL", 8, 29], ["urticaria", "DISEASE", 67, 76], ["ACD", "DISEASE", 151, 154], ["ACD", "DISEASE", 370, 373], ["Cr", "CHEMICAL", 447, 449], ["Cr", "CHEMICAL", 484, 486], ["Cr", "CHEMICAL", 547, 549], ["ACD", "DISEASE", 619, 622], ["Ni", "CHEMICAL", 696, 698], ["Co", "CHEMICAL", 228, 230], ["Cr", "CHEMICAL", 447, 449], ["Cr", "CHEMICAL", 484, 486], ["Cr", "CHEMICAL", 547, 549], ["Ni", "CHEMICAL", 696, 698], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 250, 272], ["Cr", "SIMPLE_CHEMICAL", 447, 449], ["Cr", "SIMPLE_CHEMICAL", 484, 486], ["Cr", "SIMPLE_CHEMICAL", 547, 549], ["flavoring agents", "TREATMENT", 34, 50], ["contact urticaria", "PROBLEM", 59, 76], ["ACD", "TREATMENT", 151, 154], ["Absorption in the gastrointestinal tract", "PROBLEM", 232, 272], ["sudden relapses", "PROBLEM", 316, 331], ["ACD", "TREATMENT", 370, 373], ["Cr", "TEST", 447, 449], ["Cr concentration", "TEST", 484, 500], ["the organism", "PROBLEM", 504, 516], ["Cr", "TEST", 547, 549], ["ACD", "TREATMENT", 619, 622], ["waxes", "OBSERVATION_MODIFIER", 8, 13], ["Appendix", "ANATOMY", 103, 111], ["gastrointestinal tract", "ANATOMY", 250, 272], ["low", "OBSERVATION_MODIFIER", 520, 523], ["High content", "OBSERVATION_MODIFIER", 700, 712]]], ["It is estimated that we ingest 150 mg/day of Ni and the absorption in the gastrointestinal tract is 1%-5%, sufficient to aggravate ACD and provoke urticaria and/or wheezing (Ni asthma) [221] .", [["gastrointestinal tract", "ANATOMY", 74, 96], ["Ni", "CHEMICAL", 45, 47], ["ACD", "DISEASE", 131, 134], ["urticaria", "DISEASE", 147, 156], ["wheezing", "DISEASE", 164, 172], ["asthma", "DISEASE", 177, 183], ["Ni", "CHEMICAL", 45, 47], ["Ni", "CHEMICAL", 174, 176], ["Ni", "SIMPLE_CHEMICAL", 45, 47], ["gastrointestinal tract", "ORGAN", 74, 96], ["Ni", "TREATMENT", 45, 47], ["the absorption in the gastrointestinal tract", "TREATMENT", 52, 96], ["urticaria", "PROBLEM", 147, 156], ["wheezing", "PROBLEM", 164, 172], ["Ni asthma)", "PROBLEM", 174, 184], ["gastrointestinal tract", "ANATOMY", 74, 96], ["urticaria", "OBSERVATION", 147, 156]]], ["However, it is unknown how much Ni is released by orthodontic instruments and the like [221] ; remarkably, oral Ni administration may induce a high frequency of anergic T cells with persistent suppressor activity [9] .Clinical PresentationACD is initially located in the skin sites exposed to allergen contact, often a diagnostic distribution, although it may subsequently spread to other sites.", [["oral", "ANATOMY", 107, 111], ["anergic T cells", "ANATOMY", 161, 176], ["skin sites", "ANATOMY", 271, 281], ["Ni", "CHEMICAL", 32, 34], ["Ni", "CHEMICAL", 112, 114], ["Ni", "CHEMICAL", 32, 34], ["Ni", "CHEMICAL", 112, 114], ["Ni", "GENE_OR_GENE_PRODUCT", 32, 34], ["oral", "ORGANISM_SUBDIVISION", 107, 111], ["Ni", "SIMPLE_CHEMICAL", 112, 114], ["anergic T cells", "CELL", 161, 176], ["skin", "ORGAN", 271, 275], ["Ni", "PROTEIN", 32, 34], ["anergic T cells", "CELL_TYPE", 161, 176], ["oral Ni administration", "TREATMENT", 107, 129], ["anergic T cells", "TREATMENT", 161, 176], ["persistent suppressor activity", "PROBLEM", 182, 212], ["Clinical PresentationACD", "PROBLEM", 218, 242], ["skin", "ANATOMY", 271, 275], ["allergen contact", "OBSERVATION", 293, 309]]], ["ACD can be divided into acute and chronic forms [138] .Acute FormsAt first the lesions appear on the more exposed skin sites, where the contact is easier.", [["lesions", "ANATOMY", 79, 86], ["skin sites", "ANATOMY", 114, 124], ["ACD", "DISEASE", 0, 3], ["lesions", "PATHOLOGICAL_FORMATION", 79, 86], ["skin sites", "MULTI-TISSUE_STRUCTURE", 114, 124], ["ACD", "TREATMENT", 0, 3], ["acute and chronic forms", "PROBLEM", 24, 47], ["Acute FormsAt first the lesions", "PROBLEM", 55, 86], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["lesions", "OBSERVATION", 79, 86], ["skin", "ANATOMY", 114, 118], ["sites", "OBSERVATION", 119, 124]]], ["Common sites of ACD are under rings, earrings and sites of ear-piercing, spectacle frames, bracelets, necklaces, coins in pockets, jeans studs, and other sites of metal contact (Figs.", [["sites", "ANATOMY", 7, 12], ["ear-", "ANATOMY", 59, 63], ["ACD", "DISEASE", 16, 19], ["ACD", "PROBLEM", 16, 19], ["ear-piercing", "PROBLEM", 59, 71], ["coins in pockets, jeans studs", "PROBLEM", 113, 142], ["ACD", "OBSERVATION", 16, 19], ["pockets", "OBSERVATION_MODIFIER", 122, 129], ["metal contact", "OBSERVATION", 163, 176]]], ["8.13-8.16) , and clinically the ears, neck, finger interdigital or dorsal aspects, or forearm back, the hand dorsal region, less the palms, face and less obvious sites are the lower limbs.", [["ears", "ANATOMY", 32, 36], ["neck", "ANATOMY", 38, 42], ["finger interdigital", "ANATOMY", 44, 63], ["dorsal aspects", "ANATOMY", 67, 81], ["forearm back", "ANATOMY", 86, 98], ["hand dorsal region", "ANATOMY", 104, 122], ["palms", "ANATOMY", 133, 138], ["face", "ANATOMY", 140, 144], ["sites", "ANATOMY", 162, 167], ["lower limbs", "ANATOMY", 176, 187], ["ears", "ORGAN", 32, 36], ["neck", "ORGANISM_SUBDIVISION", 38, 42], ["palms", "ORGANISM_SUBDIVISION", 133, 138], ["lower limbs", "ORGANISM_SUBDIVISION", 176, 187], ["clinically the ears, neck, finger interdigital or dorsal aspects, or forearm back, the hand dorsal region", "PROBLEM", 17, 122], ["ears", "ANATOMY", 32, 36], ["neck", "ANATOMY", 38, 42], ["finger interdigital", "ANATOMY", 44, 63], ["dorsal", "ANATOMY_MODIFIER", 67, 73], ["forearm", "ANATOMY", 86, 93], ["hand", "ANATOMY", 104, 108], ["dorsal", "ANATOMY_MODIFIER", 109, 115], ["less", "OBSERVATION_MODIFIER", 124, 128], ["palms", "ANATOMY", 133, 138], ["face", "ANATOMY", 140, 144], ["less", "OBSERVATION_MODIFIER", 149, 153], ["obvious sites", "OBSERVATION", 154, 167], ["lower limbs", "ANATOMY", 176, 187]]], ["Within 15-20 min of contact the lesion begins to itch. beyond the diaper area to the lower abdomen and to the thighs, often complicated by secondary infection.", [["lesion", "ANATOMY", 32, 38], ["diaper area", "ANATOMY", 66, 77], ["lower abdomen", "ANATOMY", 85, 98], ["thighs", "ANATOMY", 110, 116], ["itch", "DISEASE", 49, 53], ["infection", "DISEASE", 149, 158], ["lower abdomen", "ORGANISM_SUBDIVISION", 85, 98], ["thighs", "ORGANISM_SUBDIVISION", 110, 116], ["the lesion", "PROBLEM", 28, 38], ["itch", "PROBLEM", 49, 53], ["secondary infection", "PROBLEM", 139, 158], ["lesion", "OBSERVATION", 32, 38], ["diaper", "OBSERVATION", 66, 72], ["lower", "ANATOMY_MODIFIER", 85, 90], ["abdomen", "ANATOMY", 91, 98], ["thighs", "ANATOMY", 110, 116], ["secondary", "OBSERVATION_MODIFIER", 139, 148], ["infection", "OBSERVATION", 149, 158]]], ["This is certainly the most common contact dermatitis in infants, the prototype of irritant contact dermatitis (ICD), a reaction to the irritant and protracted action of ammonia deriving from urine left too long in the diaper, overly acidic feces, traces of soaps and detergents from an inappropriate cleansing of the diaper area, deodorants and preservatives in the absorbent diapers, ointments and oils, medicated or not, applied several times a day for emollient and anti-irritant purposes, and frictions, washings and wiping, often favored by the occlusive effect of plastic diapers [7] .", [["urine", "ANATOMY", 191, 196], ["diaper area", "ANATOMY", 317, 328], ["oils", "ANATOMY", 399, 403], ["dermatitis", "DISEASE", 42, 52], ["irritant contact dermatitis", "DISEASE", 82, 109], ["ICD", "DISEASE", 111, 114], ["ammonia", "CHEMICAL", 169, 176], ["ammonia", "CHEMICAL", 169, 176], ["infants", "ORGANISM", 56, 63], ["ammonia", "SIMPLE_CHEMICAL", 169, 176], ["urine", "ORGANISM_SUBSTANCE", 191, 196], ["diaper", "ORGANISM_SUBDIVISION", 218, 224], ["feces", "ORGANISM_SUBSTANCE", 240, 245], ["infants", "SPECIES", 56, 63], ["contact dermatitis", "PROBLEM", 34, 52], ["irritant contact dermatitis", "PROBLEM", 82, 109], ["ICD", "TREATMENT", 111, 114], ["a reaction", "PROBLEM", 117, 127], ["the irritant", "PROBLEM", 131, 143], ["ammonia deriving from urine", "PROBLEM", 169, 196], ["acidic feces", "PROBLEM", 233, 245], ["soaps", "TREATMENT", 257, 262], ["detergents", "TREATMENT", 267, 277], ["an inappropriate cleansing of the diaper area", "TREATMENT", 283, 328], ["deodorants", "TREATMENT", 330, 340], ["preservatives", "TREATMENT", 345, 358], ["the absorbent diapers", "TREATMENT", 362, 383], ["ointments", "TREATMENT", 385, 394], ["oils", "TREATMENT", 399, 403], ["emollient", "TREATMENT", 455, 464], ["anti-irritant purposes", "TREATMENT", 469, 491], ["frictions", "TREATMENT", 497, 506], ["washings", "TREATMENT", 508, 516], ["plastic diapers", "TREATMENT", 570, 585], ["most common", "OBSERVATION_MODIFIER", 22, 33], ["contact dermatitis", "OBSERVATION", 34, 52], ["irritant", "OBSERVATION_MODIFIER", 82, 90], ["contact dermatitis", "OBSERVATION", 91, 109], ["left", "ANATOMY_MODIFIER", 197, 201], ["diaper area", "ANATOMY", 317, 328], ["occlusive", "OBSERVATION_MODIFIER", 550, 559], ["plastic diapers", "OBSERVATION", 570, 585]]], ["This dermatitis is commonly treated, over a long period, with various topical medications, some potentially allergizing, for example, casein in a diaper ointment (Chap.", [["dermatitis", "DISEASE", 5, 15], ["casein", "SIMPLE_CHEMICAL", 134, 140], ["This dermatitis", "PROBLEM", 0, 15], ["various topical medications", "TREATMENT", 62, 89], ["casein", "TREATMENT", 134, 140], ["a diaper ointment", "TREATMENT", 144, 161], ["dermatitis", "OBSERVATION", 5, 15]]], ["9).Acute FormsContact cheilitis is more frequent than stomatitis because the transition epithelium and lesser moistening by saliva facilitate sensitization.", [["epithelium", "ANATOMY", 88, 98], ["cheilitis", "DISEASE", 22, 31], ["stomatitis", "DISEASE", 54, 64], ["epithelium", "TISSUE", 88, 98], ["saliva", "ORGANISM_SUBSTANCE", 124, 130], ["Acute FormsContact cheilitis", "PROBLEM", 3, 31], ["stomatitis", "PROBLEM", 54, 64], ["the transition epithelium", "PROBLEM", 73, 98], ["FormsContact", "OBSERVATION_MODIFIER", 9, 21], ["cheilitis", "OBSERVATION", 22, 31], ["more frequent", "OBSERVATION_MODIFIER", 35, 48], ["lesser", "OBSERVATION_MODIFIER", 103, 109]]], ["Milder cases are caused by lip dryness, chapping and lip licking, and in most severe cases it is intumescent, with erosions and crusts.", [["lip", "ANATOMY", 27, 30], ["lip", "ANATOMY", 53, 56], ["lip dryness", "DISEASE", 27, 38], ["lip licking", "DISEASE", 53, 64], ["intumescent", "DISEASE", 97, 108], ["erosions", "DISEASE", 115, 123], ["crusts", "DISEASE", 128, 134], ["lip", "ORGAN", 27, 30], ["lip", "ORGANISM_SUBDIVISION", 53, 56], ["erosions", "PATHOLOGICAL_FORMATION", 115, 123], ["crusts", "PATHOLOGICAL_FORMATION", 128, 134], ["Milder cases", "PROBLEM", 0, 12], ["lip dryness", "PROBLEM", 27, 38], ["chapping and lip licking", "PROBLEM", 40, 64], ["erosions and crusts", "PROBLEM", 115, 134], ["lip", "ANATOMY", 27, 30], ["dryness", "OBSERVATION", 31, 38], ["lip", "ANATOMY", 53, 56], ["licking", "OBSERVATION", 57, 64], ["erosions", "OBSERVATION", 115, 123], ["crusts", "OBSERVATION", 128, 134]]], ["Cheilitis stems from irritation provoked by: \u2211 Foods, especially artichoke, carrot, cheese, citrus, fennel, kiwi, mango, peach, tomato, fruit juices, etc. \u2211 Topical medications, toothpaste, lip salve, lipsticks, cosmetics. \u2211 Mouthwash and cough syrups, candied fruits and foods containing menthol. \u2211 Preservatives contained even in cold drinks and ices. \u2211 Nail polish, nail enamel and nail hardening for onychophagists; eyelid involvement is unique for nail-polish sensitivity. \u2211 Saliva may be irritant when children lick or bite their lips too often, or suck candies or chewing-gum [172] . \u2211 Lip contact with nickel-plated objects [47] .", [["fruit juices", "ANATOMY", 136, 148], ["lip", "ANATOMY", 190, 193], ["fruits", "ANATOMY", 261, 267], ["enamel", "ANATOMY", 374, 380], ["nail", "ANATOMY", 385, 389], ["eyelid", "ANATOMY", 420, 426], ["lips", "ANATOMY", 536, 540], ["Lip", "ANATOMY", 593, 596], ["Cheilitis", "DISEASE", 0, 9], ["irritation", "DISEASE", 21, 31], ["artichoke, carrot, cheese, citrus, fennel, kiwi, mango, peach, tomato, fruit juices", "CHEMICAL", 65, 148], ["cough syrups", "DISEASE", 239, 251], ["menthol", "CHEMICAL", 289, 296], ["onychophagists", "DISEASE", 404, 418], ["nickel", "CHEMICAL", 610, 616], ["menthol", "CHEMICAL", 289, 296], ["nickel", "CHEMICAL", 610, 616], ["carrot", "ORGANISM_SUBDIVISION", 76, 82], ["cheese", "ORGANISM_SUBDIVISION", 84, 90], ["citrus", "ORGANISM_SUBDIVISION", 92, 98], ["fennel", "ORGANISM_SUBDIVISION", 100, 106], ["kiwi", "ORGANISM_SUBDIVISION", 108, 112], ["mango", "ORGANISM_SUBDIVISION", 114, 119], ["peach", "ORGANISM_SUBDIVISION", 121, 126], ["tomato", "ORGANISM_SUBDIVISION", 128, 134], ["lip", "ORGANISM_SUBDIVISION", 190, 193], ["fruits", "ORGANISM_SUBDIVISION", 261, 267], ["menthol", "SIMPLE_CHEMICAL", 289, 296], ["nail enamel", "TISSUE", 369, 380], ["nail", "TISSUE", 385, 389], ["eyelid", "ORGAN", 420, 426], ["Saliva", "ORGANISM_SUBSTANCE", 480, 486], ["children", "ORGANISM", 508, 516], ["lips", "ORGANISM_SUBDIVISION", 536, 540], ["candies", "ORGANISM_SUBDIVISION", 560, 567], ["carrot", "SPECIES", 76, 82], ["cheese", "SPECIES", 84, 90], ["kiwi", "SPECIES", 108, 112], ["peach", "SPECIES", 121, 126], ["tomato", "SPECIES", 128, 134], ["fruit", "SPECIES", 136, 141], ["children", "SPECIES", 508, 516], ["peach", "SPECIES", 121, 126], ["tomato", "SPECIES", 128, 134], ["Cheilitis stems", "PROBLEM", 0, 15], ["irritation", "PROBLEM", 21, 31], ["Topical medications", "TREATMENT", 157, 176], ["toothpaste", "TREATMENT", 178, 188], ["lip salve", "TREATMENT", 190, 199], ["lipsticks", "TREATMENT", 201, 210], ["cosmetics", "TREATMENT", 212, 221], ["Mouthwash", "TREATMENT", 225, 234], ["cough syrups", "PROBLEM", 239, 251], ["Preservatives", "TREATMENT", 300, 313], ["onychophagists", "PROBLEM", 404, 418], ["eyelid involvement", "PROBLEM", 420, 438], ["irritation", "OBSERVATION", 21, 31], ["lip", "ANATOMY", 190, 193], ["Nail", "ANATOMY", 356, 360], ["nail enamel", "ANATOMY", 369, 380], ["nail", "ANATOMY", 385, 389], ["eyelid", "ANATOMY", 420, 426]]], ["Toothpastes often contain cinnamon, carnation essence, menthol, eugenol, etc. Lipsticks may contain dyestuffs such as fluorescin and eosin, as well as antioxidants, carbamate cinnamon, lanolin, methylethane, oleic alcohol, and perfumes; lipsticks and lip salve contain carmine and lanolin.", [["lip", "ANATOMY", 251, 254], ["menthol", "CHEMICAL", 55, 62], ["eugenol", "CHEMICAL", 64, 71], ["Lipsticks", "DISEASE", 78, 87], ["fluorescin and eosin", "CHEMICAL", 118, 138], ["carbamate cinnamon", "CHEMICAL", 165, 183], ["lanolin", "CHEMICAL", 185, 192], ["methylethane", "CHEMICAL", 194, 206], ["oleic alcohol", "CHEMICAL", 208, 221], ["carmine", "CHEMICAL", 269, 276], ["lanolin", "CHEMICAL", 281, 288], ["menthol", "CHEMICAL", 55, 62], ["eugenol", "CHEMICAL", 64, 71], ["fluorescin", "CHEMICAL", 118, 128], ["eosin", "CHEMICAL", 133, 138], ["carbamate cinnamon", "CHEMICAL", 165, 183], ["lanolin", "CHEMICAL", 185, 192], ["methylethane", "CHEMICAL", 194, 206], ["oleic alcohol", "CHEMICAL", 208, 221], ["carmine", "CHEMICAL", 269, 276], ["lanolin", "CHEMICAL", 281, 288], ["cinnamon", "SIMPLE_CHEMICAL", 26, 34], ["menthol", "SIMPLE_CHEMICAL", 55, 62], ["eugenol", "SIMPLE_CHEMICAL", 64, 71], ["fluorescin", "SIMPLE_CHEMICAL", 118, 128], ["eosin", "SIMPLE_CHEMICAL", 133, 138], ["carbamate cinnamon", "SIMPLE_CHEMICAL", 165, 183], ["lanolin", "SIMPLE_CHEMICAL", 185, 192], ["methylethane", "SIMPLE_CHEMICAL", 194, 206], ["oleic alcohol", "SIMPLE_CHEMICAL", 208, 221], ["lipsticks", "SIMPLE_CHEMICAL", 237, 246], ["lip", "ORGANISM_SUBDIVISION", 251, 254], ["carmine", "SIMPLE_CHEMICAL", 269, 276], ["lanolin", "SIMPLE_CHEMICAL", 281, 288], ["Toothpastes", "TREATMENT", 0, 11], ["Lipsticks", "TREATMENT", 78, 87], ["dyestuffs", "PROBLEM", 100, 109], ["fluorescin", "TREATMENT", 118, 128], ["eosin", "TREATMENT", 133, 138], ["antioxidants", "TREATMENT", 151, 163], ["carbamate cinnamon", "TREATMENT", 165, 183], ["lanolin", "TREATMENT", 185, 192], ["methylethane", "TREATMENT", 194, 206], ["oleic alcohol", "TREATMENT", 208, 221], ["perfumes", "TREATMENT", 227, 235], ["lipsticks", "TREATMENT", 237, 246], ["lip salve", "TREATMENT", 251, 260], ["carmine", "TREATMENT", 269, 276], ["lanolin", "TREATMENT", 281, 288], ["cinnamon", "OBSERVATION_MODIFIER", 26, 34], ["lip", "ANATOMY", 251, 254]]], ["From cinnamon is derived an oil cross-reacting with balsam of Peru, benzoin, colophony, vanilla and essential oils of orange peel [138] .Acute FormsContact stomatitis.", [["oil", "ANATOMY", 28, 31], ["oils", "ANATOMY", 110, 114], ["balsam of Peru, benzoin, colophony, vanilla and essential oils of orange peel", "CHEMICAL", 52, 129], ["FormsContact stomatitis", "DISEASE", 143, 166], ["cinnamon", "ORGANISM", 5, 13], ["oil", "ORGANISM_SUBSTANCE", 28, 31], ["benzoin", "SIMPLE_CHEMICAL", 68, 75], ["colophony", "SIMPLE_CHEMICAL", 77, 86], ["vanilla", "ORGANISM_SUBDIVISION", 88, 95], ["benzoin", "TREATMENT", 68, 75], ["colophony", "TREATMENT", 77, 86], ["vanilla", "TREATMENT", 88, 95], ["Acute FormsContact stomatitis", "PROBLEM", 137, 166], ["FormsContact stomatitis", "OBSERVATION", 143, 166]]], ["The skin, differently from mucosa, has several proteins in the keratin layer, which may act as a carrier for hapten-sensitizing molecules.", [["skin", "ANATOMY", 4, 8], ["mucosa", "ANATOMY", 27, 33], ["keratin layer", "ANATOMY", 63, 76], ["skin", "ORGAN", 4, 8], ["mucosa", "MULTI-TISSUE_STRUCTURE", 27, 33], ["keratin", "GENE_OR_GENE_PRODUCT", 63, 70], ["hapten-sensitizing molecules", "PROTEIN", 109, 137], ["several proteins in the keratin layer", "PROBLEM", 39, 76], ["skin", "ANATOMY", 4, 8], ["mucosa", "ANATOMY", 27, 33], ["several", "OBSERVATION_MODIFIER", 39, 46], ["proteins", "OBSERVATION", 47, 55], ["keratin layer", "OBSERVATION_MODIFIER", 63, 76]]], ["It is characterized by burning, pain, taste reduction up to ageusia and paresthesia.", [["pain", "DISEASE", 32, 36], ["taste reduction", "DISEASE", 38, 53], ["ageusia", "DISEASE", 60, 67], ["paresthesia", "DISEASE", 72, 83], ["burning", "PROBLEM", 23, 30], ["pain", "PROBLEM", 32, 36], ["taste reduction", "TREATMENT", 38, 53], ["paresthesia", "PROBLEM", 72, 83], ["burning", "OBSERVATION_MODIFIER", 23, 30], ["paresthesia", "OBSERVATION", 72, 83]]], ["Unlike the substances previously listed, when the contact involves the mouth cavity, the oral mucosa lesions vary from a barely perceptible enanthem up to a dark red coloration with edema and ulceration, which may limit ingestion of foods and drinks, talking, and occasionally breathing.", [["mouth cavity", "ANATOMY", 71, 83], ["oral mucosa lesions", "ANATOMY", 89, 108], ["edema", "ANATOMY", 182, 187], ["edema", "DISEASE", 182, 187], ["ulceration", "DISEASE", 192, 202], ["mouth cavity", "ORGANISM_SUBDIVISION", 71, 83], ["oral mucosa lesions", "PATHOLOGICAL_FORMATION", 89, 108], ["edema", "PATHOLOGICAL_FORMATION", 182, 187], ["the oral mucosa lesions", "PROBLEM", 85, 108], ["a dark red coloration", "PROBLEM", 155, 176], ["edema", "PROBLEM", 182, 187], ["ulceration", "PROBLEM", 192, 202], ["mouth cavity", "ANATOMY", 71, 83], ["oral mucosa", "ANATOMY", 89, 100], ["lesions", "OBSERVATION", 101, 108], ["dark red", "OBSERVATION_MODIFIER", 157, 165], ["coloration", "OBSERVATION_MODIFIER", 166, 176], ["edema", "OBSERVATION", 182, 187], ["ulceration", "OBSERVATION", 192, 202]]], ["The direct application of offending allergen may provoke local lesions of the urticarial type, generalized and even anaphylactic.", [["lesions", "ANATOMY", 63, 70], ["urticarial", "DISEASE", 78, 88], ["anaphylactic", "DISEASE", 116, 128], ["lesions", "PATHOLOGICAL_FORMATION", 63, 70], ["offending allergen", "TREATMENT", 26, 44], ["local lesions of the urticarial type", "PROBLEM", 57, 93], ["anaphylactic", "PROBLEM", 116, 128], ["local", "OBSERVATION_MODIFIER", 57, 62], ["lesions", "OBSERVATION", 63, 70], ["urticarial type", "OBSERVATION", 78, 93]]], ["Especially at risk in sensitive subjects are the widely used metals in dentistry [6, 224] , such as, Ni, Cr (present in wires and alloy) [224] , Hg (capping amalgam) [6] , further toothpastes and mouthwashes, rubber, essential oils, preservatives, etc. [6] .", [["oils", "ANATOMY", 227, 231], ["Ni", "CHEMICAL", 101, 103], ["Cr", "CHEMICAL", 105, 107], ["Hg", "CHEMICAL", 145, 147], ["Ni", "CHEMICAL", 101, 103], ["Cr", "CHEMICAL", 105, 107], ["Hg", "CHEMICAL", 145, 147], ["Ni, Cr", "SIMPLE_CHEMICAL", 101, 107], ["Cr", "TEST", 105, 107], ["Hg (capping amalgam", "TREATMENT", 145, 164], ["further toothpastes", "TREATMENT", 172, 191], ["mouthwashes", "TREATMENT", 196, 207], ["preservatives", "TREATMENT", 233, 246], ["essential oils", "OBSERVATION", 217, 231]]], ["Recovery is assured by removing instruments with Ni and/or Cr [224] .Acute FormsOther contact dermatitis of the mucosa [138] : \u2211 Conjunctivitis. \u2211 Contact balanitis is a glans pruritic erythema, often accompanied by preputial edema, derived from soaps, products for personal hygiene, condoms and related detergents and lubricants, too close-fitting underwear. \u2211 Contact vulvitis has an onset with pruritus and edematous, erythematous, oozing lesions, limited to the area of contact with the etiological agent, which may become chronic when it persists for a long time.", [["mucosa", "ANATOMY", 112, 118], ["glans", "ANATOMY", 170, 175], ["preputial edema", "ANATOMY", 216, 231], ["edematous", "ANATOMY", 410, 419], ["oozing lesions", "ANATOMY", 435, 449], ["Ni", "CHEMICAL", 49, 51], ["Cr", "CHEMICAL", 59, 61], ["dermatitis", "DISEASE", 94, 104], ["Conjunctivitis", "DISEASE", 129, 143], ["balanitis", "DISEASE", 155, 164], ["erythema", "DISEASE", 185, 193], ["edema", "DISEASE", 226, 231], ["vulvitis", "DISEASE", 370, 378], ["pruritus", "DISEASE", 397, 405], ["oozing", "DISEASE", 435, 441], ["Ni", "CHEMICAL", 49, 51], ["Cr [224]", "CHEMICAL", 59, 67], ["mucosa", "MULTI-TISSUE_STRUCTURE", 112, 118], ["glans", "PATHOLOGICAL_FORMATION", 170, 175], ["preputial edema", "PATHOLOGICAL_FORMATION", 216, 231], ["oozing lesions", "PATHOLOGICAL_FORMATION", 435, 449], ["Cr", "TEST", 59, 61], ["Acute FormsOther contact dermatitis of the mucosa", "PROBLEM", 69, 118], ["Conjunctivitis", "PROBLEM", 129, 143], ["Contact balanitis", "PROBLEM", 147, 164], ["a glans pruritic erythema", "PROBLEM", 168, 193], ["preputial edema", "PROBLEM", 216, 231], ["personal hygiene", "TREATMENT", 266, 282], ["condoms", "TREATMENT", 284, 291], ["related detergents", "TREATMENT", 296, 314], ["lubricants", "TREATMENT", 319, 329], ["pruritus", "PROBLEM", 397, 405], ["edematous", "PROBLEM", 410, 419], ["erythematous", "PROBLEM", 421, 433], ["oozing lesions", "PROBLEM", 435, 449], ["contact dermatitis", "OBSERVATION", 86, 104], ["mucosa", "ANATOMY", 112, 118], ["Conjunctivitis", "OBSERVATION", 129, 143], ["balanitis", "OBSERVATION", 155, 164], ["glans", "ANATOMY", 170, 175], ["pruritic", "OBSERVATION_MODIFIER", 176, 184], ["erythema", "OBSERVATION", 185, 193], ["preputial", "ANATOMY", 216, 225], ["edema", "OBSERVATION", 226, 231], ["edematous", "OBSERVATION_MODIFIER", 410, 419], ["erythematous", "OBSERVATION_MODIFIER", 421, 433], ["oozing", "OBSERVATION_MODIFIER", 435, 441], ["lesions", "OBSERVATION", 442, 449], ["may become", "UNCERTAINTY", 516, 526], ["chronic", "OBSERVATION_MODIFIER", 527, 534]]], ["Common causes are soaps, bubble baths (and related additives), hygiene sprays, products for vaginal irrigation if insufficiently diluted or frequently employed, spermicidals, the partner's condom, perfumed toilet paper, too closefitting sanitary napkins, underwear, and contact with clasps, hooks, and zippers with Ni.Acute FormsShoe dermatitis, caused by rubber and tennis shoes, boots, etc., due to a combined action of Cr and Co (tanned leather), Ni (metal decorations) and Hg, present in the upper and/or lining parts.", [["vaginal", "ANATOMY", 92, 99], ["Shoe dermatitis", "DISEASE", 329, 344], ["Cr", "CHEMICAL", 422, 424], ["Co", "CHEMICAL", 429, 431], ["tanned leather", "CHEMICAL", 433, 447], ["Ni", "CHEMICAL", 450, 452], ["Hg", "CHEMICAL", 477, 479], ["Cr", "CHEMICAL", 422, 424], ["Co", "CHEMICAL", 429, 431], ["Ni", "CHEMICAL", 450, 452], ["Hg", "CHEMICAL", 477, 479], ["vaginal", "ORGANISM_SUBDIVISION", 92, 99], ["Cr", "SIMPLE_CHEMICAL", 422, 424], ["Co", "SIMPLE_CHEMICAL", 429, 431], ["Ni (metal decorations", "SIMPLE_CHEMICAL", 450, 471], ["Hg", "SIMPLE_CHEMICAL", 477, 479], ["upper", "ORGANISM_SUBDIVISION", 496, 501], ["bubble baths", "TREATMENT", 25, 37], ["hygiene sprays", "TREATMENT", 63, 77], ["products", "TREATMENT", 79, 87], ["vaginal irrigation", "TREATMENT", 92, 110], ["zippers", "TREATMENT", 302, 309], ["Shoe dermatitis", "PROBLEM", 329, 344], ["boots", "TREATMENT", 381, 386], ["Cr", "TEST", 422, 424], ["Co (tanned leather", "TREATMENT", 429, 447], ["Hg", "TEST", 477, 479], ["vaginal", "ANATOMY", 92, 99], ["Shoe dermatitis", "OBSERVATION", 329, 344], ["tennis shoes", "OBSERVATION", 367, 379], ["upper", "ANATOMY_MODIFIER", 496, 501], ["lining", "ANATOMY_MODIFIER", 509, 515]]], ["It affects the sole (59%) and dorsum of the feet (41%) and toes (29%), sparing the interdigital spaces [214] .", [["dorsum", "ANATOMY", 30, 36], ["feet", "ANATOMY", 44, 48], ["dorsum", "ORGAN", 30, 36], ["feet", "ORGAN", 44, 48], ["toes", "PATHOLOGICAL_FORMATION", 59, 63], ["toes", "TEST", 59, 63], ["sole", "OBSERVATION_MODIFIER", 15, 19], ["dorsum", "ANATOMY_MODIFIER", 30, 36], ["feet", "ANATOMY", 44, 48], ["toes", "ANATOMY", 59, 63], ["interdigital", "ANATOMY_MODIFIER", 83, 95]]], ["Most often the lesions are symmetric.", [["lesions", "ANATOMY", 15, 22], ["lesions", "PATHOLOGICAL_FORMATION", 15, 22], ["lesions", "OBSERVATION", 15, 22], ["symmetric", "OBSERVATION", 27, 36]]], ["Common allergens in rubber shoes and boots are thiomersal [214] , MBT, BTS [102] , thiurams, carbamix [48] , mercaptans and PPDA [56] , and a shoe glue with 6.2% of reactions [7] .", [["thiomersal [214] , MBT", "CHEMICAL", 47, 69], ["BTS [102] , thiurams, carbamix [48] , mercaptans", "CHEMICAL", 71, 119], ["PPDA", "CHEMICAL", 124, 128], ["MBT", "CHEMICAL", 66, 69], ["BTS", "CHEMICAL", 71, 74], ["thiurams", "CHEMICAL", 83, 91], ["carbamix [48] , mercaptans", "CHEMICAL", 93, 119], ["PPDA", "CHEMICAL", 124, 128], ["BTS [102]", "SIMPLE_CHEMICAL", 71, 80], ["thiurams", "SIMPLE_CHEMICAL", 83, 91], ["carbamix [48] , mercaptans", "SIMPLE_CHEMICAL", 93, 119], ["PPDA [56]", "SIMPLE_CHEMICAL", 124, 133], ["Common allergens in rubber shoes", "TREATMENT", 0, 32], ["boots", "TREATMENT", 37, 42], ["MBT", "TEST", 66, 69], ["BTS", "TEST", 71, 74], ["thiurams", "TEST", 83, 91], ["carbamix", "TEST", 93, 101], ["mercaptans", "TREATMENT", 109, 119], ["a shoe glue", "TREATMENT", 140, 151], ["allergens", "OBSERVATION", 7, 16], ["rubber shoes", "OBSERVATION", 20, 32], ["boots", "ANATOMY", 37, 42]]], ["The condition is worsened by excessive foot sweating.Acute FormsClothing dermatitis depends on a wealth of sensitizers, including dyes, fabric finishes, mordents, resins, rubber antioxidants, detergents, especially cleansing solutions, synthetic fibers, wool fabric, linen, garments, socks, shirt collars and cuffs, and elastic in garments.", [["foot", "ANATOMY", 39, 43], ["fibers", "ANATOMY", 246, 252], ["cuffs", "ANATOMY", 309, 314], ["dermatitis", "DISEASE", 73, 83], ["foot", "ORGANISM_SUBDIVISION", 39, 43], ["cuffs", "TISSUE", 309, 314], ["excessive foot sweating", "PROBLEM", 29, 52], ["Acute FormsClothing dermatitis", "PROBLEM", 53, 83], ["dyes", "TREATMENT", 130, 134], ["mordents", "TREATMENT", 153, 161], ["resins", "TREATMENT", 163, 169], ["rubber antioxidants", "TREATMENT", 171, 190], ["detergents", "TREATMENT", 192, 202], ["cleansing solutions", "TREATMENT", 215, 234], ["synthetic fibers", "TREATMENT", 236, 252], ["shirt collars", "TREATMENT", 291, 304], ["cuffs", "TREATMENT", 309, 314], ["elastic in garments", "TREATMENT", 320, 339], ["worsened", "OBSERVATION_MODIFIER", 17, 25], ["excessive", "OBSERVATION_MODIFIER", 29, 38], ["foot", "ANATOMY", 39, 43], ["sweating", "OBSERVATION", 44, 52], ["dermatitis", "OBSERVATION", 73, 83], ["rubber antioxidants", "OBSERVATION", 171, 190]]], ["Obese children are more at risk.", [["Obese", "DISEASE", 0, 5], ["children", "ORGANISM", 6, 14], ["children", "SPECIES", 6, 14]]], ["Nitric substances and poorly fixed dyes may be leached out by sweating.", [["Nitric", "CHEMICAL", 0, 6], ["Nitric", "CHEMICAL", 0, 6], ["Nitric substances", "SIMPLE_CHEMICAL", 0, 17], ["Nitric substances", "TREATMENT", 0, 17], ["poorly fixed dyes", "TREATMENT", 22, 39], ["sweating", "PROBLEM", 62, 70]]], ["Clothing and accessories are implicated in 17% [7] and 56% [56] of pediatric cases.Acute FormsDye dermatitis (known since 1938) [86] .", [["FormsDye dermatitis", "DISEASE", 89, 108], ["Acute FormsDye dermatitis", "PROBLEM", 83, 108], ["dermatitis", "OBSERVATION", 98, 108]]], ["As in the clothing dermatitis, the affected areas are those where contact is prominent: neck, trunk, lateral and thigh posteromedial regions, popliteal space, antecubital space, the upper point of contact of stockings, or where other body parts come into contact with bed linen.Acute FormsDermatitis from plastic materials particularly include epoxypolymeric resins, diluent and thickenings used in dentistry (epoxyacrylate, methylacrylate and dimethylacrylate metylenglycol) [6] .", [["neck", "ANATOMY", 88, 92], ["trunk", "ANATOMY", 94, 99], ["thigh posteromedial regions", "ANATOMY", 113, 140], ["popliteal space", "ANATOMY", 142, 157], ["antecubital space", "ANATOMY", 159, 176], ["body parts", "ANATOMY", 234, 244], ["dermatitis", "DISEASE", 19, 29], ["FormsDermatitis", "DISEASE", 284, 299], ["epoxyacrylate, methylacrylate and dimethylacrylate metylenglycol", "CHEMICAL", 410, 474], ["epoxyacrylate", "CHEMICAL", 410, 423], ["methylacrylate", "CHEMICAL", 425, 439], ["dimethylacrylate metylenglycol", "CHEMICAL", 444, 474], ["neck", "ORGANISM_SUBDIVISION", 88, 92], ["trunk", "ORGANISM_SUBDIVISION", 94, 99], ["popliteal space", "MULTI-TISSUE_STRUCTURE", 142, 157], ["antecubital space", "MULTI-TISSUE_STRUCTURE", 159, 176], ["body", "ORGANISM_SUBDIVISION", 234, 238], ["epoxypolymeric resins", "SIMPLE_CHEMICAL", 344, 365], ["epoxyacrylate", "SIMPLE_CHEMICAL", 410, 423], ["methylacrylate", "SIMPLE_CHEMICAL", 425, 439], ["dimethylacrylate metylenglycol", "SIMPLE_CHEMICAL", 444, 474], ["the clothing dermatitis", "PROBLEM", 6, 29], ["the affected areas", "PROBLEM", 31, 49], ["stockings", "TREATMENT", 208, 217], ["Acute FormsDermatitis", "PROBLEM", 278, 299], ["plastic materials", "TREATMENT", 305, 322], ["epoxypolymeric resins", "TREATMENT", 344, 365], ["thickenings", "PROBLEM", 379, 390], ["epoxyacrylate", "TREATMENT", 410, 423], ["methylacrylate", "TREATMENT", 425, 439], ["dimethylacrylate metylenglycol)", "TREATMENT", 444, 475], ["clothing dermatitis", "OBSERVATION", 10, 29], ["affected", "OBSERVATION_MODIFIER", 35, 43], ["areas", "OBSERVATION_MODIFIER", 44, 49], ["neck", "ANATOMY", 88, 92], ["trunk", "ANATOMY", 94, 99], ["lateral", "ANATOMY_MODIFIER", 101, 108], ["thigh", "ANATOMY", 113, 118], ["posteromedial", "ANATOMY_MODIFIER", 119, 132], ["regions", "ANATOMY_MODIFIER", 133, 140], ["popliteal", "ANATOMY", 142, 151], ["space", "ANATOMY_MODIFIER", 152, 157], ["antecubital space", "ANATOMY", 159, 176], ["upper", "ANATOMY_MODIFIER", 182, 187], ["stockings", "OBSERVATION", 208, 217], ["FormsDermatitis", "OBSERVATION", 284, 299], ["plastic materials", "OBSERVATION", 305, 322]]], ["Artificial nails based on acrylate (similar to that employed in dentistry) can cause long-lasting finger burning, tingling, and paresthesia related to tactile sensitivity [74] .Acute FormsDermatitis from emollient and emulsifying agents found in cosmetics and topical medications such as oleic alcohol [127] .Acute FormsDermatitis from topical CSs may be unsuspected, particularly if the medication is being or has been applied for a pre-existing dermatitis, but it is diagnostic when tween 2.6% and 16.9%, and in atopic babies (2%) [218] .", [["nails", "ANATOMY", 11, 16], ["finger", "ANATOMY", 98, 104], ["acrylate", "CHEMICAL", 26, 34], ["paresthesia", "DISEASE", 128, 139], ["FormsDermatitis", "DISEASE", 183, 198], ["oleic alcohol", "CHEMICAL", 288, 301], ["FormsDermatitis", "DISEASE", 315, 330], ["dermatitis", "DISEASE", 447, 457], ["atopic babies", "DISEASE", 514, 527], ["acrylate", "CHEMICAL", 26, 34], ["oleic alcohol", "CHEMICAL", 288, 301], ["acrylate", "SIMPLE_CHEMICAL", 26, 34], ["finger", "ORGANISM_SUBDIVISION", 98, 104], ["oleic alcohol", "SIMPLE_CHEMICAL", 288, 301], ["Artificial nails", "TREATMENT", 0, 16], ["acrylate", "TREATMENT", 26, 34], ["finger burning", "PROBLEM", 98, 112], ["tingling", "PROBLEM", 114, 122], ["paresthesia", "PROBLEM", 128, 139], ["tactile sensitivity", "TEST", 151, 170], ["Acute FormsDermatitis", "PROBLEM", 177, 198], ["emollient", "TREATMENT", 204, 213], ["emulsifying agents", "TREATMENT", 218, 236], ["cosmetics", "TREATMENT", 246, 255], ["topical medications", "TREATMENT", 260, 279], ["Acute FormsDermatitis", "PROBLEM", 309, 330], ["topical CSs", "TREATMENT", 336, 347], ["the medication", "TREATMENT", 384, 398], ["a pre-existing dermatitis", "PROBLEM", 432, 457], ["nails", "OBSERVATION", 11, 16], ["FormsDermatitis", "OBSERVATION", 183, 198], ["emollient", "OBSERVATION_MODIFIER", 204, 213], ["FormsDermatitis", "OBSERVATION", 315, 330], ["dermatitis", "OBSERVATION", 447, 457]]], ["The increased incidence in children of latex allergy has recently been highlighted [112] .", [["latex allergy", "DISEASE", 39, 52], ["children", "ORGANISM", 27, 35], ["children", "SPECIES", 27, 35], ["latex allergy", "PROBLEM", 39, 52], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["incidence", "OBSERVATION_MODIFIER", 14, 23]]], ["Latex-specific IgE have been detected in 0.5%-10.2% of atopic children with IgE antibodies \u00b11,000 IU/ml; almost nobody was informed of any allergy before the visit [3] .", [["atopic", "DISEASE", 55, 61], ["allergy", "DISEASE", 139, 146], ["IgE", "GENE_OR_GENE_PRODUCT", 15, 18], ["children", "ORGANISM", 62, 70], ["IgE", "PROTEIN", 15, 18], ["IgE antibodies", "PROTEIN", 76, 90], ["children", "SPECIES", 62, 70], ["Latex", "TEST", 0, 5], ["IgE antibodies", "TREATMENT", 76, 90]]], ["SPTs are positive in 3%-6.8% of atopic children and specific IgE (sIgE) are elevated in positive challenges [152] .", [["atopic", "DISEASE", 32, 38], ["children", "ORGANISM", 39, 47], ["IgE", "GENE_OR_GENE_PRODUCT", 61, 64], ["IgE", "GENE_OR_GENE_PRODUCT", 67, 70], ["IgE", "PROTEIN", 61, 64], ["IgE", "PROTEIN", 67, 70], ["children", "SPECIES", 39, 47], ["SPTs", "TEST", 0, 4], ["atopic children", "TEST", 32, 47], ["specific IgE (sIgE", "TEST", 52, 70], ["elevated in positive challenges", "PROBLEM", 76, 107], ["positive", "OBSERVATION", 9, 17]]], ["The determination of sIgE (CAP) shows that 7.2% of 282 children are allergic.", [["allergic", "DISEASE", 68, 76], ["sIgE", "GENE_OR_GENE_PRODUCT", 21, 25], ["children", "ORGANISM", 55, 63], ["sIgE", "PROTEIN", 21, 25], ["children", "SPECIES", 55, 63], ["The determination of sIgE (CAP)", "TEST", 0, 31], ["allergic", "PROBLEM", 68, 76], ["allergic", "OBSERVATION", 68, 76]]], ["In this sample, the incidence among the atopic population varied between 1.69% and 9.5%, depending on the methodology used [66] .", [["atopic", "DISEASE", 40, 46], ["the atopic population", "TEST", 36, 57]]], ["The prevalence of IgE-mediated allergy in children with neurological abnormalities is the highest: sensitization is 18%-41%, with peaks up to 77.1% [112, 193] .", [["neurological", "ANATOMY", 56, 68], ["allergy", "DISEASE", 31, 38], ["neurological abnormalities", "DISEASE", 56, 82], ["IgE", "GENE_OR_GENE_PRODUCT", 18, 21], ["children", "ORGANISM", 42, 50], ["IgE", "PROTEIN", 18, 21], ["children", "SPECIES", 42, 50], ["IgE-mediated allergy", "PROBLEM", 18, 38], ["neurological abnormalities", "PROBLEM", 56, 82]]], ["Alternatively, atopy is present in 49% of sensitized and the initially improved ACD worsens without any apparent cause [2] .Acute FormsLatex dermatitis, latex hypersensitivity (generalized urticaria by a caoutchouc dental prosthesis), has been recognized since 1927 [198] .", [["atopy", "DISEASE", 15, 20], ["ACD", "DISEASE", 80, 83], ["dermatitis", "DISEASE", 141, 151], ["latex hypersensitivity", "DISEASE", 153, 175], ["urticaria", "DISEASE", 189, 198], ["atopy", "PROBLEM", 15, 20], ["Acute FormsLatex dermatitis", "PROBLEM", 124, 151], ["latex hypersensitivity", "PROBLEM", 153, 175], ["generalized urticaria", "PROBLEM", 177, 198], ["a caoutchouc dental prosthesis", "TREATMENT", 202, 232], ["FormsLatex dermatitis", "OBSERVATION", 130, 151], ["latex hypersensitivity", "OBSERVATION_MODIFIER", 153, 175], ["generalized", "OBSERVATION_MODIFIER", 177, 188], ["urticaria", "OBSERVATION", 189, 198]]], ["Natural latex (a variant of the original term \"latice,\" derived from the Latin root lact, due to its milky aspect) is obtained from Hevea brasiliensis: 17 allergens are listed in Table 1 .74 with a MW between 2 and 100 kD (Euphorbiaceae family) and 1% from Parthenium argentatum [216] .", [["latice", "ANATOMY", 47, 53], ["root lact", "ANATOMY", 79, 88], ["latice", "TISSUE", 47, 53], ["Hevea brasiliensis", "ORGANISM", 132, 150], ["Hevea brasiliensis", "SPECIES", 132, 150], ["Parthenium argentatum", "SPECIES", 257, 278], ["Hevea brasiliensis", "SPECIES", 132, 150], ["Parthenium argentatum", "SPECIES", 257, 278]]], ["The basic product contains natural rubber (33%), resin (2%), proteins (1.8%) and water (65%), to which ammonia is added up to 0.6% to prevent premature coagulation during transportation [216] .", [["ammonia", "CHEMICAL", 103, 110], ["premature coagulation", "DISEASE", 142, 163], ["ammonia", "CHEMICAL", 103, 110], ["water", "SIMPLE_CHEMICAL", 81, 86], ["ammonia", "SIMPLE_CHEMICAL", 103, 110], ["natural rubber", "TREATMENT", 27, 41], ["resin", "TEST", 49, 54], ["proteins", "TEST", 61, 69], ["ammonia", "TEST", 103, 110], ["premature coagulation", "PROBLEM", 142, 163], ["natural", "OBSERVATION_MODIFIER", 27, 34], ["rubber", "OBSERVATION_MODIFIER", 35, 41]]], ["During the industrial manufacture, many chemicals, such as vulcanizers, stabilizers, accelerators, antioxidants are added [216] .", [["the industrial manufacture", "TREATMENT", 7, 33], ["antioxidants", "TREATMENT", 99, 111]]], ["The worldwide increase in glove production following the advent of AIDS and now the poultry infection precautions has dramatically increased the prevalence of latex dermatitis [216] .", [["AIDS", "DISEASE", 67, 71], ["poultry infection", "DISEASE", 84, 101], ["latex dermatitis", "DISEASE", 159, 175], ["glove production", "TREATMENT", 26, 42], ["AIDS", "PROBLEM", 67, 71], ["the poultry infection precautions", "TREATMENT", 80, 113], ["latex dermatitis", "PROBLEM", 159, 175], ["worldwide", "OBSERVATION_MODIFIER", 4, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["glove production", "OBSERVATION", 26, 42], ["infection", "OBSERVATION", 92, 101], ["latex dermatitis", "OBSERVATION", 159, 175]]], ["All medical personnel at risk, as well as dentists, laboratory and health care workers must wear rubber (latex) gloves to prevent a potential contact with blood or body fluids throughout working hours, thus causing ACD in their patients [193] .", [["blood", "ANATOMY", 155, 160], ["body", "ANATOMY", 164, 168], ["ACD", "DISEASE", 215, 218], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["body", "ORGANISM_SUBDIVISION", 164, 168], ["fluids", "ORGANISM_SUBSTANCE", 169, 175], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["rubber (latex) gloves", "TREATMENT", 97, 118]]], ["For this reason, the use of condoms and diaphragms has also increased, with a great risk of sensitization [193, 218] .", [["diaphragms", "ANATOMY", 40, 50], ["diaphragms", "MULTI-TISSUE_STRUCTURE", 40, 50], ["condoms", "TREATMENT", 28, 35], ["diaphragms", "ANATOMY", 40, 50], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["great", "OBSERVATION_MODIFIER", 78, 83]]], ["Particularly exposed are operating-room workers because, in addition to the gloves, they have contact with catheters, tubes, cannulas, bags for anesthesia, etc. [114] .", [["catheters", "TREATMENT", 107, 116], ["tubes", "TREATMENT", 118, 123], ["cannulas", "TREATMENT", 125, 133], ["bags", "TREATMENT", 135, 139], ["anesthesia", "TREATMENT", 144, 154], ["tubes", "OBSERVATION", 118, 123]]], ["Among non-health care workers, there are industrial workers, housewives, customers of restaurants and food sales points, as well as consumers if the shopkeepers and dairy workers use latex gloves during their daily work [97] .Acute FormsPediatric groups at risk are in particular children exposed to some types of latex orthodontic appliance or undergoing surgical procedures, especially children with spina bifida or other urologic conditions, in whom reactions are common, due either to repeated surgery (contact with surgical gloves), or the frequent use of IV infusion sets, catheters and Rx procedures [193] .", [["spina bifida", "DISEASE", 402, 414], ["children", "ORGANISM", 280, 288], ["children", "ORGANISM", 388, 396], ["children", "SPECIES", 280, 288], ["children", "SPECIES", 388, 396], ["latex gloves", "TREATMENT", 183, 195], ["Acute FormsPediatric groups", "PROBLEM", 226, 253], ["latex orthodontic appliance", "TREATMENT", 314, 341], ["surgical procedures", "TREATMENT", 356, 375], ["spina bifida", "PROBLEM", 402, 414], ["other urologic conditions", "PROBLEM", 418, 443], ["repeated surgery", "TREATMENT", 489, 505], ["IV infusion sets", "TREATMENT", 561, 577], ["catheters and Rx procedures", "TREATMENT", 579, 606], ["orthodontic appliance", "OBSERVATION", 320, 341]]], ["In children and adolescents affected with myelomeningocele, which is associated with immature defense mechanisms of the mucous membranes [66] , the principal risk factors were the number of surgical procedures, atopy and/or sensitization to latex [167] : 60% of children had reactions outside of the operating room environment [112] .", [["mucous membranes", "ANATOMY", 120, 136], ["myelomeningocele", "DISEASE", 42, 58], ["children", "ORGANISM", 3, 11], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 120, 136], ["children", "ORGANISM", 262, 270], ["children", "SPECIES", 3, 11], ["adolescents", "SPECIES", 16, 27], ["children", "SPECIES", 262, 270], ["myelomeningocele", "PROBLEM", 42, 58], ["immature defense mechanisms of the mucous membranes", "PROBLEM", 85, 136], ["surgical procedures", "TREATMENT", 190, 209], ["atopy", "PROBLEM", 211, 216], ["latex", "TEST", 241, 246], ["myelomeningocele", "OBSERVATION", 42, 58], ["associated with", "UNCERTAINTY", 69, 84], ["immature defense", "OBSERVATION", 85, 101], ["mucous membranes", "ANATOMY", 120, 136]]], ["Children become sensitized mainly by direct contact between latex particles and blood vessels and open mucosa, whereas in adults the process takes place transcutaneously or by inhalation of aerosol particles [150] .", [["blood vessels", "ANATOMY", 80, 93], ["mucosa", "ANATOMY", 103, 109], ["Children", "ORGANISM", 0, 8], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 80, 93], ["mucosa", "MULTI-TISSUE_STRUCTURE", 103, 109], ["Children", "SPECIES", 0, 8], ["open mucosa", "PROBLEM", 98, 109], ["vessels", "ANATOMY", 86, 93], ["mucosa", "ANATOMY", 103, 109]]], ["Tables 8.10-8.12 [97, 109] show how latex allergy also develops to an incredible number of objects in common use [126, 132, 218] .Acute FormsAmong the population considered to be at risk are health care professionals, where the incidence is be-569 Allergic Contact Dermatitis 30% of nonsensitized patients, with statistically significant differences related to allergic reactions to latex, in 96% and 30% of cases, respectively [193] .", [["latex allergy", "DISEASE", 36, 49], ["Dermatitis", "DISEASE", 265, 275], ["allergic reactions", "DISEASE", 361, 379], ["patients", "ORGANISM", 297, 305], ["patients", "SPECIES", 297, 305], ["how latex allergy", "PROBLEM", 32, 49], ["Acute FormsAmong the population", "PROBLEM", 130, 161], ["Allergic Contact Dermatitis", "PROBLEM", 248, 275], ["allergic reactions", "PROBLEM", 361, 379], ["latex", "TEST", 383, 388], ["incredible", "OBSERVATION_MODIFIER", 70, 80], ["number", "OBSERVATION_MODIFIER", 81, 87], ["allergic", "OBSERVATION", 361, 369]]], ["The report of one case of anaphylaxis in 646 surgical procedures over 18 years is reassuring [167] , but latex-induced anaphylaxis occurred in 10% of patients >5 [124] .A severe anaphylactic shock occurred in an 8-year-old boy who was undergoing elective surgery for an ileostomy [94] .", [["anaphylaxis", "DISEASE", 26, 37], ["anaphylaxis", "DISEASE", 119, 130], ["anaphylactic shock", "DISEASE", 178, 196], ["patients", "ORGANISM", 150, 158], ["boy", "ORGANISM", 223, 226], ["patients", "SPECIES", 150, 158], ["boy", "SPECIES", 223, 226], ["anaphylaxis", "PROBLEM", 26, 37], ["surgical procedures", "TREATMENT", 45, 64], ["latex", "TEST", 105, 110], ["anaphylaxis", "PROBLEM", 119, 130], ["A severe anaphylactic shock", "PROBLEM", 169, 196], ["elective surgery", "TREATMENT", 246, 262], ["an ileostomy", "TREATMENT", 267, 279], ["anaphylaxis", "OBSERVATION", 119, 130], ["severe", "OBSERVATION_MODIFIER", 171, 177], ["anaphylactic shock", "OBSERVATION", 178, 196], ["ileostomy", "OBSERVATION", 270, 279]]], ["Type IV hypersensitivity to natural rubber latex may be a problem for a proportion of patients with eczema, particularly on their hands [195] .", [["hypersensitivity", "DISEASE", 8, 24], ["eczema", "DISEASE", 100, 106], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["Type IV hypersensitivity", "PROBLEM", 0, 24], ["natural rubber latex", "TREATMENT", 28, 48], ["eczema", "PROBLEM", 100, 106], ["eczema", "OBSERVATION", 100, 106]]], ["The incidence of latex allergy in the general population is unknown, but it seems to be about 0.001%, with a frequency of 0.125% in unselected surgical patients [218] .Acute FormsThe immunological mechanism is IgE-mediated [3, 43, 112, 196] , especially in children: serum sIgE are detected to natural latex [97, 196] , SPT, ELISA, and RAST.", [["serum", "ANATOMY", 267, 272], ["latex allergy", "DISEASE", 17, 30], ["patients", "ORGANISM", 152, 160], ["IgE", "GENE_OR_GENE_PRODUCT", 210, 213], ["children", "ORGANISM", 257, 265], ["serum", "ORGANISM_SUBSTANCE", 267, 272], ["sIgE", "GENE_OR_GENE_PRODUCT", 273, 277], ["IgE", "PROTEIN", 210, 213], ["serum sIgE", "PROTEIN", 267, 277], ["RAST", "PROTEIN", 336, 340], ["patients", "SPECIES", 152, 160], ["children", "SPECIES", 257, 265], ["latex allergy", "PROBLEM", 17, 30], ["Acute Forms", "PROBLEM", 168, 179], ["serum sIgE", "TEST", 267, 277], ["natural latex", "TEST", 294, 307], ["SPT, ELISA", "TEST", 320, 330], ["latex allergy", "OBSERVATION", 17, 30]]], ["RAST inhibition is also positive.", [["RAST", "GENE_OR_GENE_PRODUCT", 0, 4], ["RAST", "PROTEIN", 0, 4], ["RAST inhibition", "TEST", 0, 15], ["positive", "OBSERVATION", 24, 32]]], ["Latex exposure may occur by cutaneous, percutaneous, mucosal, parenteral, and respiratory (from inhaling latex glove powder) routes [97] .", [["cutaneous", "ANATOMY", 28, 37], ["percutaneous", "ANATOMY", 39, 51], ["mucosal", "ANATOMY", 53, 60], ["respiratory", "ANATOMY", 78, 89], ["mucosal", "MULTI-TISSUE_STRUCTURE", 53, 60], ["Latex exposure", "TREATMENT", 0, 14], ["percutaneous, mucosal, parenteral, and respiratory (from inhaling latex glove powder", "TREATMENT", 39, 123], ["mucosal", "ANATOMY", 53, 60], ["respiratory", "ANATOMY", 78, 89]]], ["By the respiratory route, the reaction is materialized within a few minutes with a progression of symptoms from rhinitis, wheezing, conjunctivitis, facial angioedema, to generalized urticaria and symptoms of anaphylactic reaction up to severe generalized reactions (Table 8 .13) [160, 216] .", [["facial", "ANATOMY", 148, 154], ["rhinitis", "DISEASE", 112, 120], ["wheezing", "DISEASE", 122, 130], ["conjunctivitis", "DISEASE", 132, 146], ["facial angioedema", "DISEASE", 148, 165], ["urticaria", "DISEASE", 182, 191], ["anaphylactic reaction", "DISEASE", 208, 229], ["the reaction", "PROBLEM", 26, 38], ["symptoms", "PROBLEM", 98, 106], ["rhinitis", "PROBLEM", 112, 120], ["wheezing", "PROBLEM", 122, 130], ["conjunctivitis", "PROBLEM", 132, 146], ["facial angioedema", "PROBLEM", 148, 165], ["generalized urticaria", "PROBLEM", 170, 191], ["symptoms", "PROBLEM", 196, 204], ["anaphylactic reaction", "PROBLEM", 208, 229], ["severe generalized reactions", "PROBLEM", 236, 264], ["rhinitis", "OBSERVATION", 112, 120], ["conjunctivitis", "OBSERVATION", 132, 146], ["facial", "ANATOMY", 148, 154], ["angioedema", "OBSERVATION", 155, 165], ["generalized", "OBSERVATION_MODIFIER", 170, 181], ["urticaria", "OBSERVATION", 182, 191]]], ["Latex allergens in respirable particulate air pollution from tires rubbing on roads is a cause of significant respiratory reactions [239] , as also is cornstarch powder on latex products for glove lubrication [205] .", [["respiratory", "ANATOMY", 110, 121], ["Latex allergens", "PROBLEM", 0, 15], ["respirable particulate air pollution", "PROBLEM", 19, 55], ["significant respiratory reactions", "PROBLEM", 98, 131], ["cornstarch powder", "TREATMENT", 151, 168], ["latex products", "TREATMENT", 172, 186], ["glove lubrication", "TREATMENT", 191, 208], ["respirable", "OBSERVATION_MODIFIER", 19, 29], ["particulate", "OBSERVATION_MODIFIER", 30, 41], ["air pollution", "OBSERVATION", 42, 55], ["significant", "OBSERVATION_MODIFIER", 98, 109], ["respiratory reactions", "OBSERVATION", 110, 131]]], ["Skin exposure induces prevalently ACD symptoms [97, 152, 193] , but the latex-fruit and latex-vegetable syndrome provokes anaphylaxis also in children.", [["Skin", "ANATOMY", 0, 4], ["vegetable syndrome", "DISEASE", 94, 112], ["anaphylaxis", "DISEASE", 122, 133], ["Skin", "ORGAN", 0, 4], ["vegetable", "ORGANISM_SUBDIVISION", 94, 103], ["children", "ORGANISM", 142, 150], ["children", "SPECIES", 142, 150], ["Skin exposure", "PROBLEM", 0, 13], ["prevalently ACD symptoms", "PROBLEM", 22, 46], ["the latex", "TEST", 68, 77], ["latex", "TEST", 88, 93], ["vegetable syndrome", "PROBLEM", 94, 112], ["anaphylaxis", "PROBLEM", 122, 133], ["vegetable syndrome", "OBSERVATION", 94, 112], ["anaphylaxis", "OBSERVATION", 122, 133]]], ["Anaphylaxis burst occurred within 5 min in a girl playing ball [126] , as well as in a girl and a boy playing with a plastic ball in play areas [73] and in allergic adults [25] , and facial edema in a boy blowing up a balloon [196] .", [["facial edema", "ANATOMY", 183, 195], ["Anaphylaxis", "DISEASE", 0, 11], ["allergic", "DISEASE", 156, 164], ["facial edema", "DISEASE", 183, 195], ["edema", "PATHOLOGICAL_FORMATION", 190, 195], ["girl", "SPECIES", 45, 49], ["girl", "SPECIES", 87, 91], ["boy", "SPECIES", 98, 101], ["Anaphylaxis burst", "PROBLEM", 0, 17], ["a plastic ball", "TREATMENT", 115, 129], ["facial edema", "PROBLEM", 183, 195], ["facial", "ANATOMY", 183, 189], ["edema", "OBSERVATION", 190, 195]]], ["Recently, a profilin has been identified as a component of natural latex, structurally correlated to profilins of different origin found in foods and pollens [220] (Table 1.", [["profilin", "GENE_OR_GENE_PRODUCT", 12, 20], ["profilin", "PROTEIN", 12, 20], ["a profilin", "TREATMENT", 10, 20], ["natural latex", "PROBLEM", 59, 72]]], ["72) , and associated with cross-reactivity between latex, taxonomically unrelated plants and several fruits and nonfruits (Table 8.", [["fruits", "ANATOMY", 101, 107], ["fruits", "ORGANISM_SUBDIVISION", 101, 107], ["latex", "TREATMENT", 51, 56]]], ["A latex-fruit syndrome was reported by 55.9% of latex-allergic patients [36] .", [["latex-fruit syndrome", "DISEASE", 2, 22], ["allergic", "DISEASE", 54, 62], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["A latex-fruit syndrome", "PROBLEM", 0, 22], ["latex", "TEST", 48, 53], ["fruit syndrome", "OBSERVATION", 8, 22]]], ["In Appendix 8.2, we indicate [36] the employment procedures of some extracts: papain and chymopapain are associated with anaphylaxis, as analyzed in Chap.", [["extracts", "ANATOMY", 68, 76], ["chymopapain", "CHEMICAL", 89, 100], ["anaphylaxis", "DISEASE", 121, 132], ["extracts", "ORGANISM_SUBSTANCE", 68, 76], ["papain", "GENE_OR_GENE_PRODUCT", 78, 84], ["chymopapain", "SIMPLE_CHEMICAL", 89, 100], ["Appendix", "TEST", 3, 11], ["papain", "TREATMENT", 78, 84], ["chymopapain", "TREATMENT", 89, 100], ["anaphylaxis", "PROBLEM", 121, 132], ["Appendix", "ANATOMY", 3, 11], ["chymopapain", "OBSERVATION", 89, 100], ["anaphylaxis", "OBSERVATION", 121, 132]]], ["20.Acute FormsOccupational ACD.", [["Acute FormsOccupational ACD", "PROBLEM", 3, 30], ["FormsOccupational ACD", "OBSERVATION", 9, 30]]], ["In children of 13-14 years, the hairdressers among them were allergic to PPD, Ni, thiuram; construction workers to Cr, cement, Co; in food industry workers, some were allergic to garlic and Ni; in the footwear industry the problem came from Cr, Co, and Ni; in the ceramic industry it was Co and Ni [85] .", [["allergic", "DISEASE", 61, 69], ["PPD", "CHEMICAL", 73, 76], ["Ni", "CHEMICAL", 78, 80], ["thiuram", "CHEMICAL", 82, 89], ["Cr", "CHEMICAL", 115, 117], ["Co", "CHEMICAL", 127, 129], ["allergic", "DISEASE", 167, 175], ["garlic", "CHEMICAL", 179, 185], ["Ni", "CHEMICAL", 190, 192], ["Cr", "CHEMICAL", 241, 243], ["Co", "CHEMICAL", 245, 247], ["Ni", "CHEMICAL", 253, 255], ["Co", "CHEMICAL", 288, 290], ["Ni", "CHEMICAL", 295, 297], ["PPD", "CHEMICAL", 73, 76], ["Ni", "CHEMICAL", 78, 80], ["thiuram", "CHEMICAL", 82, 89], ["Cr", "CHEMICAL", 115, 117], ["Co", "CHEMICAL", 127, 129], ["Ni", "CHEMICAL", 190, 192], ["Cr", "CHEMICAL", 241, 243], ["Co", "CHEMICAL", 245, 247], ["Ni", "CHEMICAL", 253, 255], ["Co", "CHEMICAL", 288, 290], ["Ni", "CHEMICAL", 295, 297], ["children", "ORGANISM", 3, 11], ["Cr", "SIMPLE_CHEMICAL", 115, 117], ["garlic", "SIMPLE_CHEMICAL", 179, 185], ["Cr", "SIMPLE_CHEMICAL", 241, 243], ["Co", "SIMPLE_CHEMICAL", 245, 247], ["Ni", "SIMPLE_CHEMICAL", 253, 255], ["Co", "SIMPLE_CHEMICAL", 288, 290], ["Ni [85]", "SIMPLE_CHEMICAL", 295, 302], ["children", "SPECIES", 3, 11], ["garlic", "SPECIES", 179, 185], ["allergic", "PROBLEM", 61, 69], ["allergic", "PROBLEM", 167, 175]]], ["Other working adolescents were allergic to metal accessories (37%), medicaments (8.1%), cosmetics (5.4%) and shoes (4.5%) [199] .", [["allergic", "DISEASE", 31, 39], ["adolescents", "ORGANISM", 14, 25], ["allergic", "PROBLEM", 31, 39], ["metal accessories", "TREATMENT", 43, 60], ["medicaments", "TREATMENT", 68, 79], ["cosmetics", "TREATMENT", 88, 97]]], ["Skin-diver dermatitis is elicited by the equipment (diving mask, fins, etc.).", [["Skin", "ANATOMY", 0, 4], ["fins", "ANATOMY", 65, 69], ["dermatitis", "DISEASE", 11, 21], ["Skin", "ORGAN", 0, 4], ["fins", "ORGANISM_SUBDIVISION", 65, 69], ["diver dermatitis", "PROBLEM", 5, 21], ["diving mask", "TREATMENT", 52, 63], ["diver dermatitis", "OBSERVATION", 5, 21]]], ["The effect is caused by constituents such as dithiocarbamates, formaldehyde, isopropyl-phenylparaphenylendiamine, mercaptobenzol, butylphenolformaldehyc resin, thiourams, etc. [7] .DiagnosisIn establishing an etiological diagnosis, it is crucial to begin with a careful, exhaustive history, the single most important and cost-effective diagnostic tool, including family and personal history, to be completed at subsequent visits.", [["dithiocarbamates", "CHEMICAL", 45, 61], ["formaldehyde, isopropyl-phenylparaphenylendiamine", "CHEMICAL", 63, 112], ["mercaptobenzol", "CHEMICAL", 114, 128], ["thiourams", "CHEMICAL", 160, 169], ["dithiocarbamates", "CHEMICAL", 45, 61], ["formaldehyde", "CHEMICAL", 63, 75], ["isopropyl-phenylparaphenylendiamine", "CHEMICAL", 77, 112], ["mercaptobenzol", "CHEMICAL", 114, 128], ["butylphenolformaldehyc", "CHEMICAL", 130, 152], ["thiourams", "CHEMICAL", 160, 169], ["dithiocarbamates", "SIMPLE_CHEMICAL", 45, 61], ["formaldehyde", "SIMPLE_CHEMICAL", 63, 75], ["isopropyl-phenylparaphenylendiamine", "SIMPLE_CHEMICAL", 77, 112], ["mercaptobenzol", "SIMPLE_CHEMICAL", 114, 128], ["butylphenolformaldehyc resin", "SIMPLE_CHEMICAL", 130, 158], ["thiourams", "SIMPLE_CHEMICAL", 160, 169], ["dithiocarbamates", "TREATMENT", 45, 61], ["formaldehyde", "TREATMENT", 63, 75], ["isopropyl", "TREATMENT", 77, 86], ["phenylparaphenylendiamine", "TREATMENT", 87, 112], ["mercaptobenzol", "TREATMENT", 114, 128], ["butylphenolformaldehyc resin", "TREATMENT", 130, 158]]], ["A clinical history of redness, itching, or swelling, or of unexplained urticaria or anaphylaxis after contact with a specific product suggests that a detailed history can be useful for the identification of allergic children.", [["redness", "DISEASE", 22, 29], ["itching", "DISEASE", 31, 38], ["swelling", "DISEASE", 43, 51], ["urticaria", "DISEASE", 71, 80], ["anaphylaxis", "DISEASE", 84, 95], ["allergic", "DISEASE", 207, 215], ["children", "ORGANISM", 216, 224], ["children", "SPECIES", 216, 224], ["redness", "PROBLEM", 22, 29], ["itching", "PROBLEM", 31, 38], ["swelling", "PROBLEM", 43, 51], ["unexplained urticaria", "PROBLEM", 59, 80], ["anaphylaxis", "PROBLEM", 84, 95], ["allergic children", "PROBLEM", 207, 224], ["redness", "OBSERVATION", 22, 29], ["itching", "OBSERVATION", 31, 38], ["swelling", "OBSERVATION", 43, 51], ["unexplained", "OBSERVATION_MODIFIER", 59, 70], ["urticaria", "OBSERVATION", 71, 80], ["anaphylaxis", "OBSERVATION", 84, 95]]], ["All children and parents should be questioned. \u2211 Does the child have a history of atopic disease? \u2211 What product was there contact with and how often? \u2211 Is a relation with a particular activity or environment suspected? 571 Allergic Contact Dermatitis \u2211 Are diapers, chemical products, detergents, cosmetics, ornaments, etc. used? \u2211 Does the infant use rubber pacifiers or do children play ball? \u2211 What type of clothing, shoes, gloves, etc. are used? \u2211 When a latex allergy is suspected, is there a history of allergy to fruits (Table 8 .14)? \u2211 What is the course of the disease? \u2211 Have topical medications been applied for an ongoing episode or an earlier skin disease? \u2211 Was symptom onset after ingestion of foods containing substances that formerly induced a skin disease? \u2211 Is ACD caused by cross-reactivity [56] ?DiagnosisThe medical examination is essential to exclude other skin conditions with lesion aspect and distribution similar to those of ACD.", [["fruits", "ANATOMY", 521, 527], ["skin", "ANATOMY", 657, 661], ["skin", "ANATOMY", 762, 766], ["skin", "ANATOMY", 881, 885], ["lesion", "ANATOMY", 902, 908], ["atopic disease", "DISEASE", 82, 96], ["Allergic Contact Dermatitis", "DISEASE", 224, 251], ["latex allergy", "DISEASE", 460, 473], ["allergy", "DISEASE", 510, 517], ["skin disease", "DISEASE", 762, 774], ["ACD", "DISEASE", 781, 784], ["ACD", "DISEASE", 953, 956], ["children", "ORGANISM", 4, 12], ["infant", "ORGANISM", 342, 348], ["children", "ORGANISM", 376, 384], ["fruits", "ORGANISM_SUBDIVISION", 521, 527], ["skin", "ORGAN", 657, 661], ["skin", "ORGAN", 762, 766], ["skin", "ORGAN", 881, 885], ["children", "SPECIES", 4, 12], ["infant", "SPECIES", 342, 348], ["children", "SPECIES", 376, 384], ["atopic disease", "PROBLEM", 82, 96], ["Allergic Contact Dermatitis", "PROBLEM", 224, 251], ["chemical products", "TREATMENT", 267, 284], ["gloves", "TREATMENT", 428, 434], ["a latex allergy", "PROBLEM", 458, 473], ["allergy", "PROBLEM", 510, 517], ["the disease", "PROBLEM", 567, 578], ["topical medications", "TREATMENT", 587, 606], ["an ongoing episode", "PROBLEM", 624, 642], ["an earlier skin disease", "PROBLEM", 646, 669], ["a skin disease", "PROBLEM", 760, 774], ["The medical examination", "TEST", 827, 850], ["other skin conditions", "PROBLEM", 875, 896], ["lesion aspect", "PROBLEM", 902, 915], ["atopic disease", "OBSERVATION", 82, 96], ["Contact Dermatitis", "OBSERVATION", 233, 251], ["disease", "OBSERVATION", 571, 578], ["skin", "ANATOMY", 657, 661], ["disease", "OBSERVATION", 662, 669], ["skin", "ANATOMY", 762, 766], ["disease", "OBSERVATION", 767, 774], ["skin", "ANATOMY", 881, 885], ["lesion", "OBSERVATION", 902, 908]]], ["In younger children the diagnosis, apart from diaper dermatitis, is facilitated by the restricted panel of age-related foreign substances to be uncovered: \u2211 Babies starting to crawl may develop leg, knee and elbow dermatitis, by contact with wax or detergents for floors, components of rugs and wall-to-wall carpeting, etc. \u2211 Babies and young children may touch or caress parents, relatives, or baby-sitters who use cosmetics, fragrances, deodorants, etc.DiagnosisPoints to be considered: \u2211 Little girls have ear-lobes pierced for earrings. \u2211 Children and adolescents of both sexes wear jeans with metal buttons or other trimmings. \u2211 Early use of cosmetics, etc. In Belgian participants, the mean age of cosmetic allergy was 12.4 years; however, earlier cases were detected at age 4 [56] . \u2211 Topical medications, also for trivial skin lesions or ear pain, are typically used more frequently compared to adults. \u2211 Similarly, orthodontic treatments are more frequent in children.DiagnosisACD diagnosis related to lesion topography (Table 8.9): \u2211 Face and neck ACD.", [["leg", "ANATOMY", 194, 197], ["knee", "ANATOMY", 199, 203], ["elbow", "ANATOMY", 208, 213], ["wall", "ANATOMY", 295, 299], ["wall", "ANATOMY", 303, 307], ["ear-lobes", "ANATOMY", 509, 518], ["skin lesions", "ANATOMY", 830, 842], ["ear", "ANATOMY", 846, 849], ["lesion", "ANATOMY", 1011, 1017], ["neck", "ANATOMY", 1053, 1057], ["diaper dermatitis", "DISEASE", 46, 63], ["dermatitis", "DISEASE", 214, 224], ["allergy", "DISEASE", 713, 720], ["ear pain", "DISEASE", 846, 854], ["children", "ORGANISM", 11, 19], ["leg", "ORGANISM_SUBDIVISION", 194, 197], ["knee", "ORGANISM_SUBDIVISION", 199, 203], ["elbow", "ORGANISM_SUBDIVISION", 208, 213], ["Babies", "ORGANISM", 326, 332], ["children", "ORGANISM", 343, 351], ["ear-lobes", "MULTI-TISSUE_STRUCTURE", 509, 518], ["Children", "ORGANISM", 543, 551], ["skin lesions", "PATHOLOGICAL_FORMATION", 830, 842], ["ear", "ORGAN", 846, 849], ["children", "ORGANISM", 968, 976], ["children", "SPECIES", 11, 19], ["Babies", "SPECIES", 326, 332], ["children", "SPECIES", 343, 351], ["girls", "SPECIES", 498, 503], ["Children", "SPECIES", 543, 551], ["adolescents", "SPECIES", 556, 567], ["participants", "SPECIES", 674, 686], ["children", "SPECIES", 968, 976], ["diaper dermatitis", "PROBLEM", 46, 63], ["leg, knee and elbow dermatitis", "PROBLEM", 194, 224], ["rugs", "TREATMENT", 286, 290], ["Topical medications", "TREATMENT", 792, 811], ["trivial skin lesions", "PROBLEM", 822, 842], ["ear pain", "PROBLEM", 846, 854], ["orthodontic treatments", "TREATMENT", 924, 946], ["lesion topography", "TEST", 1011, 1028], ["Face and neck ACD", "PROBLEM", 1044, 1061], ["diaper", "ANATOMY", 46, 52], ["dermatitis", "OBSERVATION", 53, 63], ["foreign substances", "OBSERVATION", 119, 137], ["leg", "ANATOMY", 194, 197], ["knee", "ANATOMY", 199, 203], ["elbow", "ANATOMY", 208, 213], ["dermatitis", "OBSERVATION", 214, 224], ["ear", "ANATOMY", 509, 512], ["lobes", "ANATOMY_MODIFIER", 513, 518], ["trivial", "OBSERVATION_MODIFIER", 822, 829], ["skin", "ANATOMY", 830, 834], ["lesions", "OBSERVATION", 835, 842], ["ear", "ANATOMY", 846, 849], ["pain", "OBSERVATION", 850, 854], ["lesion", "OBSERVATION", 1011, 1017], ["Face", "ANATOMY", 1044, 1048], ["neck", "ANATOMY", 1053, 1057], ["ACD", "OBSERVATION", 1058, 1061]]], ["This localization may disclose diagnostic difficulties because several agents are potentially acting: contact and photocontact substances, cosmetics and costume jewelry should be taken into account [57] .", [["diagnostic difficulties", "PROBLEM", 31, 54], ["costume jewelry", "TREATMENT", 153, 168]]], ["The application of chemical substances to the scalp can induce manifestations in distant sites such as the face, ears and neck.", [["scalp", "ANATOMY", 46, 51], ["sites", "ANATOMY", 89, 94], ["face", "ANATOMY", 107, 111], ["ears", "ANATOMY", 113, 117], ["neck", "ANATOMY", 122, 126], ["scalp", "ORGAN", 46, 51], ["sites", "MULTI-TISSUE_STRUCTURE", 89, 94], ["face", "ORGANISM_SUBDIVISION", 107, 111], ["ears", "ORGAN", 113, 117], ["neck", "ORGAN", 122, 126], ["chemical substances", "TREATMENT", 19, 38], ["manifestations in distant sites such as the face, ears and neck", "PROBLEM", 63, 126], ["chemical substances", "OBSERVATION", 19, 38], ["scalp", "ANATOMY", 46, 51], ["face", "ANATOMY", 107, 111], ["ears", "ANATOMY", 113, 117], ["neck", "ANATOMY", 122, 126]]], ["Shampoos and hair gels may provoke helix reactions. ear piercing facilitates Ni sensitization [47] and is a risk factor for AIDS. \u2211 Hand ACD.", [["hair", "ANATOMY", 13, 17], ["ear", "ANATOMY", 52, 55], ["Ni", "CHEMICAL", 77, 79], ["AIDS", "DISEASE", 124, 128], ["Ni", "CHEMICAL", 77, 79], ["Shampoos", "SIMPLE_CHEMICAL", 0, 8], ["ear", "ORGAN", 52, 55], ["Shampoos", "TREATMENT", 0, 8], ["hair gels", "PROBLEM", 13, 22], ["helix reactions", "PROBLEM", 35, 50], ["AIDS", "PROBLEM", 124, 128], ["Hand ACD", "PROBLEM", 132, 140], ["ACD", "OBSERVATION", 137, 140]]], ["About 50% of cases involve the hand, generally on the back, whereas the wrist is involved when objects are taken.", [["hand", "ANATOMY", 31, 35], ["wrist", "ANATOMY", 72, 77], ["hand", "ORGANISM_SUBDIVISION", 31, 35], ["back", "ORGANISM_SUBDIVISION", 54, 58], ["wrist", "ORGANISM_SUBDIVISION", 72, 77], ["hand", "ANATOMY", 31, 35], ["back", "ANATOMY", 54, 58], ["wrist", "ANATOMY", 72, 77]]], ["It is chiefly caused by the use of rubber gloves, cleaning products, cosmetics, but any of these substances can be the cause.", [["rubber gloves", "TREATMENT", 35, 48], ["cleaning products", "TREATMENT", 50, 67], ["cosmetics", "TREATMENT", 69, 78], ["rubber gloves", "OBSERVATION", 35, 48]]], ["Hand dermatitis is frequent in girls and boys helping in housework or in family shops (see protein contact dermatitis, PCD), in girls working as apprentice hairdressers, in boys helping bricklayers, mechanics, barmen, and the like [172, 200] , and above all the Europeans using Ni-containing coins: euro cents. \u2211 Foot ACD.", [["Hand dermatitis", "DISEASE", 0, 15], ["dermatitis", "DISEASE", 107, 117], ["PCD", "DISEASE", 119, 122], ["girls", "SPECIES", 31, 36], ["boys", "SPECIES", 41, 45], ["girls", "SPECIES", 128, 133], ["boys", "SPECIES", 173, 177], ["Hand dermatitis", "PROBLEM", 0, 15], ["Foot ACD", "PROBLEM", 313, 321], ["dermatitis", "OBSERVATION", 5, 15], ["frequent", "OBSERVATION_MODIFIER", 19, 27], ["Foot", "ANATOMY", 313, 317], ["ACD", "OBSERVATION", 318, 321]]], ["The typical location on the back and at joints does not offer diagnostic problems.", [["back", "ANATOMY", 28, 32], ["joints", "ANATOMY", 40, 46], ["back", "ORGANISM_SUBDIVISION", 28, 32], ["joints", "MULTI-TISSUE_STRUCTURE", 40, 46], ["diagnostic problems", "PROBLEM", 62, 81], ["typical", "OBSERVATION_MODIFIER", 4, 11], ["location", "OBSERVATION_MODIFIER", 12, 20], ["back", "ANATOMY", 28, 32], ["joints", "ANATOMY", 40, 46]]], ["Causative agents are those found in rubber shoes, shoe creams (see description of shoe dermatitis in preceding section) or in the coloring agent both of shoes and stockings. \u2211 Generalized and/or unusual pictures.", [["dermatitis", "DISEASE", 87, 97], ["Causative agents", "TREATMENT", 0, 16], ["shoe creams", "TREATMENT", 50, 61], ["shoe dermatitis", "PROBLEM", 82, 97], ["stockings", "TREATMENT", 163, 172], ["Generalized and/or unusual pictures", "PROBLEM", 176, 211], ["rubber shoes", "OBSERVATION", 36, 48], ["dermatitis", "OBSERVATION", 87, 97], ["stockings", "OBSERVATION", 163, 172]]], ["These are attributable to ubiquitous substances such as those in rubber (see the related additives) able to produce lesions at several sites, including the face (sponges for make-up, ear plugs, etc.), periocular region (goggles for motorcyclists, swimmers, skin-divers, etc.), thorax and belly (elasticized underwear), genitals (underwear, condom, diaphragm, pessary, etc.), legs (elasticized stockings), and dyes and other cloth constituents often unsuspected and difficult to diagnose.DiagnosisParticular contact lesions are caused in children and adolescents of both sexes by piercing, at all ages by substances employed for oral and dental hygiene and in dentistry: soaps, detergents, toothpaste, anesthetics, metallic plates and screws, and ear drops in children [172] .", [["lesions", "ANATOMY", 116, 123], ["sites", "ANATOMY", 135, 140], ["ear", "ANATOMY", 183, 186], ["periocular region", "ANATOMY", 201, 218], ["skin", "ANATOMY", 257, 261], ["thorax", "ANATOMY", 277, 283], ["belly", "ANATOMY", 288, 293], ["genitals", "ANATOMY", 319, 327], ["diaphragm", "ANATOMY", 348, 357], ["legs", "ANATOMY", 375, 379], ["DiagnosisParticular contact lesions", "ANATOMY", 487, 522], ["oral", "ANATOMY", 628, 632], ["ear", "ANATOMY", 746, 749], ["lesions", "PATHOLOGICAL_FORMATION", 116, 123], ["ear", "ORGAN", 183, 186], ["skin", "ORGAN", 257, 261], ["thorax", "ORGAN", 277, 283], ["belly", "ORGANISM_SUBDIVISION", 288, 293], ["genitals", "ORGANISM_SUBDIVISION", 319, 327], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 348, 357], ["legs", "ORGANISM_SUBDIVISION", 375, 379], ["contact lesions", "PATHOLOGICAL_FORMATION", 507, 522], ["children", "ORGANISM", 537, 545], ["oral", "ORGANISM_SUBDIVISION", 628, 632], ["ear", "ORGAN", 746, 749], ["children", "ORGANISM", 759, 767], ["children", "SPECIES", 537, 545], ["adolescents", "SPECIES", 550, 561], ["children", "SPECIES", 759, 767], ["ubiquitous substances", "PROBLEM", 26, 47], ["lesions at several sites", "PROBLEM", 116, 140], ["ear plugs", "PROBLEM", 183, 192], ["thorax and belly (elasticized underwear", "PROBLEM", 277, 316], ["condom", "TREATMENT", 340, 346], ["pessary", "TREATMENT", 359, 366], ["legs (elasticized stockings", "TREATMENT", 375, 402], ["dyes", "TREATMENT", 409, 413], ["other cloth constituents", "TREATMENT", 418, 442], ["DiagnosisParticular contact lesions", "PROBLEM", 487, 522], ["oral and dental hygiene", "TREATMENT", 628, 651], ["toothpaste", "TREATMENT", 689, 699], ["anesthetics", "TREATMENT", 701, 712], ["metallic plates and screws", "TREATMENT", 714, 740], ["ubiquitous", "OBSERVATION_MODIFIER", 26, 36], ["substances", "OBSERVATION", 37, 47], ["lesions", "OBSERVATION", 116, 123], ["face", "ANATOMY", 156, 160], ["ear", "ANATOMY", 183, 186], ["plugs", "OBSERVATION", 187, 192], ["periocular", "ANATOMY", 201, 211], ["skin", "ANATOMY", 257, 261], ["thorax", "ANATOMY", 277, 283], ["belly", "ANATOMY", 288, 293], ["genitals", "ANATOMY", 319, 327], ["diaphragm", "ANATOMY", 348, 357], ["legs", "ANATOMY", 375, 379], ["lesions", "OBSERVATION", 515, 522], ["screws", "OBSERVATION", 734, 740], ["ear", "ANATOMY", 746, 749]]], ["Dentists in turn can show symptoms after use of an anesthetic or by contact with instruments cleaned with formaldehyde [6] , a hidden allergen which gathers in ear canals or under rings during washing with formaldehyde-based products.", [["ear canals", "ANATOMY", 160, 170], ["formaldehyde [6]", "CHEMICAL", 106, 122], ["formaldehyde", "CHEMICAL", 206, 218], ["formaldehyde", "CHEMICAL", 106, 118], ["formaldehyde", "CHEMICAL", 206, 218], ["ear canals", "MULTI-TISSUE_STRUCTURE", 160, 170], ["formaldehyde", "SIMPLE_CHEMICAL", 206, 218], ["symptoms", "PROBLEM", 26, 34], ["an anesthetic", "TREATMENT", 48, 61], ["a hidden allergen", "TREATMENT", 125, 142], ["formaldehyde-based products", "TREATMENT", 206, 233], ["ear canals", "ANATOMY", 160, 170]]], ["Inhalation of related steams may induce face and periorbital swelling [16] . \u2211 Systemic ACD.", [["steams", "ANATOMY", 22, 28], ["face", "ANATOMY", 40, 44], ["periorbital", "ANATOMY", 49, 60], ["swelling", "DISEASE", 61, 69], ["related steams", "PROBLEM", 14, 28], ["face and periorbital swelling", "PROBLEM", 40, 69], ["Systemic ACD", "TREATMENT", 79, 91], ["periorbital", "ANATOMY", 49, 60], ["swelling", "OBSERVATION", 61, 69], ["Systemic ACD", "OBSERVATION", 79, 91]]], ["It is objectively rare, often dependent on re-exposure to previously used topical medications, thus sensitizing the subjects up to severe systemic reactions [200] by spread of lesions to sites far from the primary exposed region or by oral, inhalation or parenteral exposure to antigens formerly the cause of cell-mediated contact manifestations [227] .Laboratory StudiesLatex allergy.", [["lesions", "ANATOMY", 176, 183], ["sites", "ANATOMY", 187, 192], ["oral", "ANATOMY", 235, 239], ["cell", "ANATOMY", 309, 313], ["allergy", "DISEASE", 377, 384], ["lesions", "PATHOLOGICAL_FORMATION", 176, 183], ["oral", "ORGANISM_SUBDIVISION", 235, 239], ["cell", "CELL", 309, 313], ["antigens", "PROTEIN", 278, 286], ["topical medications", "TREATMENT", 74, 93], ["severe systemic reactions", "PROBLEM", 131, 156], ["lesions to sites", "PROBLEM", 176, 192], ["parenteral exposure", "TREATMENT", 255, 274], ["lesions", "OBSERVATION", 176, 183]]], ["SPT is the diagnostic procedure of choice not only in young children affected with spina bifida, but also in all subjects with positive history due to frequent exposure to latex, in those allergic to mentioned fruits and in cases of urticaria and/or anaphylaxis by unknown causes [196] .", [["fruits", "ANATOMY", 210, 216], ["spina bifida", "DISEASE", 83, 95], ["allergic", "DISEASE", 188, 196], ["urticaria", "DISEASE", 233, 242], ["anaphylaxis", "DISEASE", 250, 261], ["children", "ORGANISM", 60, 68], ["bifida", "ORGAN", 89, 95], ["fruits", "ORGANISM_SUBDIVISION", 210, 216], ["children", "SPECIES", 60, 68], ["spina bifida", "PROBLEM", 83, 95], ["latex", "TREATMENT", 172, 177], ["urticaria", "PROBLEM", 233, 242], ["anaphylaxis", "PROBLEM", 250, 261], ["spina bifida", "ANATOMY", 83, 95], ["urticaria", "OBSERVATION", 233, 242]]], ["Diagnostic screening is complicated by a number of asymptomatic children with SPT + [152] .", [["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["Diagnostic screening", "TEST", 0, 20]]], ["SPTs are efficient in children [152, 193] , in addition to prick + prick testing [126, 152] , also with gloves (Chap.", [["children", "ORGANISM", 22, 30], ["children", "SPECIES", 22, 30], ["prick + prick testing", "TEST", 59, 80]]], ["6), RAST inhibition [193] , useful for the study of crossed allergenicity [115] , and challenge tests, which appear to be correlated to RAST [152] .", [["RAST inhibition", "TEST", 4, 19], ["the study", "TEST", 39, 48], ["crossed allergenicity", "PROBLEM", 52, 73], ["challenge tests", "TEST", 86, 101]]], ["Latex gloves are the source of great heterogeneity: there are significant (sometimes striking) differences between manufacturers and product lines in the amount of free latex protein that can be released from the glove and the number and types of chemicals used in glove production [196] .", [["product lines", "CELL_LINE", 133, 146], ["latex protein", "PROTEIN", 169, 182], ["Latex gloves", "TREATMENT", 0, 12], ["free latex protein", "PROBLEM", 164, 182], ["great", "OBSERVATION_MODIFIER", 31, 36], ["heterogeneity", "OBSERVATION", 37, 50], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["product lines", "OBSERVATION", 133, 146], ["amount", "OBSERVATION_MODIFIER", 154, 160], ["free", "OBSERVATION_MODIFIER", 164, 168], ["latex protein", "OBSERVATION", 169, 182], ["glove", "OBSERVATION_MODIFIER", 213, 218]]], ["Among the stabilizers is also casein [133] , so CM allergic children may have false positive reactions to casein [133] .Differential DiagnosisDifferential diagnosis includes the following considerations: \u2211 ICD (Table 8 .15) [138] differences with ACD are rare, since both haptens and irritants decrease epidermal LC numbers, HLA-DR, CD54 and CD80 expression is diverse, and RT-PCR (reverse transcriptase-polymerase chain reaction) has shown an impressive overlap between ACD a ICD [82] .The main ICD example in children is diaper dermatitis, but one baby had physical irritation from constant friction due to occlusion by abdominal skin on a metal pin causing physical irritation [143] .", [["epidermal LC", "ANATOMY", 303, 315], ["abdominal skin", "ANATOMY", 622, 636], ["CM allergic", "DISEASE", 48, 59], ["ACD", "DISEASE", 247, 250], ["diaper dermatitis", "DISEASE", 523, 540], ["occlusion", "DISEASE", 609, 618], ["casein [133]", "SIMPLE_CHEMICAL", 30, 42], ["children", "ORGANISM", 60, 68], ["casein [133]", "SIMPLE_CHEMICAL", 106, 118], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 325, 331], ["CD54", "GENE_OR_GENE_PRODUCT", 333, 337], ["CD80", "GENE_OR_GENE_PRODUCT", 342, 346], ["children", "ORGANISM", 511, 519], ["skin", "ORGAN", 632, 636], ["CD54", "PROTEIN", 333, 337], ["CD80", "PROTEIN", 342, 346], ["reverse transcriptase", "PROTEIN", 382, 403], ["children", "SPECIES", 60, 68], ["children", "SPECIES", 511, 519], ["false positive reactions", "PROBLEM", 78, 102], ["\u2211 ICD", "TREATMENT", 204, 209], ["ACD", "TEST", 247, 250], ["irritants", "PROBLEM", 284, 293], ["epidermal LC numbers", "TEST", 303, 323], ["HLA", "TEST", 325, 328], ["CD54", "TEST", 333, 337], ["CD80 expression", "TEST", 342, 357], ["RT-PCR", "TEST", 374, 380], ["reverse transcriptase-polymerase chain reaction", "PROBLEM", 382, 429], ["ACD a ICD", "TREATMENT", 471, 480], ["The main ICD", "TREATMENT", 487, 499], ["diaper dermatitis", "PROBLEM", 523, 540], ["physical irritation", "PROBLEM", 559, 578], ["constant friction", "PROBLEM", 584, 601], ["occlusion", "PROBLEM", 609, 618], ["abdominal skin", "PROBLEM", 622, 636], ["a metal pin", "TREATMENT", 640, 651], ["physical irritation", "PROBLEM", 660, 679], ["ICD", "OBSERVATION", 206, 209], ["impressive", "OBSERVATION_MODIFIER", 444, 454], ["ICD", "OBSERVATION", 477, 480], ["main", "OBSERVATION_MODIFIER", 491, 495], ["ICD", "OBSERVATION", 496, 499], ["diaper", "OBSERVATION_MODIFIER", 523, 529], ["dermatitis", "OBSERVATION", 530, 540], ["irritation", "OBSERVATION", 568, 578], ["constant friction", "OBSERVATION", 584, 601], ["occlusion", "OBSERVATION", 609, 618], ["abdominal skin", "ANATOMY", 622, 636], ["irritation", "OBSERVATION", 669, 679]]], ["Several agents (up to 489 in number) [143] are capable of expressing a direct irritant action on skin cells, affecting the hands in 36.3% and face in 26.4% of cases [143] .", [["skin cells", "ANATOMY", 97, 107], ["skin cells", "CELL", 97, 107], ["hands", "ORGANISM_SUBDIVISION", 123, 128], ["skin cells", "CELL_TYPE", 97, 107], ["a direct irritant action on skin cells", "PROBLEM", 69, 107], ["the hands", "TEST", 119, 128], ["face", "TEST", 142, 146], ["skin", "ANATOMY", 97, 101], ["hands", "ANATOMY", 123, 128]]], ["The principal symptoms are a burning sensation (pruritus in ACD), early onset 1 h after contact, ACD diagnosis is confirmed by patch test [14, 77] : Finn chambers [14] or True test [2] (Chap.", [["burning sensation", "DISEASE", 29, 46], ["pruritus", "DISEASE", 48, 56], ["ACD", "DISEASE", 60, 63], ["The principal symptoms", "PROBLEM", 0, 22], ["a burning sensation (pruritus in ACD", "PROBLEM", 27, 63], ["Finn chambers", "TEST", 149, 162], ["True test", "TEST", 171, 180]]], ["6), selecting the haptens that more frequently are causes of ACD (standard series) or those potentially relevant in the surroundings of a single patient (special series) [14] .", [["ACD", "DISEASE", 61, 64], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152], ["selecting the haptens", "TREATMENT", 4, 25], ["ACD", "PROBLEM", 61, 64]]], ["All children with suspected ACD should undergo patch testing.", [["ACD", "DISEASE", 28, 31], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["patch testing", "TEST", 47, 60]]], ["Dentists should undergo a preventive assessment by this method [6] because of the notable spread of Ni-plated instruments .", [["a preventive assessment", "TEST", 24, 47], ["Ni-plated instruments", "TREATMENT", 100, 121]]], ["Patch testing is also helpful to reveal possible cross-reactions or concomitant hypersensitivity to additional haptens [149] , and to natural rubber latex [195] .", [["hypersensitivity", "DISEASE", 80, 96], ["Patch testing", "TEST", 0, 13], ["cross-reactions", "PROBLEM", 49, 64], ["concomitant hypersensitivity to additional haptens", "PROBLEM", 68, 118]]], ["False-positive results may depend on aspecific skin hyperreactivity, following a local increase in LC numbers, or particular conditions of both epidermis and vasculature which contribute to a pro-inflammatory cytokine increase [207] .Differential DiagnosisTo verify whether trimmings or worn objects contain Ni, some drops of a diluted ammoniacal solution containing 1% dimethylglycoxin can be applied: the Ni presence is revealed by a bright rose dye [138] . polymorphous aspect with no tendency to generalization, rapid regression after interruption of contact. \u2211 AD is often associated with ACD: Ni is accused in children with a mean prevalence of 4% [47] ; the hand eczema appearing as a dyshidrotic vesicular eruption may be largely associated with an atopic condition [63] . \u2211 To differentiate from PCD, we mention that the pathogenic agents are protein fractions of animal and vegetable origin. \u2211 Mycotic infections (see above). \u2211 Several cutaneous eruptions such as those of SLE, erythema multiforme, dermatomyositis, viral exanthems, pityriasis rosea have mostly a symmetrical aspect rather than eczematous, while ACD has peculiar locations; for example, in feet ACD involves the back (in psoriasis the sole), with a relative sparing of interdigital spaces (unlike viral infections). \u2211 Dyshidrotic eczema often begins with small congested, pruriginous and relapsing vesicular lesions, located on the internal sides of both hands and toes, but then occurs in the soles of the feet and the palms of the hands.TreatmentBeyond any rigid schema of the inhibiting effects on LCs, TNF-a [128] and UV rays with an IL 10 mediation could be utilized for therapeutic purposes [71] .", [["skin", "ANATOMY", 47, 51], ["epidermis", "ANATOMY", 144, 153], ["vasculature", "ANATOMY", 158, 169], ["hand", "ANATOMY", 665, 669], ["vesicular", "ANATOMY", 704, 713], ["vegetable", "ANATOMY", 884, 893], ["cutaneous", "ANATOMY", 946, 955], ["erythema multiforme", "ANATOMY", 988, 1007], ["feet", "ANATOMY", 1167, 1171], ["back", "ANATOMY", 1189, 1193], ["interdigital spaces", "ANATOMY", 1246, 1265], ["vesicular lesions", "ANATOMY", 1375, 1392], ["internal sides", "ANATOMY", 1409, 1423], ["hands", "ANATOMY", 1432, 1437], ["toes", "ANATOMY", 1442, 1446], ["soles", "ANATOMY", 1471, 1476], ["feet", "ANATOMY", 1484, 1488], ["palms", "ANATOMY", 1497, 1502], ["LCs", "ANATOMY", 1578, 1581], ["Ni", "CHEMICAL", 308, 310], ["dimethylglycoxin", "CHEMICAL", 370, 386], ["Ni", "CHEMICAL", 407, 409], ["AD", "DISEASE", 566, 568], ["ACD", "DISEASE", 594, 597], ["Ni", "CHEMICAL", 599, 601], ["eczema", "DISEASE", 670, 676], ["vesicular eruption", "DISEASE", 704, 722], ["PCD", "DISEASE", 805, 808], ["Mycotic infections", "DISEASE", 904, 922], ["cutaneous eruptions", "DISEASE", 946, 965], ["SLE", "DISEASE", 983, 986], ["erythema multiforme", "DISEASE", 988, 1007], ["dermatomyositis", "DISEASE", 1009, 1024], ["viral exanthems", "DISEASE", 1026, 1041], ["pityriasis rosea", "DISEASE", 1043, 1059], ["eczematous", "DISEASE", 1105, 1115], ["ACD", "DISEASE", 1123, 1126], ["ACD", "DISEASE", 1172, 1175], ["psoriasis", "DISEASE", 1198, 1207], ["viral infections", "DISEASE", 1274, 1290], ["eczema", "DISEASE", 1307, 1313], ["Ni", "CHEMICAL", 308, 310], ["ammoniacal", "CHEMICAL", 336, 346], ["dimethylglycoxin", "CHEMICAL", 370, 386], ["Ni", "CHEMICAL", 407, 409], ["Ni", "CHEMICAL", 599, 601], ["skin", "ORGAN", 47, 51], ["epidermis", "TISSUE", 144, 153], ["vasculature", "MULTI-TISSUE_STRUCTURE", 158, 169], ["ammoniacal", "SIMPLE_CHEMICAL", 336, 346], ["dimethylglycoxin", "SIMPLE_CHEMICAL", 370, 386], ["children", "ORGANISM", 616, 624], ["hand", "ORGANISM_SUBDIVISION", 665, 669], ["vesicular", "MULTI-TISSUE_STRUCTURE", 704, 713], ["vegetable", "ORGANISM_SUBDIVISION", 884, 893], ["pityriasis rosea", "ORGANISM", 1043, 1059], ["feet", "ORGANISM_SUBDIVISION", 1167, 1171], ["back", "ORGANISM_SUBDIVISION", 1189, 1193], ["vesicular lesions", "PATHOLOGICAL_FORMATION", 1375, 1392], ["hands", "ORGANISM_SUBDIVISION", 1432, 1437], ["toes", "ORGANISM_SUBDIVISION", 1442, 1446], ["soles", "ORGANISM_SUBDIVISION", 1471, 1476], ["feet", "ORGANISM_SUBDIVISION", 1484, 1488], ["palms", "ORGANISM_SUBDIVISION", 1497, 1502], ["hands", "ORGANISM_SUBDIVISION", 1510, 1515], ["LCs", "CELL", 1578, 1581], ["TNF", "GENE_OR_GENE_PRODUCT", 1583, 1586], ["IL 10", "GENE_OR_GENE_PRODUCT", 1615, 1620], ["pro-inflammatory cytokine", "PROTEIN", 192, 217], ["LCs", "CELL_TYPE", 1578, 1581], ["TNF", "PROTEIN", 1583, 1586], ["children", "SPECIES", 616, 624], ["pityriasis rosea", "SPECIES", 1043, 1059], ["False", "TEST", 0, 5], ["aspecific skin hyperreactivity", "PROBLEM", 37, 67], ["a local increase in LC numbers", "PROBLEM", 79, 109], ["a pro-inflammatory cytokine increase", "PROBLEM", 190, 226], ["trimmings", "PROBLEM", 274, 283], ["worn objects", "PROBLEM", 287, 299], ["a diluted ammoniacal solution", "TREATMENT", 326, 355], ["1% dimethylglycoxin", "TREATMENT", 367, 386], ["a bright rose dye", "PROBLEM", 434, 451], ["polymorphous aspect", "PROBLEM", 460, 479], ["tendency to generalization", "PROBLEM", 488, 514], ["the hand eczema", "PROBLEM", 661, 676], ["a dyshidrotic vesicular eruption", "PROBLEM", 690, 722], ["an atopic condition", "PROBLEM", 754, 773], ["PCD", "PROBLEM", 805, 808], ["the pathogenic agents", "TREATMENT", 826, 847], ["Mycotic infections", "PROBLEM", 904, 922], ["Several cutaneous eruptions", "PROBLEM", 938, 965], ["SLE", "PROBLEM", 983, 986], ["erythema multiforme", "PROBLEM", 988, 1007], ["dermatomyositis", "PROBLEM", 1009, 1024], ["viral exanthems", "PROBLEM", 1026, 1041], ["pityriasis rosea", "PROBLEM", 1043, 1059], ["eczematous", "PROBLEM", 1105, 1115], ["feet ACD", "PROBLEM", 1167, 1175], ["a relative sparing of interdigital spaces", "PROBLEM", 1224, 1265], ["viral infections", "PROBLEM", 1274, 1290], ["Dyshidrotic eczema", "PROBLEM", 1295, 1313], ["small congested, pruriginous and relapsing vesicular lesions", "PROBLEM", 1332, 1392], ["LCs", "TEST", 1578, 1581], ["TNF", "TEST", 1583, 1586], ["UV rays", "TREATMENT", 1599, 1606], ["an IL 10 mediation", "TREATMENT", 1612, 1630], ["skin", "ANATOMY", 47, 51], ["hyperreactivity", "OBSERVATION", 52, 67], ["increase", "OBSERVATION_MODIFIER", 87, 95], ["both", "ANATOMY_MODIFIER", 139, 143], ["epidermis", "ANATOMY", 144, 153], ["vasculature", "ANATOMY", 158, 169], ["pro-inflammatory", "OBSERVATION_MODIFIER", 192, 208], ["no", "UNCERTAINTY", 485, 487], ["hand", "ANATOMY", 665, 669], ["eczema", "OBSERVATION", 670, 676], ["vesicular eruption", "OBSERVATION", 704, 722], ["vegetable origin", "OBSERVATION", 884, 900], ["Mycotic", "OBSERVATION_MODIFIER", 904, 911], ["infections", "OBSERVATION", 912, 922], ["cutaneous", "OBSERVATION_MODIFIER", 946, 955], ["eruptions", "OBSERVATION", 956, 965], ["erythema multiforme", "OBSERVATION", 988, 1007], ["dermatomyositis", "OBSERVATION", 1009, 1024], ["viral exanthems", "OBSERVATION", 1026, 1041], ["pityriasis", "OBSERVATION_MODIFIER", 1043, 1053], ["symmetrical", "OBSERVATION_MODIFIER", 1074, 1085], ["feet", "ANATOMY", 1167, 1171], ["back", "ANATOMY", 1189, 1193], ["psoriasis", "OBSERVATION", 1198, 1207], ["sparing", "OBSERVATION_MODIFIER", 1235, 1242], ["interdigital spaces", "OBSERVATION", 1246, 1265], ["viral infections", "OBSERVATION", 1274, 1290], ["Dyshidrotic", "OBSERVATION_MODIFIER", 1295, 1306], ["eczema", "OBSERVATION", 1307, 1313], ["small", "OBSERVATION_MODIFIER", 1332, 1337], ["congested", "OBSERVATION", 1338, 1347], ["relapsing", "OBSERVATION_MODIFIER", 1365, 1374], ["vesicular", "OBSERVATION_MODIFIER", 1375, 1384], ["lesions", "OBSERVATION", 1385, 1392], ["internal", "ANATOMY_MODIFIER", 1409, 1417], ["sides", "ANATOMY_MODIFIER", 1418, 1423], ["both", "ANATOMY_MODIFIER", 1427, 1431], ["hands", "ANATOMY", 1432, 1437], ["toes", "ANATOMY", 1442, 1446], ["soles", "ANATOMY_MODIFIER", 1471, 1476], ["feet", "ANATOMY", 1484, 1488], ["palms", "ANATOMY_MODIFIER", 1497, 1502], ["hands", "ANATOMY", 1510, 1515], ["rigid schema", "OBSERVATION", 1536, 1548]]], ["Local or general management aims to reduce the clinical manifestations and avoid possible infectious complications; in both cases a preventive ascertainment of the composition of products for topic or systemic use will eliminate those containing sensitizing substances.", [["general management", "TREATMENT", 9, 27], ["the clinical manifestations", "PROBLEM", 43, 70], ["infectious complications", "PROBLEM", 90, 114], ["the composition of products", "TREATMENT", 160, 187]]], ["Treatment of allergic reactions to latex begins with immediate removal of any identified source of latex in direct patient contact.", [["allergic reactions", "DISEASE", 13, 31], ["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["allergic reactions", "PROBLEM", 13, 31], ["latex", "TREATMENT", 35, 40], ["immediate removal", "TREATMENT", 53, 70], ["allergic", "OBSERVATION", 13, 21]]], ["13 we discuss SLIT desensitization to latex.", [["SLIT desensitization to latex", "TREATMENT", 14, 43]]], ["Treatment is similar to anaphylaxis from other causes and may require the use of epinephrine [30] .CHAPTER 8Other Allergic Skin Disorders [125] .", [["anaphylaxis", "DISEASE", 24, 35], ["epinephrine", "CHEMICAL", 81, 92], ["Allergic Skin Disorders", "DISEASE", 114, 137], ["epinephrine", "CHEMICAL", 81, 92], ["epinephrine", "SIMPLE_CHEMICAL", 81, 92], ["Treatment", "TREATMENT", 0, 9], ["anaphylaxis", "PROBLEM", 24, 35], ["epinephrine", "TREATMENT", 81, 92], ["Allergic Skin Disorders", "PROBLEM", 114, 137], ["anaphylaxis", "OBSERVATION", 24, 35], ["Skin", "ANATOMY", 123, 127]]], ["For objects of common use and imitation jewelry containing Ni and/or CoCl, replacements are available in brass or low-carat gold, and drawer and utensil handles of nonmetallic material.", [["Ni", "CHEMICAL", 59, 61], ["CoCl", "CHEMICAL", 69, 73], ["Ni", "CHEMICAL", 59, 61], ["CoCl", "CHEMICAL", 69, 73], ["Ni", "SIMPLE_CHEMICAL", 59, 61], ["CoCl", "SIMPLE_CHEMICAL", 69, 73], ["Ni and/or CoCl, replacements", "TREATMENT", 59, 87], ["nonmetallic material", "OBSERVATION", 164, 184]]], ["Alternatives to perfumed cosmetics and household detergents are the fragrance-free products.", [["household detergents", "TREATMENT", 39, 59]]], ["Those who are allergic to these substances should therefore carry out strict dietetic prevention, together with contact prevention, to ensure a clear-cut clinical improvement of ACD lesions [80] .", [["lesions", "ANATOMY", 182, 189], ["allergic", "DISEASE", 14, 22], ["ACD", "DISEASE", 178, 181], ["ACD lesions", "PATHOLOGICAL_FORMATION", 178, 189], ["allergic", "PROBLEM", 14, 22], ["these substances", "TREATMENT", 26, 42], ["strict dietetic prevention", "TREATMENT", 70, 96], ["ACD lesions", "PROBLEM", 178, 189], ["ACD", "ANATOMY", 178, 181], ["lesions", "OBSERVATION", 182, 189]]], ["Women have long been encouraged to prefer Ni-free accessories, and men to give up metal watch bands, etc. But is impossible to give up handling metal coins.", [["Women", "ORGANISM", 0, 5], ["men", "ORGANISM", 67, 70], ["Women", "SPECIES", 0, 5], ["men", "SPECIES", 67, 70], ["metal coins", "OBSERVATION", 144, 155]]], ["In our opinion, difficulties will be Ni is practically irreplaceable in the alloys encountered because since it combines excellent technical properties and low price.CHAPTER 8Recently, a group of European companies has obtained a Ni-free international patent and the EU has issued directive 94/27 and thereby defined the Ni limit level at 0.5 g/cm 2 for objects in direct and prolonged contact with the epidermis.", [["epidermis", "ANATOMY", 403, 412], ["Ni", "CHEMICAL", 37, 39], ["Ni", "CHEMICAL", 37, 39], ["Ni", "CHEMICAL", 321, 323], ["epidermis", "TISSUE", 403, 412], ["patent", "OBSERVATION", 252, 258], ["epidermis", "ANATOMY", 403, 412]]], ["People allergic to Cr should employ leather tanned with vegetable systems, by ascertaining whether tannins are present, and those with ACD to dyes should wear white or plant-fiber clothing.CHAPTER 8The data available today show which measures should be suggested to patients with ACD to latex [109] .", [["allergic", "DISEASE", 7, 15], ["Cr", "CHEMICAL", 19, 21], ["ACD", "DISEASE", 280, 283], ["Cr", "CHEMICAL", 19, 21], ["tannins", "CHEMICAL", 99, 106], ["People", "ORGANISM", 0, 6], ["vegetable", "ORGANISM_SUBDIVISION", 56, 65], ["tannins", "SIMPLE_CHEMICAL", 99, 106], ["patients", "ORGANISM", 266, 274], ["People", "SPECIES", 0, 6], ["patients", "SPECIES", 266, 274], ["allergic", "PROBLEM", 7, 15], ["ACD to dyes", "TREATMENT", 135, 146], ["plant-fiber clothing", "TREATMENT", 168, 188]]], ["Latex avoidance should be advocated for all individuals with a positive skin or blood test or a positive history [30] .", [["skin", "ANATOMY", 72, 76], ["blood", "ANATOMY", 80, 85], ["skin", "ORGAN", 72, 76], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["Latex avoidance", "TREATMENT", 0, 15], ["blood test", "TEST", 80, 90], ["skin", "ANATOMY", 72, 76]]], ["Because latex glove antigen content varies among brands and among lots from the same manufacturers [193] , the allergics and surgeons can wear polyvinyl gloves, or gloves subjected during manufacture to washing after pressing and in-process steam sterilized for 1 h at 120\u00b0C [216] , or powder-free Biogel Skinsense TM N. In allergic patients, premedication with H 1 or H 2 antihistamines or prednisone has been used to prevent untoward side effects, but only as a supplementary measure in addition to discontinuing use of latex gloves, since the results are not always effective [30, 193] .", [["allergics", "DISEASE", 111, 120], ["allergic", "DISEASE", 324, 332], ["H 1 or H 2 antihistamines", "CHEMICAL", 362, 387], ["prednisone", "CHEMICAL", 391, 401], ["polyvinyl", "CHEMICAL", 143, 152], ["H 1", "CHEMICAL", 362, 365], ["prednisone", "CHEMICAL", 391, 401], ["latex glove antigen", "GENE_OR_GENE_PRODUCT", 8, 27], ["patients", "ORGANISM", 333, 341], ["H 1", "SIMPLE_CHEMICAL", 362, 365], ["H 2 antihistamines", "SIMPLE_CHEMICAL", 369, 387], ["prednisone", "SIMPLE_CHEMICAL", 391, 401], ["patients", "SPECIES", 333, 341], ["latex glove antigen content", "PROBLEM", 8, 35], ["polyvinyl gloves", "TREATMENT", 143, 159], ["gloves", "TREATMENT", 164, 170], ["powder", "TREATMENT", 286, 292], ["premedication with H", "TREATMENT", 343, 363], ["antihistamines", "TREATMENT", 373, 387], ["prednisone", "TREATMENT", 391, 401], ["untoward side effects", "PROBLEM", 427, 448], ["latex gloves", "TREATMENT", 522, 534]]], ["In atopic children, surgical procedures should be undertaken with the greatest caution since they tend to be sensitized even by the slightest contact with latex [3, 126] : in children with spina bifida, latex contact should be avoided from birth [193] .", [["atopic", "DISEASE", 3, 9], ["spina bifida", "DISEASE", 189, 201], ["children", "ORGANISM", 10, 18], ["children", "ORGANISM", 175, 183], ["children", "SPECIES", 10, 18], ["children", "SPECIES", 175, 183], ["surgical procedures", "TREATMENT", 20, 39], ["spina bifida", "PROBLEM", 189, 201], ["spina bifida", "ANATOMY", 189, 201]]], ["In particular, pacifiers should be banished [109] , surgeons should manipulate latex gloves outside an allergic patient's room to avoid airborne transmission of latex particles [112] , which are also spread by the cornstarch covering gloves and other objects [205] , during surgery catheters in silicon (silastic) and for medications tapes and bandages with acrylic adhesives should be preferred [112] .", [["allergic", "DISEASE", 103, 111], ["silicon", "CHEMICAL", 295, 302], ["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119], ["pacifiers", "TREATMENT", 15, 24], ["latex gloves", "TREATMENT", 79, 91], ["surgery catheters in silicon (silastic)", "TREATMENT", 274, 313], ["medications tapes", "TREATMENT", 322, 339], ["bandages with acrylic adhesives", "TREATMENT", 344, 375]]], ["Latex allergy should be investigated not only in multioperated patients but also in children with severe AD, fruit allergy and with urticaria or anaphylaxis by unspecified causes [196] .CHAPTER 8In case of acute, congested, edematous, exudative dermatitis, local therapy should be limited to hydrophilic packs with watery solutions at ambient T, repeated from two to four times during the day.", [["Latex allergy", "DISEASE", 0, 13], ["AD", "DISEASE", 105, 107], ["fruit allergy", "DISEASE", 109, 122], ["urticaria", "DISEASE", 132, 141], ["anaphylaxis", "DISEASE", 145, 156], ["exudative dermatitis", "DISEASE", 235, 255], ["patients", "ORGANISM", 63, 71], ["children", "ORGANISM", 84, 92], ["patients", "SPECIES", 63, 71], ["children", "SPECIES", 84, 92], ["Latex allergy", "PROBLEM", 0, 13], ["severe AD", "PROBLEM", 98, 107], ["fruit allergy", "PROBLEM", 109, 122], ["urticaria", "PROBLEM", 132, 141], ["anaphylaxis", "PROBLEM", 145, 156], ["acute, congested, edematous", "PROBLEM", 206, 233], ["exudative dermatitis", "PROBLEM", 235, 255], ["local therapy", "TREATMENT", 257, 270], ["hydrophilic packs", "TREATMENT", 292, 309], ["watery solutions", "TREATMENT", 315, 331], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["congested", "OBSERVATION", 213, 222], ["edematous", "OBSERVATION_MODIFIER", 224, 233], ["exudative", "OBSERVATION_MODIFIER", 235, 244], ["dermatitis", "OBSERVATION", 245, 255], ["local therapy", "OBSERVATION", 257, 270]]], ["A number of solutions with antiseptic and decongestant action, without the danger of unwanted allergization, are detailed in Chap.", [["antiseptic", "TREATMENT", 27, 37], ["decongestant action", "TREATMENT", 42, 61]]], ["7, along with water, oil or glycerin pastes, useful in congested and exudative stages, and inert powders in case of intolerance to wet medications.", [["oil", "ANATOMY", 21, 24], ["glycerin", "CHEMICAL", 28, 36], ["glycerin", "CHEMICAL", 28, 36], ["water", "SIMPLE_CHEMICAL", 14, 19], ["oil", "ORGANISM_SUBSTANCE", 21, 24], ["glycerin", "SIMPLE_CHEMICAL", 28, 36], ["glycerin pastes", "TREATMENT", 28, 43], ["congested and exudative stages", "PROBLEM", 55, 85], ["inert powders", "TREATMENT", 91, 104], ["intolerance", "PROBLEM", 116, 127], ["wet medications", "TREATMENT", 131, 146], ["congested", "OBSERVATION", 55, 64], ["exudative", "OBSERVATION_MODIFIER", 69, 78]]], ["When the acute and exudative stage subsides, lipophilic ointments such as Lassar paste may be appropriate.CHAPTER 8In addition, always for topical use, low or moderate potency CSs can be used (Table 7 .16) in different excipients (lotions, creams, gel, ointments), for short-term (7-10 days) exclusive application on the involved cutaneous sites in tandem or alternate therapy, taking into account possible contact reactions [2] .", [["cutaneous sites", "ANATOMY", 330, 345], ["cutaneous sites", "MULTI-TISSUE_STRUCTURE", 330, 345], ["the acute and exudative stage subsides", "PROBLEM", 5, 43], ["lipophilic ointments", "TREATMENT", 45, 65], ["Lassar paste", "TREATMENT", 74, 86], ["moderate potency CSs", "TREATMENT", 159, 179], ["different excipients", "TREATMENT", 209, 229], ["lotions", "TREATMENT", 231, 238], ["creams", "TREATMENT", 240, 246], ["gel", "TREATMENT", 248, 251], ["ointments", "TREATMENT", 253, 262], ["alternate therapy", "TREATMENT", 359, 376], ["contact reactions", "PROBLEM", 407, 424], ["acute", "OBSERVATION_MODIFIER", 9, 14], ["exudative", "OBSERVATION_MODIFIER", 19, 28], ["stage", "OBSERVATION_MODIFIER", 29, 34], ["subsides", "OBSERVATION_MODIFIER", 35, 43], ["cutaneous", "ANATOMY", 330, 339]]], ["Subsequently, topical nonsteroid medications can be used for the same length of time; this combined treatment should be sufficient to return the skin to a normal state.", [["skin", "ANATOMY", 145, 149], ["skin", "ORGAN", 145, 149], ["topical nonsteroid medications", "TREATMENT", 14, 44], ["this combined treatment", "TREATMENT", 86, 109], ["skin", "ANATOMY", 145, 149], ["normal", "OBSERVATION", 155, 161]]], ["Oral antihistamines may hold promise in relieving itching (Chap.", [["Oral", "ANATOMY", 0, 4], ["itching", "DISEASE", 50, 57], ["Oral antihistamines", "TREATMENT", 0, 19], ["relieving itching", "PROBLEM", 40, 57]]], ["The newer topical immunosuppressors, tacrolimus and pimecrolimus, may be effective in the treatment [118] .CHAPTER 8Diaper dermatitis, especially in summer, responds to rigorous hygienic measures, which are useful also for prevention: the use of cloth diapers, washed at home exclusively with Marseille soap.PreventionA unique specific management consists in the prevention of whatever new contact with responsible or suspected substances, especially if they are capable of cross-reacting with other compounds [7] , or when feasible substituting, for example, metal wires in orthodontic prostheses with acrylic ones [224] , almost always followed by ACD regression.", [["tacrolimus", "CHEMICAL", 37, 47], ["pimecrolimus", "CHEMICAL", 52, 64], ["dermatitis", "DISEASE", 123, 133], ["tacrolimus", "CHEMICAL", 37, 47], ["pimecrolimus", "CHEMICAL", 52, 64], ["tacrolimus", "SIMPLE_CHEMICAL", 37, 47], ["pimecrolimus", "SIMPLE_CHEMICAL", 52, 64], ["The newer topical immunosuppressors", "TREATMENT", 0, 35], ["tacrolimus", "TREATMENT", 37, 47], ["pimecrolimus", "TREATMENT", 52, 64], ["dermatitis", "PROBLEM", 123, 133], ["rigorous hygienic measures", "TREATMENT", 169, 195], ["cloth diapers", "TREATMENT", 246, 259], ["metal wires in orthodontic prostheses with acrylic ones", "TREATMENT", 560, 615], ["dermatitis", "OBSERVATION", 123, 133], ["orthodontic prostheses", "OBSERVATION", 575, 597]]], ["Unfortunately, labels do not fully report product composition [57] : cosmetics, antigens correlated to rubber, textiles and metals are examples.", [["metals", "SIMPLE_CHEMICAL", 124, 130], ["antigens", "PROTEIN", 80, 88]]], ["However, several clinics have a complete display of materials that contain the offending allergens, a great aid for the patient, the doctor and the industry, as well as for an exchange of information between experts in the discipline [57] .PreventionPeople allergic to Ni should exclude from their diet the above-mentioned foods and eat small amounts of carrots, cabbages, cauliflower, cucumber, wholemeal wheat or corn, fresh fruits other than pears, and lettuce.", [["carrots", "ANATOMY", 354, 361], ["cabbages", "ANATOMY", 363, 371], ["fruits", "ANATOMY", 427, 433], ["pears", "ANATOMY", 445, 450], ["allergic", "DISEASE", 257, 265], ["Ni", "CHEMICAL", 269, 271], ["carrots, cabbages, cauliflower, cucumber, wholemeal wheat", "CHEMICAL", 354, 411], ["Ni", "CHEMICAL", 269, 271], ["patient", "ORGANISM", 120, 127], ["carrots", "ORGANISM_SUBDIVISION", 354, 361], ["cabbages", "SIMPLE_CHEMICAL", 363, 371], ["cauliflower", "ORGANISM", 373, 384], ["cucumber", "ORGANISM_SUBDIVISION", 386, 394], ["wholemeal wheat", "ORGANISM", 396, 411], ["corn", "ORGANISM_SUBDIVISION", 415, 419], ["fruits", "ORGANISM_SUBDIVISION", 427, 433], ["pears", "ORGANISM_SUBDIVISION", 445, 450], ["lettuce", "ORGANISM_SUBDIVISION", 456, 463], ["patient", "SPECIES", 120, 127], ["People", "SPECIES", 250, 256], ["cauliflower", "SPECIES", 373, 384], ["cucumber", "SPECIES", 386, 394], ["wheat", "SPECIES", 406, 411], ["corn", "SPECIES", 415, 419], ["pears", "SPECIES", 445, 450], ["cauliflower", "SPECIES", 373, 384], ["cucumber", "SPECIES", 386, 394], ["wheat", "SPECIES", 406, 411], ["corn", "SPECIES", 415, 419], ["pears", "SPECIES", 445, 450], ["lettuce", "SPECIES", 456, 463], ["allergic", "PROBLEM", 257, 265], ["lettuce", "OBSERVATION", 456, 463]]], ["Older children should also exclude beer, coffee and wine.", [["children", "ORGANISM", 6, 14], ["wine", "ORGANISM_SUBDIVISION", 52, 56], ["children", "SPECIES", 6, 14]]], ["Do not cook foods in stainless steel pots, both new and used, in particular foods containing oxalic acid (spinach), malic (apple), or citric (citrus fruit), because the Ni concentration is increased significantly [125] .", [["oxalic acid", "CHEMICAL", 93, 104], ["Ni", "CHEMICAL", 169, 171], ["oxalic acid", "CHEMICAL", 93, 104], ["Ni", "CHEMICAL", 169, 171], ["oxalic acid", "SIMPLE_CHEMICAL", 93, 104], ["spinach", "ORGANISM_SUBDIVISION", 106, 113], ["malic", "SIMPLE_CHEMICAL", 116, 121], ["apple", "ORGANISM_SUBDIVISION", 123, 128], ["citric", "SIMPLE_CHEMICAL", 134, 140], ["Ni", "SIMPLE_CHEMICAL", 169, 171], ["apple", "SPECIES", 123, 128], ["oxalic acid (spinach), malic (apple)", "TREATMENT", 93, 129], ["citric (citrus fruit", "TREATMENT", 134, 154], ["the Ni concentration", "TEST", 165, 185]]], ["For metal-induced dermatitis, it is appropriate to prescribe a diet with a low content of foods that are positive to patch testing, which is needed to be supported in chil-A new form of treatment consists in asking a latex patient to wear a latex glove for increasingly longer times, or in a type of SLIT desensitization (Chap.", [["metal", "CHEMICAL", 4, 9], ["dermatitis", "DISEASE", 18, 28], ["patient", "ORGANISM", 223, 230], ["patient", "SPECIES", 223, 230], ["metal-induced dermatitis", "PROBLEM", 4, 28], ["a low content of foods", "TREATMENT", 73, 95], ["patch testing", "TEST", 117, 130], ["treatment", "TREATMENT", 186, 195], ["a latex glove", "TREATMENT", 239, 252], ["SLIT desensitization", "TREATMENT", 300, 320], ["dermatitis", "OBSERVATION", 18, 28]]], ["13).Protein Contact DermatitisDefinition PCD is an exquisitely occupational dermatitis seen in individuals exposed to animal and/or vegetable foods: cooks, veterinarians, slaughterhouse workers, housewives, boys and girls helping in family business, etc. [184] .", [["vegetable", "ANATOMY", 132, 141], ["dermatitis", "DISEASE", 76, 86], ["boys", "SPECIES", 207, 211], ["girls", "SPECIES", 216, 221], ["an exquisitely occupational dermatitis", "PROBLEM", 48, 86], ["occupational dermatitis", "OBSERVATION", 63, 86]]], ["PCD occurs as a chronic eczema accompanied by erythema, swelling and itching on fingers.", [["erythema", "ANATOMY", 46, 54], ["PCD", "DISEASE", 0, 3], ["eczema", "DISEASE", 24, 30], ["erythema", "DISEASE", 46, 54], ["swelling", "DISEASE", 56, 64], ["itching", "DISEASE", 69, 76], ["erythema", "PATHOLOGICAL_FORMATION", 46, 54], ["fingers", "ORGANISM_SUBDIVISION", 80, 87], ["PCD", "PROBLEM", 0, 3], ["a chronic eczema", "PROBLEM", 14, 30], ["erythema", "PROBLEM", 46, 54], ["swelling", "PROBLEM", 56, 64], ["itching on fingers", "PROBLEM", 69, 87], ["chronic", "OBSERVATION_MODIFIER", 16, 23], ["eczema", "OBSERVATION", 24, 30], ["erythema", "OBSERVATION", 46, 54], ["swelling", "OBSERVATION", 56, 64], ["itching", "OBSERVATION", 69, 76], ["fingers", "ANATOMY", 80, 87]]], ["Immediate recurrences in the same sites are frequent following contact with the causal agent.EtiopathogenesisPCD is another area of increasing interest with only a small rate of patients with positive family and/or personal history for atopy [186] .EtiopathogenesisThe causative agents are protein fractions of animal and vegetable origin, handled for a more or less protracted period, but the precise pathogenetic mechanism is as yet largely unexplored [1] .", [["sites", "ANATOMY", 34, 39], ["vegetable", "ANATOMY", 322, 331], ["EtiopathogenesisPCD", "DISEASE", 93, 112], ["atopy", "DISEASE", 236, 241], ["patients", "ORGANISM", 178, 186], ["vegetable", "ORGANISM_SUBDIVISION", 322, 331], ["patients", "SPECIES", 178, 186], ["Immediate recurrences in the same sites", "PROBLEM", 0, 39], ["atopy", "PROBLEM", 236, 241], ["protein fractions", "PROBLEM", 290, 307], ["recurrences", "OBSERVATION", 10, 21], ["frequent", "OBSERVATION_MODIFIER", 44, 52], ["area", "OBSERVATION_MODIFIER", 124, 128], ["increasing", "OBSERVATION_MODIFIER", 132, 142], ["interest", "OBSERVATION", 143, 151], ["small", "OBSERVATION_MODIFIER", 164, 169], ["vegetable", "OBSERVATION_MODIFIER", 322, 331], ["origin", "OBSERVATION_MODIFIER", 332, 338]]], ["It is proposed that apparently unaffected skin facilitates the passage of protein substances via the epidermis, thus producing a spongiosis, an intercellular edema of the skin's spongy layer.", [["skin", "ANATOMY", 42, 46], ["epidermis", "ANATOMY", 101, 110], ["spongiosis", "ANATOMY", 129, 139], ["intercellular edema", "ANATOMY", 144, 163], ["skin", "ANATOMY", 171, 175], ["spongy layer", "ANATOMY", 178, 190], ["spongiosis", "DISEASE", 129, 139], ["edema", "DISEASE", 158, 163], ["skin", "ORGAN", 42, 46], ["epidermis", "TISSUE", 101, 110], ["skin", "ORGAN", 171, 175], ["spongy layer", "TISSUE", 178, 190], ["unaffected skin", "PROBLEM", 31, 46], ["a spongiosis", "PROBLEM", 127, 139], ["an intercellular edema of the skin's spongy layer", "PROBLEM", 141, 190], ["skin", "ANATOMY", 42, 46], ["epidermis", "ANATOMY", 101, 110], ["spongiosis", "OBSERVATION", 129, 139], ["intercellular", "OBSERVATION_MODIFIER", 144, 157], ["edema", "OBSERVATION", 158, 163], ["skin", "ANATOMY", 171, 175], ["spongy", "OBSERVATION_MODIFIER", 178, 184], ["layer", "OBSERVATION_MODIFIER", 185, 190]]], ["Histological studies have revealed the outcome of these lesions, including superficial vesiculation, parakeratosis and lymphomonocyte infiltrate localized in the superficial dermis and in the perivascular seat.", [["lesions", "ANATOMY", 56, 63], ["parakeratosis", "ANATOMY", 101, 114], ["lymphomonocyte infiltrate", "ANATOMY", 119, 144], ["superficial dermis", "ANATOMY", 162, 180], ["perivascular seat", "ANATOMY", 192, 209], ["parakeratosis", "DISEASE", 101, 114], ["lesions", "PATHOLOGICAL_FORMATION", 56, 63], ["superficial dermis", "TISSUE", 162, 180], ["perivascular seat", "TISSUE", 192, 209], ["Histological studies", "TEST", 0, 20], ["these lesions", "PROBLEM", 50, 63], ["superficial vesiculation", "PROBLEM", 75, 99], ["parakeratosis", "PROBLEM", 101, 114], ["lymphomonocyte infiltrate", "PROBLEM", 119, 144], ["lesions", "OBSERVATION", 56, 63], ["superficial", "OBSERVATION_MODIFIER", 75, 86], ["vesiculation", "OBSERVATION_MODIFIER", 87, 99], ["parakeratosis", "OBSERVATION", 101, 114], ["lymphomonocyte infiltrate", "OBSERVATION", 119, 144], ["superficial", "ANATOMY_MODIFIER", 162, 173], ["dermis", "ANATOMY", 174, 180], ["perivascular seat", "ANATOMY", 192, 209]]], ["The mononuclear infiltrate delineates full-blown T lymphocytes with a clear-cut CD4 prevalence on CD8 T cells.", [["mononuclear infiltrate", "ANATOMY", 4, 26], ["T lymphocytes", "ANATOMY", 49, 62], ["CD8 T cells", "ANATOMY", 98, 109], ["mononuclear", "CELL", 4, 15], ["T lymphocytes", "CELL", 49, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 80, 83], ["CD8 T cells", "CELL", 98, 109], ["T lymphocytes", "CELL_TYPE", 49, 62], ["CD4", "PROTEIN", 80, 83], ["CD8 T cells", "CELL_TYPE", 98, 109], ["The mononuclear infiltrate", "PROBLEM", 0, 26], ["mononuclear", "OBSERVATION_MODIFIER", 4, 15], ["infiltrate", "OBSERVATION", 16, 26], ["blown T lymphocytes", "OBSERVATION", 43, 62], ["clear", "OBSERVATION_MODIFIER", 70, 75], ["CD8 T cells", "OBSERVATION", 98, 109]]], ["Immunohistochemical studies show an increase in the number of LCs in the vesicles, epidermis and superficial dermis [186] .EtiopathogenesisThe list of foods, fruits, and vegetables identified as etiological agents is remarkably long: see Table 8 .16 [1, 186] .Clinical PresentationThe vesiculation starts suddenly after contact with the causative agent, also following a long period of manipulations without lesions [186] .", [["LCs", "ANATOMY", 62, 65], ["vesicles", "ANATOMY", 73, 81], ["epidermis", "ANATOMY", 83, 92], ["superficial dermis", "ANATOMY", 97, 115], ["fruits", "ANATOMY", 158, 164], ["vegetables", "ANATOMY", 170, 180], ["lesions", "ANATOMY", 408, 415], ["LCs", "CELL", 62, 65], ["vesicles", "CELLULAR_COMPONENT", 73, 81], ["epidermis", "TISSUE", 83, 92], ["superficial dermis", "TISSUE", 97, 115], ["fruits", "ORGANISM_SUBDIVISION", 158, 164], ["vegetables", "ORGANISM_SUBDIVISION", 170, 180], ["LCs", "CELL_TYPE", 62, 65], ["Immunohistochemical studies", "TEST", 0, 27], ["an increase", "PROBLEM", 33, 44], ["lesions", "PROBLEM", 408, 415], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["number", "OBSERVATION_MODIFIER", 52, 58], ["LCs", "OBSERVATION", 62, 65], ["vesicles", "ANATOMY_MODIFIER", 73, 81], ["epidermis", "ANATOMY", 83, 92], ["superficial", "ANATOMY_MODIFIER", 97, 108], ["dermis", "ANATOMY", 109, 115], ["vesiculation", "OBSERVATION", 285, 297]]], ["After contact, prominent erythematous, pomphoid and vesicular manifestations appear within a few minutes on the back of the hand and/or fingers, with progressive spread of erythema, accentuation of vesiculation and itching [131] .DiagnosisSPTs are the diagnostic tests of first choice.", [["erythematous", "ANATOMY", 25, 37], ["pomphoid", "ANATOMY", 39, 47], ["vesicular", "ANATOMY", 52, 61], ["back", "ANATOMY", 112, 116], ["hand", "ANATOMY", 124, 128], ["fingers", "ANATOMY", 136, 143], ["erythema", "DISEASE", 172, 180], ["itching", "DISEASE", 215, 222], ["pomphoid", "CANCER", 39, 47], ["hand", "ORGANISM_SUBDIVISION", 124, 128], ["fingers", "ORGANISM_SUBDIVISION", 136, 143], ["erythema", "PATHOLOGICAL_FORMATION", 172, 180], ["prominent erythematous, pomphoid and vesicular manifestations", "PROBLEM", 15, 76], ["progressive spread of erythema", "PROBLEM", 150, 180], ["accentuation of vesiculation", "PROBLEM", 182, 210], ["itching", "PROBLEM", 215, 222], ["the diagnostic tests", "TEST", 248, 268], ["prominent", "OBSERVATION_MODIFIER", 15, 24], ["erythematous", "OBSERVATION_MODIFIER", 25, 37], ["vesicular manifestations", "OBSERVATION", 52, 76], ["few", "OBSERVATION_MODIFIER", 93, 96], ["back", "ANATOMY", 112, 116], ["hand", "ANATOMY", 124, 128], ["fingers", "ANATOMY", 136, 143], ["progressive", "OBSERVATION_MODIFIER", 150, 161], ["spread", "OBSERVATION_MODIFIER", 162, 168], ["erythema", "OBSERVATION", 172, 180], ["accentuation", "OBSERVATION_MODIFIER", 182, 194], ["vesiculation", "OBSERVATION_MODIFIER", 198, 210]]], ["The reactions show within 10-30 min, small vesicles that are sometimes dyshidrosiform, combined with erythema, and notably itching [131] .", [["vesicles", "ANATOMY", 43, 51], ["dyshidrosiform", "DISEASE", 71, 85], ["erythema", "DISEASE", 101, 109], ["itching", "DISEASE", 123, 130], ["vesicles", "CELLULAR_COMPONENT", 43, 51], ["small vesicles", "PROBLEM", 37, 51], ["dyshidrosiform", "PROBLEM", 71, 85], ["erythema", "PROBLEM", 101, 109], ["itching", "PROBLEM", 123, 130], ["small", "OBSERVATION_MODIFIER", 37, 42], ["vesicles", "OBSERVATION", 43, 51], ["erythema", "OBSERVATION", 101, 109]]], ["Better results are obtained with the prick + prick test, or the similar SAFT (skin applied food test) by employing fresh and raw foods [1] .", [["skin", "ANATOMY", 78, 82], ["skin", "ORGAN", 78, 82], ["the prick + prick test", "TEST", 33, 55], ["skin", "ANATOMY", 78, 82]]], ["The RAST may be reliable.Differential DiagnosisAs discussed earlier, the offending agents are protein fractions of common foods, which distinguish PCD from the haptens responsible for ACD [186] .Allergic Photodermatitis DefinitionAllergic photodermatitis is kind of CMI to chemical substances that become antigenic when activated by sunlight.", [["PCD", "DISEASE", 147, 150], ["Allergic Photodermatitis", "DISEASE", 195, 219], ["Allergic photodermatitis", "DISEASE", 230, 254], ["CMI", "DISEASE", 266, 269], ["RAST", "PROTEIN", 4, 8], ["The RAST", "TEST", 0, 8], ["PCD", "PROBLEM", 147, 150], ["Allergic Photodermatitis", "PROBLEM", 195, 219], ["Allergic photodermatitis", "PROBLEM", 230, 254], ["CMI", "PROBLEM", 266, 269], ["may be", "UNCERTAINTY", 9, 15], ["Allergic photodermatitis", "OBSERVATION", 230, 254]]], ["When skin is exposed to UV rays, cutaneous symptoms of various types may appear during a time when a patient is exposed to different exogenous or endogenous substances or is taking an offending medication topically, but most often systemically [58, 174] .PrevalenceIt is connected principally with newly introduced medications and chemical substances.", [["skin", "ANATOMY", 5, 9], ["cutaneous", "ANATOMY", 33, 42], ["skin", "ORGAN", 5, 9], ["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108], ["UV rays", "TREATMENT", 24, 31], ["cutaneous symptoms", "PROBLEM", 33, 51], ["an offending medication topically", "TREATMENT", 181, 214], ["PrevalenceIt", "TREATMENT", 255, 267], ["newly introduced medications", "TREATMENT", 298, 326], ["chemical substances", "TREATMENT", 331, 350], ["skin", "ANATOMY", 5, 9]]], ["The manifestations have alternating phases, in epidemic form when a new therapeutic agent is commercialized.", [["a new therapeutic agent", "TREATMENT", 66, 89]]], ["Generally as soon as its photosensitizing potential is ascertained, the product is withdrawn and the prevalence abates.PathogenesisUV rays are divided into UVA, with bands comprised between 400 and 315 nm, UVB between 315 and 280 nm, and UVC of <280 nm [58] .", [["UVA", "CHEMICAL", 156, 159], ["UVB", "CHEMICAL", 206, 209], ["PathogenesisUV rays", "PROBLEM", 119, 138], ["bands", "TEST", 166, 171], ["UVB", "TEST", 206, 209], ["UVC", "TEST", 238, 241], ["280 nm", "OBSERVATION_MODIFIER", 226, 232], ["UVC", "ANATOMY", 238, 241]]], ["UV rays can induce phototraumatic reactions (basically solar erythema) and photodynamic reactions, further classified into phototoxic and allergic variants [58, 174] .PathogenesisPhotoallergic Reaction.", [["erythema", "DISEASE", 61, 69], ["allergic", "DISEASE", 138, 146], ["UV rays", "TREATMENT", 0, 7], ["phototraumatic reactions", "PROBLEM", 19, 43], ["basically solar erythema", "PROBLEM", 45, 69], ["photodynamic reactions", "PROBLEM", 75, 97], ["allergic variants", "PROBLEM", 138, 155], ["PathogenesisPhotoallergic Reaction", "PROBLEM", 167, 201], ["solar", "OBSERVATION_MODIFIER", 55, 60], ["erythema", "OBSERVATION", 61, 69], ["allergic variants", "OBSERVATION", 138, 155], ["Photoallergic Reaction", "OBSERVATION", 179, 201]]], ["This immunologically mediated photosensitization is activated by longer wavelengths (UVA 320-450 nm), which alter molecular structure, thus leading to a type IV sensitization.", [["UVA", "CHEMICAL", 85, 88], ["This immunologically mediated photosensitization", "TREATMENT", 0, 48], ["UVA", "TREATMENT", 85, 88], ["a type IV sensitization", "TREATMENT", 151, 174]]], ["The radiant energy absorbed by a chromophore, for example the photoantigen, produces photochemical changes resulting in a photosensitized molecule, then conjugated with a protein carrier to occasion a complete allergen, against which is directed the immune response mediated by T lymphocytes, as in ACD [58] .", [["T lymphocytes", "ANATOMY", 278, 291], ["T lymphocytes", "CELL", 278, 291], ["T lymphocytes", "CELL_TYPE", 278, 291], ["a chromophore", "TREATMENT", 31, 44], ["photochemical changes", "PROBLEM", 85, 106], ["a photosensitized molecule", "PROBLEM", 120, 146], ["a protein carrier", "TREATMENT", 169, 186], ["radiant", "OBSERVATION_MODIFIER", 4, 11], ["photochemical changes", "OBSERVATION", 85, 106], ["photosensitized molecule", "OBSERVATION", 122, 146]]], ["In predisposed subjects, symptoms develop after a persistent exposure to sensitizing substances continuing for an adequately long period (up to 1-3 weeks).", [["symptoms", "PROBLEM", 25, 33], ["sensitizing substances", "TREATMENT", 73, 95]]], ["The wavelength of UV light is elicited by offending chemical substances.", [["The wavelength of UV light", "TREATMENT", 0, 26], ["wavelength", "OBSERVATION_MODIFIER", 4, 14], ["UV light", "OBSERVATION_MODIFIER", 18, 26]]], ["The causes are cosmetics based on natural perfumes such as bergamot ( Fig. 8.17 ) and sandal oils and synthetic perfumes (musk and coconut), fragrance ingredients and lotions containing musk ambrette, dyes such as eosin used in lipsticks and the like, known photoallergens in sunscreen products such as oxybenzone, or correlated to PABA and methylcoumarin, disinfectants (halogenate salicylic-aniline: bithionol, fenticlor, etc.) [58, 215] , and foods (Table 8 .17) [173] .TreatmentThere is no specific management.", [["sandal oils", "ANATOMY", 86, 97], ["bergamot", "CHEMICAL", 59, 67], ["oxybenzone", "CHEMICAL", 303, 313], ["PABA", "CHEMICAL", 332, 336], ["methylcoumarin", "CHEMICAL", 341, 355], ["halogenate salicylic-aniline", "CHEMICAL", 372, 400], ["bithionol", "CHEMICAL", 402, 411], ["fenticlor", "CHEMICAL", 413, 422], ["eosin", "CHEMICAL", 214, 219], ["oxybenzone", "CHEMICAL", 303, 313], ["PABA", "CHEMICAL", 332, 336], ["methylcoumarin", "CHEMICAL", 341, 355], ["halogenate salicylic-aniline", "CHEMICAL", 372, 400], ["bithionol", "CHEMICAL", 402, 411], ["fenticlor", "CHEMICAL", 413, 422], ["musk", "ORGANISM_SUBDIVISION", 122, 126], ["coconut", "ORGANISM_SUBDIVISION", 131, 138], ["musk ambrette", "SIMPLE_CHEMICAL", 186, 199], ["dyes", "SIMPLE_CHEMICAL", 201, 205], ["eosin", "SIMPLE_CHEMICAL", 214, 219], ["oxybenzone", "SIMPLE_CHEMICAL", 303, 313], ["PABA", "SIMPLE_CHEMICAL", 332, 336], ["methylcoumarin", "SIMPLE_CHEMICAL", 341, 355], ["halogenate salicylic-aniline", "SIMPLE_CHEMICAL", 372, 400], ["bithionol", "SIMPLE_CHEMICAL", 402, 411], ["fenticlor", "SIMPLE_CHEMICAL", 413, 422], ["musk", "SPECIES", 122, 126], ["musk", "SPECIES", 186, 190], ["natural perfumes", "TREATMENT", 34, 50], ["bergamot ( Fig.", "TEST", 59, 74], ["sandal oils", "TREATMENT", 86, 97], ["synthetic perfumes (musk and coconut)", "TREATMENT", 102, 139], ["fragrance ingredients", "TREATMENT", 141, 162], ["lotions", "TREATMENT", 167, 174], ["eosin", "TREATMENT", 214, 219], ["sunscreen products", "TREATMENT", 276, 294], ["oxybenzone", "TREATMENT", 303, 313], ["PABA", "TREATMENT", 332, 336], ["methylcoumarin", "TREATMENT", 341, 355], ["disinfectants", "TREATMENT", 357, 370], ["bithionol", "TREATMENT", 402, 411], ["fenticlor", "TREATMENT", 413, 422], ["Treatment", "TREATMENT", 473, 482], ["specific management", "TREATMENT", 494, 513], ["no", "UNCERTAINTY", 491, 493]]], ["Affected subjects should protect their hands with polyvinyl gloves that cover the lower forearm or, if possible, should change jobs [1] .PhytodermatitisPhytodermatitis is a particular type of contact dermatitis caused by plants, especially by chemical substances present in the leaves, stems, flowers, pollens and roots, particularly essential oils, components of the oleoresinous fraction, containing in turn phenols, aldehydes and aromatic alcohol, terpenes, hydrocarbons, aliphatic and aromatic esters, and kinones.", [["lower forearm", "ANATOMY", 82, 95], ["leaves", "ANATOMY", 278, 284], ["stems", "ANATOMY", 286, 291], ["flowers", "ANATOMY", 293, 300], ["pollens", "ANATOMY", 302, 309], ["roots", "ANATOMY", 314, 319], ["oils", "ANATOMY", 344, 348], ["oleoresinous fraction", "ANATOMY", 368, 389], ["Phytodermatitis", "DISEASE", 152, 167], ["dermatitis", "DISEASE", 200, 210], ["aldehydes", "CHEMICAL", 419, 428], ["aromatic alcohol, terpenes, hydrocarbons, aliphatic and aromatic esters", "CHEMICAL", 433, 504], ["polyvinyl", "CHEMICAL", 50, 59], ["phenols", "CHEMICAL", 410, 417], ["aldehydes", "CHEMICAL", 419, 428], ["aromatic alcohol", "CHEMICAL", 433, 449], ["terpenes", "CHEMICAL", 451, 459], ["hydrocarbons", "CHEMICAL", 461, 473], ["aliphatic and aromatic esters", "CHEMICAL", 475, 504], ["kinones", "CHEMICAL", 510, 517], ["lower", "ORGANISM_SUBDIVISION", 82, 87], ["forearm", "ORGANISM_SUBDIVISION", 88, 95], ["leaves", "ORGANISM_SUBDIVISION", 278, 284], ["stems", "TISSUE", 286, 291], ["flowers", "ORGANISM_SUBDIVISION", 293, 300], ["pollens", "ORGANISM_SUBDIVISION", 302, 309], ["roots", "ORGAN", 314, 319], ["phenols", "SIMPLE_CHEMICAL", 410, 417], ["aldehydes", "SIMPLE_CHEMICAL", 419, 428], ["aromatic alcohol", "SIMPLE_CHEMICAL", 433, 449], ["terpenes", "SIMPLE_CHEMICAL", 451, 459], ["hydrocarbons", "SIMPLE_CHEMICAL", 461, 473], ["aliphatic", "SIMPLE_CHEMICAL", 475, 484], ["aromatic esters", "SIMPLE_CHEMICAL", 489, 504], ["kinones", "SIMPLE_CHEMICAL", 510, 517], ["Affected subjects", "PROBLEM", 0, 17], ["polyvinyl gloves", "TREATMENT", 50, 66], ["PhytodermatitisPhytodermatitis", "PROBLEM", 137, 167], ["contact dermatitis", "PROBLEM", 192, 210], ["pollens and roots", "PROBLEM", 302, 319], ["the oleoresinous fraction", "PROBLEM", 364, 389], ["kinones", "PROBLEM", 510, 517], ["lower forearm", "ANATOMY", 82, 95], ["particular type", "OBSERVATION_MODIFIER", 173, 188], ["contact dermatitis", "OBSERVATION", 192, 210], ["stems", "ANATOMY", 286, 291], ["roots", "ANATOMY", 314, 319], ["aromatic alcohol", "OBSERVATION", 433, 449], ["aromatic esters", "OBSERVATION", 489, 504]]], ["The dermatitis is distinguished by the lesions provoked by irritant effects, particular to some plants such as Urticaceae, and by injecting histamine, serotonin and acetylcholine at the contact site, often leading to linear or figured aspects and bullous or pomphoid eruptions elicited by toxins of further plants, including Compositae, crucifies, lilies and Ranuculaceae (directly or following plant cutting) [7] .Allergic Phytocontact DermatitisSeveral agents cause plant contact dermatitis: \u2211 Catechols, belonging to the family of phenols, are among the more widespread allergens in the plant world, equipped with an elevated sensitizing power.", [["lesions", "ANATOMY", 39, 46], ["dermatitis", "DISEASE", 4, 14], ["histamine", "CHEMICAL", 140, 149], ["serotonin", "CHEMICAL", 151, 160], ["acetylcholine", "CHEMICAL", 165, 178], ["bullous", "DISEASE", 247, 254], ["eruptions", "DISEASE", 267, 276], ["Allergic Phytocontact Dermatitis", "DISEASE", 415, 447], ["plant contact dermatitis", "DISEASE", 468, 492], ["Catechols", "CHEMICAL", 496, 505], ["phenols", "CHEMICAL", 534, 541], ["histamine", "CHEMICAL", 140, 149], ["serotonin", "CHEMICAL", 151, 160], ["acetylcholine", "CHEMICAL", 165, 178], ["Catechols", "CHEMICAL", 496, 505], ["phenols", "CHEMICAL", 534, 541], ["lesions", "PATHOLOGICAL_FORMATION", 39, 46], ["histamine", "SIMPLE_CHEMICAL", 140, 149], ["serotonin", "SIMPLE_CHEMICAL", 151, 160], ["acetylcholine", "SIMPLE_CHEMICAL", 165, 178], ["Catechols", "SIMPLE_CHEMICAL", 496, 505], ["phenols", "SIMPLE_CHEMICAL", 534, 541], ["The dermatitis", "PROBLEM", 0, 14], ["the lesions", "PROBLEM", 35, 46], ["irritant effects", "PROBLEM", 59, 75], ["Urticaceae", "TREATMENT", 111, 121], ["histamine", "TREATMENT", 140, 149], ["serotonin", "TREATMENT", 151, 160], ["acetylcholine", "TREATMENT", 165, 178], ["bullous or pomphoid eruptions", "PROBLEM", 247, 276], ["further plants", "PROBLEM", 299, 313], ["Allergic Phytocontact Dermatitis", "PROBLEM", 415, 447], ["plant contact dermatitis", "PROBLEM", 468, 492], ["an elevated sensitizing power", "PROBLEM", 617, 646], ["dermatitis", "OBSERVATION", 4, 14], ["lesions", "OBSERVATION", 39, 46], ["irritant effects", "OBSERVATION", 59, 75], ["bullous", "OBSERVATION_MODIFIER", 247, 254], ["Phytocontact Dermatitis", "OBSERVATION", 424, 447], ["contact dermatitis", "OBSERVATION", 474, 492]]], ["These include eugenol, used in dentistry and the manufacture of soaps, perfumes and carnation oils; vanillin; pentadecilcatechol, a potent allergen of the Rhus genus, including Rhus toxicodendron, or R. radicans and R. vernix, by far the most common cause of plant contact dermatitis in the US, where they are called poison oak, poison ivy and poison sumac, and are a frequent cause of ACD in children via pets, mainly long-haired dogs, which rub against the plants and transmit oleoresin to newborns and children. \u2211 Terpenes are contained in citrus, celery, chrysanthemums, and other products such as resins and balsams. \u2211 The plants of the Compositeae family (chrysanthemums, pansy, ragweed, sunflower), those of the Alstroemeria genus and Hydrangea species, and hepatica contain sesquiterpene lactones yielding extended contact phytodermatitis on exposed skin sites, especially in florists [2] .", [["chrysanthemums", "ANATOMY", 559, 573], ["skin sites", "ANATOMY", 858, 868], ["eugenol", "CHEMICAL", 14, 21], ["vanillin", "CHEMICAL", 100, 108], ["pentadecilcatechol", "CHEMICAL", 110, 128], ["plant contact dermatitis", "DISEASE", 259, 283], ["ACD", "DISEASE", 386, 389], ["oleoresin", "CHEMICAL", 479, 488], ["Terpenes", "CHEMICAL", 517, 525], ["chrysanthemums", "CHEMICAL", 559, 573], ["sesquiterpene lactones", "CHEMICAL", 782, 804], ["phytodermatitis", "DISEASE", 831, 846], ["eugenol", "CHEMICAL", 14, 21], ["vanillin", "CHEMICAL", 100, 108], ["pentadecilcatechol", "CHEMICAL", 110, 128], ["Terpenes", "CHEMICAL", 517, 525], ["sesquiterpene lactones", "CHEMICAL", 782, 804], ["eugenol", "SIMPLE_CHEMICAL", 14, 21], ["vanillin", "SIMPLE_CHEMICAL", 100, 108], ["pentadecilcatechol", "SIMPLE_CHEMICAL", 110, 128], ["Rhus genus", "ORGANISM", 155, 165], ["Rhus toxicodendron", "ORGANISM", 177, 195], ["R. radicans", "ORGANISM", 200, 211], ["R. vernix", "ORGANISM", 216, 225], ["oak", "ORGANISM_SUBDIVISION", 324, 327], ["children", "ORGANISM", 393, 401], ["dogs", "ORGANISM", 431, 435], ["oleoresin", "GENE_OR_GENE_PRODUCT", 479, 488], ["newborns", "ORGANISM", 492, 500], ["children", "ORGANISM", 505, 513], ["Terpenes", "SIMPLE_CHEMICAL", 517, 525], ["citrus", "ORGANISM_SUBDIVISION", 543, 549], ["celery", "ORGANISM_SUBDIVISION", 551, 557], ["chrysanthemums", "SIMPLE_CHEMICAL", 559, 573], ["balsams", "SIMPLE_CHEMICAL", 613, 620], ["Compositeae", "GENE_OR_GENE_PRODUCT", 642, 653], ["chrysanthemums", "ORGANISM", 662, 676], ["ragweed", "ORGANISM_SUBDIVISION", 685, 692], ["sunflower", "ORGANISM_SUBDIVISION", 694, 703], ["Alstroemeria genus", "ORGANISM", 719, 737], ["Hydrangea species", "ORGANISM", 742, 759], ["hepatica", "ORGANISM", 765, 773], ["sesquiterpene lactones", "SIMPLE_CHEMICAL", 782, 804], ["skin sites", "MULTI-TISSUE_STRUCTURE", 858, 868], ["R. radicans", "SPECIES", 200, 211], ["R. vernix", "SPECIES", 216, 225], ["children", "SPECIES", 393, 401], ["dogs", "SPECIES", 431, 435], ["children", "SPECIES", 505, 513], ["Rhus toxicodendron", "SPECIES", 177, 195], ["R. radicans", "SPECIES", 200, 211], ["R. vernix", "SPECIES", 216, 225], ["eugenol", "TREATMENT", 14, 21], ["the manufacture of soaps", "TREATMENT", 45, 69], ["carnation oils", "TREATMENT", 84, 98], ["vanillin", "TREATMENT", 100, 108], ["pentadecilcatechol", "TREATMENT", 110, 128], ["a potent allergen", "TREATMENT", 130, 147], ["Rhus toxicodendron", "TREATMENT", 177, 195], ["plant contact dermatitis", "PROBLEM", 259, 283], ["Terpenes", "TREATMENT", 517, 525], ["chrysanthemums", "TREATMENT", 559, 573], ["other products", "TREATMENT", 579, 593], ["Hydrangea species", "PROBLEM", 742, 759], ["hepatica", "TREATMENT", 765, 773], ["sesquiterpene lactones", "TREATMENT", 782, 804], ["exposed skin sites", "PROBLEM", 850, 868], ["eugenol", "OBSERVATION", 14, 21], ["plant", "OBSERVATION", 259, 264], ["contact dermatitis", "OBSERVATION", 265, 283], ["hepatica", "ANATOMY", 765, 773], ["skin", "ANATOMY", 858, 862]]], ["The pollens are common causes in the fall season via their allergenic fractions, the oleoresinous and hydrosoluble protein, which by inhalation can cause respiratory allergy.", [["pollens", "ANATOMY", 4, 11], ["respiratory", "ANATOMY", 154, 165], ["respiratory allergy", "DISEASE", 154, 173], ["pollens", "ORGANISM_SUBDIVISION", 4, 11], ["hydrosoluble protein", "PROTEIN", 102, 122], ["the oleoresinous and hydrosoluble protein", "TREATMENT", 81, 122], ["respiratory allergy", "PROBLEM", 154, 173], ["pollens", "OBSERVATION", 4, 11], ["allergenic fractions", "OBSERVATION", 59, 79], ["respiratory allergy", "OBSERVATION", 154, 173]]], ["These conditions are differentiated from photodermatitis by the season and the lesions with shaded instead of clear-cut limits [7] .Allergic Phytocontact DermatitisPhototoxic Reactions.", [["lesions", "ANATOMY", 79, 86], ["photodermatitis", "DISEASE", 41, 56], ["Allergic Phytocontact Dermatitis", "DISEASE", 132, 164], ["lesions", "PATHOLOGICAL_FORMATION", 79, 86], ["photodermatitis", "PROBLEM", 41, 56], ["the lesions", "PROBLEM", 75, 86], ["Allergic Phytocontact DermatitisPhototoxic Reactions", "PROBLEM", 132, 184], ["lesions", "OBSERVATION", 79, 86], ["Phytocontact Dermatitis", "OBSERVATION", 141, 164]]], ["The cause is a foreign chemical substance reaching the skin either exogenously or endogenously in combination with exposure to a sufficient amount of UV rays, in this case UVB rays, which activate nonimmunological cell damage.", [["skin", "ANATOMY", 55, 59], ["cell", "ANATOMY", 214, 218], ["skin", "ORGAN", 55, 59], ["cell", "CELL", 214, 218], ["a foreign chemical substance", "PROBLEM", 13, 41], ["UV rays", "TREATMENT", 150, 157], ["this case UVB rays", "TREATMENT", 162, 180], ["nonimmunological cell damage", "PROBLEM", 197, 225], ["foreign chemical substance", "OBSERVATION", 15, 41], ["skin", "ANATOMY", 55, 59], ["UV rays", "OBSERVATION", 150, 157], ["nonimmunological cell damage", "OBSERVATION", 197, 225]]], ["The pathophysiological mechanism of phototoxic drugs involves absorption and accumulation of UV energy in the skin.", [["skin", "ANATOMY", 110, 114], ["skin", "ORGAN", 110, 114], ["phototoxic drugs", "TREATMENT", 36, 52], ["UV energy in the skin", "PROBLEM", 93, 114], ["phototoxic drugs", "OBSERVATION", 36, 52], ["UV energy", "OBSERVATION", 93, 102], ["skin", "ANATOMY", 110, 114]]], ["Photo drugs or their metabolites may combine with dermal proteins, acting as haptens solely when a significant dose of UV rays (285-310 nm) is present.", [["dermal", "ANATOMY", 50, 56], ["Photo drugs", "SIMPLE_CHEMICAL", 0, 11], ["dermal proteins", "PROTEIN", 50, 65], ["Photo drugs", "TREATMENT", 0, 11], ["dermal proteins", "TREATMENT", 50, 65], ["UV rays", "TEST", 119, 126]]], ["When this dose is higher, it is likely that the energy modifies the drug to form reactive metabolites that combine with skin proteins, thus also expressing in this case a complete allergen.", [["skin", "ANATOMY", 120, 124], ["skin", "ORGAN", 120, 124], ["skin proteins", "PROTEIN", 120, 133], ["reactive metabolites", "PROBLEM", 81, 101], ["skin proteins", "PROBLEM", 120, 133], ["reactive metabolites", "OBSERVATION", 81, 101]]], ["The period necessary to sensitization development may range from weeks to months, critical for cross-sensitizations, often triggered by low allergen doses.", [["cross-sensitizations", "PROBLEM", 95, 115]]], ["When it is all put together, the dependable molecule amplifies the skin sensitivity to UV rays.", [["skin", "ANATOMY", 67, 71], ["skin", "ORGAN", 67, 71], ["the dependable molecule", "PROBLEM", 29, 52], ["skin", "ANATOMY", 67, 71]]], ["Phototoxic effects occur by damage to the DNA chain such as by psoralens [174] .", [["DNA", "CELLULAR_COMPONENT", 42, 45], ["Phototoxic effects", "PROBLEM", 0, 18]]], ["Systemic medications and chemical substances more frequently incriminated are coal tar and derivatives, cyclamates, demeclocycline, doxycycline, griseofulvin, hexachlorophene, phenothiazine, psoralens, sulfa drugs, tetracycline and derivatives, thiazide, and photosensitizing substances such as furocoumarins (including psoralens), employed for their antimycotic action [138] .", [["tar", "CHEMICAL", 83, 86], ["cyclamates", "CHEMICAL", 104, 114], ["demeclocycline", "CHEMICAL", 116, 130], ["doxycycline", "CHEMICAL", 132, 143], ["griseofulvin", "CHEMICAL", 145, 157], ["hexachlorophene", "CHEMICAL", 159, 174], ["phenothiazine", "CHEMICAL", 176, 189], ["psoralens", "CHEMICAL", 191, 200], ["sulfa", "CHEMICAL", 202, 207], ["tetracycline", "CHEMICAL", 215, 227], ["thiazide", "CHEMICAL", 245, 253], ["furocoumarins", "CHEMICAL", 295, 308], ["psoralens", "CHEMICAL", 320, 329], ["coal tar", "CHEMICAL", 78, 86], ["cyclamates", "CHEMICAL", 104, 114], ["demeclocycline", "CHEMICAL", 116, 130], ["doxycycline", "CHEMICAL", 132, 143], ["griseofulvin", "CHEMICAL", 145, 157], ["hexachlorophene", "CHEMICAL", 159, 174], ["phenothiazine", "CHEMICAL", 176, 189], ["psoralens", "CHEMICAL", 191, 200], ["sulfa", "CHEMICAL", 202, 207], ["tetracycline", "CHEMICAL", 215, 227], ["thiazide", "CHEMICAL", 245, 253], ["furocoumarins", "CHEMICAL", 295, 308], ["psoralens", "CHEMICAL", 320, 329], ["cyclamates", "SIMPLE_CHEMICAL", 104, 114], ["demeclocycline", "SIMPLE_CHEMICAL", 116, 130], ["doxycycline", "SIMPLE_CHEMICAL", 132, 143], ["griseofulvin", "SIMPLE_CHEMICAL", 145, 157], ["hexachlorophene", "SIMPLE_CHEMICAL", 159, 174], ["phenothiazine", "SIMPLE_CHEMICAL", 176, 189], ["psoralens", "SIMPLE_CHEMICAL", 191, 200], ["sulfa drugs", "SIMPLE_CHEMICAL", 202, 213], ["tetracycline", "SIMPLE_CHEMICAL", 215, 227], ["derivatives", "SIMPLE_CHEMICAL", 232, 243], ["thiazide", "SIMPLE_CHEMICAL", 245, 253], ["photosensitizing substances", "SIMPLE_CHEMICAL", 259, 286], ["furocoumarins", "SIMPLE_CHEMICAL", 295, 308], ["psoralens", "SIMPLE_CHEMICAL", 320, 329], ["Systemic medications", "TREATMENT", 0, 20], ["chemical substances", "TREATMENT", 25, 44], ["coal tar", "TREATMENT", 78, 86], ["derivatives", "TREATMENT", 91, 102], ["cyclamates", "TREATMENT", 104, 114], ["demeclocycline", "TREATMENT", 116, 130], ["doxycycline", "TREATMENT", 132, 143], ["griseofulvin", "TREATMENT", 145, 157], ["hexachlorophene", "TREATMENT", 159, 174], ["phenothiazine", "TREATMENT", 176, 189], ["psoralens", "TREATMENT", 191, 200], ["sulfa drugs", "TREATMENT", 202, 213], ["tetracycline", "TREATMENT", 215, 227], ["derivatives", "TREATMENT", 232, 243], ["thiazide", "TREATMENT", 245, 253], ["photosensitizing substances", "TREATMENT", 259, 286], ["furocoumarins", "TREATMENT", 295, 308], ["psoralens", "TREATMENT", 320, 329], ["coal tar", "OBSERVATION", 78, 86]]], ["By a similar mechanism, phytophotodermatitis may develop after contact with plants containing natural furocoumarins, diffused in numerous vegetables: Umbrelliferae (celery, parsley, etc.), Rutaceae (citrus fruit), legumes, and Moraceae [174] .Clinical Presentation\u2211 Photoallergic reactions (Fig. 8.17 ) are elicited after re-exposure to both the photoallergen and radiating energy, taking the aspect of an urticarial eruption appearing after several minutes, or erythematous, edematous, eczematous or exuding, also involving parts of the body not exposed to the sun (\u226524 h). \u2211 Phototoxic reactions are manifested 5-18 h after the first sun exposure and reach their maximal effect after 36-72 h.", [["vegetables", "ANATOMY", 138, 148], ["legumes", "ANATOMY", 214, 221], ["body", "ANATOMY", 538, 542], ["phytophotodermatitis", "DISEASE", 24, 44], ["furocoumarins", "CHEMICAL", 102, 115], ["Umbrelliferae", "CHEMICAL", 150, 163], ["urticarial eruption", "DISEASE", 406, 425], ["eczematous", "DISEASE", 487, 497], ["furocoumarins", "CHEMICAL", 102, 115], ["furocoumarins", "SIMPLE_CHEMICAL", 102, 115], ["vegetables", "ORGANISM_SUBDIVISION", 138, 148], ["Umbrelliferae", "SIMPLE_CHEMICAL", 150, 163], ["celery", "ORGANISM_SUBDIVISION", 165, 171], ["parsley", "ORGANISM_SUBDIVISION", 173, 180], ["Rutaceae", "ORGANISM", 189, 197], ["citrus", "ORGANISM_SUBDIVISION", 199, 205], ["fruit", "ORGANISM_SUBDIVISION", 206, 211], ["legumes", "ORGANISM_SUBDIVISION", 214, 221], ["body", "ORGANISM_SUBDIVISION", 538, 542], ["celery", "SPECIES", 165, 171], ["parsley", "SPECIES", 173, 180], ["citrus fruit", "SPECIES", 199, 211], ["phytophotodermatitis", "PROBLEM", 24, 44], ["natural furocoumarins", "TREATMENT", 94, 115], ["Umbrelliferae (celery", "TREATMENT", 150, 171], ["Photoallergic reactions", "PROBLEM", 266, 289], ["radiating energy", "PROBLEM", 364, 380], ["an urticarial eruption", "PROBLEM", 403, 425], ["erythematous", "PROBLEM", 462, 474], ["edematous", "PROBLEM", 476, 485], ["eczematous", "PROBLEM", 487, 497], ["Phototoxic reactions", "PROBLEM", 577, 597], ["diffused", "OBSERVATION_MODIFIER", 117, 125], ["radiating energy", "OBSERVATION_MODIFIER", 364, 380], ["urticarial", "OBSERVATION_MODIFIER", 406, 416], ["eruption", "OBSERVATION", 417, 425], ["erythematous", "OBSERVATION_MODIFIER", 462, 474], ["edematous", "OBSERVATION", 476, 485], ["eczematous", "OBSERVATION", 487, 497], ["Phototoxic", "OBSERVATION_MODIFIER", 577, 587]]], ["Their typical aspect is characterized by hyperpigmentation, erythema, and vesicles.", [["vesicles", "ANATOMY", 74, 82], ["hyperpigmentation", "DISEASE", 41, 58], ["erythema", "DISEASE", 60, 68], ["erythema", "PATHOLOGICAL_FORMATION", 60, 68], ["vesicles", "CELLULAR_COMPONENT", 74, 82], ["hyperpigmentation", "PROBLEM", 41, 58], ["erythema", "PROBLEM", 60, 68], ["vesicles", "PROBLEM", 74, 82], ["hyperpigmentation", "OBSERVATION", 41, 58], ["erythema", "OBSERVATION", 60, 68], ["vesicles", "ANATOMY", 74, 82]]], ["The flare-ups develop in cloth-covered sites not exposed to UV radiation and that are distant from those initially involved.Clinical PresentationThe clinical picture is therefore various.", [["sites", "ANATOMY", 39, 44], ["The flare", "PROBLEM", 0, 9], ["cloth", "TREATMENT", 25, 30], ["UV radiation", "TREATMENT", 60, 72], ["flare", "OBSERVATION", 4, 9], ["radiation", "OBSERVATION", 63, 72]]], ["In certain cases, the reactions to UV rays produced by photoallergens may persist, even after prolonged abstention from sensitizing substances (for example, ambrette) [58] , or after eradication of the plant.Clinical PresentationContact photocheilitis is induced after sun exposure by dyes based on fluorescin, eosin, erythrosine, or on above-mentioned natural furocoumarins and psoralens.DiagnosisThe diagnosis, when not evident from a careful history and clinical examination, requires photopatch testing, which reveals several photoantigens including methylcoumarin, ambrette and oxybenzone [58, 223] .", [["photocheilitis", "DISEASE", 237, 251], ["fluorescin, eosin", "CHEMICAL", 299, 316], ["erythrosine", "CHEMICAL", 318, 329], ["furocoumarins", "CHEMICAL", 361, 374], ["psoralens", "CHEMICAL", 379, 388], ["methylcoumarin", "CHEMICAL", 554, 568], ["ambrette", "CHEMICAL", 570, 578], ["oxybenzone", "CHEMICAL", 583, 593], ["fluorescin", "CHEMICAL", 299, 309], ["eosin", "CHEMICAL", 311, 316], ["erythrosine", "CHEMICAL", 318, 329], ["furocoumarins", "CHEMICAL", 361, 374], ["psoralens", "CHEMICAL", 379, 388], ["methylcoumarin", "CHEMICAL", 554, 568], ["ambrette", "CHEMICAL", 570, 578], ["oxybenzone", "CHEMICAL", 583, 593], ["ambrette", "SIMPLE_CHEMICAL", 157, 165], ["fluorescin", "SIMPLE_CHEMICAL", 299, 309], ["eosin", "SIMPLE_CHEMICAL", 311, 316], ["erythrosine", "SIMPLE_CHEMICAL", 318, 329], ["furocoumarins", "SIMPLE_CHEMICAL", 361, 374], ["psoralens", "SIMPLE_CHEMICAL", 379, 388], ["methylcoumarin", "SIMPLE_CHEMICAL", 554, 568], ["ambrette", "SIMPLE_CHEMICAL", 570, 578], ["oxybenzone", "SIMPLE_CHEMICAL", 583, 593], ["the reactions", "PROBLEM", 18, 31], ["UV rays", "TREATMENT", 35, 42], ["fluorescin", "TREATMENT", 299, 309], ["eosin", "TREATMENT", 311, 316], ["erythrosine", "TREATMENT", 318, 329], ["natural furocoumarins", "TREATMENT", 353, 374], ["psoralens", "TREATMENT", 379, 388], ["clinical examination", "TEST", 457, 477], ["photopatch testing", "TEST", 488, 506], ["methylcoumarin", "TREATMENT", 554, 568], ["oxybenzone", "TREATMENT", 583, 593], ["plant", "OBSERVATION", 202, 207]]], ["However, the EU has prohibited using ambrette in cosmetics and avoiding topical antihistamines, a cause of (photo)allergic reactions when applied on the skin.Contact Dermatitis by Seawater OrganismsContact is with toxic proteins of some Coelenterates, echinoderms, molluscs, sponges, seaweeds, cercariae, and fish of various types.", [["skin", "ANATOMY", 153, 157], ["sponges", "ANATOMY", 275, 282], ["seaweeds", "ANATOMY", 284, 292], ["cercariae", "ANATOMY", 294, 303], ["ambrette", "CHEMICAL", 37, 45], ["allergic reactions", "DISEASE", 114, 132], ["Dermatitis", "DISEASE", 166, 176], ["ambrette", "SIMPLE_CHEMICAL", 37, 45], ["skin", "ORGAN", 153, 157], ["seaweeds", "TISSUE", 284, 292], ["ambrette in cosmetics", "TREATMENT", 37, 58], ["topical antihistamines", "TREATMENT", 72, 94], ["allergic reactions", "PROBLEM", 114, 132], ["Contact Dermatitis", "PROBLEM", 158, 176], ["toxic proteins", "PROBLEM", 214, 228], ["some Coelenterates", "PROBLEM", 232, 250], ["sponges", "TREATMENT", 275, 282], ["skin", "ANATOMY", 153, 157], ["Dermatitis", "OBSERVATION", 166, 176]]], ["Coelenterates are provided for attack and self-defense with nematocysts containing venomous urticating substances capable of remaining on the skin surface or penetrating it.", [["skin surface", "ANATOMY", 142, 154], ["skin", "ORGAN", 142, 146], ["attack", "PROBLEM", 31, 37], ["self-defense", "PROBLEM", 42, 54], ["nematocysts", "PROBLEM", 60, 71], ["venomous urticating substances", "TREATMENT", 83, 113], ["skin", "ANATOMY", 142, 146], ["surface", "ANATOMY_MODIFIER", 147, 154], ["penetrating", "OBSERVATION", 158, 169]]], ["Symptoms consist, in addition to urticaria and ACD, of linear erythematous or edematous eruptions that are either vesicular or hemorrhagic and toxic reactions.", [["vesicular", "ANATOMY", 114, 123], ["urticaria", "DISEASE", 33, 42], ["ACD", "DISEASE", 47, 50], ["hemorrhagic", "DISEASE", 127, 138], ["Symptoms", "PROBLEM", 0, 8], ["urticaria", "PROBLEM", 33, 42], ["ACD", "PROBLEM", 47, 50], ["linear erythematous or edematous eruptions", "PROBLEM", 55, 97], ["vesicular or hemorrhagic and toxic reactions", "PROBLEM", 114, 158], ["urticaria", "OBSERVATION", 33, 42], ["linear", "OBSERVATION_MODIFIER", 55, 61], ["erythematous", "OBSERVATION_MODIFIER", 62, 74], ["edematous", "OBSERVATION_MODIFIER", 78, 87], ["eruptions", "OBSERVATION", 88, 97], ["vesicular", "OBSERVATION_MODIFIER", 114, 123], ["hemorrhagic", "OBSERVATION_MODIFIER", 127, 138], ["toxic", "OBSERVATION_MODIFIER", 143, 148]]], ["The forms stemming from jellyfish are characterized by erythematous wheals appearing within a few hours, subsiding spontaneously after a few days.", [["jellyfish", "ANATOMY", 24, 33], ["erythematous wheals", "ANATOMY", 55, 74], ["jellyfish", "ORGANISM_SUBSTANCE", 24, 33], ["erythematous wheals", "PATHOLOGICAL_FORMATION", 55, 74], ["erythematous wheals", "PROBLEM", 55, 74], ["erythematous", "OBSERVATION_MODIFIER", 55, 67], ["wheals", "OBSERVATION", 68, 74]]], ["Echinoderm prickles elicit pain, burning, erythema and edema; pain is live, pyrotic if caused by venomous substances emitted also by morays, skates, has introduced for furocoumarins a limit of 1 mg/kg in sun-tan lotions and in sun-tanning products in general.", [["edema", "ANATOMY", 55, 60], ["pain", "DISEASE", 27, 31], ["erythema", "DISEASE", 42, 50], ["edema", "DISEASE", 55, 60], ["pain", "DISEASE", 62, 66], ["edema", "PATHOLOGICAL_FORMATION", 55, 60], ["Echinoderm prickles elicit pain", "PROBLEM", 0, 31], ["burning", "PROBLEM", 33, 40], ["erythema", "PROBLEM", 42, 50], ["edema", "PROBLEM", 55, 60], ["pain", "PROBLEM", 62, 66], ["venomous substances", "PROBLEM", 97, 116], ["furocoumarins", "TREATMENT", 168, 181], ["sun-tan lotions", "TREATMENT", 204, 219], ["pain", "OBSERVATION_MODIFIER", 27, 31], ["burning", "OBSERVATION_MODIFIER", 33, 40], ["erythema", "OBSERVATION", 42, 50], ["edema", "OBSERVATION", 55, 60]]], ["Differential diagnosis takes into account, in addition to phototoxic reactions (Table 8.", [["phototoxic reactions", "PROBLEM", 58, 78]]], ["18) [58, 174] , the extended contact phytodermatitis caused by Compositae pollens, which differ from photodermatitis since they occur in the fall season and produce the lesions with shaded instead of clear-cut limits.TreatmentNo specific management is available.", [["lesions", "ANATOMY", 169, 176], ["phytodermatitis", "DISEASE", 37, 52], ["photodermatitis", "DISEASE", 101, 116], ["Compositae", "ORGANISM", 63, 73], ["lesions", "PATHOLOGICAL_FORMATION", 169, 176], ["the extended contact phytodermatitis", "PROBLEM", 16, 52], ["Compositae pollens", "PROBLEM", 63, 81], ["photodermatitis", "PROBLEM", 101, 116], ["the lesions", "PROBLEM", 165, 176], ["TreatmentNo specific management", "TREATMENT", 217, 248], ["Compositae pollens", "OBSERVATION", 63, 81], ["lesions", "OBSERVATION", 169, 176]]], ["When it is possible to detect an eliciting substance, allergen prophylaxis is crucial.", [["an eliciting substance", "PROBLEM", 30, 52], ["allergen prophylaxis", "TREATMENT", 54, 74]]], ["Patients should avoid sunlight exposure while taking implicated drugs.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["If necessary they can protect the exposed sites with sunscreens that do not contain PABA esters [215] .", [["PABA esters", "CHEMICAL", 84, 95], ["PABA esters", "CHEMICAL", 84, 95], ["PABA esters", "SIMPLE_CHEMICAL", 84, 95], ["sunscreens", "TREATMENT", 53, 63]]], ["Topical treatment is based on packs to alleviate pruritus and burning, and topical CSs if erythema and edema appear not to resolve, rigorously 579 Allergic Photodermatitis [7] .", [["edema", "ANATOMY", 103, 108], ["pruritus", "DISEASE", 49, 57], ["erythema", "DISEASE", 90, 98], ["edema", "DISEASE", 103, 108], ["Allergic Photodermatitis", "DISEASE", 147, 171], ["edema", "PATHOLOGICAL_FORMATION", 103, 108], ["Topical treatment", "TREATMENT", 0, 17], ["packs", "TREATMENT", 30, 35], ["pruritus", "PROBLEM", 49, 57], ["burning", "PROBLEM", 62, 69], ["topical CSs", "TREATMENT", 75, 86], ["erythema", "PROBLEM", 90, 98], ["edema", "PROBLEM", 103, 108], ["Allergic Photodermatitis", "PROBLEM", 147, 171], ["erythema", "OBSERVATION", 90, 98], ["edema", "OBSERVATION", 103, 108]]], ["Lesions by Coelenterates should be treated with seawater or salted water, because fresh water is hypotonic and induces nematocysts to burst; it is sufficient to disinfect with alcohol.", [["Coelenterates", "DISEASE", 11, 24], ["alcohol", "CHEMICAL", 176, 183], ["alcohol", "CHEMICAL", 176, 183], ["alcohol", "SIMPLE_CHEMICAL", 176, 183], ["Lesions", "PROBLEM", 0, 7], ["hypotonic", "PROBLEM", 97, 106], ["nematocysts", "PROBLEM", 119, 130], ["hypotonic", "OBSERVATION", 97, 106]]], ["The more severe fish dermatitis and lesions should be cleaned with seawater then applying a tourniquet; application of hot water (>50\u00b0C, but in practice up to the degree of tolerance) helps to inactivate the poison.", [["lesions", "ANATOMY", 36, 43], ["fish dermatitis", "DISEASE", 16, 31], ["fish", "ORGANISM", 16, 20], ["lesions", "PATHOLOGICAL_FORMATION", 36, 43], ["The more severe fish dermatitis", "PROBLEM", 0, 31], ["lesions", "PROBLEM", 36, 43], ["a tourniquet", "TREATMENT", 90, 102], ["application of hot water", "TREATMENT", 104, 128], ["more", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["fish dermatitis", "OBSERVATION", 16, 31], ["lesions", "OBSERVATION", 36, 43]]], ["Depending on the circumstances, we suggest instituting a local or systemic treatment.", [["a local or systemic treatment", "TREATMENT", 55, 84]]], ["Echinoderm dermatitis is best treated by surgically removing the prickles or by dipping in hot water.", [["Echinoderm dermatitis", "DISEASE", 0, 21], ["Echinoderm dermatitis", "PROBLEM", 0, 21], ["the prickles", "TREATMENT", 61, 73], ["dermatitis", "OBSERVATION", 11, 21]]], ["Prophylactic approaches include the use of suitable shoes in shallow water and avoidance of touching such types of fish.Allergic VasculitisAllergic vasculitis, or hypersensitivity vasculitis, affects small-caliber vessels: this vasculitis is most frequent in children, also considering the objective rarity of this allergy section [34] .", [["small-caliber vessels", "ANATOMY", 200, 221], ["Allergic Vasculitis", "DISEASE", 120, 139], ["Allergic vasculitis", "DISEASE", 139, 158], ["hypersensitivity vasculitis", "DISEASE", 163, 190], ["vasculitis", "DISEASE", 228, 238], ["allergy", "DISEASE", 315, 322], ["fish", "ORGANISM", 115, 119], ["caliber vessels", "MULTI-TISSUE_STRUCTURE", 206, 221], ["children", "ORGANISM", 259, 267], ["children", "SPECIES", 259, 267], ["Prophylactic approaches", "TREATMENT", 0, 23], ["suitable shoes", "TREATMENT", 43, 57], ["Allergic Vasculitis", "PROBLEM", 120, 139], ["Allergic vasculitis", "PROBLEM", 139, 158], ["hypersensitivity vasculitis", "PROBLEM", 163, 190], ["this vasculitis", "PROBLEM", 223, 238], ["this allergy section", "TREATMENT", 310, 330], ["Vasculitis", "OBSERVATION", 129, 139], ["vasculitis", "OBSERVATION", 148, 158], ["hypersensitivity vasculitis", "OBSERVATION", 163, 190], ["small", "OBSERVATION_MODIFIER", 200, 205], ["caliber", "OBSERVATION_MODIFIER", 206, 213], ["vessels", "ANATOMY", 214, 221], ["vasculitis", "OBSERVATION", 228, 238]]], ["The allergic origin with CIC deposits is hypothesized after the report of several immunological dysfunctions and the histological and immunological aspects similar to those seen in experimental models of Arthus reaction and acute serum sickness [34] .DefinitionAllergic vasculitides in children is primarily characterized in histopathological terms by inflammation of vascular walls, possibly associated with necrosis and subsequent occlusion of vessels [24] .", [["serum", "ANATOMY", 230, 235], ["vascular walls", "ANATOMY", 368, 382], ["vessels", "ANATOMY", 446, 453], ["allergic", "DISEASE", 4, 12], ["Arthus reaction", "DISEASE", 204, 219], ["serum sickness", "DISEASE", 230, 244], ["Allergic vasculitides", "DISEASE", 261, 282], ["inflammation", "DISEASE", 352, 364], ["necrosis", "DISEASE", 409, 417], ["serum", "ORGANISM_SUBSTANCE", 230, 235], ["children", "ORGANISM", 286, 294], ["vascular walls", "MULTI-TISSUE_STRUCTURE", 368, 382], ["children", "SPECIES", 286, 294], ["The allergic origin", "PROBLEM", 0, 19], ["CIC deposits", "PROBLEM", 25, 37], ["several immunological dysfunctions", "PROBLEM", 74, 108], ["the histological and immunological aspects", "PROBLEM", 113, 155], ["Arthus reaction", "PROBLEM", 204, 219], ["acute serum sickness", "PROBLEM", 224, 244], ["Allergic vasculitides", "PROBLEM", 261, 282], ["inflammation of vascular walls", "PROBLEM", 352, 382], ["necrosis", "PROBLEM", 409, 417], ["subsequent occlusion of vessels", "PROBLEM", 422, 453], ["allergic origin", "OBSERVATION", 4, 19], ["CIC deposits", "OBSERVATION", 25, 37], ["several", "OBSERVATION_MODIFIER", 74, 81], ["immunological dysfunctions", "OBSERVATION", 82, 108], ["Arthus", "OBSERVATION", 204, 210], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["Allergic vasculitides", "OBSERVATION", 261, 282], ["inflammation", "OBSERVATION", 352, 364], ["vascular walls", "ANATOMY", 368, 382], ["possibly associated with", "UNCERTAINTY", 384, 408], ["necrosis", "OBSERVATION", 409, 417], ["occlusion", "OBSERVATION", 433, 442], ["vessels", "ANATOMY", 446, 453]]], ["They are included in a heterogeneous group of vasculopathies involving arteries with different locations and diameters, veins and capillaries, whose vessel walls have in common the typical lesions of necrotizing vasculitis, or are leukocytoclastic, always associated with inflammatory cells and perivascular infiltration of polymorphonuclear (PMN) leukocytes.ClassificationSeveral classifications based on morphology and clinical features have been proposed [11] .", [["arteries", "ANATOMY", 71, 79], ["veins", "ANATOMY", 120, 125], ["capillaries", "ANATOMY", 130, 141], ["vessel walls", "ANATOMY", 149, 161], ["lesions", "ANATOMY", 189, 196], ["inflammatory cells", "ANATOMY", 272, 290], ["perivascular", "ANATOMY", 295, 307], ["polymorphonuclear (PMN) leukocytes", "ANATOMY", 324, 358], ["vasculopathies", "DISEASE", 46, 60], ["vasculitis", "DISEASE", 212, 222], ["leukocytoclastic", "DISEASE", 231, 247], ["vasculopathies", "CANCER", 46, 60], ["arteries", "MULTI-TISSUE_STRUCTURE", 71, 79], ["veins", "MULTI-TISSUE_STRUCTURE", 120, 125], ["capillaries", "TISSUE", 130, 141], ["vessel walls", "MULTI-TISSUE_STRUCTURE", 149, 161], ["lesions", "PATHOLOGICAL_FORMATION", 189, 196], ["inflammatory cells", "CELL", 272, 290], ["perivascular infiltration of polymorphonuclear (PMN) leukocytes", "CELL", 295, 358], ["inflammatory cells", "CELL_TYPE", 272, 290], ["polymorphonuclear (PMN) leukocytes", "CELL_TYPE", 324, 358], ["vasculopathies involving arteries", "PROBLEM", 46, 79], ["necrotizing vasculitis", "PROBLEM", 200, 222], ["leukocytoclastic", "PROBLEM", 231, 247], ["inflammatory cells", "PROBLEM", 272, 290], ["perivascular infiltration of polymorphonuclear (PMN) leukocytes", "PROBLEM", 295, 358], ["heterogeneous", "OBSERVATION_MODIFIER", 23, 36], ["vasculopathies", "OBSERVATION", 46, 60], ["arteries", "ANATOMY", 71, 79], ["different", "OBSERVATION_MODIFIER", 85, 94], ["diameters", "OBSERVATION_MODIFIER", 109, 118], ["veins", "ANATOMY", 120, 125], ["capillaries", "ANATOMY_MODIFIER", 130, 141], ["vessel", "ANATOMY", 149, 155], ["walls", "ANATOMY_MODIFIER", 156, 161], ["typical", "OBSERVATION_MODIFIER", 181, 188], ["lesions", "OBSERVATION", 189, 196], ["necrotizing", "OBSERVATION_MODIFIER", 200, 211], ["vasculitis", "OBSERVATION", 212, 222], ["leukocytoclastic", "OBSERVATION_MODIFIER", 231, 247], ["always associated with", "UNCERTAINTY", 249, 271], ["inflammatory cells", "OBSERVATION", 272, 290], ["perivascular", "ANATOMY_MODIFIER", 295, 307], ["infiltration", "OBSERVATION", 308, 320], ["polymorphonuclear", "OBSERVATION_MODIFIER", 324, 341]]], ["Both the etiology and clinical features are entirely different, due to a spectrum of varying causes: Table 8 .19 [11, 17, 34, 122] classifies the principal allergic vasculitides in children.", [["allergic vasculitides", "DISEASE", 156, 177], ["children", "ORGANISM", 181, 189], ["children", "SPECIES", 181, 189], ["varying", "OBSERVATION_MODIFIER", 85, 92], ["principal", "OBSERVATION_MODIFIER", 146, 155], ["allergic vasculitides", "OBSERVATION", 156, 177]]], ["Contrary to adults, children suffer above all from SHS and to a lesser extent from hypersensitivity angiitis [31] .", [["hypersensitivity", "DISEASE", 83, 99], ["angiitis", "DISEASE", 100, 108], ["children", "ORGANISM", 20, 28], ["children", "SPECIES", 20, 28], ["hypersensitivity angiitis", "PROBLEM", 83, 108], ["lesser extent", "OBSERVATION_MODIFIER", 64, 77], ["hypersensitivity angiitis", "OBSERVATION", 83, 108]]], ["In the absence of PMN and CIC markers, the interference of CMI is also probable: active cells may be NK cells with perforins, T lymphocytes with direct cytotoxicity and/or DTH reactions, leading to increased vascular permeability and the accumulation of more leukocytes and proinflammatory molecules [24] .", [["PMN", "ANATOMY", 18, 21], ["cells", "ANATOMY", 88, 93], ["NK cells", "ANATOMY", 101, 109], ["perforins", "ANATOMY", 115, 124], ["T lymphocytes", "ANATOMY", 126, 139], ["vascular", "ANATOMY", 208, 216], ["leukocytes", "ANATOMY", 259, 269], ["PMN", "CELL", 18, 21], ["CIC", "GENE_OR_GENE_PRODUCT", 26, 29], ["cells", "CELL", 88, 93], ["NK cells", "CELL", 101, 109], ["perforins", "CELL", 115, 124], ["T lymphocytes", "CELL", 126, 139], ["DTH", "GENE_OR_GENE_PRODUCT", 172, 175], ["vascular", "MULTI-TISSUE_STRUCTURE", 208, 216], ["leukocytes", "CELL", 259, 269], ["PMN", "CELL_TYPE", 18, 21], ["CIC markers", "PROTEIN", 26, 37], ["NK cells", "CELL_TYPE", 101, 109], ["T lymphocytes", "CELL_TYPE", 126, 139], ["leukocytes", "CELL_TYPE", 259, 269], ["proinflammatory molecules", "PROTEIN", 274, 299], ["PMN", "PROBLEM", 18, 21], ["CIC markers", "TEST", 26, 37], ["CMI", "PROBLEM", 59, 62], ["active cells", "PROBLEM", 81, 93], ["NK cells", "PROBLEM", 101, 109], ["perforins", "PROBLEM", 115, 124], ["T lymphocytes", "PROBLEM", 126, 139], ["direct cytotoxicity", "PROBLEM", 145, 164], ["DTH reactions", "PROBLEM", 172, 185], ["increased vascular permeability", "PROBLEM", 198, 229], ["more leukocytes and proinflammatory molecules", "PROBLEM", 254, 299], ["also probable", "UNCERTAINTY", 66, 79], ["active cells", "OBSERVATION", 81, 93], ["may be", "UNCERTAINTY", 94, 100], ["NK cells", "OBSERVATION", 101, 109], ["increased", "OBSERVATION_MODIFIER", 198, 207], ["vascular permeability", "OBSERVATION", 208, 229], ["accumulation", "OBSERVATION_MODIFIER", 238, 250], ["more leukocytes", "OBSERVATION_MODIFIER", 254, 269]]], ["These pathogenetic models postulate that the endothelium suffers passively from the insult favored by complement activation, resulting in the production of complement breakdown products (C3a, C5a) that are chemoattractants to PMNs and PBMCs.", [["endothelium", "ANATOMY", 45, 56], ["PMNs", "ANATOMY", 226, 230], ["PBMCs", "ANATOMY", 235, 240], ["endothelium", "TISSUE", 45, 56], ["complement breakdown products", "GENE_OR_GENE_PRODUCT", 156, 185], ["C3a", "GENE_OR_GENE_PRODUCT", 187, 190], ["C5a", "GENE_OR_GENE_PRODUCT", 192, 195], ["PMNs", "CELL", 226, 230], ["PBMCs", "CELL", 235, 240], ["complement breakdown products", "PROTEIN", 156, 185], ["C3a", "PROTEIN", 187, 190], ["C5a", "PROTEIN", 192, 195], ["PMNs", "CELL_TYPE", 226, 230], ["PBMCs", "CELL_TYPE", 235, 240], ["the insult", "PROBLEM", 80, 90], ["complement breakdown products (C3a, C5a)", "PROBLEM", 156, 196], ["PMNs", "TEST", 226, 230], ["PBMCs", "TEST", 235, 240], ["endothelium", "ANATOMY", 45, 56]]], ["Usually, endothelial cells are protected from potential damage originating from CICs activated by several regulating molecules at various levels of the complement cascade; consequently 90% of CICs are eliminated by the liver (Kupffer and endothelial cells) and to a lesser extent by the alternative pathway.", [["endothelial cells", "ANATOMY", 9, 26], ["CICs", "ANATOMY", 80, 84], ["CICs", "ANATOMY", 192, 196], ["liver", "ANATOMY", 219, 224], ["Kupffer", "ANATOMY", 226, 233], ["endothelial cells", "ANATOMY", 238, 255], ["endothelial cells", "CELL", 9, 26], ["CICs", "CELL", 80, 84], ["CICs", "CELL", 192, 196], ["liver", "ORGAN", 219, 224], ["Kupffer", "CELL", 226, 233], ["endothelial cells", "CELL", 238, 255], ["endothelial cells", "CELL_TYPE", 9, 26], ["CICs", "CELL_TYPE", 80, 84], ["CICs", "CELL_TYPE", 192, 196], ["Kupffer and endothelial cells", "CELL_TYPE", 226, 255], ["endothelial cells", "PROBLEM", 9, 26], ["potential damage", "PROBLEM", 46, 62], ["CICs", "TEST", 192, 196], ["endothelial cells", "OBSERVATION", 9, 26], ["CICs", "OBSERVATION", 80, 84], ["liver", "ANATOMY", 219, 224], ["Kupffer", "ANATOMY", 226, 233], ["endothelial cells", "OBSERVATION", 238, 255], ["lesser extent", "OBSERVATION_MODIFIER", 266, 279]]], ["Similarly, if CICs react directly with erythrocytes CIC-erythrocyte complexes are transported to the liver, thus decreasing the risk of epithelial damage [11] .", [["CICs", "ANATOMY", 14, 18], ["erythrocytes", "ANATOMY", 39, 51], ["erythrocyte", "ANATOMY", 56, 67], ["liver", "ANATOMY", 101, 106], ["epithelial", "ANATOMY", 136, 146], ["epithelial damage", "DISEASE", 136, 153], ["CICs", "CELL", 14, 18], ["erythrocytes", "CELL", 39, 51], ["CIC-erythrocyte complexes", "GENE_OR_GENE_PRODUCT", 52, 77], ["liver", "ORGAN", 101, 106], ["epithelial", "TISSUE", 136, 146], ["CICs", "CELL_TYPE", 14, 18], ["erythrocytes", "CELL_TYPE", 39, 51], ["CIC", "PROTEIN", 52, 55], ["erythrocyte complexes", "PROTEIN", 56, 77], ["CICs", "TEST", 14, 18], ["erythrocytes CIC", "TEST", 39, 55], ["erythrocyte complexes", "PROBLEM", 56, 77], ["epithelial damage", "PROBLEM", 136, 153], ["liver", "ANATOMY", 101, 106], ["epithelial damage", "OBSERVATION", 136, 153]]], ["Conversely, the endothelium could also actively contribute to the development of vasculitis in the general context of inflammation [24] .ImmunopathogenesisAlthough etiopathogenesis remains in great part barely recognized, recent work speculates that CICs, after binding to endothelium, increase synthesis of adhesion molecules on the cell surfaces.", [["endothelium", "ANATOMY", 16, 27], ["CICs", "ANATOMY", 250, 254], ["endothelium", "ANATOMY", 273, 284], ["cell surfaces", "ANATOMY", 334, 347], ["vasculitis", "DISEASE", 81, 91], ["inflammation", "DISEASE", 118, 130], ["endothelium", "TISSUE", 16, 27], ["CICs", "CELL", 250, 254], ["endothelium", "TISSUE", 273, 284], ["cell surfaces", "CELLULAR_COMPONENT", 334, 347], ["CICs", "CELL_TYPE", 250, 254], ["adhesion molecules", "PROTEIN", 308, 326], ["vasculitis", "PROBLEM", 81, 91], ["inflammation", "PROBLEM", 118, 130], ["Immunopathogenesis", "PROBLEM", 137, 155], ["etiopathogenesis", "PROBLEM", 164, 180], ["adhesion molecules", "PROBLEM", 308, 326], ["endothelium", "ANATOMY", 16, 27], ["vasculitis", "OBSERVATION", 81, 91], ["inflammation", "OBSERVATION", 118, 130], ["great part", "OBSERVATION_MODIFIER", 192, 202], ["adhesion molecules", "OBSERVATION", 308, 326], ["cell surfaces", "OBSERVATION", 334, 347]]], ["Leukocytes carry integrins and selectins, and endothelial cells add CD54 and CD106 to the selectins [78, 148] , which are crucial for leukocyte migration between endothelial cells, as analyzed in Chap.", [["Leukocytes", "ANATOMY", 0, 10], ["endothelial cells", "ANATOMY", 46, 63], ["leukocyte", "ANATOMY", 134, 143], ["endothelial cells", "ANATOMY", 162, 179], ["Leukocytes", "CELL", 0, 10], ["integrins", "GENE_OR_GENE_PRODUCT", 17, 26], ["selectins", "GENE_OR_GENE_PRODUCT", 31, 40], ["endothelial cells", "CELL", 46, 63], ["CD54", "GENE_OR_GENE_PRODUCT", 68, 72], ["CD106", "GENE_OR_GENE_PRODUCT", 77, 82], ["leukocyte", "CELL", 134, 143], ["endothelial cells", "CELL", 162, 179], ["Leukocytes", "CELL_TYPE", 0, 10], ["integrins", "PROTEIN", 17, 26], ["selectins", "PROTEIN", 31, 40], ["endothelial cells", "CELL_TYPE", 46, 63], ["CD54", "PROTEIN", 68, 72], ["CD106", "PROTEIN", 77, 82], ["selectins", "PROTEIN", 90, 99], ["endothelial cells", "CELL_TYPE", 162, 179], ["Chap", "PROTEIN", 196, 200], ["Leukocytes carry integrins", "TEST", 0, 26], ["selectins", "TEST", 31, 40], ["endothelial cells", "TEST", 46, 63], ["CD54", "TEST", 68, 72], ["the selectins", "TEST", 86, 99], ["leukocyte migration between endothelial cells", "PROBLEM", 134, 179], ["endothelial", "ANATOMY", 46, 57], ["crucial for", "UNCERTAINTY", 122, 133], ["leukocyte migration", "OBSERVATION", 134, 153], ["endothelial cells", "OBSERVATION", 162, 179]]], ["A new mechanism mediating the unmatched pathogenetic processes of diverse types of vasculitis is essentially the formation of anti-endothelial cell antibodies (AECAs), CIC deposition and T lymphocyte adhesion to the vascular wall.", [["anti-endothelial cell", "ANATOMY", 126, 147], ["AECAs", "ANATOMY", 160, 165], ["T lymphocyte", "ANATOMY", 187, 199], ["vascular wall", "ANATOMY", 216, 229], ["vasculitis", "DISEASE", 83, 93], ["anti-endothelial cell antibodies", "GENE_OR_GENE_PRODUCT", 126, 158], ["AECAs", "CANCER", 160, 165], ["CIC", "GENE_OR_GENE_PRODUCT", 168, 171], ["T lymphocyte", "CELL", 187, 199], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 216, 229], ["anti-endothelial cell antibodies", "PROTEIN", 126, 158], ["AECAs", "PROTEIN", 160, 165], ["CIC", "PROTEIN", 168, 171], ["A new mechanism", "PROBLEM", 0, 15], ["vasculitis", "PROBLEM", 83, 93], ["anti-endothelial cell antibodies (AECAs)", "PROBLEM", 126, 166], ["CIC deposition", "PROBLEM", 168, 182], ["T lymphocyte adhesion", "PROBLEM", 187, 208], ["new", "OBSERVATION_MODIFIER", 2, 5], ["diverse", "OBSERVATION_MODIFIER", 66, 73], ["types", "OBSERVATION_MODIFIER", 74, 79], ["vasculitis", "OBSERVATION", 83, 93], ["anti-endothelial cell antibodies", "OBSERVATION", 126, 158], ["CIC deposition", "OBSERVATION", 168, 182], ["T lymphocyte adhesion", "OBSERVATION", 187, 208], ["vascular", "ANATOMY", 216, 224], ["wall", "ANATOMY_MODIFIER", 225, 229]]], ["Several other mechanisms may play a major part, including the release of antibodies against antigens located in the surrounding sites, phagocyte adhesion and complement dysregulation at the tissue level [24] .", [["sites", "ANATOMY", 128, 133], ["phagocyte", "ANATOMY", 135, 144], ["tissue", "ANATOMY", 190, 196], ["antibodies against antigens", "GENE_OR_GENE_PRODUCT", 73, 100], ["phagocyte", "CELL", 135, 144], ["tissue", "TISSUE", 190, 196], ["antibodies", "PROTEIN", 73, 83], ["antigens", "PROTEIN", 92, 100], ["the release of antibodies", "TREATMENT", 58, 83], ["antigens", "PROBLEM", 92, 100], ["phagocyte adhesion", "PROBLEM", 135, 153], ["complement dysregulation at the tissue level", "PROBLEM", 158, 202], ["phagocyte adhesion", "OBSERVATION", 135, 153]]], ["It is tempting to speculate that CD4 activation by antigens presented by APC in association with HLA class II molecules mediates B lymphocyte activation with subsequent production of ANCA (anti-neutrophil circulating antibodies), formation of CICs and complement activation attracting PMNs also recruited by chemokines (Fig. 8.18 ) [177] .", [["B lymphocyte", "ANATOMY", 129, 141], ["CICs", "ANATOMY", 243, 247], ["PMNs", "ANATOMY", 285, 289], ["CD4", "GENE_OR_GENE_PRODUCT", 33, 36], ["APC", "GENE_OR_GENE_PRODUCT", 73, 76], ["HLA class II", "GENE_OR_GENE_PRODUCT", 97, 109], ["B lymphocyte", "CELL", 129, 141], ["ANCA", "GENE_OR_GENE_PRODUCT", 183, 187], ["anti-neutrophil circulating antibodies", "GENE_OR_GENE_PRODUCT", 189, 227], ["CICs", "CELL", 243, 247], ["PMNs", "CELL", 285, 289], ["CD4", "PROTEIN", 33, 36], ["antigens", "PROTEIN", 51, 59], ["APC", "CELL_TYPE", 73, 76], ["HLA class II molecules", "PROTEIN", 97, 119], ["ANCA", "PROTEIN", 183, 187], ["neutrophil circulating antibodies", "PROTEIN", 194, 227], ["PMNs", "CELL_TYPE", 285, 289], ["chemokines", "PROTEIN", 308, 318], ["B lymphocyte activation", "PROBLEM", 129, 152], ["ANCA", "TEST", 183, 187], ["anti-neutrophil circulating antibodies", "TEST", 189, 227], ["CICs", "PROBLEM", 243, 247], ["CD4", "OBSERVATION", 33, 36], ["lymphocyte activation", "OBSERVATION", 131, 152], ["ANCA", "OBSERVATION", 183, 187]]], ["A set of Aab directed against PMN proteinase 3 (PR3) such as the c-ANCA (cytoplasmic ANCA) have been implicated in the pathogenesis of Wegener granulomatosis with a remarkable predictive significance, thus embodying a key diagnostic role [122] .", [["cytoplasmic", "ANATOMY", 73, 84], ["Wegener granulomatosis", "DISEASE", 135, 157], ["Aab directed against PMN proteinase 3", "GENE_OR_GENE_PRODUCT", 9, 46], ["PR3", "GENE_OR_GENE_PRODUCT", 48, 51], ["c-ANCA", "GENE_OR_GENE_PRODUCT", 65, 71], ["cytoplasmic", "ORGANISM_SUBSTANCE", 73, 84], ["ANCA", "GENE_OR_GENE_PRODUCT", 85, 89], ["Aab", "PROTEIN", 9, 12], ["PMN proteinase 3", "PROTEIN", 30, 46], ["PR3", "PROTEIN", 48, 51], ["c-ANCA", "PROTEIN", 65, 71], ["cytoplasmic ANCA", "PROTEIN", 73, 89], ["PMN proteinase", "TEST", 30, 44], ["PR3", "TEST", 48, 51], ["the c-ANCA", "TEST", 61, 71], ["cytoplasmic ANCA", "TEST", 73, 89], ["Wegener granulomatosis", "PROBLEM", 135, 157], ["ANCA", "OBSERVATION", 67, 71], ["cytoplasmic ANCA", "OBSERVATION", 73, 89], ["Wegener granulomatosis", "OBSERVATION", 135, 157]]], ["That these c-ANCA recognize PR3, p-ANCA (perinuclear ANCA), MPO (myeloperoxidase) and the elastase, shown also in patients with polyarteritis nodosa, Kawasaki syndrome and SHS, where they are of IgA class, supports the hypothesis that clinically different disorders might have aPrevalenceA study referred to by Athreya [11] points to a 4% incidence, probably an underestimate because only academic centers were involved in this data collection, and pediatricians usually see and treat cases of SHS and Kawasaki syndrome, the most common vasculitides.Histological AspectsDermal inflammatory phenomena are localized prevalently among capillaries; therefore the vasal endothelium plays a crucial role in these cases.", [["capillaries", "ANATOMY", 632, 643], ["vasal endothelium", "ANATOMY", 659, 676], ["polyarteritis nodosa", "DISEASE", 128, 148], ["Kawasaki syndrome", "DISEASE", 150, 167], ["SHS", "DISEASE", 494, 497], ["Kawasaki syndrome", "DISEASE", 502, 519], ["vasculitides", "DISEASE", 537, 549], ["c-ANCA", "GENE_OR_GENE_PRODUCT", 11, 17], ["PR3", "GENE_OR_GENE_PRODUCT", 28, 31], ["p-ANCA", "GENE_OR_GENE_PRODUCT", 33, 39], ["perinuclear ANCA", "GENE_OR_GENE_PRODUCT", 41, 57], ["MPO", "SIMPLE_CHEMICAL", 60, 63], ["myeloperoxidase", "SIMPLE_CHEMICAL", 65, 80], ["elastase", "GENE_OR_GENE_PRODUCT", 90, 98], ["patients", "ORGANISM", 114, 122], ["IgA", "GENE_OR_GENE_PRODUCT", 195, 198], ["capillaries", "TISSUE", 632, 643], ["vasal endothelium", "TISSUE", 659, 676], ["c", "PROTEIN", 11, 12], ["ANCA", "PROTEIN", 13, 17], ["PR3", "PROTEIN", 28, 31], ["p-ANCA", "PROTEIN", 33, 39], ["perinuclear ANCA", "PROTEIN", 41, 57], ["MPO", "PROTEIN", 60, 63], ["myeloperoxidase", "PROTEIN", 65, 80], ["elastase", "PROTEIN", 90, 98], ["IgA", "PROTEIN", 195, 198], ["patients", "SPECIES", 114, 122], ["PR3", "TEST", 28, 31], ["p-ANCA", "TEST", 33, 39], ["perinuclear ANCA", "TEST", 41, 57], ["MPO (myeloperoxidase", "TEST", 60, 80], ["the elastase", "TEST", 86, 98], ["polyarteritis nodosa", "PROBLEM", 128, 148], ["Kawasaki syndrome", "PROBLEM", 150, 167], ["clinically different disorders", "PROBLEM", 235, 265], ["aPrevalenceA study", "TEST", 277, 295], ["SHS", "PROBLEM", 494, 497], ["Kawasaki syndrome", "PROBLEM", 502, 519], ["Histological AspectsDermal inflammatory phenomena", "PROBLEM", 550, 599], ["elastase", "OBSERVATION", 90, 98], ["polyarteritis", "OBSERVATION_MODIFIER", 128, 141], ["nodosa", "OBSERVATION", 142, 148], ["Kawasaki syndrome", "OBSERVATION", 150, 167], ["inflammatory phenomena", "OBSERVATION", 577, 599], ["vasal endothelium", "ANATOMY", 659, 676]]], ["The vessel wall becomes a target of immune processes, characteristic of vasculitis [34] .", [["vessel wall", "ANATOMY", 4, 15], ["vasculitis", "DISEASE", 72, 82], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 4, 15], ["immune processes", "PROBLEM", 36, 52], ["vasculitis", "PROBLEM", 72, 82], ["vessel", "ANATOMY", 4, 10], ["wall", "ANATOMY_MODIFIER", 11, 15], ["immune processes", "OBSERVATION", 36, 52], ["vasculitis", "OBSERVATION", 72, 82]]], ["The vasal lesions affect the superficial dermal capillaries; endothelial cells are the seat of edema restricting the vessel lumen.", [["vasal lesions", "ANATOMY", 4, 17], ["superficial dermal capillaries", "ANATOMY", 29, 59], ["endothelial cells", "ANATOMY", 61, 78], ["edema", "ANATOMY", 95, 100], ["vessel lumen", "ANATOMY", 117, 129], ["edema", "DISEASE", 95, 100], ["vasal lesions", "CANCER", 4, 17], ["superficial dermal capillaries", "TISSUE", 29, 59], ["endothelial cells", "CELL", 61, 78], ["edema", "PATHOLOGICAL_FORMATION", 95, 100], ["vessel lumen", "MULTI-TISSUE_STRUCTURE", 117, 129], ["endothelial cells", "CELL_TYPE", 61, 78], ["The vasal lesions", "PROBLEM", 0, 17], ["endothelial cells", "PROBLEM", 61, 78], ["edema", "PROBLEM", 95, 100], ["vasal", "ANATOMY", 4, 9], ["lesions", "OBSERVATION", 10, 17], ["superficial", "ANATOMY_MODIFIER", 29, 40], ["dermal capillaries", "ANATOMY", 41, 59], ["endothelial cells", "OBSERVATION", 61, 78], ["edema", "OBSERVATION", 95, 100], ["vessel", "ANATOMY", 117, 123], ["lumen", "ANATOMY_MODIFIER", 124, 129]]], ["Thus the wall is thickened, infiltrated by fibrin deposits that extend to adjacent connective tissue, leading to fibrinoid necrosis, which derives its name from its tintorial affinity with fibrin, characteristic of necrotizing vasculitis.", [["wall", "ANATOMY", 9, 13], ["connective tissue", "ANATOMY", 83, 100], ["fibrinoid", "ANATOMY", 113, 122], ["necrosis", "DISEASE", 123, 131], ["vasculitis", "DISEASE", 227, 237], ["wall", "TISSUE", 9, 13], ["fibrin", "GENE_OR_GENE_PRODUCT", 43, 49], ["connective tissue", "TISSUE", 83, 100], ["fibrinoid", "TISSUE", 113, 122], ["fibrin", "GENE_OR_GENE_PRODUCT", 189, 195], ["fibrin", "PROTEIN", 189, 195], ["thickened", "PROBLEM", 17, 26], ["fibrin deposits", "PROBLEM", 43, 58], ["adjacent connective tissue", "PROBLEM", 74, 100], ["fibrinoid necrosis", "PROBLEM", 113, 131], ["fibrin", "PROBLEM", 189, 195], ["necrotizing vasculitis", "PROBLEM", 215, 237], ["wall", "ANATOMY_MODIFIER", 9, 13], ["thickened", "OBSERVATION", 17, 26], ["infiltrated", "OBSERVATION_MODIFIER", 28, 39], ["fibrin deposits", "OBSERVATION", 43, 58], ["connective tissue", "OBSERVATION", 83, 100], ["leading to", "UNCERTAINTY", 102, 112], ["fibrinoid", "OBSERVATION_MODIFIER", 113, 122], ["necrosis", "OBSERVATION", 123, 131], ["fibrin", "OBSERVATION", 189, 195], ["characteristic of", "UNCERTAINTY", 197, 214], ["necrotizing", "OBSERVATION_MODIFIER", 215, 226], ["vasculitis", "OBSERVATION", 227, 237]]], ["A perivascular inflammatory infiltrate complicates the wall lesions, which, along with edema, are responsible for the infiltrated character of the purpura, including various amounts of PMNs, whose nuclei undergo pyknosis and disintegrate to so-called nuclear dust.", [["perivascular inflammatory infiltrate", "ANATOMY", 2, 38], ["wall lesions", "ANATOMY", 55, 67], ["edema", "ANATOMY", 87, 92], ["PMNs", "ANATOMY", 185, 189], ["nuclei", "ANATOMY", 197, 203], ["nuclear", "ANATOMY", 251, 258], ["edema", "DISEASE", 87, 92], ["purpura", "DISEASE", 147, 154], ["wall lesions", "PATHOLOGICAL_FORMATION", 55, 67], ["edema", "PATHOLOGICAL_FORMATION", 87, 92], ["PMNs", "CELL", 185, 189], ["nuclei", "CELLULAR_COMPONENT", 197, 203], ["pyknosis", "CELLULAR_COMPONENT", 212, 220], ["PMNs", "CELL_TYPE", 185, 189], ["A perivascular inflammatory infiltrate", "PROBLEM", 0, 38], ["the wall lesions", "PROBLEM", 51, 67], ["edema", "PROBLEM", 87, 92], ["the purpura", "PROBLEM", 143, 154], ["various amounts of PMNs", "PROBLEM", 166, 189], ["pyknosis", "PROBLEM", 212, 220], ["perivascular", "OBSERVATION_MODIFIER", 2, 14], ["inflammatory", "OBSERVATION_MODIFIER", 15, 27], ["infiltrate", "OBSERVATION", 28, 38], ["wall", "ANATOMY_MODIFIER", 55, 59], ["lesions", "OBSERVATION", 60, 67], ["edema", "OBSERVATION", 87, 92], ["responsible for", "UNCERTAINTY", 98, 113], ["infiltrated", "OBSERVATION", 118, 129], ["purpura", "OBSERVATION", 147, 154], ["various", "OBSERVATION_MODIFIER", 166, 173], ["amounts", "OBSERVATION_MODIFIER", 174, 181], ["PMNs", "OBSERVATION", 185, 189], ["pyknosis", "OBSERVATION", 212, 220], ["dust", "OBSERVATION", 259, 263]]], ["PMN cell decay is known as leukocytoclasis, inconstant but with a great diagnostic value [34] .", [["PMN cell", "ANATOMY", 0, 8], ["PMN cell", "CELL", 0, 8], ["PMN cell decay", "PROBLEM", 0, 14], ["leukocytoclasis", "PROBLEM", 27, 42], ["cell decay", "OBSERVATION", 4, 14], ["inconstant", "OBSERVATION_MODIFIER", 44, 54]]], ["The infiltrate may also include intact eosinophils and mast cells, associated with PMNs; however, PBMCs could be recruited before PMNs.Vasculitis is a cause of dermal hemorrhages, clinically corresponding to purpura, more rarely of local ischemia, responsible for more or less ulcerate bullous lesions.", [["eosinophils", "ANATOMY", 39, 50], ["mast cells", "ANATOMY", 55, 65], ["PMNs", "ANATOMY", 83, 87], ["PBMCs", "ANATOMY", 98, 103], ["PMNs", "ANATOMY", 130, 134], ["dermal", "ANATOMY", 160, 166], ["ulcerate bullous lesions", "ANATOMY", 277, 301], ["Vasculitis", "DISEASE", 135, 145], ["dermal hemorrhages", "DISEASE", 160, 178], ["purpura", "DISEASE", 208, 215], ["ischemia", "DISEASE", 238, 246], ["bullous lesions", "DISEASE", 286, 301], ["eosinophils", "CELL", 39, 50], ["mast cells", "CELL", 55, 65], ["PMNs", "CELL", 83, 87], ["PBMCs", "CELL", 98, 103], ["PMNs", "CELL", 130, 134], ["dermal hemorrhages", "PATHOLOGICAL_FORMATION", 160, 178], ["bullous lesions", "PATHOLOGICAL_FORMATION", 286, 301], ["eosinophils", "CELL_TYPE", 39, 50], ["mast cells", "CELL_TYPE", 55, 65], ["PMNs", "CELL_TYPE", 83, 87], ["PBMCs", "CELL_TYPE", 98, 103], ["PMNs", "CELL_TYPE", 130, 134], ["The infiltrate", "PROBLEM", 0, 14], ["intact eosinophils", "PROBLEM", 32, 50], ["mast cells", "PROBLEM", 55, 65], ["PMNs", "PROBLEM", 83, 87], ["PBMCs", "TEST", 98, 103], ["PMNs", "TEST", 130, 134], ["Vasculitis", "PROBLEM", 135, 145], ["dermal hemorrhages", "PROBLEM", 160, 178], ["purpura", "PROBLEM", 208, 215], ["local ischemia", "PROBLEM", 232, 246], ["less ulcerate bullous lesions", "PROBLEM", 272, 301], ["infiltrate", "OBSERVATION", 4, 14], ["may also include", "UNCERTAINTY", 15, 31], ["intact", "OBSERVATION_MODIFIER", 32, 38], ["eosinophils", "OBSERVATION", 39, 50], ["mast cells", "OBSERVATION", 55, 65], ["dermal", "OBSERVATION_MODIFIER", 160, 166], ["hemorrhages", "OBSERVATION", 167, 178], ["purpura", "OBSERVATION", 208, 215], ["local", "OBSERVATION_MODIFIER", 232, 237], ["ischemia", "OBSERVATION", 238, 246], ["responsible for", "UNCERTAINTY", 248, 263], ["less", "OBSERVATION_MODIFIER", 272, 276], ["ulcerate", "OBSERVATION_MODIFIER", 277, 285], ["bullous", "OBSERVATION_MODIFIER", 286, 293], ["lesions", "OBSERVATION", 294, 301]]], ["Yet the pattern is not always that of a typical form [24] .Pathophysiological AspectsCICs have a key role in the pathophysiology of leukocytoclastic vasculitis; additional elements confirm that these vasculitides depend on type III immune reactions, based on serum anticomplement power, hypocomplementemia and above all the observation, by direct immunofluorescence, of complement and/or antibodies in the vessel walls.", [["serum", "ANATOMY", 259, 264], ["vessel walls", "ANATOMY", 406, 418], ["leukocytoclastic vasculitis", "DISEASE", 132, 159], ["vasculitides", "DISEASE", 200, 212], ["AspectsCICs", "GENE_OR_GENE_PRODUCT", 78, 89], ["leukocytoclastic vasculitis", "PATHOLOGICAL_FORMATION", 132, 159], ["serum", "ORGANISM_SUBSTANCE", 259, 264], ["complement", "GENE_OR_GENE_PRODUCT", 370, 380], ["vessel walls", "MULTI-TISSUE_STRUCTURE", 406, 418], ["AspectsCICs", "PROTEIN", 78, 89], ["antibodies", "PROTEIN", 388, 398], ["Pathophysiological AspectsCICs", "PROBLEM", 59, 89], ["leukocytoclastic vasculitis", "PROBLEM", 132, 159], ["these vasculitides", "PROBLEM", 194, 212], ["type III immune reactions", "PROBLEM", 223, 248], ["serum anticomplement power", "TEST", 259, 285], ["hypocomplementemia", "PROBLEM", 287, 305], ["direct immunofluorescence", "TEST", 340, 365], ["not always", "UNCERTAINTY", 19, 29], ["leukocytoclastic", "OBSERVATION_MODIFIER", 132, 148], ["vasculitis", "OBSERVATION", 149, 159], ["vasculitides", "OBSERVATION", 200, 212], ["hypocomplementemia", "OBSERVATION", 287, 305], ["vessel", "ANATOMY", 406, 412], ["walls", "ANATOMY_MODIFIER", 413, 418]]], ["CICs are not always demonstrable in the vessels; on the other hand, even if CICs are detected in numerous pathological conditions, only occasionally are CICs demonstrated in some forms of vasculites, or there is a parallel between CIC titer and the outcome of vessel lesions.", [["CICs", "ANATOMY", 0, 4], ["vessels", "ANATOMY", 40, 47], ["CICs", "ANATOMY", 76, 80], ["CICs", "ANATOMY", 153, 157], ["vasculites", "ANATOMY", 188, 198], ["vessel lesions", "ANATOMY", 260, 274], ["vasculites", "DISEASE", 188, 198], ["CICs", "CELL", 0, 4], ["vessels", "MULTI-TISSUE_STRUCTURE", 40, 47], ["CICs", "CELL", 76, 80], ["CICs", "CELL", 153, 157], ["vasculites", "CANCER", 188, 198], ["CIC", "CANCER", 231, 234], ["vessel lesions", "PATHOLOGICAL_FORMATION", 260, 274], ["CICs", "CELL_TYPE", 0, 4], ["CICs", "CELL_TYPE", 76, 80], ["CICs", "PROBLEM", 76, 80], ["vasculites", "PROBLEM", 188, 198], ["a parallel between CIC titer", "PROBLEM", 212, 240], ["vessel lesions", "PROBLEM", 260, 274], ["not always demonstrable", "UNCERTAINTY", 9, 32], ["vessels", "ANATOMY", 40, 47], ["CICs", "OBSERVATION", 153, 157], ["vessel", "ANATOMY", 260, 266], ["lesions", "OBSERVATION", 267, 274]]], ["Both antigens and antibodies found in the vessel walls are rarely detected [34] .", [["vessel walls", "ANATOMY", 42, 54], ["vessel walls", "MULTI-TISSUE_STRUCTURE", 42, 54], ["antigens", "PROTEIN", 5, 13], ["antibodies", "PROTEIN", 18, 28], ["Both antigens and antibodies", "TEST", 0, 28], ["vessel", "ANATOMY", 42, 48], ["walls", "ANATOMY_MODIFIER", 49, 54]]], ["PBMCs infiltrate in some vasculites, chiefly lymphocytes and partly monocytes, by lysosomal release of digestive enzymes that attack first the adventitia and then the media coat of vessel wall, thus destroying the cellular matrix of these vessels and surrounding tissues. common pathogenesis caused by antibody-mediated PMN activation [79] , and by ANCA involvement in pathogenesis.Pathophysiological AspectsMicrobial or viral infections may foster TNF-a production and thus the expression of ectoplasmatic antigens such as PR3 and MPO on PMN membrane and epithelial cells [177] .", [["PBMCs", "ANATOMY", 0, 5], ["vasculites", "ANATOMY", 25, 35], ["lymphocytes", "ANATOMY", 45, 56], ["monocytes", "ANATOMY", 68, 77], ["lysosomal", "ANATOMY", 82, 91], ["adventitia", "ANATOMY", 143, 153], ["vessel wall", "ANATOMY", 181, 192], ["cellular matrix", "ANATOMY", 214, 229], ["vessels", "ANATOMY", 239, 246], ["tissues", "ANATOMY", 263, 270], ["PMN", "ANATOMY", 320, 323], ["PMN membrane", "ANATOMY", 539, 551], ["epithelial cells", "ANATOMY", 556, 572], ["viral infections", "DISEASE", 421, 437], ["PBMCs", "CELL", 0, 5], ["vasculites", "CELL", 25, 35], ["lymphocytes", "CELL", 45, 56], ["monocytes", "CELL", 68, 77], ["lysosomal", "CELLULAR_COMPONENT", 82, 91], ["adventitia", "TISSUE", 143, 153], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 181, 192], ["cellular matrix", "CELLULAR_COMPONENT", 214, 229], ["vessels", "MULTI-TISSUE_STRUCTURE", 239, 246], ["surrounding tissues", "TISSUE", 251, 270], ["PMN", "CELL", 320, 323], ["ANCA", "GENE_OR_GENE_PRODUCT", 349, 353], ["TNF-a", "GENE_OR_GENE_PRODUCT", 449, 454], ["ectoplasmatic antigens", "GENE_OR_GENE_PRODUCT", 493, 515], ["PR3", "GENE_OR_GENE_PRODUCT", 524, 527], ["MPO", "GENE_OR_GENE_PRODUCT", 532, 535], ["PMN membrane", "CELLULAR_COMPONENT", 539, 551], ["epithelial cells", "CELL", 556, 572], ["PBMCs", "CELL_TYPE", 0, 5], ["vasculites", "CELL_TYPE", 25, 35], ["lymphocytes", "CELL_TYPE", 45, 56], ["monocytes", "CELL_TYPE", 68, 77], ["digestive enzymes", "PROTEIN", 103, 120], ["ANCA", "PROTEIN", 349, 353], ["TNF", "PROTEIN", 449, 452], ["ectoplasmatic antigens", "PROTEIN", 493, 515], ["PR3", "PROTEIN", 524, 527], ["MPO", "PROTEIN", 532, 535], ["epithelial cells", "CELL_TYPE", 556, 572], ["PBMCs infiltrate", "PROBLEM", 0, 16], ["some vasculites", "PROBLEM", 20, 35], ["partly monocytes", "PROBLEM", 61, 77], ["digestive enzymes", "TEST", 103, 120], ["common pathogenesis", "PROBLEM", 272, 291], ["antibody", "TEST", 302, 310], ["pathogenesis", "PROBLEM", 369, 381], ["Pathophysiological AspectsMicrobial or viral infections", "PROBLEM", 382, 437], ["TNF", "PROBLEM", 449, 452], ["ectoplasmatic antigens", "PROBLEM", 493, 515], ["PR3", "TEST", 524, 527], ["MPO on PMN membrane", "TEST", 532, 551], ["epithelial cells", "PROBLEM", 556, 572], ["infiltrate", "OBSERVATION", 6, 16], ["monocytes", "OBSERVATION", 68, 77], ["adventitia", "ANATOMY", 143, 153], ["vessel", "ANATOMY", 181, 187], ["wall", "ANATOMY_MODIFIER", 188, 192], ["cellular matrix", "OBSERVATION", 214, 229], ["vessels", "ANATOMY", 239, 246], ["ANCA", "OBSERVATION", 349, 353], ["viral", "OBSERVATION_MODIFIER", 421, 426], ["infections", "OBSERVATION", 427, 437], ["PMN membrane", "ANATOMY", 539, 551], ["epithelial cells", "OBSERVATION", 556, 572]]], ["Both proteins and enzyme recognized by ANCA have also been found on granulocyte surface, and are therefore more easily attacked.", [["granulocyte surface", "ANATOMY", 68, 87], ["ANCA", "GENE_OR_GENE_PRODUCT", 39, 43], ["granulocyte surface", "CELLULAR_COMPONENT", 68, 87], ["ANCA", "PROTEIN", 39, 43], ["enzyme", "TEST", 18, 24], ["ANCA", "PROBLEM", 39, 43], ["granulocyte surface", "TEST", 68, 87], ["ANCA", "OBSERVATION", 39, 43], ["granulocyte surface", "OBSERVATION_MODIFIER", 68, 87]]], ["In addition it is likely that ANCA antibodies bind PMN expressing PR3 on surface, thus causing degranulation with release of free O 2 radicals and lysosomal enzymes on surrounding epithelial tissues, or alternatively bind enzymes released by cells damaged by the inflammatory process, facilitating their transport to the tissues where the enzymes cause further damage [79] .", [["PMN", "ANATOMY", 51, 54], ["surface", "ANATOMY", 73, 80], ["lysosomal", "ANATOMY", 147, 156], ["epithelial tissues", "ANATOMY", 180, 198], ["cells", "ANATOMY", 242, 247], ["tissues", "ANATOMY", 321, 328], ["O 2", "CHEMICAL", 130, 133], ["ANCA antibodies", "GENE_OR_GENE_PRODUCT", 30, 45], ["PMN", "CELL", 51, 54], ["PR3", "GENE_OR_GENE_PRODUCT", 66, 69], ["surface", "CELLULAR_COMPONENT", 73, 80], ["O 2 radicals", "SIMPLE_CHEMICAL", 130, 142], ["lysosomal enzymes", "GENE_OR_GENE_PRODUCT", 147, 164], ["epithelial tissues", "TISSUE", 180, 198], ["cells", "CELL", 242, 247], ["tissues", "TISSUE", 321, 328], ["ANCA antibodies", "PROTEIN", 30, 45], ["PMN", "CELL_TYPE", 51, 54], ["PR3", "PROTEIN", 66, 69], ["lysosomal enzymes", "PROTEIN", 147, 164], ["enzymes", "PROTEIN", 222, 229], ["ANCA antibodies bind PMN", "PROBLEM", 30, 54], ["degranulation", "PROBLEM", 95, 108], ["lysosomal enzymes", "TEST", 147, 164], ["bind enzymes", "PROBLEM", 217, 229], ["the inflammatory process", "PROBLEM", 259, 283], ["the enzymes", "TEST", 335, 346], ["further damage", "PROBLEM", 353, 367], ["is likely", "UNCERTAINTY", 15, 24], ["ANCA", "OBSERVATION", 30, 34], ["epithelial tissues", "ANATOMY", 180, 198], ["inflammatory", "OBSERVATION", 263, 275]]], ["In parallel, the ANCA/PR3 interaction induces, by mechanisms not yet fully understood, an increased CD62E and CD106 expression, which attaching to epithelium modulates the adhesion of PMN [177] , CD54 and CD102 [78, 148] , which bind their contrareceptors CD11a/CD18, CD11b/ CD18 and CD11c/CD18.", [["epithelium", "ANATOMY", 147, 157], ["PMN", "ANATOMY", 184, 187], ["ANCA", "GENE_OR_GENE_PRODUCT", 17, 21], ["PR3", "GENE_OR_GENE_PRODUCT", 22, 25], ["CD62E", "GENE_OR_GENE_PRODUCT", 100, 105], ["CD106", "GENE_OR_GENE_PRODUCT", 110, 115], ["epithelium", "TISSUE", 147, 157], ["PMN", "CELL", 184, 187], ["CD54", "GENE_OR_GENE_PRODUCT", 196, 200], ["CD102", "GENE_OR_GENE_PRODUCT", 205, 210], ["CD11a", "GENE_OR_GENE_PRODUCT", 256, 261], ["CD18", "GENE_OR_GENE_PRODUCT", 262, 266], ["CD11b", "GENE_OR_GENE_PRODUCT", 268, 273], ["CD18", "GENE_OR_GENE_PRODUCT", 275, 279], ["CD11c", "GENE_OR_GENE_PRODUCT", 284, 289], ["CD18", "GENE_OR_GENE_PRODUCT", 290, 294], ["ANCA", "PROTEIN", 17, 21], ["PR3", "PROTEIN", 22, 25], ["CD62E", "PROTEIN", 100, 105], ["CD106", "PROTEIN", 110, 115], ["PMN", "CELL_TYPE", 184, 187], ["CD54", "PROTEIN", 196, 200], ["CD102", "PROTEIN", 205, 210], ["CD11a", "PROTEIN", 256, 261], ["CD18", "PROTEIN", 262, 266], ["CD11b", "PROTEIN", 268, 273], ["CD18", "PROTEIN", 275, 279], ["CD11c", "PROTEIN", 284, 289], ["CD18", "PROTEIN", 290, 294], ["an increased CD62E and CD106 expression", "PROBLEM", 87, 126], ["PMN", "TEST", 184, 187], ["CD54", "TEST", 196, 200], ["CD102", "TEST", 205, 210], ["CD11a", "TEST", 256, 261], ["CD18", "TEST", 262, 266], ["CD11b", "TEST", 268, 273], ["CD18", "TEST", 275, 279], ["CD11c", "TEST", 284, 289], ["CD18", "TEST", 290, 294], ["ANCA", "OBSERVATION", 17, 21], ["CD18", "ANATOMY", 262, 266], ["CD18", "ANATOMY", 275, 279]]], ["In this model, the integrins are necessary for leukocyte adhesion to endothelium.", [["leukocyte", "ANATOMY", 47, 56], ["endothelium", "ANATOMY", 69, 80], ["integrins", "GENE_OR_GENE_PRODUCT", 19, 28], ["leukocyte", "CELL", 47, 56], ["endothelium", "TISSUE", 69, 80], ["integrins", "PROTEIN", 19, 28], ["leukocyte adhesion", "PROBLEM", 47, 65]]], ["Figure 8 .18 shows the tissues damaged by a complex interaction of cells, with a prominent role played by eosinophil cationic proteins.", [["tissues", "ANATOMY", 23, 30], ["cells", "ANATOMY", 67, 72], ["eosinophil", "ANATOMY", 106, 116], ["tissues", "TISSUE", 23, 30], ["cells", "CELL", 67, 72], ["eosinophil cationic proteins", "GENE_OR_GENE_PRODUCT", 106, 134], ["eosinophil cationic proteins", "PROTEIN", 106, 134], ["Figure", "TEST", 0, 6], ["a complex interaction of cells", "PROBLEM", 42, 72], ["eosinophil cationic proteins", "TREATMENT", 106, 134], ["prominent", "OBSERVATION_MODIFIER", 81, 90]]], ["Additional etiological factors to be considered are genetic and local factors (lesions differentially affecting one organ rather than another), etc. [122] .Clinical PresentationVasculitis disorders share cutaneous and visceral symptoms [34] .Cutaneous SymptomsCutaneous vasculitis is a condition characterized by infiltrated palpable purpura (erythema not fading on vitropression), with predilection for the lower limbs, with tendency to symmetry and worsening following orthostatism.", [["lesions", "ANATOMY", 79, 86], ["organ", "ANATOMY", 116, 121], ["cutaneous", "ANATOMY", 204, 213], ["visceral", "ANATOMY", 218, 226], ["erythema", "ANATOMY", 343, 351], ["lower limbs", "ANATOMY", 408, 419], ["Vasculitis disorders", "DISEASE", 177, 197], ["cutaneous and visceral symptoms", "DISEASE", 204, 235], ["SymptomsCutaneous vasculitis", "DISEASE", 252, 280], ["purpura", "DISEASE", 334, 341], ["erythema", "DISEASE", 343, 351], ["lesions", "PATHOLOGICAL_FORMATION", 79, 86], ["organ", "ORGAN", 116, 121], ["visceral", "ORGANISM_SUBDIVISION", 218, 226], ["lower limbs", "ORGANISM_SUBDIVISION", 408, 419], ["Additional etiological factors", "PROBLEM", 0, 30], ["local factors (lesions", "PROBLEM", 64, 86], ["Clinical PresentationVasculitis disorders", "PROBLEM", 156, 197], ["cutaneous and visceral symptoms", "PROBLEM", 204, 235], ["Cutaneous SymptomsCutaneous vasculitis", "PROBLEM", 242, 280], ["infiltrated palpable purpura", "PROBLEM", 313, 341], ["erythema", "PROBLEM", 343, 351], ["vitropression", "TREATMENT", 366, 379], ["predilection for the lower limbs", "PROBLEM", 387, 419], ["tendency to symmetry", "PROBLEM", 426, 446], ["orthostatism", "PROBLEM", 471, 483], ["Vasculitis", "OBSERVATION", 177, 187], ["cutaneous", "ANATOMY", 204, 213], ["visceral", "ANATOMY", 218, 226], ["SymptomsCutaneous vasculitis", "OBSERVATION", 252, 280], ["infiltrated", "OBSERVATION_MODIFIER", 313, 324], ["palpable", "OBSERVATION_MODIFIER", 325, 333], ["purpura", "OBSERVATION", 334, 341], ["erythema", "OBSERVATION", 343, 351], ["lower limbs", "ANATOMY", 408, 419], ["worsening", "OBSERVATION_MODIFIER", 451, 460]]], ["Of 130 children, 116 had SHS and14 had hypersensitivity vasculitis [32] .", [["hypersensitivity vasculitis", "DISEASE", 39, 66], ["children", "ORGANISM", 7, 15], ["children", "SPECIES", 7, 15], ["hypersensitivity vasculitis", "PROBLEM", 39, 66], ["vasculitis", "OBSERVATION", 56, 66]]], ["The often associated lesions are mostly polymorphous, erythematous or maculopapulous, well circumscribed, occurring in crops, have dimensions from a pinpoint to several cm, often evolving to form hemorrhagic blisters or necrotic ulceration, lasting from 3-10 days, and affecting in par- ter), which appear to be infiltrated by PMNs with nuclear fragments in various stages of necrosis, releasing proteolytic enzymes resulting in damage to vascular endothelium [11] .", [["lesions", "ANATOMY", 21, 28], ["maculopapulous", "ANATOMY", 70, 84], ["blisters", "ANATOMY", 208, 216], ["PMNs", "ANATOMY", 327, 331], ["nuclear fragments", "ANATOMY", 337, 354], ["vascular endothelium", "ANATOMY", 439, 459], ["maculopapulous", "DISEASE", 70, 84], ["hemorrhagic", "DISEASE", 196, 207], ["blisters", "DISEASE", 208, 216], ["necrotic", "DISEASE", 220, 228], ["necrosis", "DISEASE", 376, 384], ["lesions", "PATHOLOGICAL_FORMATION", 21, 28], ["blisters", "PATHOLOGICAL_FORMATION", 208, 216], ["necrotic ulceration", "PATHOLOGICAL_FORMATION", 220, 239], ["PMNs", "CELL", 327, 331], ["vascular endothelium", "TISSUE", 439, 459], ["PMNs", "CELL_TYPE", 327, 331], ["proteolytic enzymes", "PROTEIN", 396, 415], ["The often associated lesions", "PROBLEM", 0, 28], ["mostly polymorphous", "PROBLEM", 33, 52], ["erythematous", "PROBLEM", 54, 66], ["maculopapulous", "PROBLEM", 70, 84], ["hemorrhagic blisters", "PROBLEM", 196, 216], ["necrotic ulceration", "PROBLEM", 220, 239], ["nuclear fragments", "PROBLEM", 337, 354], ["necrosis", "PROBLEM", 376, 384], ["releasing proteolytic enzymes", "PROBLEM", 386, 415], ["damage to vascular endothelium", "PROBLEM", 429, 459], ["lesions", "OBSERVATION", 21, 28], ["mostly", "OBSERVATION_MODIFIER", 33, 39], ["polymorphous", "OBSERVATION_MODIFIER", 40, 52], ["erythematous", "OBSERVATION_MODIFIER", 54, 66], ["maculopapulous", "OBSERVATION_MODIFIER", 70, 84], ["well circumscribed", "OBSERVATION_MODIFIER", 86, 104], ["several cm", "OBSERVATION_MODIFIER", 161, 171], ["hemorrhagic", "OBSERVATION_MODIFIER", 196, 207], ["blisters", "OBSERVATION", 208, 216], ["necrotic", "OBSERVATION_MODIFIER", 220, 228], ["ulceration", "OBSERVATION", 229, 239], ["appear to be", "UNCERTAINTY", 299, 311], ["infiltrated", "OBSERVATION", 312, 323], ["nuclear fragments", "OBSERVATION", 337, 354], ["various stages", "OBSERVATION_MODIFIER", 358, 372], ["necrosis", "OBSERVATION", 376, 384], ["vascular endothelium", "ANATOMY", 439, 459]]], ["The inflammatory and thrombotic process is likely correlated to increased biosynthesis of vasoactive prostanoids [210] .Cutaneous SymptomsA pediatric study has focussed on the action of these molecules and demonstrated a significant increment of thromboxane A 2 (TXA 2 ) and PGI 2 in acute stages correlated with the degree of clinical severity [210] .", [["thrombotic", "DISEASE", 21, 31], ["prostanoids", "CHEMICAL", 101, 112], ["thromboxane A", "CHEMICAL", 246, 259], ["prostanoids", "CHEMICAL", 101, 112], ["thromboxane A 2", "CHEMICAL", 246, 261], ["TXA 2 )", "CHEMICAL", 263, 270], ["thromboxane A 2", "GENE_OR_GENE_PRODUCT", 246, 261], ["TXA 2", "GENE_OR_GENE_PRODUCT", 263, 268], ["PGI 2", "GENE_OR_GENE_PRODUCT", 275, 280], ["PGI 2", "PROTEIN", 275, 280], ["The inflammatory and thrombotic process", "PROBLEM", 0, 39], ["increased biosynthesis of vasoactive prostanoids", "PROBLEM", 64, 112], ["pediatric study", "TEST", 140, 155], ["thromboxane A 2 (TXA", "TREATMENT", 246, 266], ["PGI 2", "PROBLEM", 275, 280], ["clinical severity", "PROBLEM", 327, 344], ["inflammatory", "OBSERVATION_MODIFIER", 4, 16], ["thrombotic", "OBSERVATION", 21, 31], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["biosynthesis", "OBSERVATION_MODIFIER", 74, 86], ["vasoactive prostanoids", "OBSERVATION", 90, 112]]], ["The TXA 2 increase is consistent with platelet activation; a lesser portion derives from activated PMNs and macrophages, while the PGI 2 increase seems to reflect endothelial cell damage by local inflammatory and thrombotic process [210] .Cutaneous SymptomsThe prostanoid, the main metabolite of arachidonic acid, is a product of vascular endothelium and has potent anti-aggregate effects on platelets.", [["platelet", "ANATOMY", 38, 46], ["PMNs", "ANATOMY", 99, 103], ["macrophages", "ANATOMY", 108, 119], ["endothelial cell", "ANATOMY", 163, 179], ["vascular endothelium", "ANATOMY", 330, 350], ["platelets", "ANATOMY", 392, 401], ["TXA", "CHEMICAL", 4, 7], ["thrombotic", "DISEASE", 213, 223], ["prostanoid", "CHEMICAL", 261, 271], ["arachidonic acid", "CHEMICAL", 296, 312], ["TXA 2", "CHEMICAL", 4, 9], ["prostanoid", "CHEMICAL", 261, 271], ["arachidonic acid", "CHEMICAL", 296, 312], ["TXA 2", "GENE_OR_GENE_PRODUCT", 4, 9], ["platelet", "CELL", 38, 46], ["PMNs", "CELL", 99, 103], ["macrophages", "CELL", 108, 119], ["PGI 2", "GENE_OR_GENE_PRODUCT", 131, 136], ["endothelial cell", "CELL", 163, 179], ["prostanoid", "SIMPLE_CHEMICAL", 261, 271], ["arachidonic acid", "SIMPLE_CHEMICAL", 296, 312], ["vascular endothelium", "TISSUE", 330, 350], ["platelets", "CELL", 392, 401], ["PMNs", "CELL_TYPE", 99, 103], ["macrophages", "CELL_TYPE", 108, 119], ["PGI 2", "PROTEIN", 131, 136], ["platelets", "CELL_TYPE", 392, 401], ["The TXA", "TREATMENT", 0, 7], ["platelet activation", "PROBLEM", 38, 57], ["activated PMNs", "TEST", 89, 103], ["macrophages", "PROBLEM", 108, 119], ["the PGI", "PROBLEM", 127, 134], ["endothelial cell damage", "PROBLEM", 163, 186], ["local inflammatory and thrombotic process", "PROBLEM", 190, 231], ["Cutaneous Symptoms", "PROBLEM", 239, 257], ["arachidonic acid", "PROBLEM", 296, 312], ["platelets", "TREATMENT", 392, 401], ["TXA", "OBSERVATION", 4, 7], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["consistent with", "UNCERTAINTY", 22, 37], ["platelet activation", "OBSERVATION", 38, 57], ["activated PMNs", "OBSERVATION", 89, 103], ["macrophages", "OBSERVATION_MODIFIER", 108, 119], ["seems to reflect", "UNCERTAINTY", 146, 162], ["endothelial cell damage", "OBSERVATION", 163, 186], ["local", "OBSERVATION_MODIFIER", 190, 195], ["inflammatory", "OBSERVATION_MODIFIER", 196, 208], ["thrombotic", "OBSERVATION", 213, 223], ["prostanoid", "ANATOMY", 261, 271], ["main", "OBSERVATION_MODIFIER", 277, 281], ["arachidonic acid", "OBSERVATION", 296, 312], ["vascular endothelium", "ANATOMY", 330, 350]]], ["It is a vasodilator and inhibits the TXA 2 -induced platelet activation on vascular lesions.", [["platelet", "ANATOMY", 52, 60], ["vascular lesions", "ANATOMY", 75, 91], ["TXA 2", "CHEMICAL", 37, 42], ["TXA 2", "CHEMICAL", 37, 42], ["TXA 2", "GENE_OR_GENE_PRODUCT", 37, 42], ["platelet", "CELL", 52, 60], ["vascular lesions", "PATHOLOGICAL_FORMATION", 75, 91], ["a vasodilator", "TREATMENT", 6, 19], ["the TXA", "TREATMENT", 33, 40], ["platelet activation on vascular lesions", "PROBLEM", 52, 91], ["platelet activation", "OBSERVATION", 52, 71], ["vascular", "ANATOMY", 75, 83], ["lesions", "OBSERVATION", 84, 91]]], ["PGI 2 of endothelial cells influences the interaction between vasal walls and leukocytes, blocking their adhesion after stimulation [210] .", [["endothelial cells", "ANATOMY", 9, 26], ["vasal walls", "ANATOMY", 62, 73], ["leukocytes", "ANATOMY", 78, 88], ["PGI 2", "GENE_OR_GENE_PRODUCT", 0, 5], ["endothelial cells", "CELL", 9, 26], ["vasal walls", "TISSUE", 62, 73], ["leukocytes", "CELL", 78, 88], ["PGI 2", "PROTEIN", 0, 5], ["endothelial cells", "CELL_TYPE", 9, 26], ["leukocytes", "CELL_TYPE", 78, 88], ["endothelial cells", "PROBLEM", 9, 26], ["leukocytes", "PROBLEM", 78, 88], ["endothelial cells", "OBSERVATION", 9, 26], ["vasal walls", "ANATOMY", 62, 73], ["leukocytes", "ANATOMY", 78, 88]]], ["Prostanoid synthesis in the vascular cells can be induced by PAF and IL 1 , both CIC-stimulated, thus confirming the CIC activity in immune-mediated vasculitis [235] .", [["vascular cells", "ANATOMY", 28, 42], ["PAF", "CHEMICAL", 61, 64], ["vasculitis", "DISEASE", 149, 159], ["Prostanoid", "CHEMICAL", 0, 10], ["Prostanoid", "SIMPLE_CHEMICAL", 0, 10], ["vascular cells", "CELL", 28, 42], ["PAF", "SIMPLE_CHEMICAL", 61, 64], ["IL 1", "GENE_OR_GENE_PRODUCT", 69, 73], ["CIC", "GENE_OR_GENE_PRODUCT", 81, 84], ["CIC", "GENE_OR_GENE_PRODUCT", 117, 120], ["vascular cells", "CELL_TYPE", 28, 42], ["PAF", "PROTEIN", 61, 64], ["IL 1", "PROTEIN", 69, 73], ["CIC", "PROTEIN", 81, 84], ["Prostanoid synthesis in the vascular cells", "PROBLEM", 0, 42], ["PAF", "PROBLEM", 61, 64], ["the CIC activity", "PROBLEM", 113, 129], ["immune-mediated vasculitis", "PROBLEM", 133, 159], ["synthesis", "OBSERVATION", 11, 20], ["vascular cells", "ANATOMY", 28, 42], ["PAF", "OBSERVATION", 61, 64], ["vasculitis", "OBSERVATION", 149, 159]]], ["In the acute stages of SHS, a PGE 2 increase has been shown, probably derived from PMN and macrophage activation.", [["PMN", "ANATOMY", 83, 86], ["macrophage", "ANATOMY", 91, 101], ["SHS", "DISEASE", 23, 26], ["PGE", "CHEMICAL", 30, 33], ["PGE 2", "CHEMICAL", 30, 35], ["PGE 2", "GENE_OR_GENE_PRODUCT", 30, 35], ["PMN", "CELL", 83, 86], ["macrophage", "CELL", 91, 101], ["PMN", "CELL_TYPE", 83, 86], ["a PGE 2", "TEST", 28, 35], ["PMN", "TEST", 83, 86], ["macrophage activation", "PROBLEM", 91, 112], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["macrophage activation", "OBSERVATION", 91, 112]]], ["Examined in greater detail, it is unclear whether its action amplifies or suppresses the inflammation characteristic of SHS [210] .", [["inflammation", "DISEASE", 89, 101]]], ["On the one hand, it is an active mediator in inflammation, by promoting blood afflux in the inflamed area and thus leukocyte infiltration; on the otherhand, it exploits a local down-regulation by inhibiting lymphocyte activation and antibody and IL production.Cutaneous SymptomsIn conclusion, both TXA 2 and PGI 2 increase allows a correlation of SHS with other affections and syndromes characterized by an increased interaction between platelets and vascular walls, so that a parallel between a wide spectrum of causes and a virtual uniformity of responses may be advocated [210] .", [["blood", "ANATOMY", 72, 77], ["inflamed area", "ANATOMY", 92, 105], ["leukocyte", "ANATOMY", 115, 124], ["lymphocyte", "ANATOMY", 207, 217], ["platelets", "ANATOMY", 437, 446], ["vascular walls", "ANATOMY", 451, 465], ["inflammation", "DISEASE", 45, 57], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["leukocyte", "CELL", 115, 124], ["lymphocyte", "CELL", 207, 217], ["IL", "GENE_OR_GENE_PRODUCT", 246, 248], ["PGI 2", "GENE_OR_GENE_PRODUCT", 308, 313], ["platelets", "CELL", 437, 446], ["vascular walls", "TISSUE", 451, 465], ["IL", "PROTEIN", 246, 248], ["platelets", "CELL_TYPE", 437, 446], ["inflammation", "PROBLEM", 45, 57], ["promoting blood afflux in the inflamed area", "PROBLEM", 62, 105], ["leukocyte infiltration", "PROBLEM", 115, 137], ["inhibiting lymphocyte activation", "TREATMENT", 196, 228], ["antibody and IL production", "TREATMENT", 233, 259], ["PGI 2", "PROBLEM", 308, 313], ["other affections", "PROBLEM", 356, 372], ["syndromes", "PROBLEM", 377, 386], ["an increased interaction between platelets and vascular walls", "PROBLEM", 404, 465], ["active", "OBSERVATION_MODIFIER", 26, 32], ["inflammation", "OBSERVATION", 45, 57], ["inflamed", "OBSERVATION_MODIFIER", 92, 100], ["leukocyte infiltration", "OBSERVATION", 115, 137], ["lymphocyte activation", "OBSERVATION", 207, 228], ["increased", "OBSERVATION_MODIFIER", 407, 416], ["interaction", "OBSERVATION", 417, 428], ["vascular", "ANATOMY", 451, 459], ["walls", "ANATOMY_MODIFIER", 460, 465]]], ["The deposition of IgA and C3 in the small vessels of the skin and renal glomeruli is characteristic.", [["small vessels", "ANATOMY", 36, 49], ["skin", "ANATOMY", 57, 61], ["renal glomeruli", "ANATOMY", 66, 81], ["IgA", "GENE_OR_GENE_PRODUCT", 18, 21], ["C3", "GENE_OR_GENE_PRODUCT", 26, 28], ["small vessels", "MULTI-TISSUE_STRUCTURE", 36, 49], ["skin", "ORGAN", 57, 61], ["renal glomeruli", "MULTI-TISSUE_STRUCTURE", 66, 81], ["IgA", "PROTEIN", 18, 21], ["C3", "PROTEIN", 26, 28], ["The deposition of IgA and C3", "PROBLEM", 0, 28], ["deposition", "OBSERVATION_MODIFIER", 4, 14], ["IgA", "OBSERVATION", 18, 21], ["C3", "ANATOMY_MODIFIER", 26, 28], ["small", "ANATOMY_MODIFIER", 36, 41], ["vessels", "ANATOMY", 42, 49], ["skin", "ANATOMY", 57, 61], ["renal glomeruli", "ANATOMY", 66, 81]]], ["Recently deposition of IgA has been shown in the intestine as well [106] ; therefore SHS is considered an IgA-mediated vasculitis of small vessels [11] .", [["intestine", "ANATOMY", 49, 58], ["small vessels", "ANATOMY", 133, 146], ["vasculitis", "DISEASE", 119, 129], ["IgA", "GENE_OR_GENE_PRODUCT", 23, 26], ["intestine", "ORGAN", 49, 58], ["IgA", "GENE_OR_GENE_PRODUCT", 106, 109], ["small vessels", "MULTI-TISSUE_STRUCTURE", 133, 146], ["IgA", "PROTEIN", 23, 26], ["IgA", "PROTEIN", 106, 109], ["Recently deposition of IgA", "PROBLEM", 0, 26], ["an IgA-mediated vasculitis of small vessels", "PROBLEM", 103, 146], ["IgA", "OBSERVATION", 23, 26], ["intestine", "ANATOMY", 49, 58], ["IgA", "OBSERVATION", 106, 109], ["vasculitis", "OBSERVATION", 119, 129], ["small vessels", "ANATOMY", 133, 146]]], ["The main clinical manifestations outlined in Tables 8.20 and 8.21 [5, 188] show that the skin manifestations, edema and purpura of both scalp and limbs, are characteristically seen in infants, while in older children the frequency of articular (arthritis may be the initial manifestation) and renal complications is increased [5, 188] .", [["skin", "ANATOMY", 89, 93], ["edema", "ANATOMY", 110, 115], ["scalp", "ANATOMY", 136, 141], ["limbs", "ANATOMY", 146, 151], ["articular", "ANATOMY", 234, 243], ["renal", "ANATOMY", 293, 298], ["edema", "DISEASE", 110, 115], ["purpura", "DISEASE", 120, 127], ["arthritis", "DISEASE", 245, 254], ["renal complications", "DISEASE", 293, 312], ["skin", "ORGAN", 89, 93], ["edema", "PATHOLOGICAL_FORMATION", 110, 115], ["scalp", "ORGAN", 136, 141], ["limbs", "ORGAN", 146, 151], ["infants", "ORGANISM", 184, 191], ["children", "ORGANISM", 208, 216], ["articular", "TISSUE", 234, 243], ["renal", "ORGAN", 293, 298], ["infants", "SPECIES", 184, 191], ["children", "SPECIES", 208, 216], ["the skin manifestations", "PROBLEM", 85, 108], ["edema", "PROBLEM", 110, 115], ["purpura of both scalp and limbs", "PROBLEM", 120, 151], ["articular (arthritis", "PROBLEM", 234, 254], ["renal complications", "PROBLEM", 293, 312], ["main", "OBSERVATION_MODIFIER", 4, 8], ["skin", "ANATOMY", 89, 93], ["manifestations", "OBSERVATION", 94, 108], ["edema", "OBSERVATION", 110, 115], ["purpura", "OBSERVATION", 120, 127], ["both", "ANATOMY_MODIFIER", 131, 135], ["scalp", "ANATOMY", 136, 141], ["limbs", "ANATOMY", 146, 151], ["articular", "ANATOMY", 234, 243], ["arthritis", "OBSERVATION", 245, 254], ["renal", "ANATOMY", 293, 298], ["complications", "OBSERVATION", 299, 312], ["increased", "OBSERVATION_MODIFIER", 316, 325]]], ["The SHS hallmark is the purpuric rash, first macular and then erythematous maculopapules, with hemorrhagic elements (petechiae and ecchymosis), involving symmetrically the lower limbs (Fig. 8.19 ), associated with edema of the scalp and/or extremities.", [["purpuric", "ANATOMY", 24, 32], ["macular", "ANATOMY", 45, 52], ["erythematous maculopapules", "ANATOMY", 62, 88], ["petechiae", "ANATOMY", 117, 126], ["ecchymosis", "ANATOMY", 131, 141], ["lower limbs", "ANATOMY", 172, 183], ["edema", "ANATOMY", 214, 219], ["scalp", "ANATOMY", 227, 232], ["extremities", "ANATOMY", 240, 251], ["rash", "DISEASE", 33, 37], ["maculopapules", "DISEASE", 75, 88], ["hemorrhagic", "DISEASE", 95, 106], ["petechiae", "DISEASE", 117, 126], ["ecchymosis", "DISEASE", 131, 141], ["edema of the scalp", "DISEASE", 214, 232], ["petechiae", "PATHOLOGICAL_FORMATION", 117, 126], ["ecchymosis", "PATHOLOGICAL_FORMATION", 131, 141], ["lower limbs", "ORGANISM_SUBDIVISION", 172, 183], ["edema", "PATHOLOGICAL_FORMATION", 214, 219], ["scalp", "ORGAN", 227, 232], ["extremities", "ORGANISM_SUBDIVISION", 240, 251], ["the purpuric rash", "PROBLEM", 20, 37], ["first macular and then erythematous maculopapules", "PROBLEM", 39, 88], ["hemorrhagic elements", "PROBLEM", 95, 115], ["petechiae", "PROBLEM", 117, 126], ["ecchymosis", "PROBLEM", 131, 141], ["edema of the scalp and/or extremities", "PROBLEM", 214, 251], ["purpuric", "OBSERVATION_MODIFIER", 24, 32], ["rash", "OBSERVATION", 33, 37], ["macular", "OBSERVATION_MODIFIER", 45, 52], ["erythematous", "OBSERVATION_MODIFIER", 62, 74], ["maculopapules", "OBSERVATION", 75, 88], ["hemorrhagic", "OBSERVATION_MODIFIER", 95, 106], ["petechiae", "OBSERVATION_MODIFIER", 117, 126], ["ecchymosis", "OBSERVATION", 131, 141], ["symmetrically", "ANATOMY_MODIFIER", 154, 167], ["lower limbs", "ANATOMY", 172, 183], ["edema", "OBSERVATION", 214, 219], ["scalp", "ANATOMY", 227, 232], ["extremities", "ANATOMY", 240, 251]]], ["Depending on the age, abdominal pain and migratory articular manifestations are more or less frequent, the onset of glomerulopathy may even be long after SHS ticular the lower limbs and feet.", [["abdominal", "ANATOMY", 22, 31], ["articular", "ANATOMY", 51, 60], ["lower limbs", "ANATOMY", 170, 181], ["feet", "ANATOMY", 186, 190], ["abdominal pain", "DISEASE", 22, 36], ["glomerulopathy", "DISEASE", 116, 130], ["abdominal", "ORGANISM_SUBDIVISION", 22, 31], ["articular", "TISSUE", 51, 60], ["lower limbs", "ORGANISM_SUBDIVISION", 170, 181], ["feet", "ORGANISM_SUBDIVISION", 186, 190], ["abdominal pain", "PROBLEM", 22, 36], ["migratory articular manifestations", "PROBLEM", 41, 75], ["glomerulopathy", "PROBLEM", 116, 130], ["abdominal", "ANATOMY", 22, 31], ["pain", "OBSERVATION", 32, 36], ["migratory", "OBSERVATION_MODIFIER", 41, 50], ["articular", "ANATOMY", 51, 60], ["glomerulopathy", "OBSERVATION", 116, 130], ["lower limbs", "ANATOMY", 170, 181], ["feet", "ANATOMY", 186, 190]]], ["Certain lesions may complicate the diagnosis such as well circumscribed ecchymotic spots, erythematous papules (palpable purpura), often with an annular arrangement appearing as a polymorphous erythema, which are able to transform into nodules, vesicles, blisters, and/or become necrotic.", [["lesions", "ANATOMY", 8, 15], ["papules", "ANATOMY", 103, 110], ["erythema", "ANATOMY", 193, 201], ["nodules", "ANATOMY", 236, 243], ["vesicles", "ANATOMY", 245, 253], ["blisters", "ANATOMY", 255, 263], ["papules", "DISEASE", 103, 110], ["purpura", "DISEASE", 121, 128], ["erythema", "DISEASE", 193, 201], ["blisters", "DISEASE", 255, 263], ["necrotic", "DISEASE", 279, 287], ["lesions", "PATHOLOGICAL_FORMATION", 8, 15], ["erythematous papules", "PATHOLOGICAL_FORMATION", 90, 110], ["erythema", "PATHOLOGICAL_FORMATION", 193, 201], ["nodules", "CANCER", 236, 243], ["vesicles", "CELLULAR_COMPONENT", 245, 253], ["blisters", "PATHOLOGICAL_FORMATION", 255, 263], ["Certain lesions", "PROBLEM", 0, 15], ["well circumscribed ecchymotic spots", "PROBLEM", 53, 88], ["erythematous papules", "PROBLEM", 90, 110], ["palpable purpura", "PROBLEM", 112, 128], ["an annular arrangement", "PROBLEM", 142, 164], ["a polymorphous erythema", "PROBLEM", 178, 201], ["nodules", "PROBLEM", 236, 243], ["vesicles", "PROBLEM", 245, 253], ["blisters", "PROBLEM", 255, 263], ["necrotic", "PROBLEM", 279, 287], ["lesions", "OBSERVATION", 8, 15], ["circumscribed", "OBSERVATION_MODIFIER", 58, 71], ["ecchymotic", "OBSERVATION_MODIFIER", 72, 82], ["spots", "OBSERVATION", 83, 88], ["erythematous", "OBSERVATION_MODIFIER", 90, 102], ["papules", "OBSERVATION", 103, 110], ["palpable", "OBSERVATION_MODIFIER", 112, 120], ["purpura", "OBSERVATION", 121, 128], ["annular", "OBSERVATION", 145, 152], ["polymorphous", "OBSERVATION_MODIFIER", 180, 192], ["erythema", "OBSERVATION", 193, 201], ["nodules", "OBSERVATION", 236, 243], ["vesicles", "OBSERVATION_MODIFIER", 245, 253], ["blisters", "OBSERVATION", 255, 263], ["necrotic", "OBSERVATION", 279, 287]]], ["Preferred sites are gravity-affected areas such as lower half of the legs and buttocks, but also forearms and hands, although in severe cases the face and trunk may be involved.", [["sites", "ANATOMY", 10, 15], ["legs", "ANATOMY", 69, 73], ["buttocks", "ANATOMY", 78, 86], ["forearms", "ANATOMY", 97, 105], ["face", "ANATOMY", 146, 150], ["trunk", "ANATOMY", 155, 160], ["sites", "MULTI-TISSUE_STRUCTURE", 10, 15], ["legs", "ORGANISM_SUBDIVISION", 69, 73], ["buttocks", "ORGANISM_SUBDIVISION", 78, 86], ["forearms", "ORGANISM_SUBDIVISION", 97, 105], ["hands", "ORGANISM_SUBDIVISION", 110, 115], ["face", "ORGANISM_SUBDIVISION", 146, 150], ["trunk", "ORGANISM_SUBDIVISION", 155, 160], ["affected areas", "PROBLEM", 28, 42], ["gravity", "OBSERVATION", 20, 27], ["affected", "OBSERVATION_MODIFIER", 28, 36], ["areas", "OBSERVATION", 37, 42], ["lower", "ANATOMY_MODIFIER", 51, 56], ["half", "ANATOMY_MODIFIER", 57, 61], ["legs", "ANATOMY", 69, 73], ["buttocks", "ANATOMY", 78, 86], ["forearms", "ANATOMY", 97, 105], ["hands", "ANATOMY", 110, 115], ["face", "ANATOMY", 146, 150], ["trunk", "ANATOMY", 155, 160]]], ["Subcutaneous nodules are small, stiff, often short-lived, most often located on the back of both hands and feet, elbows and knees.", [["Subcutaneous nodules", "ANATOMY", 0, 20], ["back", "ANATOMY", 84, 88], ["hands", "ANATOMY", 97, 102], ["feet", "ANATOMY", 107, 111], ["elbows", "ANATOMY", 113, 119], ["knees", "ANATOMY", 124, 129], ["Subcutaneous nodules", "CANCER", 0, 20], ["back", "ORGANISM_SUBDIVISION", 84, 88], ["hands", "ORGANISM_SUBDIVISION", 97, 102], ["feet", "ORGANISM_SUBDIVISION", 107, 111], ["elbows", "ORGANISM_SUBDIVISION", 113, 119], ["knees", "ORGANISM_SUBDIVISION", 124, 129], ["Subcutaneous nodules", "PROBLEM", 0, 20], ["nodules", "OBSERVATION", 13, 20], ["small", "OBSERVATION_MODIFIER", 25, 30], ["stiff", "OBSERVATION_MODIFIER", 32, 37], ["short", "OBSERVATION_MODIFIER", 45, 50], ["back", "ANATOMY", 84, 88], ["both", "ANATOMY_MODIFIER", 92, 96], ["hands", "ANATOMY", 97, 102], ["feet", "ANATOMY", 107, 111], ["elbows", "ANATOMY", 113, 119], ["knees", "ANATOMY", 124, 129]]], ["Less frequent is livedo reticularis.", [["livedo reticularis", "ANATOMY", 17, 35], ["livedo reticularis", "PROBLEM", 17, 35], ["livedo reticularis", "OBSERVATION", 17, 35]]], ["Generally such lesions are asymptomatic, but can be accompanied by pruritus, burning sensation and pain [34] .Additional SymptomsArticular manifestations are the most frequent and renal lesions condition the prognosis.", [["lesions", "ANATOMY", 15, 22], ["renal lesions", "ANATOMY", 180, 193], ["pruritus", "DISEASE", 67, 75], ["burning sensation", "DISEASE", 77, 94], ["pain", "DISEASE", 99, 103], ["lesions", "PATHOLOGICAL_FORMATION", 15, 22], ["renal lesions", "CANCER", 180, 193], ["Generally such lesions", "PROBLEM", 0, 22], ["asymptomatic", "PROBLEM", 27, 39], ["pruritus", "PROBLEM", 67, 75], ["burning sensation", "PROBLEM", 77, 94], ["pain", "PROBLEM", 99, 103], ["Additional SymptomsArticular manifestations", "PROBLEM", 110, 153], ["renal lesions condition", "PROBLEM", 180, 203], ["lesions", "OBSERVATION", 15, 22], ["pruritus", "OBSERVATION", 67, 75], ["most frequent", "OBSERVATION_MODIFIER", 162, 175], ["renal", "ANATOMY", 180, 185], ["lesions", "OBSERVATION", 186, 193]]], ["No relationship is apparent between extension of cutaneous lesions and presence or not of renal manifestations. \u2211 Musculoskeletal apparatus.", [["cutaneous lesions", "ANATOMY", 49, 66], ["renal", "ANATOMY", 90, 95], ["Musculoskeletal", "ANATOMY", 114, 129], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 49, 66], ["renal", "ORGAN", 90, 95], ["cutaneous lesions", "PROBLEM", 49, 66], ["renal manifestations", "PROBLEM", 90, 110], ["cutaneous", "ANATOMY", 49, 58], ["lesions", "OBSERVATION", 59, 66], ["not of", "UNCERTAINTY", 83, 89], ["renal", "ANATOMY", 90, 95], ["manifestations", "OBSERVATION", 96, 110], ["Musculoskeletal", "ANATOMY", 114, 129], ["apparatus", "OBSERVATION", 130, 139]]], ["Arthralgias are usually present in >40% of cases. \u2211 Kidney.", [["Kidney", "ANATOMY", 52, 58], ["Arthralgias", "DISEASE", 0, 11], ["Kidney", "ORGAN", 52, 58], ["Arthralgias", "PROBLEM", 0, 11], ["Kidney", "ANATOMY", 52, 58]]], ["Renal lesions should be investigated, although it has been suggested that the prevalence is not 25%-40% of cases, but <1% of children develop persistent renal disease [11] .", [["Renal lesions", "ANATOMY", 0, 13], ["renal", "ANATOMY", 153, 158], ["Renal lesions", "DISEASE", 0, 13], ["renal disease", "DISEASE", 153, 166], ["Renal lesions", "CANCER", 0, 13], ["children", "ORGANISM", 125, 133], ["renal", "ORGAN", 153, 158], ["children", "SPECIES", 125, 133], ["Renal lesions", "PROBLEM", 0, 13], ["persistent renal disease", "PROBLEM", 142, 166], ["lesions", "OBSERVATION", 6, 13], ["persistent", "OBSERVATION_MODIFIER", 142, 152], ["renal", "ANATOMY", 153, 158], ["disease", "OBSERVATION", 159, 166]]], ["Proteinuria is usually associated with microscopic hematuria: symptoms may persist or subside; however, <0.1% develop renal insufficiency.", [["renal", "ANATOMY", 118, 123], ["Proteinuria", "DISEASE", 0, 11], ["hematuria", "DISEASE", 51, 60], ["renal insufficiency", "DISEASE", 118, 137], ["renal", "ORGAN", 118, 123], ["Proteinuria", "PROBLEM", 0, 11], ["microscopic hematuria", "PROBLEM", 39, 60], ["symptoms", "PROBLEM", 62, 70], ["renal insufficiency", "PROBLEM", 118, 137], ["hematuria", "OBSERVATION", 51, 60], ["renal", "ANATOMY", 118, 123], ["insufficiency", "OBSERVATION", 124, 137]]], ["Renal biopsy results are discriminatory as far as the type and severity of injury are concerned. \u2211 Gastrointestinal tract.", [["Renal", "ANATOMY", 0, 5], ["Gastrointestinal tract", "ANATOMY", 99, 121], ["Renal biopsy", "MULTI-TISSUE_STRUCTURE", 0, 12], ["Gastrointestinal tract", "PATHOLOGICAL_FORMATION", 99, 121], ["Renal biopsy", "TEST", 0, 12], ["injury", "PROBLEM", 75, 81], ["biopsy", "OBSERVATION", 6, 12], ["injury", "OBSERVATION", 75, 81], ["Gastrointestinal tract", "ANATOMY", 99, 121]]], ["Abdominal pain with nausea and vomiting are frequent (15% of cases); rarely does an occlusive or hemorrhagic syndrome develop. \u2211 Central nervous system.", [["Abdominal", "ANATOMY", 0, 9], ["occlusive", "ANATOMY", 84, 93], ["Central nervous system", "ANATOMY", 129, 151], ["Abdominal pain", "DISEASE", 0, 14], ["nausea", "DISEASE", 20, 26], ["vomiting", "DISEASE", 31, 39], ["hemorrhagic", "DISEASE", 97, 108], ["Central nervous system", "ANATOMICAL_SYSTEM", 129, 151], ["Abdominal pain", "PROBLEM", 0, 14], ["nausea", "PROBLEM", 20, 26], ["vomiting", "PROBLEM", 31, 39], ["an occlusive or hemorrhagic syndrome", "PROBLEM", 81, 117], ["pain", "OBSERVATION", 10, 14], ["nausea", "OBSERVATION", 20, 26], ["occlusive", "OBSERVATION", 84, 93], ["hemorrhagic", "OBSERVATION_MODIFIER", 97, 108], ["syndrome", "OBSERVATION", 109, 117], ["nervous system", "ANATOMY", 137, 151]]], ["Rare associations include hemiparesis, neuropathies and migraine.Prominent Vasculitis Syndromes in ChildrenAs shown by Table 8 .19, the main types of primitive allergic vasculitis in children that most frequently have an immune pathogenesis are the following:Prominent Vasculitis Syndromes in ChildrenSHS, or anaphylactoid purpura, is the most common among leukocytoclastic vasculitis patients, with an estimated annual incidence highest between the ages of 4 and 6 years (99.3\u00a510 5 ) [81] .", [["hemiparesis", "DISEASE", 26, 37], ["neuropathies", "DISEASE", 39, 51], ["migraine", "DISEASE", 56, 64], ["Vasculitis Syndromes", "DISEASE", 75, 95], ["allergic vasculitis", "DISEASE", 160, 179], ["Vasculitis Syndromes", "DISEASE", 269, 289], ["ChildrenSHS", "DISEASE", 293, 304], ["anaphylactoid purpura", "DISEASE", 309, 330], ["leukocytoclastic vasculitis", "DISEASE", 357, 384], ["children", "ORGANISM", 183, 191], ["patients", "ORGANISM", 385, 393], ["Children", "SPECIES", 99, 107], ["children", "SPECIES", 183, 191], ["patients", "SPECIES", 385, 393], ["hemiparesis", "PROBLEM", 26, 37], ["neuropathies", "PROBLEM", 39, 51], ["migraine", "PROBLEM", 56, 64], ["Prominent Vasculitis Syndromes", "PROBLEM", 65, 95], ["primitive allergic vasculitis", "PROBLEM", 150, 179], ["Prominent Vasculitis Syndromes", "PROBLEM", 259, 289], ["ChildrenSHS", "PROBLEM", 293, 304], ["anaphylactoid purpura", "PROBLEM", 309, 330], ["leukocytoclastic vasculitis", "PROBLEM", 357, 384], ["hemiparesis", "OBSERVATION", 26, 37], ["neuropathies", "OBSERVATION", 39, 51], ["migraine", "OBSERVATION", 56, 64], ["Vasculitis", "OBSERVATION", 75, 85], ["main", "OBSERVATION_MODIFIER", 136, 140], ["primitive", "OBSERVATION_MODIFIER", 150, 159], ["allergic vasculitis", "OBSERVATION", 160, 179], ["Vasculitis", "OBSERVATION", 269, 279], ["anaphylactoid purpura", "OBSERVATION", 309, 330], ["most common", "OBSERVATION_MODIFIER", 339, 350], ["leukocytoclastic", "OBSERVATION_MODIFIER", 357, 373], ["vasculitis", "OBSERVATION", 374, 384]]], ["The SHS annual incidence may be 12.9\u00a510 5 children <17 years of age [245] .", [["children", "SPECIES", 42, 50]]], ["However infants aged 5-24 months have been reported [5, 188] .", [["infants", "ORGANISM", 8, 15], ["infants", "SPECIES", 8, 15]]], ["It is an immune-mediated disease, paradigmatic of cutaneous necrotizing or leukocytoclastic vasculitis, of small dermal and visceral vessels (<0.1 mm in diame-onset.", [["cutaneous necrotizing", "ANATOMY", 50, 71], ["dermal", "ANATOMY", 113, 119], ["visceral vessels", "ANATOMY", 124, 140], ["leukocytoclastic vasculitis", "DISEASE", 75, 102], ["cutaneous necrotizing", "PATHOLOGICAL_FORMATION", 50, 71], ["dermal", "TISSUE", 113, 119], ["visceral vessels", "MULTI-TISSUE_STRUCTURE", 124, 140], ["an immune-mediated disease", "PROBLEM", 6, 32], ["cutaneous necrotizing", "PROBLEM", 50, 71], ["leukocytoclastic vasculitis", "PROBLEM", 75, 102], ["small dermal and visceral vessels", "PROBLEM", 107, 140], ["disease", "OBSERVATION", 25, 32], ["cutaneous", "ANATOMY", 50, 59], ["necrotizing", "OBSERVATION", 60, 71], ["leukocytoclastic", "OBSERVATION_MODIFIER", 75, 91], ["vasculitis", "OBSERVATION", 92, 102], ["small", "OBSERVATION_MODIFIER", 107, 112], ["dermal", "OBSERVATION", 113, 119], ["visceral vessels", "ANATOMY", 124, 140]]], ["In cases not complicated by nephropathy, the prognosis is good after 24 years of follow-up; however, long-term follow-up of all patients who had severe renal symptoms at onset is needed during adulthood [171] .Prominent Vasculitis Syndromes in ChildrenHypersensitivity angiitis is another leukocytoclastic vasculitis, clinically similar to SHS, occurring mostly in children, excluding those cases in which the specific al-lergen (drugs, microbes, virus, insect stings, pesticides, etc.) is easily identifiable.", [["renal", "ANATOMY", 152, 157], ["nephropathy", "DISEASE", 28, 39], ["renal symptoms", "DISEASE", 152, 166], ["Vasculitis Syndromes", "DISEASE", 220, 240], ["angiitis", "DISEASE", 269, 277], ["leukocytoclastic vasculitis", "DISEASE", 289, 316], ["SHS", "DISEASE", 340, 343], ["insect stings", "DISEASE", 454, 467], ["patients", "ORGANISM", 128, 136], ["renal", "ORGAN", 152, 157], ["children", "ORGANISM", 365, 373], ["patients", "SPECIES", 128, 136], ["children", "SPECIES", 365, 373], ["nephropathy", "PROBLEM", 28, 39], ["severe renal symptoms", "PROBLEM", 145, 166], ["Prominent Vasculitis Syndromes", "PROBLEM", 210, 240], ["ChildrenHypersensitivity angiitis", "PROBLEM", 244, 277], ["another leukocytoclastic vasculitis", "PROBLEM", 281, 316], ["drugs", "TREATMENT", 430, 435], ["virus", "PROBLEM", 447, 452], ["not complicated", "UNCERTAINTY", 9, 24], ["nephropathy", "OBSERVATION", 28, 39], ["renal", "ANATOMY", 152, 157], ["symptoms", "OBSERVATION", 158, 166], ["Vasculitis", "OBSERVATION", 220, 230], ["angiitis", "OBSERVATION", 269, 277], ["leukocytoclastic", "OBSERVATION_MODIFIER", 289, 305], ["vasculitis", "OBSERVATION", 306, 316]]], ["Clinical manifestations include fever, myalgia, and arthralgias without frank arthritis and visceral involvement, and may sometimes resemble the SHS limited to the skin, with which it has in common the character of acute phases (one-shot disease).", [["visceral", "ANATOMY", 92, 100], ["skin", "ANATOMY", 164, 168], ["fever", "DISEASE", 32, 37], ["myalgia", "DISEASE", 39, 46], ["arthralgias", "DISEASE", 52, 63], ["arthritis", "DISEASE", 78, 87], ["visceral", "ORGANISM_SUBDIVISION", 92, 100], ["skin", "ORGAN", 164, 168], ["Clinical manifestations", "PROBLEM", 0, 23], ["fever", "PROBLEM", 32, 37], ["myalgia", "PROBLEM", 39, 46], ["arthralgias", "PROBLEM", 52, 63], ["frank arthritis", "PROBLEM", 72, 87], ["visceral involvement", "PROBLEM", 92, 112], ["acute phases", "PROBLEM", 215, 227], ["fever", "OBSERVATION", 32, 37], ["myalgia", "OBSERVATION", 39, 46], ["arthralgias", "OBSERVATION", 52, 63], ["arthritis", "OBSERVATION", 78, 87], ["visceral", "ANATOMY", 92, 100], ["skin", "ANATOMY", 164, 168], ["acute", "OBSERVATION_MODIFIER", 215, 220]]], ["The small vessels are involved, arterioles or venules, with a variable degree of vessel wall necrosis, localized and rarely occlusive.", [["small vessels", "ANATOMY", 4, 17], ["arterioles", "ANATOMY", 32, 42], ["venules", "ANATOMY", 46, 53], ["vessel wall", "ANATOMY", 81, 92], ["vessel wall necrosis", "DISEASE", 81, 101], ["small vessels", "MULTI-TISSUE_STRUCTURE", 4, 17], ["arterioles", "MULTI-TISSUE_STRUCTURE", 32, 42], ["venules", "MULTI-TISSUE_STRUCTURE", 46, 53], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 81, 92], ["vessel wall necrosis", "PROBLEM", 81, 101], ["small", "OBSERVATION_MODIFIER", 4, 9], ["vessels", "ANATOMY", 10, 17], ["arterioles", "OBSERVATION_MODIFIER", 32, 42], ["venules", "ANATOMY", 46, 53], ["variable", "OBSERVATION_MODIFIER", 62, 70], ["degree", "OBSERVATION_MODIFIER", 71, 77], ["vessel", "ANATOMY", 81, 87], ["wall", "ANATOMY_MODIFIER", 88, 92], ["necrosis", "OBSERVATION", 93, 101], ["rarely", "OBSERVATION_MODIFIER", 117, 123], ["occlusive", "OBSERVATION", 124, 133]]], ["The cutaneous lesions are typically small hemorrhagic papules, usually in sloping areas and at a similar stages of development.", [["cutaneous lesions", "ANATOMY", 4, 21], ["papules", "ANATOMY", 54, 61], ["papules", "DISEASE", 54, 61], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 4, 21], ["hemorrhagic papules", "PATHOLOGICAL_FORMATION", 42, 61], ["The cutaneous lesions", "PROBLEM", 0, 21], ["typically small hemorrhagic papules", "PROBLEM", 26, 61], ["cutaneous", "ANATOMY", 4, 13], ["lesions", "OBSERVATION", 14, 21], ["typically", "OBSERVATION_MODIFIER", 26, 35], ["small", "OBSERVATION_MODIFIER", 36, 41], ["hemorrhagic", "OBSERVATION_MODIFIER", 42, 53], ["papules", "OBSERVATION", 54, 61], ["sloping", "OBSERVATION_MODIFIER", 74, 81], ["similar stages", "OBSERVATION_MODIFIER", 97, 111]]], ["Inflammatory cells are usually PMN [72, 122] .Prominent Vasculitis Syndromes in ChildrenAcute hemorrhagic edema of infancy (Fig. 8.20) is a disease with a benign course characterized by a suddenly occurring cutaneous vasculitis in children aged 4 months to <2 years in good general condition.", [["Inflammatory cells", "ANATOMY", 0, 18], ["PMN", "ANATOMY", 31, 34], ["cutaneous", "ANATOMY", 207, 216], ["Vasculitis Syndromes", "DISEASE", 56, 76], ["ChildrenAcute hemorrhagic edema", "DISEASE", 80, 111], ["vasculitis", "DISEASE", 217, 227], ["Inflammatory cells", "CELL", 0, 18], ["PMN", "CELL", 31, 34], ["cutaneous vasculitis", "PATHOLOGICAL_FORMATION", 207, 227], ["children", "ORGANISM", 231, 239], ["Inflammatory cells", "CELL_TYPE", 0, 18], ["PMN", "CELL_TYPE", 31, 34], ["children", "SPECIES", 231, 239], ["Inflammatory cells", "PROBLEM", 0, 18], ["PMN", "TEST", 31, 34], ["Prominent Vasculitis Syndromes", "PROBLEM", 46, 76], ["ChildrenAcute hemorrhagic edema", "PROBLEM", 80, 111], ["a disease", "PROBLEM", 138, 147], ["cutaneous vasculitis", "PROBLEM", 207, 227], ["Vasculitis", "OBSERVATION", 56, 66], ["hemorrhagic", "OBSERVATION_MODIFIER", 94, 105], ["edema", "OBSERVATION", 106, 111], ["disease", "OBSERVATION", 140, 147], ["benign", "OBSERVATION_MODIFIER", 155, 161], ["cutaneous", "OBSERVATION_MODIFIER", 207, 216], ["vasculitis", "OBSERVATION", 217, 227]]], ["Large purpuric lesions are distributed on the face, auricles and lower limbs, associated with limb edema, or they are segmental, thick or soft [153] .", [["purpuric lesions", "ANATOMY", 6, 22], ["face", "ANATOMY", 46, 50], ["auricles", "ANATOMY", 52, 60], ["lower limbs", "ANATOMY", 65, 76], ["limb", "ANATOMY", 94, 98], ["edema", "DISEASE", 99, 104], ["purpuric lesions", "PATHOLOGICAL_FORMATION", 6, 22], ["face", "ORGANISM_SUBDIVISION", 46, 50], ["auricles", "CANCER", 52, 60], ["lower limbs", "ORGANISM_SUBDIVISION", 65, 76], ["limb", "ORGANISM_SUBDIVISION", 94, 98], ["Large purpuric lesions", "PROBLEM", 0, 22], ["limb edema", "PROBLEM", 94, 104], ["purpuric", "OBSERVATION_MODIFIER", 6, 14], ["lesions", "OBSERVATION", 15, 22], ["face", "ANATOMY_MODIFIER", 46, 50], ["auricles", "ANATOMY", 52, 60], ["lower limbs", "ANATOMY", 65, 76], ["limb", "ANATOMY", 94, 98], ["edema", "OBSERVATION", 99, 104], ["segmental", "OBSERVATION_MODIFIER", 118, 127], ["thick", "OBSERVATION_MODIFIER", 129, 134]]], ["In some cases, extended trunk lesions may suggest a differential diagnosis with fulminant purpura.", [["trunk lesions", "ANATOMY", 24, 37], ["fulminant purpura", "DISEASE", 80, 97], ["trunk lesions", "PATHOLOGICAL_FORMATION", 24, 37], ["extended trunk lesions", "PROBLEM", 15, 37], ["fulminant purpura", "PROBLEM", 80, 97], ["trunk", "ANATOMY", 24, 29], ["lesions", "OBSERVATION", 30, 37], ["may suggest a differential", "UNCERTAINTY", 38, 64], ["fulminant", "OBSERVATION_MODIFIER", 80, 89], ["purpura", "OBSERVATION", 90, 97]]], ["Progression is spontaneous and favorable within 2-3 weeks [83, 120, 182] , or after a 7-day oral CS course [87] .", [["oral", "ANATOMY", 92, 96], ["oral", "ORGANISM_SUBDIVISION", 92, 96], ["spontaneous", "OBSERVATION_MODIFIER", 15, 26], ["favorable", "OBSERVATION_MODIFIER", 31, 40]]], ["Vasculitis, essentially cutaneous of the leukocytoclastic type, a (very) young age, the topography of lesions, peripheral edema and common absence of arthralgias and internal organ complications (in any case benign) are diagnostic [83, 98, 120] and should be evaluated as a benign SHS variant [182] .Prominent Vasculitis Syndromes in ChildrenKawasaki syndrome [108] is the most frequent vasculitis in infancy after SHS.An epidemiological study on Data from [188] . all three layers of the vascular walls, thus destroying the internal elastic lamina: Table 8 .22 [21, 123, 147, 165, 235] reviews the many immunological features consistent with the pathogenesis.", [["cutaneous", "ANATOMY", 24, 33], ["lesions", "ANATOMY", 102, 109], ["peripheral edema", "ANATOMY", 111, 127], ["organ", "ANATOMY", 175, 180], ["vascular walls", "ANATOMY", 489, 503], ["Vasculitis", "DISEASE", 0, 10], ["peripheral edema", "DISEASE", 111, 127], ["arthralgias", "DISEASE", 150, 161], ["Vasculitis Syndromes", "DISEASE", 310, 330], ["ChildrenKawasaki syndrome", "DISEASE", 334, 359], ["vasculitis", "DISEASE", 387, 397], ["lesions", "PATHOLOGICAL_FORMATION", 102, 109], ["peripheral edema", "PATHOLOGICAL_FORMATION", 111, 127], ["organ", "ORGAN", 175, 180], ["vascular walls", "MULTI-TISSUE_STRUCTURE", 489, 503], ["Vasculitis", "PROBLEM", 0, 10], ["the leukocytoclastic type", "PROBLEM", 37, 62], ["lesions", "PROBLEM", 102, 109], ["peripheral edema", "PROBLEM", 111, 127], ["arthralgias", "PROBLEM", 150, 161], ["internal organ complications", "PROBLEM", 166, 194], ["Prominent Vasculitis Syndromes", "PROBLEM", 300, 330], ["ChildrenKawasaki syndrome", "PROBLEM", 334, 359], ["frequent vasculitis", "PROBLEM", 378, 397], ["An epidemiological study", "TEST", 419, 443], ["the pathogenesis", "PROBLEM", 643, 659], ["essentially", "OBSERVATION_MODIFIER", 12, 23], ["cutaneous", "OBSERVATION_MODIFIER", 24, 33], ["leukocytoclastic type", "OBSERVATION", 41, 62], ["lesions", "OBSERVATION", 102, 109], ["peripheral", "ANATOMY_MODIFIER", 111, 121], ["edema", "OBSERVATION", 122, 127], ["arthralgias", "OBSERVATION", 150, 161], ["internal organ", "ANATOMY", 166, 180], ["complications", "OBSERVATION", 181, 194], ["Vasculitis", "OBSERVATION", 310, 320], ["most frequent", "OBSERVATION_MODIFIER", 373, 386], ["vasculitis", "OBSERVATION", 387, 397], ["three", "OBSERVATION_MODIFIER", 469, 474], ["layers", "OBSERVATION_MODIFIER", 475, 481], ["vascular", "ANATOMY", 489, 497], ["walls", "ANATOMY_MODIFIER", 498, 503], ["internal", "ANATOMY_MODIFIER", 525, 533], ["elastic", "ANATOMY_MODIFIER", 534, 541], ["lamina", "ANATOMY", 542, 548], ["consistent with", "UNCERTAINTY", 627, 642], ["pathogenesis", "OBSERVATION", 647, 659]]], ["Another area of intensifying interest is the demonstration that ILs linked to AECA favor endothelial cell migration, thus modulating the worsening of vascular changes [180] .", [["endothelial cell", "ANATOMY", 89, 105], ["vascular", "ANATOMY", 150, 158], ["ILs", "GENE_OR_GENE_PRODUCT", 64, 67], ["AECA", "GENE_OR_GENE_PRODUCT", 78, 82], ["endothelial cell", "CELL", 89, 105], ["vascular", "MULTI-TISSUE_STRUCTURE", 150, 158], ["ILs", "PROTEIN", 64, 67], ["AECA", "PROTEIN", 78, 82], ["endothelial cell migration", "PROBLEM", 89, 115], ["vascular changes", "PROBLEM", 150, 166], ["area", "OBSERVATION_MODIFIER", 8, 12], ["AECA", "ANATOMY", 78, 82], ["favor", "UNCERTAINTY", 83, 88], ["endothelial cell migration", "OBSERVATION", 89, 115], ["worsening", "OBSERVATION_MODIFIER", 137, 146], ["vascular", "ANATOMY", 150, 158]]], ["The changes are multiplied by the high levels of adhesion molecules on endothelium, including CD54, CD102 and von Willebrand factor [78, 148] .", [["endothelium", "ANATOMY", 71, 82], ["endothelium", "TISSUE", 71, 82], ["CD54", "GENE_OR_GENE_PRODUCT", 94, 98], ["CD102", "GENE_OR_GENE_PRODUCT", 100, 105], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 110, 131], ["adhesion molecules", "PROTEIN", 49, 67], ["CD54", "PROTEIN", 94, 98], ["CD102", "PROTEIN", 100, 105], ["von Willebrand factor", "PROTEIN", 110, 131], ["adhesion molecules", "PROBLEM", 49, 67], ["CD54", "TEST", 94, 98], ["von Willebrand factor", "TEST", 110, 131], ["high levels", "OBSERVATION_MODIFIER", 34, 45]]], ["Recent data have revealed toxins acting as superantigens (SAs) on Vb2 and Vb8 [51, 123, 243] , produced by microorganisms of the respiratory or gastrointestinal tracts [51, 147] , in particular by Staphylococcus aureus and Streptococcus pyrogenus secreting TSST-1 (toxic shock syndrome toxin-1) and SPEA/SPEB (staphylococcal pyrogenic exotoxin A and B), respectively [123] .", [["respiratory", "ANATOMY", 129, 140], ["gastrointestinal tracts", "ANATOMY", 144, 167], ["respiratory or gastrointestinal tracts", "DISEASE", 129, 167], ["Staphylococcus aureus", "DISEASE", 197, 218], ["toxic shock syndrome", "DISEASE", 265, 285], ["SAs", "SIMPLE_CHEMICAL", 58, 61], ["Vb2", "GENE_OR_GENE_PRODUCT", 66, 69], ["Vb8", "GENE_OR_GENE_PRODUCT", 74, 77], ["gastrointestinal tracts", "PATHOLOGICAL_FORMATION", 144, 167], ["Staphylococcus aureus", "ORGANISM", 197, 218], ["Streptococcus pyrogenus", "ORGANISM", 223, 246], ["TSST-1", "GENE_OR_GENE_PRODUCT", 257, 263], ["toxic shock syndrome toxin-1", "GENE_OR_GENE_PRODUCT", 265, 293], ["SPEA", "GENE_OR_GENE_PRODUCT", 299, 303], ["SPEB", "GENE_OR_GENE_PRODUCT", 304, 308], ["staphylococcal pyrogenic exotoxin A", "GENE_OR_GENE_PRODUCT", 310, 345], ["B", "GENE_OR_GENE_PRODUCT", 350, 351], ["superantigens", "PROTEIN", 43, 56], ["SAs", "PROTEIN", 58, 61], ["TSST", "PROTEIN", 257, 261], ["toxic shock syndrome toxin", "PROTEIN", 265, 291], ["SPEA", "PROTEIN", 299, 303], ["SPEB", "PROTEIN", 304, 308], ["staphylococcal pyrogenic exotoxin A", "PROTEIN", 310, 345], ["B", "PROTEIN", 350, 351], ["Staphylococcus aureus", "SPECIES", 197, 218], ["Streptococcus pyrogenus", "SPECIES", 223, 246], ["Staphylococcus aureus", "SPECIES", 197, 218], ["Streptococcus pyrogenus", "SPECIES", 223, 246], ["Recent data", "TEST", 0, 11], ["toxins", "PROBLEM", 26, 32], ["Vb2", "TEST", 66, 69], ["Vb8", "TEST", 74, 77], ["Staphylococcus aureus", "PROBLEM", 197, 218], ["Streptococcus pyrogenus secreting TSST", "TEST", 223, 261], ["toxic shock syndrome toxin", "TEST", 265, 291], ["SPEA/SPEB", "TEST", 299, 308], ["staphylococcal pyrogenic exotoxin A", "TEST", 310, 345], ["respiratory", "ANATOMY", 129, 140], ["gastrointestinal tracts", "ANATOMY", 144, 167], ["Staphylococcus aureus", "OBSERVATION", 197, 218]]], ["A result still to be weighed is whether CD45RO expression is raised solely on CD8 T cells [165] .", [["CD8 T cells", "ANATOMY", 78, 89], ["CD45RO", "GENE_OR_GENE_PRODUCT", 40, 46], ["CD8", "GENE_OR_GENE_PRODUCT", 78, 81], ["CD45RO", "PROTEIN", 40, 46], ["CD8 T cells", "CELL_TYPE", 78, 89], ["CD45RO expression", "PROBLEM", 40, 57]]], ["There is a tempting suggestion that the intestine encourages causative agent entry such as microorganisms [147, 243] that are producers of toxins with SA properties (Table 8 .22).", [["intestine", "ANATOMY", 40, 49], ["intestine", "ORGAN", 40, 49], ["intestine", "ANATOMY", 40, 49]]], ["A novel human coronavirus, designated \"New Haven coronavirus\" (HCoV-NH) was identified in 8/11 infants with Kawasaki disease.", [["Kawasaki disease", "DISEASE", 108, 124], ["human", "ORGANISM", 8, 13], ["New Haven coronavirus", "ORGANISM", 39, 60], ["HCoV-NH", "CELL", 63, 70], ["infants", "ORGANISM", 95, 102], ["human", "SPECIES", 8, 13], ["coronavirus", "SPECIES", 14, 25], ["coronavirus", "SPECIES", 49, 60], ["infants", "SPECIES", 95, 102], ["human coronavirus", "SPECIES", 8, 25], ["New Haven coronavirus", "SPECIES", 39, 60], ["A novel human coronavirus", "PROBLEM", 0, 25], ["Kawasaki disease", "PROBLEM", 108, 124], ["Kawasaki disease", "OBSERVATION", 108, 124]]], ["Human coronaviruses (HCoVs) have attracted renewed interest because of the emergence of a novel HCoV associated with severe acute respiratory syndrome (SARS).", [["HCoV", "CHEMICAL", 96, 100], ["acute respiratory syndrome", "DISEASE", 124, 150], ["SARS", "DISEASE", 152, 156], ["Human coronaviruses", "ORGANISM", 0, 19], ["HCoVs", "CANCER", 21, 26], ["HCoV", "CANCER", 96, 100], ["Human", "SPECIES", 0, 5], ["Human coronaviruses", "SPECIES", 0, 19], ["HCoVs", "SPECIES", 21, 26], ["HCoV", "SPECIES", 96, 100], ["Human coronaviruses", "PROBLEM", 0, 19], ["severe acute respiratory syndrome", "PROBLEM", 117, 150], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["respiratory syndrome", "OBSERVATION", 130, 150]]], ["The median time between the onset of fever and the diagnosis of HCoV-NH was 5 days; 7/11 infants and 19/22 control subjects had respiratory symptoms that were consistent with an upper respiratory tract infection (URTI) [68] .", [["respiratory", "ANATOMY", 128, 139], ["upper respiratory tract", "ANATOMY", 178, 201], ["fever", "DISEASE", 37, 42], ["HCoV-NH", "CHEMICAL", 64, 71], ["respiratory symptoms", "DISEASE", 128, 148], ["upper respiratory tract infection", "DISEASE", 178, 211], ["URTI", "DISEASE", 213, 217], ["infants", "ORGANISM", 89, 96], ["upper", "ORGANISM_SUBDIVISION", 178, 183], ["respiratory tract", "ORGANISM_SUBDIVISION", 184, 201], ["infants", "SPECIES", 89, 96], ["fever", "PROBLEM", 37, 42], ["respiratory symptoms", "PROBLEM", 128, 148], ["an upper respiratory tract infection", "PROBLEM", 175, 211], ["fever", "OBSERVATION", 37, 42], ["consistent with", "UNCERTAINTY", 159, 174], ["upper", "ANATOMY_MODIFIER", 178, 183], ["respiratory tract", "ANATOMY", 184, 201], ["infection", "OBSERVATION", 202, 211]]], ["Table 8 .23 [189] outlines the chief diagnostic and associated symptoms.", [["associated symptoms", "PROBLEM", 52, 71]]], ["Useful diagnostic markers could be CD8 T cells [147, 165] and IL 2 R for early diagnosis [21] .", [["CD8 T cells", "ANATOMY", 35, 46], ["CD8 T cells", "CELL", 35, 46], ["IL 2 R", "GENE_OR_GENE_PRODUCT", 62, 68], ["CD8 T cells", "CELL_TYPE", 35, 46], ["diagnostic markers", "TEST", 7, 25], ["CD8 T cells", "TEST", 35, 46]]], ["Polyarteritis nodosa (PAN), divided into classic, infantile and cutaneous PAN [122] , is among the least common in childhood.", [["Polyarteritis nodosa", "DISEASE", 0, 20], ["PAN", "DISEASE", 22, 25], ["infantile", "DISEASE", 50, 59], ["PAN", "CHEMICAL", 74, 77], ["PAN", "CANCER", 22, 25], ["Polyarteritis nodosa", "PROBLEM", 0, 20], ["nodosa", "OBSERVATION", 14, 20]]], ["This is another disease that differs in presentation and etiology from that seen in 105,755 cases reported over 35 years ago in Japan [217] showed a prevalence of 4.5-8.5 cases \u00a510 5 aged <5, with the youngest patient aged 26 days, 0.006% of infants aged 30 days and 1.67% aged 3 months.", [["patient", "ORGANISM", 210, 217], ["infants", "ORGANISM", 242, 249], ["patient", "SPECIES", 210, 217], ["infants", "SPECIES", 242, 249], ["a prevalence", "TEST", 147, 159], ["disease", "OBSERVATION", 16, 23]]], ["Among newly treated children aged <5 years, the incidence was 102.6\u00a510 5 in 1995 and 108\u00a510 5 in 1996, with a male-female ratio of 1.37 [244] .", [["children", "ORGANISM", 20, 28], ["children", "SPECIES", 20, 28]]], ["The estimated annual incidence was 5.5\u00a510 5 in children <5 years, and was highest in Indian subcontinent Asian children (14.6 \u00a510 5 ) [81] .", [["children", "ORGANISM", 47, 55], ["children", "ORGANISM", 111, 119], ["children", "SPECIES", 47, 55], ["children", "SPECIES", 111, 119], ["annual", "OBSERVATION_MODIFIER", 14, 20]]], ["The incidence rate in Korean children <5 years was (\u00a510 5 ) 73.7 in 2000, 90.8 in 2001, and 95.5 in 2002.", [["children", "ORGANISM", 29, 37], ["children", "SPECIES", 29, 37]]], ["This is a multisystem disorder causing substantial symptoms of vasculitis and mucocutaneous lesions with desquamation, after 2 weeks, beginning at the nail-pulp junction (Fig. 8.21 ).", [["mucocutaneous lesions", "ANATOMY", 78, 99], ["nail-pulp junction", "ANATOMY", 151, 169], ["multisystem disorder", "DISEASE", 10, 30], ["vasculitis", "DISEASE", 63, 73], ["mucocutaneous lesions", "DISEASE", 78, 99], ["desquamation", "DISEASE", 105, 117], ["mucocutaneous lesions", "PATHOLOGICAL_FORMATION", 78, 99], ["pulp junction", "MULTI-TISSUE_STRUCTURE", 156, 169], ["a multisystem disorder", "PROBLEM", 8, 30], ["substantial symptoms", "PROBLEM", 39, 59], ["vasculitis", "PROBLEM", 63, 73], ["mucocutaneous lesions", "PROBLEM", 78, 99], ["desquamation", "PROBLEM", 105, 117], ["multisystem disorder", "OBSERVATION", 10, 30], ["vasculitis", "OBSERVATION", 63, 73], ["mucocutaneous", "OBSERVATION_MODIFIER", 78, 91], ["lesions", "OBSERVATION", 92, 99], ["desquamation", "OBSERVATION_MODIFIER", 105, 117], ["nail", "ANATOMY", 151, 155], ["pulp junction", "ANATOMY", 156, 169]]], ["It is another CIC-induced one-shot disease, characterized by a polyvasculitis of small and mediumsized vessels, especially affecting medium-sized arteries, with a predilection for coronary arteries with thrombosis and formation of aneurysms [72] , a particular risk for infants aged <6-12 months [178] .", [["mediumsized vessels", "ANATOMY", 91, 110], ["arteries", "ANATOMY", 146, 154], ["coronary arteries", "ANATOMY", 180, 197], ["polyvasculitis", "DISEASE", 63, 77], ["thrombosis", "DISEASE", 203, 213], ["aneurysms", "DISEASE", 231, 240], ["vessels", "MULTI-TISSUE_STRUCTURE", 103, 110], ["arteries", "MULTI-TISSUE_STRUCTURE", 146, 154], ["coronary arteries", "MULTI-TISSUE_STRUCTURE", 180, 197], ["infants", "ORGANISM", 270, 277], ["infants", "SPECIES", 270, 277], ["shot disease", "PROBLEM", 30, 42], ["a polyvasculitis of small and mediumsized vessels", "PROBLEM", 61, 110], ["thrombosis", "PROBLEM", 203, 213], ["aneurysms", "PROBLEM", 231, 240], ["small", "OBSERVATION_MODIFIER", 81, 86], ["mediumsized", "ANATOMY_MODIFIER", 91, 102], ["vessels", "ANATOMY", 103, 110], ["sized", "OBSERVATION_MODIFIER", 140, 145], ["arteries", "ANATOMY", 146, 154], ["coronary arteries", "ANATOMY", 180, 197], ["thrombosis", "OBSERVATION", 203, 213], ["aneurysms", "OBSERVATION", 231, 240]]], ["Ongoing antibody synthesis may foster inflammation involving adults.", [["inflammation", "DISEASE", 38, 50], ["Ongoing antibody synthesis", "PROBLEM", 0, 26], ["foster inflammation", "PROBLEM", 31, 50]]], ["More frequent is cutaneous PAN, manifested by purpura, edema, linear erythema, tender palpable nodules, high fever, arthralgias and myalgias, without important organ system involvement.", [["cutaneous PAN", "ANATOMY", 17, 30], ["edema", "ANATOMY", 55, 60], ["tender palpable nodules", "ANATOMY", 79, 102], ["organ system", "ANATOMY", 160, 172], ["PAN", "DISEASE", 27, 30], ["purpura", "DISEASE", 46, 53], ["edema", "DISEASE", 55, 60], ["erythema", "DISEASE", 69, 77], ["fever", "DISEASE", 109, 114], ["arthralgias", "DISEASE", 116, 127], ["myalgias", "DISEASE", 132, 140], ["edema", "PATHOLOGICAL_FORMATION", 55, 60], ["organ", "ORGAN", 160, 165], ["cutaneous PAN", "PROBLEM", 17, 30], ["purpura", "PROBLEM", 46, 53], ["edema", "PROBLEM", 55, 60], ["linear erythema", "PROBLEM", 62, 77], ["tender palpable nodules", "PROBLEM", 79, 102], ["high fever", "PROBLEM", 104, 114], ["arthralgias", "PROBLEM", 116, 127], ["myalgias", "PROBLEM", 132, 140], ["important organ system involvement", "PROBLEM", 150, 184], ["cutaneous", "ANATOMY", 17, 26], ["purpura", "OBSERVATION", 46, 53], ["edema", "OBSERVATION", 55, 60], ["linear", "OBSERVATION_MODIFIER", 62, 68], ["erythema", "OBSERVATION", 69, 77], ["tender", "OBSERVATION_MODIFIER", 79, 85], ["palpable", "OBSERVATION_MODIFIER", 86, 94], ["nodules", "OBSERVATION", 95, 102], ["high", "OBSERVATION_MODIFIER", 104, 108], ["fever", "OBSERVATION", 109, 114], ["arthralgias", "OBSERVATION", 116, 127], ["myalgias", "OBSERVATION", 132, 140], ["without", "UNCERTAINTY", 142, 149]]], ["It has a chronic course and a better prognosis than the systemic variants [11, 72, 98] .", [["chronic", "OBSERVATION_MODIFIER", 9, 16], ["course", "OBSERVATION_MODIFIER", 17, 23]]], ["Biopsy reveals a focal necrosis and inflammation of the walls of small and medium-sized arteries that tend to occur in a segmental way and particularly involves areas where arteries bifurcate [98] .Prominent Vasculitis Syndromes in ChildrenOther types of polyarthritis vasculitis include Wegener granulomatosis, featuring the formation of granulomas around blood vessels, with typical lung and kidney involvement, which is currently classified as one of the ANCA-associated small-vessel vasculites distinguished by its predisposition to affect the upper and lower respiratory tracts and kidneys clinically and histologically by the presence of necrosis, granulomatous inflammation, and vasculitis [246] .", [["walls", "ANATOMY", 56, 61], ["arteries", "ANATOMY", 88, 96], ["arteries", "ANATOMY", 173, 181], ["granulomas", "ANATOMY", 339, 349], ["blood vessels", "ANATOMY", 357, 370], ["lung", "ANATOMY", 385, 389], ["kidney", "ANATOMY", 394, 400], ["small-vessel vasculites", "ANATOMY", 474, 497], ["upper", "ANATOMY", 548, 553], ["lower respiratory tracts", "ANATOMY", 558, 582], ["kidneys", "ANATOMY", 587, 594], ["granulomatous", "ANATOMY", 654, 667], ["necrosis", "DISEASE", 23, 31], ["Vasculitis Syndromes", "DISEASE", 208, 228], ["polyarthritis", "DISEASE", 255, 268], ["vasculitis", "DISEASE", 269, 279], ["Wegener granulomatosis", "DISEASE", 288, 310], ["granulomas", "DISEASE", 339, 349], ["lung and kidney involvement", "DISEASE", 385, 412], ["ANCA", "DISEASE", 458, 462], ["necrosis", "DISEASE", 644, 652], ["granulomatous inflammation", "DISEASE", 654, 680], ["vasculitis", "DISEASE", 686, 696], ["arteries", "MULTI-TISSUE_STRUCTURE", 88, 96], ["arteries", "MULTI-TISSUE_STRUCTURE", 173, 181], ["granulomas", "PATHOLOGICAL_FORMATION", 339, 349], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 357, 370], ["lung", "ORGAN", 385, 389], ["kidney", "ORGAN", 394, 400], ["ANCA", "GENE_OR_GENE_PRODUCT", 458, 462], ["upper", "ORGANISM_SUBDIVISION", 548, 553], ["kidneys", "ORGAN", 587, 594], ["Biopsy", "TEST", 0, 6], ["a focal necrosis", "PROBLEM", 15, 31], ["inflammation of the walls of small and medium-sized arteries", "PROBLEM", 36, 96], ["Prominent Vasculitis Syndromes", "PROBLEM", 198, 228], ["polyarthritis vasculitis", "PROBLEM", 255, 279], ["Wegener granulomatosis", "PROBLEM", 288, 310], ["granulomas around blood vessels", "PROBLEM", 339, 370], ["typical lung and kidney involvement", "PROBLEM", 377, 412], ["the ANCA", "TEST", 454, 462], ["small-vessel vasculites", "PROBLEM", 474, 497], ["necrosis", "PROBLEM", 644, 652], ["granulomatous inflammation", "PROBLEM", 654, 680], ["vasculitis", "PROBLEM", 686, 696], ["focal", "OBSERVATION_MODIFIER", 17, 22], ["necrosis", "OBSERVATION", 23, 31], ["inflammation", "OBSERVATION", 36, 48], ["walls", "ANATOMY_MODIFIER", 56, 61], ["small", "OBSERVATION_MODIFIER", 65, 70], ["medium", "OBSERVATION_MODIFIER", 75, 81], ["sized", "OBSERVATION_MODIFIER", 82, 87], ["arteries", "ANATOMY", 88, 96], ["segmental", "ANATOMY_MODIFIER", 121, 130], ["arteries", "ANATOMY", 173, 181], ["bifurcate", "ANATOMY_MODIFIER", 182, 191], ["Vasculitis", "OBSERVATION", 208, 218], ["polyarthritis", "OBSERVATION_MODIFIER", 255, 268], ["vasculitis", "OBSERVATION", 269, 279], ["Wegener granulomatosis", "OBSERVATION", 288, 310], ["granulomas", "OBSERVATION", 339, 349], ["blood vessels", "ANATOMY", 357, 370], ["typical", "OBSERVATION_MODIFIER", 377, 384], ["lung", "ANATOMY", 385, 389], ["kidney", "ANATOMY", 394, 400], ["involvement", "OBSERVATION", 401, 412], ["ANCA", "OBSERVATION", 458, 462], ["small", "OBSERVATION_MODIFIER", 474, 479], ["-vessel vasculites", "OBSERVATION", 479, 497], ["upper", "ANATOMY_MODIFIER", 548, 553], ["lower", "ANATOMY_MODIFIER", 558, 563], ["respiratory tracts", "ANATOMY", 564, 582], ["kidneys", "ANATOMY", 587, 594], ["necrosis", "OBSERVATION", 644, 652], ["granulomatous", "OBSERVATION_MODIFIER", 654, 667], ["inflammation", "OBSERVATION", 668, 680], ["vasculitis", "OBSERVATION", 686, 696]]], ["The presence of PR3, normally restricted to neutrophil a granules, has led to the hypothesis that ANCA-induced neutrophil activation is central to a chain of events leading to T-cell activation and a CMI response involving macrophage activation, and that PR3 expression may be abnormal.", [["neutrophil", "ANATOMY", 44, 54], ["granules", "ANATOMY", 57, 65], ["neutrophil", "ANATOMY", 111, 121], ["T-cell", "ANATOMY", 176, 182], ["macrophage", "ANATOMY", 223, 233], ["ANCA", "DISEASE", 98, 102], ["PR3", "GENE_OR_GENE_PRODUCT", 16, 19], ["neutrophil", "CELL", 44, 54], ["granules", "CELLULAR_COMPONENT", 57, 65], ["ANCA", "GENE_OR_GENE_PRODUCT", 98, 102], ["neutrophil", "CELL", 111, 121], ["T-cell", "CELL", 176, 182], ["macrophage", "CELL", 223, 233], ["PR3", "GENE_OR_GENE_PRODUCT", 255, 258], ["PR3", "PROTEIN", 16, 19], ["neutrophil", "CELL_TYPE", 44, 54], ["ANCA", "PROTEIN", 98, 102], ["PR3", "PROTEIN", 255, 258], ["PR3", "PROBLEM", 16, 19], ["ANCA", "TEST", 98, 102], ["neutrophil activation", "PROBLEM", 111, 132], ["T-cell activation", "PROBLEM", 176, 193], ["a CMI response", "PROBLEM", 198, 212], ["macrophage activation", "PROBLEM", 223, 244], ["PR3 expression", "TEST", 255, 269], ["PR3", "OBSERVATION", 16, 19], ["neutrophil activation", "OBSERVATION", 111, 132], ["macrophage activation", "OBSERVATION", 223, 244], ["may be", "UNCERTAINTY", 270, 276]]], ["The cause may remain unknown, but circumstantial evidence suggests the potential roles of ANCA and infection in the pathogenesis [246] .", [["ANCA", "DISEASE", 90, 94], ["infection", "DISEASE", 99, 108], ["ANCA", "GENE_OR_GENE_PRODUCT", 90, 94], ["ANCA", "PROTEIN", 90, 94], ["ANCA", "PROBLEM", 90, 94], ["infection", "PROBLEM", 99, 108], ["ANCA", "OBSERVATION", 90, 94], ["infection", "OBSERVATION", 99, 108]]], ["Recurring infections of upper airways and respiratory infections are prominent clinical manifestations, along with cough, fever, weight loss, arthritis, neuropathy, rash, and splenomegaly.", [["upper airways", "ANATOMY", 24, 37], ["respiratory", "ANATOMY", 42, 53], ["infections", "DISEASE", 10, 20], ["respiratory infections", "DISEASE", 42, 64], ["cough", "DISEASE", 115, 120], ["fever", "DISEASE", 122, 127], ["weight loss", "DISEASE", 129, 140], ["arthritis", "DISEASE", 142, 151], ["neuropathy", "DISEASE", 153, 163], ["rash", "DISEASE", 165, 169], ["splenomegaly", "DISEASE", 175, 187], ["upper airways", "MULTI-TISSUE_STRUCTURE", 24, 37], ["splenomegaly", "PATHOLOGICAL_FORMATION", 175, 187], ["Recurring infections of upper airways", "PROBLEM", 0, 37], ["respiratory infections", "PROBLEM", 42, 64], ["prominent clinical manifestations", "PROBLEM", 69, 102], ["cough", "PROBLEM", 115, 120], ["fever", "PROBLEM", 122, 127], ["weight loss", "PROBLEM", 129, 140], ["arthritis", "PROBLEM", 142, 151], ["neuropathy", "PROBLEM", 153, 163], ["rash", "PROBLEM", 165, 169], ["splenomegaly", "PROBLEM", 175, 187], ["infections", "OBSERVATION", 10, 20], ["upper", "ANATOMY_MODIFIER", 24, 29], ["airways", "ANATOMY", 30, 37], ["respiratory", "ANATOMY", 42, 53], ["infections", "OBSERVATION", 54, 64], ["prominent", "OBSERVATION_MODIFIER", 69, 78], ["weight loss", "OBSERVATION_MODIFIER", 129, 140], ["arthritis", "OBSERVATION", 142, 151], ["neuropathy", "OBSERVATION", 153, 163], ["rash", "OBSERVATION", 165, 169], ["splenomegaly", "OBSERVATION", 175, 187]]], ["ANCA-associated glomerulonephritis has been diagnosed in 20 children, the youngest aged 11 years, but early recognition and aggressive treatment of these children may prevent end-stage renal disease [219] .Prominent Vasculitis Syndromes in ChildrenChurg-Strauss syndrome, an allergic granulomatous vasculitis also affecting small and medium-sized vessels has a predilection for lungs characterized by AR and/or asthma and presents with fever, headache, myalgia, weight loss, and peripheral blood and tissue eosinophilia exceeding 1,500 cells/m 2 .", [["renal", "ANATOMY", 185, 190], ["vessels", "ANATOMY", 347, 354], ["lungs", "ANATOMY", 378, 383], ["peripheral blood", "ANATOMY", 479, 495], ["tissue", "ANATOMY", 500, 506], ["cells", "ANATOMY", 536, 541], ["ANCA", "DISEASE", 0, 4], ["glomerulonephritis", "DISEASE", 16, 34], ["end-stage renal disease", "DISEASE", 175, 198], ["Vasculitis Syndromes", "DISEASE", 216, 236], ["ChildrenChurg-Strauss syndrome", "DISEASE", 240, 270], ["allergic granulomatous vasculitis", "DISEASE", 275, 308], ["asthma", "DISEASE", 411, 417], ["fever", "DISEASE", 436, 441], ["headache", "DISEASE", 443, 451], ["myalgia", "DISEASE", 453, 460], ["weight loss", "DISEASE", 462, 473], ["eosinophilia", "DISEASE", 507, 519], ["ANCA", "GENE_OR_GENE_PRODUCT", 0, 4], ["children", "ORGANISM", 60, 68], ["children", "ORGANISM", 154, 162], ["renal", "ORGAN", 185, 190], ["vessels", "MULTI-TISSUE_STRUCTURE", 347, 354], ["lungs", "ORGAN", 378, 383], ["AR", "GENE_OR_GENE_PRODUCT", 401, 403], ["peripheral blood", "ORGANISM_SUBSTANCE", 479, 495], ["tissue", "TISSUE", 500, 506], ["ANCA", "PROTEIN", 0, 4], ["AR", "PROTEIN", 401, 403], ["children", "SPECIES", 60, 68], ["children", "SPECIES", 154, 162], ["ANCA", "TEST", 0, 4], ["glomerulonephritis", "PROBLEM", 16, 34], ["aggressive treatment", "TREATMENT", 124, 144], ["end-stage renal disease", "PROBLEM", 175, 198], ["Prominent Vasculitis Syndromes", "PROBLEM", 206, 236], ["Strauss syndrome", "PROBLEM", 254, 270], ["an allergic granulomatous vasculitis", "PROBLEM", 272, 308], ["small and medium-sized vessels", "PROBLEM", 324, 354], ["AR", "PROBLEM", 401, 403], ["asthma", "PROBLEM", 411, 417], ["fever", "PROBLEM", 436, 441], ["headache", "PROBLEM", 443, 451], ["myalgia", "PROBLEM", 453, 460], ["weight loss", "PROBLEM", 462, 473], ["peripheral blood and tissue eosinophilia", "PROBLEM", 479, 519], ["glomerulonephritis", "OBSERVATION", 16, 34], ["20 children", "OBSERVATION_MODIFIER", 57, 68], ["stage", "OBSERVATION_MODIFIER", 179, 184], ["renal", "ANATOMY", 185, 190], ["disease", "OBSERVATION", 191, 198], ["Vasculitis", "OBSERVATION", 216, 226], ["Strauss syndrome", "OBSERVATION", 254, 270], ["allergic", "OBSERVATION_MODIFIER", 275, 283], ["granulomatous", "OBSERVATION_MODIFIER", 284, 297], ["vasculitis", "OBSERVATION", 298, 308], ["small", "OBSERVATION_MODIFIER", 324, 329], ["medium", "OBSERVATION_MODIFIER", 334, 340], ["sized", "OBSERVATION_MODIFIER", 341, 346], ["vessels", "ANATOMY", 347, 354], ["lungs", "ANATOMY", 378, 383], ["AR", "OBSERVATION", 401, 403], ["asthma", "OBSERVATION", 411, 417], ["fever", "OBSERVATION", 436, 441], ["myalgia", "OBSERVATION", 453, 460], ["weight loss", "OBSERVATION", 462, 473], ["peripheral", "ANATOMY_MODIFIER", 479, 489], ["blood", "ANATOMY", 490, 495], ["tissue", "ANATOMY", 500, 506], ["eosinophilia", "OBSERVATION", 507, 519]]], ["The systemic vasculitis may involve the skin, heart, and peripheral nerves.", [["skin", "ANATOMY", 40, 44], ["heart", "ANATOMY", 46, 51], ["peripheral nerves", "ANATOMY", 57, 74], ["vasculitis", "DISEASE", 13, 23], ["skin", "ORGAN", 40, 44], ["heart", "ORGAN", 46, 51], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 57, 74], ["The systemic vasculitis", "PROBLEM", 0, 23], ["systemic", "OBSERVATION_MODIFIER", 4, 12], ["vasculitis", "OBSERVATION", 13, 23], ["skin", "ANATOMY", 40, 44], ["heart", "ANATOMY", 46, 51], ["peripheral nerves", "ANATOMY", 57, 74]]], ["Kidneys are spared or only mildly affected [122] .", [["Kidneys", "ANATOMY", 0, 7], ["Kidneys", "ORGAN", 0, 7], ["mildly affected", "PROBLEM", 27, 42], ["spared", "OBSERVATION", 12, 18], ["mildly", "OBSERVATION_MODIFIER", 27, 33], ["affected", "OBSERVATION_MODIFIER", 34, 42]]], ["Recently three cases have been reported: a 15-year-old girl with catastrophic gastrointestinal vasculitis and multiple colonic ulcers with active bleeding [124] , a 10-year-old girl with acute abdominal pain, bloody diarrhea, pulmonary infiltrates, a 6-year history of severe asthma, and marked eosinophilia [26] , and a boy with poorly controlled bronchial asthma, AR, recurrent sinusitis and several episodes of hemophthisis since the age of 9, who developed purpuric skin lesions, generalized soreness, and symptoms of mononeuritis multiplex at age 11 [234] .", [["gastrointestinal", "ANATOMY", 78, 94], ["colonic", "ANATOMY", 119, 126], ["abdominal", "ANATOMY", 193, 202], ["pulmonary", "ANATOMY", 226, 235], ["bronchial", "ANATOMY", 348, 357], ["purpuric skin lesions", "ANATOMY", 461, 482], ["gastrointestinal vasculitis", "DISEASE", 78, 105], ["colonic ulcers", "DISEASE", 119, 133], ["bleeding", "DISEASE", 146, 154], ["abdominal pain", "DISEASE", 193, 207], ["diarrhea", "DISEASE", 216, 224], ["pulmonary infiltrates", "DISEASE", 226, 247], ["asthma", "DISEASE", 276, 282], ["eosinophilia", "DISEASE", 295, 307], ["bronchial asthma", "DISEASE", 348, 364], ["sinusitis", "DISEASE", 380, 389], ["hemophthisis", "DISEASE", 414, 426], ["skin lesions", "DISEASE", 470, 482], ["soreness", "DISEASE", 496, 504], ["mononeuritis", "DISEASE", 522, 534], ["girl", "ORGANISM", 55, 59], ["gastrointestinal vasculitis", "PATHOLOGICAL_FORMATION", 78, 105], ["colonic ulcers", "PATHOLOGICAL_FORMATION", 119, 133], ["girl", "ORGANISM", 177, 181], ["abdominal", "ORGANISM_SUBDIVISION", 193, 202], ["pulmonary", "ORGAN", 226, 235], ["skin lesions", "PATHOLOGICAL_FORMATION", 470, 482], ["girl", "SPECIES", 55, 59], ["girl", "SPECIES", 177, 181], ["boy", "SPECIES", 321, 324], ["catastrophic gastrointestinal vasculitis", "PROBLEM", 65, 105], ["multiple colonic ulcers", "PROBLEM", 110, 133], ["active bleeding", "PROBLEM", 139, 154], ["acute abdominal pain", "PROBLEM", 187, 207], ["bloody diarrhea", "PROBLEM", 209, 224], ["pulmonary infiltrates", "PROBLEM", 226, 247], ["severe asthma", "PROBLEM", 269, 282], ["marked eosinophilia", "PROBLEM", 288, 307], ["poorly controlled bronchial asthma", "PROBLEM", 330, 364], ["AR", "PROBLEM", 366, 368], ["recurrent sinusitis", "PROBLEM", 370, 389], ["hemophthisis", "PROBLEM", 414, 426], ["purpuric skin lesions", "PROBLEM", 461, 482], ["generalized soreness", "PROBLEM", 484, 504], ["symptoms", "PROBLEM", 510, 518], ["mononeuritis multiplex", "PROBLEM", 522, 544], ["catastrophic", "OBSERVATION_MODIFIER", 65, 77], ["gastrointestinal", "ANATOMY", 78, 94], ["vasculitis", "OBSERVATION", 95, 105], ["multiple", "OBSERVATION_MODIFIER", 110, 118], ["colonic", "ANATOMY", 119, 126], ["ulcers", "OBSERVATION", 127, 133], ["active", "OBSERVATION_MODIFIER", 139, 145], ["bleeding", "OBSERVATION", 146, 154], ["acute", "OBSERVATION_MODIFIER", 187, 192], ["abdominal", "ANATOMY", 193, 202], ["pain", "OBSERVATION", 203, 207], ["bloody diarrhea", "OBSERVATION", 209, 224], ["pulmonary", "ANATOMY", 226, 235], ["infiltrates", "OBSERVATION", 236, 247], ["severe", "OBSERVATION_MODIFIER", 269, 275], ["asthma", "OBSERVATION", 276, 282], ["marked", "OBSERVATION_MODIFIER", 288, 294], ["eosinophilia", "OBSERVATION", 295, 307], ["poorly controlled", "OBSERVATION_MODIFIER", 330, 347], ["bronchial", "ANATOMY", 348, 357], ["asthma", "OBSERVATION", 358, 364], ["recurrent", "OBSERVATION_MODIFIER", 370, 379], ["sinusitis", "OBSERVATION", 380, 389], ["several", "OBSERVATION_MODIFIER", 394, 401], ["episodes", "OBSERVATION_MODIFIER", 402, 410], ["hemophthisis", "OBSERVATION", 414, 426], ["purpuric", "OBSERVATION_MODIFIER", 461, 469], ["skin", "ANATOMY", 470, 474], ["lesions", "OBSERVATION", 475, 482], ["generalized", "OBSERVATION_MODIFIER", 484, 495], ["soreness", "OBSERVATION", 496, 504], ["mononeuritis", "OBSERVATION", 522, 534]]], ["These cases demonstrate that the prognosis is poorer in children than in adults [124] . induce de novo synthesis of chemokines and ILs and mastocyte degranulation with consequent increase in vascular permeability, followed by LTB 4 release.", [["mastocyte", "ANATOMY", 139, 148], ["vascular", "ANATOMY", 191, 199], ["children", "ORGANISM", 56, 64], ["ILs", "GENE_OR_GENE_PRODUCT", 131, 134], ["vascular", "MULTI-TISSUE_STRUCTURE", 191, 199], ["LTB 4", "GENE_OR_GENE_PRODUCT", 226, 231], ["chemokines", "PROTEIN", 116, 126], ["ILs", "PROTEIN", 131, 134], ["LTB 4", "PROTEIN", 226, 231], ["children", "SPECIES", 56, 64], ["chemokines and ILs", "TREATMENT", 116, 134], ["mastocyte degranulation", "PROBLEM", 139, 162], ["consequent increase in vascular permeability", "PROBLEM", 168, 212], ["consequent", "OBSERVATION_MODIFIER", 168, 178], ["increase", "OBSERVATION_MODIFIER", 179, 187], ["vascular", "ANATOMY", 191, 199], ["permeability", "OBSERVATION", 200, 212]]], ["In both ways, PMNs are recruited, resulting in the tissue damage described above.", [["PMNs", "ANATOMY", 14, 18], ["tissue", "ANATOMY", 51, 57], ["PMNs", "CELL", 14, 18], ["tissue", "TISSUE", 51, 57], ["PMNs", "CELL_TYPE", 14, 18], ["PMNs", "TEST", 14, 18], ["the tissue damage", "PROBLEM", 47, 64], ["PMNs", "OBSERVATION", 14, 18], ["tissue", "ANATOMY", 51, 57], ["damage", "OBSERVATION", 58, 64]]], ["Clinical features are those of leukocytoclastic vasculitis: clearly delimited erythematous and edematous macules are seen, and are characterized by their relatively fixed aspect, tendency to purpura, are only slightly pruritic, and the possible association with systemic manifestations or an inflammatory syndrome [27, 135, 226] .", [["erythematous", "ANATOMY", 78, 90], ["edematous macules", "ANATOMY", 95, 112], ["leukocytoclastic vasculitis", "DISEASE", 31, 58], ["purpura", "DISEASE", 191, 198], ["pruritic", "DISEASE", 218, 226], ["erythematous", "PATHOLOGICAL_FORMATION", 78, 90], ["edematous macules", "PATHOLOGICAL_FORMATION", 95, 112], ["leukocytoclastic vasculitis", "PROBLEM", 31, 58], ["erythematous and edematous macules", "PROBLEM", 78, 112], ["tendency to purpura", "PROBLEM", 179, 198], ["slightly pruritic", "PROBLEM", 209, 226], ["systemic manifestations", "PROBLEM", 262, 285], ["an inflammatory syndrome", "PROBLEM", 289, 313], ["leukocytoclastic", "OBSERVATION_MODIFIER", 31, 47], ["vasculitis", "OBSERVATION", 48, 58], ["delimited", "OBSERVATION_MODIFIER", 68, 77], ["erythematous", "OBSERVATION_MODIFIER", 78, 90], ["edematous", "OBSERVATION_MODIFIER", 95, 104], ["macules", "OBSERVATION", 105, 112], ["relatively", "OBSERVATION_MODIFIER", 154, 164], ["fixed", "OBSERVATION_MODIFIER", 165, 170], ["purpura", "OBSERVATION", 191, 198], ["slightly", "OBSERVATION_MODIFIER", 209, 217], ["pruritic", "OBSERVATION_MODIFIER", 218, 226], ["possible association with", "UNCERTAINTY", 236, 261], ["systemic", "OBSERVATION_MODIFIER", 262, 270], ["manifestations", "OBSERVATION", 271, 285], ["inflammatory", "OBSERVATION_MODIFIER", 292, 304]]], ["The lesions resemble urticaria and typically persist for more than 24 h [55] .", [["lesions", "ANATOMY", 4, 11], ["urticaria", "DISEASE", 21, 30], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["The lesions", "PROBLEM", 0, 11], ["urticaria", "PROBLEM", 21, 30], ["lesions", "OBSERVATION", 4, 11], ["urticaria", "OBSERVATION", 21, 30]]], ["Tables 8.24 and 8.25 [27, 135, 226] outline the clinical and diagnostic symptoms of urticarial vasculitis, characterized by a wide spectrum of symptoms that may lead to a more severe clinical course that is life-threatening to children, including severe anemia and renal insufficiency [135] , and hycomplementemic histopathology, compared with acute and chronic urticaria [27] , is useful for the differential diagnosis.", [["renal", "ANATOMY", 265, 270], ["urticarial vasculitis", "DISEASE", 84, 105], ["anemia", "DISEASE", 254, 260], ["renal insufficiency", "DISEASE", 265, 284], ["urticaria", "DISEASE", 362, 371], ["children", "ORGANISM", 227, 235], ["renal", "ORGAN", 265, 270], ["children", "SPECIES", 227, 235], ["Tables", "TEST", 0, 6], ["urticarial vasculitis", "PROBLEM", 84, 105], ["a wide spectrum of symptoms", "PROBLEM", 124, 151], ["a more severe clinical course", "PROBLEM", 169, 198], ["severe anemia", "PROBLEM", 247, 260], ["renal insufficiency", "PROBLEM", 265, 284], ["hycomplementemic histopathology", "PROBLEM", 297, 328], ["acute and chronic urticaria", "PROBLEM", 344, 371], ["urticarial vasculitis", "OBSERVATION", 84, 105], ["severe", "OBSERVATION_MODIFIER", 247, 253], ["anemia", "OBSERVATION", 254, 260], ["renal", "ANATOMY", 265, 270], ["insufficiency", "OBSERVATION", 271, 284], ["acute", "OBSERVATION_MODIFIER", 344, 349], ["chronic", "OBSERVATION_MODIFIER", 354, 361], ["urticaria", "OBSERVATION", 362, 371]]], ["Acute urticarial vasculitis related to postinfectious or drug-induced hypersensitivity starts as transient infiltrated purpura (Fig. 8.22 ), 2-3 weeks after antigenic aggression; several secondary types of vasculitis are induced by food additives [173, 223] , CM proteins [34] , other foods and vitamins [173] .DiagnosisVasculitis assessment should include history, physical examination, and some of the following items: \u2211 Age and epidemiology, in order of frequency SHS (Tables 8.20 Wholly particular is hypocomplementemic urticarial vasculitis, of which eight pediatric cases are known [39, 55, 135, 232] , including 2 identical twins [241] and a girl with SLE [55] .", [["vasculitis", "DISEASE", 17, 27], ["hypersensitivity", "DISEASE", 70, 86], ["purpura", "DISEASE", 119, 126], ["antigenic aggression", "DISEASE", 157, 177], ["vasculitis", "DISEASE", 206, 216], ["CM", "DISEASE", 260, 262], ["urticarial vasculitis", "DISEASE", 524, 545], ["SLE", "DISEASE", 659, 662], ["vitamins", "CHEMICAL", 295, 303], ["vitamins", "SIMPLE_CHEMICAL", 295, 303], ["girl", "SPECIES", 649, 653], ["Acute urticarial vasculitis", "PROBLEM", 0, 27], ["postinfectious or drug-induced hypersensitivity", "PROBLEM", 39, 86], ["transient infiltrated purpura", "PROBLEM", 97, 126], ["antigenic aggression", "PROBLEM", 157, 177], ["vasculitis", "PROBLEM", 206, 216], ["CM proteins", "TEST", 260, 271], ["vitamins", "TREATMENT", 295, 303], ["DiagnosisVasculitis assessment", "TEST", 311, 341], ["physical examination", "TEST", 366, 386], ["hypocomplementemic urticarial vasculitis", "PROBLEM", 505, 545], ["urticarial", "OBSERVATION_MODIFIER", 6, 16], ["vasculitis", "OBSERVATION", 17, 27], ["postinfectious", "OBSERVATION_MODIFIER", 39, 53], ["infiltrated", "OBSERVATION_MODIFIER", 107, 118], ["purpura", "OBSERVATION", 119, 126], ["vasculitis", "OBSERVATION", 206, 216], ["vasculitis", "OBSERVATION", 535, 545]]], ["Concordance in identical twins may suggest that the pathogenesis of the disease involves abnormal genetic immunoregulation [241] .", [["the disease", "PROBLEM", 68, 79], ["abnormal genetic immunoregulation", "PROBLEM", 89, 122], ["may suggest", "UNCERTAINTY", 31, 42], ["disease", "OBSERVATION", 72, 79]]], ["CIC-induced pathogenesis has an Arthus-like pattern; there is selective depression of Clq binding IgG and lesser depression of C2, C3, C4, but the levels of Clr and Cls are almost normal [135, 232] .", [["CIC", "CHEMICAL", 0, 3], ["depression", "DISEASE", 72, 82], ["depression", "DISEASE", 113, 123], ["CIC", "GENE_OR_GENE_PRODUCT", 0, 3], ["Clq", "GENE_OR_GENE_PRODUCT", 86, 89], ["IgG", "GENE_OR_GENE_PRODUCT", 98, 101], ["C2", "GENE_OR_GENE_PRODUCT", 127, 129], ["C3", "GENE_OR_GENE_PRODUCT", 131, 133], ["C4", "GENE_OR_GENE_PRODUCT", 135, 137], ["Clr", "GENE_OR_GENE_PRODUCT", 157, 160], ["Cls", "GENE_OR_GENE_PRODUCT", 165, 168], ["CIC", "PROTEIN", 0, 3], ["Clq binding IgG", "PROTEIN", 86, 101], ["C2", "PROTEIN", 127, 129], ["C3", "PROTEIN", 131, 133], ["C4", "PROTEIN", 135, 137], ["Clr", "PROTEIN", 157, 160], ["Cls", "PROTEIN", 165, 168], ["CIC-induced pathogenesis", "PROBLEM", 0, 24], ["an Arthus", "PROBLEM", 29, 38], ["selective depression of Clq binding IgG", "PROBLEM", 62, 101], ["lesser depression of C2, C3, C4", "PROBLEM", 106, 137], ["the levels of Clr", "TEST", 143, 160], ["Arthus", "OBSERVATION", 32, 38], ["like pattern", "OBSERVATION_MODIFIER", 39, 51], ["selective", "OBSERVATION_MODIFIER", 62, 71], ["depression", "OBSERVATION", 72, 82], ["Clq binding IgG", "OBSERVATION", 86, 101], ["lesser", "OBSERVATION_MODIFIER", 106, 112], ["depression", "OBSERVATION", 113, 123], ["C2", "ANATOMY_MODIFIER", 127, 129], ["C3", "ANATOMY_MODIFIER", 131, 133], ["C4", "ANATOMY_MODIFIER", 135, 137], ["Clr", "OBSERVATION_MODIFIER", 157, 160], ["almost", "OBSERVATION_MODIFIER", 173, 179], ["normal", "OBSERVATION", 180, 186]]], ["Cl, C3, C4, properdin, IgM, IgG and fibrin are often present in vascular cells and basal membrane.", [["vascular cells", "ANATOMY", 64, 78], ["basal membrane", "ANATOMY", 83, 97], ["Cl", "CHEMICAL", 0, 2], ["Cl", "CHEMICAL", 0, 2], ["Cl", "SIMPLE_CHEMICAL", 0, 2], ["C3", "GENE_OR_GENE_PRODUCT", 4, 6], ["C4", "GENE_OR_GENE_PRODUCT", 8, 10], ["properdin", "GENE_OR_GENE_PRODUCT", 12, 21], ["IgM", "GENE_OR_GENE_PRODUCT", 23, 26], ["IgG", "GENE_OR_GENE_PRODUCT", 28, 31], ["fibrin", "GENE_OR_GENE_PRODUCT", 36, 42], ["vascular cells", "CELL", 64, 78], ["basal membrane", "CELLULAR_COMPONENT", 83, 97], ["C3", "PROTEIN", 4, 6], ["C4", "PROTEIN", 8, 10], ["properdin", "PROTEIN", 12, 21], ["IgM", "PROTEIN", 23, 26], ["IgG", "PROTEIN", 28, 31], ["fibrin", "PROTEIN", 36, 42], ["vascular cells", "CELL_TYPE", 64, 78], ["Cl", "TEST", 0, 2], ["C3", "TEST", 4, 6], ["C4", "TEST", 8, 10], ["properdin", "TEST", 12, 21], ["IgM", "TEST", 23, 26], ["IgG", "TEST", 28, 31], ["fibrin", "PROBLEM", 36, 42], ["C4", "ANATOMY", 8, 10], ["fibrin", "OBSERVATION", 36, 42], ["vascular cells", "ANATOMY", 64, 78], ["basal", "ANATOMY_MODIFIER", 83, 88], ["membrane", "ANATOMY_MODIFIER", 89, 97]]], ["When complement is activated, C3a and C5a are released.", [["C3a", "GENE_OR_GENE_PRODUCT", 30, 33], ["C5a", "GENE_OR_GENE_PRODUCT", 38, 41], ["C3a", "PROTEIN", 30, 33], ["C5a", "PROTEIN", 38, 41], ["C3a and C5a", "TREATMENT", 30, 41]]], ["These anaphylotoxins with chemotactic action Data from [27, 226] .Diagnosisare useful to confirm the diagnosis.", [["anaphylotoxins", "SIMPLE_CHEMICAL", 6, 20], ["chemotactic action Data", "TEST", 26, 49]]], ["Table 8 .26 [11] gives the frequency of c-ANCA, p-ANCA and anti-MPO in several vasculitis.TreatmentThe reader is referred to reviews on therapeutic details [11, 226, 235] .", [["vasculitis", "DISEASE", 79, 89], ["c-ANCA", "GENE_OR_GENE_PRODUCT", 40, 46], ["p-ANCA", "GENE_OR_GENE_PRODUCT", 48, 54], ["anti-MPO", "SIMPLE_CHEMICAL", 59, 67], ["ANCA", "PROTEIN", 42, 46], ["ANCA", "PROTEIN", 50, 54], ["anti-MPO", "PROTEIN", 59, 67], ["c-ANCA", "TREATMENT", 40, 46], ["ANCA", "TREATMENT", 50, 54], ["anti-MPO", "TREATMENT", 59, 67], ["several vasculitis", "PROBLEM", 71, 89], ["several", "OBSERVATION_MODIFIER", 71, 78], ["vasculitis", "OBSERVATION", 79, 89]]], ["Intravenous immunoglobulins (IVIg) were administered to two children aged 2.5-3.5 with Kawasaki syndrome associated with severe AD at the dose of 4-6 g daily for 5 days with remission of hyperthermia (Chap.", [["IVIg", "CHEMICAL", 29, 33], ["Kawasaki syndrome", "DISEASE", 87, 104], ["AD", "DISEASE", 128, 130], ["hyperthermia", "DISEASE", 187, 199], ["Intravenous immunoglobulins", "SIMPLE_CHEMICAL", 0, 27], ["IVIg", "SIMPLE_CHEMICAL", 29, 33], ["children", "ORGANISM", 60, 68], ["IVIg", "PROTEIN", 29, 33], ["children", "SPECIES", 60, 68], ["Intravenous immunoglobulins (IVIg)", "TREATMENT", 0, 34], ["Kawasaki syndrome", "PROBLEM", 87, 104], ["severe AD", "PROBLEM", 121, 130], ["hyperthermia", "PROBLEM", 187, 199], ["hyperthermia", "OBSERVATION", 187, 199]]], ["The IVIg positive effect, to be started promptly and continued for the 5 days of Kawasaki syndrome [244] , lies in the inhibition of endothelial cell migration with destructive effects [180] , likely favoring the reparative phase.Pediatricians and Other Cutaneous AllergiesThis chapter presents pediatricians with a large number of different diseases and syndromes of childhood, the background to a very extensive and differentiated task.", [["endothelial cell", "ANATOMY", 133, 149], ["Kawasaki syndrome", "DISEASE", 81, 98], ["Allergies", "DISEASE", 264, 273], ["IVIg", "SIMPLE_CHEMICAL", 4, 8], ["endothelial cell", "CELL", 133, 149], ["The IVIg", "TREATMENT", 0, 8], ["Kawasaki syndrome", "PROBLEM", 81, 98], ["endothelial cell migration", "TREATMENT", 133, 159], ["destructive effects", "PROBLEM", 165, 184], ["different diseases", "PROBLEM", 332, 350], ["syndromes of childhood", "PROBLEM", 355, 377], ["positive effect", "OBSERVATION", 9, 24], ["endothelial cell migration", "OBSERVATION", 133, 159], ["destructive", "OBSERVATION_MODIFIER", 165, 176], ["likely favoring", "UNCERTAINTY", 193, 208], ["reparative phase", "OBSERVATION_MODIFIER", 213, 229], ["Cutaneous", "ANATOMY", 254, 263], ["large", "OBSERVATION_MODIFIER", 316, 321], ["different", "OBSERVATION_MODIFIER", 332, 341], ["diseases", "OBSERVATION", 342, 350]]], ["This includes several kinds of foods, additives, drugs, and insects that induce urticaria and the countless and dissimilar physical forms, as well as foods and inhalants inducing angioedema.", [["urticaria", "DISEASE", 80, 89], ["angioedema", "DISEASE", 179, 189], ["drugs", "TREATMENT", 49, 54], ["urticaria", "PROBLEM", 80, 89], ["angioedema", "PROBLEM", 179, 189]]], ["Since urticaria covers a clinical spectrum, it should not be surprising that several skin disorders have urticarial lesions.", [["skin", "ANATOMY", 85, 89], ["urticarial lesions", "ANATOMY", 105, 123], ["urticaria", "DISEASE", 6, 15], ["skin disorders", "DISEASE", 85, 99], ["urticarial lesions", "DISEASE", 105, 123], ["skin", "ORGAN", 85, 89], ["urticarial lesions", "PATHOLOGICAL_FORMATION", 105, 123], ["urticaria", "PROBLEM", 6, 15], ["several skin disorders", "PROBLEM", 77, 99], ["urticarial lesions", "PROBLEM", 105, 123], ["urticaria", "OBSERVATION", 6, 15], ["skin", "ANATOMY", 85, 89], ["urticarial", "OBSERVATION_MODIFIER", 105, 115], ["lesions", "OBSERVATION", 116, 123]]], ["ACD involving young children is provoked by buttons, clasps, jewels, cosmetics, topical medications, and the ubiquitous latex with latex-fruit and latex-vegetable syndromes and even in the materials employed by dentists.", [["ACD", "DISEASE", 0, 3], ["children", "ORGANISM", 20, 28], ["children", "SPECIES", 20, 28], ["cosmetics", "TREATMENT", 69, 78], ["topical medications", "TREATMENT", 80, 99], ["latex", "TREATMENT", 147, 152], ["vegetable syndromes", "PROBLEM", 153, 172]]], ["The most important preventive measure for patients with latex allergy or at risk for it is minimizing direct exposure to latex products, most notably latex gloves.", [["latex allergy", "DISEASE", 56, 69], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["latex allergy", "PROBLEM", 56, 69], ["latex products", "TREATMENT", 121, 135], ["latex gloves", "TREATMENT", 150, 162], ["latex gloves", "OBSERVATION", 150, 162]]], ["Recent operating room studies indicate that simple preventive measures can dramatically reduce intraoperative reactions [30] .", [["Recent operating room studies", "TEST", 0, 29], ["simple preventive measures", "TREATMENT", 44, 70], ["intraoperative reactions", "PROBLEM", 95, 119]]], ["Although rare, the different forms of infantile vasculitis are undoubtedly a challenge for most colleagues.", [["infantile vasculitis", "DISEASE", 38, 58], ["infantile vasculitis", "PROBLEM", 38, 58], ["infantile", "OBSERVATION_MODIFIER", 38, 47], ["vasculitis", "OBSERVATION", 48, 58]]], ["The clinical and laboratory findings are variable, frequently nonspecific or overlapping.", [["variable", "OBSERVATION_MODIFIER", 41, 49], ["nonspecific", "OBSERVATION_MODIFIER", 62, 73]]], ["Therefore early and correct diagnosis is imperative, but one should never delay initiation of treatment, while trying to finalize the diagnosis.", [["treatment", "TREATMENT", 94, 103]]], ["These disorders are therefore found in several chapters of infantile allergy and immunology and will put to the test more than ever not only the diagnostic and therapeutic skill of pediatricians, but also their cooperation in light of understandable parental anxieties.With treatment methods designed both to avoid side effects and limit costs, effective approaches will be centered.", [["infantile allergy", "DISEASE", 59, 76], ["These disorders", "PROBLEM", 0, 15], ["infantile allergy", "PROBLEM", 59, 76], ["treatment methods", "TREATMENT", 274, 291], ["side effects", "PROBLEM", 315, 327], ["effective approaches", "TREATMENT", 345, 365]]], ["However, clinical experience will untie several Gordian knots, thus justifying neither frustration nor polypragmatism, especially when faced by the tempting plethora of current therapeutic options.CHAPTER 8Other Allergic Skin Disorders Data from [11] .", [["polypragmatism", "DISEASE", 103, 117], ["Allergic Skin Disorders", "DISEASE", 212, 235], ["polypragmatism", "PROBLEM", 103, 117], ["Allergic Skin Disorders", "PROBLEM", 212, 235], ["Skin", "ANATOMY", 221, 225]]]], "PMC7126980": [["IntroductionPrior to the development of the transmission electron microscope, cells and bacteria could be observed by light microscopy, but the only viruses that could be visualised were the poxviruses.", [["cells", "ANATOMY", 78, 83], ["cells", "CELL", 78, 83], ["the transmission electron microscope", "TEST", 40, 76], ["bacteria", "PROBLEM", 88, 96], ["light microscopy", "TEST", 118, 134], ["the only viruses", "PROBLEM", 140, 156]]], ["Although poxviruses were the largest of the viruses known at that time (approximately 250 nm), no morphological detail could be seen under an optimally adjusted light microscope.", [["poxviruses", "ORGANISM", 9, 19], ["poxviruses", "PROBLEM", 9, 19], ["largest", "OBSERVATION_MODIFIER", 29, 36], ["viruses", "OBSERVATION", 44, 51]]], ["The resolution limit of light microscopy of approximately 200 nm formed a barrier to visualising all other viruses and bacterial ultrastructure.", [["light microscopy", "TEST", 24, 40], ["a barrier", "TREATMENT", 72, 81], ["bacterial ultrastructure", "PROBLEM", 119, 143], ["resolution", "OBSERVATION_MODIFIER", 4, 14], ["viruses", "OBSERVATION", 107, 114], ["bacterial ultrastructure", "OBSERVATION", 119, 143]]], ["The successful development of the TEM, with its resolution limit of about one thousand times greater than the light microscope and the subsequent, albeit limited, availability of commercial electron microscopes post 1945, revolutionised many aspects of virology and microbiology.", [["the TEM", "TEST", 30, 37], ["the light microscope", "TEST", 106, 126], ["commercial electron microscopes", "TEST", 179, 210], ["TEM", "OBSERVATION_MODIFIER", 34, 37], ["resolution", "OBSERVATION_MODIFIER", 48, 58]]], ["Key events in the development of electron microscopy have recently been reviewed by Haguenau and colleagues (Haguenau et al., 2003).", [["Key events", "PROBLEM", 0, 10], ["electron microscopy", "TEST", 33, 52]]], ["To fully exploit the potential of the TEM, new methods for specimen preparation and new procedures for fixation, embedding, sectioning and staining were developed (Nermut et al., 1987, Harris, 1997).", [["specimen", "ANATOMY", 59, 67], ["specimen preparation", "TREATMENT", 59, 79], ["new procedures", "TREATMENT", 84, 98], ["fixation", "TREATMENT", 103, 111], ["embedding, sectioning and staining", "TEST", 113, 147]]], ["Since viruses and bacteria are very small, it was also necessary to develop thin films to coat EM specimen grids to support these organisms.", [["viruses", "PROBLEM", 6, 13], ["bacteria", "PROBLEM", 18, 26], ["thin films", "TEST", 76, 86], ["coat EM specimen grids", "TEST", 90, 112], ["these organisms", "PROBLEM", 124, 139], ["viruses", "OBSERVATION", 6, 13], ["bacteria", "OBSERVATION_MODIFIER", 18, 26], ["very", "OBSERVATION_MODIFIER", 31, 35], ["small", "OBSERVATION_MODIFIER", 36, 41]]], ["Early imaging of viruses and bacteria was accomplished by depositing metal atoms onto the organisms to provide the necessary contrast for their visualisation: this was known as the \u2018shadow casting\u2019 technique.", [["Early imaging", "TEST", 0, 13], ["viruses", "PROBLEM", 17, 24], ["bacteria", "PROBLEM", 29, 37], ["viruses", "OBSERVATION", 17, 24]]], ["The introduction of negative contrast staining, using solutions of heavy metal salts, greatly simplified specimen preparation and revealed far greater detail in the ultrastructure of viruses and bacteria (Brenner and Horne, 1959).", [["specimen", "ANATOMY", 105, 113], ["heavy metal salts", "SIMPLE_CHEMICAL", 67, 84], ["heavy metal salts", "TREATMENT", 67, 84], ["greatly simplified specimen preparation", "TEST", 86, 125], ["bacteria", "PROBLEM", 195, 203], ["viruses", "OBSERVATION", 183, 190]]], ["Increased commercial production of TEMs made the instruments available to many institutions, including universities and hospital laboratories and, together with the new specimen preparation methods, allowed investigation of a whole range of infectious diseases.IntroductionUse of transmission electron microscopy for the study of micro-organisms peaked during the period 1970\u20131980 when it contributed to the discovery of several new viruses.", [["infectious diseases", "DISEASE", 241, 260], ["infectious diseases", "PROBLEM", 241, 260], ["transmission electron microscopy", "TEST", 280, 312], ["the study", "TEST", 317, 326], ["micro-organisms", "PROBLEM", 330, 345], ["several new viruses", "PROBLEM", 421, 440], ["infectious", "OBSERVATION", 241, 251], ["several", "OBSERVATION_MODIFIER", 421, 428], ["new", "OBSERVATION_MODIFIER", 429, 432], ["viruses", "OBSERVATION", 433, 440]]], ["Biological and medical journals of that era feature significant numbers of papers describing ultrastructural investigations of disease pathogenesis involving the study of many viruses and bacteria and their interaction with a range of cells and tissues.IntroductionDevelopment of other techniques, such as immunofluorescence, enzyme-linked immune absorbent assays (EIAs) and, in particular, the advances in molecular biology, such as the polymerase chain reaction (PCR), have all contributed to a gradual decline in the use of EM within the fields of diagnostic virology, microbiology and medicine.", [["cells", "ANATOMY", 235, 240], ["tissues", "ANATOMY", 245, 252], ["cells", "CELL", 235, 240], ["tissues", "TISSUE", 245, 252], ["ultrastructural investigations", "TEST", 93, 123], ["disease pathogenesis", "PROBLEM", 127, 147], ["the study", "TEST", 158, 167], ["many viruses", "PROBLEM", 171, 183], ["bacteria", "PROBLEM", 188, 196], ["immunofluorescence", "TEST", 306, 324], ["enzyme", "TEST", 326, 332], ["immune absorbent assays", "TEST", 340, 363], ["EIAs", "TEST", 365, 369], ["the polymerase chain reaction", "PROBLEM", 434, 463], ["PCR", "TEST", 465, 468], ["a gradual decline", "PROBLEM", 495, 512], ["disease", "OBSERVATION", 127, 134], ["viruses", "OBSERVATION", 176, 183], ["gradual", "OBSERVATION_MODIFIER", 497, 504], ["decline", "OBSERVATION", 505, 512]]], ["By the mid 1990s many laboratories and organisations were forced to rationalise their EM facilities as a result of the introduction of these new methods and financial constraints, which would not allow the automatic replacement of costly electron microscopes on a one to one basis.", [["these new methods", "TREATMENT", 135, 152], ["the automatic replacement of costly electron microscopes", "TREATMENT", 202, 258]]], ["This rationalisation allowed some facilities to survive while others were forced to close down.IntroductionThis review endeavours to outline the historical, current and future uses of EM within the fields of virology and bacteriology from a mainly UK perspective.Support films on specimen grids ::: MethodsFor examination in a TEM, suspensions of viruses, bacteria and other particulate specimens must be supported on a thin film of plastic, carbon, or a combination of the two applied to the surface of an electron microscope specimen grid.", [["specimens", "ANATOMY", 387, 396], ["surface", "ANATOMY", 493, 500], ["carbon", "CHEMICAL", 442, 448], ["carbon", "CHEMICAL", 442, 448], ["carbon", "SIMPLE_CHEMICAL", 442, 448], ["Methods", "TREATMENT", 299, 306], ["examination", "TEST", 310, 321], ["a TEM", "TEST", 325, 330], ["viruses", "PROBLEM", 347, 354], ["bacteria", "PROBLEM", 356, 364], ["other particulate specimens", "PROBLEM", 369, 396], ["a thin film of plastic, carbon", "TREATMENT", 418, 448], ["an electron microscope specimen grid", "TEST", 504, 540], ["viruses", "OBSERVATION", 347, 354]]], ["Plastic support films must be of suitable thickness in order to be durable yet not degrade the resolution of the image produced by the microscope.", [["Plastic support films", "TREATMENT", 0, 21], ["the image", "TEST", 109, 118], ["the microscope", "TEST", 131, 145]]], ["Polyvinyl formal (Formvar) is commonly used (1\u20134% in a solvent), but other compounds such as nitrocellulose (Collodion) are also suitable.", [["Polyvinyl", "CHEMICAL", 0, 9], ["Formvar", "CHEMICAL", 18, 25], ["Polyvinyl", "CHEMICAL", 0, 9], ["nitrocellulose", "CHEMICAL", 93, 107], ["Formvar", "SIMPLE_CHEMICAL", 18, 25], ["nitrocellulose", "SIMPLE_CHEMICAL", 93, 107], ["Collodion", "SIMPLE_CHEMICAL", 109, 118], ["Polyvinyl formal (Formvar)", "TREATMENT", 0, 26], ["a solvent)", "TREATMENT", 53, 63], ["nitrocellulose (Collodion", "TREATMENT", 93, 118]]], ["A carbon coating applied to the plastic film can enhance its stability and prevent deformation and rupture due to thermal stress caused by the electron beam.", [["rupture", "DISEASE", 99, 106], ["carbon", "CHEMICAL", 2, 8], ["A carbon coating", "TREATMENT", 0, 16], ["the plastic film", "TEST", 28, 44], ["deformation", "PROBLEM", 83, 94], ["rupture", "PROBLEM", 99, 106], ["thermal stress", "PROBLEM", 114, 128], ["carbon coating", "OBSERVATION", 2, 16], ["rupture", "OBSERVATION", 99, 106]]], ["Plastic films are easier to prepare and are more durable than carbon support films, but where ultimate-resolution imaging is required, carbon films alone are preferred.Metal shadowing ::: MethodsMetal shadowing was the early method used to add contrast to viruses and bacteria to enhance their visualisation by TEM.", [["carbon", "CHEMICAL", 62, 68], ["carbon", "CHEMICAL", 135, 141], ["carbon films", "SIMPLE_CHEMICAL", 135, 147], ["Plastic films", "TEST", 0, 13], ["carbon support films", "TEST", 62, 82], ["ultimate-resolution imaging", "TEST", 94, 121], ["carbon films", "TEST", 135, 147], ["MethodsMetal shadowing", "PROBLEM", 188, 210], ["contrast to viruses", "PROBLEM", 244, 263], ["bacteria", "PROBLEM", 268, 276], ["shadowing", "OBSERVATION", 174, 183], ["shadowing", "OBSERVATION", 201, 210]]], ["Metals (gold, platinum, chromium, molybdenum, tungsten) or metal alloys (gold/palladium, platinum/palladium) are vacuum deposited at an angle of between 30 and 45 \u00b0 onto the specimens adhering to the support film.", [["specimens", "ANATOMY", 174, 183], ["Metals", "CHEMICAL", 0, 6], ["gold, platinum, chromium, molybdenum, tungsten", "CHEMICAL", 8, 54], ["gold/palladium, platinum/palladium", "CHEMICAL", 73, 107], ["platinum", "CHEMICAL", 14, 22], ["chromium", "CHEMICAL", 24, 32], ["molybdenum", "CHEMICAL", 34, 44], ["tungsten", "CHEMICAL", 46, 54], ["palladium", "CHEMICAL", 78, 87], ["platinum", "CHEMICAL", 89, 97], ["palladium", "CHEMICAL", 98, 107], ["Metals", "SIMPLE_CHEMICAL", 0, 6], ["gold", "SIMPLE_CHEMICAL", 8, 12], ["platinum", "SIMPLE_CHEMICAL", 14, 22], ["chromium", "SIMPLE_CHEMICAL", 24, 32], ["molybdenum", "SIMPLE_CHEMICAL", 34, 44], ["tungsten", "SIMPLE_CHEMICAL", 46, 54], ["metal alloys", "SIMPLE_CHEMICAL", 59, 71], ["gold/palladium", "SIMPLE_CHEMICAL", 73, 87], ["platinum/palladium", "SIMPLE_CHEMICAL", 89, 107], ["Metals (gold, platinum, chromium, molybdenum, tungsten)", "TREATMENT", 0, 55], ["metal alloys (gold/palladium, platinum/palladium)", "TREATMENT", 59, 108], ["vacuum", "TREATMENT", 113, 119], ["the support film", "TEST", 196, 212], ["vacuum", "OBSERVATION", 113, 119]]], ["This procedure, carried out within a vacuum coating unit, requires careful monitoring of the thickness of the metal to avoid masking surface detail on bacteria and viruses (Fig. 1).", [["surface", "ANATOMY", 133, 140], ["This procedure", "TREATMENT", 0, 14], ["a vacuum coating unit", "TREATMENT", 35, 56], ["careful monitoring", "TEST", 67, 85], ["the thickness of the metal", "TREATMENT", 89, 115], ["masking surface detail", "PROBLEM", 125, 147], ["bacteria", "PROBLEM", 151, 159], ["viruses", "PROBLEM", 164, 171]]], ["The method is technically demanding and proved non-ideal for routine examination of clinical specimens.", [["specimens", "ANATOMY", 93, 102], ["routine examination", "TEST", 61, 80], ["clinical specimens", "TEST", 84, 102]]], ["The introduction of the far simpler negative staining technique relegated metal shadowing to specialised applications only, for example the visualisation of nucleic acids (Fig. 2).Negative staining ::: MethodsThe negative staining technique developed by Horne and colleagues was a major advance in diagnostic virology (Brenner and Horne, 1959, Horne and Wildy, 1963, Horne and Wildy, 1979).", [["nucleic acids", "CHEMICAL", 157, 170], ["nucleic acids", "SIMPLE_CHEMICAL", 157, 170], ["nucleic acids", "TEST", 157, 170], ["Methods", "TREATMENT", 202, 209], ["negative", "OBSERVATION_MODIFIER", 213, 221], ["staining", "OBSERVATION", 222, 230]]], ["This technique uses the electron scattering power of heavy metal salts to provide contrast to viruses or bacteria so that surface detail may be seen.", [["surface", "ANATOMY", 122, 129], ["heavy metal salts", "SIMPLE_CHEMICAL", 53, 70], ["heavy metal salts", "TREATMENT", 53, 70], ["contrast to viruses", "PROBLEM", 82, 101], ["bacteria", "PROBLEM", 105, 113], ["may be seen", "UNCERTAINTY", 137, 148]]], ["The convenience and simplicity of the method allows routine examination of many samples compared to the significantly more cumbersome metal shadowing technique.", [["routine examination", "TEST", 52, 71], ["shadowing", "OBSERVATION", 140, 149]]], ["Phosphotungstic acid (PTA) is probably the most commonly used negative stain within diagnostic microbiology, but there are others that are used routinely (e.g. ammonium molybdate, uranyl acetate, sodium silicotungstate, methylamine tungstate).", [["Phosphotungstic acid", "CHEMICAL", 0, 20], ["PTA", "CHEMICAL", 22, 25], ["ammonium molybdate", "CHEMICAL", 160, 178], ["uranyl acetate", "CHEMICAL", 180, 194], ["sodium silicotungstate", "CHEMICAL", 196, 218], ["methylamine tungstate", "CHEMICAL", 220, 241], ["Phosphotungstic acid", "CHEMICAL", 0, 20], ["PTA", "CHEMICAL", 22, 25], ["ammonium molybdate", "CHEMICAL", 160, 178], ["uranyl acetate", "CHEMICAL", 180, 194], ["sodium silicotungstate", "CHEMICAL", 196, 218], ["methylamine tungstate", "CHEMICAL", 220, 241], ["Phosphotungstic acid", "SIMPLE_CHEMICAL", 0, 20], ["PTA", "SIMPLE_CHEMICAL", 22, 25], ["ammonium molybdate", "SIMPLE_CHEMICAL", 160, 178], ["uranyl acetate", "SIMPLE_CHEMICAL", 180, 194], ["sodium silicotungstate", "SIMPLE_CHEMICAL", 196, 218], ["methylamine tungstate", "SIMPLE_CHEMICAL", 220, 241], ["Phosphotungstic acid", "TEST", 0, 20], ["diagnostic microbiology", "TEST", 84, 107], ["ammonium molybdate", "TREATMENT", 160, 178], ["uranyl acetate", "TREATMENT", 180, 194], ["sodium silicotungstate", "TREATMENT", 196, 218], ["methylamine tungstate", "TREATMENT", 220, 241]]], ["A solution of the stain is either mixed with a suspension of the virus or bacterial sample suspension before application to the grid or it may be applied to the grid after the sample has been adsorbed to the support film.", [["sample", "ANATOMY", 84, 90], ["sample", "ANATOMY", 176, 182], ["A solution of the stain", "TREATMENT", 0, 23], ["the virus", "TREATMENT", 61, 70], ["bacterial sample suspension", "TREATMENT", 74, 101], ["the support film", "TEST", 204, 220]]], ["The pH of the negative stain may have a significant effect on the detail seen and contrast produced in a specimen (Madeley, 1972).", [["specimen", "ANATOMY", 105, 113], ["The pH", "TEST", 0, 6], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["effect", "OBSERVATION", 52, 58]]], ["For instance, group B rotaviruses can be difficult to detect if the wrong stain is used (Nakata et al., 1987, Suzuki et al., 1987).", [["B rotaviruses", "ORGANISM", 20, 33], ["B rotaviruses", "SPECIES", 20, 33], ["group B rotaviruses", "PROBLEM", 14, 33], ["the wrong stain", "TEST", 64, 79]]], ["Also, poxviruses show better ultrastructure with uranyl acetate staining, but this stain is not necessarily good for other viruses.Resin embedding and thin sectioning ::: MethodsResin embedding and thin sectioning enables the visualisation of virus replication within cells (Fig. 3) and the investigation of bacterial infection within cells and tissues.", [["cells", "ANATOMY", 268, 273], ["cells", "ANATOMY", 335, 340], ["tissues", "ANATOMY", 345, 352], ["uranyl acetate", "CHEMICAL", 49, 63], ["bacterial infection", "DISEASE", 308, 327], ["uranyl acetate", "CHEMICAL", 49, 63], ["Resin", "CHEMICAL", 131, 136], ["poxviruses", "ORGANISM", 6, 16], ["uranyl acetate", "SIMPLE_CHEMICAL", 49, 63], ["cells", "CELL", 268, 273], ["Fig. 3", "CELL", 275, 281], ["cells", "CELL", 335, 340], ["tissues", "TISSUE", 345, 352], ["uranyl acetate staining", "TREATMENT", 49, 72], ["this stain", "TEST", 78, 88], ["other viruses", "PROBLEM", 117, 130], ["Resin embedding and thin sectioning", "TREATMENT", 131, 166], ["MethodsResin embedding", "TREATMENT", 171, 193], ["thin sectioning", "TREATMENT", 198, 213], ["virus replication", "TREATMENT", 243, 260], ["bacterial infection within cells and tissues", "PROBLEM", 308, 352], ["viruses", "OBSERVATION", 123, 130], ["bacterial", "OBSERVATION_MODIFIER", 308, 317], ["infection", "OBSERVATION", 318, 327]]], ["It is far more time consuming than the complementary technique of negative staining and is not normally used in routine diagnostic work with viruses and bacteria.", [["viruses", "PROBLEM", 141, 148], ["bacteria", "PROBLEM", 153, 161], ["far more time", "OBSERVATION_MODIFIER", 6, 19]]], ["However, some viruses, such as retroviruses, are difficult to see with negative staining and better results may be obtained from thin sections of infected cells.Resin embedding and thin sectioning ::: MethodsPreservation (fixation) of the structural elements of infected cells or tissues in a life-like state is a critical initial stage of the technique.", [["sections", "ANATOMY", 134, 142], ["cells", "ANATOMY", 155, 160], ["cells", "ANATOMY", 271, 276], ["tissues", "ANATOMY", 280, 287], ["Resin", "CHEMICAL", 161, 166], ["retroviruses", "ORGANISM", 31, 43], ["cells", "CELL", 155, 160], ["cells", "CELL", 271, 276], ["tissues", "TISSUE", 280, 287], ["infected cells", "CELL_TYPE", 146, 160], ["infected cells", "CELL_TYPE", 262, 276], ["some viruses", "PROBLEM", 9, 21], ["retroviruses", "PROBLEM", 31, 43], ["infected cells", "PROBLEM", 146, 160], ["Resin embedding and thin sectioning", "TREATMENT", 161, 196], ["MethodsPreservation (fixation)", "TREATMENT", 201, 231], ["infected cells", "PROBLEM", 262, 276], ["some", "OBSERVATION_MODIFIER", 9, 13], ["viruses", "OBSERVATION", 14, 21], ["retroviruses", "OBSERVATION", 31, 43], ["infected cells", "OBSERVATION", 146, 160], ["infected cells", "OBSERVATION", 262, 276]]], ["The fixative of choice is buffered glutaraldehyde, although others may be used (Sabatini et al., 1963).", [["glutaraldehyde", "CHEMICAL", 35, 49], ["glutaraldehyde", "CHEMICAL", 35, 49], ["glutaraldehyde", "SIMPLE_CHEMICAL", 35, 49], ["buffered glutaraldehyde", "TREATMENT", 26, 49]]], ["Normally, this primary fixation is followed by secondary fixation (post-fixation) in osmium tetroxide.", [["osmium tetroxide", "CHEMICAL", 85, 101], ["osmium tetroxide", "CHEMICAL", 85, 101], ["osmium tetroxide", "SIMPLE_CHEMICAL", 85, 101], ["this primary fixation", "TREATMENT", 10, 31], ["secondary fixation (post-fixation) in osmium tetroxide", "TREATMENT", 47, 101], ["fixation", "OBSERVATION", 23, 31], ["secondary fixation", "OBSERVATION", 47, 65]]], ["Fixed specimens are dehydrated in ethanol and usually embedded in an epoxy resin, such as Araldite\u2122 or Epon\u2122, prior to thin sectioning.", [["specimens", "ANATOMY", 6, 15], ["ethanol", "CHEMICAL", 34, 41], ["Epon\u2122", "CHEMICAL", 103, 108], ["ethanol", "CHEMICAL", 34, 41], ["epoxy", "CHEMICAL", 69, 74], ["ethanol", "SIMPLE_CHEMICAL", 34, 41], ["Araldite\u2122", "SIMPLE_CHEMICAL", 90, 99], ["Epon\u2122", "SIMPLE_CHEMICAL", 103, 108], ["Fixed specimens", "PROBLEM", 0, 15], ["dehydrated", "PROBLEM", 20, 30], ["an epoxy resin", "TREATMENT", 66, 80], ["Araldite\u2122", "TREATMENT", 90, 99], ["Epon\u2122", "TREATMENT", 103, 108], ["thin sectioning", "TREATMENT", 119, 134], ["dehydrated", "OBSERVATION", 20, 30], ["epoxy resin", "OBSERVATION", 69, 80]]], ["Ultrathin sections are cut from polymerised resin blocks and subsequently stained with heavy metal salts (usually uranyl acetate followed by lead citrate) to provide the contrast required.Detection and identification ::: MethodsViruses are identified by their characteristic morphological features.", [["sections", "ANATOMY", 10, 18], ["uranyl acetate", "CHEMICAL", 114, 128], ["lead citrate", "CHEMICAL", 141, 153], ["uranyl acetate", "CHEMICAL", 114, 128], ["citrate", "CHEMICAL", 146, 153], ["heavy metal salts", "SIMPLE_CHEMICAL", 87, 104], ["uranyl acetate", "SIMPLE_CHEMICAL", 114, 128], ["lead citrate", "SIMPLE_CHEMICAL", 141, 153], ["Ultrathin sections", "TREATMENT", 0, 18], ["polymerised resin blocks", "TREATMENT", 32, 56], ["heavy metal salts", "TREATMENT", 87, 104], ["uranyl acetate", "TREATMENT", 114, 128], ["lead citrate", "TREATMENT", 141, 153], ["MethodsViruses", "TREATMENT", 221, 235], ["resin blocks", "OBSERVATION", 44, 56]]], ["For instance, poxviruses (Fig. 4) look quite different from herpes viruses (Fig. 5).", [["herpes viruses", "DISEASE", 60, 74], ["herpes viruses", "ORGANISM", 60, 74], ["poxviruses (Fig", "TREATMENT", 14, 29], ["herpes viruses", "PROBLEM", 60, 74], ["herpes viruses", "OBSERVATION", 60, 74]]], ["If virus particles are present in large numbers, they may be seen by direct examination of negatively stained clinical specimens without any concentration.", [["specimens", "ANATOMY", 119, 128], ["virus particles", "PROBLEM", 3, 18], ["direct examination", "TEST", 69, 87], ["negatively stained clinical specimens", "PROBLEM", 91, 128], ["large", "OBSERVATION_MODIFIER", 34, 39], ["numbers", "OBSERVATION_MODIFIER", 40, 47]]], ["However, for detection of small particles like viruses, it is generally considered that there must be a minimum of 106\u2013108 virus particles/ml present in a sample to allow detection and it is therefore often necessary to concentrate the particles by such methods as differential centrifugation or ammonium sulphate precipitation (Caul et al., 1978).", [["sample", "ANATOMY", 155, 161], ["ammonium sulphate", "CHEMICAL", 296, 313], ["ammonium sulphate", "CHEMICAL", 296, 313], ["ammonium sulphate", "SIMPLE_CHEMICAL", 296, 313], ["small particles like viruses", "PROBLEM", 26, 54], ["ammonium sulphate precipitation", "TREATMENT", 296, 327], ["small", "OBSERVATION_MODIFIER", 26, 31], ["particles", "OBSERVATION", 32, 41], ["viruses", "OBSERVATION", 47, 54]]], ["For viral diagnosis, specimen grids need to be scanned at a suitable magnification (e.g. about 40,000\u00d7 for skin lesion samples).Immune electron microscopy ::: MethodsDetection sensitivity may be increased and virus identification achieved using the technique of immune electron microscopy, which employs specific antiserum to bind to a viral antigen of interest.", [["specimen", "ANATOMY", 21, 29], ["skin lesion samples", "ANATOMY", 107, 126], ["skin lesion samples", "CANCER", 107, 126], ["viral antigen", "PROTEIN", 336, 349], ["specimen grids", "TEST", 21, 35], ["skin lesion samples", "PROBLEM", 107, 126], ["MethodsDetection sensitivity", "TEST", 159, 187], ["virus identification", "TEST", 209, 229], ["immune electron microscopy", "TEST", 262, 288], ["skin", "ANATOMY", 107, 111], ["lesion", "OBSERVATION", 112, 118]]], ["There are several immune electron microscopy (IEM) methods: immune clumping, solid phase immune electron microscopy (SPIEM) and immuno-gold labelling.", [["several immune electron microscopy", "TEST", 10, 44], ["immune clumping", "PROBLEM", 60, 75], ["solid phase immune electron microscopy", "TEST", 77, 115], ["immuno", "TEST", 128, 134], ["solid phase", "OBSERVATION_MODIFIER", 77, 88]]], ["The techniques have been particularly useful for detecting viruses causing hepatitis (Almeida et al., 1969, Feinstone et al., 1973, Balayan et al., 1983) and viruses associated with gastroenteritis.", [["hepatitis", "DISEASE", 75, 84], ["gastroenteritis", "DISEASE", 182, 197], ["viruses", "PROBLEM", 59, 66], ["hepatitis", "PROBLEM", 75, 84], ["viruses", "PROBLEM", 158, 165], ["gastroenteritis", "PROBLEM", 182, 197], ["viruses", "OBSERVATION", 59, 66], ["hepatitis", "OBSERVATION", 75, 84], ["gastroenteritis", "OBSERVATION", 182, 197]]], ["Both immune clumping and SPIEM have routine uses in virology, but immunogold labelling is mainly used in research investigations.Immune clumping ::: MethodsSome of the smaller viruses lack distinctive morphological features and are thus difficult to discern from the background debris present in clinical specimens.", [["specimens", "ANATOMY", 305, 314], ["specimens", "CANCER", 305, 314], ["Both immune clumping", "PROBLEM", 0, 20], ["immunogold labelling", "TEST", 66, 86], ["research investigations", "TEST", 105, 128], ["MethodsSome", "TREATMENT", 149, 160], ["the smaller viruses lack distinctive morphological features", "PROBLEM", 164, 223], ["the background debris", "PROBLEM", 263, 284], ["clinical specimens", "TEST", 296, 314], ["immune clumping", "OBSERVATION", 5, 20], ["smaller", "OBSERVATION_MODIFIER", 168, 175], ["viruses", "OBSERVATION", 176, 183], ["distinctive", "OBSERVATION_MODIFIER", 189, 200], ["morphological features", "OBSERVATION", 201, 223], ["debris", "OBSERVATION", 278, 284]]], ["In the immune clumping method, a virus specific detector antibody is mixed with the specimen suspension.", [["specimen", "ANATOMY", 84, 92], ["virus specific detector antibody", "PROTEIN", 33, 65], ["the immune clumping method", "TREATMENT", 3, 29], ["a virus specific detector antibody", "TEST", 31, 65], ["the specimen suspension", "TREATMENT", 80, 103], ["immune", "OBSERVATION", 7, 13], ["clumping method", "OBSERVATION", 14, 29]]], ["Target virus, if present, will be aggregated by the antibody into clumps, which are much easier to detect than individual virus particles (Fig. 6).", [["Target virus", "PROBLEM", 0, 12], ["individual virus particles", "PROBLEM", 111, 137], ["virus", "OBSERVATION", 7, 12]]], ["Examples of viruses detected by this method include hepatitis B virus (Bayer et al., 1968, Almeida et al., 1969) and parvovirus B19 (Cossart et al., 1975).", [["hepatitis B", "DISEASE", 52, 63], ["parvovirus B19", "DISEASE", 117, 131], ["hepatitis B virus", "ORGANISM", 52, 69], ["parvovirus B19", "ORGANISM", 117, 131], ["hepatitis B virus", "SPECIES", 52, 69], ["parvovirus B19", "SPECIES", 117, 131], ["hepatitis B virus", "SPECIES", 52, 69], ["parvovirus B19", "SPECIES", 117, 131], ["viruses", "PROBLEM", 12, 19], ["hepatitis B virus", "PROBLEM", 52, 69], ["parvovirus B19", "PROBLEM", 117, 131], ["viruses", "OBSERVATION", 12, 19]]], ["Enteroviruses can also be typed using immune clumping with type-specific antisera (Lee et al., 1996).Solid phase immune electron microscopy (SPIEM) ::: MethodsThe solid phase immune electron microscopy (SPIEM) method provides increased sensitivity over immune clumping, allowing detection of virus when only small numbers of particles are present in a clinical sample.", [["Enteroviruses", "PROBLEM", 0, 13], ["immune clumping", "PROBLEM", 38, 53], ["Methods", "TREATMENT", 152, 159], ["The solid phase immune electron microscopy", "TEST", 159, 201], ["increased sensitivity", "PROBLEM", 226, 247], ["immune clumping", "PROBLEM", 253, 268], ["virus", "PROBLEM", 292, 297], ["small numbers of particles", "PROBLEM", 308, 334], ["a clinical sample", "TEST", 350, 367], ["solid phase", "OBSERVATION_MODIFIER", 163, 174], ["small", "OBSERVATION_MODIFIER", 308, 313], ["numbers", "OBSERVATION_MODIFIER", 314, 321], ["particles", "OBSERVATION", 325, 334]]], ["SPIEM was originally developed for the detection of plant viruses (Derrick, 1973) and was subsequently adopted by electron microscopists working with a variety of human viruses.", [["human", "ORGANISM", 163, 168], ["human", "SPECIES", 163, 168], ["human viruses", "SPECIES", 163, 176], ["plant viruses", "PROBLEM", 52, 65], ["viruses", "OBSERVATION", 58, 65]]], ["In SPIEM, a specimen grid with support film is coated with specific antibody.", [["specimen", "ANATOMY", 12, 20], ["specific antibody", "PROTEIN", 59, 76], ["a specimen grid with support film", "TEST", 10, 43]]], ["This antibody-coated grid is then floated on a drop of the virus sample under investigation.", [["This antibody", "TEST", 0, 13]]], ["Virus particles are attracted onto the grid surface and these are spread individually over the grid rather than being aggregated into clumps.", [["grid surface", "ANATOMY", 39, 51], ["Virus", "ORGANISM", 0, 5], ["grid surface", "CELLULAR_COMPONENT", 39, 51], ["Virus particles", "PROBLEM", 0, 15], ["grid", "OBSERVATION_MODIFIER", 39, 43], ["surface", "OBSERVATION_MODIFIER", 44, 51], ["spread", "OBSERVATION_MODIFIER", 66, 72], ["clumps", "OBSERVATION_MODIFIER", 134, 140]]], ["A major use of SPIEM has been for the detection of viruses associated with gastroenteritis, particularly noroviruses, which are often present in small numbers making detection by EM difficult (Lewis et al., 1988) and for enteric adenoviruses (Wood and Bailey, 1987).Immuno-gold labelling ::: MethodsImmuno-gold labelling utilises specific antibodies tagged with small particles of colloidal gold as an electron dense marker.", [["SPIEM", "CHEMICAL", 15, 20], ["gastroenteritis", "DISEASE", 75, 90], ["noroviruses", "DISEASE", 105, 116], ["enteric adenoviruses", "DISEASE", 221, 241], ["MethodsImmuno-gold", "CHEMICAL", 292, 310], ["adenoviruses", "ORGANISM", 229, 241], ["colloidal gold", "SIMPLE_CHEMICAL", 381, 395], ["SPIEM", "PROTEIN", 15, 20], ["specific antibodies", "PROTEIN", 330, 349], ["SPIEM", "TREATMENT", 15, 20], ["viruses", "PROBLEM", 51, 58], ["gastroenteritis", "PROBLEM", 75, 90], ["noroviruses", "PROBLEM", 105, 116], ["MethodsImmuno", "TEST", 292, 305], ["specific antibodies", "TEST", 330, 349], ["viruses", "OBSERVATION", 51, 58], ["gastroenteritis", "OBSERVATION", 75, 90], ["noroviruses", "OBSERVATION", 105, 116], ["small", "OBSERVATION_MODIFIER", 145, 150], ["small particles", "OBSERVATION_MODIFIER", 362, 377], ["colloidal gold", "OBSERVATION", 381, 395], ["dense marker", "OBSERVATION", 411, 423]]], ["The technique may be used to localise antigens on whole viruses or bacteria or, for example, viral or bacterial antigens in thin sections of infected cells or tissues (Williams et al., 1987).", [["sections", "ANATOMY", 129, 137], ["cells", "ANATOMY", 150, 155], ["tissues", "ANATOMY", 159, 166], ["cells", "CELL", 150, 155], ["tissues", "TISSUE", 159, 166], ["antigens", "PROTEIN", 38, 46], ["viral or bacterial antigens", "PROTEIN", 93, 120], ["infected cells", "CELL_TYPE", 141, 155], ["The technique", "TREATMENT", 0, 13], ["whole viruses", "PROBLEM", 50, 63], ["bacteria", "PROBLEM", 67, 75], ["viral or bacterial antigens", "PROBLEM", 93, 120], ["infected cells", "PROBLEM", 141, 155], ["infected cells", "OBSERVATION", 141, 155]]], ["Under the TEM, the location of the gold particles indicates the site of the antigen against which the antibody has been raised.Immuno-gold labelling ::: MethodsFor detection of antigens in cells or tissues, a mild fixation is usually required in order to preserve sample ultrastructure yet retain antigenicity.", [["cells", "ANATOMY", 189, 194], ["tissues", "ANATOMY", 198, 205], ["sample", "ANATOMY", 264, 270], ["cells", "CELL", 189, 194], ["tissues", "TISSUE", 198, 205], ["antigens", "PROTEIN", 177, 185], ["the gold particles", "TREATMENT", 31, 49], ["the antibody", "TEST", 98, 110], ["Methods", "TREATMENT", 153, 160], ["antigens in cells or tissues", "PROBLEM", 177, 205], ["a mild fixation", "TREATMENT", 207, 222], ["gold particles", "OBSERVATION", 35, 49], ["tissues", "ANATOMY", 198, 205], ["mild", "OBSERVATION_MODIFIER", 209, 213], ["fixation", "OBSERVATION", 214, 222]]], ["This constraint normally precludes the use of osmium tetroxide.", [["osmium tetroxide", "CHEMICAL", 46, 62], ["osmium tetroxide", "CHEMICAL", 46, 62], ["osmium tetroxide", "SIMPLE_CHEMICAL", 46, 62], ["osmium tetroxide", "TREATMENT", 46, 62]]], ["Dilute solutions of glutaraldehyde, formaldehyde or paraformaldehyde are commonly used fixatives for immunolabelling.", [["glutaraldehyde", "CHEMICAL", 20, 34], ["formaldehyde", "CHEMICAL", 36, 48], ["paraformaldehyde", "CHEMICAL", 52, 68], ["glutaraldehyde", "CHEMICAL", 20, 34], ["formaldehyde", "CHEMICAL", 36, 48], ["paraformaldehyde", "CHEMICAL", 52, 68], ["glutaraldehyde", "SIMPLE_CHEMICAL", 20, 34], ["formaldehyde", "SIMPLE_CHEMICAL", 36, 48], ["paraformaldehyde", "SIMPLE_CHEMICAL", 52, 68], ["Dilute solutions of glutaraldehyde", "TREATMENT", 0, 34], ["formaldehyde", "TREATMENT", 36, 48], ["paraformaldehyde", "TREATMENT", 52, 68], ["fixatives", "TREATMENT", 87, 96], ["immunolabelling", "PROBLEM", 101, 116]]], ["Post-embedding immuno-labelling may be performed on thin sections prepared from organisms, infected cells or tissues which have been embedded in a hydrophilic resin (e.g. LR White or Lowicryl), which is compatible with antigen/antibody binding.", [["sections", "ANATOMY", 57, 65], ["cells", "ANATOMY", 100, 105], ["tissues", "ANATOMY", 109, 116], ["Lowicryl", "CHEMICAL", 183, 191], ["cells", "CELL", 100, 105], ["tissues", "TISSUE", 109, 116], ["Lowicryl", "SIMPLE_CHEMICAL", 183, 191], ["infected cells", "CELL_TYPE", 91, 105], ["embedding immuno", "TEST", 5, 21], ["thin sections", "TEST", 52, 65], ["organisms", "PROBLEM", 80, 89], ["infected cells or tissues", "PROBLEM", 91, 116], ["a hydrophilic resin", "TREATMENT", 145, 164], ["antigen/antibody binding", "PROBLEM", 219, 243], ["infected cells", "OBSERVATION", 91, 105], ["hydrophilic resin", "OBSERVATION", 147, 164], ["compatible with", "UNCERTAINTY", 203, 218], ["antibody binding", "OBSERVATION", 227, 243]]], ["Pre-embedding immuno-labelling of cells, permeabilised to allow access of the labelled antibody to the antigen, may also be may carried out.", [["cells", "ANATOMY", 34, 39], ["cells", "CELL", 34, 39], ["labelled antibody", "PROTEIN", 78, 95]]], ["Should chemical fixation destroy the antigen of interest, cryofixation techniques are available (Harris, 1997).", [["chemical fixation destroy", "TREATMENT", 7, 32], ["fixation", "OBSERVATION", 16, 24]]], ["These procedures involve rapid freezing of the sample, followed by cryo-sectioning at a temperature of about minus 120 \u00b0C, using a cryo-ultramicrotome.", [["sample", "ANATOMY", 47, 53], ["These procedures", "TREATMENT", 0, 16], ["a cryo-ultramicrotome", "TREATMENT", 129, 150], ["rapid", "OBSERVATION_MODIFIER", 25, 30], ["freezing", "OBSERVATION_MODIFIER", 31, 39]]], ["Cryosections are collected on support films on specimen grids, thawed, incubated with labelled antibody and stained before TEM examination.", [["Cryosections", "ANATOMY", 0, 12], ["Cryosections", "TISSUE", 0, 12], ["Cryosections", "TEST", 0, 12], ["support films", "TEST", 30, 43], ["specimen grids", "TEST", 47, 61], ["labelled antibody", "TEST", 86, 103], ["TEM examination", "TEST", 123, 138]]], ["Cryo techniques are highly specialised and normally undertaken for research rather than diagnostic purposes.Bacteriology ::: Development of the use of electron microscopy within virology and bacteriologyThe TEM has some limited applications in the field of diagnostic bacteriology.", [["Cryo techniques", "TREATMENT", 0, 15], ["diagnostic purposes", "TEST", 88, 107], ["electron microscopy", "TEST", 151, 170], ["diagnostic bacteriology", "TEST", 257, 280]]], ["It can be used to identify structures and to locate antigens both on and within bacterial cells.", [["cells", "ANATOMY", 90, 95], ["bacterial cells", "CELL", 80, 95], ["antigens", "PROTEIN", 52, 60], ["bacterial cells", "CELL_TYPE", 80, 95], ["bacterial cells", "OBSERVATION", 80, 95]]], ["It can also be useful in identifying some bacteria in biopsy samples.", [["biopsy samples", "ANATOMY", 54, 68], ["biopsy samples", "CANCER", 54, 68], ["some bacteria", "PROBLEM", 37, 50], ["biopsy samples", "TEST", 54, 68], ["bacteria", "OBSERVATION", 42, 50]]], ["For example, spirochaete bacteria can be identified in intestinal biopsy samples, where, by light microscopy, they may be confused with the microvilli normally found on the surface of intestinal epithelial cells.", [["intestinal biopsy samples", "ANATOMY", 55, 80], ["microvilli", "ANATOMY", 140, 150], ["surface", "ANATOMY", 173, 180], ["intestinal epithelial cells", "ANATOMY", 184, 211], ["spirochaete bacteria", "CELL", 13, 33], ["intestinal biopsy samples", "MULTI-TISSUE_STRUCTURE", 55, 80], ["microvilli", "CELLULAR_COMPONENT", 140, 150], ["surface", "CELLULAR_COMPONENT", 173, 180], ["intestinal epithelial cells", "CELL", 184, 211], ["intestinal epithelial cells", "CELL_TYPE", 184, 211], ["spirochaete bacteria", "PROBLEM", 13, 33], ["intestinal biopsy samples", "TEST", 55, 80], ["light microscopy", "TEST", 92, 108], ["bacteria", "OBSERVATION", 25, 33], ["intestinal", "ANATOMY", 55, 65], ["biopsy", "OBSERVATION", 66, 72], ["intestinal epithelial cells", "OBSERVATION", 184, 211]]], ["Other bacteria such as, Mycobacterium avium intracellulare-complex organisms or Whipple's disease bacteria (Tropheryma whippelii, Fig. 7) may sometimes be found in intestinal biopsies.", [["intestinal biopsies", "ANATOMY", 164, 183], ["Whipple's disease", "DISEASE", 80, 97], ["Mycobacterium avium intracellulare", "ORGANISM", 24, 58], ["Whipple's disease bacteria", "ORGANISM", 80, 106], ["Tropheryma whippelii", "ORGANISM", 108, 128], ["intestinal biopsies", "MULTI-TISSUE_STRUCTURE", 164, 183], ["Mycobacterium avium intracellulare", "SPECIES", 24, 58], ["Tropheryma whippelii", "SPECIES", 108, 128], ["Mycobacterium avium", "SPECIES", 24, 43], ["Tropheryma whippelii", "SPECIES", 108, 128], ["Other bacteria", "PROBLEM", 0, 14], ["Mycobacterium avium intracellulare", "TEST", 24, 58], ["complex organisms", "PROBLEM", 59, 76], ["Whipple's disease bacteria", "PROBLEM", 80, 106], ["Tropheryma whippelii", "PROBLEM", 108, 128], ["intestinal biopsies", "TEST", 164, 183], ["bacteria", "OBSERVATION", 6, 14], ["Mycobacterium", "OBSERVATION_MODIFIER", 24, 37], ["Whipple", "OBSERVATION", 80, 87], ["intestinal", "ANATOMY", 164, 174], ["biopsies", "OBSERVATION", 175, 183]]], ["Bacteria with a spiral body forms, such as Helicobacter pylori (Fig. 8) and Helicobacter heilmani (synonym for Gastrospirillum hominis) can easily be identified in gastric biopsies by EM since the two organisms are morphologically distinct.", [["body", "ANATOMY", 23, 27], ["gastric biopsies", "ANATOMY", 164, 180], ["Helicobacter pylori", "DISEASE", 43, 62], ["Helicobacter pylori", "ORGANISM", 43, 62], ["Fig. 8", "ORGANISM", 64, 70], ["Helicobacter heilmani", "ORGANISM", 76, 97], ["Gastrospirillum hominis", "ORGANISM", 111, 134], ["gastric biopsies", "MULTI-TISSUE_STRUCTURE", 164, 180], ["Helicobacter pylori", "SPECIES", 43, 62], ["Helicobacter heilmani", "SPECIES", 76, 97], ["Gastrospirillum hominis", "SPECIES", 111, 134], ["Helicobacter pylori", "SPECIES", 43, 62], ["Helicobacter heilmani", "SPECIES", 76, 97], ["Gastrospirillum hominis", "SPECIES", 111, 134], ["Bacteria", "PROBLEM", 0, 8], ["a spiral body forms", "PROBLEM", 14, 33], ["Helicobacter pylori", "PROBLEM", 43, 62], ["Helicobacter heilmani", "PROBLEM", 76, 97], ["Gastrospirillum hominis", "PROBLEM", 111, 134], ["gastric biopsies", "TEST", 164, 180], ["spiral body", "OBSERVATION_MODIFIER", 16, 27], ["Helicobacter pylori", "OBSERVATION", 43, 62], ["Helicobacter heilmani", "ANATOMY", 76, 97], ["gastric", "ANATOMY", 164, 171], ["biopsies", "OBSERVATION", 172, 180]]], ["In addition, the Q-fever bacterium, Coxiella burnetti, can be identified in native or prosthetic heart valves by electron microscopy (Isalska et al., 1996).", [["heart", "ANATOMY", 97, 102], ["fever", "DISEASE", 19, 24], ["Coxiella burnetti", "DISEASE", 36, 53], ["Coxiella burnetti", "ORGANISM", 36, 53], ["heart", "ORGAN", 97, 102], ["Coxiella burnetti", "SPECIES", 36, 53], ["Q-fever bacterium", "SPECIES", 17, 34], ["Coxiella burnetti", "SPECIES", 36, 53], ["the Q-fever bacterium", "PROBLEM", 13, 34], ["Coxiella burnetti", "PROBLEM", 36, 53], ["prosthetic heart valves", "TREATMENT", 86, 109], ["electron microscopy", "TEST", 113, 132], ["Coxiella burnetti", "OBSERVATION", 36, 53], ["prosthetic heart valves", "OBSERVATION", 86, 109]]], ["However, such use of electron microscopy is not routine.Bacteriology ::: Development of the use of electron microscopy within virology and bacteriologyIn research applications, many aspects of bacterial ultrastructure, such as motility, adhesion and plasmid transfer (via surface pili and fimbriae) and sporulation (in spore forming species), have been investigated and characterised by electron microscopy.", [["plasmid", "ANATOMY", 250, 257], ["surface", "ANATOMY", 272, 279], ["surface pili", "GENE_OR_GENE_PRODUCT", 272, 284], ["fimbriae", "GENE_OR_GENE_PRODUCT", 289, 297], ["pili", "PROTEIN", 280, 284], ["fimbriae", "PROTEIN", 289, 297], ["electron microscopy", "TEST", 21, 40], ["electron microscopy", "TEST", 99, 118], ["research applications", "TREATMENT", 154, 175], ["bacterial ultrastructure", "PROBLEM", 193, 217], ["motility, adhesion", "TREATMENT", 227, 245], ["plasmid transfer (via surface pili and fimbriae", "TREATMENT", 250, 297], ["sporulation", "PROBLEM", 303, 314], ["electron microscopy", "TEST", 387, 406], ["bacterial ultrastructure", "OBSERVATION", 193, 217]]], ["Motility is an important attribute of a great many bacterial species and the best-understood form of this is swimming.", [["a great many bacterial species", "PROBLEM", 38, 68], ["bacterial species", "OBSERVATION", 51, 68]]], ["Flagella are the structures responsible for this type of translational motility, but these appendages cannot normally be resolved under the light microscope.", [["appendages", "ANATOMY", 91, 101], ["Flagella", "GENE_OR_GENE_PRODUCT", 0, 8], ["translational motility", "PROBLEM", 57, 79], ["the light microscope", "TEST", 136, 156], ["translational motility", "OBSERVATION", 57, 79]]], ["Under the TEM, bacterial flagella show a completely different structure from the flagella and cilia seen in higher organisms.", [["flagella", "ANATOMY", 25, 33], ["flagella", "ANATOMY", 81, 89], ["cilia", "ANATOMY", 94, 99], ["flagella", "CELLULAR_COMPONENT", 81, 89], ["cilia", "CELLULAR_COMPONENT", 94, 99], ["bacterial flagella", "PROBLEM", 15, 33], ["flagella", "ANATOMY_MODIFIER", 81, 89], ["cilia", "ANATOMY_MODIFIER", 94, 99], ["higher organisms", "OBSERVATION", 108, 124]]], ["The external part of the bacterial flagellum, which is normally visible, appears to be a structurally simple helical filament.", [["flagellum", "ANATOMY", 35, 44], ["bacterial flagellum", "CELLULAR_COMPONENT", 25, 44], ["a structurally simple helical filament", "PROBLEM", 87, 125], ["external", "ANATOMY_MODIFIER", 4, 12], ["bacterial flagellum", "OBSERVATION", 25, 44], ["visible", "OBSERVATION_MODIFIER", 64, 71], ["appears to be", "UNCERTAINTY", 73, 86], ["structurally", "OBSERVATION_MODIFIER", 89, 101], ["simple", "OBSERVATION_MODIFIER", 102, 108], ["helical filament", "OBSERVATION", 109, 125]]], ["However, at the base of the filament, a hook structure with complex basal architecture is embedded in the bacterial cell wall (Murray, 1978).", [["filament", "ANATOMY", 28, 36], ["cell wall", "ANATOMY", 116, 125], ["filament", "CELLULAR_COMPONENT", 28, 36], ["cell wall", "TISSUE", 116, 125], ["complex basal architecture", "PROBLEM", 60, 86], ["base", "ANATOMY_MODIFIER", 16, 20], ["filament", "ANATOMY_MODIFIER", 28, 36], ["hook", "OBSERVATION_MODIFIER", 40, 44], ["complex", "OBSERVATION_MODIFIER", 60, 67], ["basal architecture", "OBSERVATION", 68, 86], ["bacterial cell", "OBSERVATION", 106, 120], ["wall", "ANATOMY_MODIFIER", 121, 125], ["Murray", "OBSERVATION_MODIFIER", 127, 133]]], ["The organisation of this basal complex varies depending on whether the bacterium is Gram positive or Gram negative, these two groupings having different cell wall structures (DePamphilis and Adler, 1971).Bacteriology ::: Development of the use of electron microscopy within virology and bacteriologyThere are viruses, the bacteriophages, that exclusively infect bacteria (Fig. 9).", [["cell wall structures", "ANATOMY", 153, 173], ["Gram", "GENE_OR_GENE_PRODUCT", 84, 88], ["Gram", "GENE_OR_GENE_PRODUCT", 101, 105], ["cell wall structures", "TISSUE", 153, 173], ["this basal complex varies", "PROBLEM", 20, 45], ["the bacterium", "TEST", 67, 80], ["Gram positive", "PROBLEM", 84, 97], ["Gram", "TEST", 101, 105], ["electron microscopy", "TEST", 247, 266], ["viruses", "PROBLEM", 309, 316], ["the bacteriophages", "PROBLEM", 318, 336], ["basal", "ANATOMY_MODIFIER", 25, 30], ["wall", "ANATOMY_MODIFIER", 158, 162], ["viruses", "OBSERVATION", 309, 316]]], ["These were amongst the first viruses imaged by electron microscopy (Gabor, 1945).", [["electron microscopy", "TEST", 47, 66]]], ["Bacteriophages show a variety of morphologies (Kay, 1978), but usually consist of an icosahedral head and a long contractile tail.", [["head", "ANATOMY", 97, 101], ["contractile tail", "ANATOMY", 113, 129], ["head", "ORGANISM_SUBDIVISION", 97, 101], ["icosahedral", "ANATOMY_MODIFIER", 85, 96], ["head", "ANATOMY", 97, 101], ["tail", "ANATOMY", 125, 129]]], ["They can be used in \u2018phage typing schemes\u2019 to identify specific bacterial types and occasionally electron microscopy is used to characterise the bacteriophage involved (Sails et al., 1998).Virology ::: Development of the use of electron microscopy within virology and bacteriologyViruses come in a whole range of sizes and shapes, but fall into three morphological groups characterised by (1) helical symmetry, (2) cubic or icosahedral symmetry, and (3) other or complex symmetry (Horne and Wildy, 1961, Horne, 1974, Nermut, 1987, Madeley and Field, 1988).", [["specific bacterial types", "PROBLEM", 55, 79], ["occasionally electron microscopy", "TEST", 84, 116], ["electron microscopy", "TEST", 228, 247], ["Viruses", "PROBLEM", 280, 287], ["helical symmetry, (2) cubic or icosahedral symmetry, and (3) other or complex symmetry", "PROBLEM", 393, 479], ["sizes", "OBSERVATION_MODIFIER", 313, 318], ["shapes", "OBSERVATION_MODIFIER", 323, 329], ["icosahedral symmetry", "OBSERVATION", 424, 444], ["complex", "OBSERVATION_MODIFIER", 463, 470], ["symmetry", "OBSERVATION", 471, 479]]], ["Different shapes of viruses occur within each symmetry group.", [["Different shapes of viruses", "PROBLEM", 0, 27], ["shapes", "OBSERVATION_MODIFIER", 10, 16], ["viruses", "OBSERVATION", 20, 27], ["symmetry", "OBSERVATION_MODIFIER", 46, 54]]], ["Viruses are taxonomically grouped in families and genera.", [["Viruses", "PROBLEM", 0, 7]]], ["Members of a family or genus have a similar morphological appearance and it is usually possible to identify which family or genus a virus belongs to on this basis, but not necessarily the specific virus type.", [["a virus", "PROBLEM", 130, 137]]], ["For instance, the virus causing chicken pox, Herpes varicella, is identical in appearance to the herpes virus causing cold sores, Herpes simplex.Virology ::: Development of the use of electron microscopy within virology and bacteriologyThe smallest intact human viruses are about 18\u201326 nm in diameter (parvoviruses), the largest about 250 nm (poxviruses).", [["chicken pox", "DISEASE", 32, 43], ["Herpes varicella", "DISEASE", 45, 61], ["herpes virus", "DISEASE", 97, 109], ["cold sores", "DISEASE", 118, 128], ["Herpes simplex", "DISEASE", 130, 144], ["chicken pox", "ORGANISM", 32, 43], ["Herpes", "ORGANISM", 45, 51], ["varicella", "ORGANISM", 52, 61], ["herpes virus", "ORGANISM", 97, 109], ["Herpes simplex", "ORGANISM", 130, 144], ["human", "ORGANISM", 256, 261], ["chicken pox", "SPECIES", 32, 43], ["Herpes varicella", "SPECIES", 45, 61], ["herpes virus", "SPECIES", 97, 109], ["Herpes simplex", "SPECIES", 130, 144], ["human", "SPECIES", 256, 261], ["chicken pox", "SPECIES", 32, 43], ["herpes virus", "SPECIES", 97, 109], ["human viruses", "SPECIES", 256, 269], ["the virus", "PROBLEM", 14, 23], ["chicken pox", "PROBLEM", 32, 43], ["Herpes varicella", "PROBLEM", 45, 61], ["the herpes virus", "PROBLEM", 93, 109], ["cold sores", "PROBLEM", 118, 128], ["Herpes simplex", "PROBLEM", 130, 144], ["electron microscopy", "TEST", 184, 203], ["The smallest intact human viruses", "PROBLEM", 236, 269], ["Herpes varicella", "OBSERVATION", 45, 61], ["herpes virus", "OBSERVATION", 97, 109], ["Herpes simplex", "OBSERVATION", 130, 144], ["smallest", "OBSERVATION_MODIFIER", 240, 248], ["intact", "OBSERVATION", 249, 255], ["human viruses", "OBSERVATION", 256, 269], ["18\u201326 nm", "OBSERVATION_MODIFIER", 280, 288], ["diameter", "OBSERVATION_MODIFIER", 292, 300], ["largest", "OBSERVATION_MODIFIER", 321, 328], ["250 nm", "OBSERVATION_MODIFIER", 335, 341]]], ["There are also filamentous viruses, such as Marburg and Ebola, which cause haemorrhagic fevers with high mortality rates.", [["Marburg and Ebola", "DISEASE", 44, 61], ["haemorrhagic fevers", "DISEASE", 75, 94], ["Ebola", "ORGANISM", 56, 61], ["Ebola", "SPECIES", 56, 61], ["filamentous viruses", "PROBLEM", 15, 34], ["Ebola", "PROBLEM", 56, 61], ["haemorrhagic fevers", "PROBLEM", 75, 94], ["high mortality rates", "PROBLEM", 100, 120], ["filamentous viruses", "OBSERVATION", 15, 34], ["haemorrhagic", "OBSERVATION_MODIFIER", 75, 87], ["high", "OBSERVATION_MODIFIER", 100, 104]]], ["These have a diameter of about 80 nm but show great variability in length, occasionally exceeding 20 \u03bcm.", [["great variability in length", "PROBLEM", 46, 73], ["diameter", "OBSERVATION_MODIFIER", 13, 21], ["80 nm", "OBSERVATION_MODIFIER", 31, 36], ["great", "OBSERVATION_MODIFIER", 46, 51], ["variability", "OBSERVATION_MODIFIER", 52, 63], ["length", "OBSERVATION_MODIFIER", 67, 73], ["occasionally", "OBSERVATION_MODIFIER", 75, 87], ["exceeding", "OBSERVATION_MODIFIER", 88, 97], ["20 \u03bcm", "OBSERVATION_MODIFIER", 98, 103]]], ["Smaller viruses are known, but these mainly infect bacteria (bacteriophages).", [["Smaller viruses", "PROBLEM", 0, 15], ["infect bacteria (bacteriophages)", "PROBLEM", 44, 76], ["viruses", "OBSERVATION", 8, 15]]], ["The morphology of viruses is usually consistent within one group.", [["viruses", "PROBLEM", 18, 25], ["viruses", "OBSERVATION", 18, 25]]], ["For example all adenoviruses have icosahedral symmetry and are the same shape and size.", [["adenoviruses", "ORGANISM", 16, 28], ["all", "OBSERVATION_MODIFIER", 12, 15], ["adenoviruses", "OBSERVATION", 16, 28], ["icosahedral symmetry", "OBSERVATION", 34, 54], ["shape", "OBSERVATION_MODIFIER", 72, 77], ["size", "OBSERVATION_MODIFIER", 82, 86]]], ["Some viruses, such as the paramyxoviruses, which cause measles, mumps and other respiratory infections are pleomorphic (Fig. 10), but possess characteristic internal components (nucleocapsids with helical symmetry) of a specific diameter and structure.", [["respiratory", "ANATOMY", 80, 91], ["measles", "DISEASE", 55, 62], ["mumps", "DISEASE", 64, 69], ["respiratory infections", "DISEASE", 80, 102], ["nucleocapsids", "CELLULAR_COMPONENT", 178, 191], ["Some viruses", "PROBLEM", 0, 12], ["the paramyxoviruses", "PROBLEM", 22, 41], ["measles", "PROBLEM", 55, 62], ["mumps", "PROBLEM", 64, 69], ["other respiratory infections", "PROBLEM", 74, 102], ["viruses", "OBSERVATION", 5, 12], ["paramyxoviruses", "OBSERVATION", 26, 41], ["respiratory", "ANATOMY", 80, 91], ["infections", "OBSERVATION", 92, 102], ["internal", "ANATOMY_MODIFIER", 157, 165], ["diameter", "OBSERVATION_MODIFIER", 229, 237]]], ["Paramyxoviruses contain a long, thin helical nucleocapsid 18\u201322 nm in diameter, with a \u2018herringbone\u2019 appearance, which is a diagnostic feature.", [["Paramyxoviruses", "PROBLEM", 0, 15], ["a long, thin helical nucleocapsid", "TREATMENT", 24, 57], ["long", "OBSERVATION_MODIFIER", 26, 30], ["18\u201322 nm", "OBSERVATION_MODIFIER", 58, 66], ["diameter", "OBSERVATION_MODIFIER", 70, 78]]], ["It is the complex envelope of these viruses that gives rise to their variable size and shape and shows characteristic surface projections, which enable identification of their virus group as orthomyxovirus (e.g. influenza virus) or paramyxovirus.", [["surface", "ANATOMY", 118, 125], ["influenza virus", "DISEASE", 212, 227], ["influenza virus", "ORGANISM", 212, 227], ["influenza virus", "SPECIES", 212, 227], ["these viruses", "PROBLEM", 30, 43], ["their virus group", "PROBLEM", 170, 187], ["orthomyxovirus (e.g. influenza virus)", "PROBLEM", 191, 228], ["paramyxovirus", "PROBLEM", 232, 245], ["complex", "OBSERVATION_MODIFIER", 10, 17], ["envelope", "OBSERVATION_MODIFIER", 18, 26], ["viruses", "OBSERVATION", 36, 43], ["variable", "OBSERVATION_MODIFIER", 69, 77], ["size", "OBSERVATION_MODIFIER", 78, 82], ["shape", "OBSERVATION_MODIFIER", 87, 92], ["characteristic", "OBSERVATION_MODIFIER", 103, 117], ["surface", "OBSERVATION_MODIFIER", 118, 125]]], ["Observed morphology is a good predictor of other virus properties (Madeley, 1997) and these can be important in the investigation of new viruses.Rapid diagnosis of smallpox ::: Development of the use of electron microscopy within virology and bacteriologySmallpox infection is a very serious human disease with high rates of morbidity and mortality.", [["Smallpox infection", "DISEASE", 255, 273], ["human", "ORGANISM", 292, 297], ["human", "SPECIES", 292, 297], ["human", "SPECIES", 292, 297], ["new viruses", "PROBLEM", 133, 144], ["electron microscopy", "TEST", 203, 222], ["Smallpox infection", "PROBLEM", 255, 273], ["a very serious human disease", "PROBLEM", 277, 305], ["morbidity", "PROBLEM", 325, 334], ["new", "OBSERVATION_MODIFIER", 133, 136], ["viruses", "OBSERVATION", 137, 144], ["smallpox", "OBSERVATION", 164, 172], ["infection", "OBSERVATION", 264, 273], ["very", "OBSERVATION_MODIFIER", 279, 283], ["serious", "OBSERVATION_MODIFIER", 284, 291], ["high rates", "OBSERVATION_MODIFIER", 311, 321]]], ["Following an intensive worldwide vaccination programme, the World Health Assembly announced in 1980 that smallpox had been eradicated (Henderson, 2002)\u2014the first and so far the only human virus infection that has been successfully eradicated.", [["smallpox", "DISEASE", 105, 113], ["infection", "DISEASE", 194, 203], ["human", "ORGANISM", 182, 187], ["human", "SPECIES", 182, 187], ["human virus", "SPECIES", 182, 193], ["human virus infection", "PROBLEM", 182, 203], ["infection", "OBSERVATION", 194, 203]]], ["Variola, the virus causing of smallpox, was endemic in some parts of the world, but outbreaks in large centres of population are known to have occurred during many periods of recorded human history up until the mid 20th century.", [["Variola", "CHEMICAL", 0, 7], ["smallpox", "DISEASE", 30, 38], ["human", "ORGANISM", 184, 189], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 184, 189], ["Variola", "PROBLEM", 0, 7], ["the virus", "PROBLEM", 9, 18], ["smallpox", "PROBLEM", 30, 38], ["virus", "OBSERVATION", 13, 18], ["smallpox", "OBSERVATION_MODIFIER", 30, 38], ["endemic", "OBSERVATION_MODIFIER", 44, 51], ["large", "OBSERVATION_MODIFIER", 97, 102], ["centres", "OBSERVATION_MODIFIER", 103, 110]]], ["Smallpox infection is fatal in up to 30% of infected individuals.", [["Smallpox infection", "DISEASE", 0, 18], ["Smallpox infection", "PROBLEM", 0, 18], ["infected individuals", "PROBLEM", 44, 64], ["infection", "OBSERVATION", 9, 18], ["fatal", "OBSERVATION_MODIFIER", 22, 27], ["up to 30", "OBSERVATION_MODIFIER", 31, 39], ["infected", "OBSERVATION", 44, 52]]], ["Although classically seen as a skin infection, it is the release of virus from lesions in the respiratory tract and subsequent airborne transmission via the respiratory route that initiated outbreaks.", [["skin", "ANATOMY", 31, 35], ["lesions", "ANATOMY", 79, 86], ["respiratory tract", "ANATOMY", 94, 111], ["respiratory", "ANATOMY", 157, 168], ["skin infection", "DISEASE", 31, 45], ["skin", "ORGAN", 31, 35], ["lesions", "PATHOLOGICAL_FORMATION", 79, 86], ["respiratory tract", "ORGANISM_SUBDIVISION", 94, 111], ["a skin infection", "PROBLEM", 29, 45], ["virus", "PROBLEM", 68, 73], ["lesions in the respiratory tract", "PROBLEM", 79, 111], ["the respiratory route", "TREATMENT", 153, 174], ["skin", "ANATOMY", 31, 35], ["infection", "OBSERVATION", 36, 45], ["lesions", "OBSERVATION", 79, 86], ["respiratory tract", "ANATOMY", 94, 111]]], ["Poxviruses are large viruses, the two major groups of which are orthopoxviruses (Fig. 4) and parapoxviruses (Fig. 11).", [["Poxviruses", "GENE_OR_GENE_PRODUCT", 0, 10], ["Fig. 4", "ORGANISM", 81, 87], ["large viruses", "PROBLEM", 15, 28], ["orthopoxviruses", "PROBLEM", 64, 79], ["large", "OBSERVATION_MODIFIER", 15, 20], ["viruses", "OBSERVATION", 21, 28], ["orthopoxviruses", "OBSERVATION", 64, 79]]], ["Smallpox (Variola) is caused by an orthopoxvirus.", [["Smallpox (Variola", "TREATMENT", 0, 17], ["an orthopoxvirus", "PROBLEM", 32, 48], ["orthopoxvirus", "OBSERVATION", 35, 48]]], ["Clinically, the skin lesions produced in chicken pox may easily be confused with those of smallpox.", [["skin lesions", "ANATOMY", 16, 28], ["smallpox", "DISEASE", 90, 98], ["skin lesions", "PATHOLOGICAL_FORMATION", 16, 28], ["chicken", "ORGANISM", 41, 48], ["pox", "ORGANISM", 49, 52], ["chicken", "SPECIES", 41, 48], ["chicken", "SPECIES", 41, 48], ["the skin lesions", "PROBLEM", 12, 28], ["smallpox", "TREATMENT", 90, 98], ["skin", "ANATOMY", 16, 20], ["lesions", "OBSERVATION", 21, 28]]], ["Vesicle fluid is very rich in virus particles and direct EM examination of vesicle fluid or scrapings of skin lesion leads to rapid identification of the virus group involved.", [["Vesicle fluid", "ANATOMY", 0, 13], ["vesicle fluid", "ANATOMY", 75, 88], ["scrapings", "ANATOMY", 92, 101], ["skin lesion", "ANATOMY", 105, 116], ["vesicle fluid", "ORGANISM_SUBSTANCE", 75, 88], ["skin lesion", "CANCER", 105, 116], ["Vesicle fluid", "TEST", 0, 13], ["very rich in virus particles", "PROBLEM", 17, 45], ["direct EM examination", "TEST", 50, 71], ["vesicle fluid", "PROBLEM", 75, 88], ["scrapings of skin lesion", "PROBLEM", 92, 116], ["fluid", "OBSERVATION", 8, 13], ["vesicle fluid", "OBSERVATION", 75, 88], ["skin", "ANATOMY", 105, 109], ["lesion", "OBSERVATION", 110, 116], ["rapid", "OBSERVATION_MODIFIER", 126, 131], ["virus", "OBSERVATION", 154, 159]]], ["Identification of a herpes virus (Fig. 5) rather than an orthopox virus negated the need to activate the public health measures (mass vaccination, quarantine, contact tracing) that would be required in the case of smallpox.Rapid diagnosis of smallpox ::: Development of the use of electron microscopy within virology and bacteriologyAlthough smallpox and some other poxviruses and herpesviruses were investigated by electron microscopy in the late 1940s (Nagler and Rake, 1948), it was not until the 1960s and 1970s that a number of electron microscopes were bought primarily by virology departments, for the diagnostic investigation of skin lesions (Long et al., 1970).", [["skin lesions", "ANATOMY", 637, 649], ["herpes virus", "DISEASE", 20, 32], ["smallpox", "DISEASE", 214, 222], ["smallpox", "DISEASE", 342, 350], ["skin lesions", "DISEASE", 637, 649], ["herpes virus", "ORGANISM", 20, 32], ["Fig. 5", "ORGANISM", 34, 40], ["orthopox virus", "ORGANISM", 57, 71], ["herpesviruses", "ORGANISM", 381, 394], ["skin lesions", "PATHOLOGICAL_FORMATION", 637, 649], ["herpes virus", "SPECIES", 20, 32], ["herpes virus", "SPECIES", 20, 32], ["orthopox virus", "SPECIES", 57, 71], ["a herpes virus", "PROBLEM", 18, 32], ["an orthopox virus", "PROBLEM", 54, 71], ["mass vaccination", "TREATMENT", 129, 145], ["smallpox", "PROBLEM", 214, 222], ["electron microscopy", "TEST", 281, 300], ["smallpox", "TREATMENT", 342, 350], ["some other poxviruses", "PROBLEM", 355, 376], ["herpesviruses", "PROBLEM", 381, 394], ["electron microscopy", "TEST", 416, 435], ["electron microscopes", "TEST", 533, 553], ["the diagnostic investigation", "TEST", 605, 633], ["skin lesions", "PROBLEM", 637, 649], ["smallpox", "OBSERVATION", 242, 250], ["poxviruses", "OBSERVATION", 366, 376], ["skin", "ANATOMY", 637, 641], ["lesions", "OBSERVATION", 642, 649]]], ["In the UK, these microscopes were located in regional virus laboratories, Public Health Laboratories and some University Microbiology Departments, particularly in locations where imported cases of smallpox might possibly occur (Madeley, 1997).", [["smallpox", "DISEASE", 197, 205], ["UK", "GENE_OR_GENE_PRODUCT", 7, 9], ["these microscopes", "TEST", 11, 28], ["smallpox", "PROBLEM", 197, 205], ["regional virus", "ANATOMY", 45, 59]]], ["However, following the global eradication of smallpox, most laboratory stocks of the virus were destroyed and now only two centres officially hold smallpox virus, CDC, Atlanta, USA and Novosibirsk, Russian Federation (Henderson and Fenner, 2001).", [["smallpox", "DISEASE", 45, 53], ["smallpox", "DISEASE", 147, 155], ["smallpox", "TREATMENT", 45, 53], ["the virus", "PROBLEM", 81, 90], ["smallpox virus", "TREATMENT", 147, 161]]], ["Although EM is no longer required for the diagnosis of smallpox, it continues to be used for detecting other poxviruses, herpesviruses and papilloma viruses in skin lesions.Hepatitis viruses ::: Development of the use of electron microscopy within virology and bacteriologySeveral viruses can infect the liver causing acute inflammation that may result in the patient becoming jaundiced.", [["skin lesions", "ANATOMY", 160, 172], ["liver", "ANATOMY", 304, 309], ["smallpox", "DISEASE", 55, 63], ["herpesviruses and papilloma viruses", "DISEASE", 121, 156], ["Hepatitis viruses", "DISEASE", 173, 190], ["inflammation", "DISEASE", 324, 336], ["herpesviruses", "ORGANISM", 121, 134], ["papilloma viruses", "ORGANISM", 139, 156], ["skin lesions", "PATHOLOGICAL_FORMATION", 160, 172], ["Hepatitis viruses", "ORGANISM", 173, 190], ["liver", "ORGAN", 304, 309], ["patient", "ORGANISM", 360, 367], ["patient", "SPECIES", 360, 367], ["smallpox", "TREATMENT", 55, 63], ["other poxviruses", "PROBLEM", 103, 119], ["herpesviruses", "PROBLEM", 121, 134], ["papilloma viruses in skin lesions", "PROBLEM", 139, 172], ["Hepatitis viruses", "PROBLEM", 173, 190], ["electron microscopy", "TEST", 221, 240], ["Several viruses", "PROBLEM", 273, 288], ["acute inflammation", "PROBLEM", 318, 336], ["jaundiced", "PROBLEM", 377, 386], ["no longer", "UNCERTAINTY", 15, 24], ["poxviruses", "OBSERVATION", 109, 119], ["papilloma", "OBSERVATION", 139, 148], ["skin", "ANATOMY", 160, 164], ["lesions", "OBSERVATION", 165, 172], ["viruses", "OBSERVATION", 183, 190], ["viruses", "OBSERVATION", 281, 288], ["liver", "ANATOMY", 304, 309], ["acute", "OBSERVATION_MODIFIER", 318, 323], ["inflammation", "OBSERVATION", 324, 336], ["jaundiced", "OBSERVATION", 377, 386]]], ["Some viral causes of hepatitis were originally investigated using electron microscopy.Hepatitis B virus (Australia antigen) ::: Development of the use of electron microscopy within virology and bacteriologyIn 1965, Blumberg and colleagues found an antibody in some haemophiliac patients, which reacted with an antigen in a serum from an Australian Aborigine and because of this, it became known as Australia antigen (Blumberg et al., 1965).", [["serum", "ANATOMY", 323, 328], ["hepatitis", "DISEASE", 21, 30], ["Hepatitis B", "DISEASE", 86, 97], ["haemophiliac", "DISEASE", 265, 277], ["Hepatitis B virus", "ORGANISM", 86, 103], ["Australia antigen", "GENE_OR_GENE_PRODUCT", 105, 122], ["patients", "ORGANISM", 278, 286], ["serum", "ORGANISM_SUBSTANCE", 323, 328], ["Hepatitis B virus", "SPECIES", 86, 103], ["patients", "SPECIES", 278, 286], ["Hepatitis B virus", "SPECIES", 86, 103], ["hepatitis", "PROBLEM", 21, 30], ["electron microscopy", "TEST", 66, 85], ["Hepatitis B virus", "PROBLEM", 86, 103], ["electron microscopy", "TEST", 154, 173], ["an antibody", "TEST", 245, 256], ["an antigen", "TEST", 307, 317], ["viral", "OBSERVATION", 5, 10], ["hepatitis", "OBSERVATION", 21, 30]]], ["Subsequently this antigen was found in about 20% of patients with viral hepatitis and is now known as hepatitis B virus surface antigen (HbsAg).", [["viral hepatitis", "DISEASE", 66, 81], ["hepatitis B virus surface antigen", "CHEMICAL", 102, 135], ["patients", "ORGANISM", 52, 60], ["hepatitis B virus surface antigen", "GENE_OR_GENE_PRODUCT", 102, 135], ["HbsAg", "GENE_OR_GENE_PRODUCT", 137, 142], ["hepatitis B virus surface antigen", "PROTEIN", 102, 135], ["HbsAg", "PROTEIN", 137, 142], ["patients", "SPECIES", 52, 60], ["hepatitis B virus", "SPECIES", 102, 119], ["hepatitis B virus", "SPECIES", 102, 119], ["this antigen", "TEST", 13, 25], ["viral hepatitis", "PROBLEM", 66, 81], ["hepatitis B virus surface antigen", "TEST", 102, 135], ["HbsAg", "TEST", 137, 142], ["viral hepatitis", "OBSERVATION", 66, 81]]], ["For laboratory diagnosis of hepatitis B, the patient serum under investigation was mixed with a high titre immune serum and examined by EM (see Section 2.7).", [["serum", "ANATOMY", 53, 58], ["serum", "ANATOMY", 114, 119], ["hepatitis B", "DISEASE", 28, 39], ["hepatitis B", "ORGANISM", 28, 39], ["patient", "ORGANISM", 45, 52], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["serum", "ORGANISM_SUBSTANCE", 114, 119], ["patient", "SPECIES", 45, 52], ["hepatitis B", "SPECIES", 28, 39], ["hepatitis B", "PROBLEM", 28, 39], ["the patient serum under investigation", "TEST", 41, 78], ["a high titre immune serum", "PROBLEM", 94, 119], ["hepatitis", "OBSERVATION", 28, 37]]], ["Under the electron microscope three types of particle may be identified (Fig. 12): small approximately 20 nm spheres, tubules 20 nm in diameter and up to 100 nm long and complex particles about 42 nm in diameter known as Dane particles.", [["tubules", "ANATOMY", 118, 125], ["tubules", "TISSUE", 118, 125], ["the electron microscope", "TEST", 6, 29], ["small approximately 20 nm spheres", "PROBLEM", 83, 116], ["small", "OBSERVATION_MODIFIER", 83, 88], ["20 nm", "OBSERVATION_MODIFIER", 103, 108], ["20 nm", "OBSERVATION_MODIFIER", 126, 131], ["diameter", "OBSERVATION_MODIFIER", 135, 143], ["100 nm", "OBSERVATION_MODIFIER", 154, 160], ["particles", "OBSERVATION_MODIFIER", 178, 187], ["42 nm", "OBSERVATION_MODIFIER", 194, 199], ["Dane particles", "OBSERVATION", 221, 235]]], ["The Dane particle is the intact hepatitis B virus, whereas the spheres and tubules are excess viral protein (Dane et al., 1970).", [["tubules", "ANATOMY", 75, 82], ["hepatitis B", "DISEASE", 32, 43], ["hepatitis B virus", "ORGANISM", 32, 49], ["tubules", "TISSUE", 75, 82], ["viral protein", "PROTEIN", 94, 107], ["hepatitis B virus", "SPECIES", 32, 49], ["hepatitis B virus", "SPECIES", 32, 49], ["the intact hepatitis B virus", "PROBLEM", 21, 49], ["Dane particle", "OBSERVATION", 4, 17], ["intact", "OBSERVATION_MODIFIER", 25, 31], ["hepatitis B virus", "OBSERVATION", 32, 49], ["viral protein", "OBSERVATION", 94, 107]]], ["In the 1960s and 1970s, liver biopsies were sometimes performed on jaundiced patients and liver cells examined for the presence of Dane particles or core particles (internal components of Dane particles) migrating from the liver nuclei into the cytoplasm (Almeida et al., 1971).", [["liver biopsies", "ANATOMY", 24, 38], ["liver cells", "ANATOMY", 90, 101], ["liver nuclei", "ANATOMY", 223, 235], ["cytoplasm", "ANATOMY", 245, 254], ["liver biopsies", "MULTI-TISSUE_STRUCTURE", 24, 38], ["patients", "ORGANISM", 77, 85], ["liver cells", "CELL", 90, 101], ["liver", "ORGAN", 223, 228], ["cytoplasm", "ORGANISM_SUBSTANCE", 245, 254], ["liver cells", "CELL_TYPE", 90, 101], ["patients", "SPECIES", 77, 85], ["liver biopsies", "TEST", 24, 38], ["liver cells", "TEST", 90, 101], ["Dane particles", "PROBLEM", 131, 145], ["core particles", "PROBLEM", 149, 163], ["Dane particles", "TREATMENT", 188, 202], ["liver", "ANATOMY", 24, 29], ["biopsies", "OBSERVATION", 30, 38], ["liver", "ANATOMY", 90, 95], ["Dane particles", "OBSERVATION", 188, 202], ["liver", "ANATOMY", 223, 228], ["nuclei", "ANATOMY_MODIFIER", 229, 235], ["cytoplasm", "ANATOMY_MODIFIER", 245, 254]]], ["The immune electron microscopy method of detecting Australia antigen remained in use until about the mid 1980s when alternative methods of detection, such as radioimmuno assay, and later EIA became available.Hepatitis A and hepatitis E ::: Development of the use of electron microscopy within virology and bacteriologyUnlike hepatitis B, which is a bloodborne infection, hepatitis A and hepatitis E are enterically transmitted infections.", [["Hepatitis A and hepatitis E", "DISEASE", 208, 235], ["hepatitis B", "DISEASE", 325, 336], ["bloodborne infection", "DISEASE", 349, 369], ["hepatitis A and hepatitis E", "DISEASE", 371, 398], ["enterically transmitted infections", "DISEASE", 403, 437], ["Australia antigen", "GENE_OR_GENE_PRODUCT", 51, 68], ["Hepatitis A", "ORGANISM", 208, 219], ["hepatitis B", "ORGANISM", 325, 336], ["hepatitis A", "ORGANISM", 371, 382], ["hepatitis E", "ORGANISM", 387, 398], ["Hepatitis A", "SPECIES", 208, 219], ["hepatitis B", "SPECIES", 325, 336], ["hepatitis A", "SPECIES", 371, 382], ["The immune electron microscopy", "TEST", 0, 30], ["Australia antigen", "TEST", 51, 68], ["radioimmuno assay", "TEST", 158, 175], ["later EIA", "TEST", 181, 190], ["electron microscopy", "TEST", 266, 285], ["hepatitis B", "PROBLEM", 325, 336], ["a bloodborne infection", "PROBLEM", 347, 369], ["hepatitis A", "PROBLEM", 371, 382], ["hepatitis E", "PROBLEM", 387, 398], ["transmitted infections", "PROBLEM", 415, 437], ["hepatitis", "OBSERVATION", 224, 233], ["hepatitis", "OBSERVATION", 325, 334], ["bloodborne", "OBSERVATION_MODIFIER", 349, 359], ["infection", "OBSERVATION", 360, 369], ["hepatitis", "OBSERVATION", 371, 380], ["infections", "OBSERVATION", 427, 437]]], ["They may be transmitted directly between persons but may also be transmitted via contaminated food and water.", [["persons", "ORGANISM", 41, 48], ["persons", "SPECIES", 41, 48]]], ["Electron microscopy played a key role in the discovery of both of these viruses.", [["Electron microscopy", "TEST", 0, 19], ["viruses", "OBSERVATION", 72, 79]]], ["Hepatitis A virus is a small icosahedral particle that has been classified with the Picornaviridae family.", [["Hepatitis A", "DISEASE", 0, 11], ["Hepatitis A virus", "ORGANISM", 0, 17], ["Hepatitis A virus", "SPECIES", 0, 17], ["Hepatitis A virus", "SPECIES", 0, 17], ["Hepatitis A virus", "PROBLEM", 0, 17], ["a small icosahedral particle", "PROBLEM", 21, 49], ["virus", "OBSERVATION", 12, 17], ["small icosahedral particle", "OBSERVATION_MODIFIER", 23, 49]]], ["It was first identified by immune electron microscopy (IEM) using faecal specimens (virus) and sera (antibody) from volunteers who had been infected with hepatitis A (Feinstone et al., 1973).", [["faecal specimens", "ANATOMY", 66, 82], ["sera", "ANATOMY", 95, 99], ["hepatitis A", "DISEASE", 154, 165], ["faecal specimens", "ORGANISM_SUBSTANCE", 66, 82], ["sera", "ORGANISM_SUBSTANCE", 95, 99], ["volunteers", "ORGANISM", 116, 126], ["hepatitis A", "SPECIES", 154, 165], ["immune electron microscopy", "TEST", 27, 53], ["faecal specimens (virus)", "TEST", 66, 90], ["sera (antibody", "TEST", 95, 109]]], ["Hepatitis E virus was also discovered using IEM (Balayan et al., 1983).", [["Hepatitis E", "DISEASE", 0, 11], ["Hepatitis E virus", "ORGANISM", 0, 17], ["Hepatitis E virus", "SPECIES", 0, 17], ["Hepatitis E virus", "SPECIES", 0, 17], ["Hepatitis E virus", "PROBLEM", 0, 17]]], ["Morphologically this virus resembles the caliciviruses, but currently remains unclassified (Berke and Matson, 2000).Parvovirus B19 in blood serum ::: Development of the use of electron microscopy within virology and bacteriologyThe parvovirus group consists of small viruses, some of which cause disease in humans.", [["caliciviruses", "ANATOMY", 41, 54], ["blood serum", "ANATOMY", 134, 145], ["caliciviruses", "DISEASE", 41, 54], ["Parvovirus B19", "DISEASE", 116, 130], ["parvovirus group", "DISEASE", 232, 248], ["caliciviruses", "CANCER", 41, 54], ["Parvovirus B19", "ORGANISM", 116, 130], ["blood", "ORGANISM_SUBSTANCE", 134, 139], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["parvovirus", "ORGANISM", 232, 242], ["humans", "ORGANISM", 307, 313], ["Parvovirus B19", "SPECIES", 116, 130], ["parvovirus group", "SPECIES", 232, 248], ["humans", "SPECIES", 307, 313], ["Parvovirus B19", "SPECIES", 116, 130], ["humans", "SPECIES", 307, 313], ["Parvovirus B19 in blood serum", "TEST", 116, 145], ["electron microscopy", "TEST", 176, 195], ["small viruses", "PROBLEM", 261, 274], ["disease in humans", "PROBLEM", 296, 313], ["virus", "OBSERVATION", 21, 26], ["caliciviruses", "OBSERVATION", 41, 54], ["parvovirus", "OBSERVATION", 232, 242], ["small", "OBSERVATION_MODIFIER", 261, 266], ["viruses", "OBSERVATION", 267, 274], ["disease", "OBSERVATION", 296, 303]]], ["Some human parvovirus infections were discovered by electron microscopy.", [["parvovirus infections", "DISEASE", 11, 32], ["human", "ORGANISM", 5, 10], ["parvovirus", "ORGANISM", 11, 21], ["human", "SPECIES", 5, 10], ["human parvovirus", "SPECIES", 5, 21], ["Some human parvovirus infections", "PROBLEM", 0, 32], ["electron microscopy", "TEST", 52, 71], ["parvovirus infections", "OBSERVATION", 11, 32]]], ["For example, parvovirus B19 virus (Fig. 6) was discovered while looking for hepatitis B virus in serum by immune electron microscopy (Cossart et al., 1975).", [["serum", "ANATOMY", 97, 102], ["parvovirus B19", "DISEASE", 13, 27], ["hepatitis B", "DISEASE", 76, 87], ["parvovirus B19 virus", "ORGANISM", 13, 33], ["hepatitis B virus", "ORGANISM", 76, 93], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["parvovirus B19 virus", "SPECIES", 13, 33], ["hepatitis B virus", "SPECIES", 76, 93], ["parvovirus B19 virus", "SPECIES", 13, 33], ["hepatitis B virus", "SPECIES", 76, 93], ["parvovirus B19 virus", "PROBLEM", 13, 33], ["hepatitis B virus", "PROBLEM", 76, 93], ["parvovirus B19", "OBSERVATION", 13, 27]]], ["B19 is the cause of a common childhood rash disease, erythema infectiosum, colloquially known as \u2018slapped cheek syndrome\u2019 because of the bright red cheeks induced by the rash.", [["erythema", "ANATOMY", 53, 61], ["cheek", "ANATOMY", 106, 111], ["cheeks", "ANATOMY", 148, 154], ["B19", "DISEASE", 0, 3], ["rash disease", "DISEASE", 39, 51], ["erythema infectiosum", "DISEASE", 53, 73], ["cheek syndrome", "DISEASE", 106, 120], ["rash", "DISEASE", 170, 174], ["B19", "ORGANISM", 0, 3], ["cheek", "ORGANISM_SUBDIVISION", 106, 111], ["cheeks", "ORGANISM_SUBDIVISION", 148, 154], ["B19", "SPECIES", 0, 3], ["a common childhood rash disease", "PROBLEM", 20, 51], ["erythema infectiosum", "PROBLEM", 53, 73], ["colloquially", "PROBLEM", 75, 87], ["\u2018slapped cheek syndrome", "PROBLEM", 97, 120], ["the bright red cheeks", "PROBLEM", 133, 154], ["the rash", "PROBLEM", 166, 174], ["common", "OBSERVATION_MODIFIER", 22, 28], ["childhood", "OBSERVATION_MODIFIER", 29, 38], ["rash", "OBSERVATION", 39, 43], ["erythema", "OBSERVATION", 53, 61], ["cheek", "ANATOMY", 106, 111], ["syndrome", "OBSERVATION", 112, 120], ["cheeks", "ANATOMY", 148, 154], ["rash", "OBSERVATION", 170, 174]]], ["We now know that this virus not only infects infants, but infection during pregnancy can seriously damage the developing foetus leading to hydrops fetalis and in some cases to spontaneous abortion.", [["foetus", "ANATOMY", 121, 127], ["infection", "DISEASE", 58, 67], ["hydrops fetalis", "DISEASE", 139, 154], ["infants", "ORGANISM", 45, 52], ["foetus", "ORGAN", 121, 127], ["infants", "SPECIES", 45, 52], ["this virus", "PROBLEM", 17, 27], ["infection", "PROBLEM", 58, 67], ["the developing foetus", "PROBLEM", 106, 127], ["hydrops fetalis", "PROBLEM", 139, 154], ["spontaneous abortion", "PROBLEM", 176, 196], ["infection", "OBSERVATION", 58, 67]]], ["B19 infection is also a problem in individuals with chronic haemolytic disease (e.g. sickle cell anaemia), as infection can result in a significant and dangerous depression of haemoglobin levels (aplastic crisis).", [["sickle cell", "ANATOMY", 85, 96], ["B19 infection", "DISEASE", 0, 13], ["chronic haemolytic disease", "DISEASE", 52, 78], ["sickle cell anaemia", "DISEASE", 85, 104], ["infection", "DISEASE", 110, 119], ["depression", "DISEASE", 162, 172], ["aplastic crisis", "DISEASE", 196, 211], ["B19", "ORGANISM", 0, 3], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 176, 187], ["B19", "SPECIES", 0, 3], ["B19 infection", "PROBLEM", 0, 13], ["chronic haemolytic disease", "PROBLEM", 52, 78], ["sickle cell anaemia", "PROBLEM", 85, 104], ["infection", "PROBLEM", 110, 119], ["a significant and dangerous depression of haemoglobin levels", "PROBLEM", 134, 194], ["aplastic crisis", "PROBLEM", 196, 211], ["infection", "OBSERVATION", 4, 13], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["haemolytic disease", "OBSERVATION", 60, 78], ["sickle cell anaemia", "OBSERVATION", 85, 104], ["significant", "OBSERVATION_MODIFIER", 136, 147], ["dangerous", "OBSERVATION_MODIFIER", 152, 161], ["depression", "OBSERVATION", 162, 172], ["aplastic crisis", "OBSERVATION", 196, 211]]], ["Development of other diagnostic techniques, particularly PCR, has resulted in EM now being rarely used for routine diagnosis of this virus, although it is occasionally used in reference laboratories where there are conflicting or equivocal results by other methods.", [["PCR", "TEST", 57, 60], ["this virus", "PROBLEM", 128, 138]]], ["Accurate diagnosis is important in pregnant women and those with haemolytic disorders as it can influence the clinical management of the patient.Viral gastroenteritis ::: Development of the use of electron microscopy within virology and bacteriologyGastroenteritis (diarrhoea and/or vomiting) is a common illness.", [["haemolytic disorders", "DISEASE", 65, 85], ["Viral gastroenteritis", "DISEASE", 145, 166], ["Gastroenteritis", "DISEASE", 249, 264], ["diarrhoea and/or vomiting", "DISEASE", 266, 291], ["women", "ORGANISM", 44, 49], ["patient", "ORGANISM", 137, 144], ["women", "SPECIES", 44, 49], ["patient", "SPECIES", 137, 144], ["haemolytic disorders", "PROBLEM", 65, 85], ["the clinical management", "TREATMENT", 106, 129], ["Viral gastroenteritis", "PROBLEM", 145, 166], ["electron microscopy", "TEST", 197, 216], ["bacteriologyGastroenteritis", "PROBLEM", 237, 264], ["diarrhoea", "PROBLEM", 266, 275], ["vomiting", "PROBLEM", 283, 291], ["a common illness", "PROBLEM", 296, 312], ["gastroenteritis", "OBSERVATION", 151, 166]]], ["There are many causative organisms, but most involve either bacterial infection (such as Camplylobacter or Salmonella) or viral infection.", [["bacterial infection", "DISEASE", 60, 79], ["Camplylobacter", "CHEMICAL", 89, 103], ["viral infection", "DISEASE", 122, 137], ["many causative organisms", "PROBLEM", 10, 34], ["bacterial infection", "PROBLEM", 60, 79], ["Camplylobacter", "PROBLEM", 89, 103], ["Salmonella", "PROBLEM", 107, 117], ["viral infection", "PROBLEM", 122, 137], ["many", "OBSERVATION_MODIFIER", 10, 14], ["causative organisms", "OBSERVATION", 15, 34], ["bacterial", "OBSERVATION_MODIFIER", 60, 69], ["infection", "OBSERVATION", 70, 79], ["viral", "OBSERVATION_MODIFIER", 122, 127], ["infection", "OBSERVATION", 128, 137]]], ["Infantile diarrhoea is a major cause of mortality in the developing world and even though relatively few infants die of gastroenteritis in the developed world, viral gastroenteritis is a leading cause of admissions to hospital of young children.", [["Infantile diarrhoea", "DISEASE", 0, 19], ["gastroenteritis", "DISEASE", 120, 135], ["viral gastroenteritis", "DISEASE", 160, 181], ["infants", "ORGANISM", 105, 112], ["children", "ORGANISM", 236, 244], ["infants", "SPECIES", 105, 112], ["children", "SPECIES", 236, 244], ["Infantile diarrhoea", "PROBLEM", 0, 19], ["gastroenteritis", "PROBLEM", 120, 135], ["viral gastroenteritis", "PROBLEM", 160, 181], ["diarrhoea", "OBSERVATION", 10, 19], ["mortality", "OBSERVATION", 40, 49], ["gastroenteritis", "OBSERVATION", 120, 135], ["viral gastroenteritis", "OBSERVATION", 160, 181]]], ["In the 1950s and 1960s it was assumed that viruses were associated with some diarrhoeal illness, but it was only with the availability of electron microscopes in the 1970s that these viral causes of gastroenteritis were elucidated.Viral gastroenteritis ::: Development of the use of electron microscopy within virology and bacteriologyAttempts to grow viruses thought to be associated with diarrhoeal symptoms in cell culture systems were common in the 1950s and 1960s.", [["cell culture", "ANATOMY", 413, 425], ["diarrhoeal illness", "DISEASE", 77, 95], ["gastroenteritis", "DISEASE", 199, 214], ["Viral gastroenteritis", "DISEASE", 231, 252], ["cell culture", "CELL", 413, 425], ["viruses", "PROBLEM", 43, 50], ["some diarrhoeal illness", "PROBLEM", 72, 95], ["electron microscopes", "TEST", 138, 158], ["gastroenteritis", "PROBLEM", 199, 214], ["Viral gastroenteritis", "PROBLEM", 231, 252], ["electron microscopy", "TEST", 283, 302], ["grow viruses", "PROBLEM", 347, 359], ["diarrhoeal symptoms", "PROBLEM", 390, 409], ["cell culture systems", "TEST", 413, 433], ["viruses", "OBSERVATION", 43, 50], ["gastroenteritis", "OBSERVATION", 199, 214], ["gastroenteritis", "OBSERVATION", 237, 252], ["viruses", "OBSERVATION", 352, 359]]], ["Some viruses could be grown from some stool samples, but it was subsequently shown that these were not the causative agents of viral gastroenteritis.", [["stool samples", "ANATOMY", 38, 51], ["viral gastroenteritis", "DISEASE", 127, 148], ["stool samples", "ORGANISM_SUBSTANCE", 38, 51], ["Some viruses", "PROBLEM", 0, 12], ["some stool samples", "TEST", 33, 51], ["viral gastroenteritis", "PROBLEM", 127, 148], ["viruses", "OBSERVATION", 5, 12], ["viral gastroenteritis", "OBSERVATION", 127, 148]]], ["Convincing evidence of an association between cultivable viruses and diarrhoea was rare.", [["cultivable viruses", "DISEASE", 46, 64], ["diarrhoea", "DISEASE", 69, 78], ["cultivable viruses", "PROBLEM", 46, 64], ["diarrhoea", "PROBLEM", 69, 78], ["cultivable", "OBSERVATION_MODIFIER", 46, 56], ["viruses", "OBSERVATION", 57, 64]]], ["However, in the early 1970s, EM was used to examine diarrhoeal samples from patients with no bacterial cause for their symptoms and a number of new, non-cultivable viruses were discovered.", [["samples", "ANATOMY", 63, 70], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["diarrhoeal samples", "PROBLEM", 52, 70], ["bacterial cause", "PROBLEM", 93, 108], ["their symptoms", "PROBLEM", 113, 127], ["new, non-cultivable viruses", "PROBLEM", 144, 171]]], ["Viruses were found to be common causes of infantile non-bacterial gastroenteritis and were responsible for many outbreaks of gastroenteritis in all age groups.", [["infantile non-bacterial gastroenteritis", "DISEASE", 42, 81], ["gastroenteritis", "DISEASE", 125, 140], ["Viruses", "PROBLEM", 0, 7], ["infantile non-bacterial gastroenteritis", "PROBLEM", 42, 81], ["gastroenteritis", "PROBLEM", 125, 140], ["infantile", "OBSERVATION_MODIFIER", 42, 51], ["non-bacterial gastroenteritis", "OBSERVATION", 52, 81], ["gastroenteritis", "OBSERVATION", 125, 140]]], ["The first of these viruses was Norwalk virus, which was derived from a community outbreak in Norwalk, OH, USA (Kapikian and Wyatt, 1972, Kapikian, 2000).", [["Norwalk virus", "ORGANISM", 31, 44], ["Norwalk virus", "SPECIES", 31, 44], ["Norwalk virus", "PROBLEM", 31, 44], ["viruses", "OBSERVATION", 19, 26]]], ["Using IEM, Kapikian and colleagues were able to demonstrate the presence of virus in volunteers who developed enteric symptoms after ingesting stool filtrates from samples from this outbreak.", [["samples", "ANATOMY", 164, 171], ["enteric symptoms", "DISEASE", 110, 126], ["volunteers", "ORGANISM", 85, 95], ["stool filtrates", "ORGANISM_SUBSTANCE", 143, 158], ["virus", "PROBLEM", 76, 81], ["enteric symptoms", "PROBLEM", 110, 126], ["stool filtrates", "PROBLEM", 143, 158], ["this outbreak", "PROBLEM", 177, 190], ["virus", "OBSERVATION", 76, 81]]], ["Under the electron microscope, the virus was characterised by its round shape, small size of 30\u201335 nm and its \u2018fuzzy\u2019 or ragged edge (Fig. 13).", [["the electron microscope", "TEST", 6, 29], ["the virus", "PROBLEM", 31, 40], ["virus", "OBSERVATION", 35, 40], ["round", "OBSERVATION_MODIFIER", 66, 71], ["shape", "OBSERVATION_MODIFIER", 72, 77], ["small", "OBSERVATION_MODIFIER", 79, 84], ["size", "OBSERVATION_MODIFIER", 85, 89], ["30\u201335 nm", "OBSERVATION_MODIFIER", 93, 101], ["ragged", "OBSERVATION_MODIFIER", 121, 127], ["edge", "OBSERVATION_MODIFIER", 128, 132]]], ["Similar viruses with the same morphology were discovered elsewhere and were given interim names such as \u2018Norwalk-like viruses\u2019 or \u2018small round structured viruses\u2019 (SRSVs) to reflect their appearance in the electron microscope (Caul and Appleton, 1982).", [["\u2018", "ORGANISM", 104, 105], ["Norwalk-like viruses", "ORGANISM", 105, 125], ["Similar viruses", "PROBLEM", 0, 15], ["\u2018Norwalk-like viruses\u2019", "PROBLEM", 104, 126], ["\u2018small round structured viruses", "PROBLEM", 130, 161], ["viruses", "OBSERVATION", 8, 15], ["small", "OBSERVATION_MODIFIER", 131, 136], ["round", "OBSERVATION_MODIFIER", 137, 142], ["structured", "OBSERVATION_MODIFIER", 143, 153], ["viruses", "OBSERVATION", 154, 161]]], ["The interim names for this group of viruses have recently been reviewed and they are now officially known as \u2018noroviruses\u2019 (Mayo, 2002).", [["viruses", "PROBLEM", 36, 43]]], ["Noroviruses are regarded as the commonest cause of non-bacterial gastroenteritis in developed countries.", [["Noroviruses", "DISEASE", 0, 11], ["gastroenteritis", "DISEASE", 65, 80], ["Noroviruses", "PROBLEM", 0, 11], ["non-bacterial gastroenteritis", "PROBLEM", 51, 80], ["non-bacterial", "OBSERVATION_MODIFIER", 51, 64], ["gastroenteritis", "OBSERVATION", 65, 80]]], ["They are highly infectious, readily transmissible from person to person and are also the most frequent and important cause of foodborne viral infections (Appleton, 2000).", [["foodborne viral infections", "DISEASE", 126, 152], ["person", "SPECIES", 55, 61], ["person", "SPECIES", 65, 71], ["foodborne viral infections", "PROBLEM", 126, 152], ["highly", "OBSERVATION_MODIFIER", 9, 15], ["infectious", "OBSERVATION", 16, 26]]], ["Until fairly recently, EM was the main method of norovirus detection, but has been largely superseded by EIA and PCR methods.Viral gastroenteritis ::: Development of the use of electron microscopy within virology and bacteriologyIn 1973 in Australia, Ruth Bishop and her team discovered a second virus associated with enteric symptoms in infants (Bishop et al., 1973).", [["Viral gastroenteritis", "DISEASE", 125, 146], ["enteric symptoms", "DISEASE", 318, 334], ["norovirus", "ORGANISM", 49, 58], ["infants", "ORGANISM", 338, 345], ["infants", "SPECIES", 338, 345], ["norovirus", "SPECIES", 49, 58], ["norovirus detection", "PROBLEM", 49, 68], ["EIA", "TEST", 105, 108], ["PCR methods", "TEST", 113, 124], ["Viral gastroenteritis", "PROBLEM", 125, 146], ["electron microscopy", "TEST", 177, 196], ["a second virus", "PROBLEM", 287, 301], ["enteric symptoms", "PROBLEM", 318, 334], ["norovirus", "OBSERVATION", 49, 58], ["gastroenteritis", "OBSERVATION", 131, 146]]], ["Using thin sections of resin embedded duodenal biopsy samples taken from infants with acute diarrhoea, she and her colleagues described a virus in the cytoplasm of duodenal enterocytes.", [["sections", "ANATOMY", 11, 19], ["duodenal biopsy samples", "ANATOMY", 38, 61], ["cytoplasm", "ANATOMY", 151, 160], ["duodenal enterocytes", "ANATOMY", 164, 184], ["acute diarrhoea", "DISEASE", 86, 101], ["resin", "TISSUE", 23, 28], ["duodenal biopsy samples", "CANCER", 38, 61], ["infants", "ORGANISM", 73, 80], ["cytoplasm", "ORGANISM_SUBSTANCE", 151, 160], ["duodenal enterocytes", "MULTI-TISSUE_STRUCTURE", 164, 184], ["duodenal enterocytes", "CELL_TYPE", 164, 184], ["infants", "SPECIES", 73, 80], ["resin embedded duodenal biopsy samples", "TEST", 23, 61], ["acute diarrhoea", "PROBLEM", 86, 101], ["a virus", "PROBLEM", 136, 143], ["duodenal", "ANATOMY", 38, 46], ["biopsy", "OBSERVATION", 47, 53], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["diarrhoea", "OBSERVATION", 92, 101], ["duodenal enterocytes", "ANATOMY", 164, 184]]], ["Elsewhere, examination of stool samples from similar patients by negative staining also demonstrated the presence of this new virus (Flewett et al., 1973), which because of its' wheel-like ultrastructure (Fig. 14) was named \u2018Rotavirus\u2019.", [["stool samples", "ANATOMY", 26, 39], ["Rotavirus", "DISEASE", 225, 234], ["stool samples", "ORGANISM_SUBSTANCE", 26, 39], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["examination of stool samples", "TEST", 11, 39], ["this new virus", "PROBLEM", 117, 131]]], ["Rotaviruses are now considered to be the most important enteric viral infection in infancy and are associated with an estimated 600,000 deaths per year, particularly in the developing world (Parashar et al., 2003).", [["Rotaviruses", "DISEASE", 0, 11], ["enteric viral infection", "DISEASE", 56, 79], ["deaths", "DISEASE", 136, 142], ["Rotaviruses", "PROBLEM", 0, 11], ["enteric viral infection", "PROBLEM", 56, 79], ["viral", "OBSERVATION_MODIFIER", 64, 69], ["infection", "OBSERVATION", 70, 79]]], ["In addition to human infection, rotaviruses also cause serious diarrhoeal disease in some animal species, such as cattle and sheep, where they have an economically important impact on farming.Viral gastroenteritis ::: Development of the use of electron microscopy within virology and bacteriologyTwo new adenoviruses associated with enteric symptoms were discovered by EM in stool samples in 1975 by Flewett et al. (1975).", [["stool samples", "ANATOMY", 375, 388], ["infection", "DISEASE", 21, 30], ["rotaviruses", "DISEASE", 32, 43], ["diarrhoeal disease", "DISEASE", 63, 81], ["Viral gastroenteritis", "DISEASE", 192, 213], ["enteric symptoms", "DISEASE", 333, 349], ["human", "ORGANISM", 15, 20], ["rotaviruses", "ORGANISM", 32, 43], ["sheep", "ORGANISM", 125, 130], ["adenoviruses", "ORGANISM", 304, 316], ["human", "SPECIES", 15, 20], ["rotaviruses", "SPECIES", 32, 43], ["cattle", "SPECIES", 114, 120], ["sheep", "SPECIES", 125, 130], ["human", "SPECIES", 15, 20], ["cattle", "SPECIES", 114, 120], ["sheep", "SPECIES", 125, 130], ["human infection", "PROBLEM", 15, 30], ["rotaviruses", "PROBLEM", 32, 43], ["serious diarrhoeal disease", "PROBLEM", 55, 81], ["Viral gastroenteritis", "PROBLEM", 192, 213], ["electron microscopy", "TEST", 244, 263], ["Two new adenoviruses", "PROBLEM", 296, 316], ["enteric symptoms", "PROBLEM", 333, 349], ["infection", "OBSERVATION", 21, 30], ["serious", "OBSERVATION_MODIFIER", 55, 62], ["diarrhoeal disease", "OBSERVATION", 63, 81], ["some animal species", "OBSERVATION_MODIFIER", 85, 104], ["gastroenteritis", "OBSERVATION", 198, 213], ["new", "OBSERVATION_MODIFIER", 300, 303], ["adenoviruses", "OBSERVATION", 304, 316], ["enteric", "ANATOMY", 333, 340], ["symptoms", "OBSERVATION", 341, 349]]], ["Adenoviruses already comprised a large group of antigenically distinct viruses causing a wide range of symptoms from mild respiratory illness and sore throats to tumours.", [["respiratory", "ANATOMY", 122, 133], ["tumours", "ANATOMY", 162, 169], ["respiratory illness", "DISEASE", 122, 141], ["sore throats", "DISEASE", 146, 158], ["tumours", "DISEASE", 162, 169], ["tumours", "CANCER", 162, 169], ["Adenoviruses", "PROBLEM", 0, 12], ["antigenically distinct viruses", "PROBLEM", 48, 78], ["symptoms", "PROBLEM", 103, 111], ["mild respiratory illness", "PROBLEM", 117, 141], ["sore throats to tumours", "PROBLEM", 146, 169], ["large", "OBSERVATION_MODIFIER", 33, 38], ["antigenically distinct", "OBSERVATION_MODIFIER", 48, 70], ["viruses", "OBSERVATION", 71, 78], ["wide range", "OBSERVATION_MODIFIER", 89, 99], ["mild", "OBSERVATION_MODIFIER", 117, 121], ["respiratory illness", "OBSERVATION", 122, 141], ["sore throats", "OBSERVATION", 146, 158]]], ["The two new adenoviruses, designated adenoviruses types 40 and 41 were specifically associated with gastroenteritis and formed a new group, the F adenoviruses (Gary et al., 1979).", [["gastroenteritis", "DISEASE", 100, 115], ["adenoviruses", "ORGANISM", 12, 24], ["adenoviruses types 40", "ORGANISM", 37, 58], ["adenoviruses", "ORGANISM", 146, 158], ["F adenoviruses", "SPECIES", 144, 158], ["The two new adenoviruses", "PROBLEM", 0, 24], ["gastroenteritis", "PROBLEM", 100, 115], ["two", "OBSERVATION_MODIFIER", 4, 7], ["new", "OBSERVATION_MODIFIER", 8, 11], ["adenoviruses", "OBSERVATION", 12, 24], ["gastroenteritis", "OBSERVATION", 100, 115]]], ["Unlike many other adenoviruses, these two new adenoviruses could not readily be cultured in the laboratory and hence became known as \u2018fastidious adenoviruses\u2019.", [["adenoviruses", "ORGANISM", 18, 30], ["adenoviruses", "ORGANISM", 46, 58], ["adenoviruses", "ORGANISM", 145, 157], ["many other adenoviruses", "PROBLEM", 7, 30], ["these two new adenoviruses", "PROBLEM", 32, 58], ["fastidious adenoviruses", "PROBLEM", 134, 157], ["adenoviruses", "OBSERVATION", 18, 30], ["new", "OBSERVATION_MODIFIER", 42, 45], ["adenoviruses", "OBSERVATION", 46, 58]]], ["All adenoviruses are morphologically identical.", [["adenoviruses", "ORGANISM", 4, 16], ["All adenoviruses", "TREATMENT", 0, 16], ["adenoviruses", "OBSERVATION", 4, 16]]], ["They are non-enveloped icosahedral viruses with a diameter of about 80 nm (Fig. 15).Viral gastroenteritis ::: Development of the use of electron microscopy within virology and bacteriologyHuman astroviruses were discovered by EM of stool samples from infants with diarrhoea in 1975 (Appleton and Higgins, 1975, Madeley and Cosgrove, 1975).", [["astroviruses", "ANATOMY", 194, 206], ["stool samples", "ANATOMY", 232, 245], ["Viral gastroenteritis", "DISEASE", 84, 105], ["diarrhoea", "DISEASE", 264, 273], ["Human", "ORGANISM", 188, 193], ["astroviruses", "CANCER", 194, 206], ["stool samples", "ORGANISM_SUBSTANCE", 232, 245], ["infants", "ORGANISM", 251, 258], ["Human", "SPECIES", 188, 193], ["infants", "SPECIES", 251, 258], ["Human", "SPECIES", 188, 193], ["Viral gastroenteritis", "PROBLEM", 84, 105], ["electron microscopy", "TEST", 136, 155], ["Human astroviruses", "PROBLEM", 188, 206], ["stool samples", "TEST", 232, 245], ["diarrhoea", "PROBLEM", 264, 273], ["non-enveloped", "OBSERVATION_MODIFIER", 9, 22], ["icosahedral viruses", "OBSERVATION", 23, 42], ["diameter", "OBSERVATION_MODIFIER", 50, 58], ["80 nm", "OBSERVATION_MODIFIER", 68, 73], ["gastroenteritis", "OBSERVATION", 90, 105]]], ["Astroviruses are morphologically distinct from other enteric viruses, being about 28 nm in diameter with a five or six-pointed surface star (Fig. 16).", [["Astroviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["Astroviruses", "PROBLEM", 0, 12], ["other enteric viruses", "PROBLEM", 47, 68], ["enteric", "OBSERVATION_MODIFIER", 53, 60], ["viruses", "OBSERVATION", 61, 68], ["28 nm", "OBSERVATION_MODIFIER", 82, 87]]], ["They often appear to be smooth-edged, but do not pack closely when observed in large groups.", [["smooth", "OBSERVATION_MODIFIER", 24, 30]]], ["Surface projections were thought to be the reason that the viruses could not pack closely (Appleton and Higgins, 1975, Caul and Appleton, 1982) and the presence of these has been confirmed by Risco et al. (1995).", [["the viruses", "PROBLEM", 55, 66], ["thought to be", "UNCERTAINTY", 25, 38], ["viruses", "OBSERVATION", 59, 66]]], ["Human astroviruses tend to cause a less severe diarrhoea in infants than rotavirus infection and eight astrovirus serotypes are known.", [["diarrhoea", "DISEASE", 47, 56], ["rotavirus infection", "DISEASE", 73, 92], ["astrovirus", "DISEASE", 103, 113], ["Human", "ORGANISM", 0, 5], ["infants", "ORGANISM", 60, 67], ["rotavirus", "ORGANISM", 73, 82], ["Human", "SPECIES", 0, 5], ["infants", "SPECIES", 60, 67], ["Human", "SPECIES", 0, 5], ["rotavirus", "SPECIES", 73, 82], ["Human astroviruses", "PROBLEM", 0, 18], ["a less severe diarrhoea in infants", "PROBLEM", 33, 67], ["rotavirus infection", "PROBLEM", 73, 92], ["eight astrovirus serotypes", "PROBLEM", 97, 123], ["less", "OBSERVATION_MODIFIER", 35, 39], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["diarrhoea", "OBSERVATION", 47, 56], ["astrovirus serotypes", "OBSERVATION", 103, 123]]], ["Astroviruses have also been found in several other mammalian and avian species (Kurtz and Lee, 1987).Viral gastroenteritis ::: Development of the use of electron microscopy within virology and bacteriologyWhilst looking at stool samples from infants with diarrhoea another virus related to the noroviruses but with distinctive morphology was found.", [["stool samples", "ANATOMY", 223, 236], ["Viral gastroenteritis", "DISEASE", 101, 122], ["diarrhoea", "DISEASE", 255, 264], ["noroviruses", "DISEASE", 294, 305], ["Astroviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["stool samples", "ORGANISM_SUBSTANCE", 223, 236], ["infants", "ORGANISM", 242, 249], ["infants", "SPECIES", 242, 249], ["Astroviruses", "PROBLEM", 0, 12], ["Viral gastroenteritis", "PROBLEM", 101, 122], ["electron microscopy", "TEST", 153, 172], ["stool samples", "TEST", 223, 236], ["diarrhoea", "PROBLEM", 255, 264], ["another virus", "PROBLEM", 265, 278], ["the noroviruses", "PROBLEM", 290, 305], ["avian species", "OBSERVATION", 65, 78], ["gastroenteritis", "OBSERVATION", 107, 122], ["noroviruses", "OBSERVATION", 294, 305]]], ["This virus had the appearance of a calicivirus, being about 32\u201335 nm in diameter with surface hollows (Madeley and Cosgrove, 1976).", [["surface", "ANATOMY", 86, 93], ["calicivirus", "DISEASE", 35, 46], ["calicivirus", "ORGANISM", 35, 46], ["This virus", "PROBLEM", 0, 10], ["a calicivirus", "PROBLEM", 33, 46], ["calicivirus", "OBSERVATION", 35, 46], ["diameter", "OBSERVATION_MODIFIER", 72, 80], ["surface", "OBSERVATION_MODIFIER", 86, 93]]], ["Enterically transmitted caliciviruses are now named sapoviruses (Kogasaka et al., 1981) and are most often associated with gastroenteritis in young children (whereas noroviruses infect all age groups).", [["Enterically transmitted caliciviruses", "DISEASE", 0, 37], ["gastroenteritis", "DISEASE", 123, 138], ["noroviruses", "DISEASE", 166, 177], ["caliciviruses", "CANCER", 24, 37], ["children", "ORGANISM", 148, 156], ["children", "SPECIES", 148, 156], ["Enterically transmitted caliciviruses", "PROBLEM", 0, 37], ["gastroenteritis", "PROBLEM", 123, 138], ["caliciviruses", "OBSERVATION", 24, 37], ["gastroenteritis", "OBSERVATION", 123, 138]]], ["The two viruses have morphological similarities and both are classified in the Calicivirus family, although in separate genera.Viral gastroenteritis ::: Development of the use of electron microscopy within virology and bacteriologySome electron microscopy units struggled to correctly identify the smaller and often taxonomically unclassified viruses found in faecal specimens, such as astroviruses and noroviruses.", [["faecal specimens", "ANATOMY", 360, 376], ["Viral gastroenteritis", "DISEASE", 127, 148], ["noroviruses", "DISEASE", 403, 414], ["faecal specimens", "ORGANISM_SUBSTANCE", 360, 376], ["Viral gastroenteritis", "PROBLEM", 127, 148], ["electron microscopy", "TEST", 179, 198], ["Some electron microscopy units", "TEST", 231, 261], ["the smaller and often taxonomically unclassified viruses", "PROBLEM", 294, 350], ["faecal specimens", "PROBLEM", 360, 376], ["astroviruses", "PROBLEM", 386, 398], ["noroviruses", "PROBLEM", 403, 414], ["two", "OBSERVATION_MODIFIER", 4, 7], ["viruses", "OBSERVATION", 8, 15], ["Calicivirus", "OBSERVATION", 79, 90], ["gastroenteritis", "OBSERVATION", 133, 148], ["smaller", "OBSERVATION_MODIFIER", 298, 305], ["viruses", "OBSERVATION", 343, 350], ["faecal specimens", "OBSERVATION", 360, 376], ["astroviruses", "OBSERVATION", 386, 398], ["noroviruses", "OBSERVATION", 403, 414]]], ["This led to an interim scheme for classification based on the morphological appearance of the various viruses in the electron microscope (Caul and Appleton, 1982).", [["various viruses", "OBSERVATION", 94, 109]]], ["This \u2018interim\u2019 scheme remained useful for a number of years until advances in molecular techniques led to the development of alternative diagnostic tests and a more definitive classification for these viruses.Investigation of outbreaks of viral gastroenteritis ::: Development of the use of electron microscopy within virology and bacteriologyThe Public Health Laboratory Service (PHLS) within England and Wales, now superseded by the Health Protection Agency, originally sited many electron microscopes in laboratories near to significant concentrations of population to investigate gastroenteritis.", [["viral gastroenteritis", "DISEASE", 239, 260], ["gastroenteritis", "DISEASE", 584, 599], ["alternative diagnostic tests", "TEST", 125, 153], ["these viruses", "PROBLEM", 195, 208], ["viral gastroenteritis", "PROBLEM", 239, 260], ["electron microscopy", "TEST", 291, 310], ["gastroenteritis", "PROBLEM", 584, 599], ["viruses", "OBSERVATION", 201, 208], ["viral gastroenteritis", "OBSERVATION", 239, 260], ["gastroenteritis", "OBSERVATION", 584, 599]]], ["However, by the late 1990s, EM within the PHLS was in decline due to the introduction of new methods of virus detection that were more sensitive than EM and could readily be used for dealing with large numbers of specimens, although initially these tests were only available in specialised laboratories.", [["specimens", "ANATOMY", 213, 222], ["specimens", "CANCER", 213, 222], ["virus detection", "TEST", 104, 119], ["large numbers of specimens", "PROBLEM", 196, 222], ["these tests", "TEST", 243, 254]]], ["The reduction in EM facilities necessitated a rationalised virological EM specimen testing policy for the investigation of outbreaks of viral gastroenteritis (Curry et al., 1999).", [["viral gastroenteritis", "DISEASE", 136, 157], ["viral gastroenteritis", "PROBLEM", 136, 157], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["viral gastroenteritis", "OBSERVATION", 136, 157]]], ["Large numbers of outbreaks with many specimens being generated from each outbreak, could not be handled by the remaining PHLS EM facilities and in order to give a good diagnostic service with limited facilities it was necessary for the number of samples examined from each outbreak to be restricted.", [["specimens", "ANATOMY", 37, 46], ["Large numbers of outbreaks", "PROBLEM", 0, 26], ["many specimens", "PROBLEM", 32, 46], ["numbers", "OBSERVATION_MODIFIER", 6, 13], ["outbreaks", "OBSERVATION_MODIFIER", 17, 26]]], ["It had been recognised that most community outbreaks of gastroenteritis were caused by noroviruses and hence if two or more samples were found to be norovirus positive, then the outbreak was declared to be a positive norovirus outbreak and no further samples were examined.", [["samples", "ANATOMY", 124, 131], ["samples", "ANATOMY", 251, 258], ["gastroenteritis", "DISEASE", 56, 71], ["noroviruses", "DISEASE", 87, 98], ["norovirus", "DISEASE", 149, 158], ["norovirus", "DISEASE", 217, 226], ["samples", "CANCER", 124, 131], ["norovirus", "ORGANISM", 149, 158], ["samples", "CANCER", 251, 258], ["gastroenteritis", "PROBLEM", 56, 71], ["noroviruses", "PROBLEM", 87, 98], ["norovirus positive", "PROBLEM", 149, 167], ["a positive norovirus outbreak", "PROBLEM", 206, 235], ["further samples", "TEST", 243, 258], ["most", "OBSERVATION_MODIFIER", 28, 32], ["community", "OBSERVATION_MODIFIER", 33, 42], ["gastroenteritis", "OBSERVATION", 56, 71], ["noroviruses", "OBSERVATION", 87, 98], ["positive", "OBSERVATION_MODIFIER", 208, 216], ["norovirus", "OBSERVATION", 217, 226]]], ["This testing algorithm allowed EM units to continue to diagnose norovirus infections until widespread use of specific PCR tests for noroviruses were adopted in routine virus laboratories or specific norovirus EIAs became commercially available.", [["norovirus infections", "DISEASE", 64, 84], ["noroviruses", "DISEASE", 132, 143], ["norovirus", "DISEASE", 199, 208], ["norovirus", "ORGANISM", 64, 73], ["noroviruses", "ORGANISM", 132, 143], ["norovirus", "ORGANISM", 199, 208], ["norovirus", "SPECIES", 64, 73], ["norovirus", "SPECIES", 199, 208], ["This testing algorithm", "TEST", 0, 22], ["norovirus infections", "PROBLEM", 64, 84], ["specific PCR tests", "TEST", 109, 127], ["noroviruses", "PROBLEM", 132, 143], ["routine virus laboratories", "TEST", 160, 186], ["specific norovirus EIAs", "TEST", 190, 213]]], ["Norovirus EIAs were introduced to the UK during the latter half of 2002.", [["Norovirus", "DISEASE", 0, 9], ["Norovirus", "ORGANISM", 0, 9], ["Norovirus EIAs", "PROBLEM", 0, 14]]], ["Norovirus EIA and PCR tests are in the process of or have now superseded EM as the front-line tests for the investigation of non-bacterial gastroenteritis outbreaks in routine virology laboratories.Polyomaviruses ::: Development of the use of electron microscopy within virology and bacteriologyTwo new human polyomaviruses, which are members of the papovavirus group, were discovered by electron microscopy.", [["gastroenteritis", "DISEASE", 139, 154], ["Norovirus", "ORGANISM", 0, 9], ["human", "ORGANISM", 303, 308], ["polyomaviruses", "ORGANISM", 309, 323], ["papovavirus", "GENE_OR_GENE_PRODUCT", 350, 361], ["human", "SPECIES", 303, 308], ["human polyomaviruses", "SPECIES", 303, 323], ["Norovirus EIA", "TEST", 0, 13], ["PCR tests", "TEST", 18, 27], ["the front-line tests", "TEST", 79, 99], ["non-bacterial gastroenteritis", "PROBLEM", 125, 154], ["electron microscopy", "TEST", 243, 262], ["new human polyomaviruses", "PROBLEM", 299, 323], ["electron microscopy", "TEST", 388, 407], ["non-bacterial", "OBSERVATION_MODIFIER", 125, 138], ["gastroenteritis", "OBSERVATION", 139, 154]]], ["These viruses are called BK virus and JC virus.", [["BK virus", "ORGANISM", 25, 33], ["JC virus", "ORGANISM", 38, 46], ["BK virus", "SPECIES", 25, 33], ["BK virus", "SPECIES", 25, 33], ["JC virus", "SPECIES", 38, 46], ["These viruses", "PROBLEM", 0, 13], ["BK virus", "PROBLEM", 25, 33], ["JC virus", "PROBLEM", 38, 46], ["viruses", "OBSERVATION", 6, 13], ["JC virus", "OBSERVATION", 38, 46]]], ["Both are about 45 nm in diameter and feature skewed symmetry of the proteins (capsomeres) making up the capsid of the virus.", [["capsomeres", "SIMPLE_CHEMICAL", 78, 88], ["capsomeres", "PROTEIN", 78, 88], ["the virus", "PROBLEM", 114, 123], ["45 nm", "OBSERVATION_MODIFIER", 15, 20], ["skewed", "OBSERVATION_MODIFIER", 45, 51], ["symmetry", "OBSERVATION_MODIFIER", 52, 60], ["virus", "OBSERVATION", 118, 123]]], ["JC virus was originally discovered in thin sections of brain biopsies from patients with progressive multifocal leucoencephalopathy (Zu Rhein and Chou, 1965), whereas BK virus (Fig. 18) was found in negatively stained preparations of urine from organ transplant patients (Gardner et al., 1971).", [["sections", "ANATOMY", 43, 51], ["brain biopsies", "ANATOMY", 55, 69], ["urine", "ANATOMY", 234, 239], ["organ", "ANATOMY", 245, 250], ["multifocal leucoencephalopathy", "DISEASE", 101, 131], ["JC virus", "ORGANISM", 0, 8], ["thin sections", "MULTI-TISSUE_STRUCTURE", 38, 51], ["brain biopsies", "MULTI-TISSUE_STRUCTURE", 55, 69], ["patients", "ORGANISM", 75, 83], ["BK virus", "ORGANISM", 167, 175], ["urine", "ORGANISM_SUBSTANCE", 234, 239], ["organ", "ORGAN", 245, 250], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 262, 270], ["JC virus", "SPECIES", 0, 8], ["BK virus", "SPECIES", 167, 175], ["JC virus", "PROBLEM", 0, 8], ["brain biopsies", "TEST", 55, 69], ["progressive multifocal leucoencephalopathy", "PROBLEM", 89, 131], ["BK virus", "PROBLEM", 167, 175], ["brain", "ANATOMY", 55, 60], ["biopsies", "OBSERVATION", 61, 69], ["progressive", "OBSERVATION_MODIFIER", 89, 100], ["multifocal", "OBSERVATION_MODIFIER", 101, 111], ["leucoencephalopathy", "OBSERVATION", 112, 131]]], ["Infection is common and usually goes unnoticed, but virus may become reactivated and cause symptoms in immunosuppressed patients, such as organ transplant recipients.", [["organ", "ANATOMY", 138, 143], ["Infection", "DISEASE", 0, 9], ["patients", "ORGANISM", 120, 128], ["organ", "ORGAN", 138, 143], ["patients", "SPECIES", 120, 128], ["Infection", "PROBLEM", 0, 9], ["virus", "PROBLEM", 52, 57], ["symptoms", "PROBLEM", 91, 99], ["immunosuppressed patients", "PROBLEM", 103, 128], ["organ transplant recipients", "TREATMENT", 138, 165]]], ["Immune EM was used for specific diagnosis of these two viruses until the development of molecular tests.Skin lesion investigation and deliberate release of dangerous pathogens. ::: Current and future use of electron microscopy within virologyElectron microscopy still has an important role in the investigation of skin lesions as any viral pathogen involved can be detected and identified within 30 min of receipt of the sample.", [["Skin lesion", "ANATOMY", 104, 115], ["skin lesions", "ANATOMY", 314, 326], ["sample", "ANATOMY", 421, 427], ["Skin", "ORGAN", 104, 108], ["skin lesions", "CANCER", 314, 326], ["these two viruses", "PROBLEM", 45, 62], ["molecular tests", "TEST", 88, 103], ["Skin lesion investigation", "PROBLEM", 104, 129], ["dangerous pathogens", "PROBLEM", 156, 175], ["electron microscopy", "TEST", 207, 226], ["Electron microscopy", "TEST", 242, 261], ["skin lesions", "PROBLEM", 314, 326], ["any viral pathogen", "PROBLEM", 330, 348], ["the sample", "TEST", 417, 427], ["lesion", "OBSERVATION", 109, 115], ["dangerous pathogens", "OBSERVATION", 156, 175], ["skin", "ANATOMY", 314, 318], ["lesions", "OBSERVATION", 319, 326]]], ["A skilled electron microscopist can distinguish herpesviruses (Fig. 5) from the various poxviruses (Fig. 4, Fig. 11) and papilloma viruses in skin scrapings or aspirated fluid from a lesion.", [["skin scrapings", "ANATOMY", 142, 156], ["fluid", "ANATOMY", 170, 175], ["lesion", "ANATOMY", 183, 189], ["papilloma viruses", "DISEASE", 121, 138], ["herpesviruses", "ORGANISM", 48, 61], ["Fig. 5", "ORGANISM", 63, 69], ["papilloma viruses", "ORGANISM", 121, 138], ["skin scrapings", "TISSUE", 142, 156], ["lesion", "CANCER", 183, 189], ["A skilled electron microscopist", "TEST", 0, 31], ["herpesviruses", "PROBLEM", 48, 61], ["the various poxviruses", "PROBLEM", 76, 98], ["papilloma viruses in skin scrapings", "PROBLEM", 121, 156], ["aspirated fluid", "PROBLEM", 160, 175], ["a lesion", "PROBLEM", 181, 189], ["papilloma viruses", "OBSERVATION", 121, 138], ["skin", "ANATOMY", 142, 146], ["scrapings", "OBSERVATION", 147, 156], ["aspirated fluid", "OBSERVATION", 160, 175], ["lesion", "OBSERVATION", 183, 189]]], ["Such investigation is important, particularly if the patient is immunocompromised or on a ward with other immunocompromised patients.", [["patient", "ORGANISM", 53, 60], ["patients", "ORGANISM", 124, 132], ["patient", "SPECIES", 53, 60], ["patients", "SPECIES", 124, 132], ["immunocompromised", "PROBLEM", 64, 81], ["immunocompromised", "OBSERVATION", 64, 81]]], ["Rapid availability of diagnostic results can positively influence patient management.Skin lesion investigation and deliberate release of dangerous pathogens. ::: Current and future use of electron microscopy within virologyElectron microscopy will have a vital frontline diagnostic role in the event of biological agents being deliberately released into the community and it is, therefore, essential that expertise be maintained (Miller, 2003).", [["Skin lesion", "ANATOMY", 85, 96], ["patient", "ORGANISM", 66, 73], ["Skin", "ORGAN", 85, 89], ["patient", "SPECIES", 66, 73], ["patient management", "TREATMENT", 66, 84], ["Skin lesion investigation", "PROBLEM", 85, 110], ["dangerous pathogens", "PROBLEM", 137, 156], ["electron microscopy", "TEST", 188, 207], ["Electron microscopy", "TEST", 223, 242], ["biological agents", "TREATMENT", 303, 320], ["lesion", "OBSERVATION", 90, 96], ["dangerous pathogens", "OBSERVATION", 137, 156]]], ["The terrible events of September 11th 2001 and the unrelated deliberate release of anthrax spores in the USA at around the same time has alerted most countries to the serious consequences of deliberate release of other infectious agents such as smallpox.", [["anthrax", "DISEASE", 83, 90], ["smallpox", "DISEASE", 245, 253], ["anthrax spores", "PROBLEM", 83, 97], ["other infectious agents", "TREATMENT", 213, 236], ["terrible", "OBSERVATION_MODIFIER", 4, 12]]], ["Diagnostic facilities must be in place to rapidly identify the causative agent present in atypical or suspicious skin lesions, be it smallpox or other viruses, so that unnecessary public panic can be avoided and appropriate control measures established.", [["skin lesions", "ANATOMY", 113, 125], ["smallpox", "DISEASE", 133, 141], ["panic", "DISEASE", 187, 192], ["skin lesions", "PATHOLOGICAL_FORMATION", 113, 125], ["suspicious skin lesions", "PROBLEM", 102, 125], ["smallpox", "PROBLEM", 133, 141], ["other viruses", "PROBLEM", 145, 158], ["public panic", "TREATMENT", 180, 192], ["suspicious", "OBSERVATION_MODIFIER", 102, 112], ["skin", "ANATOMY", 113, 117], ["lesions", "OBSERVATION", 118, 125]]], ["Electron microscopy has an important role in a rapid emergency diagnostic service and must be maintained as part of a balanced diagnostic response system, so that only orthopox samples are referred to specialist centres for definitive identification by molecular typing.", [["orthopox samples", "ANATOMY", 168, 184], ["orthopox samples", "CANCER", 168, 184], ["Electron microscopy", "TEST", 0, 19], ["molecular typing", "TEST", 253, 269]]], ["Such a system requires a small network of well supported regionally based EM units with the necessary staff expertise in place to monitor viruses associated with skin lesions and to act as an early warning to the deliberate release of smallpox or other microbial agents.", [["skin lesions", "ANATOMY", 162, 174], ["smallpox", "DISEASE", 235, 243], ["skin lesions", "PATHOLOGICAL_FORMATION", 162, 174], ["viruses", "PROBLEM", 138, 145], ["skin lesions", "PROBLEM", 162, 174], ["smallpox", "TREATMENT", 235, 243], ["other microbial agents", "TREATMENT", 247, 269], ["small", "OBSERVATION_MODIFIER", 25, 30], ["skin", "ANATOMY", 162, 166], ["lesions", "OBSERVATION", 167, 174]]], ["The risk of smallpox reappearing is small, but if a terrorist group were to obtain the virus, the possibility exists that it could be genetically modified to accentuate its pathogenic traits.", [["smallpox", "DISEASE", 12, 20], ["the virus", "PROBLEM", 83, 92], ["its pathogenic traits", "PROBLEM", 169, 190], ["smallpox", "OBSERVATION", 12, 20], ["small", "OBSERVATION_MODIFIER", 36, 41]]], ["A consequence of this would be that primers used in specific smallpox PCR tests might not amplify the nucleic acid, thereby rendering PCR as a means of diagnosis temporarily invalid.", [["nucleic acid", "CHEMICAL", 102, 114], ["primers", "PROBLEM", 36, 43], ["specific smallpox PCR tests", "TEST", 52, 79], ["the nucleic acid", "TEST", 98, 114], ["PCR", "TEST", 134, 137]]], ["Such a modified virus would still be recognisable morphologically as a poxvirus under the electron microscope.", [["a modified virus", "PROBLEM", 5, 21], ["the electron microscope", "TEST", 86, 109]]], ["This presents strong justification for the need to keep a network of microscopes and microscopists skilled in viral diagnosis, since EM is not dependant on detection of viral nucleic acid or expressed antigen.Skin lesion investigation and deliberate release of dangerous pathogens. ::: Current and future use of electron microscopy within virologyAlthough smallpox is an exclusively human pathogen with no animal reservoir, other poxviruses can mimic its clinical symptoms.", [["Skin lesion", "ANATOMY", 209, 220], ["nucleic acid", "CHEMICAL", 175, 187], ["smallpox", "DISEASE", 356, 364], ["Skin", "ORGAN", 209, 213], ["human", "ORGANISM", 383, 388], ["poxviruses", "ORGANISM", 430, 440], ["viral nucleic acid or expressed antigen", "PROTEIN", 169, 208], ["human", "SPECIES", 383, 388], ["human", "SPECIES", 383, 388], ["viral nucleic acid", "PROBLEM", 169, 187], ["expressed antigen", "PROBLEM", 191, 208], ["Skin lesion investigation", "PROBLEM", 209, 234], ["dangerous pathogens", "PROBLEM", 261, 280], ["electron microscopy", "TEST", 312, 331], ["smallpox", "PROBLEM", 356, 364], ["animal reservoir", "TREATMENT", 406, 422], ["other poxviruses", "TREATMENT", 424, 440], ["its clinical symptoms", "PROBLEM", 451, 472], ["lesion", "OBSERVATION", 214, 220], ["dangerous pathogens", "OBSERVATION", 261, 280]]], ["During 2003, monkeypox (a virus similar to smallpox) was detected by EM in humans in the USA (Fig. 4).", [["monkeypox", "DISEASE", 13, 22], ["smallpox", "DISEASE", 43, 51], ["monkeypox", "ORGANISM", 13, 22], ["humans", "ORGANISM", 75, 81], ["humans", "SPECIES", 75, 81], ["humans", "SPECIES", 75, 81], ["monkeypox", "PROBLEM", 13, 22], ["a virus", "PROBLEM", 24, 31]]], ["Prior to this, it was thought that monkeypox only occurred in the tropical forest regions of Africa, where it was fatal in up to 10% of human cases.", [["monkeypox", "DISEASE", 35, 44], ["monkeypox", "ORGANISM", 35, 44], ["human", "ORGANISM", 136, 141], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 136, 141], ["monkeypox", "PROBLEM", 35, 44], ["monkeypox", "OBSERVATION", 35, 44]]], ["Some clinicians who had treated infected individuals in the USA outbreak had initially mistaken the monkeypox lesions for smallpox or chickenpox (Reed et al., 2004).", [["lesions", "ANATOMY", 110, 117], ["monkeypox lesions", "DISEASE", 100, 117], ["smallpox", "DISEASE", 122, 130], ["chickenpox", "DISEASE", 134, 144], ["individuals", "ORGANISM", 41, 52], ["monkeypox", "ORGANISM", 100, 109], ["lesions", "PATHOLOGICAL_FORMATION", 110, 117], ["the monkeypox lesions", "PROBLEM", 96, 117], ["smallpox", "PROBLEM", 122, 130], ["chickenpox", "PROBLEM", 134, 144]]], ["Most infections appeared in owners of exotic pet rodents or workers in veterinary centres or pet shops.", [["infections", "DISEASE", 5, 15], ["Most infections", "PROBLEM", 0, 15], ["infections", "OBSERVATION", 5, 15]]], ["Other unrelated cases of unusual orthopoxvirus infections have recently been reported.", [["orthopoxvirus infections", "DISEASE", 33, 57], ["unusual orthopoxvirus infections", "PROBLEM", 25, 57], ["unusual", "OBSERVATION_MODIFIER", 25, 32], ["orthopoxvirus", "OBSERVATION_MODIFIER", 33, 46], ["infections", "OBSERVATION", 47, 57]]], ["A case of severe generalized cowpox infection has recently been seen in Finland and was diagnosed using EM, cell culture (virus isolation) and molecular techniques (Pelkonen et al., 2003).", [["cell", "ANATOMY", 108, 112], ["cowpox infection", "DISEASE", 29, 45], ["cowpox", "ORGANISM", 29, 35], ["cell", "CELL", 108, 112], ["severe generalized cowpox infection", "PROBLEM", 10, 45], ["cell culture", "TEST", 108, 120], ["virus isolation", "TREATMENT", 122, 137], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["generalized", "OBSERVATION_MODIFIER", 17, 28], ["cowpox infection", "OBSERVATION", 29, 45]]], ["In the USA, a woman who was revaccinated against smallpox showed a variety of symptoms including lesions on the face, legs, trunk and upper extremities (Miller et al., 2003).", [["lesions", "ANATOMY", 97, 104], ["face", "ANATOMY", 112, 116], ["legs", "ANATOMY", 118, 122], ["trunk", "ANATOMY", 124, 129], ["upper extremities", "ANATOMY", 134, 151], ["smallpox", "DISEASE", 49, 57], ["woman", "ORGANISM", 14, 19], ["lesions", "PATHOLOGICAL_FORMATION", 97, 104], ["face", "ORGANISM_SUBDIVISION", 112, 116], ["legs", "ORGANISM_SUBDIVISION", 118, 122], ["trunk", "ORGANISM_SUBDIVISION", 124, 129], ["upper extremities", "ORGANISM_SUBDIVISION", 134, 151], ["woman", "SPECIES", 14, 19], ["smallpox", "PROBLEM", 49, 57], ["symptoms", "PROBLEM", 78, 86], ["lesions on the face, legs, trunk and upper extremities", "PROBLEM", 97, 151], ["variety", "OBSERVATION_MODIFIER", 67, 74], ["lesions", "OBSERVATION", 97, 104], ["face", "ANATOMY", 112, 116], ["legs", "ANATOMY", 118, 122], ["trunk", "ANATOMY", 124, 129], ["upper extremities", "ANATOMY", 134, 151]]], ["The presence of orthopoxviruses in lesion fluid was demonstrated by electron microscopy.", [["lesion fluid", "ANATOMY", 35, 47], ["orthopoxviruses", "GENE_OR_GENE_PRODUCT", 16, 31], ["lesion fluid", "ORGANISM_SUBSTANCE", 35, 47], ["orthopoxviruses in lesion fluid", "PROBLEM", 16, 47], ["electron microscopy", "TEST", 68, 87], ["orthopoxviruses", "OBSERVATION", 16, 31], ["lesion", "OBSERVATION_MODIFIER", 35, 41], ["fluid", "OBSERVATION", 42, 47]]], ["This was the first report of generalized vaccinia among civilians receiving vaccination against smallpox in the current heightened alert state and highlights the concerns associated with the re-introduction of widespread use of smallpox vaccine.Investigation of viral gastroenteritis ::: Current and future use of electron microscopy within virologyThe introduction of commercial EIAs for detection of rotaviruses, adenoviruses and noroviruses in many laboratories has greatly reduced the reliance on EM for investigation of both infantile gastroenteritis and outbreaks.", [["vaccinia", "DISEASE", 41, 49], ["smallpox", "DISEASE", 96, 104], ["viral gastroenteritis", "DISEASE", 262, 283], ["noroviruses", "DISEASE", 432, 443], ["infantile gastroenteritis", "DISEASE", 530, 555], ["vaccinia", "ORGANISM", 41, 49], ["smallpox", "ORGANISM", 228, 236], ["rotaviruses", "ORGANISM", 402, 413], ["adenoviruses", "ORGANISM", 415, 427], ["generalized vaccinia", "PROBLEM", 29, 49], ["vaccination", "TREATMENT", 76, 87], ["smallpox", "TREATMENT", 96, 104], ["smallpox vaccine", "TREATMENT", 228, 244], ["viral gastroenteritis", "PROBLEM", 262, 283], ["electron microscopy", "TEST", 314, 333], ["commercial EIAs", "TEST", 369, 384], ["rotaviruses", "PROBLEM", 402, 413], ["adenoviruses", "PROBLEM", 415, 427], ["noroviruses", "PROBLEM", 432, 443], ["both infantile gastroenteritis", "PROBLEM", 525, 555], ["viral gastroenteritis", "OBSERVATION", 262, 283], ["rotaviruses", "OBSERVATION", 402, 413], ["noroviruses", "OBSERVATION", 432, 443], ["infantile", "OBSERVATION_MODIFIER", 530, 539], ["gastroenteritis", "OBSERVATION", 540, 555]]], ["Some virus laboratories that have retained EM still use it to examine EIA negative samples for other enteric viruses, for example, astroviruses and sapoviruses, and to investigate discrepant results from other tests.", [["Some virus laboratories", "TEST", 0, 23], ["EIA", "TEST", 70, 73], ["other enteric viruses", "PROBLEM", 95, 116], ["astroviruses", "PROBLEM", 131, 143], ["other tests", "TEST", 204, 215], ["virus", "OBSERVATION", 5, 10], ["viruses", "OBSERVATION", 109, 116]]], ["There is, however, great genetic diversity among norovirus strains, and strains may change from year to year.", [["norovirus", "ORGANISM", 49, 58], ["norovirus strains", "PROBLEM", 49, 66], ["strains", "PROBLEM", 72, 79], ["great", "OBSERVATION_MODIFIER", 19, 24], ["genetic", "OBSERVATION_MODIFIER", 25, 32], ["diversity", "OBSERVATION_MODIFIER", 33, 42], ["norovirus strains", "OBSERVATION", 49, 66]]], ["Noroviruses may not always be detectable by EIA or PCR assays in routine use, but may still be visualised by EM.", [["Noroviruses", "PROBLEM", 0, 11], ["EIA", "TEST", 44, 47], ["PCR assays", "TEST", 51, 61]]], ["If strains of noroviruses detected by EM are different from those included in the EIA or by the PCR primers, steps can be taken to modify or enhance these more specific diagnostic methods to take account of currently circulating strains.Investigation of viral gastroenteritis ::: Current and future use of electron microscopy within virologyElectron microscopy is still incorporated into surveillance programmes for gastroenteric illness and with the expected introduction of safe rotavirus vaccines, some virology EM units will be involved in monitoring emerging patterns of infantile gastroenteritis.", [["noroviruses", "DISEASE", 14, 25], ["viral gastroenteritis", "DISEASE", 254, 275], ["gastroenteric illness", "DISEASE", 416, 437], ["infantile gastroenteritis", "DISEASE", 576, 601], ["noroviruses", "ORGANISM", 14, 25], ["rotavirus", "ORGANISM", 481, 490], ["PCR primers", "DNA", 96, 107], ["rotavirus", "SPECIES", 481, 490], ["noroviruses", "PROBLEM", 14, 25], ["the PCR primers", "TEST", 92, 107], ["currently circulating strains", "PROBLEM", 207, 236], ["viral gastroenteritis", "PROBLEM", 254, 275], ["electron microscopy", "TEST", 306, 325], ["Electron microscopy", "TEST", 341, 360], ["gastroenteric illness", "PROBLEM", 416, 437], ["safe rotavirus vaccines", "TREATMENT", 476, 499], ["infantile gastroenteritis", "PROBLEM", 576, 601], ["noroviruses", "OBSERVATION", 14, 25], ["viral gastroenteritis", "OBSERVATION", 254, 275], ["gastroenteric", "ANATOMY", 416, 429], ["infantile", "OBSERVATION_MODIFIER", 576, 585], ["gastroenteritis", "OBSERVATION", 586, 601]]], ["First generation rotavirus vaccines had significant side effects, including intussusception (a form of intestinal obstruction), in a small number of cases (Murphy et al., 2001), but safer second-generation vaccines are in development.", [["intestinal", "ANATOMY", 103, 113], ["intussusception", "DISEASE", 76, 91], ["intestinal obstruction", "DISEASE", 103, 125], ["rotavirus", "ORGANISM", 17, 26], ["intestinal", "ORGAN", 103, 113], ["rotavirus", "SPECIES", 17, 26], ["First generation rotavirus vaccines", "TREATMENT", 0, 35], ["significant side effects", "PROBLEM", 40, 64], ["intussusception", "PROBLEM", 76, 91], ["intestinal obstruction", "PROBLEM", 103, 125], ["safer second-generation vaccines", "TREATMENT", 182, 214], ["side effects", "OBSERVATION_MODIFIER", 52, 64], ["intussusception", "OBSERVATION", 76, 91], ["intestinal", "ANATOMY", 103, 113], ["obstruction", "OBSERVATION", 114, 125], ["small", "OBSERVATION_MODIFIER", 133, 138]]], ["If widespread vaccination of infants is undertaken, EM will be used in specialist centres to monitor any possible changes in the pattern of infection by the different enteric viruses.Investigation of viral gastroenteritis ::: Current and future use of electron microscopy within virologyIt is still the case that no pathogen is detected in 40% of incidents of non-bacterial gastroenteritis.", [["infection", "DISEASE", 140, 149], ["viral gastroenteritis", "DISEASE", 200, 221], ["gastroenteritis", "DISEASE", 374, 389], ["infants", "ORGANISM", 29, 36], ["infants", "SPECIES", 29, 36], ["infection", "PROBLEM", 140, 149], ["the different enteric viruses", "PROBLEM", 153, 182], ["viral gastroenteritis", "PROBLEM", 200, 221], ["electron microscopy", "TEST", 252, 271], ["pathogen", "PROBLEM", 316, 324], ["non-bacterial gastroenteritis", "PROBLEM", 360, 389], ["infection", "OBSERVATION", 140, 149], ["enteric viruses", "OBSERVATION", 167, 182], ["viral gastroenteritis", "OBSERVATION", 200, 221], ["non-bacterial gastroenteritis", "OBSERVATION", 360, 389]]], ["There may be other viruses awaiting discovery and, if so, EM will have a role in this.Investigation of immunocompromised patients ::: Current and future use of electron microscopy within virologyElectron microscopic investigation of samples from immunocompromised individuals remains an important use of EM.", [["samples", "ANATOMY", 233, 240], ["patients", "ORGANISM", 121, 129], ["samples", "CANCER", 233, 240], ["patients", "SPECIES", 121, 129], ["other viruses", "PROBLEM", 13, 26], ["electron microscopy", "TEST", 160, 179], ["Electron microscopic investigation", "TEST", 195, 229], ["immunocompromised individuals", "PROBLEM", 246, 275], ["may be", "UNCERTAINTY", 6, 12], ["viruses", "OBSERVATION", 19, 26], ["immunocompromised", "OBSERVATION", 103, 120]]], ["Immunocompromised patients with gastrointestinal symptoms should be investigated and because EM is a \u2018catch all\u2019 method any viral cause of symptoms can be elucidated on examination of negatively stained diarrhoeal samples providing the virus is present in sufficiently high numbers.", [["gastrointestinal", "ANATOMY", 32, 48], ["samples", "ANATOMY", 214, 221], ["gastrointestinal symptoms", "DISEASE", 32, 57], ["patients", "ORGANISM", 18, 26], ["gastrointestinal", "ORGAN", 32, 48], ["patients", "SPECIES", 18, 26], ["gastrointestinal symptoms", "PROBLEM", 32, 57], ["symptoms", "PROBLEM", 139, 147], ["examination", "TEST", 169, 180], ["negatively stained diarrhoeal samples", "PROBLEM", 184, 221], ["the virus", "PROBLEM", 232, 241], ["gastrointestinal", "ANATOMY", 32, 48]]], ["In addition, investigation of skin lesions and bloody urine by EM can quickly reveal a possible viral cause of symptoms so that appropriate treatment can be instigated.", [["skin lesions", "ANATOMY", 30, 42], ["bloody urine", "ANATOMY", 47, 59], ["skin lesions", "CANCER", 30, 42], ["urine", "ORGANISM_SUBSTANCE", 54, 59], ["skin lesions", "PROBLEM", 30, 42], ["bloody urine", "PROBLEM", 47, 59], ["viral cause of symptoms", "PROBLEM", 96, 119], ["appropriate treatment", "TREATMENT", 128, 149], ["skin", "ANATOMY", 30, 34], ["lesions", "OBSERVATION", 35, 42]]], ["Urine examination by EM can quickly reveal the presence of polyomavirus (BK) (Fig. 18) or adenoviruses (Gardner et al., 1971, Cotterill et al., 1992, Appleton, 2005).", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["polyomavirus", "ORGANISM", 59, 71], ["adenoviruses", "ORGANISM", 90, 102], ["Urine examination", "TEST", 0, 17], ["polyomavirus (BK", "PROBLEM", 59, 75], ["polyomavirus", "OBSERVATION", 59, 71]]], ["Typing of these viruses is now undertaken by other methods, usually PCR, but EM remains useful for obtaining a rapid diagnostic result.Investigation of immunocompromised patients ::: Current and future use of electron microscopy within virologySymptoms of viral infection can mimic organ rejection in transplant patients and hence rapid investigation of potential virus infection is vital.", [["organ", "ANATOMY", 282, 287], ["viral infection", "DISEASE", 256, 271], ["infection", "DISEASE", 370, 379], ["patients", "ORGANISM", 170, 178], ["organ", "ORGAN", 282, 287], ["patients", "ORGANISM", 312, 320], ["patients", "SPECIES", 170, 178], ["patients", "SPECIES", 312, 320], ["these viruses", "PROBLEM", 10, 23], ["electron microscopy", "TEST", 209, 228], ["viral infection", "PROBLEM", 256, 271], ["organ rejection", "PROBLEM", 282, 297], ["transplant patients", "TREATMENT", 301, 320], ["rapid investigation", "TEST", 331, 350], ["potential virus infection", "PROBLEM", 354, 379], ["viruses", "OBSERVATION", 16, 23], ["immunocompromised", "OBSERVATION", 152, 169], ["viral infection", "OBSERVATION", 256, 271], ["rejection", "OBSERVATION", 288, 297], ["virus infection", "OBSERVATION", 364, 379]]], ["Treatment for organ rejection, by inducing further immunosuppression, would actually prolong virus replication.", [["organ", "ANATOMY", 14, 19], ["organ", "ORGAN", 14, 19], ["Treatment", "TREATMENT", 0, 9], ["organ rejection", "PROBLEM", 14, 29], ["further immunosuppression", "TREATMENT", 43, 68], ["virus replication", "TREATMENT", 93, 110], ["organ", "ANATOMY", 14, 19], ["rejection", "OBSERVATION", 20, 29]]], ["Herpesvirus infections, such as chicken pox, can be serious and even life threatening in immunocompromised patients, hence rapid diagnosis by EM can significantly aid patient management by indicating the need for the administration of antiviral drugs.Investigation of new infectious agents ::: Current and future use of electron microscopy within virologyElectron microscopy showed its worth in the 2003 investigation of respiratory samples from patients with severe acute respiratory symptoms, particularly those in Hong Kong and Southern China or those travelling from that part of the world.", [["respiratory samples", "ANATOMY", 421, 440], ["respiratory", "ANATOMY", 473, 484], ["Herpesvirus infections", "DISEASE", 0, 22], ["chicken pox", "DISEASE", 32, 43], ["acute respiratory symptoms", "DISEASE", 467, 493], ["Herpesvirus", "ORGANISM", 0, 11], ["chicken", "ORGANISM", 32, 39], ["patients", "ORGANISM", 107, 115], ["patient", "ORGANISM", 167, 174], ["patients", "ORGANISM", 446, 454], ["chicken pox", "SPECIES", 32, 43], ["patients", "SPECIES", 107, 115], ["patient", "SPECIES", 167, 174], ["patients", "SPECIES", 446, 454], ["chicken pox", "SPECIES", 32, 43], ["Herpesvirus infections", "PROBLEM", 0, 22], ["antiviral drugs", "TREATMENT", 235, 250], ["electron microscopy", "TEST", 320, 339], ["Electron microscopy", "TEST", 355, 374], ["respiratory samples", "TEST", 421, 440], ["severe acute respiratory symptoms", "PROBLEM", 460, 493], ["infections", "OBSERVATION", 12, 22], ["new", "OBSERVATION_MODIFIER", 268, 271], ["infectious", "OBSERVATION", 272, 282], ["respiratory", "ANATOMY", 421, 432], ["severe", "OBSERVATION_MODIFIER", 460, 466], ["acute", "OBSERVATION_MODIFIER", 467, 472], ["respiratory", "ANATOMY", 473, 484], ["symptoms", "OBSERVATION", 485, 493]]], ["Laboratory investigation, including EM, resulted in the discovery of the SARS agent (severe acute respiratory syndrome), a newly recognised viral infection of humans.", [["SARS", "DISEASE", 73, 77], ["acute respiratory syndrome", "DISEASE", 92, 118], ["viral infection", "DISEASE", 140, 155], ["humans", "ORGANISM", 159, 165], ["humans", "SPECIES", 159, 165], ["humans", "SPECIES", 159, 165], ["Laboratory investigation", "TEST", 0, 24], ["the SARS agent", "PROBLEM", 69, 83], ["severe acute respiratory syndrome", "PROBLEM", 85, 118], ["a newly recognised viral infection of humans", "PROBLEM", 121, 165], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory syndrome", "OBSERVATION", 98, 118], ["viral", "OBSERVATION_MODIFIER", 140, 145], ["infection", "OBSERVATION", 146, 155]]], ["The virus had the characteristic ultrastructural features of a coronavirus (Fig. 19).", [["coronavirus", "DISEASE", 63, 74], ["The virus", "PROBLEM", 0, 9], ["a coronavirus", "PROBLEM", 61, 74], ["virus", "OBSERVATION", 4, 9], ["coronavirus", "OBSERVATION", 63, 74]]], ["Such viruses are covered with club-shaped surface projections, resembling petals (Ksiazek et al., 2003, Falsey and Walsh, 2003).", [["surface", "ANATOMY", 42, 49], ["petals", "ANATOMY", 74, 80], ["Such viruses", "PROBLEM", 0, 12], ["club-shaped surface projections", "TREATMENT", 30, 61], ["viruses", "OBSERVATION", 5, 12], ["shaped", "OBSERVATION_MODIFIER", 35, 41], ["surface", "OBSERVATION_MODIFIER", 42, 49]]], ["The value of EM was also demonstrated in Australia in 1995 during investigations of a respiratory infection that caused fatal disease in horses and humans.", [["respiratory", "ANATOMY", 86, 97], ["respiratory infection", "DISEASE", 86, 107], ["humans", "ORGANISM", 148, 154], ["humans", "SPECIES", 148, 154], ["horses", "SPECIES", 137, 143], ["humans", "SPECIES", 148, 154], ["a respiratory infection", "PROBLEM", 84, 107], ["fatal disease in horses", "PROBLEM", 120, 143], ["respiratory", "ANATOMY", 86, 97], ["infection", "OBSERVATION", 98, 107], ["fatal", "OBSERVATION_MODIFIER", 120, 125], ["disease", "OBSERVATION", 126, 133]]], ["Investigations, including EM, showed that a new morbillivirus (Hendra virus, belonging to the family Paramyxoviridae) was the causative agent (Murray et al., 1995, Halpin et al., 2000).", [["Hendra virus", "DISEASE", 63, 75], ["morbillivirus", "ORGANISM", 48, 61], ["Hendra virus", "ORGANISM", 63, 75], ["Hendra virus", "SPECIES", 63, 75], ["Hendra virus", "SPECIES", 63, 75], ["a new morbillivirus (Hendra virus", "PROBLEM", 42, 75], ["new", "OBSERVATION_MODIFIER", 44, 47], ["morbillivirus", "OBSERVATION", 48, 61]]], ["A related new virus, Nipah virus, has more recently been discovered, primarily in pig farmers, in Malaysia (Chua et al., 1999).Investigation of \u2018exotic\u2019 virus infections ::: Current and future use of electron microscopy within virologyThe use of EM to investigate \u2018exotic\u2019 infections such as haemorrhagic fevers only takes place in specialist centres with the highest level of containment for infectious agents (Biosafety level 4).", [["Nipah virus", "DISEASE", 21, 32], ["infections", "DISEASE", 159, 169], ["infections", "DISEASE", 273, 283], ["haemorrhagic fevers", "DISEASE", 292, 311], ["Nipah virus", "ORGANISM", 21, 32], ["pig", "ORGANISM", 82, 85], ["\u2018exotic\u2019 virus", "ORGANISM", 144, 158], ["Nipah virus", "SPECIES", 21, 32], ["pig", "SPECIES", 82, 85], ["Nipah virus", "SPECIES", 21, 32], ["pig", "SPECIES", 82, 85], ["\u2018exotic\u2019 virus", "SPECIES", 144, 158], ["A related new virus", "PROBLEM", 0, 19], ["Nipah virus", "PROBLEM", 21, 32], ["electron microscopy", "TEST", 200, 219], ["exotic\u2019 infections", "PROBLEM", 265, 283], ["haemorrhagic fevers", "PROBLEM", 292, 311], ["infectious agents", "TREATMENT", 393, 410], ["new", "OBSERVATION_MODIFIER", 10, 13], ["virus", "OBSERVATION", 14, 19], ["Nipah virus", "OBSERVATION", 21, 32], ["infections", "OBSERVATION", 273, 283], ["haemorrhagic", "OBSERVATION_MODIFIER", 292, 304]]], ["Viruses from a number of different families with different morphologies may cause haemorrhagic fever in humans.", [["haemorrhagic fever", "DISEASE", 82, 100], ["humans", "ORGANISM", 104, 110], ["humans", "SPECIES", 104, 110], ["humans", "SPECIES", 104, 110], ["Viruses", "PROBLEM", 0, 7], ["haemorrhagic fever in humans", "PROBLEM", 82, 110], ["may cause", "UNCERTAINTY", 72, 81], ["haemorrhagic", "OBSERVATION_MODIFIER", 82, 94], ["fever", "OBSERVATION", 95, 100]]], ["For example, the virus causing Lassa fever is an arenavirus while Crimean\u2013Congo haemorrhagic fever is caused by a bunyavirus.", [["Lassa fever", "DISEASE", 31, 42], ["arenavirus", "DISEASE", 49, 59], ["Crimean\u2013Congo haemorrhagic fever", "DISEASE", 66, 98], ["Lassa fever", "ORGANISM", 31, 42], ["Crimean\u2013Congo haemorrhagic fever", "ORGANISM", 66, 98], ["Lassa fever", "SPECIES", 31, 42], ["Congo haemorrhagic fever", "SPECIES", 74, 98], ["Crimean\u2013Congo haemorrhagic fever", "SPECIES", 66, 98], ["the virus", "PROBLEM", 13, 22], ["Lassa fever", "PROBLEM", 31, 42], ["an arenavirus", "PROBLEM", 46, 59], ["Congo haemorrhagic fever", "PROBLEM", 74, 98], ["a bunyavirus", "PROBLEM", 112, 124], ["Lassa", "OBSERVATION_MODIFIER", 31, 36], ["bunyavirus", "OBSERVATION", 114, 124]]], ["Marburg and Ebola, the most dangerous of these viruses, are members of the filovirus family (Fig. 20).", [["Marburg and Ebola", "DISEASE", 0, 17], ["Marburg", "ORGANISM", 0, 7], ["Ebola", "ORGANISM", 12, 17], ["filovirus", "ORGANISM", 75, 84], ["Ebola", "OBSERVATION", 12, 17], ["most dangerous", "OBSERVATION_MODIFIER", 23, 37], ["viruses", "OBSERVATION", 47, 54]]], ["Some bunyaviruses, such as Rift Valley Fever virus and Hantavirus, cause severe and sometimes fatal encephalitis in humans.", [["Rift Valley Fever", "DISEASE", 27, 44], ["Hantavirus", "DISEASE", 55, 65], ["encephalitis", "DISEASE", 100, 112], ["Rift Valley Fever virus", "ORGANISM", 27, 50], ["humans", "ORGANISM", 116, 122], ["Rift Valley Fever virus", "SPECIES", 27, 50], ["humans", "SPECIES", 116, 122], ["Rift Valley Fever virus", "SPECIES", 27, 50], ["humans", "SPECIES", 116, 122], ["Some bunyaviruses", "PROBLEM", 0, 17], ["Rift Valley Fever virus", "PROBLEM", 27, 50], ["Hantavirus", "PROBLEM", 55, 65], ["sometimes fatal encephalitis in humans", "PROBLEM", 84, 122], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["fatal", "OBSERVATION_MODIFIER", 94, 99], ["encephalitis", "OBSERVATION", 100, 112]]], ["Other viruses causing severe encephalitis, such as West Nile Fever and Dengue, are flaviviruses.", [["encephalitis", "DISEASE", 29, 41], ["West Nile Fever", "DISEASE", 51, 66], ["Dengue", "DISEASE", 71, 77], ["flaviviruses", "DISEASE", 83, 95], ["West Nile Fever", "ORGANISM", 51, 66], ["Nile Fever", "SPECIES", 56, 66], ["West Nile Fever", "SPECIES", 51, 66], ["Other viruses", "PROBLEM", 0, 13], ["severe encephalitis", "PROBLEM", 22, 41], ["West Nile Fever", "PROBLEM", 51, 66], ["Dengue", "PROBLEM", 71, 77], ["flaviviruses", "PROBLEM", 83, 95], ["viruses", "OBSERVATION", 6, 13], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["encephalitis", "OBSERVATION", 29, 41], ["flaviviruses", "OBSERVATION", 83, 95]]], ["Humans are not the natural hosts for any of these zoonotic viruses and normally only become infected by exposure to the animal vector.", [["Humans", "ORGANISM", 0, 6], ["these zoonotic viruses", "PROBLEM", 44, 66], ["infected", "OBSERVATION", 92, 100]]], ["Rodents are the natural hosts for arenaviruses, and bunyaviruses and flaviviruses are transmitted by arthropods, mainly blood-sucking ticks and mosquitoes.", [["blood", "ANATOMY", 120, 125], ["arenaviruses", "DISEASE", 34, 46], ["flaviviruses", "DISEASE", 69, 81], ["Rodents", "ORGANISM", 0, 7], ["arenaviruses", "ORGANISM", 34, 46], ["bunyaviruses", "GENE_OR_GENE_PRODUCT", 52, 64], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["ticks", "ORGANISM", 134, 139], ["arenaviruses", "PROBLEM", 34, 46], ["bunyaviruses", "PROBLEM", 52, 64], ["flaviviruses", "PROBLEM", 69, 81], ["flaviviruses", "OBSERVATION", 69, 81]]], ["Despite much investigative work, the natural host of the filoviruses has yet to be identified.", [["filoviruses", "CANCER", 57, 68], ["the filoviruses", "PROBLEM", 53, 68]]], ["Most haemorrhagic fever viruses are associated with tropical regions, but recently interest has focused on West Nile Fever, which emerged in birds in New York in 1999.", [["haemorrhagic fever", "DISEASE", 5, 23], ["Nile Fever", "DISEASE", 112, 122], ["West Nile Fever", "ORGANISM", 107, 122], ["West Nile Fever", "SPECIES", 107, 122], ["Most haemorrhagic fever viruses", "PROBLEM", 0, 31], ["tropical regions", "PROBLEM", 52, 68], ["Nile Fever", "PROBLEM", 112, 122], ["viruses", "OBSERVATION", 24, 31]]], ["Human infections subsequently occurred throughout North America and there are now ongoing studies of bird flocks in several countries.", [["Human infections", "DISEASE", 0, 16], ["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human infections", "PROBLEM", 0, 16], ["bird flocks", "PROBLEM", 101, 112], ["infections", "OBSERVATION", 6, 16], ["bird flocks", "OBSERVATION", 101, 112]]], ["The distinctive filamentous morphology of Filoviruses allows their detection by EM in acute phase patient serum.", [["serum", "ANATOMY", 106, 111], ["patient", "ORGANISM", 98, 105], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["patient", "SPECIES", 98, 105], ["their detection", "TEST", 61, 76], ["distinctive", "OBSERVATION_MODIFIER", 4, 15], ["filamentous", "OBSERVATION_MODIFIER", 16, 27], ["morphology", "OBSERVATION_MODIFIER", 28, 38], ["Filoviruses", "OBSERVATION", 42, 53], ["acute", "OBSERVATION_MODIFIER", 86, 91]]], ["However, this technique is not routinely employed for the diagnosis of other haemorrhagic fever viruses, but is used in supporting research on the structure and pathogenesis of these agents and in the development of other diagnostic methods and therapeutic regimes.", [["haemorrhagic fever", "DISEASE", 77, 95], ["other haemorrhagic fever viruses", "PROBLEM", 71, 103], ["these agents", "TREATMENT", 177, 189], ["diagnostic methods", "TEST", 222, 240], ["therapeutic regimes", "TREATMENT", 245, 264], ["haemorrhagic", "OBSERVATION_MODIFIER", 77, 89], ["fever", "OBSERVATION", 90, 95]]], ["Most of these viruses have high mortality rates and must be inactivated before processing for EM.", [["high mortality rates", "PROBLEM", 27, 47], ["viruses", "OBSERVATION", 14, 21]]], ["The fixatives used for this (such as buffered formaldehyde) must be carefully chosen so as not to mask or degrade the morphological features of interest.Investigation of recombinant proteins, antigens and viral capsids ::: Current and future use of electron microscopy within virologyRecombinant virus proteins and recombinant virus-like particles (virus capsids) can also be investigated by EM.", [["formaldehyde", "CHEMICAL", 46, 58], ["formaldehyde", "CHEMICAL", 46, 58], ["formaldehyde", "SIMPLE_CHEMICAL", 46, 58], ["recombinant virus-like particles", "ORGANISM", 315, 347], ["virus capsids", "ORGANISM", 349, 362], ["recombinant proteins", "PROTEIN", 170, 190], ["antigens", "PROTEIN", 192, 200], ["Recombinant virus proteins", "PROTEIN", 284, 310], ["The fixatives", "TREATMENT", 0, 13], ["this (such as buffered formaldehyde)", "TREATMENT", 23, 59], ["recombinant proteins", "PROBLEM", 170, 190], ["electron microscopy", "TEST", 249, 268], ["Recombinant virus proteins", "PROBLEM", 284, 310], ["recombinant virus", "PROBLEM", 315, 332], ["virus", "OBSERVATION", 296, 301], ["recombinant virus", "OBSERVATION", 315, 332]]], ["The use of EM for such investigations is restricted to specialist centres, but shows the value of a combined molecular and EM approach to the production and characterisation of recombinant viral proteins (Cohen and Richmond, 1982, Clarke et al., 1998).", [["recombinant viral proteins", "PROTEIN", 177, 203], ["such investigations", "TEST", 18, 37]]], ["Although not of direct clinical relevance, this use of EM can be important in research applications and particularly in the production of antigens for vaccine and assay development (Warnes et al., 1995).Investigation of cytopathic effect (CPE) in cell culture ::: Current and future use of electron microscopy within virologyIncubation of patient samples in cultured cell lines to induce growth of virus is still a relatively common procedure in most virus laboratories, although routine use of this method is also in decline.", [["cell", "ANATOMY", 247, 251], ["samples", "ANATOMY", 347, 354], ["cell lines", "ANATOMY", 367, 377], ["cell", "CELL", 247, 251], ["patient", "ORGANISM", 339, 346], ["cell lines", "CELL", 367, 377], ["antigens", "PROTEIN", 138, 146], ["cultured cell lines", "CELL_LINE", 358, 377], ["patient", "SPECIES", 339, 346], ["research applications", "TREATMENT", 78, 99], ["vaccine", "TREATMENT", 151, 158], ["cytopathic effect", "PROBLEM", 220, 237], ["cell culture", "TEST", 247, 259], ["electron microscopy", "TEST", 290, 309], ["patient samples", "TEST", 339, 354], ["cultured cell lines", "TREATMENT", 358, 377], ["growth of virus", "PROBLEM", 388, 403], ["this method", "TREATMENT", 495, 506], ["cytopathic", "OBSERVATION_MODIFIER", 220, 230], ["cell lines", "OBSERVATION", 367, 377], ["virus", "OBSERVATION", 398, 403]]], ["Viruses often produce characteristic cytopathic effects in cell cultures, which may be observed by light microscopy to allow indirect identification of the viral agent involved.", [["cell cultures", "ANATOMY", 59, 72], ["cell cultures", "CELL", 59, 72], ["cell cultures", "CELL_LINE", 59, 72], ["Viruses", "PROBLEM", 0, 7], ["characteristic cytopathic effects in cell cultures", "PROBLEM", 22, 72], ["light microscopy", "TEST", 99, 115], ["the viral agent", "TREATMENT", 152, 167], ["characteristic", "OBSERVATION_MODIFIER", 22, 36], ["cytopathic", "OBSERVATION_MODIFIER", 37, 47], ["cell cultures", "OBSERVATION", 59, 72]]], ["Atypical cytopathic effects or cytopathic effects induced by new agents sometimes require investigation by EM (Ksiazek et al., 2003).", [["Atypical cytopathic effects", "PROBLEM", 0, 27], ["cytopathic effects", "PROBLEM", 31, 49], ["cytopathic", "OBSERVATION_MODIFIER", 9, 19], ["cytopathic", "OBSERVATION_MODIFIER", 31, 41]]], ["This is a minor use of EM in most laboratories, but may aid and speed up the identification of viral pathogens.DiscussionThe role of EM in bacteriology and virology has continually evolved since its introduction.", [["viral pathogens", "PROBLEM", 95, 110], ["minor", "OBSERVATION_MODIFIER", 10, 15], ["viral pathogens", "OBSERVATION", 95, 110]]], ["As newer methods of virus detection have become available, so EM has been utilised in new and different areas.", [["virus detection", "TEST", 20, 35], ["new", "OBSERVATION_MODIFIER", 86, 89]]], ["The great expansion of diagnostic electron microscopy that occurred in the1970s and 1980s, mainly for the detection and characterisation of the causative agents of viral gastroenteritis, has ended.", [["viral gastroenteritis", "DISEASE", 164, 185], ["diagnostic electron microscopy", "TEST", 23, 53], ["the detection", "TEST", 102, 115], ["viral gastroenteritis", "PROBLEM", 164, 185], ["great", "OBSERVATION_MODIFIER", 4, 9], ["expansion", "OBSERVATION_MODIFIER", 10, 19], ["viral gastroenteritis", "OBSERVATION", 164, 185]]], ["EM is now applied to the investigation of a much wider range of viruses, but this is becoming confined to fewer specialist centres, which are usually associated with laboratories undertaking research activities as well as routine diagnostic microbiology.", [["viruses", "PROBLEM", 64, 71], ["routine diagnostic microbiology", "TEST", 222, 253], ["viruses", "OBSERVATION", 64, 71]]], ["However, maintaining facilities and ensuring availability of experienced microscopists is now becoming a problem in many parts of the UK.DiscussionThere is a very pertinent saying\u2014\u2018a picture paints a thousand words\u2019.", [["UK", "GENE_OR_GENE_PRODUCT", 134, 136]]], ["The SARS virus, a new human viral pathogen, required the use of several investigative methods, including EM, to determine that it was a coronavirus.DiscussionAttitudes to EM have also become very polarised.", [["SARS", "DISEASE", 4, 8], ["coronavirus", "DISEASE", 136, 147], ["SARS virus", "ORGANISM", 4, 14], ["human", "ORGANISM", 22, 27], ["human", "SPECIES", 22, 27], ["SARS virus", "SPECIES", 4, 14], ["human", "SPECIES", 22, 27], ["The SARS virus", "PROBLEM", 0, 14], ["a new human viral pathogen", "PROBLEM", 16, 42], ["a coronavirus", "PROBLEM", 134, 147], ["SARS virus", "OBSERVATION", 4, 14], ["very", "OBSERVATION_MODIFIER", 191, 195], ["polarised", "OBSERVATION", 196, 205]]], ["Also, specimens for EM require individual examination by an experienced electron microscopist, a process that cannot be automated and results in a relatively limited throughput of specimens.", [["specimens", "ANATOMY", 6, 15], ["specimens", "ANATOMY", 180, 189], ["specimens", "CANCER", 180, 189], ["individual examination", "TEST", 31, 53], ["specimens", "TEST", 180, 189]]], ["Over the long-term, despite the high initial capital costs, EM comes out as a very cost effective technique.", [["long-term", "OBSERVATION_MODIFIER", 9, 18], ["high", "OBSERVATION_MODIFIER", 32, 36], ["capital costs", "OBSERVATION", 45, 58]]], ["In addition, consumable costs are almost negligible compared to expensive molecular diagnostic reagents.", [["consumable costs", "PROBLEM", 13, 29], ["consumable", "OBSERVATION_MODIFIER", 13, 23], ["costs", "OBSERVATION", 24, 29], ["negligible", "OBSERVATION_MODIFIER", 41, 51]]], ["Electron microscopy still has much to offer and if such narrow attitudes persist, there may be a need for a national strategy to be put in place in order to safeguard EM capability within virology in the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 204, 206], ["Electron microscopy", "TEST", 0, 19], ["a national strategy", "TREATMENT", 106, 125]]], ["This may mean concentrating EM in a few specialist centres.DiscussionElectron microscopy still has a role as a diagnostic tool for the investigation of gastrointestinal virus infections.", [["gastrointestinal virus infections", "DISEASE", 152, 185], ["gastrointestinal virus", "ORGANISM", 152, 174], ["Electron microscopy", "TEST", 69, 88], ["gastrointestinal virus infections", "PROBLEM", 152, 185], ["gastrointestinal", "ANATOMY", 152, 168], ["virus", "OBSERVATION", 169, 174]]], ["Indeed, it remains the only \u2018catch-all\u2019 method, capable of detecting multiple infections in one test.", [["infections", "DISEASE", 78, 88], ["multiple infections in one test", "PROBLEM", 69, 100], ["multiple", "OBSERVATION_MODIFIER", 69, 77], ["infections", "OBSERVATION", 78, 88]]], ["If EIAs and PCR testing predominate, then a battery of tests may be required to detect multiple infections and this may negate some of the perceived advantages of these new alternative diagnostic techniques.", [["infections", "DISEASE", 96, 106], ["EIAs", "TEST", 3, 7], ["PCR testing", "TEST", 12, 23], ["a battery of tests", "TEST", 42, 60], ["multiple infections", "PROBLEM", 87, 106], ["infections", "OBSERVATION", 96, 106]]], ["Despite this, EIAs and PCR methods are now perceived as more convenient, sensitive, relatively cheap and do not requiring highly skilled staff.", [["EIAs", "TEST", 14, 18], ["PCR methods", "TEST", 23, 34]]], ["However, most gastroenteritis viruses contain an RNA genome, susceptible to spontaneous mutation, which may alter the RNA or expressed proteins, making them undetectable by existing EIAs or PCR assays.", [["gastroenteritis", "DISEASE", 14, 29], ["RNA genome", "DNA", 49, 59], ["most gastroenteritis viruses", "PROBLEM", 9, 37], ["an RNA genome", "PROBLEM", 46, 59], ["spontaneous mutation", "PROBLEM", 76, 96], ["expressed proteins", "PROBLEM", 125, 143], ["PCR assays", "TEST", 190, 200], ["gastroenteritis viruses", "OBSERVATION", 14, 37], ["RNA genome", "OBSERVATION", 49, 59], ["spontaneous mutation", "OBSERVATION", 76, 96]]], ["It is, therefore, prudent that EM should remain a part of the diagnostic regime to enable genetically mutated enteric viruses to remain detectable on the basis of their characteristic morphology.DiscussionElectron microscopy also has a particular advantage in other viral diagnostic applications.", [["the diagnostic regime", "TREATMENT", 58, 79], ["genetically mutated enteric viruses", "PROBLEM", 90, 125], ["Electron microscopy", "TEST", 205, 224]]], ["The rapid provision of results when investigating skin lesions is currently of high priority to counter the threat posed by terrorist groups who potentially may be able to obtain stocks of pathogens, such as smallpox, with the intention to release such agents into largely non-immune population centres (widespread vaccination ceased with the worldwide eradication of smallpox).", [["skin lesions", "ANATOMY", 50, 62], ["skin lesions", "DISEASE", 50, 62], ["smallpox", "DISEASE", 208, 216], ["smallpox", "DISEASE", 368, 376], ["skin lesions", "PATHOLOGICAL_FORMATION", 50, 62], ["skin lesions", "PROBLEM", 50, 62], ["pathogens", "PROBLEM", 189, 198], ["smallpox", "TREATMENT", 208, 216], ["largely non-immune population centres", "TREATMENT", 265, 302], ["widespread vaccination", "TREATMENT", 304, 326], ["skin", "ANATOMY", 50, 54], ["lesions", "OBSERVATION", 55, 62]]], ["It is vitally important that EM facilities involved in such emergency response participate in external quality control schemes to maintain and augment recognition skills for potential viral bioterrorism agents.DiscussionConventional silver-based \u2018wet\u2019 photography is now in decline and EM is currently embracing digital image capture.", [["silver", "CHEMICAL", 233, 239], ["silver", "CHEMICAL", 233, 239], ["silver", "SIMPLE_CHEMICAL", 233, 239], ["external quality control schemes", "TREATMENT", 94, 126], ["viral bioterrorism agents", "TREATMENT", 184, 209]]], ["Although expensive to retrofit to electron microscopes, digital EM cameras allow rapid acquisition of images and their instant sharing between networked facilities.", [["electron microscopes", "TEST", 34, 54], ["digital EM cameras", "TEST", 56, 74], ["rapid acquisition of images", "TEST", 81, 108]]], ["This is particularly important in relation to bioterrorism, as images of viruses may be quickly scrutinised by geographically separated experts.", [["viruses", "PROBLEM", 73, 80]]], ["Digital photography is opening up a new area of communication between microscopists.", [["Digital photography", "TEST", 0, 19], ["new", "OBSERVATION_MODIFIER", 36, 39]]], ["It is making it easier to provide images and to promote enthusiasm for EM to a wider audience both scientific and non-scientific.DiscussionElectron microscopy should have a continuing role in virological and bacteriological investigations, but this requires that its use must be encouraged and supported.", [["images", "TEST", 34, 40], ["Electron microscopy", "TEST", 139, 158], ["bacteriological investigations", "TEST", 208, 238]]], ["In the biomedical field, this may mean that electron microscope facilities have to be centralised to ensure a sufficient volume of work is undertaken to keep the cost of investigations at an acceptable level.", [["investigations", "TEST", 170, 184]]], ["An example of this approach is virology users linking with established EM units undertaking the investigation of, for example, renal disease where EM remains an important investigative technique (Pearson et al., 1994, Shore and Moss, 2002).DiscussionAlthough molecular techniques are having and will have an increasingly important role in virology and bacteriology, EM still has much to contribute.", [["renal", "ANATOMY", 127, 132], ["renal disease", "DISEASE", 127, 140], ["renal", "ORGAN", 127, 132], ["the investigation", "TEST", 92, 109], ["renal disease", "PROBLEM", 127, 140], ["renal", "ANATOMY", 127, 132], ["disease", "OBSERVATION", 133, 140]]], ["Electron microscopy should be seen as being capable of producing different, but equally relevant, information about infectious agents.", [["Electron microscopy", "TEST", 0, 19], ["infectious agents", "TREATMENT", 116, 133]]], ["Electron microscopy is complementary to other investigative techniques, not a rival to them.", [["Electron microscopy", "TEST", 0, 19]]], ["Using such a combined approach will enable us to elucidate many new aspects of both previously known and emerging organisms and the diseases they produce in humans and animals.DiscussionThe future for electron microscopy within virology and microbiology lies in its contribution to research, in the epidemiology of enteric viruses and the rapid differential diagnosis of skin lesion viruses, where EM examination may rapidly exclude the presence of serious bioterrorism-related agents.", [["skin lesion", "ANATOMY", 371, 382], ["enteric viruses", "DISEASE", 315, 330], ["skin lesion viruses", "DISEASE", 371, 390], ["humans", "ORGANISM", 157, 163], ["skin", "ORGAN", 371, 375], ["humans", "SPECIES", 157, 163], ["humans", "SPECIES", 157, 163], ["a combined approach", "TREATMENT", 11, 30], ["the diseases", "PROBLEM", 128, 140], ["electron microscopy", "TEST", 201, 220], ["enteric viruses", "PROBLEM", 315, 330], ["skin lesion viruses", "PROBLEM", 371, 390], ["EM examination", "TEST", 398, 412], ["related agents", "TREATMENT", 470, 484], ["enteric", "ANATOMY", 315, 322], ["viruses", "OBSERVATION", 323, 330], ["skin", "ANATOMY", 371, 375], ["lesion", "OBSERVATION", 376, 382]]], ["Discrepant laboratory results can also be investigated and possible reagent contamination readily identified.", [["reagent contamination", "PROBLEM", 68, 89]]], ["In addition EM is being increasingly used in development and quality control of vaccines in specialist centres.DiscussionThe role of electron microscopy within the diagnosis and study of infectious disease is at a critical period.", [["infectious disease", "DISEASE", 187, 205], ["electron microscopy", "TEST", 133, 152], ["infectious disease", "PROBLEM", 187, 205], ["infectious", "OBSERVATION", 187, 197]]], ["In order to secure its' long-term future, a new generation of electron microscopists must be encouraged to acquire the required technical skills.", [["a new generation of electron microscopists", "TREATMENT", 42, 84]]], ["Most importantly, the significant knowledge and experience required for meaningful image interpretation, must be handed on by the declining band of skilled microscopists while they are still in post.", [["meaningful image interpretation", "TEST", 72, 103]]], ["Institutions with a commitment to electron microscopy must ensure sensible programmes of succession planning are put in place to ensure the long-term survival of electron microscopy and its essential contribution to microbiology.", [["electron microscopy", "TEST", 34, 53], ["succession planning", "TREATMENT", 89, 108], ["electron microscopy", "TEST", 162, 181]]]], "3f2e214a0b4ba8cfa2d3f4acbb41de2de9e47de2": [["introduce the abstract OCD concepts to agile development stakeholders [5] .", [["OCD", "DISEASE", 23, 26]]], ["Although previous research experimented with the SCM, the method was applied in isolation, i.e. not within a real-world agile software development context.", [["the method", "TREATMENT", 54, 64]]], ["The main contribution of this study is to demonstrate how the SCM is used within an agile software development approach to solve existing deficiencies at a Fintech company.", [["this study", "TEST", 25, 35], ["existing deficiencies", "PROBLEM", 129, 150], ["main", "OBSERVATION_MODIFIER", 4, 8]]]], "PMC7378982": [["An event is serious (based on the ICH definition) when the patient outcome is:", [["ICH", "DISEASE", 34, 37], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["the ICH definition", "TEST", 30, 48], ["serious", "OBSERVATION_MODIFIER", 12, 19]]]]}